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CHAPTER 1
1. Pre-Analytical Effects on Laboratory Examinations
Authors: RNDr. Zdeněk Švagera, Ph.D.; Mgr. Radka Šigutová
Reviewer: RNDr. Jiří Zadina, CSc.
1.1. Introduction
The laboratory diagnostic process to obtain a result can be divided into three phases: the pre-analytical, analytical 
and post-analytical phases (see the diagram).
The pre-analytical phase is defined as the period from the physician’s indication of the test up to the laboratory 
analysis of the biological material. In other words, this phase involves an individual’s preparation for collection of the 
biological material, the collection itself, storage of the collected sample and its transport to the laboratory, and prepa-
ration of the sample for the assay. The importance of this phase is also supported by many publications mentioning the 
fact that up to 46 – 68 % of erroneous results are caused by failure to follow or respect the pre-analytical phase rules. 
That is why the primary task of the laboratory is to provide clients with all necessary instructions (on patient prepara-
tion, sample collection, biological material storage and transport, pre-analytical sample treatment) so as to minimize 
the risk of errors that could consequently cause harm to the patient. All this information is summarized in the manuals 
of testing laboratories.
The pre-analytical phase is followed by the analytical phase, involving the sample analysis itself. Each laboratory 
must have an established quality control system to ensure the validity of the issued results. The analytical phase ends 
with the post-analytical phase, defined as the period from obtaining the lab result to its hand-over to the physician.
It is necessary to keep in mind that biological samples constitute a risk of infection, and therefore personal protecti-
ve equipment (rubber gloves, protective coat) should be used for work with biological material (material collection, lab 
work with the sample). In addition, a face mask and safety goggles must be used for highly infectious samples such as 
HIV or hepatitis C. If clothes or skin is contaminated by the biological material, the affected area should be washed and 
then disinfected. In the event of injury, the wound must be treated (let it bleed for several minutes, wash with soap, 
disinfect) and medical attention sought.
1.2. Pre-Analytical Phase and Its Sources of Variability
As mentioned in the introduction, the pre-analytical phase, i.e. before the analysis of the sample (specified para-
meter) in the laboratory, can be a source of many errors. Therefore, it is necessary to explain what factors affect the 
pre-analytical phase most. These factors can be divided chronologically:
1.3. Before the Biological Material Collection
Factors affecting the pre-analytical phase before the biological material collection can be further divided into cont-
rollable and uncontrollable factors. Controllable factors include, for example, adherence to some daily regimen, dietary 
habits, etc. Uncontrollable factors are variables such as age, gender, race, etc.
1.3.1. Controllable Factors before the Biological Material Collection
Food is an important controllable factor before the biological material collection. Blood should ALWAYS be collec-
ted after a fasting period. Where this is not the case, increased levels of some metabolites can be observed due to in-
gested nutrient metabolism. Glucose, triacylglycerol, free fatty acid and lipoprotein levels are elevated. People whose 
diet is rich in fats will primarily have an elevated serum triacylglycerol concentration on the one hand, and a decreased 
serum nitrogen substance concentration on the other. Protein-rich food leads to increased ammonia and urea levels. 
At the same time, postprandial hormones (e.g. insulin, which reduces potassium and phosphate levels) are released. 
Food composition may also affect the pH of urine. For example, vegetable and fruit consumption makes urine more 
alkaline, while meat, fat and protein-rich food makes it more acidic. Some metabolite levels may also be influenced 
by the consumption of certain beverages (caffeine increases the glucose level in blood). Alcohol also significantly af-
fects biochemical assays. After alcohol ingestion, the blood lactate concentration increases almost immediately, while 
hydrogencarbonate and glucose levels go down. Long-term alcohol burden in the body leads to liver damage, which 
is manifested by increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl-
transferase (GGT) levels. Triacylglycerol and cholesterol concentrations are also elevated.
Another factor that may affect the final result is physical strain before the collection. The impact on the result 
will depend on the type of physical activity: either a short-term activity, with high-intensity anaerobic metabolism of 
the body, or a long-term (endurance) activity where the body predominantly employs aerobic metabolism. Medium 
physical exertion increases the glucose level and insulin secretion is stimulated. Muscular activity also increases levels 
of AST, lactate dehydrogenase (LD) and creatine kinase (CK) enzymes as well lactate and fatty acid levels. Long-term 
strenuous activity results in a decrease in blood sugar, an increase in creatinine, and multiple-fold increase in lactate 
levels. Cholesterol and triacylglycerol levels are also reduced.
Another controllable factor before the biological material collection is mechanical trauma; for example, muscle 
trauma, including intramuscular injections, causes the release of enzymes (CK, ALT, AST) and muscle tissue proteins 
(e.g. myoglobin). Cycling may cause mechanical trauma to the prostate, which may manifest itself by the release of 
prostatic serum antigen leading to a false positive result for this test. Marathon running and heart valve defects lead to 
the mechanical haemolysis of erythrocytes.
A very common problem, which is very difficult to control, is the effect of drugs. Drugs may affect the level of some 
monitored analytes; for example, acetylsalicylic acid (aspirin) increases serum AST and ALT and urine protein levels, 
furosemide increases serum glucose, amylase (AMS) and alkaline phosphatase (ALP), and decreases sodium cation 
levels. Drugs may also interfere with the analytical assay procedure. For example, since vitamin C has strong reduction 
properties, it causes a false decrease in the level of analytes detected using peroxide. Drugs may also affect the rate of 
metabolism or monitored analyte elimination, or damage certain organs – the hepatotoxicity of narcotic agents being 
an example.
Stress is also a major factor. Stress situations cause the release of stress hormones such as renin, aldosterone, so-
matotropin, catecholamines, cortisol, glucagon and prolactin. This is why blood collection for prolactin assays should 
be performed within three hours after waking up. Another example might be the 60% drop in cholesterol compared 
with the initial level within 24 hours after acute myocardial infarction. It takes many weeks before its concentration 
reverts to normal. For this reason, blood collection for cholesterol, HDL and LDL cholesterol assays is not recommended 
when patients with suspected acute myocardial infarction are being hospitalized. In contrast, slight stress may increase 
cholesterol concentration. Post-operative stress decreases the concentration of thyroidal hormones and transferrin, 
and secondarily increases the concentration of ferritin.
1.3.2. Uncontrollable Factors before the Biological Material Collection
Uncontrollable factors before biological material collection include age, gender, race and biological rhythms. A 
further uncontrollable factor which might be included here is pregnancy. However, since this example of influence on 
the pre-analytical phase is too specific, it will not be described in this communication. Except for biological rhythms 
and pregnancy, these effects do not require any special attention as they are beyond our control and are considered 
through reference limits for the relevant analyte.
Age is a very important uncontrollable factor, since most monitored analytes are age related. An older person will 
have higher cholesterol levels than a younger person. Children and adolescents exhibit higher total alkaline phospha-
tase activity than adults due to a higher production of the bone isoform of this enzyme as the body grows. The reason 
is that the assay includes total alkaline phosphatase activity, including the bone isoform. Attention must also be paid 
to the higher total ALP level in pregnant women due to the higher production of the placental isoform of this enzyme.
Gender also has a major influence on the result of the assay. It is commonly known that many parameters depend 
on the hormone set and physical constitution. For example, men have higher levels of creatine kinase (CK), ALT, AST, 
ALP, uric acid, urea, haemoglobin, ferritin, iron and cholesterol than women.
Furthermore, the non-Caucasian population is increasing in the Czech Republic. For example, the CK and AMS acti-
vity or the granulocyte count rise in ascending order from Caucasian through Asian to African-American populations 
(African-Americans have up to twice as much CK activity and Asians have a higher salivary amylase activity and a higher 
total bilirubin concentration).
Other effects that should be considered are biological rhythms with their different time periods, either occurring 
within a single day (circadian) or cycles taking roughly a year to complete (circannual). Circadian changes vary for 
different parameters; for example, there is up to 50 % change in iron levels during the day. Other parameters such as 
AST, ALT, LD and ALP show changes in the range of tens of percent. Maybe the most notable circadian change occurs in 
cortisol – about 250 % with minimal levels in the evening. An example of circannual rhythm is the change in vitamin D 
concentration, with maximum levels in summer months due to skin exposure to intense sunlight.
1.4. During the Biological Material Collection
Factors influencing the pre-analytical phase during the biological material collection are primarily related to the 
work of the sample-collecting nurse, who has to keep in mind the basic sampling principles that may affect the result 
of the test. In particular, such principles include collection timing, selecting the appropriate collection set, the patient 
position during the collection, venostasis and local metabolism effects, as well as the effect of infusion and transfusion 
in the hospital environment.
1.4.1. Collection Timing
Collection timing plays a very important part in the strategy to obtain valid results. Most often, collections take 
place in the morning when we can be sure that the patient has fasted (provided the patient respects general pre-collec-
tion recommendations) and the circadian rhythm effect mentioned in the chapter above is limited. A different example 
is blood sugar monitoring (blood sugar profile) or pharmacotherapy monitoring, where samples are taken based on 
drug elimination half-life.
1.4.2. Patient Position during the Collection
Patient position during the collection is also important. It must be kept in mind that the difference in protein con-
centration when comparing a standing vs. sitting position for 15 minutes is 5 – 8 %, and about 10 – 20 % for a standing 
vs. recumbent position. In the standing position, water transfers from the intravasal to the interstitial space, which sub-
sequently leads to a rise in high-molecular substances, primarily proteins, lipoproteins and protein-bound substances 
such as calcium cation and hormones (cortisol, thyroxin), or some drugs. In general, biological material should always 
be collected in the same position, preferably the standard sitting position, which is not always possible in hospitalized 
patients, though.
1.4.3. Use of Tourniquet and Local Metabolism Effect
The effect of local metabolism when a tourniquet is used for collection is also interesting. The evidence shows that 
one minute after constricting the arm with a tourniquet there is already a significant transfer of water and ions from 
the vessel to the interstitium, with a subsequent rise in protein and blood protein-bound substance concentration. 
Long-term constriction or overcooling of the arm leads to a change in local metabolism due to hypoxia, which results 
in a rise in partial carbon dioxide pressure and potassium and lactate concentration, which in turn results in a drop in 
pH. In addition, there are homeostasis changes connected with the release of the tissue factor. Exercising the arm is 
not recommended, or it is even forbidden, as it primarily causes an increase in potassium concentration. For these rea-
sons, the period for which the arm is constricted should not exceed one minute, and the tourniquet should be released 
immediately after the venipuncture.
1.4.4. Choosing the Collection System and the Effect of Anticoagulants
The choice of the collection system is also very important. Options include a closed or an open sample collection 
system. The open collection system consists of a classical needle and a Luer-taper syringe. Following venipuncture, 
freely flowing blood is taken directly into the test tube or by gently pulling the plunger. Collection into a closed system 
is the preferred option today as it minimizes the risk of contaminating the collecting person through the blood, and 
collection tubes are colour coded depending on the added preservative or anticoagulant. Another advantage of the 
closed system is that the ratio of anticoagulant (preservative) to collected blood is maintained.
As mentioned above, anticoagulant (heparinate, citrate, oxalate, etc.) can be chosen depending on the required 
test. Nevertheless, attention needs to be paid when choosing the anticoagulant for cation tests, since the anticoagulant 
must not contain the cation being determined. For example, the use of EDTA with potassium will lead to highly patho-
logical potassium concentrations in the sample! EDTA is not suitable for determining bivalent cation concentration as it 
acts as a chelating agent, binding these cations to form a complex, and it results in finding a falsely low concentration 
of these ions. In some cases, another substance (preservative) such as sodium fluoride is added to the anticoagulant in 
order to determine glucose concentration. The addition of sodium fluoride will cause glycolysis inhibition in red blood 
cells, thus preventing a drop in glucose concentration over time.
In addition, we must keep in mind that if a collection set containing an anticoagulant is used, we should gently mix 
the collected blood immediately after the collection. Without mixing, the anticoagulant effect is limited and undesired 
blood clotting will occur. A suitable needle lumen should be selected for blood collection to avoid red blood cell hae-
molysis.
1.4.5. Effect of Infusion and Transfusion
Patients in a critical condition have to receive transfusion and infusion products containing high concentrations of 
selected substances and low concentrations of others. Infusion may therefore affect the determination of some sub-
stances, usually by direct contamination during collection or just due to their properties. For example, the infusion of 
glucose with potassium results in a false increase in glucose and potassium levels. The infusion of lipid emulsion cau-
ses serum chylosis and Hartmann infusions containing high lactate concentration (>15 mmol/l) cause a false increase 
in lactate concentration. On the other hand, Plasmalyte infusion causes a false normalisation of ion concentration in 
the collected sample. This is why certain rules should be followed during the sample collection following an infusion. 
Ideally, collect blood from the other arm, i.e. where the infusion was not applied, or stop the infusion for 15 minutes 
and then take the sample.
With respect to the pre-analytical phase, the age of transfusion must be taken into account. With the growing age 
of the erythrocyte concentrate, sodium and glucose concentrations decrease due to red erythrocyte metabolism, whe-
reas, in contrast, potassium and lactate concentrations increase.
1.5. Between Biological Material Collection and Analysis
This period includes the time from the collection of biological material until its analysis in the laboratory, and 
involves handling the sample following the collection, its subsequent transport to the laboratory, and centrifuging or 
pre-treatment before the analysis.
In general, if anticoagulated blood is taken (collection container with anticoagulant), the test tube should gently 
be shaken immediately after the collection. If non-anticoagulated blood is taken, wait about 30 minutes before trans-
porting the sample to allow sample clotting (exact time required for clotting is indicated by the manufacturer of the 
collection set). Immediate transport of the biological material after the collection may cause haemolysis and sample 
deterioration. The problem of haemolysis interfering with the assay is not only related to the release of erythrocyte 
content into the serum or plasma with a subsequent increase in the concentration of these substances in the tested 
material, but also to the release of haemoglobin, whose colour interferes directly with a photometric assay or with the 
agent used for the assay. Take care – haemolysis may also occur due to sample overcooling, high centrifuge speed or a 
narrow sampling needle. The following table describes the effect of haemolysis on selected biochemical assays.
Increase in concentration 
or activity
Potassium, magnesium cation, lactate dehydrogenase, aspar-
tate aminotransferase, alanine aminotransferase, creatine kinase, 
acid phosphatase
Decrease in concentration 
or activity
Gamma-glutamyltransferase, alkaline phosphatase, amylase
Storage of the sample before the transport and the very transport of the biological material are very important 
and must be given adequate attention, especially if samples are transported from practitioners in the periphery and 
brought to a specialized laboratory. The transport time will vary; however, always avoid exposing the sample to extre-
me conditions (heat/freezing) during the transport, minimize shaking the sample and avoid complete deterioration 
which will occur if the sample is spilled. This is why samples have to be transported in temperature-controlled trans-
port boxes protected against spillage. Some samples (tissues) must be transported frozen even at very low temperatu-
res (-80°C) on dry ice. If the maximum time before sample processing is exceeded or transport conditions are not ad-
hered to, some substance concentrations in the material for testing will change. One example is a decrease in glucose 
concentration or an increase in lactate concentration due to the anaerobic glycolysis of blood elements. Some analytes 
in biological material are thermolabile at room temperature (most parameters) and some, paradoxically, at 4°C (e.g. 
ALT activity decreases or potassium concentration increases due to the ATPase inhibition in the erythrocyte). Some 
analytes are photo-sensitive (e.g. bilirubin and porphyrins), and their amount drops unless transported and stored in 
the dark. For these reasons, some analytes have specific recommendations for storage and transport. For example, the 
recommendations for a plasma ammonia assay are as follows: carry out the anaerobic collection, prevent haemolysis, 
maintain the anticoagulant to blood ratio and transport in a transport container or on melting ice; analyse within 20 
minutes after the collection.
As soon as the samples are delivered to and received by the laboratory, they are either analysed directly (when 
whole blood is used), or must be centrifuged to obtain serum or plasma. The required conditions must be adhered to 
during centrifuging to achieve perfect serum (plasma) separation from erythrocytes and perfect leukocyte sedimen-
tation in the plasma. If the speed (relative centrifugal force) is too high during centrifuging, the cells may break and 
their content may get released. Many analytes require centrifuging at lower ambient temperatures (cooled centrifu-
ges), for hormone assays, for example.
Urine analysis requires a chapter to itself, since it requires the use of collected, first morning or single random spe-
cimens. Very often, patients are not instructed about the collection rules; they typically collect urine for a longer or a 
shorter time than required; moreover, obtaining an exact reading of the quantity of urine collected over the collection 
period, usually 24 hours, is always problematic. Nor it is possible to ensure the required storage of the collected urine 
in the fridge or the urine pre-treatment needed to stabilize the tested parameter. First morning urine collection poses 
a similar problem, since it has to be delivered for sediment analysis within one hour of collection. There is often a delay 
in delivering the collected urine to the laboratory, which leads to false negative or false positive results (increase in the 
bacteria count, increase in the pH value due to the urease of bacteria and cell element degradation).
In general, the transport and storage conditions required for transported samples/material must be followed. Ma-
terial transport in extreme (very hot, very cold) conditions requires special care.
Ten pieces of advice for obtaining correct results
• Instruct the patient (why they are being tested, diet, physical strain)
• Time the collection correctly
• Fill in the order slip correctly
• Choose the right collection procedure
• Choose the right test tube
• Take the recommended amount of material
• Do not spill any biological material
• Label the test tubes correctly
• Ensure appropriate storage for biological material before transport
• Ensure appropriate transport to the lab
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2.1. Introduction
Laboratory test results are indisputably a very important source of information when choosing the right treatment 
for the patient. Among other things, they help determine or specify the diagnosis, select, optimize and monitor the 
therapeutic procedure, or determine the prognosis of the patient’s condition.
When the results are interpreted, in most cases, the extent to which a result is consistent with values that might be 
reasonably expected in the selected reference population is considered. In other words, a specific result is compared 
with the limits defining the interval of result values obtained in the same laboratory test of a sample of the reference 
population, i.e. with the reference interval.
2.2. Basic Terms and Definitions
Reference interval (reference range): A generally accepted definition of this term is: the determination of limits 
between which 95 % of reference values fall (an interval encompassing up to 99 % is used for certain parameters).
This is usually the interval between the lower and the upper reference limits, which are typically the 2.5th and 
97.5th percentile of a set of values obtained through the analysis of a sufficiently homogeneous and large sample of 
the defined reference population.
Sometimes, from a clinical point of view, only the upper or the lower reference limit may be important, which cor-
responds to the 95th percentile, or the 5th percentile, respectively.
Examples of some specific variables and their assignment to the reference interval type are shown below (Table 1).
Reference values: These are the values (results of measuring the relevant variable) obtained from a selected group 
of individuals with a defined health condition.
Reference value distribution: Distribution of individual measurement results corresponding to some of the statisti-
cal distributions. The relevant type of distribution (normal, also called Gaussian, log-normal, Laplace distribution, etc.) 
is tested using suitable statistical methods.
Reference population: The set of all individuals meeting certain criteria concerning their health status or other 
defined requirements (age, gender, race). Absence of a certain disease is usually required; it is clear, however, that this 
defined notion of „health” is very relative and in its way imperfect.
Reference individual: An individual selected from the set of reference population.
Reference population selection (reference sampling group): A randomly selected part of the reference population 
from whom reference sampling values are obtained by measurement in order to estimate the reference limits. It is 
unrealistic to make measurements on the entire reference population, and therefore only a randomly selected sample 
is measured. Sampling characteristics obtained by measurement of this sample are thereby a more or less plausible 
estimate of actual values.
Likelihood estimation: Agreement between the estimate and the actual value typical of the entire population. This 
depends on many factors, the primary one being the size of the reference population sample. At least 120 reference 
individuals are typically required as a minimum; the confidence interval of estimates contracts considerably with the 
size of the reference sampling group. The likelihood estimation is further affected by pre-analytical aspects (method of 
collection, transport and storage of samples), the measurement method and the statistical evaluation method used.
Reference Interval Type Measured Variable (Parameter)
LRL – URL Na+, K+, Ca2+, glucose, transferrin, thyroid hormones
below URL bilirubin, AST, ALT, CK, troponin I, tumour markers
above LRL cholinesterase, prealbumin
Table 2.1. Examples of reference interval types relative to the clinical importance of reference limits (LRL – Lower 
Reference Limit, URL – Upper Reference Limit)
Figure 2.1. Relationships between terms in connection with determining the reference interval
2.3. Options for Determining Reference Intervals
One of two methods is usually chosen to determine reference intervals from actual measurement results.
The first method, referred to as the direct (inductive) method of estimating reference limits, is applied when the 
possibility exists of obtaining a sufficiently large reference sampling population on which the studied variable is me-
asured, providing the relevant pre-analytical conditions are adhered to. Selecting the requirements for reference in-
dividuals is quite a complicated task which may substantially affect the resulting reference limit values. In the NORIP 
study (Malmø, 27/4-2004), some of these requirements were proposed together with the pre-analytical conditions 
that should be followed when determining reference intervals. The conditions that reference individuals should meet 
include:
• Be feeling subjectively well;
• Have reached the age of 18;
• Not be pregnant or breast-feeding;
• Not have been hospitalized or seriously ill during the last few months;
• Not have had more than 24 g of alcohol in the last 24 hours;
• Not have given blood as a donor in the last 5 months;
• Not have taken prescribed drugs during the last 2 weeks;
• Not have smoked during the last few hours prior to sampling.
The second method, also referred to as the indirect (deductive) method, is applied if no suitable reference sam-
pling population is available, and only the results of the variable obtained by measurement of a „mixed” population 
comprising healthy and ill individuals can be used.
2.3.1. Direct Method of Reference Interval Estimation
This method is based on the statistical processing of measured reference values. Data obtained by measurement 
can be evaluated either parametrically or non-parametrically, depending on whether parameters characterizing the 
reference value distribution are used to establish the reference limits, which are then used to derive the numerical 
values of corresponding quantiles determining the reference limits. Although the non-parametric procedure is more 
universal, in this case the quantile likelihood estimates are lower.
2.3.1.1. Parametric Procedure
Use of the parametric procedure is only legitimate in selections coming from a normal (Gaussian) distribution, or 
from distributions that can be transformed into a normal distribution. Only in these cases is it possible to use the para-
meters of this distribution, i.e. the sample mean and sample standard deviation, as the best estimates of position and 
variance characteristics of this distribution, and to derive from them the relevant percentile values.
An important step in selecting the reference limit method is to confirm the assumption of normality for the dis-
tribution of obtained reference values, with the primary requirement being the symmetry of distribution. Various 
statistical tests such as Kolgomorov-Smirnov, Anderson-Darling or D’Agostino-Pearson tests are used to evaluate this 
normality. However, it should be kept in mind that different statistical tests can have different predicative abilities, and 
so are more likely to inform us that there is something wrong with the anticipated normality of the distribution. These 
tests are often used in combination with graphical methods; this has the advantage of enabling a comparison between 
the distribution of measured reference values (usually shown in a histogram) and a normal distribution with the same 
parameters using a frequency function diagram (probability density). Common statistical programs also enable the 
plotting of diagrams called rankit-plots, which are used to compare sampling distribution quantiles with normal distri-
bution quantiles. If the sampling distribution matches the normal distribution, the dependence is linear.
Figure 2.2. The histogram of distribution of the reference values obtained (x-axis: measurand value, y-axis: frequency 
of occurrence) and its approximation using the frequency function with the same parameters, and the rankit plot compa-
ring empirical distribution quantiles (y-axis) and normal distribution quantiles (x-axis)
So that the parameter estimate is unbiased, a test must be conducted to ensure that the reference values obtained 
by measurement do not contain outlying results or gross errors. Some common tests for outliers (Grubb’s test, Dean-
-Dixon test, etc.) or some graphical techniques can be used for this purpose. If the data contain outliers or gross errors, 
the next step must be their exclusion.
The normal distribution is clearly characterized by its parameters, the mean µ and the variance σ2. Only estimates 
of these parameters can be determined from the sampling dataset, which are the sample mean arithmetic mean and 
the sample variance s2. Both parameters can be computed from the following equations:
 
The sample standard deviation s is then computed by a simple root extraction of the variation value. Knowing these 
parameters, the 2.5th and the 97.5th percentile can be easily estimated. Assuming normal distribution, these quantiles 
can be computed as
As a general rule for normal distribution, the total area under the density curve equals 1, and the probability that 
a random variable acquires values from a certain interval is equal to the area defined under the curve of density above 
this interval.
For example, for an interval with limits < μ – 1.96 σ; μ +1.96 σ >, the size of this area is exactly 0.95.
Figure 2.3. Diagram of the probability density of the random variable X with normal distribution N(µ,σ2), represen-
ting the confidence level of the variable occurrence within the intervals of µ -1.96σ to µ+1.96σ
In practice, the coefficient 1.96 is often rounded to 2, so the reference interval limits are then determined more 
easily as arithmetic mean ± 2 s. 
Greater coefficients can be used to determine a reference interval with a coverage of probability greater than 95 
%. For example, the coefficient 2.57 corresponds to a probability of 99 %.
In practice, only a limited set of biologically significant variables meets the condition of normal distribution. This 
type of distribution can be expected only in analytes with a relatively narrow biological distribution, for example during 
serum ion concentration measurement (Na+, K+, Cl-, Ca2+, etc.).
Figure 2.4. Diagram of probability density of the random variable X with asymmetric distribution skewed to the right 
(“right-tailed” distribution)
However, in practice, we generally encounter variables with an asymmetric distribution of values, i.e. distribution 
skewed towards greater values. Examples of such variables are concentrations of glucose, creatinine, urea, AST, ALT, CK 
enzymes, thyroid-stimulating hormone, etc.
This skewed asymmetric distribution is often modelled using log-normal distribution, which can be easily trans-
formed into normal distribution using logarithmic transformation by simple logarithmic calculation of the measured 
values. If this transformation is insufficiently effective, another transformation such as a power transformation or Box-
-Cox transformation can be used.
To determine the reference interval, a similar procedure to selection from the normal distribution is used: the nor-
mality of transformed data is verified, sample parameters (transformed mean and standard deviation) are estimated 
and then used to calculate the transformed reference limits LRLT and URLT
The inversion function used for the transformation is then used to determine the reference range limits. For exam-
ple, if logarithmic transformation is used, the computed limit values are exponentiated (exp is inverse to the log func-
tion).
2.3.1.2. Non-Parametric Procedure
The non-parametric procedure is primarily used where a sufficiently large reference sampling group is available. 
In addition, this method of determinig the reference interval limit is more general, without any requirements for data 
distribution.
The below procedure is followed when determining reference limits:
• Measured data are sorted into ascending order by size;
• Each value is assigned a sequence number from 1 to N with the minimum value having 1 and the maximum 
value having N;
• The elements in the sorted set are assigned sequence numbers determining the 2.5th and 97.5th percen-
tile - n(2.5) and n(97.5);
• The LRL is assigned the value of the element corresponding to the sequence number of the 2.5th percenti-
le, and the URL is assigned the value of the element corresponding to the sequence number of the 97.5th 
percentile (if either of n(2.5) or n(97.5) is not an integer, the reference limit value is obtained by linear 
interpolation between the values of elements with sequence numbers bilaterally closest to this number);
• The median of selected reference values is considered the reference interval mean.
• The following steps can be taken to determine the sequence numbers of corresponding percentiles (IFCC 
recommendation):
or, alternatively, in accordance with the steps recommended by Linnet (Linnet K., Clin Chem 2000,46, 867-9):
Figure 2.5. Ascending sorting of selected reference values by size
2.3.1.3. Efficiency of Reference Limit Estimates
Since we only work with the reference sampling population, whatever the method we use, only reference limit 
estimates and not their actual values are obtained. The measure of likelihood of these estimates can be, for example, 
the size of their 90% confidence interval. This is closely related to the range of the reference sampling population, i.e. 
the number of reference individuals included in the selection.
If a non-parametric procedure is used, confidence intervals are generally wider than those in the parametric pro-
cedure. To reach a comparable confidence level for both procedures, the sampling range in the non-parametric pro-
cedure would have to be about twice the size as that for the parametric procedure. It is important to note that it is 
indeed possible, nonetheless, to improve the efficiency of a non-parametric procedure, i.e. to reach the same quality 
with a sampling range of about 5-15 % lower. This procedure is referred to as the “bootstrap” principle. This involves 
repeating the non-parametric procedure, always on a subset of reference values (range n) randomly selected from the 
entire sampling population with the original range N. For example, the number of repetitions might be k=100. Each 
repetition yields a pair of specific limits – the lower LRLi and the upper URLi. The average of all partial lower limits is 
considered the final lower reference limit estimate, and the average of partial upper limits is considered the upper 
reference limit estimate.
2.3.2. Indirect Method of Reference Interval Estimation
This method of estimating reference interval limits can be used if there is no real possibility of obtaining a suffici-
ently large and representative reference sampling population, but results of variable measurement obtained in nor-
mal, routine laboratory operation are available. This method requires a relatively high number of data, in the order of 
thousands. On the one hand, data are obtained from a “mixed” population containing both healthy and ill individuals 
without the possibility of meeting pre-defined sampling requirements. On the other hand, this is a population of actu-
ally examined individuals, which, if large enough, enables the carrying out of their stratification by age or gender, for 
example.
Real result processing is based on the assumption that in a sufficiently large sample, the proportion of healthy to 
ill individuals is substantially higher, and that if an appropriate result evaluation method is used, the reference interval 
limit estimates obtained will correspond to a healthy population. However, reference intervals obtained using this 
method will be wider than those obtained using the direct method, with a possible shift towards values typical of an 
ill population. In addition, this method prevents any objective estimation of the probability density distribution type in 
the healthy population.
Brief overview of the method (Baadenhuijsen):
• Histogram plotting (about 50 classes, at least 1200 values);
• Data smoothing using the Golay-Savicky filter;
• Plotting the derivation of measured value frequency to concentration logarithms;
• Calculation of intercept (a) and slope (b) of the straight line plotted in the linear part of the dependence;
• μ = a/b;  σ = -1/b;
• Reference limits RL = μ ± 1.96 σ.
2.4. Importance of Reference Interval when Interpreting Results
The reference interval is used in practice in interpreting measurement results by defining the limits of a “normal” 
finding, i.e. the range within which the result of a healthy individual is supposed to lie. To provide more descriptive 
information, laboratory result reports often supplement the numerical result with a graphical representation of the 
result position against reference limits. This is usually only a schematic illustration of whether the measurement result 
lies within or outside the reference interval (example: the use of * = result; within or outside brackets = reference in-
terval). However, should a physician automatically interpret a measurement result lying outside the reference range as 
a pathological finding, regardless of how far the result is from the reference limit, it would be a grave mistake.
It should be borne in mind when evaluating laboratory test results against the reference interval that the reference 
interval is plotted using estimates of its limits. This means that these limits are not points but intervals, and so for each 
limit there is a confidence interval to express the area where the actual limit is located with a certain confidence level.
In the first place, be cautious when interpreting results which occur near reference limits, regardless of whether 
they are within or outside the reference interval. In addition, measurement result uncertainty, an attribute inherent 
in every analytical method, plays a role in such borderline situations. Due to such uncertainty, even a measured result 
has to be understood not as a point corresponding to its value but also as an interval where the measurement result 
occurs with 95% probability.
It follows from the above that there can be a non-zero probability in these cases that the real measurement result 
can be on the opposite side of the actual reference limit.
In addition, it must be realized that interpreting laboratory results using the 95% reference value interval also 
includes the following proviso: even in a healthy individual there is a 5% probability that their result will be lower (2.5% 
probability) or higher (2.5% probability) than the lower or upper reference limit.
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3.1. Introduction
Inherent in every measurement, and therefore in every method used in biochemistry laboratories, is a typical set 
of properties, generally referred to as the performance characteristics of the method. Their level indicates the options 
for measurement made using this method, which is why they are a determining factor in the usability of the method 
for the required application.
The level of analytical properties of the method is also a determining factor in the use of the method for clinical 
purposes. Therefore, every physician who uses measurement results should be aware of the basic analytical properties 
of the method used.
The process, the aim of which is, besides determining the functional characteristics of the method, to compre-
hensively evaluate the suitability of the method for the intended clinical purpose, is called method validation. Reali-
zation of this process is an integral part of method development. Basic analytical properties of the method are also 
checked before the method is first used in the laboratory, and they are likewise regularly checked during routine use of 
the method. This process is known as verification of the method.
The set of operations carried out in the laboratory aimed at ensuring the adequate likelihood of measurement 
results is wider in scope. These activities are generally referred to as quality control.
This set of activities is primarily intended to assure the quality of the analytical process in the clinical laboratory. 
In line with general trends, even medical laboratories implement comprehensive quality management systems to ma-
nage all laboratory operations; their aim is not only to maintain but also gradually improve the quality of laboratory 
services provided. The implementation of these mechanisms in laboratory management is inspected and certified by 
independent bodies in certification or accreditation processes, and is also increasingly required by healthcare payers.
3.2. Performance Characteristics of the Analytical Method
The basic analytical properties of the method undoubtedly include two terms referred to as precision (in Czech: 
preciznost) and trueness (in Czech: pravdivost). Their combined projection in a specific measurement result then con-
stitutes the property of the result referred to as accuracy (in Czech: přesnost).
3.2.1. Precision 
Precision is the closeness of agreement between independent measurement results obtained under pre-specified 
conditions.
Measurement precision is expressed numerically by measures of imprecision, which define dispersion between 
independently obtained results, such as standard deviation, variance, or coefficient of variation.
Precision is the evaluation of the impact of random errors in measurement that can never be eliminated and whose 
magnitude is inherent in a certain method or specific measurement procedure. These errors are caused by accidental 
effects (instability of instruments, fluctuation of ambient measurement conditions such as temperature, variations in 
the operator’s actions, etc.). Their action results in differences between repeated measurement results. If there is a suf-
ficient number of repetitions, they are uniformly dispersed around their average value due to the randomness of their 
origin. Minimum deviations are most frequent and their number decreases with the increasing value of deviations. The 
distribution of deviation frequency corresponds to the normal (Gaussian) distribution. The measure of dispersion, i.e. 
the imprecision of results, is the standard deviation s. Since it is expressed in units of the measured quantity (measu-
rand) and depends on its magnitude, use of a relative expression of standard deviation, i.e. the coefficient of variation 
CV expressed in % (sometimes also referred to as the relative standard deviation), is preferred.
The precision of the method is not the same throughout the method’s working range. The dependence of preci-
sion on the measurand magnitude is called precision profile, and is an important scale of quality of the measurement 
method. The CV reaches lowest values in the middle area of the measurement range, whereas values grow towards the 
ends (growth is significant especially in the area of very low values of the measurand). The magnitude of imprecision is 
affected by the actual working range of the method. One condition for its selection might be that CV should not exceed 
the required level, 10 % for example - see Figure 6.
The specified measurement conditions in the precision definition could be conditions of repeatability or reprodu-
cibility.
The condition of measurement repeatability covers the same measurement procedure, operating staff, measuring 
system, working conditions, the same site and repeating the measurement on the same or similar object over a short 
period of time.
The condition of measurement reproducibility covers different sites, operating staff, measuring systems, and re-
peating the measurement on the same or similar object. The relatively large freedom in the setting of these conditions 
always requires detailed specification as to which factors were variable.
Specific conditions of reproducibility involving measurements made using the same procedure, on the same site, 
and by repeating the measurements on the same or similar objects, but over a more extended period of time, are 
referred to as conditions of intermediate measurement precision. Measurement over a longer period of time may 
involve the effect of other variable factors such as changes in calibration or calibrators, use of a different lot of reagents 
or a change of operators. Precision determined under these conditions is the best measure of the quality of method 
execution in specific laboratory conditions.
3.2.2. Trueness
Trueness is the closeness of agreement between the average value obtained from a large series of measurement 
results and either the actual value or an accepted reference value x0. The measure of method trueness is its bias b:
or, in the relative expression:
The actual (true) value of the measured quantity (measurand) is in practice inaccessible on principle, and could 
only be obtained by perfect measurement. Therefore, it is replaced by an accepted reference value as the best pra-
ctical approximation of the actual value of the quantity. The reference value is usually obtained based on a quantity 
measurement using a generally accepted reference method or other generally recognized process (by measurement in 
selected reference laboratories, etc.).
Method trueness is determined by the existence of a systematic error incidental to measurement. This kind of 
error may affect the measurement result either in a constant way (results are shifted always by the same value), pro-
portionally (always by the same multiple), or in a combination of these two ways. In this connection, we speak of the 
constant and the proportional components of systematic error.
While random errors cannot be avoided during measurement (only their magnitude can be influenced), systematic 
measurement errors can sometimes be eliminated or at least partially corrected by appropriate adjustment.
3.2.3. Accuracy
Accuracy is the closeness of agreement between the result of a measurement and the true value of a measurand. 
This property applies to one measurement result and is actually the current expression of the combination of the 
precision and trueness of a method. It is the contribution of the Random Error (RE) and Systematic Error (SE) that oc-
curred at the moment of a specific measurement. The sum of these contributions is referred to as the Total Error (TE) 
of measurement.
As mentioned above, the measure of the contribution of the random error component in a given method is expre-
ssed by an estimate of standard deviation s; the measure of the contribution of the systematic error component is the 
deviation b. By using these two parameters, the method can be characterized by estimating the total analytical error 
TEA occurring in the measurement:
The estimate confidence level is expressed by the coefficient k that is equal to the corresponding quantile of the 
selected one-sided confidence interval (1.65 for 95 % and 2.33 for 99 %).
Besides the two aforementioned characteristics, the clinical applicability of the method is also affected by the na-
tural diversity of the observed parameter in the normal population, called the biological variability of the parameter 
(tested analyte). With respect to the origin of the contribution to overall biological variability, interindividual (among 
different individuals of the population) and intraindividual (within the same biological individual) variability is distin-
guished, and if coefficients of variation are used for their relative expression, they are usually denoted as CVG or CVI, 
respectively. The specific values of both contributions for many significant biological parameters have been monitored 
and published in the technical literature.
In terms of assessing a method’s clinical applicability, it is desirable that the relative analytical precision CVA of the 
method should be optimally better than a half of intraindividual biological variability, i.e.
It is required for the acceptable relative analytical trueness BA of the method that it should be better than a quarter 
of the total biological variability, i.e.
Thus, for the total analytical error TEA of the method to be acceptable there follows the requirement that:
The values of the analytical precision of the method and the intraindividual variability of the analyte are used 
to compute the Critical Difference CD (sometimes also referred to as the Least Significant Change LSC) between two 
consecutive patient results. This is the difference between two measurement results that can be, depending on the 
aforementioned characteristics, indicated as significant at the selected confidence level with certain probability, usu-
ally 95 %. It is a parameter that indisputably plays an important role in the clinician’s decision-making process when a 
laboratory result changes over time.
3.2.4. Relationship between the Precision and Trueness of a Method
As mentioned above, the mutual interaction of the two characteristics over a certain period of measurement re-
sults in a specific accuracy level of the measurement result (see Fig 1).
Figure 3.1. The relationship between the terms of precision, trueness and accuracy of measurement
The overall quality of a method can be evaluated in relation to the levels of both characteristics. This relationship is 
illustrated using the example of target shooting shown in Figure 2. As the quality of the method improves, so another 
property of the method namely uncertainty (see below), also improves.
Figure 3.2. Relationship between precision and trueness of the method and their effect on the uncertainty of the me-
thod
3.2.5. Measurement Result Uncertainty
Uncertainty is a parameter associated with the result of measurement which characterizes the measure of disper-
sion of values that could reasonably be attributed to the measurand.
The concept of uncertainty has replaced the previous concept of error in contemporary metrology. Unlike the 
previous concept, this latest better describes the fact that a measurement result is just an estimate of reality with a de-
gree of uncertainty. This means that it is not a point estimate differing from reality by a specified error; rather that the 
measurement result lies with certain confidence within a bounded interval of possible values. Knowing the uncertainty 
allows measurement results to be better compared between each other or with reference intervals, for example. An 
estimate of the measurement result uncertainty obtained using a method is also part of its validation, where it is used 
to assess whether the method is adequate enough for the required purpose.
The principle of determining the uncertainty consists in evaluating effects that can affect the measurement re-
sult, and subsequently in estimating an interval for which we can state with a specified measure of confidence that it 
contains the actual measurand value. The total uncertainty is the result of the composite action of many sources. The 
effect of each one is their individual contributions to the resulting uncertainty. This contribution is referred to as a com-
ponent of uncertainty. The quantification of the contribution of certain components can be obtained from statistical 
distributions of measurement series results characterized by their experimental standard deviation (A-type uncerta-
inty components). The quantification of the contribution of other components is obtained from probability functions 
based on experience or other information (B-type uncertainty components). The numerical value of each uncertainty 
component transformed into the standard deviation is called standard uncertainty and denoted as ux (the index x ex-
presses its relation to the component x). Insignificant standard uncertainty contributions are ignored, and the rest are 
aggregated under the propagation of uncertainty rule into the combined uncertainty uC:
Note: The above algorithm is a very simplified method of measurement uncertainty estimation and does not con-
stitute the only possible procedure.
In practice, measurement results are accompanied by the expanded uncertainty UC, which is actually a combined 
uncertainty multiplied by the expansion coefficient (coverage factor) k so that the uncertainty estimate corresponds 
to the required confidence level. The coefficient value for 95% probability is 1.96, but the rounded value 2 is usually 
used in practice:
The specific measurement result is then presented as a value determined by measurement and is accompanied by 
expanded combined uncertainty, for example: 132 ± 6 nmol/l.
In addition to uncertainty sources associated with the analytical method itself, the resulting uncertainty of a mea-
surement result also includes contributions from sources inherent primarily in the pre-analytical phase of the test. See 
Figure 3.3.
Figure 3.3. Main sources of laboratory test uncertainty in a clinical laboratory
The importance of indicating uncertainty consists not only in the expression of a certain measure of the indeter-
minacy of a result, which may occur with a given probability within the entire bounded interval, but also the result 
uncertainty has to be taken into account when interpreting the result against decision limits, especially if the result is 
close to these limits.
3.2.6. Traceability of the Method
The traceability of a method is the property of a measurement result whereby the result can be related to a refe-
rence through a documented unbroken chain of calibrations, each contributing to the measurement uncertainty.
This is a very important property of the method in respect of reaching its optimum trueness. If within the method 
each of the quantity inputs included in the measurement model is traceable to a basic SI unit, then the traceability of 
the method can be considered optimally ensured and the results of measurement are qualified as comparable on a 
worldwide scale. This means in practice that particularly the calibrators used in the measurement process are required 
to be traceable to standards of higher metrological quality. This principle is ensured by the existence of a hierarchical 
structure of reference materials and methods, through which the working calibrator is gradually traced to the very 
highest standard, to an SI unit in optimal cases. This hierarchy also comprises different entities responsible for perfor-
ming individual steps.
Figure 3.4. Hierarchy of calibration and metrological traceability to SI
Note: according to ČSN EN ISO 17511:2004;
CGPM – General Conference on Weights and Measures; BIPM – International Bureau of Weights and Measures;
NMI – National Metrology Institute; ARML – Accredited Reference Measurement Laboratory; MCL – Manufacturer’s 
Calibration Laboratory; ML – Manufacturer’s Laboratory; Mf - Manufacturer
Several types of standards (reference materials) occur at different levels:
• Primary reference material – substances of maximum attainable purity; the materialized measurement 
unit is produced by weighing or measuring its volume;
• Secondary (certified) reference material – usually a matrix (protein matrix content); it is accompanied by 
a certificate declaring the analyte content, determined using a method traceable to the primary reference 
material (usually a reference method with minimum uncertainty);
• Working calibrator – intended for routine method calibration; their values are derived from certified refe-
rence materials or manufacturer’s working calibrators traceable to them.
Testing the traceability of the method is an integral part of the method validation process.
3.2.7. Sensitivity of the Method
In practice, several characteristics referred to as sensitivity are used. They relate to the ability of a method to distin-
guish between certain levels of the measurand (mainly in the area of very low values). Various attributes or separate 
terms are used to distinguish between the characteristics (analytical sensitivity, functional sensitivity, detection limit, 
or limit of determination).
Caution! It must be kept in mind that these characteristics describe the method in terms of their analytical pro-
perties. However, the term “diagnostic sensitivity” is also often used in clinical practice to characterize the method in 
terms of its clinical usability, which is usually its ability to distinguish healthy individuals from ill ones. Diagnostic sensi-
tivity is described in detail in chapter 4 Sensitivity and Specificity of the Method, Interrelations, Laboratory Screening.
3.2.7.1. Analytical Sensitivity
Analytical sensitivity is the ratio of change in the response of measuring equipment (measuring device output sig-
nal) to the corresponding change in the stimulus (input signal, measurand). In other words, analytical sensitivity points 
to the size of change in the detected response caused by a change in the measurand.
It is constant in linear methods and corresponds to the slope (gradient) of the calibration curve. Analytical sensitivi-
ty in non-linear methods will naturally change with the change of the calibration curve slope. The analytical sensitivity 
of the method depends primarily on the principle of response detection used.
Figure 3.5. Determining the analytical sensitivity ca of the method
3.2.7.2. Functional Sensitivity
Functional sensitivity of the method is the measurand value (e.g. the measured analyte concentration in the sam-
ple) where the repeatability of measurement is at a pre-defined level (usually CV = 20 %). It is simply found from the 
precision profile, which is the dependence of the precision of the method on the measurand magnitude (see Figure 6).
Figure 3.6. Determining functional sensitivity cf from the precision profile of the method
3.2.7.3. LD – Limit of Detection
The limit of detection is the lowest amount of analyte in a sample that can be detected (distinguished from zero), 
but not necessarily quantified as an exact value with certain uncertainty. This limit value separates the area of noise of 
the detection device from a detectable signal.
It is usually determined from the data of sample measurement with zero measurand content (blank) under condi-
tions of repeatability (5 – 10 repetitions). The measured response values are used to compute the average yB and the 
standard deviation sB. The measurand value corresponding to the signal is then read from the calibration dependence:
3.2.7.4. LQ – Limit of Quantification
In contrast to the above, the limit of quantification defines the lowest amount of analyte in a sample (measurand 
value) that can be quantitatively determined as an exact value with the required measure of uncertainty.
The calculation is similar to LD, only the coefficient 3 is replaced by 6 or 10, depending on what measure of uncer-
tainty, or confidence level, is required. The measurand value corresponding to the calculated signal level is then also 
read from the calibration dependence:
The results of measurement under the limit LD cannot be issued, and results between LD and LQ can be only consi-
dered as qualitative results.
Figure 3.7. Determining the limits of detection and quantification 
3.2.8. Linearity of the Method
This is understood as the linear dependence between two random variables, i.e. between the signal (measured 
response of the analytical method) and the measurand. In other words, it is the ability of a method to provide a de-
tectable measurement response that is directly proportional to the measurand magnitude within the given range (e.g. 
the analyte concentration in the sample). It is advantageous if the method works in the area of linear calibration de-
pendence because only two measured points, the blank and one calibrator are then sufficient to plot the dependence 
(a two-point calibration is made). After reading the blank signal, the linear calibration dependence is then defined 
practically by a single number, the calibration factor F that can be easily determined from the quotient of the known 
measurand value in the calibrator xK and the corresponding calibrator signal response magnitude yK. This factor and the 
measured sample response y then can be used to easily determine the measurand value x in the sample.
If the linear area of the method is limited from above and samples with a greater measurand value need to be 
analyzed, then appropriate dilution of the sample should be selected.
3.2.9. Working Range
The working range of the method is a closed interval of measurand values that can be determined using a measu-
ring procedure, whereby the interval is most commonly limited by the lower and upper limits of quantification (provi-
ded measurement uncertainty in this area is acceptable) or the range of linearity of the method. See Figure 8.
In practice there are, however, also many methods with non-linear behaviour of the calibration dependence. Two-
-point calibration is obviously not sufficient in such cases. The calibration curve is usually plotted based on the mea-
surement of at least 6 calibrators, while the calculation of the measurand value in an unknown sample is much more 
complicated in this case since a more complex mathematical apparatus has to be used. The working range of the met-
hod is then limited in the upper area of the calibration dependence by other limiting factors (the limit of quantification 
in the area near 0).
Figure 3.8. Effect of the limit of quantification and linearity on the working range of the method
3.2.10. Analytical Specificity
Analytical specificity is the ability of the measuring procedure to determine only the measurand intended for de-
termination.
Analytical specificity is usually expressed as non-specificity, i.e. as the effect of any sample component other than 
the analyte that causes a change in the signal and measuring device indication, thereby introducing a systematic error.
The analytical specificity of the method can be worsened, for example, by the presence of various interferents, 
components commonly present in the biological matrix of analyzed samples. The effects of elevated triacylglycerol, 
bilirubin or haemoglobin levels are most commonly studied as potential sources of interferences. Also drugs and their 
active agents may have a marked effect on the course of reactions during the analysis.
Cross-reactions with substances having a structure very similar to the studied analyte occur in some method types 
such as immunoanalytical methods. These are usually various precursors or metabolites of the analytes, aggregated 
molecules or their grafts containing identical active sites or antigenic determinants.
Immunoassays as methods based on the use of specific antibodies can also be affected by the presence of various 
heterophilic antibodies in the analyzed samples. The effect of HAMA (Human Anti-Mouse Antibodies) is often menti-
oned because their occurrence in the population is growing. The measurement result may be affected in these cases 
both positively as well as negatively.
The effect of cross-reacting or interfering substances is also connected to contributing to measurement uncertain-
ty. Determining the content of any interfering analyte present in the biological sample matrix increases measurement 
uncertainty due to an increase in the systematic error.
The action of cross-reactions or interferences on measurement results is difficult to evaluate. Experimental pro-
cedures do exist but they are almost impracticable in routine clinical laboratory conditions. They are based on the 
presence of a sufficient amount of individual potentially cross-reacting substances or interferents. Testing their effect 
should be part of the method validation. One common way of presenting this information is, for example, stating what 
amount of some interfering quantity does not cause a measurement deviation greater than 10 %.
3.2.11. Recovery
Recovery is a property of the method indicating the method’s ability to cover the entire analyte present in the 
sample with the measured signal, and so it relates to the overall trueness of the method. It is a measure of efficiency 
of the method.
Recovery also identifies any influence of the differences between the composition of samples and standards on 
the assay results.
In mathematical terms, recovery is defined as the ratio or percentage of substances obtained under specified 
conditions from the total amount of substance that should be theoretically determined. It is obvious from the relative 
expression that calculated values of this characteristic should tend to 100 %.
where: 
R(a)…Recovery of analyte assay in the matrix under specified conditions
Q(a)…Amount of analyte determined by the assay
Q ... Actual amount of the analyte in the matrix
3.2.12. Robustness of the Method 
This property describes the ability of a method to provide acceptable measurement results despite small deviati-
ons in the measurement procedure or sample composition. There are many factors that may change slightly in the 
course of the process; typically these include a slight change in temperature or reaction environment, a change in 
incubation times, change of operator, etc. It is obvious that the aim is to have an analytical method whose response to 
the slight deviations that can commonly occur in practice is minimal.
3.2.13. Comparability of the Method
As a general requirement, methods used for measuring the same quantity should be mutually comparable. Prima-
rily this is a precondition for the compatibility of results obtained using different methods. Comparability of the met-
hod is also important if the method used in the laboratory is changed and a new method is compared with a previous 
one. It is clear that existing differences may be a source of problems when results are interpreted.
Different regression analysis procedures are used to compare the results of two methods when pair data obtained 
by parallel analysis of a set of samples are evaluated using both methods. The output is the evaluation of linear re-
gression and the significance of the differences of their parameters from optimum values (the regression line intercept 
close to 0 and its slope close to 1). It is performed jointly by evaluating the level of correlation between the results of 
both methods. In the optimal case, the correlation coefficient r should have a value close to 1, i.e. the pair data should 
be assembled as close as possible to the regression line. Another form of output is a graphical presentation of the com-
parison. Results obtained using the comparative method (reference/original method) are plotted against each other on 
the x-axis of the diagram, and results obtained using the compared (new) method on the y-axis – see Figure 9.
Figure 3.9. Example of graphic comparison of two methods together with regression dependence
3.3. Validation and Verification of Methods
As mentioned in the introduction to the chapter, the basic characteristics of the analytical method are tested at 
the stage of method development with the aim of confirming that the method complies with the requirements for its 
intended use. This process is called method validation and also includes the evaluation of the method in terms of the 
intended clinical use. This is a very demanding and complex process that has to be planned in detail beforehand and 
the process steps and results have to be carefully documented. The process output is a validation report that clearly 
concludes whether the method is suitable for the given intended use.
European legislation requires that manufacturers or importers of in vitro diagnostic medical devices (IVD MD) 
should affix the CE marking to the devices before putting them on the European market. Requirements for the confor-
mity assessment may vary depending on the diagnostic device classification, but they always also involve diagnostic 
agent validation. The use of commercial diagnostic devices is a prevalent trend in the current routine practice of clinical 
biochemistry laboratories. If a laboratory develops their own analytical method or modifies a commercial method, the 
requirement for method validation is transferred to the laboratory personnel.
Method verification is performed to a much lesser extent, and only verifies whether the diagnostic agent also 
fulfils the selected declared properties when used in a specific laboratory. The method is verified in this way not only 
before putting it into practice, but also subsequently at appropriate intervals, usually once a year. The basic characte-
ristics of the method verified in the verification process primarily include repeatability and the intermediate precision 
of the method, including the estimate of uncertainty.
3.4. Quality Control
The term quality control generally refers to a set of activities performed in a laboratory with the aim of ensuring 
the sufficient likelihood of measurement results. These activities in practice only impact upon ensuring the analytical 
confidence of the methods used. Depending on who takes part in such activities, quality control is further divided into:
• Internal Quality Control (IQC) – performed only by lab personnel;
• External Quality Assessment (EQA) – external entities are called in to organize and evaluate.
3.4.1. Internal Quality Control
This type of control is performed by continuously monitoring the intermediate precision and/or trueness of the 
method, and is achieved through the continuous measurement of the control samples analyzed in every assay series. 
Knowledge of the target measurand value in the control sample is required only to monitor the trueness of the met-
hod. This option is offered, for example, by various commercial control samples with a test certificate. In other cases, 
samples without a test certificate can also be used for precision monitoring, while an alternative procedure can be 
chosen for monitoring trueness.
A series of assays usually refers to the length of one working shift, for continuous or automatic shift operation, or 
one assay made in a group (batch) of samples, for manual methods.
The number of control samples is not strictly defined and depends on knowledge of the overall quality level of the 
given method. In practice, 2-3 samples with different measurand value are commonly used. It is a good idea to use one 
control sample with this value within the reference interval, and the other one outside the reference interval, above 
the upper limit, for example.
The results of control sample measurements are assessed in connection with results found at an earlier stage. In 
principle, this means monitoring the magnitude and character of current control sample measurement errors, with 
the aim of identifying situations that are unacceptable in terms of stipulated quality requirements and avoiding issuing 
inadequate results by taking operative measures.
The commonest form of this monitoring is visualising the results in diagrams known as control charts. This method 
is based on evaluating the measurand value fluctuation around the central line of the chart (target/declared measu-
rand values); the allowable range is given by the interval between the lower and upper control limit. These limits are 
usually an appropriate multiple of the standard deviation derived from the intermediate precision of the method rea-
ched in the previous period. An example of a control chart is shown in Figure 10.
Figure 3.10. Example of a control chart without suspicious results
Two limits are plotted in the chart in most cases – the warning limits at the ±2s level and the control limit (requiring 
intervention) at the ±3s level. If the deviation of the control measurement result exceeds the value 3s, this is a signal 
to search out the possible cause of the deviation and to take operative intervention; one such intervention might be to 
repeat the whole series of sample measurement preceding the assay of controls.
The control chart also shows other situations that may require intervention, for example, if control results repea-
tedly deviate from the centre line always in the same direction, or if consecutive results have the same trend (see Fig. 
11).
Figure 3.11. Control chart with different types of anomalies
Algorithms aimed at obtaining the maximum probability of error detection with the minimum probability of false 
series rejection (combined Westgard rules) have been developed to ensure the greatest possible objectivity in asses-
sing internal control results. Today, these algorithms are part of control software analyzers and are also often built into 
laboratory information systems (LIS), which contributes making evaluation simpler. Some manufacturers of reagents 
or commercial control samples also offer an option to automatically submit control measurement results through the 
Internet to an assessment centre, where they are evaluated in the context of other users of the same control materials 
(example: BioRad, Randox, etc.). This method of the internal quality control in some respects comes close to an exter-
nal assessment.
3.4.2. External Quality Assessment
The principle of the External Quality Assessment (EQA) is the evaluation of an analytical method by the mutual 
comparison of measurement results obtained through the analysis of identical samples in different laboratories. This 
evaluation is organized and performed under predefined and harmonized conditions (in accordance with applicable 
standards and terms of the region where the evaluation is made).
The EQA arrangement and evaluation is provided by a generally recognized entity – EQA provider. SEKK s.r.o. is the 
provider for clinical biochemistry tests in the Czech Republic. In addition, there are many foreign EQA schemes. The 
measurement itself is of course carried out in the participating laboratory. Control measurements are usually provided 
several times a year as part of various EQA schemes.
The EQA process consists of the following steps:
• Distribution of identical control samples to laboratories; the samples must be as commutable as possible 
(i.e. have properties similar to the properties of samples analyzed on a routine basis), must be homoge-
neous and stable enough so that the requirement for all participants having the same conditions is met;
• Participating laboratories perform assays concurrently within a specific scheme, and send their results to 
the scheme provider on a prearranged date;
• The results are evaluated by the provider using predefined principles and criteria made known to the par-
ticipants in advance;
• The evaluation of results is summarized in a pre-arranged format in writing and distributed to the partici-
pants; the information is presented as confidential, with anonymous participants identified by codes.
In general, several samples are distributed in one EQA round (mostly 2 samples, but there are control schemes 
where 5 samples are distributed in one round). The agreement of the participant’s result with the assigned value (tar-
get value) is assessed during the evaluation. Several types of assigned value can be distinguished depending on the 
level of traceability of the measurement of a variable and the availability of control material. If a reference method for 
measuring the variable exists, a Certified Reference Value (CRV) can be the assigned value. Another alternative is the 
Consensus Value from Experts (CVE), a value obtained by measurement in selected expert laboratories, or the Consen-
sus Value from Participants (CVP), a value computed either from the results of all participants in a specific EQA round 
or from the results of a group of participants using the same measurement procedure. 
To assess agreement with the assigned value, maximum tolerance limits are specified and must not be exceeded 
if the participant is to be rated as successful. These limits express the acceptable difference Dmax in percent from the 
assigned value (they define the neighbourhood of the assigned value where results are considered acceptable). This 
value is compared with the deviation D% computed simply as the relative participant’s error from the participant’s 
result x and the assigned value X:
Despite various providers’ efforts towards unification, the specific level of allowable deviations differs. Some of the 
following possible approaches can be applied to determine them:
• Based on biological variances (intra- and inter-individual variability of the measurand within the populati-
on is taken into account in the calculation);
• Based on contemporaneous analytical possibilities (e.g., as a value of interlaboratory precision reached in 
20 % of the best laboratories per EQA round).
From the limit applicable to a certain analyte in the EQA scheme, the limit for an internal check can also be derived, 
and compliance with the limit should ensure successful EQA evaluation. In simple terms, the limit for the internal check 
(limit of acceptable intermediate precision of the method) should be one third of the EQA limit. 
The evaluation involves a simple assessment whether the laboratory deviation D% is lower than Dmax. For an EQA 
round participant to be successful, the absolute value of the ratio of both values, referred to as the P-score, is lower 
than 1:
Some EQA schemes use a different assessment method based on the z-score to assess participant success. This 
score measures the deviation of participant’s result x from the assigned value X and the detected interlaboratory pre-
cision of the EQA round participants’ results expressed as a standard deviation. For a participant to be successful, it is 
required that the absolute value z be lower than 3 (values under 1 are considered very good and under 2 acceptable):
The successful participation of a laboratory in EQA schemes is a mark of the quality of its work, and is required not 
only by authorities auditing the functioning of the laboratory’s quality management system, but also by healthcare 
payers. Beside this somewhat repressive aspect, EQA schemes have a significant educative character consisting, for 
example, in the comments from authorized experts (supervisors) attached to audit round results, the provision of con-
sultations, publication of articles in journals, etc.
3.4.3. Quality Management System in Clinical Laboratories
The responsible approach to ensuring the quality of clinical laboratory work cannot be reduced to simply ensuring 
the quality of the analytical process. In line with general trends, comprehensive Quality Management Systems (QMS) 
are also put into practice in clinical laboratories. In addition to ensuring the quality of the actual measurement of vari-
ous quantities, emphasis is given to managing all laboratory operations with an eye to quality.
This concerns not only the actual management of the laboratory, including the provision of high-quality resources 
(personnel, hardware, laboratory environment and resources used for analysis), the maintenance of proper supplier-
-customer relationships and responsible behaviour towards laboratory service customers, but also organizing work 
to ensure that all pre- and post-analytical analysis requirements are met, information is obtained and stored in the 
laboratory information system, etc.
In order for QMS to function properly, all lab processes and operations should be responsibly described and do-
cumented, and subsequently maintained as controlled documents. This creates a situation where only currently valid 
documents exist in the laboratory; outdated versions are filed and any records related to lab operations required later 
continue to remain retrievable. The availability of uniform and complete documents to all laboratory personnel for 
their work is a precondition for the reduction to a minimum of serious errors caused, for example, by the flawed trans-
fer of information.
QMS documentation typically has the following structure:
• Quality Manual describing the whole system;
• Guidelines and rules characterizing the basic laboratory processes;
• Laboratory Manual, a document primarily informing laboratory clients about the services offered and con-
ditions of service provision; 
• Standard Operating Procedures describing the steps of individual analytical methods and the operation of 
technical equipment;
• Records on the use of technical equipment and the quality of measurements.
3.4.4. Certification and Accreditation
As in other industries, health care providers have also been recently under growing pressure over their ability to 
prove the care taken over the quality of their work. These pressures can be enforced by regulating mechanisms within 
the society, or they can reflect an entity’s effort to succeed in the market environment, or they might simply represent 
a voluntary effort to present their qualifications for achieving the commensurate quality of their work.
Today, two major internationally recognized and supported mechanisms are in force attesting to the implementati-
on of a functioning QMS, or that certify a certain entity’s capacity to perform specified activities. The first is the certi-
fication of QMS compliance with the requirements stipulated by the internationally recognized standard. The second 
is accreditation, a process confirming whether the competence of a certain entity also complies with international 
standard requirements.
The general requirements for a functional QMS are summarized in the standards of the ISO 9000 series, specifically 
in ČSN EN ISO 9001. This standard specifies requirements for a QMS implemented at any entity so that the system is 
set correctly and works towards ensuring the quality (and improvement) of such entity’s operations. At present there 
are many certification bodies, i.e. legal entities, who assess an applicant’s QMS compliance with the requirements of 
the standard mentioned above. There are also many companies (different organizations in general, but also including 
some clinical laboratories) that are holders of such certificate. Nevertheless, this method is not particularly popular in 
Czech healthcare or, more particularly, in medical laboratories.
The requirements specified in ČSN EN ISO 15189 particular to medical laboratories are better suited to the specific 
conditions of the work such undertakings carry out. For this reason, in the clinical laboratory sector the process of 
accreditation to certify laboratory proficiency in accordance with standard requirements has been adopted to a much 
greater extent. Within any one country accreditation is usually provided by a single national accreditation body; in the 
Czech Republic this is the Český institut pro akreditaci, o.p.s. (Czech Accreditation Institute or ČIA).
A similar process is the system for testing how the system of laboratory work has been set up, which is organized 
by the Národní autorizační středisko pro klinické laboratoře (National Authorization Centre for Clinical Laboratories 
or NASKL). This body of the Czech Medical Association performs educational audits of labs registered in the Clinical 
Laboratory Register. Two consecutive audits I and II test whether the laboratory complies with requirements specified 
in national accreditation standards. The content of these requirements is very similar to those stipulated by ISO 15189. 
Both the above forms are continuous processes repeated over time in the form of re-audits and regular monitoring 
activities.
Proof of care of laboratory quality is currently a necessary condition laid down by some healthcare payers prior 
to concluding healthcare payment contracts with healthcare providers. For example, Všeobecná zdravotní pojišťovna 
(VZP) health insurance company recognizes only one of the previous alternatives, i.e. the ČIA accreditation or the 
NASKL certificate for audit II. The requirement for functioning processes that ensure laboratory quality thus fulfils the 
analogous role of regulatory mechanisms, virtually allowing the provision of clinical laboratory services only to those 
laboratories that have undergone these processes successfully and hold the required certificates.
CHAPTER 4
4. Diagnostic Sensitivity, Specificity of the Method, Methods of Determination, In-
terrelations, Laboratory Screening
Authors: Ing. František Všianský; Ing. Vladimír Bartoš, Ph.D.
Reviewer: Ing. Václav Senft
4.1. Introduction
Apart from the basic analytical characteristics of the method, persons evaluating laboratory methods must also 
know the clinical (diagnostic) characteristics of the method in accordance with the patient diagnosis. These characte-
ristics allow the efficiency of biochemical methods to be compared in respect of their ability to distinguish between 
the healthy and the diseased.
Calculations of these clinical characteristics are based on a four-fold table, where a set of individuals is divided into 
a group of healthy and diseased individuals based on a definitive method, and the individuals have been examined by 
the tested laboratory test. Depending on the laboratory method result, the individuals can be divided into 4 groups:
• The diseased with a positive test result (True Positive – TP);
• The diseased with a negative test result (False Negative – FN);
• The healthy with a positive test result (False Positive – FP);
• The healthy with a negative test result (True Negative – TN).
Healthy Diseased
Positive test FP TP
Negative test TN FN
This situation can also be shown on a graph where the x-axis represents the measurand value, the tested analyte 
concentration, for example, and the y-axis represents the relative frequency of this quantity occurrence in the group 
of healthy individuals (left-hand curve) and in the group of diseased individuals (right-hand curve). The picture is only 
illustrative; mutual position and the forms of the two curves will naturally vary for each method.
4.2. Diagnostic Sensitivity and Specificity of the Method
These terms are often confused with analytical sensitivity and specificity (often just because only sensitivity and 
specificity are mentioned). However, they characterize the smallest amount of analyte the method is able to capture 
and whether the method specifically detects just one substance. Therefore, they are not relevant at all to the ability of 
the method to distinguish between the healthy and the diseased.
4.2.1. Diagnostic Sensitivity
This parameter is used to diagnose the disease, and evaluates the ability of a laboratory method to detect the 
presence of a disease. Diagnostic sensitivity takes values from 0 to 1 (0 – 100 %). The higher the sensitivity, the better 
is the ability of the test to detect the presence of a disease.
4.2.2. Diagnostic Specificity
This is used to rule out a disease in a group of healthy individuals, and expresses the probability of a negative result 
in a healthy person. Again, this parameter’s values may range from 0 to 1 (0 – 100%). It is advisable that the laboratory 
method should have the greatest possible diagnostic specificity value; the greater the specificity, the better is the abi-
lity of the test to filter out healthy individuals from the studied set.
 
4.2.2.1. Cut-Off
This is the laboratory test result value used in practice to distinguish individuals with the presence of a disease 
from individuals without the disease. Consequently this means that if the cut-off is exceeded, some action is taken 
(diagnosis is established, treatment is started, etc.). The cut-off is set to have an optimum sensitivity to specificity ratio 
for the given purpose (as high a sensitivity as possible for screening and, conversely, a high specificity to prevent a risky 
therapeutic intervention in a healthy person).
The chosen discrimination cut-off value then corresponds to specific numbers of individuals included in the groups 
– True Negative (TN), False Negative (FN), True Positive (TP) and False Positive (FP). For the given method, the chosen 
cut-off value will always correspond not only to the specific level of sensitivity and specificity attained, but also to like-
lihood or predictive values (see below).
Figure 4.1. The cut-off (e.g. selected according to expert-based consensus) is represented by the vertical line in the 
picture.
4.2.2.2. ROC Analysis
It is obvious from the calculation of the diagnostic sensitivity and specificity values of a method that both these 
characteristics of a method behave as communicating vessels. If the sensitivity of a method falls, its specificity rises 
and vice versa. The selection of a certain cut-off value is decisive for the corresponding values of both characteristics.
The relationship between diagnostic specificity and sensitivity is evaluated by the ROC analysis. (ROC stands for 
Receiver Operating Characteristic. The term dates back to World War Two when this method was used to assess the 
ability of radars to discriminate real signals from noise.) In practice, this relationship is graphically represented using 
the ROC curve.
The ROC curve is usually represented as the relationship between the true positive rate or diagnostic sensitivity 
(ranging between 0 and 1, or 0 and 100 if expressed as a percentage) on the y-axis and the false positive rate, i.e. 
1-specificity (or 100-specificity if expressed as a percentage) on the x-axis. It is sometimes also expressed directly as 
the diagnostic specificity, in which case it directly concerns the relationship between the sensitivity and specificity of a 
method. However, the range of values on the x-axis is then shown contrariwise, i.e. from 1 to 0 (or 100 – 0 %). The cur-
ve itself represents the set of points corresponding to the specificity and sensitivity always determined for the chosen 
cut-off value. The sensitivity for certain specificity and vice versa, attained using the method with the chosen cut-off, 
can then be read on the axes.
 
The evaluation criterion used is the area under the ROC curve (AUC, Area Under the Curve). The area equals 1.0 for 
the theoretically most efficient method. For an inefficient method, the curve coincides with the diagonal and the AUC 
equals 0.5. Methods can be classified in the following way depending on the AUC size.
AUC Rating
0.90 – 1.00 Excellent
0.80 – 0.89 Good
0.70 – 0.79 Fair
0.60 – 0.69 Poor
0.50 – 0.59 Fail
Comparing ROC curves for different methods also allows the clinical usability of methods to be mutually evaluated. 
A clinically more suitable (better discriminating) method has the ROC curve located more to the upper left corner, while 
the curve of a worse discriminating method is close to the diagonal.
A suitable statistical program can be used to test whether the AUCs differ from each other, i.e. whether the effici-
ency of one method is significantly better than the efficiency of another.
4.3. Other Clinical Characteristics
4.3.1. Prevalence
This is the probability of the occurrence of a disease in a population. Sometimes also referred to as an a-priori or 
pre-test probability.
4.3.1.1. Positive predictive value, PV+
This expresses the probability of the occurrence of a disease with a positive test result. It is influenced by the pre-
valence of the disease. Where prevalence is low, even an “excellent” diagnostic test has an elevated number of false 
positive results.
4.3.1.2. Negative predictive value, PV-
Expresses the probability of the absence of a disease with a negative laboratory test result. It is also dependent on 
the disease prevalence.
4.3.2. LR – Likelihood Ratio
4.3.2.1. Positive likelihood ratio, LR+
This expresses the ability of a laboratory test to capture the presence of a disease with a result higher than the 
cut-off.
It indicates how many times the probability of an increase above the cut-off in diseased individuals (relapse) is 
higher than the probability of an increase above the cut-off in a group of individuals without the disease.
4.3.2.2. Negative likelihood ratio, LR-
It indicates how many times the probability of a result below the cut-off in a group of individuals without a disease 
is higher than the probability of a result below the cut-off in a group of diseased individuals.
4.3.2.3. LR interpretation
• LR = 1 Test without any diagnostic value (ROC is exactly the diagonal of the graph; the method cannot 
discriminate between the healthy and the diseased);
• LR+ > 1 The test result is usually considered a highly positive result;
• LR- < 1 The test result is usually considered a highly negative result.
4.3.2.4. Odds ratio
The odds ratio is the ratio of the chance of a positive test in diseased individuals to the chance of a positive test in 
healthy individuals. Or, the odds ratio can be understood as the chance of a disease occurrence when the test is posi-
tive to the chance of a disease occurrence when the test is negative.
The odds ratio is used for the retrospective evaluation of studies where the numbers of patients with whom the 
study objective was/was not achieved are known. For example, the study objective can be to differentiate patients with 
the risk (chance) of a disease from patients without such risk (chance).
OR = 1 means the inability of a test to divide patients according to the test result into groups with different chances. 
The higher the odds ratio, the higher is the discriminating capability of the test.
4.4. Laboratory Screening
Screening is an organized activity with a widespread impact, intended to find people with a significant risk of a cer-
tain disease among other people in the population. The aim is to find such people at an early or subclinical stage of the 
disease so that they might benefit from their participation in the screening programme thanks to a timely intervention. 
Depending on the selected population screened for the disease, we distinguish between universal screening (congeni-
tal hypothyrosis screening) and selective screening (in the at-risk population – mammographic screening).
In order to divide a population into healthy and at-risk or potentially ill individuals, appropriately selected and, if 
possible, simple screening tests are used, either clinical or laboratory tests or a combination thereof (sometimes even 
several laboratory tests supplemented by clinical tests – Down syndrome screening).
The screening test divides the population of tested people into two groups:
• A group of individuals with a positive test and a high probability that they have the disease or are at risk;
• A group of individuals with a negative test and a high probability that they do not have the disease or are 
not at risk.
Following the primary screening test, individuals with a positive screening result undergo a highly specific dia-
gnostic test, which greatly reduces the number of people without the condition that had been formerly evaluated as 
diseased.
As in every laboratory test, the test used for screening purposes has its clinical characteristics, i.e. its diagnostic 
specificity and sensitivity.
The proportion of healthy individuals in the total number of individuals in the first group is the False Positive Rate 
(FP or FPR) of the screening test. The specificity of the screening test is the difference 1 – FP, in other words the ability 
to detect genuinely healthy individuals as being healthy.
The proportion of diseased individuals captured by the test in the total number of the diseased is referred to as the 
sensitivity of the screening test (DR – Detection Rate).
A suitable screening test is required to have the highest sensitivity possible and sufficient diagnostic specificity (a 
minimum false positive rate) at the same time. A test with low non-specificity (a false positive rate) is acceptable provi-
ded the subsequent diagnostic test in the second round rules out individuals with a false positive screening test result.
In quantitative tests there is a relationship between the two parameters, which is given by the mutual position of 
test value distributions for the healthy and affected populations (the overlap) and the position of the discriminating 
cut-off limit, which defines from what screening test value the result will be taken as a positive result.
These parameters (the specificity or sensitivity of the test) do not give us an entirely objective assessment of the 
efficiency of a screening programme. To achieve this, the prevalence of the disease must be taken into account. The 
probability that an individual with a positive screening test is genuinely ill is described by the positive predictive value 
PV+. The PV+ is greatly influenced by prevalence: if the disease prevalence is low, the PV+ will be low even in the case 
of a highly sensitive and specific test.
A characteristic of screening test efficiency describing disease prevalence is a parameter referred to as the OAPR 
(the Odds of being Affected given a Positive Result), which indicates what the chance is of a diseased individual being 
captured by the screening test. The parameter is calculated as a ratio of truly positive individuals with positive test 
results to the number of negative individuals with a positive test result:
The OAPR parameter is expressed as a ratio of two figures (example 1:20) and expresses the disease prevalence in 
a group of people selected by screening.

CHAPTER 5
5. Basic Urine Tests
Author: MUDr. Daniel Rajdl, Ph.D.
Reviewers: Doc. MUDr. Milan Dastych, CSc. MBA; MUDr. Marie Šolcová
5.1. Summary
Kidneys are organs which play a fundamental role helping to maintain an optimum internal environment throughout 
the body. The intermediary for such role is urine, and it is urine which therefore shows how the kidneys are functioning 
and reflects the blood composition. Urine is produced by filtering blood through the glomerular filtration membrane 
of nephron (1) and by subsequent modifications (reabsorption of important substances such as water and excretion 
of waste substances such as urea). These modifications take place in renal tubules. This chapter deals with basic urine 
tests that should always be an integral part of kidney examination. Further renal function tests are described in the 
chapter Kidney Function Tests.
5.2. Sample Collection and the Pre-Analytical Phase
Urine is one of the most easily obtainable biological materials and urine tests bring valuable information. At the 
same time, it is a potentially infectious biological material which requires the use of gloves and respect for all the rules 
of working with biological material. Most mistakes that may eventually irrevocably impair the urine test result stem 
from the method of collecting and storing the sample and by failure to adhere to the time to analysis. The basic types 
of clinically used samples are shown in Table 5.1.
Urine Type Typical Use Comment
First morning urine Chemical urine tests and sediment 
Pregnancy tests
See also random specimen
Second morning urine Microalbuminuria, glycosuria Microalbuminuria is expressed 
in mg/mmol creatinine
Random specimen Chemical urine tests and sediment, bacterio-
logy (cultivation + sensitivity), amylase, etc.1
Taken any time during the day
Catheterized specimen Bacteriology (cultivation + sensitivity)
24-hour urine specimen Creatinine clearance 
Waste in urine
Frequent mistakes in collection 
Example: ion waste (e.g. Na, K) 
protein, nitrogen, hormones
Short-term collection (about 4 hrs) Fractional excretion See Kidney Function Tests
Pediatric specimen2 Chemical urine tests and sediment (little 
children with nappies)
Warn parents about the difficul-
ty of the task
1  Nephron is the basic functional unit of the kidney. It consists of the glomerulus (a tuft of capillaries with a se-lectively permeable filtering membrane; blood is filtered here to form primary urine) and tubules (the basic elements are the proximal tubule, loop of Henle, distal tubule and collecting ducts). The function of tubules is to absorb, excrete and metabolize, etc.
Table 5.1. Urine samples: Basic types and use
„Non-collected” (single) urine samples in general are taken after carefully cleaning the genitals (normal washing is 
enough, immoderate use of disinfectant is not acceptable), a midstream specimen of urine is caught in the test tube (at 
least about 2-3 seconds from the start of urination). Collecting a correct sample from women during menses (without 
catheterization) is impossible.
Urine is usually collected over 24 hours (shorter intervals are also possible) using the following steps:
• After getting up in the morning, the patient urinates normally, i.e. not into the collection container.
• After that time, the patient collects all voided urine in the container(s) provided.
• The next morning after getting up (exactly 24 hrs later) the patient urinates into the collection container.
Then the entire volume of urine collected is mixed (if several containers are used, the contents should be emptied 
into one big container), measured (accurate to 100 ml) and a representative sample is taken.
Tests requiring urine collection (e.g. creatinine clearance) are being abandoned at present as collection is often 
subject to considerable error (incomplete collection, poor sample mixing, inaccurate measurement of the sample volu-
me, etc.) and is inconvenient for patients (2). So, if there is a relatively reliable alternative not involving urine collection, 
it should be preferred.
The time from sample collection to analysis, time to analysis (see below for specific examples), should be adhered 
to for each urine analyte. If this is not possible (e.g. if timely transport of the sample to the laboratory cannot be provi-
ded), preservatives that extend this time can sometimes be useful. The simplest and commonest preservatives are cold 
and dark, i.e. a refrigerator. Storage in a refrigerator prevents significant bacterial growth for about 24 hours. Before 
analysis, allow the sample to reach room temperature (otherwise amorphous phosphates and urates may precipitate 
in the sediment, and increased specific gravity may occur). Chemical preservatives are usually only suitable for one 
or a few analyses, and, as a downside, may interfere with other assays; in practice, their use is generally reserved for 
specific applications (see Pre-Analytical Phase). There are also commercially available test tubes that (according to the 
manufacturer) are able to provide reliable sample preservation for up to 72 hours (at room temperature).
Failure to deliver urine samples to the laboratory (and analyze them) in time may significantly affect the results. 
Some alterations relate to bacterial multiplication in the sample: bacteria metabolize glucose (which then decreases 
in the sample), some bacteria have the enzyme urease (which metabolizes urea in the sample to CO
2 
and NH
3
 [ammo-
nia] – which binds H+ to form NH
4
+, thus increasing the pH of the sample). In addition, ketone bodies may evaporate or 
bilirubin may oxidize (when exposed to light). Refer to the chapter Pre-Analytical Phase for more details.
5.3. Physical Properties of Urine
Physical properties of urine include density, appearance (colour, turbidity), odour or even taste (3). Density will 
be dealt with below; the other physical properties of urine usually have a very approximate or negligible diagnostic 
significance.
Appearance of urine can be the main reason why the patient visits the doctor. Normal urine is straw-yellow and 
the intensity of this colour usually roughly corresponds to urine density. Normal urine is also clear, without turbidity 
(unless there has been sample collection error or artificial alterations due to urate/phosphate precipitation when sto-
red in the refrigerator). The commonest pathological urine colours are summarized in Table 5.3.
Colour Cause Comments
Light yellow to colourless Normal after larger fluid intake; polyuria 
in diabetes mellitus, diabetes insipidus
Increased urine volume per 24 hrs in 
polyuria; glucose in urine in diabetes 
mellitus
2  Ensuring adequate conditions for collection can be difficult in outpatient conditions for an active person lea-ding a normal life.3  This is no longer an acceptable way of testing; formerly used to diagnose diabetes mellitus, for example (sweet urine).
Dark yellow Concentrated sample, 
use of riboflavin (vitamin B
2
) 
Normal in first morning sample or after 
strenuous exercise 
Amber Dehydration during fever or burns
Orange Bilirubin, urobilin (yellow-orange colour, 
formed by photo-oxidation of urobilino-
gen), drugs (nitrofurantoin), 
carotenes from food
Bilirubin and urobilinogen can be de-
tected using a test strip (not after pho-
to-oxidation)
Yellow-green, yellow-brown Biliverdin (bilirubin oxidation) Test for bilirubin is then false negative
Pink/red/brown Presence of blood, methaemoglobin is 
brown (haemoglobin oxidation with aci-
dic pH of urine); 
haemoproteins (myoglobin, haemoglo-
bin 
porphyrins (chemical blood test is nega-
tive) 
drugs (e.g. rifampicin) 
food (raw beetroot + alkaline urine = 
red; blackberries + acidic urine = red; 
blueberries [pink -> red], senna [yellow 
to reddish brown], rhubarb [brown])
Erythrocytes, haemoglobin and my-
oglobin react with a blood test strip 
(positive result). Distinguishable by the 
appearance of urine (usually turbid in 
presence of blood) or serum (may be 
red in intravascular haemolysis, not 
in myoglobinuria); or by specific tests 
(e.g. myoglobin in urine, complement 
fixation reaction)
Brown 
Black
Bilirubin, urological tea, melanoma, al-
kaptonuria
Chemical blood test is negative
Blue/Green Bacterial infection (Pseudomonas), 
drugs (methylene blue, amitryptilyn …), 
inborn errors of amino acid metabo-
lism3, carbolism
Table 5.2. Commonest pathological urine colours (modified according to [2])
Turbidity of urine need not be a pathological sign (collection error, especially in women; presence of sperm; white 
turbidity can be caused by urate or phosphate precipitation in a sample stored in the refrigerator), although turbidity 
is often seen in the presence of leukocytes and bacteria (urinary tract infection) or blood.
An unusual urine odour may warn of ketoacidosis (sweet, fruity odour) or an inherited metabolic disorder (e.g. the 
“musty” or „mousy“ smell in phenylketonuria, or maple syrup smell in maple syrup urine disease).
5.4. Chemical Examination of Urine Using Test Strip (Dipstick)
This is a very common preliminary examination, which takes us closer to or directs us towards the definitive dia-
gnosis and therapeutic action. Urine chemistry is typically indicated in the following diseases and conditions:
• Urinary tract infection
• Diabetes mellitus
• Renal function tests + suspected renal disease (screening)
• Jaundices (hyperbilirubinaemia)
In outpatient conditions, the test result is commonly read by eye; the process is automated and more objective in 
hospital labs (reflective photometry-based measurement). Instructions for correct use of the test strip:
1. Mix the urine sample thoroughly.
2. Allow samples stored in the refrigerator to reach room temperature.
3. Completely immerse the strip in the sample for a short time.
4. Run the edge of the strip against the rim of the specimen container to remove excess urine. Put the strip 
on disposable absorbent material (e.g. pulp).
5. Compare the colour change of reagent pads to the manufacturer’s colour chart (usually on the package 
label). Read results according to the chart’s time frame (see manufacturer’s instructions) and under good 
lighting conditions.
6. Do not forget about possible interferences and pre-analytical errors during interpretation.
5.4.1. Individual Determinations
Test strips contain either individual tests or a combination thereof (e.g. for urinary tract infection or diabetes mel-
litus compensation check), but they often contain all of the 10 most frequent parameters. The tests are outlined below 
– the principle of determination is mentioned only if it is important for interpreting results (relatively frequent false 
positive or false negative results).
5.4.1.1. Specific Gravity (Density)
Specific gravity expresses the density ratio of the sample to distilled water, and so is a dimensionless quantity. The 
specific gravity of plasma is 1.010, and typically ranges from 1.015 to 1.025 in the definitive urine of a healthy person 
(4). It is measured using physical (e.g. densitometer or refractometer) or chemical means (5). Individual principles of 
measurement do not provide comparable results; osmometer measurement is most accurate (6).
The specific gravity of urine reflects renal tubule functions (the secretion and absorption of ions and water, in 
particular) and may be one of the first signs of renal damage (in particular a loss of reaction to changes in fluid intake).
Indications: Distinguishing between pre-renal and renal cause of renal failure, test for renal concentrating ability 
(this indication requires more accurate measurement for urine osmolality, see also Kidney Function Tests).
For a pre-renal cause of renal failure (e.g. dehydration), a high specific gravity of urine can be expected (maximum 
concentration); with a renal cause, tubule functions are damaged and the kidneys produce less concentrated urine.
5.4.1.2. pH
Hydrogen ion concentration in urine reflects the balance of H+ production, metabolism and excretion; however, it 
may also be a sign of a kidney or urinary tract disease. First morning urine pH ranges from 5 to 6, but a random sample 
from a healthy person may also have a pH of 4.5 or 8 (more alkaline after a meal, more acidic after physical strain, di-
etary influences…) (7). The reference range for urine pH is rather misleading, and the result should be evaluated along 
with other data (e.g. acid-base balance status). Acidic urine is found in acidosis and alkaline urine in alkalosis (compens-
ation or correction) of the disorder by the kidneys; unless of course the kidneys are the cause of the acid-base balance 
disorder). Vegetable diets (low protein content, e.g. a vegetarian diet) usually lead to a lower basic production of H+ 
and more alkaline urine.
Indications: Primarily the diagnosis of urinary tract infection, but also the evaluation of acid-base balance disor-4  It may also range from 1.003 to 1.035 (samples with specific gravity < 1.003 are probably not urine, > 1.035 might occur following i.v. administration of radiopaque substances). The very wide range is caused by the influence of hydration (fluid intake) on this parameter.5  Or as osmolality, typically using a cryoscopic method (see Kidney Function Tests).6  Osmolality only depends on the particle count in the solution. Density is also affected by particle size. There-fore, Na+ will increase specimen density less than a higher urea or glucose content. The chemical principle of specific gravity measurement (on a test strip) detects only ions and so it is not affected by the presence of urea, glucose or a contrast agent; however, the presence of protein (anion) leads to a false increase in the results. In clinical terms, these limitations are usually negligible due to the preliminary character of the examination.7  Specimens of urine with pH < 4.5 and > 9 are an indication for a new sawmple collection (probably contamina-ted or artificial proliferation of bacteria with urease).
ders or the diagnosis and monitoring of urolithiasis treatment.
Urinary tract infections caused by bacteria with urease (e.g. Klebsiella) cause alkaline urine pH. The creation of 
renal calculi also depends on urine pH. Renal calculi (calcium oxalate) are typically formed in acidic urine and it is advi-
sable to maintain a more alkaline urine pH (mainly by dietary measures) to prevent recurrence.
Falsely high values can be expected if the sample is supplied late (bacterial activity, see above); falsely low values 
may occur if the sample is contaminated by reagents from the adjacent reagent pad (typically in protein determination 
where the reaction takes place in a strongly acidic environment).
5.4.1.3. Leukocytes, Nitrites
The main purpose of both tests is to rule out/confirm suspected urinary tract infection (8) and, if needed, sub-
sequent indication of microbiological urine culture, and identification of the pathogen and pathogen sensitivity to 
antibiotics. This test is not therefore used for the precise diagnosis and therapy of urinary tract infection (this is done 
based on microbiological examination). The leukocyte test detects one of the granulocytic leukocyte enzymes (estera-
se). The test for nitrites utilizes the ability of the bacteria to reduce nitrates to nitrites, which is an ability possessed, 
for example, by enterobacteria such as E. coli or Proteus. The true positivity (sensitivity) of the test is conditional upon 
urine being in the urinary bladder for at least 4 hours (required to reduce a sufficient amount of nitrates) and the pati-
ent having a sufficient amount of nitrates in the diet (9).
Indications: Diagnostics, urinary tract infection screening
5.4.1.4. Protein
The determination of protein (albumin) using a test strip is one of the most important basic urine examinations, 
since it can reveal a developing renal pathology at an early stage. A small amount of albumin (relative molecular weight 
is about 70 kDa) and all small proteins (microproteins) penetrate through a healthy glomerulus, although most of these 
physiologically filtered proteins are then reabsorbed by proximal tubule cells. In a renal disease, either the glomerular 
membrane (glomerular proteinuria) or tubular cells (tubular proteinuria) are damaged. The limit for proteinuria has 
been set to 150 mg/24 hrs.
Principle of determination: Acid-base indicator that changes colour in the presence of protein (particularly albu-
min that has many binding sites for protons and may remove them from the indicator). To avoid colour changes due 
to changes in urine pH, the strip contains a buffer, ensuring a constant (acidic) pH of around 3 (see Figure 5.1). This 
method of determination is most sensitive to albumin (less so to other proteins). The strip usually captures albumin 
concentrations over 150 mg/l.
8  For the early detection of cystitis, especially in cases of inapparent clinical problems.9  Vegetables are the main source of nitrates in the diet. This is why the urine nitrite test may be falsely negative in some inpatients (e.g. fasting due to surgery, on parenteral nutrition).
Figure 5.1. The principle of urine protein determinat ion using a diagnostic strip and potential false positive and false 
negative results
False positive results may be caused by strongly alkaline (pH > 8) and buffered urines. These can remove protons 
from the indicator (and change its colour) even in the absence of albumin. This can be solved by using another test 
(e.g. sulfosalicylic acid precipitation test) for strongly alkaline urines, or repeating the examination at a later time (e.g. 
in non-complicated urinary tract infections with a high pH of urine, it is reasonable to repeat the determination after 
antibiotic treatment of the uroinfection).
False negative results can be expected in most pre-renal and tubular proteinurias (a relatively low protein concen-
tration in urine and a low indicator sensitivity), including the Bence Jones protein (free light chains in the urine in mul-
tiple myeloma). In addition, albumin in the microalbuminuria zone (30-150 mg/l) is usually not detected by standard 
test strips (refer to Diabetes for more information about microalbuminuria Diabetes/microalbuminuria).
There are also other ways of urine protein (albumin) determination using a test strip that do not suffer so much 
from pH interference (e.g. sulfosalicylic acid precipitation reaction or the newer chromogenic and immunochemical 
strip methods).
Depending on the location of the cause, proteinuria is usually divided (10) into the following types (see Figure 5.2):
• Pre-renal proteinuria (11) – caused by an increased supply of microprotein (which also penetrates a healthy 
glomerulus) to tubules that do not manage to take it up. This usually involves a low amount of protein 
(under 1 g per day). Examples of such proteins are β2-microglobulin, α1-microglobulin, acute phase rea-
ctants, Bence Jones protein, myoglobin and haemoglobin. The presence of these proteins does not prima-
rily mean damaged renal function, and often it is not detected by the test strip at all. If Bence Jones protein 
is suspected, serum protein electrophoresis and urine immunofixation must be carried out;
• Renal proteinuria – the cause is kidney damage at the level of glomeru-
li or tubules. Glomerular proteinuria is caused by a higher permeation of the glomeru-
lus (12) and occurs in many glomerulonephritides, diabetic nephropathy or renal amyloidosis; 10  A classical laboratory test to determine the type of proteinuria is SDS-PAGE electrophoresis, where proteins are sorted out by size (thereby easily determining their origin).11  Sometimes also referred to as “overflow” proteinuria.12  Can be further subdivided into selective (albumin and/or transferrin penetrate the glomerular membrane) and non-selective (even large proteins such as immunoglobulins penetrate the glomerular memberane) glomerular protein-uria. The prognosis and response to therapy are usually better in diseases with selective glomerular proteinuria.
Tubular proteinuria is subject to damage to tubules (proximal tubules in particular), for example, during 
poisoning by heavy metals (Hg, Cd), as an adverse effect of some drugs (gentamicin, cyclosporin, cisplatin, 
lithium …) or in some viral infections (13);
• Post-renal proteinuria – presence of proteins from efferent urinary tract (e.g. α2-macroglobulin or IgM), 
the cause being inflammation or bleeding, or a pre-analytical error (e.g. menstrual blood, prostatic secre-
tion, sperm).
Figure 5.2. The distribution of proteins in urine by size during electrophoresis (takes place in polyacrylamide gel and 
proteins are usually sodium dodecyl sulfate-coated – SDS-PAGE)
Nephrotic syndrome 
Nephrotic syndrome can be defined as a proteinuria capable of causing hypoalbuminaemia and oedemas. The 
amount of proteinuria may vary; usually it is > 3.5 g/24 hrs. Nephrotic syndrome may be caused by glomerulonephritis 
with minimal changes, proliferative glomerulonephritis or systemic lupus erythematosus.
U_protein/U_creatinine ratio
This ratio is evidently very useful and practical and can replace urine collection to quantify proteinuria. The ratio 
is usually expressed in mg (protein)/mmol (creatinine); numerically, the limit is 15 mg/mmol for proteinuria and 350 
mg/mmol for nephrotic syndrome.
5.4.1.5. Blood
Principle of determination: Oxidation of chromogen (detection pigment) by haem (pseudoperoxidase activity of 
haem). The haem is detected, so the strip is sensitive both to erythrocytes (lysed in contact with the reagent pad) and 
haemoglobin or myoglobin (also contains haem). False positive results can be measured if the sample contains oxidi-
zers (e.g. disinfectant residues from test tube decontamination); false negative results can be seen in classical tests in 
the presence of a high concentration of vitamin C (14).13	 	The	determination	of	relatively	stable	microproteins	(cystatin	C	or	α1-microglobulin) in the urine is currently used to diagnose this type of proteinuria.14  Note the resemblance of interferences with the determination of glucose. The basic principle in both is chro-
The following haematuria types are distinguished by intensity:
• Macroscopic haematuria (visible to the eye, urine is pink to red in colour, turbidity present – see Appea-
rance of Urine for more details);
• Microscopic haematuria (detectable microscopically or chemically).
• The following haematuria types are distinguished by cause:
• Pre-renal haematuria – haemoglobin gets into the urine (due to the intravascular haemolysis of erythro-
cytes, e.g. in haemolytic anaemia, during incompatible transfusion), or myoglobin enters the urine (e.g. 
in extensive muscular trauma, burns, as a rare consequence of hypolipidaemic treatment by statins and 
fibrates), from the blood. The massive presence of each of the aforementioned proteins can cause acute 
renal failure (obstruction of tubules by precipitated protein) (15). Erythrocytes are not found in microscopic 
examination. Making the distinction between myoglobin or haemoglobin is based on patient history, the 
appearance of urine and serum (see Table 5.3) or other laboratory tests (high LD activity and immeasura-
ble haptoglobin in haemolytic anaemia; high CK and AST in muscular damage; alternatively, both proteins 
can be distinguished in an immunoassay by determining their concentration);
• Renal sometimes also called glomerular haematuria, usually caused by glomerulonephritis. It can be distin-
guished from non-glomerular haematuria using phase contrast microscopy. This method visually highlights 
the edges of erythrocytes in the urine – dysmorphic erythrocytes (16) (erythrocytes with “thorny” projec-
tions, also called acanthocytes are typical – a consequence of passage through the glomerular sieve, see 
Figure 3) can be found in glomerular erythrocyturia. This type of haematuria is often accompanied by 
proteinuria and the presence of erythrocyte cylinders (see below);
 
Figure 5.3. Dysmorphic erythrocytes (acanthocytes) – diagram. Acanthocytes are typical of the glomerular origin of 
erythrocytes
• Subrenal sometimes also called non-glomerular haematuria, usually caused by bleeding in the urinary 
tract during urinary tract inflammation, urolithiasis, or urinary tract or renal tumour. Traumatic bleeding 
after catheterization (especially with concurrent anticoagulation therapy) is quite common. A relatively 
minimal proteinuria is typical of this type of haematuria. Normally shaped (biconcave, biscuit-shaped) 
erythrocytes can be found in the phase contrast image.
Sometimes even exercise-induced haematuria (temporary, following strenuous exercise, after becoming chilled) or 
artificial haematuria (the patient intentionally adds blood into the urine sample) may occur.
5.4.1.6. Glucose
Principle of determination: Chromogen (detection pigment) oxidation by hydrogen peroxide produced by enzyma-
tic decomposition of glucose (glucose is oxidized by glucose oxidase to form gluconolactone and H
2
O
2
). The determi-
nation is specific for glucose (other reducing carbohydrates such as galactose or fructose do not react) (17).
False positive results can be expected in the presence of oxidizers (e.g. some disinfectants used for test tube decon-
tamination), false negative results are found in the presence of ascorbic acid (vitamin C) (18) or, most often, in samples mogen oxidation (oxidizing agents will therefore cause false positive results and reducing agents false negative ones). Newer strips prevent vitamin C interference by an added agent that oxidizes the vitamin C, thereby rendering it ineffec-tive.15  The basic precaution (acute renal failure prevention) in massive myoglobinuria and haemoglobinuria is increa-sed fluid intake.16  Acanthocytes disintegrate very easily, so the sample has to be delivered to the lab very early – ideally, the sam-ple should be taken there directly.w17  The reaction with the Benedict’s reagent is still in use (CuSO4 in alkaline environment + heating -> Cu2O [pre-cipitate colour from blue-green to brick red]). It is of major importance in galactosemia screening and this test is re-commended in some countries in all children under 2 years of age.18  Some manufacturers add a substance able to oxidize ascorbate into the reaction mix, which prevents interfe-
delivered late (bacterial decomposition).
Indications: In particular, primary diagnosis of diabetes mellitus.
Glucose filtered by the glomerulus of a healthy person is almost completely absorbed in the proximal tubule. If 
concentration in blood exceeds about 10 mmol/l (known as the renal threshold for glucose), tubular cells are no longer 
able to take it up and glucose will appear in the urine. Therefore, the causes of glycosuria can be as follows:
• Most commonly, exceeding the renal threshold for glucose (as is the case in diabetic patients);
• Lower renal threshold (Fanconi syndrome, also in healthy individuals) – referred to as renal glycosuria;
• During pregnancy when glomerular filtration is increased (therefore also an increased amount of glucose 
passing through tubules) and the renal threshold for glucose may be lowered.
Glycosuria may appear even in a healthy person after a meal rich in carbohydrates, so it is advisable to use the 
second morning urine for (preliminary) diagnostic purposes (19) and the patient should be fasting until the sample col-
lection (the first morning urine may contain postprandial glucose from the evening meal). It should be recalled that the 
sensitivity of this test is not ideal (glucose appears in the urine when concentration in the blood exceeds 10 mmol/l); 
the renal threshold for glucose can be highly individual and may vary in the course of diabetes mellitus. Glycosuria is 
therefore just a simple preliminary diagnostic test and is not suitable for the monitoring of diabetes compensation.
5.4.1.7. Ketone bodies
Principle of determination: Reaction of a keto group with nitroprusside (in an alkaline environment).
Ketone bodies are primarily produced by the incomplete oxidation of free fatty acids (from fats) in situations with 
a lack of glucose (e.g. fasting, diabetes mellitus – type 1 in particular, intensive physical strain, vomiting).Ketone bo-
dies include β-hydroxybutyrate (BHB) and its oxidized form, acetoacetate (AcAc), the spontaneous decarboxylation of 
which generates acetone (20) - see Figure 5.4.
Figure 5.4. Ketone bodies. Note the lilac-shaded acetoacetate and acetone keto group (reacting with nitroprusside). In 
β-hydroxybutyrate the keto group is replaced by the hydroxy group, so it does not react with nitroprusside
In quantitative terms, β-hydroxybutyrate is predominant in urine (about 80%), while acetoacetate forms the rest 
(the acetone amount is negligible). Only the acetoacetate and acetone keto group reacts with nitroprusside. For exam-
ple, a significant increase in the BHB/AcAc ratio may occur in severe diabetic ketoacidosis accompanied by hypoxia and 
shock, or in alcoholic ketoacidosis. As BHB does not react with nitroprusside, a quantitative underestimation of results 
may occur in this (exceptional) situation.
Indications: Primarily the monitoring of diabetes mellitus compensation, insulinotherapy in type 1 diabetes pati-
ents in particular. If ketone bodies occur in a type 1 diabetes patient’s urine (on insulinotherapy), it means they are 
lacking insulin and the insulin dose has to be adjusted.rence with glucose determination.19  The definitive diagnosis of diabetes mellitus is established from the plasma (see Diabetes Mellitus).20  More information about ketone body pathophysiology can be found in Acid-Base_Balance_Preparation -> pro-duction of H+
5.4.1.8. Bilirubin, urobilinogen
Conjugated bilirubin in the blood (as opposed to non-conjugated bilirubin bound on albumin) freely penetrates 
into the urine, where it is detected in obstructive jaundice or liver damage, for example. Urobilinogen appears in the 
urine in liver damage or haemolytic anaemia, for example. Refer to the chapter Liver for more information.
5.5. Microscopic Examination of Urine
The examination of urine sediment supplements the information obtained from the chemical examination of urine 
using a test strip. Every laboratory has its own algorithm for sample processing and urine sediment examination. The 
chemical examination is usually for ‘screening’ purposes, while the urine sediment examination follows only if the 
result is pathological (mostly in the case of positive leukocytes, nitrites, blood or proteinuria). In most cases, the exami-
nation takes place in automatic analyzers on mixed, non-condensed urine specimens. The principle of determination is 
either a software analysis of the digital microscopic image taken by a digital camera, or flow cytometry (identification 
of elements is based on the measurement of impedance, diffusion of light and fluorescence). When in doubt however, 
decisions are taken based on a classical microscopic examination (21) made following standard condensation by centri-
fuging (e.g. centrifuge 12 ml of urine for 5 minutes at 400 RCF, no braking; then pipette 11 ml, resuspend and apply to 
the slide) (22). The examination can be made on the native sample or following staining (to highlight nuclei, cell mem-
branes and other structures). Results are issued as the number of elements per µl.
Correct sample collection and timely processing are very important – cells and cylinders fall apart very quickly, 
especially in hypotonic and alkaline urine. Urine sediment should be processed within 1 hour of collection.
5.5.1. Composition of Urine Sediment
The urine sediment of a healthy person can contain many shaped structures. These also include a small amount of 
erythrocytes (< 5/µl), leukocytes (<10/µl), some epithelial cells (mainly squamous epithelium), hyaline cylinders or va-
rious crystals. In most cases, just a few squamous epithelium cells and phlegm can be found in normal urine sediment.
5.5.1.1. Erythrocytes
Above all, a urine sediment examination confirms whether the positive result of a chemical blood test strip is 
accompanied by erythrocyturia or not, or whether it is myoglobinuria or haemoglobinuria. In addition, in the urine 
sediment we can distinguish erythrocytes of glomerular and non-glomerular origin (Figure 5.5, also see above).
Figure 5.5. Dysmorphic erythrocytes
21  Alternatively, use phase contrast microscopy (dysmorphic erythrocytes, identification of cylinders and some cells).22  There are commercially available slides that standardize this phase (volume of sample applied).
5.5.1.2. Leukocytes
In general, leukocytes in the urine sediment signal urinary tract inflammation. The etiology can be infectious (e.g. 
pyelonephritis, cystitis) or non-infectious (e.g. autoimmune damage). Neutrophils are usually most abundant; the dia-
gnosis of drug-induced interstitial nephritis may be supported by the finding of eosinophils (special staining is required).
5.5.1.3. Epithelia
The following types can be distinguished, depending on the origin of epithelia:
• Squamous (from the vagina and the lower 1/3 of the urethra) – large cells with a centrally located nucleus 
(about the size of an erythrocyte); a physiological part of urine;
• Transitional (renal pelvis lining through calyces, ureters, urinary bladder to the proximal part of the ure-
thra) – smaller than squamous epithelia, centrally located nucleus, different shapes (e.g. spherical, “tai-
led”); a small quantity is physiological, a large quantity after catheterization and other invasive interventi-
ons; atypical cells in tumours or viral infections;
• Tubular cells (come from tubules) – different shape depending on the origin (triangular, spherical [unlike 
the transitional epithelia, the nucleus has an eccentric position], cuboidal) – always pathological, a sign of 
tubular necrosis (e.g. heavy metal poisoning, haemoglobin and myoglobinuria, nephrotoxical drugs, viral 
infections [HBV], acute transplant rejection).
Figure 5.6. A transitional epithelial cell (on the left) and tubular cells (on the right)
5.5.1.4. Bacteria and Yeast
The presence of bacteria along with leukocyturia is usually a sign of urinary tract infection (Figure 2). The occur-
rence of yeast (Figure 5.7) is more common in diabetic patients (glycosuria + acidic urine), immunosuppressed patients 
and patients with vaginal moniliasis. Isolated bacteriuria and the occurrence of yeast (particularly with non-sterile 
collection and a late sample delivery) do not have diagnostic significance.
Figure 5.7. Flood of bacteria (on the left – resembling “scattered tea leaves”) and yeast (on the right). Notice the bud-
ding yeast and mycelia that help distinguish them from erythrocytes
5.5.1.5. Parasites
The most common parasite is Trichomonas vaginalis, characterized by 3 flagella and an undulating membrane (Fi-
gure 5.8). This parasite causes vaginal inflammations.
Figure 5.8. Trichomonas vaginalis in an unstained preparation. The arrow points to 3 flagella
5.5.1.6. Mucus
Mucus is a protein from genito-urinary tract glands or tubules (Tamm-Horsfall protein). It is common in physiologi-
cal urine and has no diagnostic significance (although it can be confused for hyaline cylinders – see below).
5.5.1.7. Cylinders
Cylinders form in distal parts of the nephron. They are composed of the Tamm-Horsfall protein secreted by tubu-
lar cells and other parts which differ according to the specific pathology (e.g. erythrocytes, leukocytes). Their shape 
(width) copies the size of tubules – which is why wide cylinders always come from pathologically dilated tubules.
Some cylinders contain cell structures:
• Erythrocytic (in erythrocyturia of a glomerular origin);
• Leukocytic (in pyelonephritis);
• Epithelial (containing tubular cells – e.g. in toxic damage by heavy metals, poisons or drugs; transplant 
rejection), it is sometimes difficult to distinguish them from leukocytes;
• Bacterial cylinders, sometimes also contain leukocytes, can be found in pyelonephritis.
We can also distinguish between hyaline cylinders (most common; small amounts can be physiological, large 
amounts point non-specifically to renal pathology – e.g. acute glomerulonephritis, pyelonephritis, chronic renal in-
sufficiency), granulated cylinders (come from renal tubular cell lysosomes or from disintegrated leukocytes; the dia-
gnostic significance is disputable – depending on further findings they can indicate tubular damage, leukocyturia or 
no pathology at all), and waxy cylinders (“chronic renal failure cylinders”, usually found with other cylinders). Simply 
put, a hyaline cylinder in the tubule becomes granulated over time (with a progressive urinary stasis in the tubule) and 
finally waxy.
Figure 5.9. Cylinders
5.5.1.8. Crystals
A finding of crystals in the urine is not usually pathological, or indicative of the type of urolothiasis (23) (if present). 
An exception are cystine crystals that cannot occur in a healthy person’s urine. A flood of oxalate crystals may be asso-
ciated with ethylene glycol poisoning (along with metabolic acidosis, see Toxicology).
Figure 5.10. Crystals.
23  The most common stone is calcium oxalate; nevertheless, oxalate crystals are common in the urine of comple-tely healthy people (dietary sources of oxalates – e.g. spinach, rhubarb).
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Summary:
Kidneys are metabolically very active organs that play a major role in maintaining an optimum internal environ-
ment. Some kidney functions such as glomerular filtration and certain tubule functions are also tested in regular clinical 
practice.
Glomerular filtration „cleans out waste substances from the blood“. Blood is constantly pressed through filter po-
res of the glomerular membrane (in simple terms similar to a sieve) and only small molecule substances make it to the 
other („urine”) side1. The filtered fluid („plasma ultrafiltrate” or primary urine) is then gradually exposed to the effect 
of renal tubules, which return necessary substances (e.g. water and minerals) to the blood, and excrete waste substan-
ces (e.g. hydrogen ions) into the urine.
6.1. Glomerular Filtration Tests (GF)
Whenever „kidney tests” are discussed, what is often being referred to (inaccurately), are methods to determine 
glomerular filtration. The level of glomerular filtration is used to adjust the dose of some drugs excreted by the kidneys 
(e.g. the antibiotic gentamicin or low-molecular heparins), the administration of some substances may be also con-
traindicated (usually nephrotoxic substances such as X-ray radiocontrast agents or the antitumour drug cisplatin), and 
it is used to evaluate the development of renal insufficiency, or indicate an extracorporeal cleaning method („dialysis”).
Glomerular filtration usually decreases with age (after maturity is reached), increases by about 50% in pregnancy, 
and the reference range also depends on the gender.
6.1.1. Serum Creatinine (S-Crea) and Derived Calculations
Creatinine is generated in muscles from creatine and creatine phosphate (molecules providing the muscle with 
energy). Creatinine has a small molecule, so it passes through the glomerular „sieve” completely. It is partially secre-
ted, nonetheless, in tubules (< 10% in a healthy person) – this „error”2 is usually disregarded, but must be taken into 
account at more advanced stages of renal insufficiency (the percentage excreted by tubular secretion into the urine 
grows with the growing serum creatinine concentration).
The greatest limit for using creatinine as a GF marker is the dependence on muscle mass. Creatinine production 
is different in a „bodybuilder” and a cachectic patient; muscle mass physiologically decreases with age, women have 
smaller muscle mass than men, etc. Therefore, GF estimates based on serum creatinine in patients not having an 
„average” muscle mass are subject to great error3. The following methods can be used to estimate GF using serum 
creatinine.
Directly by serum creatinine concentration – the problem of this approach consists in the impracticality of its eva-
luation against the reference range, which depends on age and gender. It is relatively difficult for a physician to imagine 1  A guidance limit for the molecule size is 70 kDa – if the molecules are larger, they do not pass through a healthy glomerular membrane. Nevertheless, filtration also depends on the charge of the filtered molecule and other factors (see Introduction to the Topic).2  An ideal marker for glomerular filtration is fully filtered by the glomerulus and is not re-absorbed or secreted in the tubules. Besides which, of course, it is inexpensive, easily and reliably measurable…3  Proportionate to age and gender. Disproportionate (small) muscle mass can be found in the undernourished, people confined to bed (e.g. following ictus), or people with serious conditions (operation, infection, sepsis, burns). In such cases, GF estimated from serum creatinine will be greater than the actual value (false overestimation). In contrast, sportspeople (strength-based sports in particular) have disproportionately large muscle mass.
quantitatively the relationship between the GF and current serum creatinine level in the given patient.
Using different calculations, usually considering age and gender (or race – African Americans often have a larger 
muscle mass) in addition to serum creatinine; the result is expressed in regular units for GF (mL/s). Quantitative inter-
pretation is then easier. The MDRD (Modification of Diet in Renal Disease) formula is an example of such calculation. 
Currently the most widespread MDRD is the four-variable version that includes serum creatinine, age, gender and race 
(only for African Americans). The MDRD formula is recommended as a population screening method to capture decre-
ased GF. The formula cannot be used for children and pregnant women4.
Another problem (in addition to the dependence on muscle mass) of creatinine is the method of determination. 
The principle of determination is the reaction with picric acid in a strongly alkaline environment5. Relatively many inter-
fering substances such as acetoacetate, protein or glucose are known, and usually lead to falsely higher results. These 
interferences can be minimized (at least partially) using different procedures. There is an effort to establish an enzy-
matic method for determining creatinine, which does not suffer from these interferences. It is certain that the results 
of this method are systematically lower (compared with the Jaffé method), but it is unclear whether this is important 
for clinical practice6.
6.1.2. Serum Cystatin C
Cystatin C is a low-molecular protein (13 kD) and a physiological inhibitor of cysteine proteases. It is therefore an 
important part of the protease - antiprotease balance, which is why a constant amount of cystatin C is usually expre-
ssed by all nucleated cells. It is also a microprotein, which freely penetrates the glomerular membrane and is fully 
re-absorbed and degraded by proximal tubule cells. If GF decreases, it is retained (like the other microproteins7) and 
its serum concentration increases in correspondence with the decrease in GF. There are also formulas expressing the 
serum cystatin C concentration in GF units (mL/s).
Advantages of using serum cystatin C:
• Earlier detection of the initial forms of glomerular injury (the reaction in acute renal failure is 1 - 2 days 
earlier than S_Crea);
• No need to collect urine, no gender differences;
• No analytical interferences.
However, the assumption that it is produced in constant amounts is not absolutely true: it is known that cortico-
therapy, increased thyroid function and some tumours increase cystatin C production; similarly, diabetes mellitus and 
gender have some effect on cystatin C production. It is also certain, though, that this effect is much lower than S_Crea.
A GF estimate based on serum cystatin C is favoured mainly for children and pregnant women. In hospitalized pa-
tients, some recommend measuring the GF estimate based on both MDRD and serum cystatin C8.
6.1.3. Creatinine Clearance
Sometimes it is also called endogenous creatinine clearance9. All methods based on measuring the clearance10 of 
a particular substance try to approximate the „ideal”, i.e. the substance will be fully filtered in glomeruli, will not be 
subject to tubular secretion or re-absorption, and will be easy to measure (and the procedure will not be burdenso-4  There are many other formulas:
is used for children [factor 0.6 is used only as a guide – age and gender must be considered for a more accurate calculation], Lund-Malmö, CKD-EPI and other equations have been used recently for children from 1 year as wells as adults, etc. All of them are based on S_Crea and usually only differ in terms of the populations for which they have been validated (and are valid for). Relationships based on S_Crea are not used for pregnant women, but other suitable op-tions are available: serum cystatin C and creatinine clearance.5  Known as the Jaffé reaction. Substances reacting with the agent are also called „Jaffé-positive chromogens”.6  It is not clear what percentage of people would be incorrectly classified as having reduced GFR. The positive bias of creatinine assay using the Jaffé method, which can be found particularly in serum concentrations < 140 µmol/L, can be minimized by recalibration to the ID-MS reference method. Muscle mass and tubular excretion interferences are still probably the biggest source of errors.
7	 	For	example,	β2-microglobulin, amylase or myoglobin.8  One can judge which result is closer to reality based on the discrepancy between the estimates and the patient’s history. For example, the MDRD-based estimate will be significantly overestimated in a cachectic person, and the GF estimate from serum cystatin C underestimated in a person on corticotherapy (see also below).9  To emphasize that it is a substance generated by the body, not supplied externally (such as inulin).10  Clearance is the virtual volume of plasma cleared of the substance per unit of time (with units such as mL/s).
me for the patient). Creatinine is fully filtered, although it is also partially secreted in tubules (see the chapter Serum 
Creatinine (S_Crea) and Derived Calculations). Theoretically, the creatinine clearance formula can be derived from11:
[values are converted to a standard surface area of 1.73 m2]
Creatinine clearance is used mainly for early diagnosis of reduced GF or GF tests in pregnancy. Serum creatinine 
and serum creatinine-based calculations should be used at the later phases of reduced GF. The greatest disadvantage 
of creatinine clearance is that collecting urine is required, usually for 24 hours. Collection-induced errors (incomplete 
collection) are very common and degrade the result of the test12. This is the reason why methods requiring urine colle-
ction are generally being abandoned.
6.1.4. Practical Approach to GF Evaluation
Procedures based on S_Crea as well as estimates from serum cystatin C are suitable for use in hospital practice. 
Two independent estimates are then available, presenting 3 possible situations:
Both estimates are (roughly) the same – the estimate is considered a real value;
The cystatin C-based GF estimate << MDRD
The discrepancy is caused by reduced muscle mass in patients confined to bed, suffering from chronic diseases or 
catabolic conditions. MDRD estimates muscle tissue only by age and gender (or race), and is unable to take into ac-
count the muscle loss mentioned above. Reduced creatinine production thus leads to a relatively lower S_Crea level, 
from which MDRD derives a falsely high GF level.
S_Crea-based estimates are considerably overestimated; cystatin C-based estimates should be used.
The patient is taking corticosteroids or has hyperthyroidism – cystatin C production is thus increased and the serum 
concentration is higher than the real GF. The cystatin C-based GF estimate is therefore underestimated and the S_Crea-
-based estimate should be used.
The cystatin C-based GF estimate >> MDRD – this is caused either by the patient having an unusually large muscle 
mass (higher than expected creatinine production → higher S_Crea → falsely lower GF estimate from MDRD), or GF is 
in the zone over 1.5 mL/s. S_Crea-based estimates are not validated for this zone and their accuracy decreases.
6.1.4.1. Case Report 1
An 86-year-old woman was taken by ambulance from the nursing home, where she had been confined to bed for 
a long time due to septic fevers (the 3rd day repeatedly over 40 °C). Chronic medication: antihypertensive (perindopril), 
furosemide; acute medication: Augmentin (empirically). Following admission, the following serum values were measu-
red (selection of pathological results): S_Crea 160 µmol/L, urea 26 mmol/L, Na 131 mmol/L, K 5.8 mmol/L. Urine values 
were: U_ery 96/µL, U_Leuco 670/µL, nitrites +++, pH 8.6.
Formulate a hypothesis as to the diagnosis, explain the probable cause(s) of the measured pathological results, and 
suggest additional tests.
It is probable that the patient has considerably reduced glomerular filtration (MDRD 0.45 mL/s). The dispropor-11  “What enters the glomerule equals what is excreted.” We know that creatinine is excreted by tubules in the urine, so its concentration in the urine is higher than ideal. The creatinine clearance-based GF estimate is therefore slightly overestimated. This overestimation grows with a growing S_Crea concentration, and creatinine clearances over 180 µmol/L should not be used (it is also pointless).12  The patient should be instructed to urinate as usual in the morning after waking up, and then to collect urine in the collection container(s) the rest of the day, before collecting the last sample, also in the container, the following morning. The entire volume of collected urine should be mixed (in one container), the volume should be measured (ac-curate to 10 mL) and a representative sample should be taken. It is clear, and has been shown in practice, that this pro-cedure leads to frequent errors.
tionally high urea is indicative of a prerenal (and acute) component. Signs of urinary tract infection (UTI) in the urine 
sediment are evident (high pH, leucocytes, positive nitrites). Given the history, it is obvious that the patient has a con-
siderably reduced muscle mass volume (prolonged immobilization, current catabolic condition). Therefore, a cystatin 
C test should be indicated. The cystatin-based GF estimate was 0.25 mL/s (the estimate from MDRD was probably 
considerably overestimated). This condition was caused by a UTI connected with loss of appetite and insufficient fluid 
supply, in combination with a persistent use of furosemide. This led to acute prerenal kidney failure, water retention 
(hyponatraemia) and insufficient potassium excretion (hyperkalaemia)13. Following antibiotic therapy of the UTI (based 
on the microbiology assay for the pathogen and pathogen sensitivity to antibiotics) and appropriate hydration, the 
condition gradually improved and the patient was discharged with a cystatin C-based GF of 0.75 mL/s.
6.2. Tubule Function Test
The main function of tubules is to absorb and secrete various substances such as Na+, K+, Cl-, H+, HCO
3
- and water – 
refer to the introduction to clinical biochemistry in nephrology for details. Metabolically, the most active is the proximal 
tubule, but the other parts of the nephron are also important in this regard.
6.2.1. Secretion and Reabsorption: Fractional Excretion of Low-Molecular Substances
Fractional excretion (FE) is that part of the total amount of filtered substance, which can be found in the definitive 
urine. For example, the kidneys filter about 180 L of primary urine (plasma ultrafiltrate) a day, while about 1.8 L a day 
is urinated. Considering that urine (primary and definitive) is mainly water, then the FE of water is 1.8 of 180 = 1%.
The derivation of the FE formula can be demonstrated in the example of the fractional excretion of sodium:
Filtered amount of sodium in millilitres per second is
glomerular filtration [GF; mL/s] * plasma sodium concentration [P
Na
; mmol/L]
Excreted amount of sodium into the urine in millilitres per second is
urine volume [V; mL/s] * sodium concentration in urine [U
Na
; mmol/L]
if creatinine clearance is substituted for GF (Ucrea* V / Pcrea).
The formula shows that 24-hour collected urine is not necessary for the FE calculation (volumes V cancel each 
other out); a short collection period (e.g. 4-hr) is optimal to make up for short-term effects (fluid intake, etc.). Any low-
-molecular substance the FE of which should be calculated can be substituted for the serum and urine sodium concen-
tration (e.g. potassium, see below).
Therefore, the FE of water is calculated as a plasma-to-urine creatinine concentration ratio. (U
x
 and P
x
 are not sub-
stituted from the formula since the proportion of water [water “concentration”] in the primary and definitive urines is 
roughly the same).
It is evident that although FE is a sign of tubule functions, it is not quite independent of the GF. To avoid significant 
change in the internal environment, a decrease in GF must lead to a compensatory increase in FE14.
Examples of using FE:
• FE of water
Reference range (RR): 1 - 2%; max.: 35%
Increase: increased fluid intake, diuretics, diabetes insipidus, tubulopathy, tubular compensation for decreased GF13  The ACEI therapy could also have contributed to the hyponatraemia and hyperkalaemia.14  Otherwise a 50% decrease in the GF (from 180 L/day to 90 L/day) would lead (with a maintained FE of wa-ter = 1%) to the excretion of half the amount of water in the definitive urine (a drop in diuresis from 1.8 L to 0.9 L) and water would accumulate in the body. The pathophysiological basis of a decrease in the GE is a drop in the number of functional nephrons; these remaining (residual) nephrons then have to make a greater effort to excrete the same amount of waste matter from a lower number of nephrons.
Decrease: dehydration, etc.
• FE
Na
RR: 0.4 - 1.2%; max.: 30 - 40%
Increase: diuretics, increased intake, tubulopathy, tubular compensation of decreased GF, hypoaldosteronism, 
some drugs (renin axis-blocking drugs – angiotensin-converting-enzyme inhibitors [ACEI], spironolacton, etc.)
Decrease: extrarenal losses, lack of Na, hyperaldosteronism
• FE
K
RR: 4 - 19%; max.: 150 - 200%15
Increase: diuretics, increased intake, hyperaldosteronism, catabolism, tubulopathy, tubular compensation for de-
creased GF
Decrease: extrarenal losses, lack of K, hypoaldosteronism, drugs (potassium-sparing diuretics, ACEI), anabolism
• FE of bicarbonate – increased in the diagnosis of proximal renal tubular acidosis (type II).
• FE of amylase – if < 1%, macroamylasemia suspected see chapter Laboratory diagnostics in gastroentero-
logy.
6.2.2. Renal Concentrating Ability
The main physiological regulation of water absorption is due to the action of the antidiuretic hormone (ADH). It af-
fects receptors opening aquaporins (water channels) mostly in the distal tubule and collecting ducts. The main stimulus 
for ADH secretion in the hypothalamus is increased serum osmolality (but it also reacts to a decrease in pressure and 
other stimuli such as vomiting; see preparatory materials). In simplified terms, the following ADH secretion disorders 
are distinguished:
• Diabetes insipidus (DI)
• Insufficient ADH secretion (central DI – hypothalamus or neurohypophysis disorder)
• Insufficient ADH effect (nephrogenic DI – tubule function disorder; congenital or acquired tubulopathies 
such as toxicity of metals Cd, Hg, Li, Pt + other substances – furosemide, gentamicin, RTG contrast agents, 
and the effect of severe ion imbalances – hypokalaemia and hypercalcaemia)
• SIADH – syndrome of inappropriate ADH secretion: hypothalamus produces more ADH than the amount 
corresponding to the current serum osmolality. This leads to an increased absorption of water in the kid-
neys and “dilution” manifested as hyponatraemia. This may be due to a brain disease or ectopic production 
in small-cell lung cancer, TBC or pancreatic cancer.
6.2.2.1. Electrolyte-Free Water Clearance (EWC)
Electrolyte-free water clearance (EWC) is a parameter sensitively evaluating ADH-renal axis disorders (whether or 
not the volume of urine corresponds to effective osmolality and expected ADH secretion). It is the difference between 
the volume of urine [V; mL/s] and clearance16 of the major osmotically active substances (referred to as electrolyte 
clearance, Cl
El
; mL/s):
If other effective solutes (causing the transfer of water between intracellular and extracellular spaces, e.g. glucose 
or mannitol17) are also present in the plasma and urine, this should be considered in the calculation.
Interpretation of EWC:
15  FE greater than 100% means that more substance is excreted than filtered in the primary urine (caused by active secretion in the tubules).16  According to definition, clearance is the virtual volume of the given substance (Na and K in this case) cleared in a unit of time.17  In contrast, urea or ethanol pass freely between the ICF and the ECF, do not cause transfers between these spaces and therefore are not regarded as effective solutes (they do not affect effective osmolality).
Increased effective osmolality (e.g. hypernatraemia) leads to an increase in ADH secretion in the hypothalamus and 
an increased absorption of water in the kidneys (the volume of urine V decreases). EWC should be < 0.005 mL/s. If it is 
higher, the hypothalamus excretes less ADH than it should with the given effective osmolality (e.g. diabetes insipidus).
Decreased effective osmolality (e.g. hyponatraemia) leads to a decrease in ADH secretion in the hypothalamus and 
increased losses of water in the kidneys (the volume of urine V increases). EWC should be > 0.116 mL/s. If it is lower, 
the hypothalamus excretes more ADH than it should with the given effective osmolality (e.g. SIADH).
6.2.2.2. Concentration Test
Renal concentrating ability is usually determined for the differential diagnosis of unexplained polyuria18. If renal 
concentrating ability is to be tested, the following options are available:
Deprive the patient of fluids;
Administer a synthetic ADH analogue (1-deamino-8-D-arginine vasopressin = DDAVP).
Always monitor urine osmolality (U_Osm) as a reflection of the kidney’s capacity to absorb water. A combination of 
the two approaches is usually chosen, e.g. depriving the patient of fluids overnight (normal situation: patient sleeps = 
does not drink) and U_Osm is measured in the morning. If it is higher than 800 mmol/kg, no further testing is required 
(the renal concentrating ability is good). Where it is lower, DDAVP can be administered (intranasally) and urine osmola-
lity monitored (4 samples every hour). IF U_Osm reaches the relevant value (in tables for the specific age), the reaction 
of kidneys to the ADH is good, and the cause of polyuria is then insufficient ADH secretion (disorder in the hypothala-
mus or the pituitary). If the reaction of the kidneys is insufficient, it is probably due to nephrogenic DI.
6.2.3. Acidification and Alkalinization of Urine
This renal ability is tested only in exceptional circumstances see also Introduction to Acid-Base Balance Disorders; 
the diagnosis of renal tubular acidosis (RTA) is practically the only indication. In general, if hyperchloraemic acidosis not 
due to bicarbonate losses from the digestive tract is found, RTA should be considered. However, one should first make 
sure that the patient does not have renal failure, hyperparathyroidism, and is not receiving saline (frequent causes of 
hyperchloraemic acidosis). Kalaemia may then be useful in determining the type of RTA (Table 1). The Acidification 
test is used for the diagnosis of type I renal tubular acidosis (Table 1). The principle of the test is the administration 
of an acidifying substance (usually ammonium chloride; this cannot be administered to patients with severe hepatic 
function disorder or reduced GF) and subsequent urine pH monitoring (8 times every hour). If urine pH in any urine 
sample falls below 5.5 (even before the test), the acidification ability of the kidneys is intact (and the diagnosis of RTA 
is improbable).
RTA I and II are usually treated by administering bicarbonate and potassium, but RTA II requires significantly higher 
doses of bicarbonate.
Type Cause Comments K+1
I (distal) Poor excretion of H+ in distal tubule Diagnosis by acidification test, 
phosphate urolithiasis
↓
II (proximal) Poor absorption of HCO
3
- in proximal tubule Diagnosis of the FE of bicarbonate 
(alkalinization test2);
Often combined in Fanconi syn-
drome (glucose, amino acids and 
phosphates are not absorbed in 
the proximal tubule)
↓
III Combination of I and II (rare; in premature new-
born infants)
↓
IV Poor excretion of H+ and K+ in distal tubule Also in hypoaldosteronism ↑
Table 6.1. Renal tubular acidoses18  For example, trying to find the cause of polyuria in a decompensated diabetic is pointless.
6.3. Acute Renal Failure
Acute renal failure is characterized by the fast progress (hours to several days) of the worsening, or loss of, renal 
function. Since the transition between the worsening and loss of function (failure) is continuous, modern literature 
uses the term acute kidney injury (AKI). AKI is very common19, particularly in patients in intensive care; it often occurs 
therefore with other diseases (cardiac failure, sepsis, etc.) and frequently accompanies chronic renal insufficiency. An 
important difference (compared to chronic renal failure) is that AKI is potentially reversible (although certainly not in 
every case).
Traditionally, acute renal failure is divided into:
• Prerenal – most common; usually caused by cardiac failure, hypovolaemia (loss of blood and fluids) or 
hypotension (sepsis, drugs), less often with renal artery occlusion → low perfusion pressure (often poten-
tiated by the medication of ACEI or non-steroid anti-inflammatory drugs [NSAID]);
• Renal – may be caused, for example, by glomerulonephritis or nephrotoxins (aminoglycosides, heavy me-
tals, cisplatin, Li, NSAID);
• Postrenal – bilateral obstruction (unless there is only one functioning kidney) of urine drainage, most com-
monly due to prostate, cervical, urinary bladder or retroperitoneal tumours; or bilateral nephrolithiasis see 
Case report 2.
In prerenal and postrenal failure, kidney injury (renal failure) will also always gradually develop, but tubule functi-
ons are maintained at the beginning (concentrating ability, tubular reabsorption), which helps to distinguish it from a 
renal cause (Table 26.2).
Parameter Prerenal Renal
U Na (mmol/L) < 20 > 40
FE Na (%) < 1 > 2
U osm (mmol/kg) > 400 < 350
U osm / P osm > 1.5 < 1.1
U urea / P urea > 10 < 5
Table 6.2. Laboratory differences between prerenal and renal failure
Therefore, AKI is always accompanied by a decrease in GF, and usually also decreased urine production. Hyperka-
laemia in particular may be life-threatening (accompanied by metabolic acidosis). Nevertheless, if tubule functions are 
impaired, loss of ions and water (more common in postrenal causes of AKI or damage by nephrotoxins such as heavy 
metals, or in kidney repair following AKI) may predominate, which leads to polyuria and, for example, hyponatraemia, 
hypokalaemia, hypomagnesaemia and hypophosphataemia.
Current classifications of AKI (Table 3) are based on changes in serum creatinine concentration and urine producti-
on. The relevance of both parameters is considerably limited (the S_Crea rise is late, muscle mass and tubular secretion 
bias; patients without AKI also show decreased urine production, but normal or increased urine production does itself 
not rule out AKI); this is why researchers are trying to find new biomarkers for early and specific detection of a develo-
ping kidney injury. The most promising markers available for clinical practice include NGAL and cystatin C.
RIFLE Stage S_Crea Urine Production
Risk > 1.5 x < 0.5 mL/kg/hr for 6 hrs
Injury > 2 x < 0.5 mL/kg/hr for 12 hrs
Failure > 3 x < 0.3 mL/kg/hr for 24 hrs
Loss AKI or complete loss of renal functions persists for more 
than 4 weeks
End-stage renal di-
sease
Complete loss of renal functions for more than 3 mon-
ths
Table 6.3. RIFLE classification of acute kidney injury20.
19  It is reported in about 7% of inpatients; the mortality of patients with AKI in intensive care units is > 50%. The earlier AKI is detected, the better the patient’s prognosis.
20  The newer Acute Kidney Injury Network (AKIN) classification is based on parameters similar to RIFLE (S_Crea 
and urine production), but the combination of criteria is different (addition of the criterion for an absolute rise in S_Crea).
6.3.3.1. Case Report 2. Postrenal kidney failure
A 69-year-old man, treated for chronic arterial hypertension (calcium channel blocker monotherapy), admitted for 
epigastric pain and urination problems (inability to urinate), worsening for about 2 days and visible addition of blood in 
the urine. Following admission (selected results): S_Urea 16 mmol/L, S_Crea 192 µmol/L (MDRD-based GF 0.5 mL/s), 
S_Na 123 mmol/L, S_Cl 99 mmol/L, S_K 7.6 mmol/L, a flood of red blood cells in the urine. According to ultrasonic 
examination, the probable cause of the problems is prostatic hyperplasia combined with a clot in the bladder; bilateral 
hydronephrosis is present. Urine chemistry or urine sediment tests were not made at any time during hospitalization. 
Following prostate removal, spontaneous urination re-established; the patient had polyuria (diuresis of about 4 L), and 
Na had to be substituted (significant losses in the urine due to tubule compression during obstruction), and there was 
a partial improvement of renal functions (MDRD-based GF 0.8 mL/s when discharged from hospital).
Benign prostatic hyperplasia may lead to bilateral hydronephrosis and renal failure, which is often accompanied by 
signs of damaged tubule functions (hyponatraemia, polyuria – impaired renal concentrating ability).
6.3.1. NGAL
NGAL (neutrophil gelatinase associated lipocalin, lipocalin-2) is a protein produced in the nephron’s distal tubule, 
and is considered an early marker of kidney injury. NGAL grows much earlier than creatinine (2-3 days earlier; an in-
crease is noticeable as early as 2 hours after kidney injury), it is therefore able to predict the development of AKI and 
allow timely therapeutic intervention. The usefulness of NGAL has been proved in the AKI diagnosis, e.g. after cardiac 
surgeries or the administration of a contrast agent. Clinical algorithms and decision limits have not been sufficiently va-
lidated for different groups of patients, however. NGAL test sets are commercially available for immediate assay. Serum 
and urine NGAL can be measured. Urine NGAL assays seem to be more beneficial for AKI diagnosis.
Notice: Due to its expected benefit, NGAL is sometimes compared to troponin. However, unlike troponin, NGAL is 
not organ-specific (NGAL is produced in neutrophils, the liver, lung, bone marrow and other organs, it is also produced 
by some tumours and corticotherapy enhances NGAL expression).
6.3.2. Cystatin C
Cystatin C see Serum Cystatin C can also be measured in urine as an indicator of tubule functions. All filtered cy-
statin is normally absorbed and completely decomposed in proximal tubule cells. If proximal tubule cells are damaged, 
cystatin appears in the urine (tubular type of proteinuria) see also chapter Basic Urine Tests.
Serum cystatin C concentration is reported as a relatively early indicator of AKI (compared to S_Crea).
6.4. Chronic Renal Failure
Chronic renal insufficiency (CRI) is an irreversible, progressive process, usually developing for a couple of years or 
even tens of years. CRI is most commonly caused by diabetic and hypertensive nephropathy or polycystic kidney di-
sease. Gradual loss of all renal functions is typical. Chronic renal insufficiency is classified into 5 stages, depending on 
glomerular filtration.
Stage GF (mL/s)
1 > 1.5 + other kidney pathology3
2 1.0 – 1.5
3 0.5 – 0.99
4 0.25 – 0.49
5 < 0.25
Table 6.4. Classification of chronic renal insufficiency (based on KDOQI)
The decrease in GF is compensated by an increased function of residual nephrons increased fractional excretion – 
see Secretion and Reabsorption for a very long time; after these compensatory mechanisms have been depleted, the 
internal environment starts to change slowly (hyperkalaemia, acidosis, hyperphosphataemia). Other problems that can 
be found include anaemia (reduced erythropoetin production in the kidneys), bone disease (reduced activation = vita-
min D hydroxylation in position 1 → reduced absorption of Ca2+ from the intestine → secondary hyperparathyroidism) 
and a significantly increased risk of cardiovascular diseases.
Footnotes
1.  All cases involve hyperchloraemic acidosis with normal AG
2. Give sodium bicarbonate until urine pH reaches about 7.8; then measure accurate urine pH and pCO2, 
calculate HC
O3-, followed by the FE of bicarbonate (the value for RTA II will be > 15%). The test is carried out only very rarely.
3. For example, a finding of protein in the urine (including microalbuminuria) [[see chapter 28 Diabetes Mel-
litus]]
CHAPTER 7
7. The Importance of Plasma Protein Assays
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7.1. Methods for Plasma Protein Examination
7.1.1. Determination of Total Protein Concentration
The biuret reaction is used to determine the serum protein concentration, and it is also currently used as a refe-
rence method. The principle is the formation of a red-purple copper (II) cation complex with nitrogen atoms involved 
in peptide bonds in an alkaline environment. The intensity of staining is proportional to the number of peptide bonds, 
and its dependence on other properties of each of the proteins is relatively small. Falsely elevated values are measu-
red in strongly lipaemic and strongly haemolytic sera and in marked hyperbilirubinaemia; falsely lower values occur in 
marked hyperammonemia (competing reaction of ammonia with Cu2+ ions). This method cannot be used to determine 
urine protein or cerebrospinal fluid concentrations lower by two to three orders; in such cases turbidimetric reacti-
ons (the measurement of turbidity formed by adding trichloroacetic acid or benzethonium chloride to the sample) or 
various dyes (pyrogallol red-molybdate, Coomassie blue) binding to specimen proteins are used. These methods are 
more dependent on the properties of the protein being measured: the dye bond depends on the aromatic amino acid 
content, and turbidimetric reactions on the molecule shape.
7.1.2. Serum Protein Electrophoresis
This method employs the different mobility of proteins in the electric field. In an alkaline buffer environment, pro-
teins migrate from the cathode to the anode. Five to six fractions can be distinguished by protein mobility: albumin, 
alpha-1, alpha-2, beta (often beta-1 and beta-2) and gamma globulins. Prealbumin migrating even faster than albumin 
is not normally apparent.
Figure 7.1. Serum protein electrophoresis. A distinct M-gradient is apparent in positions 3, 11 and 13
Electrophoresis is important primarily as a low-cost screening examination for the diagnosis of monoclonal gam-
mopathy. It also provides an overview of the protein spectrum and allows judgements to be made concerning the 
presence of an acute or chronic inflammation, hepatopathy or conditions connected with a loss of proteins (through 
the kidneys or gastrointestinal tract).
Albumin Alpha-1 Alpha-2 Beta Gamma Comment
Acute inflammation N - ¯      
Chronic inflammation ¯      
Hepatitis ¯¯ ¯ ¯ ¯   
Hepatic cirrhosis ¯¯  ¯   Beta-gamma 
bridge
Nephrotic syndrome ¯¯      
Hypogammaglobulinaemia     ¯¯  
Hypergammaglobulinaemia ¯      
Alpha-1 antitrypsin deficiency  ¯¯     
Paraprotein   M-gradient M-gradient M-gradient  
Table 7.1. Commonest anomalies on the electropherogram
Some sites today use the technique of capillary electrophoresis, where proteins are separated in very thin silica ca-
pillaries from the anode to the cathode depending on their ion mobility using electroosmotic flow, and detected at the 
cathode using photometry in the UV region. The option of “statim” (immediate) analysis is favourable; however, there 
is no option of direct visual evaluation. Figure 2 shows an electropherogram waveform with an apparent M-gradient 
(paraprotein, see below in the text).
Figure 7.2. Electropherogram. Left to right: albumin, alpha-1, alpha-2, beta-1, beta-2 globulins, and a high, narrow 
paraprotein peak (M-gradient) in the gamma-globulin zone
Note: The electropherogram is actually plotted from right to left during capillary electrophoresis, i.e. gamma glo-
bulins are detected first in the arrangement above, and albumin last. Go back over the principles of protein fragmen-
tation by electrophoresis and capillary electrophoresis (particularly the concept of electroosmotic flow) and work out 
why this is the case!
7.1.3. Determination of Plasma Protein Concentration
Specific protein concentrations are measured using immunochemical methods, i.e. methods employing reactions 
of the protein with the specific antibody. The turbidimetric or nephelometric principle of measurement, which has 
completely superseded radial immunodiffusion previously used in clinical laboratories, can be used for most major 
plasma proteins. Labelled reactant methods (ELISA, RIA, chemiluminescence, fluorescence) are used for proteins pre-
sent in very low concentrations. An exception is the determination of plasma albumin, where either a calculation from 
the total protein concentration and the relative albumin proportion on the electropherogram can be used (it is not 
possible to determine the other proteins in this way because the fractions in which they migrate in electrophoresis are 
generally formed by proteins impossible to distinguish from one another), or else a simple photometric reaction is used 
based on the stain bond to albumin (bromcresol green) with a subsequent change in their absorption maximum (the 
BCG-albumin complex gives a marked maximum at 630 nm).
7.1.4. Overview of Major Plasma Proteins
A variety of views exist regarding the sorting out of proteins. We choose to sort proteins by their electrophoretic 
mobility, from prealbumin and albumin through alpha-1, alpha-2 and beta globulins to gamma globulins or immuno-
globulins. Following immunoglobulins, we will examine the issue of monoclonal gammopathies. Protein groups sharing 
common features will then be described: the group of acute phase reactants, the group of low molecular weight pro-
teins and the group of enzymes. The issue of protein hormones is dealt with in another chapter.
Protein Mol. Weight (Da) Reference Limits 
(Adults)
Electroph. Mobility
Prealbumin 55,000 0.1 – 0.4 g/l Prealbumin
Albumin 66,000 35 – 55 g/l Albumin
Alpha-1-acid glycoprotein 44,100 0.55 – 1.20 g/l   
Alpha-1 
 
Alpha-1-antitrypsin 54,000 2 – 4 g/l Alpha-1
Alpha-1-antichymotrypsin 68,000 0.3 – 0.6 g/l Alpha-1
Haptoglobin Hp 1-1: 85,000 
Hp 2-1: 120,000 
Hp 2-2: 160,000
1.0 – 2.4 g/l 
1.5 – 3.2 g/l 
1.1 – 2.8 g/l
Alpha-2
Gc-globulin (group specific compo-
nent; vitamin-D binding protein)
51,000 0.2 – 0.55 g/l Alpha-2
Alpha-2-macroglobulin 725,000 1.5-4 g/l Alpha-2
Transferrin 76,500 2.0 – 4.0 g/l Beta-1
Haemopexin 57,000 0.5 – 1.2 g/l Beta-1
Caeruloplasmin 151,000 0.1 – 0.6 g/l Beta-1
Beta-2-microglobulin 12,000 0.9 – 2.3 mg/l Beta-2
C3 180,000 0.8 – 1.6 g/l Beta-2
C4 206,000 0.20 – 0.65 g/l Beta-2
CRP 135,000 0 – 10 mg/l Beta-2
Fibrinogen 341,000 2.8 – 4.5 g/l Beta-gamma interzone
IgM 900,000 0.6 – 2.5 g/l Beta-gamma 
IgA 160,000 0.9 – 4.5 g/l Beta-gamma
IgG 150,000 8.0 – 18.0 g/l Gamma
Table 7.2. Blood serum proteins – molecular weight, reference limits and electrophoretic mobility
Protein Reduced Concentration Elevated Concentration
Prealbumin Malnutrition (best indicator – short half-life!) 
Hepatic disease 
Acute phase reaction 
Newborns (about half the concentration 
compared to adults) 
Slight drop after 50 years of age
Effect of glucocorticoids and androgens
Albumin Reduced synthesis
Congenital (analbuminaemia)
Acquired (e.g. inflammation, hepatic disease, 
inhibition of synthesis by alcohol)
Increased catabolism 
Losses through urine (nephrotic syndrome), 
gastrointestinal tract 
Malnutrition (slow response)
(Acute dehydration)
AAG Reduced synthesis (effect of oestrogens) 
Increased losses (nephrotic syndrome, losses 
through gastrointestinal tract)
Acute phase reaction (3 – 4x, peak 3 – 5 days 
from disease onset) 
Ulcerative colitis (activity marker) 
Effect of glucocorticoids (Cushing’s syndrome, 
corticotherapy)
AAT Genetic defect (phenotypes Pi Z, 00) 
Increased utilization (neonatal respiratory 
distress syndrome, neonatal hepatitis, severe 
pancreas diseases) 
Losses through urine or gastrointestinal tract
Acute phase reaction (from day 2, peak in 3 – 
4 days) 
Stimulation of synthesis by oestrogens (preg-
nancy, oestrogen therapy)
Caeruloplasmin Genetic defect (rare) 
Secondary in Cu2+ deficiency in food, Menkes 
disease, Wilson’s disease
Acute phase reaction (slow and small increa-
se) 
Stimulation of synthesis by oestrogens (oest-
rogen therapy, pregnancy), cholestasis
CRP  Acute phase reaction (fast and marked increa-
se particularly in bacterial infections)
Alpha-1-foetoprotein In maternal serum in Down syndrome Tumour marker: hepatocellular carcinoma, 
germ cell tumours 
In maternal serum in neural tube defects
Haptoglobin Genetic defect (rare) 
In vivo haemolysis 
Effect of oestrogens 
Hepatic disease 
Newborns
Acute phase reaction (4 – 6 days from disease 
onset) 
Protein losses in connection with Hp 2-1 or 
2-2 phenotypes
Effect of androgens or glucocorticoids
Alpha-2-macroglobulin Acute phase reaction 
Pancreatitis 
Prostate carcinoma (AMG binds PSA and 
complex is very quickly taken up by liver, 
unlike PSA complex with alpha-1-antichymo-
trypsin)
Effect of oestrogens 
In childhood (two to three times higher than 
concentration in adults) 
Nephrotic syndrome (compensation of renal 
losses of lower molecular weight proteins)
Transferrin Iron deficiency anaemia (low iron saturation) 
Anaemia due to defect of iron incorporation 
into red blood cells (high iron saturation) 
Acute phase reaction 
Chronic hepatic diseases 
Malnutrition 
Protein losses through urine or gastrointesti-
nal tract 
Congenital defect (atransferrinemia)
Effect of oestrogens (pregnancy, oestrogen 
therapy)
C3 Genetic defect 
Increased C3 activation (systemic connective 
tissue disease, severe infections, septicae-
mia) 
Concentration in newborns 1/3 lower than 
adults
Acute phase reaction (slight increase) 
Biliary tract obstruction 
Focal glomerulosclerosis (30% of patients, 
correlates with favourable prognosis)
C4 Genetic defect (associated with high preva-
lence of autoimmune diseases, SLE in parti-
cular) 
Consumption (SLE, hereditary angioedema, 
autoimmune haemolytic anaemia, autoim-
mune nephritis) 
Newborns (1/2 to 1/4 lower concentration 
than adults)
Acute phase reaction (slight increase)
Immunoglobulins Primary humoral immunodeficiencies (rare) 
Secondary humoral immunodeficiencies:
Synthesis disorder (IgM drops first, then IgA, 
and IgG last): lymphoproliferative diseases, 
effect of drugs (phenytoin, penicillamine)
Loss of proteins (nephrotic syndrome, burns, 
losses through gastrointestinal tract)
Polyclonal increase: response to infection, 
chronic inflammations, autoimmune disease 
(primary biliary cirrhosis: increase in IgM in 
particular) 
Monoclonal: paraprotein
Table 7.3. Changes in plasma protein concentration in some pathological conditions
7.1.4.1. Prealbumin and Retinol Binding Protein
Prealbumin (transthyretin – can bind two thyroxine or triiodothyronine molecules) is formed in the nuclei and cho-
roid plexus of brain ventricles. It is partially associated with retinol-binding protein in a 1:1 ratio. It is a non-glycosylated 
tetrameric protein consisting of four identical subunits. Due to its short biological half-life (48 hours; retinol-binding 
protein 12 hours) it is a sensitive marker of acute malnutrition and proteosynthesis.
Note: Prealbumin determination is sometimes used in calculating the Prognostic Inflammatory and Nutrition Index 
(PINI):
Normal PINI values are <1; low-risk patients have values of 1 – 10, medium-risk patients 11 – 20 and high-risk pa-
tients 21 – 30.
Prealbumin is one of the negative acute phase reactants (see below). Prealbumin concentration drops in inflam-
matory and tumour diseases, hepatic cirrhosis and losses of proteins through the kidneys or gastrointestinal tract. The 
retinol-binding protein is a monomeric all-trans retinol-carrying protein (a form of vitamin A). It is synthesized in the 
liver and its secretion from hepatocytes is stimulated by the retinol bond. The production of the complex with preal-
bumin prevents filtration of the retinol-binding protein in glomeruli. The retinol release is followed by prealbumin and 
retinol-binding protein complex dissociation, which is then eliminated in the kidneys. Elevated retinol-binding protein 
concentrations can be found in patients with chronic renal disease, reduced concentrations in hepatic diseases and 
protein malnutrition.
7.1.4.2. Albumin
Albumin is synthesized solely in the liver, which has a high reserve in case of increased need or loss of albumin. 
Albumin is one of the few plasma proteins that does not contain carbohydrates. The charge is negative with a physi-
ological pH. Due to its high plasma concentration, albumin plays a substantial role in maintaining the colloid osmotic 
pressure. In quantitative terms, it is the most important transport protein in the body. Many substances in the blood 
bind to albumin; this is conditioned by the presence of numerous charged groups, ion- and specific hydrophobic bin-
ding sites. In particular, these are insoluble substances (unconjugated bilirubin, fatty acids, hormones, drugs). Hydro-
philic substances can bind to albumin by adsorption (e.g. Ca2+, Zn2+, uric acid). The transporting function of albumin is 
non-specific, unlike the specific transport proteins mentioned below. In addition, albumin takes part in antioxidation 
activity, acts as a buffer in pathological conditions, and inhibits the production of leucotrienes and actin. Albumin is a 
negative acute phase reactant; albumin concentration drops in the presence of proinflammatory cytokines (TNF-alpha, 
IL-1, IL-6).
7.1.4.3. Alpha-1-Globulins
Alpha-1 Lipoprotein (HDL) – refer to relevant chapter
Orosomucoid (Alpha-1-Acid Glycoprotein, AAG)
For the most part, orosomucoid is synthesized in the liver, but the synthesis in granulocytes and monocytes contri-
butes considerably to the increase in plasma concentration in septic conditions. Catabolism takes place predominantly 
through the uptake of desialylated AAG by hepatic receptors for asialoglycoproteins; while the biological half-life of an 
intact AAG is about 3 days, the half-life of desialylated AAG is just a few minutes. AAG belongs to lipocalins, i.e. proteins 
binding lipophilic substances. Its function is not yet fully known; it is supposed to have an immunomodulatory effect, 
probably conditioned by the structure of oligosaccharide chains of the AAG molecule.
Alpha-1-Foetoprotein
Alpha-1-foetoprotein has the function of albumin in the foetus, and is replaced by albumin after birth. AFP is a 
major marker in prenatal diagnosis (elevated amniotic fluid and also maternal serum concentrations in neural tube 
defects, but also in multiple pregnancy; reduced concentrations in Down syndrome – only a combined determination 
with beta-HCG and/or unconjugated oestriol in maternal serum, the “triple test”, is currently used in this indication for 
screening for congenital developmental defects [“CDD screening” in the 2nd trimester]). In non-pregnant adults, AFP is 
elevated in hepatocellular carcinoma and germ cell tumours; it can also be elevated in hepatic cirrhosis and hepatitis.
Alpha-1-Antitrypsin (Alpha-1-Proteinase Inhibitor, AAT, Alpha-1-Pi)
In quantitative terms, alpha-1-antitrypsin is the most important proteinase inhibitor in the plasma. In the case of 
a significant genetic reduction or absence (PiZZ and Pi00 genotypes) there is insufficient inactivation of proteinases 
(elastases in alveoli) released by granulocytes and macrophages during phagocytosis, and proteolytic tissue degradati-
on occurs. This leads to pulmonary emphysema with a ventilation disorder and a tendency to severe airway infections, 
and often liver damage.
Alpha-1-Antichymotrypsin
Alpha-1-antichymotrypsin is another proteinase inhibitor; it inhibits cathepsin G, mast cell chymase and PSA (in-
creased concentrations of PSA bound to alpha-1-antichymotrypsin can be found in patients with prostate carcinoma).
7.1.4.4. Alpha-2-Globulins
Alpha-2-Macroglobulin
Alpha-2-macroglobulin (AMG) is another proteinase inhibitor. It is composed of four polypeptide chains; the active 
unit is a dimer (one AMG molecule can bind two proteinase molecules). For the most part, it is synthesized by hepa-
tocytes. The biological half-life of an intact protein is a few days, but after cleaving the intrachain thioester bond or 
cleaving off sialic acid, it is quickly (within minutes) taken up by receptors in hepatocytes. Apart from its main function 
– proteinase inhibition – AMG participates in the transport of many peptides (cytokines, growth factors) and bivalent 
cations (Zn2+ in particular), and modulates inflammatory reactions.
Increased AMG concentrations can be found in nephrotic syndrome; children have higher concentrations than 
adults, and women of reproductive age have higher concentrations than men of the same age (oestrogens increase 
AMG synthesis). Reduced AMG concentrations are found in pancreatitis and advanced prostate carcinomas (AMG 
binds to PSA and this complex is very quickly taken up by the liver).
Haptoglobin
Haptoglobin binds haemoglobin generated during intravasal haemolysis; the formed complex is quickly taken up 
from the bloodstream by RES cells in the liver. This prevents the loss of haemoglobin (Fe2+) in urine as well as the creati-
on of the dangerous hydroxy radical involving free haemoglobin.
Haptoglobin is a sensitive marker of haemolysis, which causes a marked drop in haptoglobin concentration down 
to zero. Reduced concentrations are also associated with disorders of proteosynthesis in the liver; the haptoglobin 
level correlates with the severity of hepatitis. Increased concentrations are found in the acute phase reaction.
Caeruloplasmin
The main function of caeruloplasmin is ferroxidase activity (oxidizes Fe2+ to Fe3+, thus allowing iron to bind to 
transferrin). One caeruloplasmin molecule binds 6 – 8 atoms of copper, but the main copper-carrying protein is albu-
min.
Markedly decreased concentrations of caeruloplasmin are found in Wilson’s disease (mostly < 0.1 g/l) and Men-
kes syndrome. Caeruloplasmin concentrations can be reduced secondarily in the case of protein losses and protein 
synthesis disorders (hepatic cirrhosis). Elevated concentrations do not have any diagnostic significance; they can be 
found in inflammations and tumours, during pregnancy or the use of oral contraceptives (effects of oestrogens) and in 
cholestasis.
Gc-Globulin (Group Specific Component, Vitamin-D Binding Protein)
This is sometimes referred to as “inter-alpha globulin” as it can migrate in the alpha-1-alpha-2 interzone. Gc-globu-
lin is the main vitamin D-carrying protein; another function is the uptake of actin released from damaged cells. Women 
have slightly higher Gc-globulin concentrations than men; the levels rise in pregnancy and fall in acute hepatic disease 
or following serious trauma.
7.1.4.5. Beta Globulins
Transferrin
Each transferrin molecule has two binding sites for the ferric cation (Fe3+). Apo-transferrin is synthesized primarily 
in the liver; synthesis increases with a lack of iron in the body. Transferrin is the major iron-carrying element from the 
sites of absorption (small intestine) and takes part in haemoglobin degradation in haematogenous organs, where it 
binds to erythroblasts through the receptor. In situations where there is a lack of iron, transferrin receptor synthesis 
is stimulated and soluble transferring receptor (sTfR – the released extracellular domain of the membrane receptor) 
concentration increases. The sTfR concentration is not affected by the acute phase reaction; sTfR (or the sTfR concen-
tration to ferritin concentration logarithm ratio) is therefore a valuable marker helping to distinguish iron-deficiency 
anaemia from chronic anaemias.
The percentage saturation of transferrin with iron can be calculated from the following formula:
Physiologically, about 1/3 of transferrin is saturated with iron; vacant sites for the iron bond represent the free bin-
ding capacity. (The total iron-binding capacity of transferrin is given by the number of transferrin molecules available 
as well as the fact that one transferrin molecule has two binding sites for Fe3+.)
Transferrin contains 2 N-linked glycans that may further branch out; each branch is capped by a negatively charged 
molecule of sialic acid. Theoretically, a transferrin molecule can contain 0 – 8 sialic acid molecules; most molecules con-
tain 4 (64 – 80 %) or 5 (12 – 18 %) sialic acid molecules. The isoelectric point of transferrin increases with the decreasing 
number of sialic acid molecules. Alcoholics show an elevated concentration of transferrin isoforms containing a lower 
number of sialic acid residues (CDT – carbohydrate-deficient transferrin, i.e. disialo-, monosialo- and asialotransferrin) 
and therefore a higher pI, which can be used to monitor these patients. However, the isoelectric point of transferrin 
decreases with the Fe3+ bond, so transferrin should be saturated with iron before the CDT assay.
Haemopexin
Haemopexin binds haem. A decrease in haemopexin is a less sensitive (delayed) indicator of haemolysis than hap-
toglobin. When the haptoglobin capacity to bind haemoglobin is exhausted, the remaining haemoglobin circulates in 
the plasma; it is then partly taken up by liver cells, partly excreted in urine (haemoglobinuria) and partly oxidized to 
methaemoglobin, which readily dissociates haem. Haem can bind to haemopexin and is transported to liver cells in this 
bond. Haem can also bind non-specifically to albumin to form methaemalbumin, from which it can be “given back” to 
haemopexin as soon as haemopexin is available.
The haemopexin concentration is usually decreased in haemorrhagic pancreatitis and bleeding into body cavities 
with concurrent normal concentrations of haptoglobin.
Beta-Lipoprotein
Lipoprotein in the beta-2-zone corresponds to low density lipoprotein (LDL). LDLs (low density lipoproteins) are the 
main lipoprotein particles that carry cholesterol in the blood plasma. Their density is 1,019 to 1,063 kg/m3, i.e. 1.019 
to 1.063 g/ml; they are produced in IDL and VLDL catabolism, and their major apoprotein is apo-B-100. The major part 
comes from VLDL transformation, but some are synthesized directly (especially in patients with familial hypercho-
lesterolemia). LDL can be catabolized by various cell types (75 % in the liver), using both the LDL-receptor dependent 
mechanism and mechanisms independent of these receptors (e.g. using “scavenger” receptors).
C3 and C4 Complement Components
The complement system consists of about 30 proteins that can be sorted into several groups by their function:
• Classical pathway proteins (C1, C4, C2, C3);
• Alternative pathway proteins (C3, factors B and D, properdin);
• Membrane attack complex (C5 – C9);
• Aforementioned pathway inhibitors;
• Cell receptors.
 The main functions of the complement system are:
• Opsonization (a fragment of the C3 component referred to as C3b that firmly binds to the microbial surfa-
ce);
• Chemotaxis (fragments C3a and C5a);
• Osmotic lysis (C5b-C9 complex penetrating into the plasma membrane of the attacked cell and making 
pores in it; most microorganisms are protected from this lytic action by the cell wall).
The C3 and C4 components are determined most often in clinical practice. Their concentration rises slightly in the 
acute phase reaction, while it decreases with their activation or consumption in some systemic autoimmune diseases. 
The C3 component has the highest plasma concentration of all complement components. It is synthesized primarily in 
the liver; bacterial endotoxin also induces synthesis in monocytes and fibroblasts. The C4 component is likewise syn-
thesized primarily by liver cells, a small amount in other tissues.
Fibrinogen
Fibrinogen is a glycoprotein with a molecular weight of 340 kDa. It migrates between beta and gamma globulins in 
electrophoresis. It is a symmetric dimer consisting of three pairs of alpha, beta and gamma chains.
During haemocoagulation, fibrinopeptide A is released by the action of the proteolytic enzyme, thrombin, to form 
fibrin monomer. Thrombin then cleaves off fibrinopeptide B and fibrin monomer polymerization occurs as activated 
coagulation factor XIII cross-links fibrin to form a stable thrombus.
Fibrinogen is one of the positive acute inflammation phase reactants. Within a few hours of the onset of inflam-
mation the fibrinogen level increases by the induction of increased synthesis in the liver, and in a few days may reach 
many times higher levels than the baseline. High concentrations can be found in inflammatory connective tissue disea-
ses, for example. Fibrinogen is a risk factor for aterosclerosis.
A decrease in concentration can be caused by insufficient synthesis in severe hepatopathies or by increased con-
sumption, for instance in disseminated intravascular coagulopathy (DIC).
Fibrinogen can be found in the beta-gamma interzone on the electropherogram. It can be confused for the M-gra-
dient (and vice versa), which is the main reason why serum is preferred over plasma for electrophoresis.
7.1.4.6. Gamma Globulins
Immunoglobulins
Immunoglobulins (antibodies) detect an antigen and initiate mechanisms to destroy it. All immunoglobulin mole-
cules consist of two identical H-chains (H for heavy) (alpha for IgA, delta for IgD, gamma for IgG, mu for IgM, epsilon 
for IgE) and two identical L-chains (L for light) (kappa or lambda). Each of the chains has a constant part and a variable 
part, the latter participating in the distinguishing and binding of antigens. The variable part of the heavy and light chain 
consists of a single domain; the constant part of the light chain also consists of a single domain, but the constant part 
of the heavy chain consists of multiple domains. The light chain together with the variable part and the first domain 
of the constant part of the heavy chain form the Fab fragment (“ab” stands for “antigen binding” – antigen-binding 
fragment); the other domains of the constant parts of heavy chains form the Fc fragment (“c” stands for crystallizable). 
Therefore, every immunoglobulin molecule has two Fab fragments and one Fc fragment. Unlike most plasma proteins 
synthesized in the liver, immunoglobulins are synthesized and secreted by plasma cells.
Immunoglobulins are glycoproteins; oligosaccharide is always bound on the constant part of the heavy chain (one 
oligosaccharide binds to the gamma chain, multiple oligosaccharide molecules bind to the other H-chain types).
Figure 7.3. The simplest schematic representation of an immunoglobulin molecule consisting of two heavy (H) chains 
and two light (L) chains. The light chains have a variable (V) part and a constant (C) part of about the same size, while 
the variable part of heavy chains is just about one quarter, and the constant part about three quarters (C1 – C3) of its 
size. The lines between the chains represent disulphide bonds. Intra-chain disulphide bonds are not shown. The number of 
disulphide bonds in the hinge region (connecting both heavy chains) varies in different classes and subclasses of immuno-
globulins
Immunoglobulin G (IgG)
Quantitatively this is the most common (70 – 75 % of total immunoglobulins). 65 % of IgG is present extravascular-
ly. The main function of IgG is to neutralize toxins in tissues. IgG contains one molecule of oligosaccharide capped by 
glucosamine (GlcN) bound by the N-glycosidic bond to asparagine in the constant part of the heavy chain. IgG is sorted 
into several subclasses (IgG1 – IgG4), distinguished from each other primarily by the hinge region arrangement.
Immunoglobulin M (IgM)
IgM is the first immunoglobulin synthesized during the antibody response, and also the only immunoglobulin nor-
mally synthesized in newborns. It exists as a monomer bound to the membrane, while most IgM present in the serum 
is a pentamer consisting of five monomer immunoglobulin units linked by a small glycopeptide known as the J-chain. 
IgM contains about 10 % carbohydrates. The large molecular weight of IgM (MW 900,000 per pentamer) prevents it 
from escaping into the extravascular space. IgM effectively activates the complement; this function is provided by the 
Fc part of the molecule.
Immunoglobulin A (IgA)
Immunoglobulin A represents 10 to 15 % of serum immunoglobulins. IgA contains 10 % carbohydrates, and the 
biological half-life is about 6 days. The majority of IgA is present as monomers but 10 to 15 % of serum IgA is dimeric. 
The dimer is more resistant to destruction by pathogenic microorganisms. Another form of IgA is secretory IgA, which is 
present in tears, saliva, sweat, milk, colostrum, and airway and digestive tract secretions. Secretory IgA MW is 380,000 
and consists of two monomeric IgA units, the secretory component (MW 70,000) and the J-chain (MW 15,600). It is 
synthesized primarily by plasmocytes in the intestine and bronchi mucosa, and in mammary gland outlets. The secre-
tory component provides secretory IgA with an increased resistance to enzymes, thereby protecting mucosas against 
microorganisms. IgA presence in the colostrum and milk protects newborns against intestinal infections.
Immunoglobulin D (IgD)
Immunoglobulin D represents less than 1 % of serum immunoglobulins. It is a monomer containing 12 % carbohyd-
rates, with a MW of 184,000. It is present as a membrane receptor for antigen on B lymphocytes.
Immunoglobulin E (IgE)
IgE contains 15 % carbohydrates and has a MW of 188,000. IgE molecules bind to the surface of mast cells (with 
their Fc region). If antigen (allergen) is bound and the two linked IgE molecules connected, mast cells are stimulated to 
release histamine and other vasoactive substances responsible for allergic reaction manifestations.
Physiological, temporary hypogammaglobulinaemia can be found in newborns and infants (see Figure 4). Antibody 
immunodeficiencies lead to permanently low to zero immunoglobulin levels; immunoglobulins of all isotypes (e.g. 
Bruton’s X-linked agammaglobulinaemia), or just some isotypes (e.g. common variable immunodeficiency with IgG and 
IgA antibody disorder, or selective IgA deficiency, locally the commonest antibody immunodeficiency) can be affected. 
Secondary (acquired) antibody immunodeficiencies are more frequent than these primary immunodeficiencies. The 
former occur in intestinal inflammations, nephrotic syndrome, long-term immunosuppresive or cytostatic therapy and 
B-cell malignancies.
Figure 7.4. Schematic representation of changes in immunoglobulin concentrations in the first months of life. Trans-
placental IgG antibodies (mIgG) decrease to zero in the first year of life; the lowest concentration of total IgG is between 
the 3rd and the 6th month. The IgA concentration reaches adult values around 10 years of age
Kappa and Lambda Free Light Chains
Light chains are part of the immunoglobulin molecule; their physiological production is slightly higher than the 
production of heavy chains, which is why they can be also found in the blood serum. It seems that they have a certain 
importance in immune response regulation. Markedly elevated (even by several orders) concentrations of free light 
chains of one type can be found in the blood serum in tumorous plasma cell proliferations; besides absolute concen-
trations, the ratio (free kappa/free lambda), or more recently the difference (free kappa – free lambda, or vice versa) 
of their concentrations are also monitored. Their determination requires the use of a specific antibody against hidden, 
“invisible” determinants, if the light chain is bound to the heavy chain in the complete immunoglobulin molecule. The 
issue of free light chain immunochemistry is therefore highly specific and has not been satisfactorily resolved up to 
now; nevertheless, they are a valuable marker in the diagnosis and monitoring of monoclonal gammopathy patients, as 
well as a promising marker of some autoimmune disease activity (systemic lupus erythematosus, rheumatoid arthritis, 
Sjögren’s syndrome, etc.).
7.1.4.7. Monoclonal Gammopathies
This term refers to the presence of immunoglobulins (or fragments thereof) produced by one clone of plasma cells. 
In accordance with the 2003 international classification, they include the following conditions:
• Monoclonal gammopathy of undetermined significance (MGUS)
• Asymptomatic (smouldering) multiple myeloma (ASMM)
• Symptomatic multiple myeloma
• Solitary bone plasmacytoma
• Extramedullary plasmacytoma
• Multiple solitary plasmacytoma
• Plasma cell leukaemia
Monoclonal immunoglobulins can also be rarely found in non-tumour diseases such as AIDS, chronic hepatitis, 
cirrhosis or rheumatoid arthritis; a part of such cases probably coincides with MGUS.
Serum protein electrophoresis is used as a screening test for monoclonal gammopathy diagnosis. If a monoclonal 
(M) gradient is found, immunofixation electrophoresis is added to determine the M-gradient type (IgG, IgA, IgM, kap-
pa, lambda, and/or free kappa, free lambda, IgD and IgE). IgM monoclonal gammopathies are accompanied by a di-
sease known as Waldenström’s macroglobulinaemia. Other immunoglobulins may bind to monoclonal IgM molecules 
during immunofixation and “false” positive results may occur in the other classes. This situation can be elegantly solved 
by adding a small amount of mercaptoethanol or dithiothreitol (see Figures 7.5a-c).
Figure 7.5. a.
Figure 7.6. b.
 Figure 7.7.  c.
Figure 7.8. Immunofixation electrophoresis
ELP: electrophoresis
G, A, M, K, L: Immunofixation using antisera against gamma, alpha, mu, kappa and lambda chains.
IgG-kappa paraprotein
IgG-lambda paraprotein
IgM-kappa paraprotein apparent after sample incubation with dithiothreitol; “false” positive results occur in all 
positions of the sample without dithiothreitol
If paraprotein is found, its quantity is determined using densitometry. Immunofixation should be added at the first 
examination to determine the heavy and the light chain type; the lab report for the attending physician then looks like 
this: “IgG-kappa paraprotein, 30 g/l by densitometry”. As long as paraprotein is quantifiable by densitometry, immu-
nofixation is not repeated during further patient follow-up. Paraprotein often disappears when modern therapeutic 
methods are used; as soon as it is no longer quantifiable, immunofixation is indicated again. Stem cell transplantation 
is sometimes followed by an oligoclonal response (some bands are only detectable by electrophoresis or immunofi-
xation; they may belong to different light or heavy chain classes); this does not mean a relapse of the disease but a 
temporary dysregulation of immunoglobulin production after transplantation.
Cryoglobulinaemia
Cryoglobulins are immunoglobulins reversibly precipitating at temperatures lower than human body temperature. 
There are 3 types of cryoglobulins:
• Type I: Isolated monoclonal cryoglobulins (IgM paraproteins, rarely IgG, IgA paraproteins or monoclonal 
light chains);
• Type II: Mixed cryoglobulins (a combination of paraprotein with polyclonal immunoglobulin, usually IgM 
paraprotein with antibody activity against polyclonal IgG);
• Type III: Polyclonal immunoglobulins, where cryoglobulin consists of immunoglobulins of one or multiple 
classes forming an antigen-antibody complex.
Cryoglobulinaemia affects many laboratory examinations (e.g. it slows down sedimentation); the serum or plasma 
specimen should be preheated for all assays; incubation of the serum with mercaptoethanol or dithiothreitol is some-
times recommended before electrophoresis.
Even rarer than cryoglobulins are pyroglobulins; these are monoclonal immunoglobulins irreversibly precipitating 
at 56°C.
Polyclonal Gammopathy
Elevated concentrations of polyclonal gammaglobulins (i.e. the homogeneous increase in gammaglobulins during 
electrophoresis) can be found in connective tissue diseases (systemic lupus erythematosus, Sjögren’s syndrome, rhe-
umatoid arthritis, etc.), liver diseases (autoimmune and viral hepatitis, primary biliary cirrhosis, primary sclerosing 
cholangitis, haemochromatosis, alcoholic liver damage, α1-antitrypsin deficiency), chronic infections, lymphoprolifera-
tive diseases and non-haematological malignancies. Skin, lung and intestine diseases and also some liver diseases are 
often accompanied by an elevated IgA concentration, while systemic infections lead to elevated concentrations of all 
immunoglobulins, IgG in particular.
7.1.4.8. Acute Phase Reactants
This term refers to proteins whose concentration in the plasma alters in an acute inflammatory involvement. Acu-
te phase reactants are divided into positive reactants (CRP, SAA and others), whose concentration increases in such 
circumstances, and negative reactants (prealbumin, albumin, transferrin), whose serum concentration conversely de-
creases.
C-Reactive Protein (CRP)
The name of this protein is derived from its ability to bind the cell wall C-polysaccharide of Streptococcus pneumo-
niae. However, not only does it bind a variety of polysaccharides on the surface of bacteria, fungi and protozoa, but 
also phosphatidylcholines and polyanions. After binding, the complement is activated in the classical way. The main 
function of the CRP is to detect potentially toxic substances released from damaged tissues.
The CRP is the most important positive acute phase reactant as the CRP assay is easily available and its concen-
tration rises quickly (within 24 – 48 hours). CRP levels increase in bacterial infections, but also following myocardial 
infarction, traumas, surgeries and tumour diseases.
Serum Amyloid A (SAA)
Serum Amyloid A is a protein with a total MW of 220,000 – 235,000, consisting of monomers with a MW of 12,500. 
For the most part, it is bound to HDL lipoproteins. This is a group of small lipoproteins that take up lipid residues from 
cell membranes during acute infection, thereby having a positive effect; during chronic inflammations, on the other 
hand, the precursor protein SAA may form insoluble deposits in organs and participate in secondary amyloidosis (un-
like secondary amyloidosis, primary amyloidosis is typical of light immunoglobulin chains in malignant myeloma and 
related diseases). The serum SAA concentration is also increased in some malignant tumours and rises as the disease 
progresses.
Procalcitonin (PCT)
Procalcitonin increases in the plasma in bacterial infections, sepsis and multiple organ failure. The main stimulus is 
bacterial endotoxins. An increase in the plasma occurs after 2 hours; concentrations are clearly elevated in 6 – 8 hours 
and remain elevated for 72 hours.
Ferritin
Above all, ferritin is a reserve protein for iron; one molecule of apoferritin can bind up to 4500 iron atoms (Fe3+). 
Since it is a positive acute phase reactant at the same time, it is mentioned here.
7.1.4.9. Some Low-Molecular Weight Proteins
Some of the major low-molecular weight proteins will now be described. A general feature of low-molecular weight 
proteins is a rise in serum concentration with a decrease in glomerular filtration; they are therefore used as renal di-
sease markers, and are discussed in the relevant chapter as such. Only the most important ones are mentioned here:
Beta-2-Microglobulin
Beta-2-microglobulin is a simple non-glycosylated polypeptide consisting of 100 amino acids with one disulphide 
bridge and a molecular weight of 11,800 Da. It is a part of the HLA system on the cell surface. The plasma beta-2-
-microglobulin is mainly a product of myeloid and lymphoid cells, and can be used as a tumour marker reflecting a 
proliferation of cells of this origin.
Beta-2-microglobulin freely passes through the fully functional glomerulus. Its level in the urine rises in tubular cell 
lesion; the serum level increases with a decrease in glomerular filtration. A long-term increase of serum beta-2-micro-
globulin concentration, in dialysed patients for example, may be the cause of secondary amyloidosis.
Cystatin C
Cystatin C is a protein from the cysteine protease inhibitor family, filtered by glomeruli and fully reabsorbed by 
renal tubules, and suitable for evaluating glomerular filtration. Cystatins have an evolutionary and functional relation-
ship to serine protease inhibitors. Cystatin C, which is an eminent subject of interest for clinical biochemists, belongs to 
cystatin Family 2, consisting of a group of extracellular cysteine protease inhibitors. Each representative of this group 
has a serial number, although the third cystatin continues to be referred to as cystatin C.
Beta-Trace Protein
Beta-Trace Protein is an enzyme converting PGH
2
 to PGD
2
 (prostaglandin-H
2
 D-isomerase), with a MW of 25 kDa. 
It originates solely in the brain; the main point of synthesis is the choroid plexus and leptomeninges. From there, BTP 
is released into the cerebrospinal fluid (CSF). BTP is present in traces also in other body fluids, including serum. Its CSF 
concentration is 32 times higher than its serum concentration. Therefore, it is an excellent marker of liquorrhea. Apart 
from being used in CSF diagnosis, it is sometimes used as a marker of glomerular filtration (like cystatin C). One draw-
back to the assay is its high cost.
Cytokines
The term “cytokine” refers to a signal substance of cellular origin. Cytokines are low-molecular weight (often glyco-
sylated) proteins produced by immune system cells (lymphocytes, monocytes, macrophages, neutrophil granulocytes) 
as well as classical “non-immune” cells (endothelial cells, fibroblasts, etc.). They are distinguished by their major action 
on the cells that produce them, and on cells in their close vicinity (autocrine and paracrine action). They act in very low 
concentrations and have a very short half-life (minutes).
Interleukin 6 (IL-6)
The IL-6 level rises in 2 – 4 hours in acute inflammation, independently of liver function. It is therefore especially 
suitable for an early diagnosis. The IL-6 concentration in the plasma or serum of healthy people is <11.3 ng/l; concent-
rations >400 ng/l give rise to a strong suspicion of sepsis. The sensitivity of the assay is almost 100 %, while specificity 
depends on the underlying disease. Elevated concentrations may be found in autoimmune diseases, glomerulonephri-
tis, tumours, and in the first days after a surgery.
Interleukin 8 (IL-8)
Interleukin 8 has a similar significance as IL-6. Elevated concentrations can be found in acute inflammations, but 
also tissue hypoxias and traumas.
Tumour Necrosis Factor (TNF-α)
Tumour Necrosis Factor is considered a marker of Systemic Inflammatory Response Syndrome (SIRS). The determi-
nation is a problematic one. Following stimulation, TNF-α is secreted for just a few hours and its half-life is <5 minutes. 
It is necessary to distinguish between tests determining biologically active TNF-α (trimer), and tests determining “to-
tal” TNF-α (which also detects monomers and splitting products).
A concurrent increase in IL-8 and TNF-α concentrations is indicative of monocyte activation (SIRS). If only IL-8 is 
elevated, this is indicative of non-immune cell activation, such as that following the attachment of bacteria or their 
lipopolysaccharides to endothelial cells.
A drawback is the high cost of cytokine assays, of which only the IL-6 assay as an early acute inflammation marker 
has been widely used.
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8.1. Natrium
8.1.1. Basic Properties, Absorption
Sodium is the major extracellular cation. Sodium metabolism and transfers between the body compartments are 
closely associated with the transfer of water. Changes in water volume in the body are expressed by a deviation of se-
rum Na+ concentration from the standard level. Any loss of water in extracellular fluid (ECF) while retaining Na+ reserves 
is associated with an increase in Na+ concentration (hypernatraemia). Conversely, an increase in water volume in ECF 
leads to a drop in Na+ concentration (hyponatraemia). Water and sodium metabolisms are closely related, and the rule 
“where sodium goes, water follows” generally applies. Sodium is absorbed in the small intestine, often in association 
with the absorption of other substances (amino acids, glucose), where sodium, or the sodium concentration gradient, 
drives the transport of other substances (co-transport). Sodium is pumped from cells to the extracellular space through 
the action of ubiquitary Na+K+-ATPase. The energy from this transport comes from ATP produced in oxidative processes 
in mitochondria during the metabolism of energy substrates.
Water and Na+ absorption is completed in the ileum, where tight junctions are present which are minimally perme-
able to Na+ intraluminally from the paracellular space of red blood cells. This is why any loss of ileum and the creation 
of a jejunostomy or jejuno-colon anastomosis leads to significant water and sodium losses and the development of 
dehydration of the organism. The absorption of amino acids and energy substrates (carbohydrates, fats) is usually not 
disturbed if the jejunum is kept.
8.1.2. Daily Requirement in Sickness and in Health
The minimum estimated daily Na+ requirement is 50 – 85 mmol, which corresponds to 35 g of NaCl. Since sodium 
is excreted from the body primarily through the kidneys, the 24-hr urine Na+ output is indicative of Na+ intake in food 
and fluids. Common amounts of Na+ output in 24-hr urine are 80 – 250 mmol, which correspond to 5 – 15 g of NaCl 
(1 g NaCl contains 17 mmol Na+). Intake depends on the needs of the body and relates to sweating, the presence of 
diarrhoea, polyuria, drugs, etc.
The NaCl intake in this population exceeds the minimum requirement several times, being 10 – 15(20) g a day on 
average. This excessive intake is caused by modern food processing, preservation, and a high consumption of meat 
products and cheeses. Most people are able to cope with this increased Na+ intake; only one third of “salt sensitive” 
people consequently develop hypertension.
A low sodium intake can lead to the development of hypo-osmolar dehydration, or, if pure water intake is mainta-
ined, to a “water poisoning” condition with clinical signs of cerebral oedema. Low sodium intake is rare under these 
conditions; most cases concern a relatively higher pure water intake with the potential development of hyponatrae-
mia. Seniors with a decreased sensation of thirst and patients with anorexia nervosa are an exception.
An increased sodium requirement is typical for people with increased losses and limited absorption that cannot 
be made up for by increased oral intake of Na+. These patients require infusion treatment. This is the case with the 
following conditions:
• Resection of small bowel, the ileum in particular;
• High-output small bowel fistulas, pancreatic fistulas;
• Intestinal malabsorptions with exudative enteropathy (inflammatory bowel diseases (IBD), coeliac disease, 
Whipple disease, postradiation enteritis, vasculitis, bowel ischaemia, drug-induced intestinal injury);
• Polyuric phase of renal failure with increased sodium excretion.
The NaCl requirement in these conditions increases to 15 – 25 g/day. The optimal supply should be determined 
based on the measurement of daily urine output; losses in sweat and stool should be estimated, and osmolality and 
serum Na+ concentration determined. An important approach in estimating the Na+ requirement in these conditions 
is observing the dynamics of change over time. Any reliable determination of the requirement from a single assay is 
impossible. It is advisable to monitor output trends and the development of natraemia, osmolality and diuresis for at 
least seven days, or on Day 1, 3 and 7. This monitoring is used to determine the long-term daily requirement and a 
decision should be made regarding i.v. substitution. I.v. hydration should be considered especially in conditions with 
a loss of weight and a loss of diuresis under 800 ml/24 hrs. The urine Na+ output in these conditions drops under 20 
mmol/24 hrs and the urine potassium output increases, with the potential development of hypokalaemia. The abo-
ve-mentioned alterations are a sign of secondary hyperaldosteronism. If this condition develops even in the case of 
maximum tolerated increase in the daily sodium intake (salt addition, NaCl cps [3x2g] rehydration solutions), patients 
are candidates for long-term i.v. substitution.
8.1.3. Sodium Balance
Daily patient weight monitoring as a global indicator of the total water and sodium balance is an important met-
hod for determining sodium balance. Daily changes in body weight correspond to changes in body hydration, or sodi-
um retention/mobilization. A retention or loss of 140 mmol Na+ (8 g NaCl) corresponds to a retention or loss of 1 litre 
of water.
Weight loss over 3 days corresponds to water (Na+) losses and may warn of a changing clinical situation:
• Originally normovolemic patients (healthy patients with developing diarrhoeas of varied etiology) are at 
risk of dehydration (lassitude, faintness, reduced blood pressure, increased heart rate, increased albumin, 
increased haemoglobin), and should be treated by infusion;
• In originally hypervolemic patients (oedema conditions – cardiac failure, hepatic cirrhosis, sepsis, acute 
pancreatitis, polytrauma), it is a favourable situation signalling the mobilization of fluids.
The clinical difference of these situations is considerable and must not be confused because treatment is exactly 
the opposite, infusion therapy for rehydration in the former case, and not increasing daily fluid intake, or a diuretic 
therapy, in the latter.
Weight increase within days should be evaluated as sodium and water retention, which may correspond to a wor-
sening of the disease (cardiac failure, increased portal hypertension) with the occurrence of oedemas, or the develop-
ment of catabolism (metabolic stress) with sodium retention.
24-hour urine sodium output is an indicator of similar importance. If the 24-hr Na+ outputs fall under 20 mmol, 
two situations may have occurred:
• Sodium deficiency in extrarenal sodium losses (diarrhoea, sweating, fistulas) even with the diuresis main-
tained. Na+ is reabsorbed in the kidneys due to an increased aldosterone level. K+ and H+ outputs increase 
under the influence of this hormone. Developing hypokalaemia and alkalosis are then a sign of Na+ deple-
tion and dehydration of the body. Hypokalaemia cannot be adjusted by simple substitution of K+; sodium 
and water must also be replenished.
• The situation in oedema conditions is different in that the Na+ content in the body is increased, even in the 
presence of hyponatraemia. The reason is a systemic disease that leads to circulatory alterations with re-
nin-angiotensin-aldosterone system (RAAS) activation and Na+ and water retention. The principle of trea-
ting this condition is quite different. It consists in limiting water and sodium intake and mobilizing fluids 
and Na+ using diuretics. When choosing diuretics, it is best to combine aldosterone antagonists (spirono-
lactone), which interfere directly with the activated RAAS axis, together with loop diuretics (furosemide).
High sodium outputs (more than 250 mmol/24 hrs) indicate sodium and fluid mobilization during transition to an 
anabolic condition after overcoming metabolic stress (sepsis, acute pancreatitis, polytrauma), the positive effect of 
diuretics, or a renal disease with sodium reabsorption disorder (tubulointerstitial nephritis).
Plasma Na concentration 135 – 145 mmol/l
Na+ reserve in ECF 1400 mmol
Na+ reserve in ICF 1000 mmol
Na+ intake 140 – 260 mmol/24 hrs
Na+ output in urine 120 – 240 mmol/24 hrs
Na+ output in stool 10 mmol/24 hrs
Na+ output in sweat 10 – 80 mmol/24 hrs
Total Na+ output 140 – 260 mmol/24 hrs
Table 8.1. Sodium balance and distribution
8.1.4. Hyponatraemia
Hyponatraemia is a condition where the serum concentration of sodium drops under 135 mmol/l. It is the commo-
nest electrolyte disorder in clinical practice. Hyponatraemia develops more often due to Na+ dilution than as a result 
of Na+ depletion. Hyponatraemia is clinically significant when Na+ drops under 130 mmol/l, and becomes serious or 
potentially life-threatening at levels under 120 mmol/l. The development rate is also important for clinical seriousness; 
the faster the development, the more dangerous are the consequences. In the terms of therapy, it is important to 
distinguish whether it is acute hyponatraemia (a Na+ decrease under 125 mmol/l within 48 hours), or chronic hypo-
natraemia, where a drop in Na+ occurs within more than 48 hours. Treatment for acute hyponatraemia should be ag-
gressive and fast, in particular if an Na+ decrease under 120 mmol/l has clinical symptoms such as confusion, faintness, 
muscle twitches, headache, vomiting, or coma as a clinical impact of cerebral oedema. On the other hand, aggressive 
treatment of chronic hyponatraemia may have fatal consequences in the form of developing CNS demyelination (de-
myelinating syndrome) due to the fast transfer of water from the ICF to the ECF in the brain as a result of the osmotic 
gradient. Following a temporary improvement of the condition, clinical signs include disorientation, pyramidal tract 
symptoms with spasm of the extremities and pseudobulbar palsy developing at different rates. The final result may be 
vigil coma or exitus. Chronic hyponatraemia must, therefore, be treated slowly, with a maximum increase in natrae-
mia of 8 – 10 mmol/l/24 hrs. Clinical symptoms of chronic hyponatraemia such as faintness, somnolence and muscle 
twitches are slighter and insidious. If properly treated, patients can survive without consequences even at Na+ levels 
of around 90 mmol/l.
8.1.4.1. Pseudohyponatraemia
This condition occurs with high serum protein (more than 100 g/l) or lipoprotein (chylous serum) levels. These 
large molecules take up considerable space in the plasma, and the water and Na+ content in the plasma decreases. 
The amount of sodium per ml of plasma is lower. Serum osmolality related to 1 kg of water is normal in pseudohypo-
natraemia.
Hyponatraemia may be associated with an increase in osmolality, which is due to a higher concentration of pa-
thologically elevated osmotic substances (glucose, urea). Water is transported to the extracellular space and sodium 
concentration decreases during hyperglycaemia. An increase in blood sugar by 5.5 mmol/l above the upper limit of 
the normal range is connected with a decrease in Na+ by about 1.6 mmol/l. In other cases, hyponatraemia is always 
associated with hypoosmolality.
8.1.4.2. Hyponatraemia during Dehydration (Hypovolaemia)
The principle of this condition is the fact that Na+ losses are higher than pure water losses. Increased sodium losses 
have extrarenal and renal causes.
• Extrarenal losses are due to diarrhoea, sweating, vomiting and 
high output to stomata or fistulas (intestinal, biliary, pancreatic). 
In these situations, the Na+ concentration in the urine is low and decreases under 20 mmol/l, while urine 
osmolality is high and increases over 400 mOsmol/kg H
2
O;
• Renal losses are induced by interference with the tubular reabsorption of Na+ due to different causes:
o Diuretics (thiazides, loop diuretics);
o Renal diseases leading to tubular reabsorption disorder (tubulointerstitial nephritis, polycystic kidney 
disease, the polyuric phase of acute renal failure);
o Transplanted kidney;
o Non-sodium osmotic diuresis where polyuria and increased fractional excretion of Na+ occur due to 
pathologically increased excretion of osmotically active substances (glucose, ketone bodies, urea);
o Mineralocorticoid and cortisol deficiency – Addison’s disease.
In these situations, the concentration of Na+ in the urine is high, or higher than 20 mmol/l, Na+ losses are higher 
than 20 mmol/d and urine osmolality is low – lower than 400 mOsmol/kg H
2
O.
Gastric juices 10 – 115 mmol/l
Jejunal secretion 85 – 150 mmol/l
Ileal secretion 85 – 118 mmol/l
Pancreatic fistula 115 – 150 mmol/l
Biliary fistula 130 – 160 mmol/l
Diarrhoeic stool 30 – 60 mmol/l
Table 8.2. Na+ concentration in intestinal secretions
8.1.4.3. Euvolaemic Hyponatraemia
This condition is due to slight solute-free water retention (undetectable using common clinical methods) without 
any clinical development of oedema, with ECF dilution and the occurrence of hyponatraemia. In this situation, solute-
-free water excretion is reduced (the fractional excretion of pure water is decreased) and sodium excretion is maintai-
ned. The commonest cause of this condition is the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 
Due to the secretion of substances with an ADH effect, there is a lower excretion of solute-free water in this condition. 
However, there is no clinically manifested occurrence of oedemas, most probably because slight water retention with 
low intravascular volume expansion is a sufficiently strong volumoregulation stimulus for increased renal Na+ excretion 
through natriuretic peptides. The diagnosis of this condition is based on serum osmolality and hyponatraemia deter-
mination (under 130 mmol/l) without clinically manifested oedemas and maintained renal Na+ excretion with urine os-
molality over 100 mOsmol/kg H
2
O. It is sometimes difficult to distinguish this syndrome from the Cerebral Salt Wasting 
Syndrome (CSWS). In CSWS, the increased Na+ losses in the urine are conditioned by the action of pathologically 
produced natriuretic peptide. Patients show clinical signs of dehydration. The treatment of SIADH consists in limiting 
the oral intake of fluids to under 1 litre in 24 hrs. Severe symptomatic hyponatraemia is treated by loop diuretics with 
Na+ loss compensation to achieve pure water excretion with maintained sodium balance. CSWS should be treated by 
Na+ substitution together with solute-free water. The causes of SIADH include pulmonary diseases (pneumonia, TBC, 
aspergillosis), tumours (lungs, pancreas or duodenum tumours, thymomas, lymphomas), CNS diseases (encephalitis, 
meningitis, cerebrovascular disease, tumours, abscesses, Guillain-Barré syndrome, psychoses), drugs stimulating ADH 
output (narcotics, barbiturates, carbamazepine, nicotine), or potentiating the effect of ADH (NSAID, cyclophosphami-
de, clofibrate).
Another cause of euvolemic hyponatraemia can be psychogenic polydipsia, accompanying disease conditions such 
as anorexia nervosa, neurosis or schizophrenia. If hyponatraemia is found with absent oedemas (euvolaemia), poten-
tial hypocorticalism (Addison’s disease) or hypothyreosis should be taken into account.
8.1.4.4. Hypervolaemic Hyponatraemia
ECF is increased in this case, and oedemas are clinically evident in patients. The pathophysiological background for 
this condition is insufficient renal excretion of Na+ and water due to circulatory alterations and organ disorders:
• Hepatic failure (RAAS activation);
• Cardiac failure (RAAS activation);
• Nephrotic syndrome with the development of hypoalbuminaemic oedemas;
• Anuric renal failure with hyperhydration;
• Severe malnutrition.
Normonatraemic hypervolaemia is frequent at the beginning of these conditions. If organ failure continues, gene-
ral alterations in the body occur with the development of catabolism due to lack of energy substrastes in fasting. The 
manifestation of total energy depletion in the body is a decrease in Na+K+-ATPase activity with intracellular Na+ and 
extracellular K+ accumulation, and the development of terminal hyponatraemia.
8.1.5. Hypernatraemia
Hypernatraemia is characterized by increased Na+ concentrations over 145 mmol/l. Clinical manifestations occur 
at levels over 150 mmol/l; levels over 160 mmol/l are often lethal. The clinical presentation is dominated by thirst, 
decreased skin turgor, CNS disorders, cephalalgia, vomiting, spasms and coma. This condition is caused most often by 
predominant pure water losses with clinical symptoms of dehydration. More rarely, hypernatraemia occurs in euvolae-
mia or hypervolaemia, usually due to iatrogenic overloading by infusions containing sodium.
8.1.5.1. Hypernatraemia Due to Lack of Water – Hypernatraemic Dehydration
This condition may be caused by insufficient intake or increased losses of pure water. Seniors with a decreased 
sensation of thirst are predisposed to pure water deficiency due to insufficient water intake. Even a slight water de-
ficiency may lead to mental state alterations in elderly patients. If the situation is not assessed and treated correctly 
with an i.v. supply of pure water (or 5% glucose), or, conversely, if the patient is sedated by antipsychotic drugs, then 
dehydration and disorientation worsens, and coma with fatal consequences will occur. Fluid intake disorder can also 
be caused by diseases featuring swallowing problems such as dysphagia of various origin, pseudobulbar syndrome 
following cerebrovascular disease (CVD), head and neck injuries, or orofacial tumours.
A laboratory finding in pure water deficiency reports hypernatraemia with Na+ over 145 mmol/l and hyperosmolali-
ty of more than 300 mOsmol/kg H
2
O. The kidneys reabsorb water and sodium to a maximum extent; diuresis decreases 
and urine osmolality increases. Increased water losses are due to extrarenal and renal losses.
Extrarenal pure water losses with the development of hypernatraemia are caused by feverish conditions that 
increase perspiratio insensibilis (insensible perspiration) as well as sweat output. The sodium concentration in sweat 
is individual (9 – 77 mmol/l) and the increased sodium output may affect Na+ and H
2
O losses to different degrees. In 
the vast majority of cases, water loss from sweating is higher than sodium loss. In addition, water loss may be caused 
by vomiting, resulting in metabolic alkalosis, and diarrhoea, resulting in hypokalaemia, and metabolic acidosis due to 
bicarbonate losses.
Increased renal water losses occur in the polyuric phase of acute renal failure as a result of tubule function disor-
der in tubulointerstitial nephritis (TIN) or septic kidneys, where the renal medulla is unable to produce concentrated 
urine. An important cause of renal water losses is insufficient ADH production – central (neurogenic) diabetes insipi-
dus. An insensitivity of the renal tubules to ADH is referred to as nephrogenic diabetes insipidus. The above-mentioned 
increased renal water losses are manifested in laboratory results by a fall in urine osmolality below the level of serum 
osmolality, 250 mOsmol/kg H
2
O being considered the limit; the values drop beneath 100 mOsmol/kg H
2
O in maximum 
water polyuria, fractional pure water excretion increases over 2 % and polyuria occurs (daily diuresis over 2500 ml, 
diuresis reaches 8000 – 10000 ml/24 hrs in extreme cases of diabetes insipidus).
Body temperature Perspiratio insensibilis (ml/24 hrs)
37.2 550
37.8 600
38.3 800
38.9 900
39.4 1000
Table 8.3. Dependence of perspiratio insensibilis (insensible perspiration) on body temperature
8.1.5.2. Hypernatraemia with Euvolaemia or Hypervolaemia
Hypernatraemia without signs of dehydration occurs in rare cases. Most cases involve an increase in sodium inta-
ke in the form of infusion solutions, where therapeutic use is excessive (e.g. saline = 0.9% NaCl solution contains 154 
mmol/l Na+ = 9 g NaCl). In addition, this condition may be caused by primary hyperaldosteronism or Cushing’s syndro-
me.
8.2. Kalium
8.2.1. Basic Properties
K+ is the major intracellular cation. Potassium concentrations in the ICF range from 100 to 160 mmol/l. A person 
weighing 70 kg has about 4000 mmol K+. The high K+ concentration in the ICF is provided by Na+/K+-ATPase. That is why 
ATP availability and the energy balance of the body are of crucial importance for the proper distribution of K+. Na+/
K+-ATPase transports 3 Na+ ions from the cell and transports 2 K+ ions into the cell. It therefore generates the electro-
negativity of the intracellular space, which is caused by, among other factors, for example differing cell membrane 
permeability to Na+ and K+ (the cell membrane is more permeable to K+ than Na+). The result of this ion distribution 
is the genesis of resting membrane electric potential, which is fundamental for many physiological processes such as 
neuromuscular transmission, nerve impulse propagation or the function of the heart. Given the fundamental role of K+ 
in the generation of resting membrane electric potential, changes in K+ concentration in body fluids have far-reaching 
and often fatal consequences.
Hypokalaemia may cause muscular weakness and slower nerve impulse propagation, which may become clinically 
manifested by reduced ventilation (among other effects), resulting in respiratory insufficiency and the necessity of 
artificial lung ventilation.
The function of smooth muscles is also reduced at lower potassium levels, resulting in paralytic ileus.
The function of the heart is pathologically affected by both hypokalaemia as well as hyperkalaemia with its po-
tential development of malignant arrhythmias – ventricular fibrillation or asystoles. It is evident from the above that 
maintaining the proper K+ level in the body compartments is of major importance.
8.2.2. Potassium Requirement, Balance, Relation to ABB and Nutritional Status
The daily requirement of K+ ranges from 1 to 2 mmol/kg per day. This requirement is increased during anabolism, 
when insufficient K+ substitution results in serious hypokalaemia. In physiological conditions, potassium is excreted via 
the kidneys and the regulation of excretion is related to the effect of aldosterone.
The anion counterpart of intracellular potassium is phosphate ions in the form of organic macromolecular phospha-
tes. Although macromolecular phosphates do not pass the cell membrane, they may affect the K+ level. Their intra-
cellular concentration decreases as they disintegrate and deplete during catabolism, K+ is released into the ECF due 
to decrease of the negative charge of the ICF. During anabolism, however, when the synthesis of macromolecular 
phosphates increases, potassium flows to the cells due to an increase of the negative ICF charge. During anabolism, in-
tracellular potassium concentration increases and the potassium pool is replenished. Severely undernourished people 
have an enormous intracellular potassium deficiency, which may reach 800 – 1000 mmol.
If the patient is re-alimented, a sufficient substitution of potassium of 250 – 300 mmol/24 hrs is required along 
with the substitution of phosphorus and magnesium. Failure to maintain an increased supply of intracellular ions at 
the beginning of nutritional intervention in seriously undernourished patients may lead to refeeding syndrome and the 
potential death of the patient. The cause of death is usually muscular weakness, respiratory failure, coma and cardiac 
arrhythmia.
The K+ transport between the ICF and ECF may also take place in exchange for H+, which points to the relation be-
tween the acid-base balance (ABB) and the K+ concentration in the ICF and ECF. Changes in the ABB lead to transfers of 
K+, whereby MAC supports the development of hyperkalaemia, and MAL supports the development of hypokalaemia. 
A drop in pH of 0.1 increases kalaemia by 0.4 mmol/l on average.
Plasma concentration 3.8 – 5.2 mmol/l
Intracellular concentration 100 – 160 mmol/l
Urine concentration 30 – 80 mmol/l
Intracellular reserve 3200 mmol
Extracellular reserve 60 mmol
Intake 50 – 100 mmol/24 hrs
Output 50 – 100 mmol/24 hrs
Table 8.4. Potassium balance and distribution
8.2.3. Hypokalaemia
Hypokalaemia is defined as a drop in serum K+ concentration under 3.5 mmol/l, serious hypokalaemia under 3 
mmol/l, and life-threatening hypokalaemia under 2.5 mmol/l. The rate of change is important for clinical manifestati-
on. The faster hypokalaemia develops, the more serious is the impact. Hypokalaemia may have serious clinical manife-
stations such as malignant cardiac arrythmia, respiratory muscle paralysis with respiratory insufficiency, or a decrease 
in smooth muscle activity with the development of paralytic ileus.
8.2.3.1. Extrarenal Hypokalaemia
The 24-hr urine K+ output is used to differentiate between extrarenal and renal hypokalaemia. 24-hr urine K+ out-
puts under 20 mmol are indicative of extrarenal origin. Extrarenal hypokalaemia is caused by low potassium intake in 
patients with anorexia nervosa, fasting people, insufficient K+ supply during parenteral (PN) or enteral nutrition (EN) 
of undernourished people. Increased extrarenal losses are caused by vomiting, gastric juice losses with an inserted 
nasogastric tube, fistulas, diarrhoea and stomata. Losses from the proximal part of the digestive tract lead to the deve-
lopment of MAL with decreasing K+; losses in the distal part of the digestive tube (ileum, colon) lead to decreased HCO3- 
and K+, resulting in hypokalaemia with MAC. Increased potassium losses may also be caused by overuse of laxatives.
8.2.3.2. Renal Hypokalaemia
Renal losses are usually caused by renal tubular acidosis, the polyuric phase of acute renal failure, chronic renal 
failure, tubulointerstitial nephritis, Gitelman syndrome, Bartter syndrome and magnesium deficiency. Hypokalaemia 
due to major renal losses may also be caused by chronic treatment by or abuse of saluretics (furosemide, thiazides). 
Long-term hypokalaemia induces hypokalaemic nephrosis with tubule involvement, which leads to elevated K+ losses 
in the urine. Increased renal losses are also caused by a primary or secondary increase in the aldosterone level. Causes 
of primary hyperaldosteronism include: adrenal adenoma, increased ectopic ACTH production in tumours, increa-
sed ACTH production in hypophyseal adenoma. Secondary hyperaldosteronism occurs in cardiac failures and hepatic 
cirrhosis as a manifestation of decreased intravascular volume or cardiac output. In these cases, the use of aldosterone 
antagonists (spironolactone) is recommended to treat hypokalaemia.
Clinical signs of hypokalaemia are listed above. Flattened T-waves, a pronounced U-wave, ST depression and pre-
mature ventricular contractions (PVC) can be found on the ECG waveform. Ventricular fibrillation and muscular rhab-
domyolysis are dangerous complications. Renal tubules become damaged in long-term hypokalaemia.
8.2.3.3. Treatment for Hypokalaemia
The kalaemia level should always be evaluated in relation to the ABB, water balance and energy balance of the 
body (catabolism vs. anabolism). Potassium output in urine over 12 (or preferably 24) hours should be determined to 
make the right decision about treatment. Kalaemia determination alone reveals very little about the cause and does 
not allow the right therapeutic strategy to be chosen. Steps to take for hypokalaemia treatment are as follows:
• Acid-base imbalance treatment;
• Supply of energy substrates through appropriately selected nutritional intervention and energy balance 
adjustment; intracellular K+ deficiency cannot be adjusted without concurrent synthesis of intracellular 
phosphate macromolecules – an anion partner of K+ in the ICF;
• Removal of dehydration of the body that leads to secondary hyperaldosteronism with increased renal 
excretion of K+, H+ and reabsorption of Na+ and water. This hypokalaemia cannot be treated by mere K+ 
substitution without adequate hydration;
• Magnesium substitution, if a deficiency is found;
• Increased K+ supply by infusions. Determine the daily dose depending on the urine K+ output and estima-
ted deficiency under regular monitoring of serum K+ concentrations. The rate of substitution is usually 50 
mmol/6 hrs, and the dose 100 – 200 mmol/24 hrs. In extreme situations, substitutions may be about 300 
mmol/24 hrs. For K+ levels of 1.4 mmol/l with ECG alterations, the rate of supply can be 40 mmol/hr with 
regular K+ level monitoring every 2 hours. If administration through a peripheral vein is used, the potassi-
um solution concentration should not exceed 30 mmol/l and the rate 10 mmol/hr;
• Conditions with elevated aldosterone levels should be treated by aldosterone antagonists. Hyperaldoste-
ronism is manifested by a decrease in the U-Na/U-K concentration ratio to under 1. In other words, the 
urine potassium output exceeds the sodium output;
• Removal of the cause of potassium losses.
8.2.4. Hyperkalaemia
Slight hyperkalaemia is defined by a K+ concentration of 5.5 – 6.5 mmol/l, medium hyperkalaemia by 6.5 – 7.5 
mmol/l, and severe hyperkalaemia by more than 7.5 mmol/l. Like hypokalaemia, hyperkalaemia also has renal and 
extrarenal causes.
8.2.4.1. Extrarenal Hyperkalaemia
24-hr urine K+ outputs are used to find the cause of hyperkalaemia. With an extrarenal cause, 24-hr urine K+ out-
puts exceed 50 mmol, and the urine K+ concentration increases to more than 100 mmol/l with severe catabolism. Ex-
trarenal hyperkalaemia occurs as a result of K+ redistribution between the ICF and the ECF. Potassium discharge from 
cells is caused by intracellular acidosis from various causes and catabolism during fasting, which results in the loss of 
phosphate macromolecules. The total K+ reserve in the body may become decreased in these situations. An increased 
supply of K+ in i.v. solutions due an incorrect determination of the balance may lead to artificial hyperkalaemia.
8.2.4.2. Renal Hyperkalaemia
This type of hyperkalaemia is caused by an absolute decrease in glomerular filtration in acute or chronic renal 
failure with a decreased renal K+ output and concomitant acidosis. Another cause is diseases and conditions affecting 
the tubular functions of the kidneys, specifically a decrease in tubular K+ secretion. These are several endocrinopathies 
with a low aldosterone level (Addison’s disease, hypoaldosteronism, hypopituitarism) and medicines (ACEI, Cyclospo-
rin A, NSAID, spironolactone). In these cases, potassium outputs in the urine decrease under 50 mmol/24 hrs, or under 
30 mmol/l, respectively.
Major clinical signs of hyperkalaemia include cardiac arrythmia (bradyarrythmia, asystole) and paresthesias of the 
muscles. In most cases, the patient’s clinical picture is given by the underlying disease that caused the disorder. The 
ECG shows peaked T waves, widened QRS complexes and bradycardia.
8.2.4.3. Treatment for Hyperkalaemia
In addition to determining serum K+ concentration, for correct hyperkalaemia treatment S-creatinine, S-urea, ABB 
and 24-hr urine K+ outputs also have to be determined. Urine K+ outputs allow renal and extrarenal causes of the con-
dition to be distinguished. Excessive input or significant catabolism lead to a urine K+ concentration increase over 100 
mmol/l, while renal insufficiency leads to a urine K+ concentration decrease under 30 mmol/l. An important moment 
in hyperkalaemia treatment is to discontinue the use of drugs that lead to potassium retention. The intensity of hyper-
kalaemia treatment depends on serum K+ concentration, the dynamics of the increase, the clinical condition and ECG 
alterations. Dialysis or conservative treatment is indicated based on these indicators. Acute haemodialysis is indicated 
for K+ levels of more than 7 mmol/l, or K+ levels of more than 6 mmol/l with clinical signs not responding to the con-
servative treatment.
The conservative therapy of acute hyperkalaemia includes:
• Administration of Calcium gluconicum 10 – 30 ml i.v.;
• Administration of bicarbonate 8.4% 80 ml. i.v.;
• Administration of 500 ml 10% glucose + 10 U insulin;
• Ion exchangers (Resonium 100 g in the form of an enema).
The conservative therapy of slight chronic hyperkalaemia includes:
• Decreasing daily potassium supply to under 1.5 g (under 40 mmol);
• Enhanced excretion through the use of loop diuretics (furosemide);
• Oral bicarbonate treatment in MAC;
• Sufficient hydration;
• Ruling out drugs that decrease K+ excretion;
• Ion exchangers (Resonium 15 g 3x a day).
8.3. Chloride Anion
Chloride anion is a major extracellular space anion and its distribution space corresponds to 20% of body weight. 
An increase or decrease in the chloride content is accompanied by changes in the Na+ reserve because chloride is an 
anion partner of sodium. Cl- is also in electroneutral balance with bicarbonate, so changes in the chloride concentrati-
on are associated with ABB alterations. Hyperchloridaemia causes acidosis and hypochloridaemia alkalosis.
8.3.1. Hyperchloridaemia
Hyperchloridaemia is accompanied by sodium retention and occurs due to inadequate pure water retention and 
ECF expansion. If the ECF expands together with Na+ retention, the Cl- reserve grows but the serum concentration re-
mains unchanged. Metabolic acidosis and hypernatraemia develop due to hyperchloridaemia. This is usually caused by 
increased chloride supply in the form of infusion solutions, or decreased excretion in hepatic cirrhosis, cardiac failure 
or renal failure. Hyperchloridaemia is also found in patients with ureteroileostomy following cystectomies, as a result 
of increased absorption of chlorides excreted in the urine by the neovesica made from the intestine. Oral bicarbonate 
treatment should be used in this case. In the other cases, treatment consists in reducing the supply of chlorides (most 
often in infusions) and enhancing their excretion using saluretics.
8.3.2. Hypochloridaemia
As in hyperchloridaemia, if Na+ and water deficiency are concurrent, thereby leading to a lower ECF volume, hy-
pochloridaemia will not develop but the Cl- reserve in the body will decrease. The chloride concentration in the ECF 
does not change in this situation.
If the ECF volume is maintained, hypochloridaemia will develop together with hypochloremic alkalosis, hypoka-
laemia and, in most cases, hyponatraemia. This condition is most often caused by the loss of intestinal secretions by 
vomiting, losses by fistulas in the proximal part of the GIT, or withdrawal of gastric content through a NG tube. Fur-
thermore, hypochloridaemia occurs due to increased excretion via the kidneys – the polyuric phase of renal failure or 
massive saluretic treatment. Hypochloridaemia treatment consists primarily in removing the inciting cause (vomiting, 
fistula, inadequate diuretic treatment) and sufficient chloride substitution in the form of saline infusion solutions. If 
there is a marked ECF expansion, arginine chloride solutions are recommended since they do not contain Na+ and do 
not cause fluid retention. If hypokalaemia is present, balanced solutions such as Ringer, Ringerfundin or Darrow’s so-
lutions containing K+ are available.
Plasma concentration 100 mmol/l
Reserve in ICF 1400 mmol
Reserve in ECF 1000 mmol
Intake 140 – 260 mmol 24/hrs
Output in urine 120 – 240 mmol/24 hrs
Output in stool 10 mmol/24 hrs
Output in sweat 10 – 80 mmol/24 hrs
Total output 140 – 260 mmol/24 hrs
Table 8.5. Chloride reserve and distribution in the body
CHAPTER 9
9. Metabolism of Calcium, Phosphorus and Magnesium
9.1. Metabolism of Calcium, Phosphorus and Magnesium – Preparation
Author: MUDr. Richard Pikner, Ph.D.
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9.1.1. Introduction
Together with sodium, potassium and chlorides, calcium (Ca), phosphorus i.e. phosphates HPO
4 
2- (P) and mag-
nesium (Mg) form a substantial part of human body’s inorganic component. Regulation of calcium, phosphorus and 
magnesium is humoral, and calciotropic hormones play a role in this: parathormone (PTH), parathormone-related 
protein (PTHrP), vitamin D, calcitonin (CT) and fibroblast growth factor 23 (FGF23). The hypophosphaturic effect in the 
kidneys takes place through the interaction of FGF23 and the Klotho protein as a local co-factor. This chapter provides 
an overview of the physiology and pathophysiology of Ca, P and Mg metabolism.
In conclusion the key information summarizes essential information from the entire chapter.
9.1.2. Calcium, Ca
A healthy person’s body contains approximately 1.0 to 1.3 kg Ca; 99 % is found in the bones and teeth, 1 % in soft 
tissues, and 0.1 % in extracellular space. The concentration of Ca in intracellular fluid (ICF) is about 10,000 lower than 
in extracellular fluid (ECF). In plasma, 50 % of Ca exists in a free (ionised) form bound to proteins, mainly albumin (40 
%), and 10 % of Ca in complexes with citrate and bicarbonate. Ca contained in complexes and ionised Ca represent a 
diffusible, biologically active fraction. This biologically active Ca component is strictly regulated by humoral mecha-
nisms – calciotropic hormones.
Ca concentration is greatly affected by 2 factors:
• Albumin concentration: The albumin level affects the overall Ca level in plasma. Patients with hypoalbumi-
naemia (↓ albumin) have lower overall calcium concentrations but the ionised, biologically active fraction 
is usually normal. This is relatively common cause of hypocalcaemia in hospitalised patients without clini-
cal symptoms;
• Changes in pH: Acidosis reduces the calcium bond to albumin and increases the ionised calcium fraction, 
while alkalosis reduces the ionised calcium fraction and invokes clinical symptoms connected to hypocal-
caemia. A typical example is hyperventilation tetany, where quickly induced respiratory alkalosis causes 
hypocalcaemia with tetany and limited activity of respiratory muscles, which deepens dyspnoea. CAVE: For 
this reason acute treatment involves normalisation of alkalaemia, not calcaemia.
Physiology
Calcium is an important regulator of many biological processes, which is why the ionised calcium level is very 
strictly controlled and kept within a fairly narrow reference range.
Regulation mechanisms are set up to maintain serum normocalcaemia.
The small intestine (absorption), bone tissue (deposits) and kidneys (excretion) are involved in regulating the Ca 
level.
Calcium is important for:
• Bone mineralization;
• Blood clotting;
• Neuromuscular transfer (creation and propagation of impulses);
• Muscle contraction;
• Cytoskeleton function (endo and exocytosis, cell division);
• Intracellular signal transfer – 2nd messenger;
• Enzyme activation (protein kinase, phosphorylase).
Daily metabolism of calcium:
An optimum daily intake ranges from 1000 to 1500 g depending on growth, pregnancy or lactation.
Absorption takes place in the small intestine, is greatest in the duodenum in the presence of acid pH, and gradually 
decreases towards the ileum. The process of intestinal resorption is partly a passive paracellular process following the 
concentration gradient, but mostly an active process (Ca bond on the specific carrier calbindin) via enterocytes. Active 
calcium resorption is stimulated by the presence of active vitamin D (1,25 (OH)
2
D). Some food constituents (fat, oxala-
tes) have an adverse effect on Ca absorption.
Absorbed Ca enters the ECF where it is exchanged for Ca from bones. Ca is deposited in the period of growth or 
with free bone capacity – positive calcium balance. The exchange is controlled by calcitropic hormones, PTH in parti-
cular.
Ca is excreted in the kidneys. Most filtered Ca is absorbed passively in the proximal tubule and the loop of Henle. 
Active regulation takes place in the distal tubule – about 8 – 10 % of Ca. This is an active process controlled by calcitro-
pic hormones, predominantly by PTH with minimal involvement of calcitonin.
Excretion is also affected by drugs such as diuretics. Loop diuretics (furosemide) reduce the tubular resorption of 
both Na and Ca, while thiazide diuretics boost Ca resorption with increased secretion of Na and Cl.
Metabolic acidosis (excretion) of hydrogen ions also prevents Ca resorption in the distal tubule.
9.1.3. Phosphorus
The human body contains about 700 – 800 g of phosphorus, 85 % of which is deposited in bones, less than 1 % is 
in the ECF and the rest (14 %) is deposited in tissues. The phosphate anion is the most important intracellular anion; its 
ICF concentration is 100 times as high as its ECF concentration. Around 88 % of P contained in the plasma is 53 % of dif-
fusible P in free (ionised) form and 35 % in the form of complexes. The rest (12 %) is non-diffusible P bound to proteins.
Physiology: 
Phosphorus not only forms an integral part of the skeleton, but is also essential for key cell structures. It forms part 
of nucleic acids, energy metabolism (high-energy phosphates), buffer systems and the phospholipid membrane.
Absorption takes place in the small intestine and is the greatest in the jejunum. Intestinal resorption is proportio-
nate to the amount of phosphates in food and is stimulated by the presence of 1,25(OH)
2
D and its stimulating effect 
on the Na-P co-transporter.
Like Ca, absorbed P enters the ECF where it is exchanged for P from bones which are a major site of phosphate de-
posits in the body. P is excreted in the kidneys. 75 – 85 % is absorbed in the proximal tubule, 10 – 15 % in the distal tu-
bule and 5 – 10 % in the collecting duct. It is an active process involving specific Na-P co-transporters, whose activity is 
controlled by the presence of FGF23 and its specific renal Klotho co-factor. The presence of FGF23-Klotho subsequently 
leads to increased phosphaturia.
Although phosphorus is essential for many intracellular processes, its permanently elevated serum concentration 
is toxic for the body. This accelerates the cell aging process and is, among other things, responsible for vascular calcifi-
cations in chronic dialysed patients.
 Figure 9.1. Summary of daily calcium and phosphorus metabolism
9.1.4. Magnesium
The human body contains only about 24 g of Mg, 50 % of which is in the skeleton, and the remaining 50 % is in the 
ICF, mostly in muscles. Less than 1 % is found in the ECF. About 70 – 80 % of Mg in plasma represents diffusible ionised 
Mg, and 1 – 2 % is bound in complexes. The remaining 20 – 30 % is non-diffusible Mg bound to proteins.
Physiology
Mg is the 2nd most common cation in the ICF, is involved in about 300 enzymatic reactions (energy metabolism, 
nucleic acid synthesis, cytoskeleton, membrane stability). Mg plays a major role in modulation, maintaining home-
ostasis and intracellular calcium concentration. In addition, Mg mediates immunological reactions and PTH production 
and secretion, regulates smooth muscle tonus and skeletal muscle relaxation. The recommended daily allowance is 320 
– 420 mg. Absorption takes place actively in the small intestine and is likely affected by the presence of 1,25 (OH)
2
D.
Mg is excreted in the kidneys. 15 – 20 % is resorbed in the proximal tubule, 60 – 70 % (passively) in the cortical 
ascending arm of the loop of Henle, and 5 – 10 % actively in the distal tubule, probably under similar regulating effects 
as Ca.
9.1.5. Parathyroid Hormone (PTH)
Polypeptide – basic regulating hormone of the calcium-phosphate metabolism.
PTH is a polypeptide consisting of 84 amino acids. It is produced in the parathyroid glands as a 115-amino acid pre-
-pro PTH and then cleaved to the 90-amino acid PTH. The last cleavage in the Golgi apparatus either produces an intact 
(biologically active) 1-84 PTH, or a 7-84-amino acid (biologically inactive) fragment. Both 1-84 and 7-84 are released 
into the circulation. The intact 1-84 PTH is around 30 – 40 % of the total PTH released into the circulation. The serum 
ionised calcium level regulates PTH secretion through negative feedback; the signal is transferred through the specific 
calcium sensing receptor (CaSR). PTH production in the parathyroid glands is affected by the phosphorus level (stimu-
lation), whereas hypomagnesemia and hypermagnesemia and 1,25 (OH)2D suppress the PTH production. Degradation 
takes place in the liver and kidneys by cleaving the 33-34-amino acid and 36-37-amino acid molecules to form other 
inactive PTH fragments. The intact 1-84 PTH biological half-life is about 5 minutes.
Figure 9.2. PTH metabolism
Physiology
The main effect of the PTH is an increase to plasma Ca concentration.
The effect is takes place through 2 types of receptors: PTH1 and PTH2. PTH 1 is common for the PTH and PTH-rela-
ted protein (PTHrP – see below) and is found in bones and kidneys.
• In the bone, PTH induces a change in OPG-RANKL production indirectly through osteoblasts with indirect 
osteoclast stimulation (osteoresorption) and the release of Ca into the ECF. (For description of local regu-
lation of osteoblasts and osteoclasts see Bone Metabolism.);
• PTH increases reabsorption of Ca and excretion of P in the kidneys and oosts the production of alpha-1-
-hydroxylase (enzyme forming active 1,25 (OH)
2
D).
Circadian rhythm with a maximum at 3:00 a.m. and a minimum at 11:00 a.m.
9.1.6. PTH-Related Protein (PTHrP)
PTHrP is a peptide with a gene comprising 9 exons, and their different expression levels are responsible for the 
formation of 3 possible isoforms (139 amino acids, 141 amino acids and 173 amino acids). Owing to the homology in 
the first 13 amino acids, PTHrP binds to the same PTH/PTHrP-1 receptor. Unlike PTH, PTHrP is produced by many cells 
and its mechanism of action is primarily autocrine or paracrine. Known functions of PTHrP include:
• Influence on enchondral ossification – blocks chondrocyte maturation (bone growth in the prenatal peri-
od);
• Breastfeeding – production of PTHrP in the mammary gland to provide an adequate supply of calcium 
in breast milk. PTHrP systemically increases osteoresorption and is locally involved in transporting Ca to 
breast milk;
• Transepithelial transport of calcium in the placenta;
• Unlike PTH, PTHrP does not stimulate 1-hydroxylase in the kidneys.
Increased production of PTHrP in adults with malignant diseases is primarily linked to hypercalcaemia. It is a 
paraneoplastic overproduction of PTHrP with tumour cells (bone metastases) leading to the formation of osteolytic 
bone metastases.
9.1.7. Vitamin D – 1,25 (OH)2D (Calcitriol)
Ranks among hormones in terms of its mechanism of action since it has its specific receptor.
Vitamin D ranks among fat-soluble hormones. Vitamin D exists in two basic forms: vitamin D2 (ergocalciferol) 
and vitamin D3 (cholecalciferol). Ergocalciferol arises from UV-B irradiation of fungal steroid ergosterol, and naturally 
occurs as a rare form of vitamin D, but is a major vitamin D produced in the pharmaceutical industry. Cholecalciferol 
arises from UV-B irradiation of a 7-dehydrocholesterol precursor, high levels of which are found in the skin. The time 
for reaching the maximum D3 precursor level in the skin depends on the strength of UV radiation, time of exposure 
and skin pigmentation. In addition, UV radiation prevents overproduction of cholecalciferol, since it is photo-degraded 
into inactive metabolites (lumisterol, tachysterol) following maximum saturation of tissue. When transported into the 
circulation, 85 % of ergosterol and cholecalciferol is bound to vitamin D-binding protein (DBP) and 15 % to albumin. 
In addition to conversion in the skin, vitamin D is absorbed in the intestine from food. The liver is the site of vitamin D 
conversion into 25(OH) vitamin D (calcidiol). 1,25 (OH)
2
D (calcitriol) is an active hormone produced by hydroxylation of 
calcidiol (25 (OH)D) with α1-hydroxylase. Around 15 % of calcitriol is produced in the kidneys and is supplied to tissues 
without their own 1-hydroxylase such as enterocytes or pancreas. 85 % of calcitriol is produced by hydroxylation right 
in the peripheral tissues with their own 1-hydroxylase (epithelial cells, nerve and immune systems, prostate, breast, 
colorectum). Its role here is primarily autocrine and paracrine, and it is responsible for non-skeletal effects of vitamin D.
24,25-(OH)
2
D is a degradation product of the vitamin D metabolism without any biological function.
Figure 9.3. Vitamin D production
Physiology
The main function of calcitriol produced by the kidneys is calcium and phosphate absorption regulation in the small 
intestine.
More broadly, vitamin D acts through the specific intracellular vitamin D-receptor (VDR) and subsequently the 
retinoid X receptor (RXR). The calcitriol-VDR-RXR complex binds to specific DNA sites known as vitamin D response 
elements (VDRE). This bond initiates the transcription of specific DNA and RNA with corresponding protein production. 
Calcitriol is presently assumed to have an influence on the expression of around 2000 genes in the human body, mea-
ning vitamin D has skeletal (calcium-phosphate metabolism) and non-skeletal effects.
Skeletal effects of vitamin D:
• Intestine: Increases calcium and phosphorus absorption;
• Bone: Minimal importance;
• Kidneys: Stimulates PTH receptor and Ca-carrying protein production – increases calcium reabsorption.
Non-skeletal effects of vitamin D: 
• Stimulates insulin secretion;
• Immunomodulatory and antibacterial function;
• Affects muscle fibre formation and calcium metabolism in muscles;
• Suppresses the production of renin;
• Improves differentiation and supports cell apoptosis, suppresses proliferation, angiogenesis (prostate, bre-
ast, epithelia, colorectum).
Main forms in the circulation:
• 25 OH vitamin D (calcidiol) – active calcitriol precursor and a reserve prohormone for conversion in peri-
pheral tissues. Indicator of vitamin D supply status;
• 1,25 (OH)
2
D (calcitriol) – active vitamin, its serum level correlates to production in the kidneys.
9.1.8. Calcitonin (CT)
Hormone, 32-amino acid peptide is produced by parafollicular C-cells of the thyroid; involved in controlling the 
homeostasis of calcium-phosphate metabolism and is a sensitive tumour marker for medullary thyroid cancer.
Physiology
CT primarily inhibits osteoclast-mediated bone resorption. Calcitonin secretion is controlled by the serum ionised 
calcium level. Calcitonin also has a slight renal effect where it inhibits reabsorption of Ca and P. Despite this physio-
logical effect, calcium-phosphate homeostasis is not greatly dependent on calcitonin. After undergoing a complete 
thyroidectomy medullary cancer, patients display practically normal calcium levels.
9.1.9. Fibroblast Growth Factor 23 FGF23 and Klotho Protein
These are molecules with a primary effect on the concentration of phosphate. The main source of FGF23 is the 
bone tissue (1,25 (OH)
2
D stimulates its production), whereas Klotho protein is produced in the kidneys. Klotho protein 
mediates the tissue-specific effect of FGF23 in the kidneys which makes it a co-factor for the FGF23 function. FGF23 
blocks protein production in renal cells responsible for reabsorbing phosphates. It has a substantial phosphaturic effect 
while blocking 1-α- hydroxylase production in the kidneys, thus reducing the 1,25 (OH)
2
D level as well as resorption of 
phosphates and calcium in the small intestine.
9.1.10. Regulation of Calcium and Phosphate Metabolism
The regulation of calcium and phosphate metabolism is based on mutual interaction with PTH-1,25 (OH)
2
D-CT and 
FGF23-Klotho.
Figure 9.4. Basic mechanisms of Ca, Mg and P concentrations
Mg metabolism regulation is practically identical to calcium regulation, and is also likely controlled by the PTH-
1,25 (OH)
2
D system. Serum Mg concentration affects PTH secretion. Both a lack and surplus of magnesium block PTH 
production.
The basic goal of homeostasis is to maintain normocalcaemia and normophosphataemia. Physiologically, it is 
more difficult for the human organism to provide sufficient calcium levels and excrete excess phosphorus. Magne-
sium is above all an intracellular cation, so except for severe deficiency or surplus forms, serum Mg concentration 
does not reflect its current deficiency or surplus in tissues.
PTH, 1,25 (OH)
2
D and calcitonin are involved in calcaemia regulation.
Hypercalcaemia is induced by PTH (↓ EF Ca in the kidneys and ↑ osteoresorption). At the same time, magnesium 
directly stimulates 1,25 (OH)
2
D production, which increases calcium resorption from food in the small intestine.
Conversely, 1,25 (OH)
2
D partially inhibits PTH production. However, the main regulator of PTH production is the 
ionised calcium level through the calcium sensing receptor (CaSR).
Hypocalcaemia is induced by calcitonin (CT) which, as the only hormone, directly blocks osteoclast function and 
thereby resorption in bones. CT slightly increases calciuria and phosphaturia in the kidneys. Nonetheless, its biological 
effect on the human body is insignificant, because the main causes of hypocalcaemia are a deficient supply of Ca in 
food or a parathyroid gland disorder (PTH deficiency).
The body retains normocalcaemia in 3 ways:
• Sufficient supply from food supported by 1,25 (OH)
2
D. 1,25 (OH)
2
D concurrently stimulates the production 
of FGF23, which supports phosphate production and blocks 1,25 (OH)
2
D production, thus finely balancing 
the whole system;
• Release from bones which makes up for temporary fluctuations of ionised calcium levels by increasing 
or inhibiting PTH secretion. The body makes up for a long-term calcium deficiency by increasing PTH se-
cretion. This results in raised osteoresorption leading to damaged bone integrity. Concurrently released P 
from bones is excreted by a direct phosphaturic effect of PTH in the kidneys and owing to increased FGF23 
production in the bones. At the same time PTH stimulates 1,25 (OH)
2
D production as well as the effort for 
a physiological increase of calcaemia;
• Retention of calcium in the kidneys – indirect effect of PTH: 1,25 (OH)
2
D via the stimulation of PTH recep-
tor production.
If calcium is not present in food, increasing 1,25 (OH)
2
D production does not help.
(It’s not possible to select something from nothing.)
FGF23, PTH and 1,25 (OH)
2
D are involved in phosphataemia regulation.
Hypophosphataemia is primarily induced by the FGF23-Klotho complex in the kidneys (phosphaturic effect), which 
concurrently blocks 1,25 (OH)
2
D production, thus also reducing phosphate resorption in the small intestine. On the one 
hand PTH increases phosphataemia by osteoresorption from bones, while on the other hand also reduces phosphatae-
mia by directly stimulating phosphaturia in the kidneys.
Hyperphosphataemia is primarily induced by an inability to excrete phosphorus from the body in diseases such as 
chronic renal failure, and by increasing intake from food in the presence of 1,25 (OH)
2
D.
The effect of 1,25 (OH)
2
D in the intestine is limited to the phosphorus amount in food.
Normophosphataemia is primarily retained by the body through FGF23, its direct phosphaturic effect in the kid-
neys, and indirectly by blocking 1,25 (OH)
2
D production. PTH has an auxiliary phosphaturic effect in the kidneys, which 
is partially balanced by stimulating P release with bone resorption and 1,25 (OH)
2
D production stimulation (increased 
resorption of phosphates in the small intestine).
Thus it can be said that all calcitropic hormones fine-tune the ultimate Ca and P concentration through their 
mutual positive and negative interactions. Disturbed plasma (serum) P and Ca levels are subsequently a sign of de-
pletion or disorder of these regulatory mechanisms.
Figure 9.5. Ca, Mg and P regulation: regulating hormones and their interactions (major regulatory mechanisms in 
bold)
9.1.11. Summary – Key Information
• The basic goal is to maintain normocalcaemia and normophosphataemia. Physiologically, it is more diffi-
cult for the human organism to provide sufficient calcium and excrete excess phosphorus;
• Ca concentration in the extracellular fluid (ECF) is 1000 times higher than Ca concentration in the intracel-
lular fluid (ICF);
• Ca and Na are major ECF cations, while Mg and K are major ICF cations. Bones work as a deposit site for all 
3 components, which is why the Ca, Mg and P reserve is the highest here;
Figure 9.6. Distribution of Ca, P and Mg in the body 
• The huge concentration gradient of Ca between the ECF and the ICF is the reason why Ca is used in regula-
ting and activating functions at an intracellular level;
• The regulation and biological effects are based on ionised fractions of Ca, Mg and P, which represent about 
50 % of their overall value in the plasma;
Figure 9.7. Forms of Ca, P and Mg in the plasma
• PTH, 1,25 (OH)
2
D and CT are involved in regulating calcaemia;
• FGF23 PTH, 1,25 (OH)
2
D are involved in regulating phosphataemia;
• Mg metabolism regulation is practically identical to calcium regulation, and is also likely controlled by the 
PTH-1,25 (OH)
2
D system;
• PTH is produced in the parathyroid glands, has a hypercalcemizing effect while its production is controlled 
by the Ca2+ level;
o In bones – stimulates osteoresorption and release of Ca and P from the bones into the ECF;
o In the kidneys – retains Ca and increases P secretion while also stimulates 1,25 (OH)
2
D production;
• 1,25 (OH)
2
D is produced in the kidneys or locally right in tissues from 25 (OH) D. It is predominantly found 
in the small intestine where it increases Ca and P resorption, while also regulates bone metabolism and 
stimulates FGF23 production in bones;
• Calcitonin is produced in parafollicular C-cells of the thyroid; plays a minor role in regulating calcaemia in 
the human body; has the following functions:
o In the bones: blocks osteoclasts, thus reducing calcaemia
o In the kidneys: increases secretion of Ca and P
o In the CNS: stimulates endorphin production – relieves pain
• FGF23 is produced in the bones and released into the circulation; its production is stimulated by PTH and 
1,25 (OH)
2
D; in the kidneys FGF23 and Klotho protein substantially increase P secretion into urine. In addi-
tion to this, it has so far displayed unexplained systemic functions.
• The source of Ca, Mg and P is food; absorption takes place in the small intestine, which is largely passive 
and largely controlled by 1,25 (OH)
2
D. Absorbed Ca, P and Mg thus enter the circulation and are deposi-
ted in bones or intracellularly (Mg, P). Deposition and resorption from bones are primarily controlled by 
1,25 (OH)
2
D and PTH. The deposition of Ca, Mg and P is a multihormonal process involving 1,25 (OH)
2
D , 
oestrogens, androgens, IGF1, calcitonin, leptin, etc. Conversely, PTH plays a crucial role in bone resorption. 
Excretion takes place in the kidneys, passively in the proximal tubule, actively in the distal tubule, and the 
resulting amount of urine is controlled by hormones (PTH, CT, FGF23).
Figure 9.8. Summary of basic hormonal regulatory mechanisms of homeostasis of Ca, Mg, P (EF = excretion fraction)
• The body reaches normocalcaemia in two ways:
o Sufficient supply from food with support from 1,25 (OH)
2
D, which concurrently stimulates the produc-
tion of FGF23, which conversely supports the excretion of phosphates taken from food, and blocks 1,25 
(OH)
2
D production, thus finely balancing the whole system and avoiding disturbance to bone integrity.
o Release from bones, which makes up for the temporary fluctuations of ionised calcium levels by incre-
asing PTH secretion. Chronically increased PTH secretion leads to disturbed bone integrity. Ca and P re-
leased from bones are excreted through direct PTH stimulation in the kidneys and by increasing FGF23 
production in the bones. PTH stimulates 1,25 (OH)
2
D production and as such an effort for increasing 
the physiological method of retaining calcaemia.
• The body primarily retains normophosphataemia via FGF23, by direct phosphaturic effect in the kidneys 
and indirect blocking of 1,25 (OH)
2
D production. PTH is an auxiliary hormone, whose phosphaturic ef-
fect is partially balanced by the stimulation of P release with bone resorption and 1,25 (OH)
2
D production 
stimulation, which leads to increased resorption of phosphates in the small intestine.
• Disturbed plasma (serum) P and Ca levels are a sign of depletion or disorder of regulatory mechanisms or 
target organs.
• Calcium is an important regulator of many biological processes, which is why the ionised calcium level is 
very strictly controlled and kept within a fairly narrow reference range.
• The overall plasma/serum calcium concentration is affected by albumin concentration. The most common 
cause of pseudo-hypocalcaemia in hospitalised patients is hypoalbuminaemia (the level of ionised, biolo-
gically active Ca does not change).
• A change to the pH will considerably alter the ionised Ca level: Acidosis reduces the calcium bond to albu-
min and increases the ionised calcium fraction, and vice versa.
• Phosphorus is essential for many intracellular processes, but its permanently elevated plasma level is toxic 
for the body and accelerates the cell aging process. Among other things, it is responsible for vascular cal-
cifications in chronic dialysed patients.
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9.3.1. Learning Material
The preceding Preparation chapter described basic physiology and analytes and provides a basis for the clinical and 
biochemical part – Learning Material. Again, this chapter is divided into subchapters addressing the use of laboratory 
methods, indication principles, requirements for sampling (variability and stability) and basics of interpretation. The 
last section Key Information summarizes the basic important facts of this chapter.
9.3.2. Indications for Assay
Assays for calcium and phosphate metabolism form an integral part of medical practice. Test selection corresponds 
to the expected disease and pathophysiological mechanisms. It is usually good to gain comprehensive information 
regarding all parameter concentrations and assess them with regard to the clinical status, imaging methods and other 
factors.
The basic test is the plasma or serum Ca, P and Mg assay, namely total plasma Ca, P and Mg concentrations and not 
the metabolically active ionised fraction, which is technically more difficult. The plasma Ca, P and Mg test is a relatively 
insensitive tool for calcium and phosphate metabolism examination for the following reasons:
• A change in calcium concentration with a stable pH value occurs when regulatory mechanisms become 
depleted, i.e. PTH, 1,25 (OH)
2
 D and calcitonin. So calcium concentration measurement is a relatively rough 
tool to detect calcium and phosphate metabolism disorders. If additional PTH or 1,25 (OH)
2
 D tests are 
chosen, they will help detect imbalances which have not led to a fluctuation of Ca concentration so far;
• Total serum calcium concentration depends on albumin concentration. Changes in albumin concentration 
lead to a change in overall Ca concentration without substantially changing the ionised Ca level;
• Ionised Ca concentration depends on the current pH; the measurement is made on an ion-selective elect-
rode with a pH measurement on POCT (Point-of-Care Testing) analysers;
• Mg is primarily an intracellular cation; its amount in the ECF is negligible compared to the ICF. Serum con-
centration tests only reflect the current intake rather than its tissue concentration;
• More broadly, assays for total or ionised serum Ca, P and Mg levels provide a picture of the current status 
in relation to regulating hormones;
• Tests of Ca, P and Mg loss in urine inform about the supply in the body assuming normal regulation in the 
kidneys. If kidney function is impaired, plasma and urinary concentrations together with regulating hor-
mones should be examined;
• Urine tests are often subject to great error in the pre-analytical part (wrong urine volume measurement, 
instable solution – a stabilizing agent (HCl) should be added, sample should be stirred after collection and 
before taking a new sample, unwashed containers, etc.); there are great inter-individual differences due to 
diet, physical activity, etc;
• Assays for regulating hormones: PTH, 25 OH vitamin D, 1,25 OH
2
 vitamin D, calcitonin and FGF23 are only 
performed using specialist sites; great differences among test manufacturers;
• The PTH assay and interpretation of results depend on the method selected, i.e. cross reactivity with frag-
ments;
• The immunoassay selected for 25 OH vitamin D decides whether D2 or D3 is measured, or in what propor-
tion. A method determining 100 % D2 and D3 should be used. The reference method is HPLC allowing for 
all vitamin D fractions and metabolites to be determined;
• So far the FGF23 assay is only a research method;
• The calcitonin assay has practically only one indication in the differential diagnosis of hypocalcaemia, whe-
re one of the possible causes is medullary cancer with the overproduction of calcitonin.
When a disorder of calcium and phosphate metabolism regulation is suspected, it is often necessary to prescribe 
a complete range of tests from plasma Ca, P and Mg concentrations through regulating hormones to urinary Ca, P and 
Mg losses. In primary hyperparathyroidism, for example, the laboratory findings are often a more sensitive indicator 
than imaging methods.
9.3.3. Sampling Variability and Sample Stability, Collection of Urine
Minimum diurnal variability except for the PTH; concentrations depend on food; collection should be performed 
in the fasted state.
Ca, Mg and P tests:
• Samples must not be taken into tubes with EDTA or citrate as they counterbalance all Ca and Mg in the 
sample;
• Haemolysis increases Mg and P values;
• PTH and PTHrP tests: If taken into EDTA tubes, samples are stable for 24 hours after centrifuging at 4 – 8 
°C.;
• 25 OH vitamin D is a stable serum and plasma parameter and does not require other than usual measures.
9.3.3.1. Stability
Serum
Total Ca, P and Mg concentrations are stable for 7 days at 8 °C.
Whole blood
Not longer than 2 hours; haemolysis increases P and Mg, and does not affect the overall Ca level.
The total calcium level is affected by plasma albumin concentration; a low albumin concentration leads to hy-
pocalcaemia, which is only relative because the ionised calcium level is usually normal. Ca concentration should be 
corrected with regard to albumin in all patients with hypoalbuminaemia.
Ionised forms of Ca2+ and Mg2+: Collection the same as Astrup (heparinised venous, arterial, mixed blood). Process 
within 2 hours with pH measurement. Ionised Ca2+ and Mg2+ concentrations should be corrected with respect to cur-
rent pH (usually done automatically by the analyser).
Urine
Ca, P and Mg values are stable at -20 °C for at least 3 weeks, at +4 °C for 3 days, though they tend to precipitate or 
sediment; the sample should be stabilised and thoroughly stirred before the analysis.
Urine collection:  itself introduces many inaccuracies to the measurement. Collection is easy from patients with a 
urinary catheter. There is a high risk of collection errors in patients without a catheter.
24-hour urine collection: Thoroughly wash the container for urine collection, then provide 50 – 100- ml graduati-
ons, measure total volume in ml after collection. Collection containers should be washed with hot water only without 
detergents or disinfectants. Urine should be collected from 6:00 a.m. to 6:00 a.m. Start collecting urine in the morning 
after waking up by urinating outside the container, then save all urine in the collection container, also at night, and take 
the last urine in the morning after waking up 24 hours from starting the collection. Before starting the collection, add 
10 ml 6 M HCl to the urine. Keep the container in a dark, cool place; stir thoroughly after collection, take a sample into 
a test tube and bring for the test. Adhere to usual drinking and dietary regimen during urine collection.
A sufficient volume of urine should be reached by drinking steady and suitable amounts of liquids during urine 
collection. A suitable intake of liquids should produce 1500 – 2000 ml of urine from an adult over 24 hours. This means 
that the patient should drink around ¾ of a litre of liquids (water or mineral water) for every 6 hours of urine collection 
(not at night).
Nordin index – 2-hour urine collection
Urine is collected from fasting patients from 8:00 a.m. to 10:00 a.m. The patient urinates before the test, then 
drinks at least 250 ml of liquid, and all urine is collected during the 2 hours. The test is used to measure Ca, creatinine 
and the Ca/Cr ratio.
Most common mistakes in urinary Ca, P and Mg assays:
• Wrong volume measurement – thorough instruction, ideally a special collection container with 50-ml gra-
duations;
• Insufficient stirring of the collected volume before taking the sample leads to falsely lower concentrations;
• Washing the collection container and leaving phosphate detergent residues – falsely high urinary phospho-
rus loss;
• Ca, P and Mg precipitations – acidification is required to protect the urine from insoluble complex formati-
on.
Most pre-analytical errors in urine collection lead to falsely lower values. Falsely higher values are received if only 
night and first morning urine is collected, when urinary Ca, Mg and P losses are elevated.
In common outpatient practice, urine is mostly collected at home; handling HCl (acidifying agent) is associated with 
too many risks of patient and material injury, so collection is usually made without the agent.
Other options for urinary Ca, P and Mg loss determination:
• 24-hour calcium loss conversion to 1 kg of body weight – very useful mainly in children and overweight 
patients;
• Ca/Mg ratio determination – nephrolithiasis risk assessment;
• Calculation of Ca, P and Mg fractional excretions and comparison with reference intervals.
9.3.4. Test Methods
• Photometric tests are used to determine total Ca, Mg and P concentrations. A false increase in Mg level 
often occurs due to haemolysis;
• The ionised Ca (Ca2+ and Mg2+) level is measured using ion-selective methods with concurrent pH measu-
rement. Collection must be performed immediately prior to the measurement, which is done on the acid-
-base analyser, and values are adjusted to the current pH. Mg2+ measurements are rare;
• Immunoassays based on a specific antigen-antibody reaction are used to measure PTH, PTHrP and FGF23. 
These are very sensitive methods where the selected antibody is essential for the test specificity, i.e. cross 
reactivity with related substances or degradation products;
• PTHrP and FGF23 assays are not routine tests, so the immunoassays are usually manual (ELISA or EIA);
• The PTH assay is a routine test available on automatic immunoanalysers. Currently used tests measure 
“intact” PTH, i.e. a mix of intact 1-84 PTH (biologically active PTH) and its 7-84 PTH fragment (35% : 65% 
ratio). At present there are only a few methods to determine 1-84 PTH only (Diasorin, Roche).
• Vitamin D assay:
o Although an overwhelming majority of circulating vitamin D is the D3 form, most vitamin supplements 
contain D2. They have equivalent biological effects. In addition to this, 25 OH D and 1,25 (OH)
2
 D assays 
should be distinguished. The 25 OH D level provides information about the status of the vitamin D sup-
ply, and is therefore a key parameter measured. Active 1,25 (OH)
 2
 D hormone measurement provides 
information about renal 1α-hydroxylase activity, and warns of potential ectopic production. 1,25 (OH) 
2
 D concentrations produced locally by tissues cannot be detected;
o The basic test method is either HPLC or liquid chromatography – mass spectrophotometry. These me-
thods provide accurate information about the concentrations of D3 and D2 isoform fractions, main me-
tabolites 25 OH D and 1,25 (OH)
 2
 D and catabolites 24,25 OH D. The test is very accurate and specific 
but the instruments are expensive, it is difficult to handle while the instruments have a small capacity;
o Immunoassays are practically only used to measure 25 OH D on automatic analys-ers; the measure-
ment is less accurate and the antibody quality determines whether both D3 and D2 isoforms will be 
detected. Ideally the method detects D3 and D2. The immunoassay for determining 1,25 (OH)
2
D re-
quires extraction (sample preparation), and is performed only manually using enzyme or radioisotope 
methods.
9.3.5. Interpretation of Results
9.3.5.1. Reference Limits:
Serum, plasma
• Ca: 2.18 – 2.6 mmol/l (Klatovy donors data, n=96);
• Ca2+: 1.15 – 1.35 mmol/l;
• Mg: 0.7 – 1.1 (1.3) mmol/l;
• P: 0.84 – 1.45 mmol/l;
o 25 OH D: 75 – 150 nmol/l;
o Intact PTH: 22 – 77 pg/ml (N-tact PTH, ILMA, Dia Sorin, Klatovy hospital donors n= 96) limits are me-
thod-dependent;
o 1-84 PTH: 8 – 28 pg/ml (ILMA, Dia Sorin, Klatovy hospital donors n= 96).
Urine
• 24-hour Ca loss, reference limit under 6.20 mmol Ca/24 hrs for women, and under 7.5 mmol Ca/24 hrs for 
men of average body weight;
• 24-hour Ca loss per kg – reference limit under 0.1 mmol Ca/1 kg b.w.;
• Ca Nordin index – reference limit under 0.6 mmol Ca/mmol creatinine;
• Ca/Mg index reference interval 1.0 – 2.0;
• Fractional excretion: FE Ca under 5 %, FE P 5 – 20 %, FE Mg under 3 %;
• 24-hour Mg loss: reference interval with average body weight 3 – 5 mmol Mg/24 hrs;
• Mg/creatinine 0.2 – 0.05 mmol/mmol crea.
9.3.5.2. Calculations
• Formula for total Ca adjustment to current serum albumin level 
Ca adjusted = Ca measured (mmol/l) + 0.020*(41.3 – c. albumin in g/l);
• Formula for ionised calcium Ca2+ adjustment to pH 7.40 
Ca2+ adjusted pH 7.40 = Ca2+ measured (mmol/l) * (1-0.53*(7,4 – pH measured));
• Fractional excretion 
FE Ca = UCa* SCrea/ Ca2+ estimate */UCrea (mmol/l) … similarly for P and Mg;
• Estimated ionised calcium concentration 
Ca2+estimate = 878*SCa/(SAlbumin *15.384+1053) SCa in mmol/l, Albumin in g/l;
• Nordin index 
UCa
NI
 = UCa/UCrea (mmol/l);
• Lithogenic index = UCa/UMg (mmol/l).
9.3.5.3. Hypercalcaemia
In addition to primary hyperparathyroidism, some of the other most common causes are tumour diseases with 
bone metastases and PTHrP overproduction, multiple myeloma, Paget’s disease, granulomatous diseases with vitamin 
D overproduction (sarcoidosis).
Diff. dg. of hypercalcaemia:
• Increased calcium intake: Milk-alkali syndrome;
• Increased calcium absorption in the intestine:
o Vitamin D intoxication;
o Sarcoidosis, tuberculosis;
o Acromegaly;
o Addison’s disease.
• Increased bone resorption:
o Primary hyperparathyroidism (sporadic, MEN 1 or MEN 2A, familial);
o Ectopic secretion of PTHrP;
o Thyrotoxicosis;
o Haematological malignancies (osteoclast-activating factor, lymphotoxin, TNF);
o Thiazide diuretics;
o Lithium;
o Immobilisation.
• Decrease in renal excretion – familial hypocalciuric hypercalcaemia;
• Abnormal serum proteins (increase in bound fraction):
o Hyperalbuminemia, multiple myeloma, hyperglobulinemia;
o Waldenström’s macroglobulinemia.
9.3.5.4. Hypocalcaemia
Relative hypocalcaemia is most common in hospitalised patients – the decreased overall Ca concentration is 
determined by the low albumin concentration.
Acute conditions include hypocalcaemia in acute pancreatitis from repeated administration of transfusion prepa-
rations containing citrate, and complex formation in crush syndrome.
Acute hypocalcaemia is also responsible for clinical symptoms of hyperventilation tetany. Quickly induced respira-
tory alkalosis leads to a drop in ionised calcium (through an increased albumin bond) and clinical symptoms of hypo-
calcaemia (tetanic spasms), which even worsen the clinical presentation.
Most common chronic causes of hypocalcaemia:
 Conditions associated with insufficient calcium and vitamin D in-
take (malabsorption, osteomalacia), chronic kidney disease, hypomagnesemia. 
More rarely it can be due to hypoparathyroidism (insufficient PTH production), most commonly iatrogenic, or medul-
lary cancer (calcitonin overproduction).
Diff. dg. of hypocalcaemia:
• Hypoparathyroidism;
• Hypomagnesemia;
• Resistance to PTH;
• Osteoclast-inhibiting drugs (calcitonin, bisphosphonates);
• Vitamin D deficiency (hereditary and acquired d.);
• Resistance to vitamin D (vitamin D receptor deficiency);
• Acute administration of complex-forming agents or calcium depositions;
o Acute (also iatrogenic) hyperphosphatemia;
o Crush syndrome with myonecrosis;
o Acute pancreatitis;
• Transfusion containing citrate.
9.3.5.5. Hypophosphatemia
Acute phosphatemia occurs when P is transferred to the ICF after administering glucose (anabolic phase), also in 
alcoholics.
Diff. dg. of chronic hypophosphatemia:
• Malabsorption;
• Severe vitamin D deficiency;
• Primary hyperparathyroidism;
• Renal disorders – losses (Fanconi syndrome) or tumours producing FGF23;
• STH deficiency;
• Hyperinsulinism;
• Phenylketonuria;
• Alcoholism;
• Tumours producing PTHrP;
• De Toni-Debre-Fanconi syndrome = distal tubular acidosis and glycosuria, renal rickets, aminoaciduria;
• Phosphate diabetes = Albright-Buttler-Bloomberg syndrome – retarded vitamin D-resistant rickets.
9.3.5.6. Hyperphosphatemia
Major causes: Renal failure, hypoparathyroidism, acute metabolic acidosis (transfer of P from the ICF), crush syn-
drome and acute tumour lysis syndrome
Diff. dg. of hyperphosphatemia:
• Renal failure;
• Hypoparathyroidism;
• Pseudohypoparathyroidism;
• Acute metabolic acidosis;
• Crush syndrome;
• Acute tumour lysis syndrome;
• Addison’s disease;
• STH overproduction.
9.3.5.7. Hypermagnesemia: is quite rare
Diff. dg. of hypermagnesemia:
• Acute kidney injury and chronic kidney disease;
• Addison’s disease;
• Acute kidney injury and chronic kidney disease;
• Hyperparathyroidism;
• Hypothyroidism;
• Addison’s disease;
• Lithium intoxication;
• Surplus of antacids and laxatives containing magnesium;
• Familial hypocalciuric hypercalcaemia.
9.3.5.8. Hypomagnesemia
Causes are similar to those of hypocalcaemia; also primary hyperaldosteronism, Bartter syndrome, Gitelman syn-
drome; most common causes include insufficient intake from food, or malabsorption or increased renal losses concur-
rently with calcium disorders.
Diff. dg. of hypomagnesemia:
• Acute respiratory alkalosis;
• Acute pancreatitis;
• Intestinal malabsorption;
• Renal tubular injury;
• Drug-induced (furosemide, aminoglycosides, digoxin, cisplatin);
• Hypercalcaemia and hypophosphatemia;
• Hyperaldosteronism;
• Hyperthyroidism;
• Hypoparathyroidism;
• Alcoholism.
9.3.5.9. Vitamin D
Classification of vitamin D insufficiency based on serum 25 OH D levels
Severe deficiency  < 25 nmol/l
 Insufficiency  25 – 49 nmol/l
Slight lack 49 – 74 nmol/l 
Adequate level 75 – 150 nmol/l
Risk of intoxication > 500 nmol/l
Reduced levels are usually due to a lack of exposure to sunlight (also due to the use of sunscreens), impaired intake 
(malabsorption) or impaired conversion to active vitamin D in kidney damage. Impaired 1,25 (OH)
2
D production due 
to FGF23 overproduction is rare.
Increased levels are found in granulomatous 1,25 (OH)
2
D diseases (sarcoi-
dosis) and due to substitution preparation overdosing – increased 25 OH D level. 
The immunoassay is negative in the case of overdosing on active vitamin D metabolites (HPLC or mass spectrophoto-
metry detection is required).
9.3.5.10. PTH
The laboratory diagnosis of hyperparathyroidism is based primarily on tests for PTH, Ca, Ca2+ and their urinary los-
ses; 25 OH vitamin D is added in differential diagnosis.
Primary hyperparathyroidism most often afflicts post-menopausal women, and is also part of familial MEN1 and 
MEN2B syndromes, mostly involving parathyroid adenoma, or carcinoma in rare cases.
Most common causes of secondary hyperparathyroidism are: Vitamin D insufficiency, malabsorption syndromes, 
and bone disease in kidney damage.
Tertiary hyperparathyroidism is caused as autonomous parathyroid hyperplasia with previous secondary hyperpa-
rathyroidism in kidney damage.
9.3.6. Summary – Key Information:
9.3.6.1. Indications
• The basic test is the plasma or serum Ca, P and Mg assay, namely overall plasma Ca, P and Mg concentra-
tions and not the metabolically active ionised fraction, which is technically more difficult;
• Assays for overall or ionised serum levels provide a picture of the current status in relation to regulating 
hormones;
• Plasma Ca, P and Mg assays are not very sensitive tools for examining calcium and phosphate metabolism 
since changes in the levels occur when regulating mechanisms have been depleted;
• The overall plasma calcium concentration depends on albumin concentration. Changes in albumin con-
centration lead to a change in total Ca concentration without substantially changing the ionised Ca level 
(patients have low Ca levels but do not display symptoms of hypocalcaemia);
• Ionised Ca concentration depends on the current pH; the measurement is made on an ion-selective elect-
rode with a pH measurement on POCT (Point-of-Care Testing) analysers;
• Mg is primarily an intracellular cation; serum concentration tests only reflect the current intake rather than 
its tissue concentration;
• Tests of Ca, P and Mg loss in urine point to information about the supply in the body assuming normal 
regulation in the kidneys, and are also subject to a high error rate during sample collection;
• Assays for regulating hormones: PTH, 25 OH vitamin D, 1,25 OH
2
 vitamin D, calcitonin and FGF23 are only 
performed by specialist sites; great differences between test manufacturers lead to possible different in-
terpretations.
9.3.6.2. Stability
• Samples for Ca, Mg and P assays must not be taken into tubes with EDTA or citrate as they counterbalance 
all Ca and Mg in the sample; overall Ca, P and Mg concentrations are stable at 8 °C for 7 days; haemolysis 
increases Mg and P levels;
• PTH and PTHrP tests: If taken into EDTA tubes, samples are stable for 24 hours after centrifuging at 4 – 8 °C;
• 25 OH vitamin D is a stable serum and plasma parameter and does not require other than usual measures;
• Ionised forms of Ca2+ and Mg2+: Collection identical to Astrup (heparinised venous, arterial, mixed blood). 
Process within 2 hours with pH measurement;
• Urinary Ca, P and Mg: Ca, P and Mg values are stable at -20 °C for at least 3 weeks, at +4 °C for 3 days, 
though tend to precipitate or sediment; the sample should be stabilised (10 ml 6Mol HCl for 24-hour coll-
ection) and thoroughly stirred before the analysis.
Test Methods:
• Immunoassays are used for determining PTH, PTHrP and FGF23; different tests use different reference 
limits (differences in test specificity and sensitivity);
• Currently widely available PTH tests detect 1-84 PTH as well as 7-84 PTH fragment. Methods measuring 
only biologically active 1-84 PTH are also possible, however these have substantially lower reference limits;
• Liquid chromatography-mass spectrophotometry is ideal for measuring vitamin D as it measures all meta-
bolites, but this is not a routine test. Immunoassays are used for routine testing with varying specificity to 
D2 and D3 isoforms (equal measurement of 25-OH-vitamin D2 and D3 isoforms is ideal).
Interpretation:
• Formula for overall Ca adjustment to current serum albumin level 
Ca adjusted = Ca measured (mmol/l) + 0.020*(41.3 – c. albumin in g/l);
• Major causes of hypercalcaemia: Primary hyperparathyroidism, tumour diseases with bone metastases 
and PTHrP overproduction, multiple myeloma, Paget’s disease, granulomatous diseases with vitamin D 
overproduction (sarcoidosis);
• Acute hypocalcaemia: quickly induced respiratory alkalosis leads to a decrease in ionised Ca – hyperventi-
lation tetany;
• Chronic hypocalcaemia: conditions associated with insufficient calcium and vitamin D intake (malabsorpti-
on, osteomalacia), chronic kidney disease, hypoparathyroidism, medullary carcinoma;
• Hypophosphatemia is most common in the following conditions: Malabsorption, severe vitamin D defici-
ency, primary hyperparathyroidism, renal disorders, tumour diseases;
• Hyperphosphatemia is most common in the following conditions: Renal failure, hypoparathyroidism, acute 
metabolic acidosis (transfer of P from the ICF), crush syndrome and acute tumour lysis syndrome;
• 25 OH vitamin D is an indicator of vitamin D supply status: adequate level 75 – 150 nmol/L (severe defici-
ency < 25 nmol/L, often associated with secondary elevation of PTH);
For differential diagnosis of primary and secondary hyperparathyroidism see Fig. 9.1
Figure 9.9. Differential diagnosis of hyperparathyroidism (HPT)
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10.1. Esential Trace Elements
The human body as part of the terrestrial ecosystem draws its elementary composition from the elements of the 
Earth’s crust. If a sufficiently sensitive analytical method is used, practically all the elements of Mendeleev’s periodic 
system can be demonstrated in the human body. However, it is very difficult, and perhaps impossible, to interpret such 
finding at present.
Table 10.1 shows the percentage (elemental) composition of the Earth’s crust and the human body. Given the 
prevalence of organic matter, the building blocks of organic compounds (O, C, H, N) dominate in the elemental com-
position of the human body.
Element Percen-
tage (%)
Earth’s Crust Human Body
O 47 Mg 2.1 O 62.8 Na 0.26
Si 28 Ti 0.4 C 19.4 K 0.23
Al 8 H 0.1 N 9.3 Cl 0.18
Fe 5 Al 5.1 Mg 0.04
Ca 4 Ca 1.4 Fe 0.009
Na 2.8 P 0.63 Zn 0.00003
K 2.6 S 0.60 Cu 0.000001
Table 10.1. Percentage (elemental) composition of the Earth’s crust and the human body
Trace elements are found in the body in very low, “trace” amounts not exceeding 0.01 % of body weight, with ty-
pical concentrations of μmol/l (μg/l) and lower.
They can be divided into essential and non-essential trace elements. Trace elements essential for humans are: Fe, 
Zn, Cu, Se, Cr, Co, Mn, Mo, I; possibly essential trace elements: Al, Si, F, V, Ni; trace elements with hitherto unknown 
physiological function, considered toxic heavy metals: Pb, Cd, Hg, As, Bi, Sn, Ag, Au, Pt, Ti, Rb, Sr, Ba, Y (Table 2).
Table 10.2. Arrangement of the elements listed above in Mendeleev’s periodic system
10.1.1. Definition of essentiality
Essentiality is generally defined by the occurrence of a specific defect in the structure or function of a tissue or 
organ resulting from a deficiency of the relevant element, and the remedy or prevention of such defect when such 
element is replenished. The definition of essentiality is currently supplemented by the requirement for knowledge and 
description of the element’s action at the molecular level, including the specific physiological effect in the body.
Most essential trace elements have an important function as co-factors of enzymatic catalysis processes such as 
metalloenzymes and non-enzymatic metalloproteins.
Trace element deficiency may be caused by insufficient intake in food or by their reduced utilization from food, de-
creased absorption (maldigestion, malabsorption), increased losses (diarrhoea, bleeding in the GIT, exudative entero-
pathies) or by increased requirement (stress, fever, sepsis, tumours, traumas, burns). The early years of total parenteral 
nutrition without the supplementation of essential trace elements can be used as a model case of induced essential 
trace element deficiency. Numerous interactions between trace elements and other nutrients are known which may 
also cause their deficiency in the organism. There are also genetic defects in the population that have a considerable 
effect on trace element metabolism (Zn-Acrodermatitis enteropatica, Cu-Menkes disease, Wilson’s disease, congenital 
thyroid disorders, haemochromatosis).
In addition to their essentiality, some trace elements show high toxicity at higher concentrations (Se); others are 
toxic at high doses in connection with poisoning or chronic, often occupational exposure.
10.1.2. The diagnosis of essential trace element deficiency
The diagnosis of essential trace element deficiency is currently based on the following three principles:
• Laboratory assays of the trace element content in different body fluids (plasma, serum, urine, saliva) and 
cells or tissues (erythrocytes, leukocytes, thrombocytes, hair, nails, bioptic material);
• Determination of the activity of trace element-dependent enzymes;
• Clinical signs of the deficiency.
Clinical signs are usually accompanied by severe whole-body deficiency conditions. The absence of a sufficiently 
sensitive and specific test to reveal a slight or medium deficiency of trace elements presents a continuing problem.
It is advisable to combine all three procedures alongside their comprehensive assessment and evaluation, re-
specting all available knowledge about specific and non-specific signs of deficiency, including other influences on the 
monitored parameters. In such situation, a therapeutic test continues to have a high predicative ability. Where causal 
connection exists, administration of the suspected deficient micronutrient will lead to an improvement in the clinical 
and laboratory signs.
10.1.3. Methods for trace element determination in biological material
Flame or electrothermal atomic absorption spectrometry (AAS) is the commonest used method for determining 
trace element concentration (except for iodine). It is absolutely essential to respect all precautions for trace assays in 
the pre-analytical and analytical phase, to use special collection sets, acid-washed laboratory glassware, “suprapure” 
reagents, the highest quality of water and gases (for AAS), and to maintain a clean, dust-free laboratory environment, 
especially for ultra-trace assays.
10.1.4. General rules for adequate and safe intake of essential trace elements from food
As the essentiality of each trace element for the human body was discovered, the essential trace elements were 
included in recommendations for their dietary intake from food. Issues concerning the definition and determination of 
recommended values for the optimum daily dietary intake of essential micronutrients (trace elements and vitamins) 
continue to be discussed today. Such issues have a long history. The first recommendations, Recommended Dietary 
Allowances (RDA), were published in the US in 1941 in connection with World War Two and the introduction of the 
food rationing system. They included recommended nutrient doses, including micronutrients (particularly vitamins), 
intended to ensure their sufficient intake for the general population. Emphasis was put on preventing the occurrence 
of nutritional rickets, scurvy and pellagra. RDAs for essential trace elements were only specified in later revisions of this 
document. Today, RDAs are being replaced with a newly defined term, Daily Recommended Intake (DRI), intended to 
incorporate four other terms: Estimated Average Requirement (EAR), Recommended Daily Allowance (RDA), Adequate 
Intake (AI) and tolerable Upper Limit. The Population Reference Intake (PRI) is defined in Europe. Definitions of the 
above terms differ in details and in the range of their application to differently stratified populations of healthy and 
diseased people.
In general, they meet the following criteria:
• Minimum micronutrient amount preventing a specific disorder from occurring;
• Amount required to maintain an optimum nutritional status;
• Daily intake with the lowest risk of potential toxic effect.
In respect of the health of the local population, it can be stated that the normal mixed diet is a sufficient source of 
nutrients, including trace elements, except perhaps for iodine and selenium.
10.1.5. Food chain and food production
The content of essential trace elements in food largely relates to the food chain (soil, plants, livestock and humans). 
The content of trace elements in the soil, which is subject to considerable, in global terms often vast, regional differen-
ces, may directly influence grazing cattle in particular. Other farm animals, for example pigs and poultry, fully rely on 
the supply of trace elements in prepared feed and feed mixes. Serious deficiencies afflicting entire breeds may occur 
and do actually exist even here. The influence of local food production is decreasing to some extent due to ongoing 
globalization within the worldwide trade, export and import of staple foods.
10.1.6. Utilization of trace elements from food – interactions
Trace elements are an integral part of the human diet. In particular, they come from animal products, whose or-
ganically bound elements are better utilizable for the human body than their inorganic forms. The mutual interactions 
of micro and macronutrients and other food components should be understood and respected when considering the 
adequate intake of essential trace elements. The commonest interfering substances are phosphates, fibre, phytanic 
acid (inositol-hexaphosphate) and other chelating agents. In general, one element supplied in excess may negatively 
affect the absorption and metabolism of others.
The text below deals with Iodine, Iron, Zinc, Copper and Selenium in detail. The other essential trace elements, 
Chromium, Cobalt, Manganese and Molybdenum will be mentioned only marginally, since they have yet to find any 
clear practical application in clinical medicine.
10.2. Iodine
10.2.1. Biochemistry and metabolism
Iodine is absorbed in the intestine in the form of iodide. It is very efficiently taken up from the blood plasma by 
the thyroid parenchyma using the iodide pump with the participation of Na/K dependent ATPase under TSH control. 
Through the action of thyreoperoxidase, the tyrosine molecule is gradually iodized to form mono, di, tri and tetraiodo-
tyrosine (thyroxine), which is saved (concentrated) in the thyroidal follicle colloid. The main active form of the thyroid 
hormone triiodothyronine is produced by cleaving one iodine atom away from the tetraiodotyrosine (thyroxine) mole-
cule through the action of selenium-dependent 5´-deiodase.
Iodine is excreted from the body in the urine. Iodine output correlates with iodine intake from food, and so iodi-
neuria can be used to estimate the intake.
10.2.2. Biological functions
Iodine is numbered among the essential trace elements for its single but essential and unique function in the body. 
It is indispensable for the synthesis and function of thyroid hormones, triiodothyronine T3 (3 I atoms) and tetraiodothy-
ronine T4 (4 I atoms).
Inadequate iodine supply from food leads to a reduction of T4 and T3 synthesis, as well as the T4 and T3 blood 
level.
On the negative feedback principle, the hypophysis reacts to this situation by increased secretion of TSH, which 
leads to thyroid hypertrophy and, at a later stage, goitre.
Due to the suboptimal function of thyroid hormones, iodine deficiency causes disorders of CNS development and 
function, growth and sexual maturation disorders, disorders of energy metabolism regulation, temperature regulation 
and other functions.
In adulthood, iodine deficiency is manifested by complex symptoms of myxoedema, usually with goitre.
A guaranteed source of iodine in food is sea fish; iodine in other vegetable and animal products depends in the 
iodine content in the ambient environment. An important source can be the targeted or even accidental enrichment 
of foodstuffs with iodine (e.g. contamination of milk by traces of iodine agents used for disinfecting dairy vessel and 
tubing).
The recommended daily dose of iodine for men is 150 μg, 120 μg for women and 170 μg in pregnancy.
10.2.3. Deficiency – causes and signs
Iodine Deficiency Disorders (IDD) are globally regarded as the most widespread cause of CNS damage with signs of 
mental retardation which could be removed through targeted and consistent prevention.
Based on the WHO records, about 1/3 of the world’s population (about 2.2 billion people) is at risk from iodine 
deficiency signs. Iodine is naturally found in soil and seawater. There are regions on Earth with very low iodine content 
in the ambient environment, with a high incidence of iodine deficiency signs and marked clinical signs such as goitre 
and mental disorders. The severest intellectual disorders (e.g. imbecility) specific to these regions have given rise to 
the name endemic cretinism.
The name sporadic cretinism refers to the same clinical picture caused by a congenital thyroid function defect that 
was not identified in time and treated immediately after the birth of the afflicted child.
Observations of the widespread global endemic occurrence of iodine deficiency signs have led to efforts to elimi-
nate them through widespread iodine supplementation. This was started in the US in 1920 and has spread over time 
to most regions at risk of iodine-deficiency in more than 140 countries of the world. From the many possible ways of 
iodine supplementation, table salt iodization has proved the optimal method. Salt is accessible to all social and econo-
mic groups, shows an even intake without seasonal swings, there is no risk of overdosing, and iodization by adding KI 
is easy and inexpensive.
10.2.4. Diagnosis of the deficiency
Iodine deficiency is accompanied by a drop in the thyroid hormone (fT4, fT3) level and a feedback increase in the 
TSH level.
Insufficient iodine intake from food leads to decreased iodine excretion in urine (iodineuria); < 20 μg per litre is 
indicative of a serious deficiency compared to normal levels of 100 – 200 μg per litre.
10.2.5. Toxicity
Excessive iodine intake may go together with an excessive intake of sea products, mostly, however, without marked 
somatic signs. An iatrogenic excessive intake (e.g. KI) may cause signs of thyroid hyperfunction, including hyperfuncti-
oning goitre.
10.3. Iron
Iron is the most abundant essential trace element in the human body. The global incidence of iron deficiency re-
sembles that of iodine.
10.3.1. Biochemistry and metabolism
Most iron in the body is bound in haemoglobin (60 %), the rest in myoglobin, ferroproteins and iron-dependent 
enzymes. The metabolic pathway of iron from food to target molecules in cells, tissues and organs requires the syner-
gism of different systems. The prevalent form of iron in food (Fe3+) must be reduced to Fe2+ to be absorbed in the 
small intestine. This reduction is enhanced by HCl in the gastric juice, vitamin C, citric acid and lactic acid. Following 
absorption, iron is re-oxidized by action of caeruloplasmin (also called ferroxidase) and embedded in the transferrin 
molecule. Transferrin brings iron to cells, into which it is incorporated through surface receptors. Iron is incorporated 
in haemoglobin in bone marrow, myoglobin in muscles, and iron-dependent enzymes and reserve metalloproteins 
(ferritin, haemosiderin) in other cells.
Daily iron loss (0.35 mg) is due to occult blood losses in the digestive system, bile, skin and urine (80 μg). These 
losses may rise significantly during GI tract diseases, particularly bleeding and menstrual cycle disorders in women.
The daily requirement depends on age and gender, the quality and composition of food and the amount of losses; 
10 mg for men and 15 mg for women (25 mg during pregnancy).
10.3.2. Biological functions
The biological function of iron is closely connected with oxygen energy metabolism. Hexavalent iron in haemoglo-
bin (four valences go to nitrogen ions in the four pyrrole nuclei, the fifth link binds globin-coupled histidine, and the 
sixth valence is free for oxygen) provides a unique transport of oxygen to tissues and cells, where cytochrome redox 
chains (Fe2+ … Fe3+) release energy for producing the high-energy phosphate bonds of ATPs.
Primarily, iron is essential for haemoglobin synthesis in erythrocytes. Iron deficiency is responsible for microcytic 
hypochromic anaemia.
10.3.3. Deficiency – causes and signs
Iron deficiency is the commonest nutritional deficiency and the commonest cause of anaemia. Sideropenic anae-
mia afflicts 500 – 600 million people. Sideropenic anaemia is the commonest blood disease occurring during childhood.
Iron deficiency in the body is caused by an unequal relationship between iron intake and increased losses (someti-
mes even just obligatory losses).
Iron deficiency is more common among women due to blood losses during menses.
Another cause may be inadequate dietary composition with a low iron content, the presence of substances re-
ducing iron utilization (oxalic acid and polyphenols in coffee, tea and chocolate which form insoluble complexes with 
iron), or an excessive supply of trace elements (Zn, Cu, Mn) causing a competitive decrease in iron absorption in the 
intestine.
10.3.4. Diagnosis of the deficiency
Marked iron deficiency in the body leads to hypochromic microcytic anaemia. Iron assays and serum transferrin, 
ferritin and soluble transferrin receptor saturation assays are used to confirm the aetiological role of iron deficiency, 
see Table 9.3.
S-iron 9.0 – 30.0 μmol/l
Serum transferrin saturation < 16 %
S-ferritin < 15 μg/l
S-soluble transferrin receptors > 8.5 mg/l
Table 10.3. Laboratory parameters for the diagnosis of iron-deficiency anaemia.
10.3.5. Toxicity
Typical symptoms of the toxic action of iron surplus in the body accompany haemochromatosis with congenital 
abnormally high iron absorption in the intestine, which leads to liver damage, diabetes and skin pigmentations (bronze 
diabetes). Secondary disorders may be due to excessive iron intake or abundant transfusion. Iron toxicity relates to the 
pro-oxidation action of iron. Excessive Fe3+ not bound to binding proteins may induce an increased production of free 
radicals and tissue damage by oxidation.
Molecular Level (Patho)physiological Functions Clinical Signs
Fe-metalloenzymes
Cytochromes C Oxygen energy metabolism Hypoxia
Cytochromes P450 Transformation of xenobiotics Inefficiency/toxicity of drugs
Fe-proteins
Haemoglobins Oxygen transport in blood Hypoxia
Myoglobin Oxygen metabolism in muscles, 
intracellular O
2 
transport 
Transferrin Fe-carrying protein, acute-phase protein Anaemic conditions
Ferritin Fe-storage proteins Anaemic conditions
Haemosiderin Proteins saving iron surplus
Table 10.4. Molecular basis of clinical signs of iron deficiency (examples)
10.4. Zinc
Professor Prasad was the first to describe completely documented clinical and laboratory observations of severe 
human zinc deficiency in 1961 in Iran.
Nevertheless, it was only the discovery by Barnes and Moynahan (1970) of the role of zinc in the aetiology and 
clinical signs of acrodermatitis enteropathica, and its causal treatment with a complete remission of signs following 
zinc supplementation, which led to the inclusion of zinc among the essential trace elements and the assessment of the 
RDA for zinc (1974).
10.4.1. Biochemistry and metabolism of zinc
Total plasma zinc (13 – 18 μmol/l) includes zinc freely bound to albumin, more strongly bound to other plasma pro-
teins, particularly alpha-2-macroglobulin, diffusible zinc bound to plasma amino acids, particularly histidine, cysteine 
and lysine, and a low amount of ionized zinc. Plasma zinc represents only about 0.1 % of the total zinc content in the 
body.
The recommended daily dose of zinc in a normal mixed diet containing animal proteins ranges between 8 and 15 
mg/day.
The output side in the zinc balance consists mainly of zinc losses in the digestive tract, stool 15 – 30 μmol/day (1 ˗ 
2 mg/day), urine 7.5 μmol/day (0.5 mg/day) and sweat 7.5 μmol/day (0.5 mg/day).
10.4.2. Biological functions of zinc
More than 200 enzymes are known to require the presence of zinc in their molecule to be functional. They include 
almost all groups of enzymes through which zinc widely participates in the metabolism of carbohydrates, lipids, pro-
teins and nucleic acids, including many other metabolic processes.
Zinc is required for the synthesis and metabolism of nucleic acids (DNA, RNA), through which it is closely related to 
the cell division rate and therefore growth, differentiation, morphogenesis, regeneration, the healing of wounds, etc.
As part of Zn,Cu-superoxide dismutase, zinc is an essential part of the anti-oxidative protection of cells against 
superoxide radical (O
2
.-) damage.
Zinc is important in maintaining the integrity and proper barrier function of the skin. Severe deficiencies are ac-
companied by various skin alterations, parakeratosis, vesiculo-pustular exanthema with crusts, and frequent infections 
with a major occurrence of circumoral and genitoanal alterations and alterations on peripheral extremities. The most 
pronounced signs accompany acrodermatitis enteropathica with a zinc absorption defect in the intestine.
The participation of zinc in the effective function of the immune system is extremely complex. The cellular part 
of immunity is afflicted most; the T lymphocyte count and differentiation decreases, as well as the T
4
+/T
8
+ lymphocyte 
sub-population ratio.
This condition is associated with thymus atrophy accompanied by a marked decrease in thymulin concentration in 
the plasma. The clinical sign of the effect of zinc deficiency on immune functions may be a reduced immunity to infec-
tions, relapsing infections and chronic inflammatory affections of the skin and mucosa.
10.4.3. Deficiency of zinc – causes and signs
Depending on its severity, zinc deficiency may induce serious, life-threatening conditions, including developmental 
defects, retardation of growth and sexual maturation, or just discrete skin alterations, slightly lower stature, taste di-
sorder, night blindness or a greater liability to different infections.
In general, zinc deficiency in the body may be provoked by lower zinc intake, increased losses, increased require-
ment or a combination of these effects. Animal products represent a more valuable source of zinc due to the higher 
zinc utilization during absorption in the digestive tract. Legumes and nuts are the best source of zinc for vegetarians.
Zinc absorption disorder goes together with chronic intestinal diseases such as Crohn’s disease, coeliac sprue, ul-
cerous collitis, chronic diarrhoeas, jejunal bypass, external pancreatic secretion insufficiency, etc.
Increased zinc losses, especially in the urine, are associated with increased catabolism such as burns, polytraumas, 
sepsis, neuroinfections, etc.
An increased requirement of zinc is typical of fast growth periods, pregnancy, lactation and the anabolic phase 
following heavy strain with catabolism.
10.4.4. Diagnosis of the deficiency
Serum zinc is used most often for assays due to its sampling accessibility. Albumin (hypalbuminaemia reduces 
zincaemia) and CRP levels must be known at the same time. Infections and inflammations cause zinc redistribution 
from plasma to cells through cytokines, so a reduced serum zinc concentration is not indicative of any whole-body zinc 
deficiency.
Preventing the contamination of collection and transport containers poses a substantial pre-analytical problem. 
Even brief contact of blood or urine with a rubber stopper may cause gross errors. Rubber filler contains ZnO and zinc 
elution from rubber is very fast.
Attempts at assays for zinc in leukocytes, thrombocytes, hair and muscles have not led to any wider practical use.
The determination of zinc-dependent cellular enzyme activities seemed to be promising. These enzymes included 
erythrocyte carboanhydrase, leucocyte alkaline phosphatase, erythrocyte Zn,Cu-superoxide dismutase and others. 
However, findings have not been so far clearly and consistently interpreted.
Given the difficulty of obtaining clear laboratory proof of boundary zinc deficiency in particular, a therapeutic test 
is indicated in cases of clinical suspicion of whole-body deficiency. Signs induced by zinc deficiency will promptly disap-
pear following zinc supplementation.
The problem of zinc substitution in the acute conditions of critically ill patients with hypozincaemia (as in the case 
of iron) remains unresolved.
10.4.5. Toxicity of zinc
Zinc is a relatively low-toxic element. Acute and chronic zinc intoxications are described as occupational diseases 
in people inhaling metal zinc fumes or fine dust (metal fume fever or zinc shakes) with manifestations such as fatigue, 
headache, cough, chills and fever.
Molecular Level (Patho)physiological Functions Clinical Signs
Zn-metalloenzymes 
Thymidine kinase
DNA polymerase
Nucleic acid metabolism
Cell division, growth, regeneration
Delayed growth, dwarfism, poor 
healing of wounds
Zn,Cu-superoxide dismutase Anti-oxidative protection Oxidative stress signs
Retinol dehydrogenase Visual purple regeneration Night blindness
Collagenase Collagen fibre metabolism Connective tissue disorders
Zn-proteins 
Metallothionein Essential and other trace element 
metabolism
Cell membrane stabilization
Signs of deficiency, toxicity of ele-
ments 
Gene regulation, Zn-finger-proteins 
and expression of different protein 
genes
Reduced expression of different pro-
tein genes,
cell growth, differentiation, morpho-
genesis
Developmental defects of neural 
tube, spina bifida, meningocele, an-
encephaly 
Spermatogenesis Lower sperm count, lower testostero-
ne level, hypogonadism
Barrier functions of skin Parakeratosis, genito-oral and acral 
vesiculo-papilous exanthema 
Thymulin Differentiation of T lymphocytes, che-
motaxis, antigenic T-cell response Bb 
antigens 
Reduced immunity to infections, 
relapsing infections, chronic inflamm-
atory affections of skin and mucosa
Glucocorticoid and oestrogen recep-
tors
Specific cortisol and oestrogen bond Hormonal disorders
Table 10.5. Molecular basis of clinical signs of zinc deficiency (examples)
10.5. Copper
As an essential trace element, copper is third in abundance in the human body after iron and zinc.
In routine clinical practice, copper metabolism disorder is usually encountered in the differential diagnosis and 
monitoring of Wilson’s disease (hepatolenticular degeneration).
10.5.1. Biochemistry and metabolism of copper
Copper is widespread in biological tissues, where it is found in the form of organic complexes, mostly metallopro-
teins and metalloenzymes.
Copper in the blood is generally divided between erythrocytes and plasma. Most copper in red blood cells is conta-
ined in Cu,Zn-superoxide dismutase. Physiological plasma copper concentrations range from 11 to 22 μmol/l. Women 
have about 10 % higher plasma copper concentrations with up to a threefold increase in the late stage of pregnan-
cy, and levels are also increased in women using oestrogen-based contraceptives. Copper along with caeruloplasmin 
levels increase during non-specific reaction to stress exposure (traumas, operations, malignant tumours, biliary ob-
structions, etc.).
Copper metabolism is very closely connected with the synthesis and functions of caeruloplasmin.
Caeruloplasmin is a plasma protein synthesized in the liver, containing 6 – 7 copper atoms and showing marked 
enzyme oxidase activity. Copper bound in caeruloplasmin represents 80 – 93 % of plasma copper concentration. The 
remaining 7 % is freely united to albumin and some plasma amino acids.
The major copper excretory pathway is copper excretion in the bile in the form of poorly absorbable complexes 
leaving the body with the stool. Only very small amounts are excreted in the urine in normal circumstances (32 – 64 
μg/24 hrs, 0.5 – 1.0 μmol/24 hrs).
Given their high reactivity, copper atoms bind to different carriers to be transported within and between cells of 
the body. The copper transport system in the plasma consists of caeruloplasmin, albumin and some amino acids. Cop-
per absorbed in the intestine is bound to albumin through amino nitrogen and histidine imidazole nitrogen, and is car-
ried to the liver by portal blood. Here it is embedded in caeruloplasmin and released with it into the circulatory system.
10.5.2. Biological functions of copper
The numerous physiological functions of copper are derived from the well-known activities of copper-dependent 
metalloenzymes. These activities include, first and foremost, the action of caeruloplasmin as ferroxidase I in iron and 
haemoglobin metabolism, and the lysyl oxidase enzyme, which is a key enzyme in tissue cross-linking.
An important oxidase activity of caeruloplasmin in the plasma acts as an essential means of bivalent (Fe2+) to triva-
lent (Fe3+) iron oxidation. This allows the mobilisation of reserve iron from ferritin, its incorporation into transferrin and 
its use for the synthesis of haemoglobin.
Lysyl oxidase catalyzes the oxidation of lysyl and hydroxy lysyl residues in polypeptide chains of elastin and col-
lagen. The condensation of the formed aldol groups produces configurations bridging polypeptide chains which are 
crucially important for the strength, elasticity and flexibility of major fibrous connective tissue proteins.
Wilson’s disease, a genetic, familial disease, represents a separate entity in copper pathophysiology. A pathogno-
monic sign is the considerably reduced incorporation of copper in caeruloplasmin and reduced copper excretion in the 
bile. This leads to a positive copper balance and gradual copper accumulation in the liver. Non caeruloplasmin-bound 
plasma copper increases, which leads to increased excretion of copper in the kidneys, and copper deposits in other 
extrahepatic tissues such as the cornea, where it forms the well-known Kayser-Fleischer ring, the brain (primarily in 
basal ganglia regions), kidneys, muscles and bones.
Reduced or even zero caeruloplasmin concentrations are typical in laboratory reports. Serum copper is usually 
reduced together with caeruloplasmin, but normal or elevated levels may be found, too. Nevertheless, the “free”, non 
caeruloplasmin-bound copper, which is toxic, is indicative of decompensation of the disease with frequently occurring 
accompanying intravascular haemolysis. Copper excretion in the urine is elevated.
An increased copper content in the liver (more than 300 μg/g of dry tissue) can be proved.
An afflicted individual’s siblings must be examined very carefully and rigorously, as there is a higher chance of a 
copper metabolism disorder in the family. An active approach in diagnosing Wilson’s disease can prevent delayed dia-
gnosis and permanent consequences.
10.5.3. Copper deficiency – causes and signs
A severe, purely nutritional copper deficiency with clinical signs is quite rare. Such cases may occur in infants on 
artificial nutrition, re-alimentation lacking trace elements following severe malnutrition and catabolic conditions, and 
during long-term, insufficiently balanced parenteral nutrition.
Developed copper deficiencies occur more often due to enteropathies and malabsorptions of different origin.
The most abundant source is liver, lobster meat, oysters, as well as nuts, peas and chocolate.
Menkes disease is a rare inherited copper metabolism disorder with fatal consequences and clinical signs of copper 
deficiency. The disease is caused by a copper absorption, transport and utilization disorder.
10.5.4. Laboratory diagnosis of copper deficiency
Decreased serum caeruloplasmin and copper levels may warn of copper deficiency. A constant sign of copper de-
ficiency is hypochromic microcytic anaemia not responding to iron administration, and leucopenia. Significant altera-
tions can be seen in bones, especially in children. These are signs of osteoporosis, fiberized calyciform metaphyses of 
long bones and periostal appositions accompanied by an increased serum alkaline phosphatase activity.
10.5.5. Toxicity of copper
If inhaled in the form of aerosol or fine dust, copper induces signs of acute intoxication (“metal fever”) with the 
same signs as those typical of zinc poisoning: cough, chills, fever, fatigue and headache.
Molecular Level (Patho)physiological Functions Clinical Signs
Cu-metalloenzymes
Cytochrome C oxidase Electron transport in respiratory 
chains
Non-specific, erythropoiesis disorders
Superoxide dismutase Scavenging superoxide radical Oxidative stress signs
Monoamine oxidase Catecholamine metabolism Non-specific CNS disorders
Tyrosinase Melanin synthesis Skin pigmentation disorders
Lysyl oxidase Connective tissue metabolism, cross-
links 
Collagen disorders, cutis laxa, laxity of 
joints
Cu-proteins
Caeruloplasmin Acute phase proteins, Fe2+ oxidation Anaemia
Metallothionein Cu binding and transport in cells Cu deficiency/toxicity
Table 10.6. Molecular basis of clinical signs of copper deficiency (examples)
10.6. Selenium
Unlike zinc and copper, selenium is a highly controversial element in medical terms. In the 1930s, selenium was 
identified as a major toxic element in veterinary and human medicine. It was surprising, therefore, when its essentiality 
was recognized and serious signs of selenium deficiency found. Selenium substitution is anticipated to have a positive 
effect on tumour incidence in regions with a low intake of selenium, while selenium sulphide is considered carcino-
genic, with anti-oxidizing as well as pro-oxidizing qualities. It is evident that its atomic structure provides selenium 
compounds with diverse, often contrasting physical, chemical and biological properties. Selenium has therefore been 
subject to intense basic as well as applied research in technical and biological fields.
10.6.1. Biochemistry and metabolism
Selenium is part of numerous metalloenzymes and metalloproteins, where it is mostly found in the form of seleni-
um methionine and selenium cysteine. Selenium methionine is solely of vegetable origin and represents about 50 % of 
the daily selenium intake. Among other things, it is used for selenium cysteine synthesis in the body.
Between 50 – 60 % of plasma selenium is bound to selenoprotein P, 30 % is found in glutathione peroxidase (GSH-
Px-3) and the remaining part is found in selenium methionine.
Reference limits in this population, rather lower than in Europe in general, are 0.8 – 1.4 μmol/l.
The recommended daily intake for adults is 55 μg. Cereals, legumes and in particular nuts are a good source of 
selenium.
10.6.2. Biological functions
Selenium is involved in human tissue protection against oxidative stress, anti-infection protection, and modulating 
growth and development.
There are two groups of selenium-dependent enzymes. The first contains glutathione peroxidases in four isoforms 
and thioredoxin reductase involved in antioxidation protection against reactive oxygen radicals.
The second group consists of three types of selenium-dependent 5‘-deiodinases essential for thyroxine (tetraio-
dothyronine T4) conversion into a physiologically more efficient (active) triiodothyronine (T3).
The three isoforms differ in their quantity and function in different tissues and organs.
Concurrence of selenium and iodine deficiencies is known, as are their synergies in hypothyroidism signs. Selenium 
is important for spermatogenesis and the proper function of sperm, muscle metabolism as well as the function and 
immunity of the body.
10.6.3. Deficiency – causes and signs
Nutritional deficiency of selenium fundamentally (significantly) depends on the regional selenium content in the 
soil at the beginning of the food chain.
The clinical signs of severe selenium deficiency described below do not occur in this population. However, very 
similar signs are not rare in some livestock breeds in this country.
Kashin-Beck disease is an endemic, chronic osteoarthropathy in children in China, Russia and Korea, with primary 
involvement of articular cartilages (atrophy, degeneration, necrosis) and marked signs of deformed, arthrotic joints. 
Another apparent sign is shorter stature due to multifocal necroses in the region of growth plates in long bones. This 
nosological entity was first described by Kashin in the Baikal region (1848) and Beck in China (1906). The aetiology of 
the disease is not quite clear yet. Apart from selenium deficiency, the effect of mould-contaminated grain and other 
factors are considered.
Keshan disease is an endemic disease afflicting mostly children and young women in certain Chinese regions with 
low selenium content in the soil. The predominant pathological and anatomical finding is multifocal myocardium ne-
croses leading to dilatation of the heart, congestive heart failure and death. Although the incidence of acute and sub-
-acute cases of the disease has decreased dramatically following selenium supplementation, the aetiological role of 
selenium has recently undergone change; today it is seen rather as a predisposing factor.
Clinical signs of selenium deficiency, caused mainly by malnutrition in local conditions, are non-specific and com-
plex in the same manner as our definition of the effects of increased oxidative stress on the body remains non-specific.
Populations living in areas with low selenium content in the soil (Nordic countries and also the CR) have a lower 
selenium concentration in the serum. As a result of worldwide globalization of food sources and large-scale livestock 
production (feed mixes, etc.), the soil foodweb has partly lost its immediate importance. The discussion on the need 
for widespread selenium substitution in this population still remains open.
10.6.4. Laboratory diagnosis of deficiency
The commonest method is to determine the selenium concentration in the blood, plasma or serum using atomic 
absorption spectrometry. Another method used is the determination of GSHPx activity in erythrocytes or selenopro-
tein P concentration.
When evaluating the findings of the above methods, one should take into account that all of the parameters are 
affected by redistribution and plasma level decrease due to stress, trauma, inflammation, etc.
10.6.5. Toxicity of selenium
Of more than 1500 species of Astragalus plants, only about 25 are primary accumulators of selenium. They are 
able to accumulate selenium from soil with selenium levels ranging from normal up to highly toxic concentrations (up 
to 1000 ppm). Secondary accumulators of selenium are plants accumulating selenium in regions with high selenium 
content in the soil. If consumed by farm animals, both types of plants cause lethal diseases referred to as alkali disease 
in beef cattle, and blind staggers in sheep.
The toxic selenium effect in humans manifests itself in the same way as in animals: brittleness, alterations and loss 
of hair, nail alterations (brittleness, cracks, colour changes), and including the typical garlicky breath odour. Selenium 
toxicity consists in its interaction with thiols; selenite reacts with glutathione and H
2
Se to form a superoxide radical 
(O
2
.-). The subsequent peroxidation of biogenic molecules and membranes represents the molecular basis for the toxic 
effects of certain forms of selenium.
Molecular Level (Patho)physiological Functions Clinical Signs
Se-metalloenzymes 
Glutathione peroxidases (1,2,3,4) Decomposition of inorganic and orga-
nic peroxides
Oxidative stress signs
Thioredoxin reductase Intracellular redox status Ditto
5‘-deiodinases (1,2,3) Thyroxine conversion into triiodothy-
ronine
Signs of hypothyroidism
? Connective tissue metabolism Connective tissue disorders
Se-proteins 
Selenoprotein P Se-storage form in plasma Signs of deficiency
Selenoprotein W Muscular form of Se Signs of deficiency
Selenoprotein – sperm Proper sperm function Infertility?
Table 10.7. Molecular basis of clinical signs of selenium deficiency (examples)
10.7. Chromium
Chromium plays a role in the normal metabolism of glucose and cholesterol and affects spermatogenesis and ferti-
lity. Sufficient valid information is not available for determining the daily intake. Cases of chromium deficiency are rare, 
perhaps as part of cases of severe malnutrition.
Chromium deficiency may cause glucose tolerance disorders, hypercholesterolaemia, decreased sperm count and 
fertility disorders.
Cr3+ has a high allergenic potential that leads to a high incidence of occupational contact eczema in people working 
in the building industry (cement), leather industry, printing and metal-working industries.
10.8. Manganese
Manganese forms part of numerous metalloenzymes (arginase, pyruvate carboxylase, Mn-superoxide dismutase 
in mitochondria, etc.).
Manganese has a non-specific activation effect on some enzymes (hydrolases, decarboxylases and transferases), in 
which the function of manganese may be replaced by other trace elements such as Fe and Cu.
The signs of the deficiency are non-specific.
10.9. Molybdenum
Molybdenum forms part of three metalloenzymes (xanthine oxidase, aldehyde oxidase and sulfite oxidase).
Congenital molybdenum deficiency with mortality in the first year of life has been described.
10.10. Cobalt
The only function known to determine the essentiality of cobalt is its presence in the vitamin B
12
 molecule (Coba-
lamin).
Reference limits; output in urine; recommended doses (table)
Reference Limits
(Serum)
24-hr Output
in Urine 
Rec. Daily Intake
(Oral)
Rec. Daily Intake
(Parenteral)
Zinc 10.7 – 18.4 µmol/l 3.0 – 12.0 µmol 
196 – 780 µg
12 – 15 mg 3.2 – 6.5 mg
Copper M 11.0 – 22.0 µmol/l 
F 12.6 – 24.3 µmol/l
0.5 – 0.9 µmol 
30 – 60 µg
0.9 – 1.2 mg 0.3 – 1.3 mg
Iron M 11.6 – 30.4 mol/l 
F 9.0 – 27.0 µmol/l
1.8 – 3.6 µmol 
100 – 200 µg
M 10 mg 
F 15 (25*) mg
1.2 mg
Selenium 0.7 – 1.24 µmol/l 0.1 – 1.3 µmol 
10 – 100 µg
55 µg 30 – 60 µg
Iodine 0.28 – 0.25 µmol/l 0.8 – 1.6 µmol 
100 – 200 µg
120 – 150 µg 130 µg
Chromium 1.0 – 10.0 nmol/l 9.6 – 38.5 nmol 
0.5 – 2.0 µg
50 – 200 µg 10 – 20 µg
Manganese 7.0 – 13.0 nmol/l 9.0 – 36.0 nmol 
0.5 – 0.2 µg
2 – 5 mg 0.2 – 0.3 mg
Molybdenum 1.0 – 30.0 nmol/l 208 – 313 nmol 
20 – 30 µg
50 µg 19 µg
Cobalt 1.9 – 7.6 nmol/l 8.8 – 35.1 nmol 
0.5 – 2.0 µg
Table 10.8. Reference limits, output in urine, recommended oral and parenteral doses of essential trace elements 
(*pregnancy)
Content of essential trace elements in pharmaceutical products
Parenteral products (table)
TRACUTIL
[10 ml]
ADDAMEL
[10 ml] 
ELOTRACE
[100 ml]
Zinc 3.3 mg 6.6 mg 6.0 mg
Copper 0.76 mg 1.3 mg 1.2 mg
Iron 2.0 mg 1.1 mg 1.1 mg
Selenium 24 µg 32 µg 12 µg
Iodine 127 µg 127 µg 127 µg
Chromium 10 µg 10 µg X
Manganese 550 µg 110 µg 300 µg
Molybdenum 10 µg 20 µg 20 µg
Fluorine 570 µg 950 µg 950 µg
Table 10.9. Content of trace elements in products for parenteral administration
Enteral products (table)
NUTRIDRINK
[100 ml] 
FRESUBIN
[100 ml] 
NUTRISON
[100 ml]
Zinc 2.9 mg 1.5 mg 1.8 mg
Copper 0.43 mg 0.3 mg 0.27 mg
Iron 3.8 mg 2.0 mg 2.4 mg
Selenium 14 µg 10 µg 8.5 µg
Iodine 132 µg 30 µg 20 µg
Chromium 16 µg 10 µg 10 µg
Manganese 800 µg 400 µg 500 µg
Molybdenum 24 µg 15 µg 15 µg
Fluorine 200 µg
Table 10.10. Content of trace elements in products for enteral administration
CHAPTER 11
11. Vitamins
11.1. Vitamins – Preparation
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11.1.1. Vitamins
Human nutrition consists of primary nutrients (carbohydrates, proteins and fats); in addition to this, food should 
contain other essential substances which the body is unable to produce by transforming from other components. Such 
components include essential amino acids, essential fatty acids, mineral compounds and vitamins. Vitamins are classi-
fied as either fat-soluble or water-soluble. Among other things, this classification helps estimate what foods the vita-
min may be present in, and under circumstances vitamin deficiency can be expected. A balanced diet prepared from 
fresh foodstuffs usually contains the necessary amounts of all vitamins. A prolonged low supply of some of the vitamins 
may cause either hypovitaminosis with non-specific symptoms, or more serious disorders with typical symptoms (avi-
taminosis). Vitamin deficiency may also occur as a result of a disorder of their absorption in the digestive tract, or an 
increased vitamin requirement during diseases or other conditions (convalescence, pregnancy, breastfeeding). Excess 
hydrophilic vitamins taken from food are usually quickly excreted from the body in urine. On the other hand, fat-so-
luble vitamins may deposit in the body for a longer time: vitamins A and D, and vitamin K to a limited extent in the liver, 
and tocopherols in the adipose tissue. Toxic symptoms can only be caused by repeated high doses of retinol or calciols 
(sometimes referred to as hypervitaminosis A or D). These almost always occur as a consequence of inappropriate 
dosage for therapeutic use.
11.1.2. Water-Soluble Vitamins
They do not deposit in the body (except for vitamin B
12
); excess amounts are excreted in the urine, meaning their 
consistent intake from food is important. They are enzyme cofactor components in the body.
11.1.2.1. Thiamine (Vitamin B1)
Thiamine is a pyrimidine and thiazole derivative. Thiamine is fairly unstable in solutions and unstable to heat. Thi-
amine diphosphate coenzyme is a biologically active form, which binds the reaction intermediate in the course of py-
ruvate and 2-oxoglutarate oxidative decarboxylation. This makes it essential for degrading all nutrients, carbohydrates 
in particular. The approximate daily requirement for adults is 1 – 2 mg. The requirement is much greater in the case of 
excess sugar in the food, profuse sweating when working in the heat, and in alcoholics. Thiamine is present in many ve-
getable and animal foods; the main source is meat, pork in particular, giblets, yeast, and wholemeal cereals and bread. 
White bread and glazed rice lose most of their original thiamine content during processing. The initial signs of thiamine 
insufficiency include increased tiredness, muscle weakness, and proneness to neuritis. Extreme avitaminosis known as 
beriberi in Southeast Asia is rare here; typical features include various cardiovascular and neurological disorders and 
gastrointestinal symptoms. This disease occurs if diet consists almost solely of peeled rice.
11.1.2.2. Riboflavin (Vitamin B2)
Riboflavin consists of a heterocyclic isoalloxazine ring bound to ribitol. It is the component of flavin mononucleo-
tide (FMN) or flavin adenine dinucleotide (FAD), cofactors of flavin dehydrogenases and other oxidoreductases. The 
daily riboflavin requirement is about 2 mg for an adult. The source of riboflavin in food is milk and dairy products, eggs, 
meat and a variety of vegetable foods. Riboflavin is usually present as bound in FMN or FAD; only milk contains free 
riboflavin. Avitaminosis B
2
 is not known. A limited intake usually manifests itself by mucous membrane involvement 
(inflammation of the lips, tongue, corners of the mouth, corneal edge vascularisation) and facial skin.
11.1.2.3. Niacin (Vitamin B3)
Niacin is the name for two pyridine derivatives: nicotinic acid and its amide, nicotinamide. Although they may be 
produced in the human and other mammalian body from tryptophan, niacin belongs to B-group vitamins. The bioche-
mical importance of nicotinamide is in that it is part of pyridine nucleotides, NAD+ and NADP+, working as coenzymes 
for hydrogen transfer in reactions catalysed by many dehydrogenases. The daily niacin requirement for a healthy adult 
is 13 – 20 mg. The intake of sufficient amounts of biologically valuable proteins from milk or eggs covers the niacin 
requirement despite its very low content, because niacin is produced in cells from tryptophan. Liver, meat and yeast 
are rich in niacin. Severe niacin deficiency causes pellagra, a disease characterised mainly by diarrhoea, skin inflam-
mation with pigmentation (dermatitis) and psychiatric disorders (dementia) – disease of the three Ds, and cardiac and 
neurological disorders at a later stage. Pellagra is endemic only where corn (low tryptophan content) is eaten as a 
staple food.
11.1.2.4. Pantothenic Acid (Vitamin B5)
Pantothenic acid is an amide formed from beta-alanine by binding the acyl radical of pantoic acid to its amino 
group. It is plentiful in natural resources (pantothen from the Greek “from everywhere”), with sufficient amounts in 
food. It is present in the blood, in cells mostly as a pantethine component, a part of coenzyme-A and fatty acid synthase 
multienzyme complex. The daily requirement of about 6 – 8 mg is covered by a varied diet. Rich sources are liver or egg 
yolks. Pantothenate supplementation is required in complete parenteral nutrition. Deficiency does not display typical 
symptoms. Calcium salt or alcohol precursor panthenol (dexpanthenolum) may be used as supplements improving the 
healing of uninfected burns, superficial injuries or catarrh of the upper respiratory tract.
11.1.2.5. Vitamin B6
Vitamin B
6
 is a common name for three related derivatives of substituted pyridine. All of them have the same biolo-
gical activity, and differ from each other in the group bound at position 4; pyridoxine (pyridoxol) has a primary alcoholic 
group, pyridoxal an aldehyde group and pyridoxamine a primary amine group. Pyridoxal 5-phosphate cofactor is the 
active form, a prosthetic group of enzymes primarily contributing in the conversion of amino acids (aminotransfera-
se, decarboxylase). The daily requirement of about 2 mg in adults is covered by a normal, varied diet, but increases 
greatly during lactation, in all catabolic conditions, or large consumption of ethanol. Absolute deficiency of vitamin B
6
 
is rare; insufficiency may manifest itself in alcoholics, pregnant or breastfeeding women by skin and mucosa disorders 
or anaemia.
11.1.2.6. Folic Acid (Folate, Vitamin B11)
Folic acid is a common name for pteroyl-glutamic acid. Animals are unable to synthesise these compounds, and 
depend on their supply from food. Tetrahydrofolate, a cofactor transferring one-carbon residues in different oxidation 
states, is the active form in cells. The daily folate requirement for an adult is about 0.15 – 0.2 mg. The richest source is 
liver, vegetable foods such as leafy vegetables (cabbage, kale, spinach) and yeast. Folate insufficiency is usually caused 
by insufficient resorption, with manifestations in the blood count (megaloblastic anaemia, thrombocytopenia). Lack of 
folates during pregnancy is associated with congenital developmental defects of the foetus, in particular neural tube 
defects.
11.1.2.7. Vitamin B12 (Cobalamin)
Cobalamin has a fairly complex structure. It is based on the tetrapyrrole-corrin ring with a cobalt ion bound in the 
centre. It is only produced by microorganisms, and is only found in animal foodstuffs, not in vegetable foods. A specific 
glycoprotein excreted by the gastric mucosa, called the intrinsic factor, is required to resorb cobalamin supplied from 
food. Resorbed cobalamin is stored in the liver. When in cells, cobalamin is converted to cofactors methylcobalamin 
and deoxyadenosylcobalamin. They are required to eliminate some amino acids and, together with folic acid, for me-
thylation reactions (remethylation of homocysteine to methionine, one of the requirements for continuous synthesis 
of nucleic acid base pairs). The daily requirement of B
12
 is about 2 µg in adults. Rich sources are giblets, followed by 
meat, dairy products and eggs. Cobalamin is also formed by the gut flora, but does not absorb and is excreted in the 
stools. It is relatively rare for cobalamin deficiency to be caused by an insufficient diet such as vegans who avoid food-
stuffs of animal origin. Intrinsic factor deficiency and insufficient cobalamin resorption from food are more common 
causes. Manifestations include megaloblastic or macrocytic anaemia or neurological disorders.
11.1.2.8. Vitamin C (Ascorbic Acid)
L-ascorbic acid is a monosaccharide derivative. This is not carboxylic acid; the distinct acidic character is derived 
from the presence of two enolic hydroxyles. It is synthesized by plants and most animals except for humans, apes and 
guinea pigs. It is an important hydrophilic reducing agent (antioxidant). L-ascorbic acid readily oxidized to biologically 
inactive L-dehydroascorbic acid; the reaction is reversible, however a sufficiently effective reducing agent for reverse 
reduction is usually missing. It is involved in hydroxylation reactions in the synthesis of collagen, bile acids and adre-
nalin, and in tyrosine degradation by keeping metalloenzyme metal ions in the reduced state. Vitamin C also increases 
iron resorption in the digestive tract. Unlike other vitamins, the daily requirement is one or two orders higher, 50 – 70 
mg for adults. L-ascorbate is mainly present in plants, namely fresh fruits and vegetables. The richest source is citrus 
fruit, kiwi fruit, blackcurrant, peppers, potatoes. Ascorbate is readily deteriorated by oxidation from atmospheric oxy-
gen at higher temperatures, especially in the presence of traces of heavy metals, Cu and Fe. People with a relatively 
low vitamin C intake get easily tired, more prone to minor infections, sometimes have swollen and bleeding gums or 
hypodermic haemorrhage from fragile capillaries. Extreme avitaminosis (scurvy, scorbutus) is currently rare. Prolonged 
ingestion of high ascorbate doses (over 0.5 g daily) is not considered beneficial. Excess vitamin C is quickly excreted in 
urine; larger ascorbate amounts are degraded to oxalate (risk of urolithiasis), and there may be a higher risk of acid-
-base disorders (acidosis). Ascorbate as an antioxidant protects against the action of free oxygen radicals however too 
high concentrations support the presence of reduced forms of metal ions, which catalyse the formation of aggressive 
oxygen radicals (Fenton’s reaction).
11.1.2.9. Biotin (Formerly Vitamin H)
The biotin molecule contains a condensed heterocyclic system consisting of thiolane and imidazolidine. It acts as 
a cofactor of carboxylases catalysing carboxylation reactions. The nitrogen heteroatom binds a CO
2
 molecule to form 
carboxybiotin, which is a donor of the carboxy group for carboxylation of compounds such as pyruvate to oxaloacetate, 
or acetyl-coenzyme-A to malonyl-coenzyme-A. It thus plays an important role in gluconeogenesis (synthesis of glucose 
from lactate and some amino acids), for the citric acid cycle (synthesis of oxaloacetate), and for synthesis of fatty acids. 
Biotin is found in most foodstuffs. In addition to this, a considerable part of the required amount is synthesised by the 
large bowel flora. Biotin deficiency is therefore quite rare in humans. It can be induced by excess consumption of raw 
egg whites. They contain a thermally unstable glycoprotein avidin, a specifically biotin-binding protein (the complex is 
not broken down by digestive enzymes) that prevents biotin absorption.
11.1.3. Fat-Soluble Vitamins
They have a non-polar (hydrophobic) character, since they are isoprenoids themselves (A and D), or their molecule 
contains an isoprenoid chain (E and K). In vegetable and animal foodstuffs they are usually dissolved in fats that are 
absorbed through the intestines. Long-term fat digestion disorders lead to reduced fat resorption, and hypovitaminosis 
may develop despite sufficient intake of fats from food. Fats enter the circulation as part of chylomicrons.
11.1.3.1. Vitamin A (Retinol)
Retinol ranks among isoprenoids. Retinol is produced by oxidative cleavage of beta-carotene provitamin present in 
vegetables and fruit. The liver has some retinol reserves in the form of its esters. Retinal aldehyde is part of rhodopsin 
(visual purple in the rods and cones of the retina). Retinoic acid in cells plays a role in controlling the expression of some 
genes. One of the first signs of retinol deficiency is night blindness followed by skin and mucosa disorders (dryness and 
keratinisation), and conjunctiva and cornea damage (xerophthalmia). Repeated multiple doses of retinol are toxic and 
may, among other things, pose a risk to foetal development during pregnancy. Major sources in food are liver, oily fish, 
yolk and butter. Carotenes are contained in yellow, red and green vegetables and fruit.
11.1.3.2. Vitamin D
Calciol (vitamin D
3
, cholecalciferol) and ercalciol (vitamin D
2
, ergocalciferol) are 9,10-secosterols. Calciol may form 
in the skin by 7-dehydrocholesterol exposure to UV radiation, and similarly, ercalciol forms in plants from ergosterol. 
Their hydroxylation in the liver and kidneys produces the hormone calcitriol (1,25-dihydroxycalciol) which, together 
with parathormone and calcitonin, plays a major role in the Ca2+ and phosphate management. Calcitriol induces the 
synthesis of a protein, which enables resorption of Ca2+ in the intestine, and regulates bone tissue mineralisation. Cal-
ciol deficiency results in insufficient mineralisation of the organic bone component. Serious deficiency is manifested as 
rickets in children, and osteomalacia in adults. Repeated administration of excessive vitamin D doses leads to hypercal-
caemia, sometimes even undesirable calcifications in various tissues or calcium urolithiasis. The main source is fish oil, 
cod liver, oily fish, and also enriched tub margarines.
11.1.3.3. Vitamin E
Vitamin E refers to a group of natural antioxidants featuring qualitatively the same biological activity as alpha-
-tocopherol, which is the most effective and most naturally widespread of them. Vitamin E was first isolated from 
wheat-germ oil. All of these antioxidants are derivatives of a chromate with a 16-carbon isoprenoid residue attached at 
position 2. The phenolic hydroxyl at position 6 is essential for its function. Some of the free radicals are neutralised by 
the hydrogen atom, and the phenoxy-radical thus formed is either regenerated by ascorbate to the original tocopherol, 
or is irreversibly degraded by another radical. Tocopherols reduce peroxidation of membrane lipids and lipoproteins 
unsaturated fatty acids, and also prevent other important compounds from oxidation. The daily requirement is about 
15 mg of alpha-tocopherol, and increases by boosting intake of poly-unsaturated fats. Rich sources include vegetable 
oils, nuts, seeds, and cereal germs. The tocopherol content is greatly reduced in dehydrated or frozen foods due to 
auto-oxidation. Tocopherol deficiency does not present typical manifestations in humans; perhaps may cause anaemia 
and some neurological symptoms.
11.1.3.4. Vitamin K
Vitamin K is a common name for a group of naphthoquinone derivatives referred to as antihaemorrhagic vitamin. 
Naturally occurring are phyloquinone (K
1
, 3-phytylmenadione) and menaquinones (K
2
) with an attached polyisoprene 
side chain, which makes them fat-soluble. Synthetic, water-soluble menadiol or menadione has the same effect. They 
are essential for the final biosynthesis of blood coagulation factors II (prothrombin), VII, IX and X, and proteins impor-
tant for bone mineralisation due to their contribution to forming binding sites for Ca2+ (by introducing another carboxy 
group to side chains of glutamic acid residues). This explains why they are used to prevent or treat increased bleeding. 
Their deficiency in adults is not common since vitamin K is relatively plentiful in foods (most in leaf vegetables), and is 
also produced by large bowel flora. A bleeding tendency due to vitamin K deficiency may occur in newborns (their gut 
is sterile), in all fat resorption disorders, most commonly in insufficient bile acid secretion, or in the absence of gut flora 
caused by broad-spectrum antibiotics. Anticoagulants (warfarin) are important vitamin K antagonists.
11.2. Vitamins
In addition to primary nutrients (carbohydrates, proteins and fats), human nutrition has to contain other essential 
components that the human body is unable to synthesize. Such components include essential amino acids, essential 
fatty acids, mineral compounds and vitamins. Vitamins and cofactors derived from these are indispensable for the nor-
mal course of many metabolic processes. Depending on their solubility, vitamins are classified as either fat-soluble (A, 
D, E, K) and water-soluble (the other vitamins). This classical classification is also practical – among other things it helps 
estimate in what foods the vitamin may be present, and under what circumstances vitamin deficiency can be expected. 
A balanced diet prepared from fresh foodstuffs usually contains the necessary amounts of all vitamins.
A prolonged low supply of some of the vitamins may cause either hypovitaminosis, at first subclinical, when a 
reduced amount of that particular vitamin in the body can be proved (common in vitamins D or B
12
), and later clinical 
hypovitaminosis with non-specific symptoms, or more serious disorders with typical symptoms (avitaminosis). Vitamin 
deficiency may also occur as a result of a disorder in absorbing these in the digestive tract, or an increased vitamin 
requirement when suffering from diseases or other conditions (convalescence, pregnancy, breastfeeding), or their 
increased excretion.
Excess hydrophilic vitamins taken from food are usually excreted quickly in urine from the body (with the exception 
of vitamin B
12
 – see below). On the other hand, fat-soluble vitamins may deposit in the body for a longer time: vitamins 
A and D, and vitamin K to a limited extent in the liver, and tocopherols in the adipose tissue.
Toxicity manifestations (sometimes referred to as hypervitaminosis) can only be found in vitamins A and D. They 
almost always occur as a consequence of wrong dosage for therapeutic use.
11.2.1. Recommended Daily Allowances of Vitamins
The Recommended Daily Allowance (RDA) is the daily dietary intake level of a nutrient considered sufficient to 
meet the requirements of 97% – 98% of healthy individuals in each life-stage and gender group. RDA is derived from 
research studies on the physiological needs of healthy people. For example, the RDA of a vitamin is determined from 
the amount required to maintain its adequate blood level in a tested healthy person.
These values may have different interpretations, and may be more or less varied between countries. Neither are 
RDA values recommended for optimum nutrition. Although a lot of research has been carried out, the definitive appro-
ach to optimum vitamin intake is still being debated (vitamin D is currently a good example).
Vitamin Unit Amount
B
1
 mg 1.1
B
2
mg 1.4
Niacin mg 16
Pantothenic acid mg 6
B
6
mg 1.4
Folic acid μg 200
B
12
μg 2.5
Vitamin C mg 80
Biotin μg 50
A μg 800
D μg 10 (400 IU)
E mg 12
K μg 75
Table 11.1. RDAs of vitamins pursuant to Decree No. 225/2008 Coll.
http://eagri.cz/public/web/mze/legislativa/ostatni/100065067.html 
11.2.2. Vitamin Test Methods
There are different approaches to determining the vitamin level in the body, when vitamin deficiency is suspected. 
The vitamin may either be tested directly (most often in the serum, however plasma, whole blood, RBC, WBC or biopsy 
tissue sample level can also be tested), by urinary vitamin excretion tests (without or after load), or tested using indi-
rect methods. Such methods include tests for typical metabolite of the vitamin, or a typical product of the vitamin’s 
activity (after load), and tests for catalytic activity of a suitable enzyme, whose cofactor is that vitamin. The specific 
options for each vitamin are listed.
11.2.3. Water-Soluble Vitamins
These vitamins are not stored in the body (except for vitamin B
12
); excess amounts are excreted in the urine, mea-
ning so their consistent intake from food is important. They are enzyme cofactor components in the body. Hydrophilic 
vitamins (again except for vitamin B12) are absorbed through the saturable active Na+-dependent multivitamin trans-
porter; simple diffusion also occurs in the case of higher concentrations in food.
11.2.3.1. Thiamine (Vitamin B1)
Thiamine is the oldest known vitamin – since 1905. It is a derivative of pyrimidine and thiazole linked by a methy-
lene bridge. Thiamine diphosphate (TDP) is the biologically active form.
Major sources of thiamine in food are cereal germs, yeast, legumes, nuts, meat, milk and dairy products. By con-
trast, its content in white bread and glazed rice is low, so cereals and bread are enriched with thiamine in many coun-
tries (including the CR).
Thiamine is readily absorbed from food. Absorption takes place in the upper intestine using two mechanisms. 
Active saturable transport by the thiamine Na+-dependent transporter (symport) takes place when low concentrations 
are involved. Passive diffusion transport takes place when the daily intake is greater than 5 mg. This is important for 
alcoholics since alcohol only inhibits the active transport.
Animation: Absorption of vitamin B
1
 (low vitamin – symport with Na, high vitamin - transporter is saturated, diffu-
sion begins)
Thiamine is transported through the portal vein to the liver where it is phosphorylated by the thiamine disphospho-
transferase enzyme (also present in the brain) into active TDP. ATP is the source of diphosphate. 90% of thiamine trans-
ported in the plasma is free thiamine. The body contains roughly 30 mg of thiamine, about one half in the muscles, and 
the rest in the myocardium, liver, kidneys and nerve tissue. 90 % occurs as TDP, and 10 % in the nerve tissue as thiamine 
triphosphate. Excess thiamine is excreted in urine.
TDP is a cofactor for oxidative decarboxylation of 2-oxo acids (examples: conversion of pyruvate → acetyl-CoA, 
2-oxoglutarate → succinylCoA, citric acid cycle; 2-oxo acids from valine, leucine and isoleucine; 2-oxobutyrate in methi-
onin catabolism, etc.) and the transketolase reaction of the pentose cycle. It is therefore essential for carbohydrate and 
other nutrient metabolism. If TDP is deficient, pyruvate cannot metabolize to AcCoA, the level of lactate rises and la-
ctate acidosis refractory to hydrogen carbonate develops. Accumulation of 2-oxo acids produced from branched amino 
acids leads to maple syrup disease symptoms. Thiamine also stimulates the function of neutrophils and lymphocytes; 
when deficient, proneness to infections develops.
Thiamine deficiency often occurs due to malnutrition, chronic alcoholism, administration of diuretics or malaria. 
Typical causes of insufficient intake include consumption of unfortified glazed rice or wheat products and also raw 
fish containing microbial thiaminase. Deficiency in alcoholics develops due to reduced intake, and also due to limited 
absorption as a result of active transport inhibition. In old age, insufficient intake typically combines with the adminis-
tration of diuretics mentioned above (mainly for cardiac failure treatment).
Signs of deficiency include mood changes (irritability, depression), memory disorders, peripheral neuropathy; se-
vere deficiency results in beriberi. Manifestations of beriberi include confusion, gastrointestinal symptoms (loss of 
appetite, poor digestion, weight loss), muscle weakness, ataxia, peripheral paraesthesia, ophthalmoplegia, oedemas 
(wet beriberi), tachycardia, cardiac failure (dry beriberi) or even coma. Typical manifestations in alcoholics include 
Wernicke-Korsakoff encephalopathy (loss of memory, confabulation, delirium, nystagmus, ataxia + beriberi symptoms).
The test for transketolase in erythrocytes reveals information about the thiamine reserve in tissues. Enzyme acti-
vity is measured in RBC haemolysate before and after TDP addition.
11.2.3.2. Riboflavin (Vitamin B2)
A riboflavin molecule consists of the heterocyclic isoalloxazine ring attached to alcohol ribitol. It is a basic compo-
nent of FAD and FMN flavin nucleotides used as the prosthetic groups of many dehydrogenases and other enzymes 
needed for electron transport.
Bound riboflavin is present in food in the form of FAD and FMN; free riboflavin is contained in milk. Major sources 
are dairy products, eggs, liver, meat, broccoli, parsley, yeast.
Through the action of gastric HCl, flavinoids taken from food released from the noncovalent bond to proteins and 
the action of intestinal enzymes releases free riboflavin. Riboflavin is mainly resorbed in the jejunum through the sa-
turable Na+-dependent active transport. Resorption is boosted by bile acids, reduced by metals (Cu, Zn, Fe), vitamin C, 
nicotinamide, tryptophane, caffeine, theophylline and some drugs (antibiotics, antacid drugs etc.). Blood transports 
B
2
 bound to albumin, immunoglobulins and other proteins. B
2
 is converted to cofactors in the cells of most tissues, 
in particular enterocytes, the liver, myocardium and kidneys. FMN is first produced by phosphorylation through the 
action of riboflavin kinase in the presence of ATP, and a greater part further converts to FAD through the action of 
ATP-dependent FAD synthase. The body has a low B
2
 reserve; excess vitamin is excreted in the urine, meaning renal 
excretion reflects the daily intake of B
2
.
FAD and FMN take part in many redox processes – respiratory chain (cytochrome C reductase), citric acid cycle 
(succinyl CoA-dehydrogenase), synthesis and elimination of fatty acids, metabolism of purins (xanthine oxidase), some 
amino acids, xenobiotics (part of CYP 450), part of glutathione reductase (anti-oxidative function), peroxidase, 2-oxo 
acid oxidases and other enzymes.
Riboflavin deficiency is usually accompanied by a deficiency in the other B-group vitamins. Typical symptoms inclu-
de angular stomatitis (inflammation of the corners of the mouth), cheilosis, glossitis, swelling of mucous membranes, 
seborrhoeic dermatitis and other dermal defects, conjunctivitis, corneitis and nervous disorders.
When riboflavin deficiency is suspected, glutathione reductase activity in haemolysed erythrocytes is determined 
before and after supplying FAD.
11.2.3.3. Niacin (Vitamin B3)
Niacin refers to pyridine derivatives, nicotinic acid and its amide - nicotinamide, a structural component of many 
NAD and NADP dehydrogenase cofactors.
Good sources are foods such as meat (turkey, tuna), liver, sunflower seeds, peanuts, brown bread, legumes, 
however a major part of niacin is produced endogenously from tryptophan.
Nicotinic acid absorbs in the stomach, and nicotinamide also absorbs in the small intestine. The process is referred 
to as saturable Na+-dependent active transport. When the level in food is high and the transporter saturated, passive 
diffusion transport is also possible. Nicotinamide is the most common form circulating in the blood. Hepatocytes con-
tain a small amount of free nicotinamide, and transformation into nucleotides takes place in other cells. Nicotinamide 
deamination to nicotinic acid and production of desamidoNAD+ take place in cytosol. DesamidoNAD+ is adenylated 
using ATP to active NAD+. NADP+ is phosphorylated in mitochondria. The body has a low reserve; excess niacin is excre-
ted primarily as N-methyl nicotinamide produced by methylation in the liver.
Target organs include all tissues, liver and muscles in particular. Nicotinamide cofactors are essential for redox rea-
ctions in the citric acid cycle, respiratory chain, glycolysis, metabolism of fatty acids, amino acids and many other pro-
cesses; they affect the function of more than 200 enzymes. They also play a role in vasodilation, non-redox reactions in 
DNA replication and reparation, apoptosis, increase the HDL level, and decrease the LDL, cholesterol and triglyceride 
level.
Deficiency occurs due to insufficient intake from food, alcoholism, cirrhosis, low intake (corn-based diet) or tryp-
tophan absorption disorders such as carcinoid, when tryptophan excessively (up to 60 % vs. normal 1 %) converts to 
serotonin, 5-hydroxytryptophan and 5-hydroxyindoleacetic acid. Acute deficiency may occur as a result of isoniazid 
treatment (competitive inhibition of pyridoxal phosphate needed converting tryptophan to niacin).
Pellagra is a typical vitamin deficiency disease – disease of the three Ds – dermatitis, diarrhoea and dementia. 
Pigment rash primarily affects areas exposed to sun; also the oral cavity and tongue mucosa are affected. Diarrhoea 
develops as a result of mucosal inflammation; other neurological symptoms include depression, irritability, disorien-
tation, hallucinations or catatonia.
Niacin is used as a drug for dyslipoproteinemia (antiatherogenic activity), carcinoid and congenital tryptophane ab-
sorption disorder (Hartnup disease). It can be used as a supplement for diabetics (improves tolerance of saccharides), 
or patients with vascular diseases. Clinical monitoring is advisable in respect to overdose symptoms such as vasodila-
tation (reddening, tingling, headache, nausea, vomiting), hepatitis, myopathy and thrombocytopathy.
Determination of urinary excretion of N’-methyl nicotinamide and N’-methyl-2-pyridone-5-carboxylamide meta-
bolites using liquid chromatography is used to assess deficiency.
11.2.3.4. Pantothenic Acid (Vitamin B5)
Pantothenic acid is a six-carbon branched-chain pantoic hydroxy acid bound to alanine. Coenzyme-A and acyl car-
rier protein (ACP) are its active forms.
It is plentiful in foodstuffs such as animal foodstuffs, wholemeal products, vegetables, legumes. It is mainly found 
as a component of coenzyme-A (CoA) and its esters. They are hydrolysed in the intestine and pantothenate is sub-
sequently absorbed through the saturable active Na+-dependent multivitamin transporter; simple diffusion also occurs 
in the case of higher concentrations in food. Pantothenic acid is transported in blood to hepatocytes and other tissues 
(muscles, kidneys, adrenal glands, testes) where it enters through a mechanism similar to that used for enterocytes, 
and synthetises CoA or ACP here.
CoA and ACP are needed for transporting acyl residues, ACP in fatty acid synthesis, CoA in many reactions: the citric 
acid cycle, oxidation and synthesis of fatty acids, synthesis of cholesterol, glycolysis, gluconeogenesis, catabolism of 
amino acids, xenobiotic acetylating reactions, haem synthesis and other reactions. Pantothenate increases resistance 
to infections and allergies and also improves wound healing.
Isolated deficiency does not occur in humans; reduced serum levels can be found in anorexia nervosa, malabsorp-
tion syndrome, sepsis, immunodeficiency.
Therapeutic administration is used for malnutrition, as a supplement in catabolic conditions or ethanol intoxicati-
on.
Laboratory tests include serum, whole blood and urine tests while CoA can be measured in erythrocytes; these are 
scarcely used in practice, however.
11.2.3.5. Vitamin B6
The term vitamin B
6
 includes pyridine derivatives: pyridoxine (pyridoxol), pyridoxal, pyridoxamine and their 
5-phosphates. The active form of the vitamin is pyridoxal-5’-phosphate (PLP) and pyridoxamine-5’-phosphate produ-
ced by ATP-dependent phosphorylation by pyridoxal kinase in the cytosol.
Vitamin B
6
 is widely distributed in animal and plant tissues with predominating PLP and pyridoxamine-5’-phospha-
te; plants also contain pyridoxin-5’-glucoside with a different mode of absorption. Vitamin B
6
 occurs in the form of 
pyridoxin hydrochloride in drugs. Good sources are foods such as giblets, poultry meat, fish, potatoes, nuts, legumes, 
bananas, yeast and wholemeal cereals.
Phosphorylated forms taken from food are hydrolyzed by intraluminal alkali phosphatase in the small intestine, and 
unphosphorylated vitamin is absorbed by passive diffusion primarily in the jejunum. Pyridoxin-5’-glucoside is hydroly-
sed intracellularly by non-specific glucosidases. Phosphorylation takes place in enterocytes. Unused PLP is dephospho-
rylated again in the enterocyte (non-specific alkaline phosphatase of the plasma membrane), and enters the liver 
through the portal vein and to the circulation. Here it is transported as pyridoxal attached to albumin or haemoglobin 
in red blood cells. PLP is the main form present in tissues and muscles are the main reserve of B
6
 (about 80 %). All forms 
of B
6
 are excreted in urine, 4-pyridoxine acid (PA) being the main metabolite in high concentrations.
PLP is a cofactor for more than 100 enzymes – amino transferases (ALT, AST), amino acid decarboxylases (formation 
of catecholamines and serotonin) and deaminases, transsulphurases, cystathionine beta synthase (CBS, homocysteine 
metabolism), glycogen phosphorylase and other enzymes. It is also essential for gluconeogenesis, synthesis of haem, 
myelin, DNA and taurine, modulates hormone effect and is important for immune functions.
Deficiency is rare and occurs as part of a mixed deficiency in other B-group vitamins. Symptoms may manifest 
themselves as hypochromic sideroblastic anaemia, dermatitis with cheilosis and glossitis, follicular hyperkeratosis, in-
flammations of the corners of the eye or epilepticogenic spasms. Clinical deficiency of PLP-dependent enzymes such as 
CBS (homocystinuria – mental retardation, skeleton deformities, thromboembolism) is also known. Vitamin B
6
 (under 
300 mg/day) is administered in all of these conditions as well as in treating tuberculosis with isoniazid or together with 
penicillamine (treatment for Wilson’s disease or cystinuria).
Excess B
6
 (from vitamin preparations) may lead to the development of neurotoxic and photosensitive symptoms; 
taking more than 100 mg B
6
 per day is therefore not recommended.
There are direct and indirect methods for testing the B
6
 level in the body. Direct methods include the whole blood 
PLP and urinary 4-PA excretion assays, mainly using HPLC. The determination of enzyme activity of erythrocyte ALT and 
AST in the haemolyzate before and after adding PLP is an indirect method.
11.2.3.6. Folic Acid (Folate, Vitamin B11)
Folic acid is pteroyl-glutamic acid, a substituted pteridine with p-aminobenzoic acid (PABA) and glutamic acid. The 
active form in the body is tetrahydrofolate transferring one-carbon residues. Among other things, it is required for 
synthesising nucleic acids.
Animals cannot synthesize PABA and have to take folate in their food. The main sources are liver, kidneys, leaf ve-
getables and citrus fruit.
Folic acid is taken in the form of polyglutamate from food. Intestinal mucosa enzymes hydrolyze it into monogluta-
mate, which is absorbed through active transport (low concentrations) and diffusion (higher concentrations). It is then 
reduced and methylated in enterocytes, and 5-methyltetrahydrofolate is released into the circulation. It is transported 
as bound to albumin and folate-binding protein. The main target organ is the liver, however folates are utilised in most 
tissues. Cells are the site of demethylation and conversion into polyglutamate through the action of polyglutamate syn-
thase, which helps keep folates within the cells, because reverse conversion to monoglutamate is required for release 
into the circulation. The folate reserve in the body covers 2-4 months. Folates are excreted in the urine and bile via the 
enterohepatic circulation.
The main function of folic acid in the body is the transfer of one-carbon residues. They are used for the synthesis of 
purine nucleotides, dTMP and in converting homocysteine to methionine in the form of S-adenosyl methionine, which 
is the main and universal donor of methyl in methylation reactions (synthesis of creatine, adrenaline, phosphatidycho-
line, carnitine, methylation in nucleic acids).
Folic acid deficiency commonly occurs due to malabsorption (resection, celiac disease, inflammatory bowel disea-
ses), increased losses (dialysis), decreased intake from food (chronic alcoholism), increased requirement (pregnancy, 
lactation, hepatic diseases, malignancies), and drug interactions (methotrexate, phenytoin). The condition leads to cell 
division disorders, typically manifested as pancytopenia with megaloblastic anaemia. Gastrointestinal, neurological 
and psychiatric symptoms are less frequent. Folate deficiency in the 1st trimester of pregnancy is associated with neural 
tube defects (spina bifida, encephalocele, anencephaly), so supplementation should be started in the preconception 
period.
The serum and erythrocyte level are determined to examine the folate supply. Erythrocyte concentration is more 
adequate for monitoring the long-term supply. Just as is the case for vitamin B
12
, chemiluminescence immunoassay is 
used, while testing both vitamins together is advisable.
11.2.3.7. Vitamin B12 (Cobalamin)
The term of vitamin B
12
 includes a group of cobalamins differing from each other in the side group type bound to 
cobalt in the corrin ring. Active forms of the vitamin are methylcobalamin and deoxyadenosylcobalamin; hydroxycoba-
lamin and cyanocobalamin are taken from the diet or therapeutic drugs. All of these forms are of microbial origin; the 
main source is solely animal foodstuffs – meat and dairy products. Although B
12
 is also produced by the large bowel 
flora, it does not absorb and is excreted in the stools.
Vitamin B
12
 released from food binds to the protein haptocorrin in the stomach. The complex disintegrates in the 
small intestine, and haptocorrin is broken down by pancreatic enzymes. The released B
12
 binds to the intrinsic factor 
(IF) – a glycoprotein secreted by parietal cells of the gastric mucosa. The B
12
-IF complex in the distal ileum enters the 
enterocyte by endocytosis via the CUBN receptor (cubulin; in the epithelium of the ileum, proximal renal tubules and 
yolk sac; the cubulin-megalin complex = multiligand receptor for the transport of most proteins such as transferrin 
in reabsorption in the kidneys). The complex disintegrates in the enterocyte, and free B
12
 binds to holotranscobala-
min (HTC, formerly referred to as transcobalamin II). The B
12
-HTC complex leaves the enterocyte by active transport 
through the transporter, and enters the liver through the portal vein. B
12
 is stored here and released into the circulation 
if necessary. Here it occurs in a complex with HTC (active B
12
 available to cells, half-life 5 – 6 minutes) or haptocorrin (80 
– 85 %, a strong bond lasting a few months to one year, half-life > 2 weeks). Approximately 1 mg B
12 
is normally stored 
in the liver, which covers the body’s normal requirements for about 2000 days (5.5 years). Symptoms of deficiency thus 
occur after up to five year’s latency.
B
12
 is constantly excreted to bile and reversely resorbed from the intestine – enterohepatic circulation amounts to 
70 – 80 %. If the amount of circulating vitamin B
12
 exceeds the HTC capacity, it is excreted in the urine. Roughly 0.2 % 
of the total daily reserve is excreted in bile, stools and urine.
Vitamin B
12
 is a cofactor of many enzymes, of which methionin synthase (MS) and methylmalonyl-CoA mutase are 
most important. Methylcobalamin is a cofactor for MS. This enzyme is essential for converting homocysteine to methi-
onine, converting folate coenzymes, and all methylation reactions in the body. Its deficiency leads to the development 
of hyperhomocysteinaemia and folate trap (accumulation of N
5
-methyltetrahydrofolate which cannot give its methyl 
group to B
12
, while levels of other folate forms required for the synthesis of nucleic acid bases decrease). A cofactor 
for methylmalonyl-CoA mutase is deoxyadenosylcobalamin. This enzyme is essential for the catabolism of some amino 
acids and formation of succinylCoA (anaplerotic reaction of the citric acid cycle). Its deficiency leads to the develop-
ment of methylmalonic aciduria and metabolic acidosis. Vitamin B
12
 is required for the continuous synthesis of nucleic 
acids, cell proliferation, formation and stability of membranes, synthesis of myelin, adrenaline, creatine and other 
compounds, RBC maturation and haematopoiesis, while it also has an antipernicious effect.
Deficiency occurs due to malnutrition (vegans), malabsorption (typically in atrophic gastritis when IF is lacking, 
or intestinal inflammations), chronic pancreatitis and interaction with some drugs and alcohol. Deficiency is classi-
fied in four stages: 1. ↓ plasma concentration; 2. ↓ cell concentration; 3. metabolic disorders (hyperhomocysteine-
mia, homocystinuria, acidosis, etc.); 4. clinical manifestation of the deficiency. This includes megaloblastic, pernicious 
anaemia (blockage of DNA synthesis in the bone marrow leads to the accumulation of megaloblasts) and neuropathy 
(paresthaesia, pain in the limbs, hypotonia, spasms, paralysis, position sense disorders, confusion, memory disorders, 
bradypsychism, dementia, depression).
A chemiluminescence immunoassay is most commonly used for the laboratory determination of serum concentra-
tion. As B
12
 function is linked to the folate function, the two vitamins should be tested at the same time.
11.2.3.8. Vitamin C (Ascorbic Acid)
Ascorbic acid is a derivative of monosaccharides, a gulonic acid lactone. It is an important antioxidant due to the 
presence of two enolic hydroxyls. It converts into biologically inactive dehydroascorbic acid during the reaction. The 
reaction is reversible, however the agent for reverse reduction to ascorbate is usually missing. Vitamin C is synthesized 
by plants and animals except for humans, apes and guinea pigs.
Major local food sources include potatoes, peppers, sauerkraut, citrus fruit, strawberries and blackcurrant. Vitamin 
C is sensitive to freezing, prolonged heating, drying, salting, exposure to oxygen, light and metal ions (Cu, Fe, Al and Pb 
in particular).
Vitamin C absorbs in the jejunum and ileum via the Na+-dependent active transport. This also plays a main role in 
renal tubules; vitamin C enters other cells in transporters similar or identical to the glucose transporter GLUT-1 (facilita-
ted diffusion); simple diffusion plays a minor role. This vitamin does not accumulate in the body except for the adrenal 
glands. The highest concentrations can be found in growing and young cells, particularly glands, leukocytes, liver and 
the eye lens. The main metabolite is oxalic acid. This is important when high doses of this vitamin are consumed, which 
leads to the risk of oxalate urolithiasis. Unused vitamin C is excreted in the urine.
Normal doses of vitamin C have antioxidant effects; vitamin C reduces ferric ions to ferrous ions thus helping their 
absorption, protecting against oxidation (adrenaline), is essential for the function of many hydroxylases such as lysine 
and proline (important for the formation of cross-linking bridges in collagen), phenylalanine and tyrosine (their cata-
bolism + formation of catecholamines), cholesterol (conversion to bile acids), formation of steroid hormones, seroto-
nin, metabolism of folic acid, histamine, carnitin, etc. It is essential for functioning of the immune system, protecting 
against the toxic effects of metals.
Long-term use of high doses of vitamin C however leads to manifestations of toxicity. The risk of oxalate urolithiasis 
increases. The body becomes acidified (the risk of metabolic acidosis may increase) and theoretically osmotic diruresis 
may occur. Excessively formed reduced metal ions (Fe2+ in particular) increase the production of reactive oxygen forms, 
meaning a pro-oxidative effect of the vitamin prevails. Haemolytic anaemia may develop in patients with a glucose-6-
-phosphate dehydrogenase deficiency.
Vitamin C deficiency manifests itself as fatigue, increased proneness to infections, worse healing of wounds, weak-
ness, muscle pain, loss of appetite, disorders of the mucous membranes, depression, and hypercholesterolemia as a 
result of reduced conversion to bile acids. Scurvy is a typical deficiency disease. Symptoms include bleeding from the 
gums and mucous membranes, loosening of the tooth attachment apparatus, haematomas and anaemia.
When vitamin C deficiency is suspected, its plasma level is tested (mostly using HPLC) even though this test does 
not offer information about vitamin C reserve in the tissues. This is measured in leukocytes. Leukocytes and thrombo-
cytes take up ascorbate from the plasma even against the concentration gradient. Another option is the saturation test: 
at least 50 % of ascorbate is excreted following administration of 500 mg ascorbate; deficiency leads to lower amounts.
11.2.3.9. Biotin (Formerly Vitamin H)
Biotin is a derivative of 2 condensed heterocycles, imidazolidine and thiolane, with valeric acid.
Foods rich in biotin include yolks, liver, chocolate, yeast, cereals, legumes, sea fish or nuts. A great portion of the 
human requirement is covered by biotin synthesis from the gut flora. Biotin is mostly bound to proteins in food. The-
se are cleaved to biotinylated peptides, from which biotin is released by biotinidase. Egg white contains a thermally 
unstable protein avidin which binds strongly to biotin, thus preventing its absorption. Absorption involves a saturable 
active Na+-dependent multivitamin transporter (competition with pantothenate). Biotin uses the same mechanism to 
enter cells, mainly in the liver, muscles and kidneys, where it is present in cytosol and mitochondria as a cofactor for 
carboxylases. The active form is enzyme-bound carboxybiotin requiring HCO
3
-, ATP, Mg++ and AcCoA to be produced. 
Major carboxylation reactions include acetyl-CoA carboxylase, fatty acid synthesis, production of oxaloacetate and 
succinyl-CoA (anaplerotic reaction of the citric acid cycle). Biotin is also essential for cholesterol and leucin metabolism, 
gluconeogenesis and cell growth.
Deficiency may occur due to malnutrition, poor parenteral nutrition or a large intake of raw egg white. Biotinidase 
deficiency is rare. Clinical symptoms include dermatitis, alopecia, depression, nausea and vomiting.
Biotin mitigates muscle pain, prevents grey hair and hair loss, improves nail quality and helps treat skin diseases.
Laboratory tests include direct determination of serum/plasma concentration, or indirect determination of biotin-
-dependent enzyme activity. Urinary metabolite (3-hydroisovaleric acid) levels may be used to measure renal excretion.
11.2.4. Fat-Soluble Vitamins
These vitamins in vegetable and animal foodstuffs are dissolved in fats which are absorbed through the intestines. 
Hypovitaminosis may therefore also occur due to prolonged malabsorption of lipids despite sufficient intake of fats 
from food. They are absorbed in the proximal small intestine, absorption is facilitated by bile acids. Vitamins in entero-
cytes become part of chylomicrons which are released into the lymph and then the blood.
11.2.4.1. Vitamin A (Retinol)
Vitamin A ranks among isoprenoids. Its molecule contains 4 double bonds in the side chain which may form corre-
sponding cis and trans-isomers, of which only two are biologically active.
Vitamin A is present in food in the form of retinol or carotenoids, of which beta-carotene is the best known and is 
6 times less efficient than retinol. A part of beta-carotene is hydrolysed to retinol in the intestine by the beta-carotene 
15,15’-dioxygenase enzyme. Therefore, beta-carotene is a provitamin of vitamin A. Liver, yolk, rich dairy products and 
fish are sources of retinol. Carotenoids are present in leaf, yellow and orange vegetables and fruits.
Vitamin A is resorbed in the duodenum. Retinol esters are first hydrolysed, free retinol then enters enterocytes 
where it is oxidised to retinal. Retinal is either reverse reduced to retinol (most of it) or oxidised to retinoic acid. Retinol 
is re-esterified by fatty acids (mainly palmitic acid) and built in chylomicrons which enter the lymph and eventually the 
blood. Retinol esters with chilomicron remnants enter the liver where they are stored (retinyl palmitate, 80 – 90 % of 
total vitamin A amount in the body).
If needed, retinol is released from the liver and transported by blood to extrahepatic tissues in a bond to retinol-
-binding protein (RBP, MW 22,000) which then binds to prealbumin. Retinoic acid binds to albumin and carotenoids 
circulate in a bond to LDLs and HDLs. The Retinol-RBP complex uptake by tissues is enabled by specific receptors on 
the cell surface.
11-cis-retinal and retinoic acid are active forms of vitamin A in cells. 11-cis-retinal is essential for reproduction 
and sight; deficiency causes night blindness. The biologically active form of vitamin A in the retina is all-trans-retinol; 
as soon as it enters the cell it is esterified and 11-cis-retinol is eventually released by hydrolysis. It is oxidised by alco-
hol dehydrogenase to 11-cis-retinal, which becomes part of rhodopsin pigment together with the opsin protein (the 
gene mutation for rhodopsin leads to retinitis pigmentosa). After photon absorption, isomerisation of 11-cis-retinal to 
all-trans-retinal takes place, causing it to be released from the bond to opsin. All-trans-retinal is reduced to all-trans-
-retinol and the whole cycle starts again. Retinoic acid is responsible for the other effects of vitamin A, which include 
the induction of growth and differentiation of epithelial cells, bone growth, is important for lipoprotein and lysosome 
integrity, and is essential for the synthesis of steroid and thyroid hormone as well as calcitriol. Retionic acid is produced 
from retinol by oxidation in target tissue cells. It binds to specific nuclear receptors, and the activated complex interacts 
with chromatin and activates the transcription of specific genes such as the gene for keratin synthesis in epithelial cells.
Figure: Resorption, transportation and conversions of vitamin A (adapted from Lippincott’s illustrated reviews Bio-
chemistry, 5th ed., p. 383, cannot insert to GD)
Symptoms of vitamin A deficiency include night blindness, xerophthalmia, keratinisation of epithelial cells, xero-
derma, hyperkeratosis or ichthyosis, dental caries, loss of appetite. Deficiency leads to a predisposition for immunity 
disorders, infections, particularly those of the digestive and respiratory system, and serious deficiency leads to corneal 
keratinisation or ulceration and blindness.
The total vitamin A level in the serum may decrease until the liver reserve is depleted. This occurs in diseases 
associated with fat-soluble vitamin deficiency (malabsorption of lipids, cystic fibrosis, inflammatory bowel diseases, 
defective apoB48, etc.), and severe hypoproteinemia as a result of RBP and prealbumin deficiency.
Retinol and its precursors (esters, carotenes) are used to treat deficiency. Retinoic acid is used in dermatology to 
treat acne (13-cis-retinoic acid and isotretinoin orally; all-trans-retinoic acid and tretinoin locally) and psoriasis (treti-
noin), and in oncology to treat promyelocytic leukaemia (tretinoin).
Excessive intake (100 times the RDA for adults) of vitamin A is toxic and teratogenic, whereas increased intake of 
carotenoids is not. Pregnancy should be avoided while being treated with retinoic acid; 3 mg of retinol is considered a 
risk dose, especially if the woman takes it in the first 10 weeks of pregnancy. In this regard every woman planning to be-
come pregnant should be advised to avoid using vitamin preparations and foodstuffs with a high content of vitamin A.
Early manifestations of hypervitaminosis include dryness and itching of the skin followed by alopecia, hepatomega-
ly or even cirrhosis, neurological disorders (increased intracranial pressure, cephalalgia, diplopia). Prolonged deficiency 
also leads to an increase in the HDL/LDL ratio and bone disorders. Teratogenic effects include abortions and vitamin 
A embryopathy (congenital developmental defects of the heart, ears and nose, mandibular hypoplasia, cleft palate, 
hydrocephalus).
Laboratory tests allow serum vitamin A concentration measurement, however this test does not provide any infor-
mation about the vitamin reserve in tissues. Liquid chromatography is the method used for the tests.
11.2.4.2. Vitamin D
The term of vitamin D refers to sterols ercalciol (ergocalciferol, vitamin D
2
) and calciol (cholecalciferol, vitamin D
3
), 
which, in themselves, are not biologically active. Their conversion in the body produces the active hormone 1,25-di-
hydroxycholecalciferol (calcitriol).
Ercalciol originates from vegetables and is taken solely in food. Calciol is either taken from animal foodstuffs, or is 
produced from 7-dehydrocholesterol by skin exposure to UV radiation. 15 minutes of everyday exposure of face and 
arms to sunlight (without sunscreens) is enough to reach sufficient plasma levels. In old age, synthesis of 7-dehydro-
cholesterol and its conversion to calciol (cholecalciferol) decreases. Main food sources include oily fish, egg yolk, liver, 
cheese, butter, fortified margarines and other fats.
Lipophilic vitamin D absorbs from food in the proximal small intestine. In the enterocyte it becomes part of chylo-
microns and is eventually transported in the blood to the liver. In the liver it is hydroxylated to calcidiol (main reserve 
form of vitamin D in the body), which is further hydroxylated in the kidneys (and placenta) to biologically active calcit-
riol. Calcidiol and other metabolites are subject to enterohepatic circulation. Vitamin D is transported in the plasma 
as bound to alpha1-globulin and the DBP (vitamin D-binding protein, transcalciferin), while also binds to albumin and 
lipoproteins with a lower affinity. The DBP has a high affinity to calcidiol and its inactive form, 24,25-dihydroxyD
3
, but it 
poorly binds calcitriol, which makes this hormone readily biologically available. Adipose tissue presents a major reser-
ve of calciol; more than 50 % of this vitamin is stored here under physiological conditions.
Together with parathormone (PTH), and calcitonin, calcitriol plays a major role in calcium and phosphate mana-
gement. It binds to nuclear receptors in target cells (intestine, bones, kidneys, placenta, breast), and directly affects 
transcription. In the intestine it increases Ca and phosphate absorption by its easier access to the enterocyte through 
the cytosolic calmodulin conformational change, through its easier transport in the enterocyte through the calbindin 
synthesis induction, and by easier transport of Ca from the enterocyte through Ca++-ATPase synthesis induction. In the 
bones it accelerates osteoclast maturation, while also affects mineralisation by osteoblast stimulation. In the kidneys 
it increases Ca and phosphate resorption while also increases their transport in the placenta and mammary glands. 
Recent research has also shown that calcitriol has immunomodulatory, antiproliferative and pro-differentiation effects.
 Synthesis and the calcitriol level are regulated by many mechanisms. The main site of regulation is the last step 
of calcitriol synthesis – reaction catalysed by 1-alpha-hydroxylase. Here the main activator is parathormone, while Ca 
(directly and indirectly via ↓ PTH), phosphates and the reaction product (calcitriol) have an inhibitory effect. Enzy-
me activity is also modulated by the acid-base balance and other hormone concentrations (calcitonin, insulin, STH-
-IGF-I, prolactin, sex hormones). Another mechanism of regulating calcitriol homeostasis is activation of synthesis by 
24,25-dihydroxyD
3 
calciol and inhibition of PTH. 24,25-dihydroxyD
3
 is considered to be an inactive degradation product; 
its function is not quite clear.
Figure 11.1. Regulation of calcitriol level and synthesis (is it next to Ca, bones, hormones?)
Deficiency occurs due to insufficient intake from food, disorders of absorption, cholestasis (lack of bile acids), in-
sufficient exposure to sunlight (season of the year, indoor lifestyle, sunscreens), reduced hydroxylation (hepatic and 
renal diseases, hypoparathyroidism), nephrotic syndrome. Demineralisation of the bones leads to the development of 
rickets in children, and osteomalacia in adults. Vitamin D is used for treatment, and calcitriol for resistant cases. In chro-
nic renal failure osteodystrophy develops as a result of reduced 1-alpha-hydroxylation. Patients are given calcitriol and 
the phosphate level should be decreased to prevent formation of calcium-phosphate stones. A long-term low vitamin 
D saturation is currently estimated to exist in at least 1/3 of the healthy European population. It is not associated with 
typical symptoms of deficiency, but increases the risk of autoimmune (thyroiditis, rheumatoid arthritis) and lifestyle 
diseases (tumours, depressions, etc.).
Symptoms of toxicity such as loss of appetite, nausea, diarrhoea and vomiting, thirst, itching or stupor may occur 
as a result of prolonged very high doses of vitamin D. Hypercalcaemia develops and leads to calcifications of the vessel 
walls and kidneys.
Plasma concentration of calcidiol and calcitriol is currently determined by immunochemical techniques or HPLC. 
Calcidiol (25-hydroxycholecalciferol) is proving to be the most adequate method for measuring total reserve of vitamin 
D in the body.
Note on the intake and RDA: 1 µg = 40 IU; RDA = 10 µg = 400 IU
Vitamin D intake µg IU % RDA
10 – 15-minute whole body exposure to sun 250 – 500 10 000  – 20 000 2 500 – 5 000
Salmon /100 g 12 480 120
Sardines /100 g 5 200 50
Butter /100 g 1 40 10
Table 11.2. Vitamin D – sources
11.2.4.3. Vitamin E
Vitamin E refers to a group of eight tocopherols and tocotrienols, of which alpha-tocopherol has the highest bio-
logical activity. It is also the most common in food, with cereal germs, nuts, poppy seed and egg yolk being the richest 
sources.
Lipopholic vitamin E resorbs from food with fats (the resorption rate is roughly 35%); in enterocytes it is built in 
chylomicrons and goes to the lymph and blood. It enters the cells of tissues with active lipoprotein lipase; the rest with 
remnants goes to the liver. Here it is built in VLDL and re-enters the circulation. The target organs are all tissues; higher 
content can be found in cells with high pO2 (erythrocytes, lungs); it is stored in the adipose tissue. 70 – 80% is excreted 
through the liver, the rest in urine as tocopheric acid and glucurono-gamma-lactones.
Vitamin E has antioxidant properties. The body uses it principally to protect poly-unsaturated fatty acids in plasma 
membranes and lipoproteins against the action of free radicals, also to prevent oxidation of other important com-
pounds. It is important for membrane integrity, protecting erythrocytes against haemolysis, inhibiting mutagens in the 
digestive tract, and playing a role in cell signalling pathways.
Vitamin E deficiency may occur as a rare complication of severe and long-term steatorrhoea and poor parenteral 
nutrition or malnutrition. Children in particular may develop haemolytical anaemia as a result of corrupted erythrocyte 
membrane stability. The life of erythrocytes is shorter and thrombocyte aggregability is greater. Changes in peripheral 
nerve function, elevated excretion of creatinine and increased CK activity occur as a result of damaged membrane and 
skeletal muscle cell disintegration. Long-term deficiency is accompanied by myopathy, necrosis of muscles, hypo- or 
even areflexia, spinocerebellar ataxia and retinopathy.
Toxic overdosing symptoms include gastrointestinal problems, tiredness, headaches, muscle weakness. Overdosing 
in pregnant women (20 – 70 times RDA) may cause damage to the foetus (congenital heart defects, omphalocele, non-
-standard birth weight).
Liquid chromatography with UV or fluorescent detection is commonly used to determine plasma or serum vitamin 
E levels; alternatively gas chromatography with mass spectrometry can be used.
11.2.4.4. Vitamin K
Vitamin K refers to derivatives of naphthoquinone: phylloquinone (phytomenadione, K
1
) and menaquinones (K
2
). 
The source of phylloquinone is food such as leaf vegetables, broccoli and oatflakes; menaquinone is synthesised by 
intestinal bacteria (synthesis normally covers demand for vitamin K) and is also contained in fermented foodstuffs 
(yoghurt, cheese) and the liver of ruminants. Synthetic derivatives menadiol and menadione are soluble in water and 
have the same effects as the natural vitamin. Resorption takes place in the small and large intestine, 10  – 80% of in-
gested vitamin K, which is transported by the lymph followed by the blood to target tissues. K
2
 is stored in the liver; the 
reserve is limited, which requires permanent substitution.
Vitamin K is needed for post-translational conversion of glutamate residues in proteins into gamma-carboxygluta-
mate, which can subsequently bind Ca2+. This conversion takes place in blood coagulation factors II, VII, IX and X, protein 
C and S and osteocalcin, a protein produced by osteoblasts, which is required for new bone formation and remodelling.
Vitamin K deficiency most commonly occurs as a result of anticoagulant treatment (coumarins = warfarin – vitamin 
K cycle inhibition in the endoplasmic reticulum of the liver), and the typical manifestation is proneness to bleeding. 
Less common causes of deficiency include malabsorption of lipids (obstructive icterus) and lack of gut flora resulting 
from antibiotic therapy. Deficiency and required substitution are physiological in newborns as vitamin K does not pass 
the placental barrier and the newborn gut is sterile.
Vitamin K
1
 is used as an antidote for oral anticoagulant overdosing, in addition to blood plasma transfusion. As its 
effect persists several days to weeks, short-term anticoagulant treatment with heparin is required when bleeding stops.
Liquid chromatography is commonly used to determine vitamin K
1
 concentration in plasma.
11.2.5. Case Reports
A patient with icterus and pain in the right epigastrium was hospitalised. He is pale, feverish and has chills.
Laboratory findings: ALP 8.5 micro kat/l, AST 0.64 micro kat/l, total bilirubin 418 micro mol/l, conjugated bilirubin 
311 micro mol/l, positive urinary bilirubin, negative urobilinogen, prolonged prothrombin time, total cholesterol 7.5 
mmol/l.
What is the most likely cause of icterus in this patient? Why is prothrombin time prolonged?
Answers: Icterus is caused by an extrahepatic obstruction. Prothrombin time prolongation is caused by lacking 
vitamin K required to activate prothrombin. Vitamin K is fat-soluble and malabsorption of lipids occurs in cholestasis.
Prothrombin time improved after administering vitamin K as an injection.
CHAPTER 12
12. Thyroid Gland
12.1. Thyroid Gland – Preparation
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12.1.1. Introduction
The thyroid gland is an organ weighing roughly20 g and with a volume of 18  – 22 ml in adults. Thyroid disorder 
affects the intermediary metabolism of all cells within the human body. Thyroid dysfunction with obesity and diabetes 
present a triad of the most common endocrinopathies afflicting the population. Laboratory testing is the basic pillar in 
diagnosing, treating and monitoring thyroid disorders, because a change in parameters often comes before developing 
clinical symptoms.
12.1.2. Notes to Anatomy and Histology
The thyroid gland is formed as a diverticulum in the floor of the pharynx, descending to the base of the tongue 
and down in front of the trachea (this path is called the thyroglossal duct, ductus thyreoglossus). Ultimately the thyroid 
gland is located just below the cricoid cartilage and above the jugular notch at the level of C5-Th1 vertebra. It consists 
of the right and left lobes connected via the thyroid isthmus. The size of the lobes depends on the iodine supply, age 
and gender. When the iodine supply is sufficient, the normal thyroid size is under 18 ml in adult women and under 22 
ml in men (measured by sonography).
The thyroid is richly supplied with blood from both sides of a. thyroidea superior and a. thyroidea inferior, supply-
ing the two thyroid lobes, and a. thyroidea ima supplying the isthmus. The blood is drained via the v. thyroidea superior, 
media and inferior. Close to the thyroid anatomy and along both lobe edges pass n. laryngeus recurrens dexter and 
sinister, which, when damaged, often present a complication of thyroid surgery. On the rear surface of the lobes, lying 
on the posterior side of the lobes at their upper and central part, on each side there are two parathyroid glands. These 
are responsible for producing parathormone. (Figure 11p.1)
Figure 12.1. Thyroid gland and surrounding structures – from behind
The follicle is the basic functional unit of the thyroid gland. These almost spherical formations are 300 µm in dia-
meter. The wall consists of follicle cells, whose base lies on the interfollicular space with a rich vascular and lymphatic 
supply. The inner, apical part is turned to the follicle lumen and contains a colloid with thyroglobulin as the main com-
ponent. Apart from the rich vascular and lymphatic drainage system, the interfollicular space contains parafollicular 
cells (C-cells) producing calcitonin which travelled to the thyroid during embryogenesis. (Figs. 2 and 3)
Figure 12.2. Thyroidal follicles
12.1.3. Metabolism of Thyroid Hormones
The thyroid gland is the site where thyroid hormones T
4
 (tetraiodothyronine, thyroxine) and T
3
 (triiodothyronine) 
are produced. T
4
 is a major thyroid product, while T
3
 is a cellularly active hormone. The human body thus has to trans-
port the produced T
4
 and subsequently convert it to active T
3
, followed by deactivation and degradation of T
3
. Tissue 
deiodinase enzymes are responsible for converting T
4
 to T
3
 and deactivating T
4
 and T
3
.
12.1.3.1. Metabolism of Iodine
Iodine and selenium are essential elements for thyroid hormone metabolism. A sufficient supply of iodine is requi-
red to produce T
4
 (T
3
) in the thyroid. Iodine deficiency leads to insufficient production of thyroid hormones with clinical 
symptoms from goitre to severe CNS damage (cretinism) in newborns. Iodine intake is geographically dependent on its 
content in natural resources. In terms of natural content, the Czech Republic ranks to iodine-deficient regions, meaning 
iodisation of food (salt) and water is necessary. The normal daily iodine requirement of an adult is about 80 µg/day, and 
up to 200 µg/day for pregnant women. Iodine is received by re-using the T
4
 and T
3
 hormones, and uptake of this from 
the blood. The main loss of iodine following T
4
 and T
3
 degradation takes place in the kidneys and in stools, with 
the loss in stools being relatively constant, about 16 µg/day. Iodineuria measurement provides the basic information 
about the iodine supply. Therefore, the optimum daily iodine intake is about 100  – 150 µg/day, and 150-200 µg/day 
for pregnant women.
12.1.3.2. Thyroid Hormone Synthesis
Iodine uptake on the basal membrane of follicle cells is an active process via the ATP dependent sodium-iodine 
symporter (NIS). Its activity is increased by the TSH and blocked by competitive inhibitors such as thiocyanate (SCN-) 
and perchlorate (ClO4-) anions. NIS is also physiologically present in other organs such as the mammary gland, salivary 
gland, placenta and the CNS. NIS transports iodine from the mammary gland to breast milk.
Iodine is transported towards the apical (luminal) side following on from uptake on the basal membrane. Here it is 
oxidized with thyroid peroxidase (TPO) to reactive free iodine, which immediately binds to tyrosines in the thyroglobu-
lin molecule. This process takes place in the colloid close to the apical membrane. Thyroglobulin rich in iodinated tyro-
sines (monoiodotyrosine, MIT, and diiodotyrosine, DIT) is thus formed. Thanks to its spatial arrangement (proximity of 
MIT and DIT on thyroglobulin), thyroglobulin is the place where 2 tyrosine molecules combine to form triiodothyronine 
(T
3
) and tetraiodothyronine – thyroxine (T
4
), again in the presence of TPO (Figs. 4 and 5).
Figure 12.3. T-hormones synthesis
Figure 12.4. T-hormones synthesis - chemical formulae 
Thyroglobulin containing T
4
, T
3
 and DIT and MIT is endocyted back to thyrocyte. Tg is hydrolysed through the action 
of phagolysosomes; Tg releases T
3
 and T
4
 to secretory granules, from where T
4
 and T
3
 are subsequently released into 
the circulation. MIT and DIT cleave away an iodide, which just like Tg is recycled inside the cell for further synthesis. T
4
 
and T
3
 secretion into the circulation is regulated by the TSH. The thyroid gland produces more T
4
 (70 %) than T
3
. T
3
 is 
more metabolically active (3-8 times), so T
4
 is rather a prohormone. After being transported in the blood to peripheral 
tissues, T
4
 is converted to active T
3
.
12.1.3.3. Transport of T4 and T3 to Peripheral Tissue:
T
4
 and T
3
 are transported into the plasma as bound to transport proteins. Only a little part in the plasma is free 
(metabolically active), and is measured as free T
4
 (0.02  – 0.05 % of total T
4
 – TT
4
) and free T
3
 (0.01  – 0.3 %). The main 
transport proteins are thyroxine-binding globulin (TBG), prealbumin (transthyretin) and albumin. T
4
 and T
3
 bound to 
transport proteins present a thyroid hormone pool for tissues, ensure stable levels of free T-hormones, and protect 
T
4
 and T
3
 from getting lost in urine. On the other hand, free FT
4
 and FT
3
 levels practically do not change with changing 
binding protein concentrations, except in extreme cases. For example, a 200% increase in TBG occurs during pregnan-
cy, while free FT
4
 and FT
3
 remain unchanged. In cases of malnutrition the TBG level drops while FT
4
 and FT
3
 levels do 
not change.
12.1.3.4. Conversion and Elimination of T4 and T3:
Around1/3 of T
4
 produced by the thyroid converts to T
3
, another 1/3 to rT
3
 (metabolically inactive), and the rest is 
degraded by glucuronidation and sulfation in the liver. The conversion of T
4
 to active T
3
 or inactive rT
3
 is catalysed by 
tissue-specific deiodinase enzymes (selenium-dependent enzymes). These also ensure rT
3
 and T
3
 degradation to T
2
. 
There are 3 types of deiodinases in the body, which differ in their localisation in organs, specificity to the substrate and 
sensitivity to propylthiouracyl (PTU). They require selenium to function; selenium subsequently removes iodide in the 
reaction.
Type I deiodinase. D1 – present in the liver, kidneys, thyroid; primarily degrades rT
3
 to T
2
, and T
4
 to T
3
, is the source 
of major T
3
 pool in the circulation, and contributes to maintaining iodine for further thyroid hormone synthesis. This 
means that D1 activity increases in hyperthyroidism, causing the condition to worsen further; PTU is inhibited.
Type II deiodinase. D
2
 – present in the brain, pituitary gland, heart, brown adipose tissue; locally produces T
3
 from 
T
4
, is only slightly sensitive or not at all to PTU.
Type III deiodinase. D
3
 – brain, placenta, skin; responsible for T
4
 inactivation to rT
3
 and T
2
, regulates the passage of 
hormones from the placenta to foetal circulation, only slightly sensitive or not at all to PTU.
12.1.3.5. The Physiological Effects of Thyroid Hormones:
Thyroid hormones have an intracellular receptor (TR). T
3
 shows a greater affinity and biological activity. The recep-
tors are located in the cell nucleus. A hormone bound to the receptor forms the thyroid response element (TRE), which 
binds to DNA and induces the expression of specific genes, or suppression of other genes. The TR is a part of the group 
of nuclear receptors including receptors for: oestrogens, progesterone, androgens, gluco- and mineralocorticoids, and 
vitamin D. TRs exist in at least 4 isoforms: TRα
1
, TRα
2
, TRβ
1
, and TRβ
2
. The DNA-binding domain contains zinc. The main 
metabolic effect of T
3
 is regulating the basal metabolic rate. In addition to lipolysis, glycogenolysis and gluconeogene-
sis, T
3
 increases cell sensitivity to catecholamines, while increasing O
2
 consumption and heat production.
12.1.4. Regulation of Thyroid Hormones
12.1.4.1. Hypothalamus-Pituitary-Thyroid-Peripheral Tissue Axis
The top and first degree of regulation of thyroid hormone synthesis is the CNS. Therefore, the production of neu-
rotransmitters has both a stimulating and inhibiting effect on the production and release of the TRH. 
Regulatory mechanisms at the hypothalamic level:
• Stimulating factors of TRH production: Stress, cold, leptin, adrenergic receptor pathways;
• Inhibiting factors: Heat, T
3
, dopaminergic and opioid receptor pathways.
Regulation at the pituitary level primarily involves the TRH, which stimulates TSH release in the pituitary, while 
somatostatin inhibits TSH secretion. Major feedback inhibition takes place via T
3
 (T
4
). In addition to these mechanisms, 
many other mediators, signalling molecules and hormones are involved in regulation.
Regulatory mechanisms at the pituitary level:
• TSH release inhibition: Androgens, T
3
 (T
4
), cortisol, inflammatory cytokinins (IL6, TNF α, IL1β), malnutriti-
on, cholecystokinin (CCK), gastrin-releasing peptide (GRP), neuropeptide-Y (NPY);
• TSH release stimulation: Leptin, growth hormone (GH), oestrogens, arginine vasopressin (AVP), glucagon-
-like peptide-1 (GLP-1), galanin.
It should be kept in mind that the biological effect of TSH itself depends on post-translational modification, i.e. gly-
cation. This fact may be manifested in some forms of central hypothyroidism, when the measured TSH does not match 
the clinical condition – TSH with a lower biological activity is produced.
TSH and feedback via T
3
 (T
4
) are the major regulatory mechanisms at the thyroid level. Thyroid hormone synthesis 
is also inhibited by excess iodine, namely by blocking hydrogen peroxide production with subsequent iodine oxidation 
and bonding to thyroglobulin (referred to as the Wolff-Chaikoff effect). Thyroid hormone synthesis is also blocked by 
agents used to treat hypothyroidism, thioamides (propylthiouracil and methimazole).
Figure 12.5. T-hormones regulation
There is a logarithmic correlation between FT
4
 and TSH (see Fig. 7); TSH subsequently reacts 100 times more sensi-
tively to changes in FT
4
 levels, so TSH is also used as the most sensitive parameter to detect thyroid dysfunctions.
Figure 12.6. Connection TSH and FT4 – log dependence
12.1.5. Description of Laboratory Parameters
12.1.5.1. Thyroid-Stimulating Hormone (TSH, Thyrotropin)
TSH is a glycoprotein hormone with a molecular weight of 28-30 kDA, produced by thyrotrope cells (basophilic 
cells) in the anterior pituitary gland. TSH ranks among the group of glycoprotein hormones (FSH, LH, hCG) with the 
same α-subunit and differing in the β-subunit. The α-subunit is coded by the common gene on chromosome 6, and 
consists of 4 exons and 3 introns. The β-subunit is coded by the gene on chromosome 1, and consists of 3 exons and 2 
introns. Thus the protein itself consists of an α-chain of 92 amino acids, and a β-chain of 112 amino acids. This β-chain 
is in 38% homology with the hCG molecule β-chain. This grows in importance during pregnancy or in the case of hyda-
tidiform mole (mola hydatidosa), when excess hCG and partial homology lead to the stimulation of TSH receptors in the 
thyroid and thereby to hyperthyroidism. Carbohydrates take 15-20% of the relative molecular weight of the TSH, and 
contain 3 oligosaccharide chains (2 of them bound to the α-subunit and 1 to the β-subunit). The process of glycation 
is very important for biological activity of the TSH. Some forms of central hypothyroidism are caused by reduced bio-
logical activity due to impaired TSH glycation. TSH release into the blood circulation is controlled by the hypothalamus 
through the TRH and somatostatin.
The TSH binds to its specific TSH receptor, which stems from the group of G-protein activating receptors.
The TSH receptor consists of:
• Extracellular domain: binds TSH and antibodies against TSH, 40% match with receptors for the FSH and LH, 
398 amino acids;
• Transmembrane domain – 7 transmembrane domains, 70% match with the FSH and LH receptors, 346 
amino acids, G-protein activation on the third loop.
Assuming an intact hypothalamic-pituitary axis, the TSH has a logarithmic relation with free T
4
, which means that 
even a little change in FT
4
 results in a 10 times greater change in the TSH.
TSH function:
• Stimulates various functions of thyrocytes: Uptake and organification of iodine, production of Tg and pro-
duction and secretion of thyroid hormones;
• Supports thyrocyte growth – hypertrophy and hyperplasia;
• Inhibits thyrocyte apoptosis;
• Extrathyroidal functions: Affects lymphocytes, adipocytes, adrenal and testicular cells through its recep-
tors.
12.1.5.2. Thyroid Hormones T4 and T3
Thyroid hormones are thyroxin (T
4
), triiodothyronine (T
3
) and reverse triiodothyronine (rT
3
), diiodothyronines (T
2
) 
and monoiodothyronines (T1). Most hormones circulating in the blood are bound to transport proteins, and thus bio-
logically inactive. Only a small part of hormones present in free form in the blood is biologically active.
Overall thyroid hormone concentrations, total T
3
 (TT
3
) and total T
4
 (TT
4
), have a diagnostic value only if the binding 
capacity of transport proteins is not changed (use of drugs, serious systemic disease, etc.).
Conversely, free fractions of thyroxin (FT
4
) and triiodothyronine (FT
3
) provide information about current functio-
ning of the thyroid gland.
12.1.5.3. Thyroxin-Binding Globulin (TBG)
TBG is the main transport protein of T-hormones into plasma, has a relative molecular weight of 5400 Da, is pro-
duced in the liver and consists of 395 amino acids. The TBG gene is localised on the X chromosome and consists of 6 
exons. Indications for testing are very rare; these days it is primarily due to a congenital TBG deficiency and discrepancy 
of TT
4
 and FT
4
 results.
12.1.5.4. Thyroglobulin (Tg)
Human Tg is a glycoprotein containing iodine and has a relative molecular weight of 660 kDa. Tg consists of 2 iden-
tical polypeptide chains. Carbohydrates form less than 10% of its weight. Around 30% of iodine bound to Tg has the 
form of T
3
 and T
4
; the rest is inactive precursors monoiodotyrosine (MIT) and diiodotyrosine (DIT). Concentration in 
the follicular lumen reaches 200  – 300 g/l. The Tg gene is located on chromosome 8 and contains 48 exons. Tg is syn-
thesized in follicular cells of the thyroid gland in normal conditions. Its synthesis is controlled by the TSH. The plasma 
half-life is 3  – 4 days.
1 g of normal thyroid tissue produces 1  – 2 ug/l of Tg at a normal TSH concentration, while its concentration cor-
relates to the thyroid volume, thyroid activity (increased in the case of hyperfunction), it also increases with active 
inflammatory or tumour processes.
12.1.5.5. Autoantibodies
Autoimmune thyroid diseases are the most common cause of thyroid disorders. It is 4 times more frequent in 
women than the prevalence in men in regions without iodine deficiency. The test for autoantibodies is important for 
differential diagnosis and prognosis.
Methods of anti-TPO, anti-Tg and anti-TSH testing have highly heterogeneous results and different sensitivity and 
specificity, which is due to the fact that:
• Antibodies recognize different interindividual epitopes, have different affinity, and mostly comprise a mix-
ture of heterogeneous antibodies;
• Manufacturers use different standards, different detection methods (competitive and non-competitive), 
and antigens are prepared using different methods.
These two basic postulates lead to different results between methods, which differ in the order of tens to hundreds 
of percent. 
TSH Receptor Antibodies – Anti-TSH (aTSH, TRAb)
TSH receptor antibodies may be divided into 2 groups depending on their function:
• TRAbS (Thyroid receptor stimulating antibodies) – The bond to the N-terminal region leads to imitation of 
the TSH function, stimulation of production and release of thyroid hormones and cell growth. They are an 
aetiological factor of Graves’ thyrotoxicosis;
• TRAbB (Thyroid receptor blocking antibodies) – The bond to the C-terminal region leads to the inhibition 
of TSH function and reduced release of thyroid hormones.
These two antibodies are undistinguishable with regular immunoassays; they can be distinguished using biological 
analyses. One individual may possess both the stimulating and inhibiting antibodies (exceptionally), either simulta-
neously or consecutively, which greatly affects the clinical presentation. They are also responsible for clinical manife-
station of endocrine ophthalmopathy in euthyroid individuals. The antibodies cross the placenta and are risk factors of 
foetal hyperthyroidism.
Thyroid Peroxidase Antibodies – Anti-TPO (aTPO, TPOAb)
Thyroid peroxidase is an enzyme located on the apical membrane of thyrocytes, and catalyses hydrogen peroxide 
formation followed by iodine organification and bond to Tg. It has a relative molecular weight of 100 kDa. The gene for 
TPO is situated on chromosome 2. In normal cases the gene acts as a code for two proteins (TPO
1
 and TPO
2
) formed by 
post-transcriptional modifications of mRNA.
Anti-TPO were originally described as autoantibodies against microsomes; only later was thyroid perodixase detec-
ted as a major antigen.
Anti-TPO are IgG-class antibodies with high interindividual variability in subclasses IgG1, IgG
2
 and IgG
3
 and reacti-
vity. Unlike anti-Tg, they are able to fix the complement. They are the main marker of chronic lymphocytic thyroiditis.
Thyroglobulin Antibodies – Anti-Tg (aTg, TG Ab)
Unlike anti-TPO, they are unable to fix the complement, and have a higher heterogeneity given the large number 
of epitopes on Tg.
They are a similar marker of autoimmune thyroiditis, but have a higher incidence of positivity than anti-TPO in 
iodine-deficient regions and patients with modular goitre.
They can interfere with Tg tests (cause false positivity or negativity), and have a higher interindividual variability 
and variability of reactivity than anti-TPO.
12.1.6. Summary – Key Information
12.1.6.1. Metabolism of Thyroid Hormones
• Iodine is required for thyroid hormone synthesis; the daily requirement is around 100  – 200 µg/day; iodi-
sed salt is the source of iodine in the CR;
• Thyrocyte actively take up iodine from the circulation; iodine binds chemically on the apical side to tyro-
sine amino acid in thyroglobulin;
• Thyroid hormones are synthesized in the colloid, and thyroglobulin is the donator of tyrosine and also a 
matrix where iodinated tyrosyl amino acids combine to form tetraiodothyronine (T
4
) and triiodothyronine 
(T
3
);
• T
4
 is the main product of the thyroid;
• T
4
 and T
3
 are bound in the plasma to transport proteins (TBG, transthyretin, albumin), which maintain a 
stable level of circulating T
4
 and T
3
;
• Thyroid gland is the source of only 20 % of T
3
 concentration in the circulation; the majority of T
3
 occurs as 
a result of deiodination from T
4
 in peripheral tissues;
• Only 0.03 % of T
4
 and 0.03 % of T
3
 circulate in the free, biologically available form, referred to as free T
4
 (FT
4
) 
and free T
3
 (FT
3
), whose levels are responsible for the biological effect;
• T
4
 is converted in peripheral tissues to biologically active T
3
, or deactivated to reverse T
3
 (rT
3
) through the 
action of specific deiodinase enzymes (dependent on sufficient amounts of selenium – selenoenzymes);
• T
3
 and partially T
4
 are actively transported to cells, where the main effect of T
3
 takes place through nuclear 
receptors for T
3
;
• T
3
 increases the basal metabolic rate in the first place (lipolysis, glycogenolysis and gluconeogenesis and 
also O
2
 consumption and heat production);
• T
4
 and T
3
 degradation takes place as deiodination by deiodinases, and by sulphonidation and glucuroni-
dation.
12.1.6.2. Regulation of Thyroid Hormones
• There are 4 key components of thyroid hormone production regulation (Fig. 4):
o Hypothalamus (production of the thyrotropin-releasing hormone, TRH);
o Pituitary gland (production of the thyroid-stimulating hormone, TSH);
o Thyroid gland (production of T
4
, minimal amounts of T
3
 - 15 %);
o Peripheral tissues (production of T
3
).
• TSH plays a key role in regulation. TSH is stimulated by TRH and retroactively inhibited by free fractions of 
FT
4
 and FT
3
 independently of each other;
• Many local factors affect TRH and TSH secretion at the local level (e.g. somatostatin, dopamine, stress, 
cold); they are usually temporary and do not affect FT
4
 and FT
3
 levels;
• TSH has a stimulating effect on thyrocytes, which leads to their hypertrophy and proliferation, and finally 
to increased production of T
4
;
• The TSH level is 100 times more sensitive to individual changes in FT
4
 levels; the TSH is the most sensitive 
marker of changes in potential thyroid disorder;
• T
4
 levels depend on TSH production, a sufficient amount of iodine, while overall fraction levels depend on 
binding protein levels;
• It is assumed that every individual has a genetically defined optimal level of thyroid hormones, so referen-
ce limits for FT
4
 have a relatively broad range;
• The T
3
 level depends on T
4
 production, function of deiodinases (sufficient amount of selenium) and meta-
bolic condition (see the low T
3
 syndrome);
• Proper thyroid function thus requires normal functioning of the hypothalamic-pituitary axis, sufficient 
amounts of iodine and selenium, an undamaged thyroid (most commonly autoimmune diseases) and ab-
sence of serious co-morbidities.
12.1.6.3. Laboratory Parameters for Thyroid Tests
• TSH:
o Common beta-subunit with the FSH, LH and hCG; excess levels cause thyroid stimulation (pregnancy, 
hydatidiform mole);
o TSH stimulates hormone production in thyrocytes and also has a proliferative effect.
• T
4
 and T
3
:
o Their free fractions are biologically active;
o T
4
 concentration reflects its production in the thyroid gland;
o T
3
 concentration reflects the activity of peripheral deiodinases (mainly from the liver), however thyroid 
hyperfunction also occurs due to isolated T
3
 overproduction.
• TBG:
o Production is stimulated by oestrogens (pregnancy); production disorders are very rare Tg (thyroglo-
bulin);
o Serum concentration correlates with the size and activity of the thyroid, and with the activity of thyroid 
diseases (inflammations, tumours).
• Anti-TSH:
o These are mostly stimulating agents which cause Graves’ thyrotoxicosis; they have rarely an inhibitory 
effect causing hypothyroidism;
o They are responsible for endocrine orbitopathy in Graves’ thyrotoxicosis.
• Anti-TPO, Anti-Tg:
o Major markers of Hashimoto’s thyroiditis – chronic lymphocytic inflammation; Anti-TPO are the major 
risk marker; Anti-Tg occur sporadically in iodine-deficient patients and patients with a nodular goitre;
o These tests provide the most considerable differences in resulting concentrations determined using 
different methods;
o Anti-Tg present in serum may interfere with the Tg test and lead to falsely positive or negative results.
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12.3.1. Introduction
Specific laboratory tests for thyroid gland disorders are very important as laboratory signs of thyropathies are often 
more sensitive than clinical symptoms. On the other hand, some thyropathies do not manifest themselves in laborato-
ry results (eufunctional goitre, thyroid nodules).
This text only deals with parameters covered by public health insurance and therefore used in normal practice.
Specific parameters of thyropathy tests include: 
• Basic tests:
o Thyroid function parameters: TSH Thyroid-stimulating hormone (TSH), free T
4
 (FT
4
), free T
3
 (FT
3
), total 
T
4
 (TT
4
), total T
3
 (TT
3
);
o Autoimmune parameters: TSH receptor antibodies (Anti TSH, TRAK, TRAb), thyroid peroxidase antibo-
dies (Anti TPO,TPOAb), thyroglobulin antibodies (Anti Tg, TgAb).
• Other tests: Thyroglobulin (Tg), iodineuria, Thyroxin-Binding Globulin (TBG), calcitonin
12.3.2. Indications for Testing
12.3.2.1. General
• TSH is a more sensitive parameter for thyropathies assuming proper functioning of the hypothalamus-pi-
tuitary axis and the absence of serious non-thyroidal disease;
• TSH tests with functional sensitivity of at least 0.02 mIU/l are recommended, as they allow thyroid hyper-
function to be distinguished from quite common TSH suppression;
• Tests for free T
4
 and T
3
 are preferred to their total concentrations;
• The T
3
 test is only indicated for thyroid hyperfunction; it is not indicated for hypofunction since the major 
product of the thyroid gland is T
4
;
• Autoantibodies are tested to clarify aetiology of the disease, assess the risk of thyropathy in the future and 
to monitor the effect of anti-TSH treatment;
• Anti-TPO and Anti-Tg tests are indicated every 2 years or when the clinical condition changes; always when 
potential thyropathy is suspected;
• Anti-Tg is tested with Tg if Tg is used as a tumour marker to monitor patients’ condition after thyroid cancer 
treatment;
• Anti-TSH is indicated if Graves’ thyrotoxicosis is suspected, to monitor the effect of its treatment, and to 
clarify the aetiology of exophthalmos;
• Thyroglobulin (Tg) test is indicated as a tumour marker in patients with differentiated thyroid cancer. Pre-
-operative tests are used to assess the scope of disease, the effect of treatment and for early diagnosis of 
a relapsed disease, always with Anti-Tg;
• In addition, Tg tests help monitor acute and subacute thyroid inflammations and when T
4
 abuse is suspec-
ted;
• TBG tests are indicated if a genetic TBG production disorder is suspected;
• Iodineuria tests are primarily used in epidemiological studies to determine the status of iodine supply 
within the population;
• Calcitonin tests are indicated if medullary thyroid carcinoma is suspected for the same reasons as Tg tests; 
also in the differential diagnosis of hypocalcaemia.
12.3.2.2. Specific Diagnosis and Monitoring of Thyropathies
• The first-choice method for outpatients is the TSH test as this is also capable of diagnosing subclinical di-
sorders as well;
• Laboratory tests (TSH, FT
4
) of patients treated for thyroid hypofunction should be repeated after 6 weeks, 
when their condition is normalised every 6 months in the first 2 years and following on from this annually;
• Laboratory tests (TSH, FT
4
, FT
3
 and Anti-TSH for Graves’ thyrotoxicosis) of patients treated for thyroid hy-
perfunction should be repeated after 6 weeks, and when their condition normalises every 6 months.
12.3.2.3. Specific Diagnosis and Monitoring of Thyropathy – Risk Groups
• In general, regular follow-up TSH tests should be indicated to risk groups;
• When a TSH level outside the reference interval is found, FT
4
 should be tested (also FT
3
 if hyperthyroidism 
is suspected), and repeated Anti-TPO, Anti-Tg using the same method are recommended either every year 
or every 2 years when the finding is negative;
• Groups at risk of thyropathy include:
o Pregnant women – TSH, FT
4
 and Anti-TPO at the beginning of pregnancy;
o Patients with fertility disorders – TSH and Anti-TPO;
o Women over 50 years – TSH every 4 years;
o Patients with other autoimmune diseases (type I DM, celiac disease, etc.);
o Patients with manifested IHD, tachyarrhythmias – TSH annually;
o Patients with medication or treatment inducing thyropathies (amiodarone, lithium, interferons gamma 
or other, radiotherapy of the neck and chest) – TSH tests every 6 months during treatment.
12.3.3. Sampling – Sources of Variability during Sampling for Thyroid Tests
The presence of autoantibodies is not physiological, so there is no physiological biological variability, and all 
information relates to TSH, FT
4
, FT3, and Tg.
All thyroid analytes reveal higher inter-individual variability when compared with intra-individual variability. Inter-
-individual variability is particularly high for Tg and serum autoantibody concentrations 40 – 150 %. Serum TSH levels 
also show a high degree of inter- and intra-individual variability (25 %; 19 %). This fact primarily relates to the short TSH 
half-life (~60 minutes) and also circadian and diurnal variability.
Biological and analytical variability values could allow for changes (LSC) of minimal significance to be calculated for 
each parameter.
LSC refers to the change which has to occur in the measured parameter (considering the measurement uncertainty 
and biological variability) to have a significant change.
LSC
FT
4
6.0  pmol/l
FT
3
1.5  pmol/l
TSH 0.75 mIU/l
Tg 1.5 µg/l (ng/ml)
LSC in % is more precise however absolute LSC values within the reference interval are presented just to give an 
illustration. For example, if TSH changes from the last test (6 weeks ago) from the baseline 3.6 mlU/l to 4.1 ml/l (0.5 
mlU/l change), it is not a significant change, meaning the difference may be caused by the sum of the intra- and inter-
-individual variability error and analytical error.
• Circadian rhythm: Exists with lowest values in late morning and highest values befo-
re sleeping. TSH also shows pulsatile secretion with 2 – 6-hour intervals during the day 
and shorter intervals and frequency while asleep. TSH levels vary within the range of 0.5 
– 2.0 multiples of the average daily level while the fluctuations are clinically insignificant. 
• Age – the reference intervals of newborns and children are different. Foetus and newborn – TSH first 
appears around the 13th week of pregnancy, the values subsequently increase to many times the nor-
mal adult value. Childhood – TSH and reference interval values gradually decrease from birth; nor-
mal adult values are reached between 5 and 10 years of age; adult reference intervals are the same. 
• Gender – no difference. 
• Pregnancy – TSH drops in the first trimester in about 20 % of normal pregnancies, which is caused by thyro-
id gland stimulation by human chorionic gonadotropin (hCG). Minimum TSH and elevated FT
4
 levels occur 
concurrently at week 10 – 12 of pregnancy. About 10 % of these cases (2 % of all pregnancies) may lead 
to gestational transient thyrotoxicosis (GTT) syndrome, which is typical of more or less clinically apparent 
symptoms of thyrotoxicosis. This clinical condition is often accompanied by more frequent vomiting in 
the first trimester of pregnancy. This is not serious in terms of clinical prognosis, and the problem usually 
subsides spontaneously.
Increased oestrogen production during pregnancy increases average TBG concentration 2 – 3 times. This results in 
a shift of the reference range for TT
4
 and TT
3
 in week 16 of gestation to about 1.5 times the non-pregnant value, but FT
4
 
and FT
3
 practically do not change from non-pregnant values.
Serum Tg concentration usually rises throughout normal pregnancy. These values turn to normal 6 to 8 weeks after 
birth.
• Hepatic or renal dysfunction – mainly binding protein disorders; chan-
ges in free T
4
 and T
3
 are manifested only in severe deficiency cases. 
• Drugs – thyroid parameters show frequent drug interactions; this is namely the case of binding protein 
concentration and thyroid hormone displacement from the bond to binding proteins. This can be avoided 
by choosing free T
4
 and T
3
 tests whose serum levels are relatively stable. 
• Most drugs or pathological agents affect the TSH level by blocking or stimulating at the hypothalamus and 
pituitary level (typical examples are the inhibition of TSH secretion by dopamine, GH-RH analogs, stress, 
etc.).
• Amiodarone – a drug with a high iodine content; long-term administration induces thyropathy in about 15 
% of patients, commonly with prior autoimmune thyroid disease (AITD).
Use of T
4
 (levothyroxine) – use of drugs containing T
4
 (Letrox, Euthyrox) markedly increases FT
4
 levels from 30 – 60 
% for at least 6 hours from the use of the drug. FT
3
 levels respond similarly if combined formulations containing T
4
 and 
T
3
 are used. On principle, samples are taken from these patients before using drugs with T
4
 or T
3
.
• Stability – thyroid hormones are relatively stable; serum: 24 – 48 hrs at +22 °C, 5 – 7 days 
at +4 – 8 °C, and at least 6 months at -20 °C (this applies to all parameters and antibodies) 
• Freezing – does not affect the levels provided the serum is proper-
ly mixed after thawing by inverting the test tubes (vortex mixing is not sufficient). 
• Haemolysis, lipaemia and hyperbilirubineamia – do not significantly interfere with immunoassays. 
• Gel tubes – samples taken into gel tubes do not affect the results of most TSH or thyroid hormone tests. 
• Heterophilic antibodies (HAMA)
Patient serum may contain heterophilic HAMA antibodies classified into two classes. Either these are relatively 
weak multi-specific, polyreactive antibodies, often IgM rheumatoid factors, or alternatively can be widely reactive 
antibodies induced by infection or treatment containing monoclonal antibodies. They are sometimes referred to as hu-
man anti-mouse antibodies (HAMA). On occasions they may be specific human anti-animal immunoglobulins (HAAA) 
created against well defined specific antigens following the administration of a therapeutic agent containing animal 
antigens (mouse antibodies), or alternatively occur randomly by immunisation at the workplace (by handling animals). 
Both HAMA and HAAA rather affect the non-competitive test methods than competitive immunoassays by creating 
bridges between binding and detection antibodies, thus generating a false signal that causes inadequately high values.
• Non-Thyroidal Illness (NTI)
Patients with a serious illness often have pathological thyroid tests, although thyroid dysfunction is not found. This 
is caused by poorly regulated central inhibition of hypothalamic releasing hormones including the TRH.
FT
4
 and TSH tests are useful only if clinical symptoms are present or the patient has a history of thyroid disorders. 
In addition to the cause mentioned above, the illness may be induced by various drugs such as dopaminergic drugs, 
glucocorticoids, furosemide or heparin, which either inhibit the pituitary TSH directly or indirectly by inhibiting the T
4
 
bond to serum proteins. The diagram of thyroid hormone changes in NTI is shown in Figure 11.1.
Figure 12.7. Non-thyroideal illnesses and T-hormones changes
Diagnosis and treatment of thyroid disorders in patients with serious non-thyroid illnesses are not at all easy, so it is 
recommended to collaborate with specialised endocrinologists, or, preferably, postpone the thyroid hormone testing. 
Levels 2 – 3 times as distant from the reference range do not typically indicate a serious thyroid illness.
12.3.4. Interpreting Laboratory Results of Thyroid Parameters
12.3.4.1. Reference Limits (Intervals)
The correct evaluation of laboratory results requires the determination of reference limits. Reference limits are 
generally used to diagnose a disease. Reference limits have to consider the incidence of thyroid disease, specific phy-
siological conditions during pregnancy, age, gender and other aspects (selected population). When treating thyroid 
diseases, terms such as replacement or suppressive therapy are used, which means clinical conditions which have 
recommended target concentrations of thyroid tests regardless of reference limits refer to arbitrary limits. Furthermo-
re, one should keep in mind that immunoassays are able to measure extremely low concentrations of free fractions 
(pmol/l), however their results depend on the method used, in particular as regards antibody quality, selection of stan-
dards and other factors, which may lead to marked differences of results between laboratories. These differences are 
relatively small for THS and free FT
4
 and FT
3
 (20 – 30 % on average), but very significant for autoantibodies (anti-TSH, 
Anti-TPO, anti-Tg) and thyroglobulin. Apart from the pressure on mutual standardization between manufacturers, the 
only solution is to interpret results using reference limits corresponding to the method used.
Two types of limits are used in laboratory diagnosis of thyropathies:
Reference limits for diagnosing thyropathies
These limits have been set based on the reference population sample using selection criteria with respect to the 
relatively high prevalence of thyropathies (autoimmune thyroid diseases or iodine deficiency) being over 5 %. The 95% 
confidence interval of the general “healthy” population cannot be used to set reference limits – really healthy indivi-
duals have to be selected from this population. Selection criteria are specific for the particular laboratory method. The 
following criteria have been recommended by consensus for setting reference limits in thyroid diagnosis:
Selection criteria for TSH, FT4 and FT3
Reference intervals should be set based on 95% confidence interval (for TSH log transformed) of values from 120 
healthy euthyroid volunteers (60 males and 60 females) examined who:
• Had negative serum Anti-TPO and Anti-TgAb – immunoassays;
• Do not have thyroid dysfunction or other autoimmune illnesses in their personal or family history;
• Do not have any visible or palpable goitre;
• Do not use any drugs;
• Ideal age limit is 70 – 75 years, had ultrasonic thyroid examination.
Expected upper and lower reference limits:
TSH 0.3 – 0.5 and 3.5 – 4.5 mIU/l
FT
4
9.0 – 11.0 and 21.0 – 24.0 pmol/l
FT
3
 3.2 – 3.6 and 6.1 – 6.5 pmol/l.
Selection criteria for Anti-TPO, Anti-Tg and Anti-TSHR
Reference intervals for thyroid antibody tests are significantly method-dependent. They should be set based on 
tests of 120 “normal” individuals without a history of thyroid illnesses. Such individuals should be selected so as to 
exclude AITD-predisposed persons. Ideally their thyroid should be examined on ultrasound. The following individuals 
are considered normal:
• Males – age 18 – 30 years, no visible or palpable goitre;
• Serum TSH concentrations 0.5 – 2.0 mlU/l;
• No thyroid disease in personal or family history;
• No non-thyroid autoimmune illness such as celiac disease, type I DM, lupus or other diseases.
Given the great variability of results between manufacturers, quantitative reference limits cannot usually be speci-
fied. The results are generally either positive or negative.
Selection criteria for Thyroglobulin (Tg)
The reference interval for Tg should be set depending on the locality as serum Tg concentrations are affected by 
iodine intake. In countries with sufficient iodine supply (including the CR) the reference interval for serum Tg for the 
euthyroid population (TSH, FT
4
 within the reference range plus negative to Anti-Tg antibodies) ranges from 3 to 40 μg/l.
The following target values (arbitrary limits) are recommended for patients being treated for thyropa-
thies (replacement therapy):
Replacement therapy with levothyroxine (LT4):
Target TSH value: 0.3 – 3.0 mIU/l, near upper threshold values are tolerated in elderly (over 80 years) or on an 
individual basis. FT
4
 levels are within the reference limits.
Suppressive therapy with levothyroxine (LT4):
In the case of patients post thyroid surgery and radioiodine therapy for differentiated thyroid cancer, levothyroxine 
(LT
4
) doses are indicated in order to suppress TSH under the normal reference limit, thus reducing its proliferation-
-stimulating effect on thyrocytes. Target TSH values are arbitrarily recommended with FT
4
 often being slightly over the 
upper limit.
o TSH under 0.1 mIU/l – high and medium-risk patients, within 5 years of operation;
o TSH: 0.1 – 0.5 mIU/l – for low-risk patients, or at 5 – 10 years from operation, providing the condition 
is favourable.
This recommendation does not apply to the preparation period for radioiodine therapy (targeted induction of hy-
pothyroidism, TSH elevation) when it is desirable to reach TSH over 30 mlU/l either by discontinuing the levothyroxine 
treatment or by administering hrTSH.
Reference limits for paediatric population:
The hypothalamic-pituitary regulation axis of the paediatric population reacts to the changed environment and 
maturates after birth. That is why children under 1.5 years have markedly higher TSH levels, while FT
4
 reaches its adult 
level at around 3 months of age. Figure 2 shows all ratios/multiples of TSH and FT
4
 when compared with adults and 
demonstrates significant differences in TSH levels in the first 1.5 years of life, most markedly in the first months of life.
Usual values in children in proportion to adults
Age TSH child/ TSH adult TSH referential va-
lues (ml/U/l)
FT4 child/FT4 adult FT4 referential va-
lues (pmol/L (ng/
dL))
Foetus in the middle 
of pregnancy
2.41 0.7 – 11 0.2 2 – 4 (0.15 – 0.34)
Serum oft he umbili-
cal vein
4.49 1.3 – 20 0.8 8 – 17 (0.64 – 1.4)
Newborn during the 
birth
4.28 1.3 – 19 1 10 – 22 (0.8 – 1.9)
3-day newborn 3.66 1.1 – 17 2.3 22 – 49 (1.8 – 4.1)
10-week infant 2.13 0.6 – 10 1 9 – 21 (0.8 – 1.7)
14-month child 1.4 0.4 – 7.0 0.8 8 – 17 (0.6 – 1.4)
5-year child 1.2 0.4 – 6.0 0.9 9 – 20 (0.8 – 1.7)
14-year child 0.97 0.4 – 5.0 0.8 8 – 17 (0.6 – 1.4)
Adult 1 0.4 – 4.0 1 9 – 22 (0.8 – 1.8)
*FT
4
 assessed using the method of equilibration dialysis
Figure 12.8. Values for children vs. values for adults
Reference limits of pregnant women
Pregnancy has a major effect on the TSH level, which drops significantly with the growing hCG level; the greatest 
TSH suppression can be expected at the end of the first trimester. FT
4
 rises slightly in the first trimester, and then, con-
versely, drops slightly under the average of normal population until the end of pregnancy. Trimester-specific reference 
limits should be used for TSH. Changes in free FT
4
 near the limits are significant, while values for the normal population 
can be used with an individual assessment.
The following TSH values can be expected during pregnancy:
1st trimester TSH 0.1 – 2.5 mIU/l
2nd trimester TSH 0.2 – 3.0 mIU/l
3rd trimester TSH 0.3 – 3.0 mIU/l
12.3.4.2. Interpretation of Thyroid Test Results
The patient’s clinical condition, risk factors and history always have to be taken into account when interpreting 
results. Drug interferences and stress should be taken into account in hospitalized and multimorbid outpatients.
The following figure lists expected thyroid parameter values, however the possible effects of coincident diseases 
and drug interferences are not considered.
Diagnosis /Laborato-
ry tests
TSH FT
4
FT3 Tg antiTPO antiTg antiTSHR
Central disorders
Central hypothyroi-
dism
↑N↓ ↓ ↓ neg. neg. neg.
Central hyperthyroi-
dism
↑ ↑ ↑ ↓ neg. neg. neg.
Primary disorders - hypofunction
Subclinical hypothy-
roidism
↑ N N neg./pos. neg./pos. neg./pos.
Hypothyroidism ↑↑ ↓ ↓N↑ neg./pos. neg./pos. neg./pos.
Deficiency in iodine 
hypothyroidism
↑↑ ↓ ↑↑ neg. pos. neg.
Postresection hypo-
thyreosis
↑↑ ↓ neg.
Hypofunctional 
phase of AITD
↑↑ ↓ ↓ pos. pos. neg./pos.
Primary disorders – hyperfunction
Subclinical hyper-
thyreosis
↓ N N N↑
Grave’s disease ↓↓ ↑↑ ↑↑ ↑↑ pos.
Hyperfunctional ade-
noma
↓ ↑ ↑ ↑N neg.
T
3
 - hyperfunction ↓ N ↑ ↑N neg.
Chronic overuse of T
4
↓↓ ↑↑ ↑↑ ↓ negat.
Transitory pregnancy 
toxicosis
↓↓ ↑ ↑ ↑N
Hyperfunctional 
phase of AITD
↓↓ ↑↑ ↑ ↑↑ pos. pos. neg./pos.
Other disorders
Eufunctional struma 
(diffuse, nodose)
N N N ↑ N
Hashimoto‘s thyroidi-
tis (AITD)
N N N N pos. pos. neg.
Circulating antiTSH ↑N↓ ↑N↓ ↑N↓ N↑ neg. neg. pos.
T
3
 and T
4
 resistance ↑N ↑↑ ↑↑ ↑↑
Low T
3
 syndrome N↓ N↓ ↓↓
Figure 12.9. Basic interpretation of thyroideal tests
Specific Interpretations
Changes in thyroid hormone levels after initiating thyroid hypofunction or hyperfuction treatment:
As demonstrated in the following figure, the development of thyroid dysfunction is relatively slow, starting with 
the subclinical phase (change to TSH with free fractions within the reference limits), and gradually transferring to the 
clinical phase (periods 1 and 2). When treatment is started, free fractions and TSH gradually return to normal; this 
transitional period may last from some weeks to 9 – 12 months (see Fig. 11.4).
Figure 12.10. The course of hypothyroidism and hyperthyroidism
• Primary hypofunction, most commonly on an autoimmune basis, demonstrated by a positive anti-TPO or 
Anti-Tg, exceptionally positive blocking anti-TSHR.
The subclinical (latent) form: only TSH level changes however FT
4
 or FT
3
 remain within the reference interval; usu-
ally no or minimally expressed clinical symptoms. Diagnosis of subclinical thyropathy (pathological TSH, normal FT
4
) 
should be confirmed by at least two pathological results of TSH at 6 – 8-week intervals (the follow-up result is normal 
in up to 25 % cases).
Manifest form – the disorder is fully developed: clinical symptoms, changed TSH and FT
4
• Increased thyroid function (primary hyperfunction, thyrotoxicosis): suppressed to an undetectable TSH 
level, elevated FT
4
 and FT
3
. Roughly 5 % of cases only indicate sporadically elevated FT
3
 (T3-thyrotoxicosis). 
• Graves’ disease – typically positive Anti-TSHR (an aetiological factor of the disease), but of-
ten only medium-positive Anti-TPO, Anti-Tg, undetectable TSH and high FT
4
 and FT
3
. The-
re are also blocking anti-TSHR, which mostly induce clinically apparent hypofuncti-
ons with an orbitopathy. A change in the antibody response from stimulating to blocking 
antibodies (from hyperfunction to hypofunction) can occur in the patient on relatively rare occasions. 
• Amiodarone-induced thyrotoxicosis occurs in about 15 % treated persons as a result of excess iodine 
in amiodarone, which causes thyrotoxicosis: present suppression of (undetectable) TSH, elevated FT
4
 
and slightly elevated FT
3
, antibodies may or may not be identified – help distinguish between type I and 
II. Anti-TPO are positive in type 1; ultrasound examination helps distinguish between the two types. 
• Subacute thyroiditis at the incipient stage – the clinical presentation (pain, high FW), la-
boratory signs of hyperfunction (thyrocyte causes damage – release of the reser-
ve of produced T-hormones), negative antibodies, low 131I accumulation, and uneven acti-
vity distribution on scintigraphy, high thyroglobulin level (marker of thyrocyte damage). 
• Autoimmune thyroid disease (AITD) – Hashimoto’s thyroiditis
Prevalence 10 %; fertile women are usually eufunctional; positivity grows with age; up to 40 – 50 % in women over 
65 years; prevalence among men is several times lower.
They can be eufunctional; positive anti-TPO induces chronic lymphocytic inflammation, which, if prolonged, leads 
to thyroid destruction and ultimately to the development of subclinical and clinical primary hypofunction. The dysfunc-
tion development time is quite individual; the higher the anti-TPO concentration, the more likely it will develop quickly.
Acute exacerbation (example: postpartum thyroiditis) first takes place as a hyperfunction stage followed by a hy-
pofunction stage, which often becomes permanent, or the function normalizes. A further antibody response may de-
velop, for example anti-TSHT and the development of Graves’ thyrotoxicosis.
The eufunction stage features TSH and FT
4
 within the reference limits, positive Anti-TPO and/or Anti-Tg.
• Postpartum thyroiditis develops in the postpartum period in 50 % of women with positive Anti-TPO with 
a typical waveform as shown in the following figure (Figure 11.5). Anti-TPO and/or Anti-Tg antibodies in-
crease after birth. 
Figure 12.11. Postpartum thyreoidism
•	 Non-thyroid disease
Often observed in acutely hospitalised patients with a clinically serious condition (shock, sepsis), extensive surge-
ries, patients hospitalised at the ICU – any TSH, FT
4
 and FT
3
 outside the reference limits can be found. This is due to 
many factors: caloric deficit, hyposaturation of tissues with oxygen, the effect of cytokinins acting at the central level. 
The administration of dopamine and similar substances features TSH suppression or even undetectable TSH and nor-
mal FT
4
.
• Low T3 syndrome: primarily in patients with a metabolic disorder, shock conditions or other clinically very 
serious diseases. Develops on the basis of elevated T
4
 conversion to (reversible) metabolically inactive rT
3
; 
laboratory results include low FT
3
 levels and normal or slightly decreased FT
4
 and TSH. A critical decrease 
in the T
3
 level is a poor prognostic indicator.
Thyroid parameters should always be treated with caution in non-thyroid diseases; slight laboratory imbalances 
of 2 – 3 times the normal values usually do not present serious thyropathy and are induced by non-thyroid diseases.
• Thyroid hormone overdosing (tyreotoxicosis factitia) – laboratory signs of hyperfuncti-
on but a very low thyroglobulin level and a low storage capacity of the radiopharmaceutical. 
• Central hypothyroidism features decreased FT
4
, while TSH may be slightly under the lower limit, nor-
mal or slightly elevated (if biologically inactive TSH is produced). TRH test results are pathological. 
• Central hyperfunction: the most common cause is pituitary adeno-
ma with TSH overproduction; TSH, FT
4
 and FT
3
 levels subsequently increase. 
• Thyroid hormone resistance syndrome
Usually caused by thyroid hormone receptor beta mutations occurring in 1:50,000 live born children. Serum FT
4
 
and FT
3
 levels are typically increased and are associated with a normal or slightly increased serum TSH level. However, 
TSH secretion is not disproportionate as the tissue response to the thyroid hormone is decreased and requires higher 
thyroid hormone levels to maintain a normal metabolism. TSH is markedly elevated in the TRH test. There are no sym-
ptoms of hyperthyroidism however tachycardia or dysrhythmia may occur.
12.3.5. Discordant Result
This is a situation when the measured laboratory results do not correspond with the patient’s clinical condition. 
This is identified by the attending physician, who should notify the responsible laboratory about it.
Discordant results may have many causes: ranging from a technical error including wrong sample identification to 
an error in the laboratory procedure, or the presence of interfering agents or unusual isoforms such as TSH isoforms.
Recommended steps:
• Notify the testing laboratory about the discordant result;
• Compare the discordant result with possible interfering drugs which the patient is taking;
• Verify that the sample has been correctly identified;
• Request a repeated sample measurement;
• Take a new sample and measure the sample.
Request a sample measurement in another laboratory using another technology, if the inter-laboratory variability 
of results is over 50 %, interference is probable (does not apply to Anti-TPO and Anti-Tg measurements where variabi-
lity between manufacturers is in the order of tens to hundreds in terms of percent).
The laboratory takes further steps in line with their own internal quality control system.
12.3.6. Summary – Key Information:
12.3.6.1. Indications for Testing
General:
• TSH tests with functional sensitivity of at least 0.02 mIU/l are recommended;
• Free T
4
 and T
3
 tests are preferred;
• The T
3
 test is only indicated for thyroid hyperfunction;
• Anti-TPO and Anti-Tg tests are indicated when autoimmune thyroid disease is suspected, as well as for risk 
groups;
• Anti-TSH is indicated if Graves’ thyrotoxicosis is suspected, to monitor the effect of its treatment, and to 
clarify the aetiology of exophthalmos;
• Thyroglobulin (Tg) test is indicated as a tumour marker in patients with differentiated thyroid cancer, al-
ways with Anti-Tg;
• Calcitonin tests are indicated if medullary thyroid carcinoma is suspected.
Specific Diagnosis and Monitoring of Thyropathies
• The first-choice method for outpatients is the TSH test since this is also capable of diagnosing subclinical 
disorders;
• TSH and FT
4
 tests are carried out in patients undergoing treatment for thyroid hypofunction;
• TSH, FT
4
 and FT
3
 tests are carried out in patients undergoing treatment for thyroid hyperfunction, and Anti-
-TSH for Graves’ thyrotoxicosis.
Specific Diagnosis and Monitoring of Thyropathy – Risk Groups
• Regular follow-up tests of TSH, Anti-TPO and Anti-Tg are indicated for risk groups every 2 years;
• Groups at risk of thyropathy include:
o Pregnant women;
o Patients with fertility disorders;
o Women over 50 years;
o Patients with other autoimmune diseases (type I DM, celiac disease, etc.);
o Patients with IHD manifestation and tachyarrythmias;
o Patients on medication or treatment inducing thyropathies (amiodarone, lithium, interferons gamma 
or other, radiotherapy of the neck and chest).
12.3.6.2. Collection:
• Samples may be taken at any time in the morning however always before using a drug containing T
4
 or T
3
 
(FT
4
 and FT
3
 levels increase by 30 – 60 % for 6 hours);
• The sample may be stored in the fridge until the next day; refrigerated serum is stable for one week;
• Reference limits do not vary with age and gender except for children under 5 years (TSH levels are higher 
and the FT
4
 and FT
3
 range is wider in children under 5 years);
• Interferences of drugs and external influences such as stress primarily affect the TSH and total T
4
 and T
3
 
(TT
4
 and TT
3
) assays;
• Iodineuria is measured in the first morning urine; store in the fridge; no urine stabilizers are required.
12.3.6.3. Interpretation of Results:
• Results have to be assessed considering the clinical condition, patient history and drugs taken;
• Reference limits, if used for diagnosing thyroid disorders, should be defined based on the selected popu-
lation of healthy individuals according to the recommended selection criteria;
• Pregnant women have specific TSH reference limits for each trimester. The first trimester is characterized 
by a decrease in TSH with a slight elevation in FT
4
 levels (thyroid stimulation by the hCG molecule);
• Patients on replacement therapy and patients undergoing treatment for differentiated thyroid cancer have 
arbitrarily recommended target TSH levels that differ from the reference limits;
• Subclinical disorders usually feature absent or minimal of clinical symptoms, while the TSH level is outside 
the reference limits, and free hormone levels are within the reference limits;
• Primary disorder means a disorder afflicting the thyroid gland. Hypofunction is characterised by low FT
4
 
and elevated TSH levels, while hyperfunction by elevated FT
4
 and FT
3
, and low or undetectable TSH con-
centrations;
• The most common cause of primary hypofunction is autoimmune thyroid disease (Hashimoto’s thyroiditis, 
AITD) with typically positive Anti-TPO and/or Anti-Tg results. The most frequent cause of hyperfunction is 
thyrotoxicosis (Graves’ disease) with typically positive Anti-TSH autoantibodies. Positive autoantibodies 
are not physiological, and their presence with normal TSH and FT
4
 is indicative of eufunctional thyroiditis;
• Successful treatment of patients with thyropathies leads to the faster normalisation of free hormones (FT
4
 
and FT
3
); TSH reverts to normal following some weeks up to 1 year of treatment;
• Hospitalised patients with a clinically serious condition (shock, sepsis), extensive surgeries, patients hos-
pitalised in the ICU have imbalanced thyroid parameters, ranging from low T
3
 syndrome to mere TSH sup-
pression due to dopamine treatment. This may lead to great differences in results, which is usually not 
caused by thyroid disease but rather the acute condition and its treatment. Thyroid tests revert to normal 
after convalescence;
• A discordant result is a situation when the measured laboratory results do not correspond with the patient’s 
clinical condition. This is identified by the attending physician, who should notify the responsible labora-
tory about it. Discordant results may have many causes: ranging from a technical error including wrong 
sample identification to an error occurring during a laboratory procedure, or the presence of interfering 
agents or unusual isoforms such as TSH isoforms.
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CHAPTER 13
13. Hormones of hypothalamus and hypophysis
Author: MUDr. Tomáš Franěk
Reviewers: doc. RNDR. Kristian Šafarčík, Ing. Vladimír Bartoš, Ph.D.
13.1. Prolactin
Prolactin is a polypeptide hormone produced in eosinophilic cells of the anterior pituitary, whose secretion is cen-
trally inhibited from the hypothalamus through the action of prolactin-inhibiting hormone (PIH) and dopamine; con-
versely, its secretion is stimulated by the effect of serotonergic neurons, prolactin-releasing hormone and some drugs. 
Prolactin stimulates the transformation of lobuloalveolar epithelium in the mammary gland into the secretory type 
with subsequent breast milk formation. The action of prolactin on ovaries inhibits follicle maturation and aromatase 
activity with a subsequent decrease in oestradiol synthesis.
 Indications for the prolactin assay include infertility, menstrual cycle disorders such as amenorrhoea, dysmenorr-
hoea and galactorrhoea, gynaecomastia in males, tumours and traumas in the sella turcica region, and signs of virili-
zation.
 Physiological elevated values can be found in pregnant women, postpartum lactation, extreme stress, prolactino-
mas and ectopic production. Furthermore, prolactin secretion is stimulated by the following drugs: chlorpromazine, 
haloperidol, phenothiazines, cimetidine, tricyclic antidepressants and reserpine, metoclopramide.
13.2. FSH – Follicle Stimulating Hormone
FSH is a glycoprotein secreted by the basophilic gonadotrophic cells of the anterior pituitary. The function of FSH 
is to stimulate the growth and maturation of ovarian follicles; FSH together with LH support oestrogen secretion and 
participate in endometrium transformation in the proliferative phase of menstrual cycle. The stimulation of Sertoli cells 
by the FSH helps maintain male spermatogenic epithelium, and affects the synthesis of inhibin and binding protein for 
angrogens (SHBG) in seminiferous tubules.
 Indications for the FSH assay include amenorrhoea, dysmenorrhoea, oligomenorrhoea, infertility, primary and se-
condary hypogonadism, conditions following cytostatic treatment or radiation, atypical sexual maturation in children, 
pituitary traumas and tumours, gonadal dysgenesis, and hypothalamic-pituitary-gonadal axis disorders. The LH and 
FSH assay is also important for diagnosis in polycystic ovary syndrome where the FSH level decreases or is normal and 
the LH level increases, so that the LH/FSH ratio increases in contrast to healthy individuals. 
 Elevated values can be found in primary ovarian insufficiency, Turner syndrome, climacterium praecox, gonadotro-
pinomas, and physiologically elevated values in the menopausal period and primary hypogonadism in males. Reduced 
levels can be found in pituitary traumas and endocrine-inactive tumours, anorexia nervosa, secondary ovarian insuffi-
ciency and pseudopubertas praecox.
13.3. LH – Luteinizing Hormone
LH is a glycoprotein secreted by the basophilic gonadotropic cells of the adenohypophysis. The function of LH is to 
act on ovarian theca cells where stimulation of steroid synthesis takes place. With the assistance of FSH, the steroids 
subsequently transform into oestradiol. In addition, LH is responsible for the final ripening of the ovarian follicles and 
also induces ovulation and the early development of the corpus luteum with subsequent progesterone secretion. In 
males, LH stimulates testosterone synthesis in Leydig cells in the interstitial tissue of the testicles.
Indications for the LH assay include amenorrhoea, dysmenorrhoea, oligomenorrhoea, infertility, primary and se-
condary hypogonadism, conditions following cytostatic treatment or radiation, atypical sexual maturation in children, 
pituitary traumas and tumours, gonadal dysgenesis, selected chromosome aberrations, and hypothalamic-pituitary-
-gonadal axis disorders.
Elevated values can be found in primary ovarian insufficiency, Turner syndrome, climacterium praecox, gonadotro-
pinomas, and physiologically elevated values in the menopausal period and primary hypogonadism in males. Reduced 
levels can be found in pituitary traumas and tumours, anorexia nervosa, secondary ovarian insufficiency and pseudo-
pubertas praecox.
13.4. Oxytocin
Oxytocin is a peptide hormone formed primarily in the paraventricular nuclei of the hypothalamus, from where it 
is transported and deposited in the granules of posterior pituitary nerve endings. The function of this hormone is to 
act on myoepithelial cells lining mammary gland outlets, which causes milk to be ejected from the mammary gland. 
Another important function is the effect on the smooth muscles of the uterus during pregnancy, by which it enhances 
labour at the end of pregnancy. Assays for this hormone are not common as their importance for diagnosis is low.
13.5. ADH – Antidiuretic Hormone
ADH or vasopressin is another hormone stored in the posterior pituitary. This hormone is composed of 9 amino 
acids. The basic physiological action of ADH is water retention in the body, and ADH thus participates in the home-
ostasis of the body. ADH is secreted as a result of an increase in blood plasma osmolality, and its function is to incre-
ase the permeability of distal tubules and collecting ducts in the kidneys so thatwater can enter the hypertonic renal 
interstitium. Secretion disorders, or disorders at the peripheral receptor level, will manifest themselves as diabetes 
insipidus with the inability of the kidneys to concentrate urine, with specific clinical impacts. The opposite situation 
occurs following some traumas or bleeding in the CNS when ADH overproduction occurs with normal blood plasma 
osmolality. This condition is referred to as inappropriate ADH secretion (SIADH). Indications for the ADH assay include 
diabetes insipidus and SIADH.
13.6. TSH – Thyroid-Stimulating Hormone or Thyrotropin
TSH is a peptide hormone synthesized by thyrotrope cells in the anterior pituitary gland. The function of this hor-
mone is to stimulate thyroid cells to produce peripheral hormones, i.e. thyroxine and triiodothyronine. Secretion of 
this tropic hormone is partly regulated by direct inhibitory (negative) feedback caused by a high thyroid hormone level 
in the blood, which inhibits the adenohypophysis. A partial role is also played by neural mechanisms acting through 
the hypothalamus.
The assay for this hormone is essential for the diagnosis of thyroid gland disorders. Elevated levels can be found in 
hypothyroidism, subclinical hypothyroidism, following thyroidectomy, or pituitary adenoma producing TSH. Reduced 
levels can be found in hyperthyroidism, hypopituitarism and some non-thyroidal diseases such as febrile conditions, 
myocardial infarction, serious traumas and operations.
13.7. ACTH – Adrenocorticotropic Hormone
ACTH is a hormone synthesized in adenohypophysis cells in the form of a precursor, pro-opiomelanocortin (POMC). 
This precursor is subsequently cleaved by enzymes into several physiologically active peptides, one of them being 
ACTH. This hormone is the main hormone that regulates the production of glucocorticoid hormones in the adrenal 
cortex. Assays for this hormone are not common due to specific and complicated pre-analytical factors, and are solely 
used in the diagnosis of adrenal cortex function disorders, in particular to distinguish between a primary and secondary 
disorder of cortisol secretion.
Elevated levels can be found in primary hypercorticalism, Addison’s disease, adrenogenital syndrome, Cushing’s 
disease and adrenal damage. Reduced levels can be found in Cushing’s syndrome, when feedback ACTH inhibition 
occurs.
13.8. STH – Somatotropin (GH – growth hormone)
STH is a polypeptide hormone produced by acidophil cells in the adenohypophysis. Secretion is regulated from the 
hypothalamus by regulatory hormones such as somatoliberin and somatostatins. The function of this hormone is to 
control and stimulate growth due to different effects on metabolism. Major effects include the stimulation of proteo-
synthesis and inducing a positive nitrogen balance; furthermore, STH has anti-insulin effects and increases the content 
of free fatty acids in the blood plasma. Peripheral effects of this hormone depend on the production of peptide growth 
factors known as somatomedins (IGF-1 and IGF-2).
Indications for the STH assay include growth disorders, nanism or acromegaly. Elevated levels can be found in gi-
gantism, endocrine-active pituitary tumours and acromegaly. Reduced levels can be seen in nanism.
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14. Adrenal Cortex Hormones
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14.1. Biochemistry Histology, Secretion Regulation and Effects of Adrenal Cortex Hor-
mones
The adrenal gland of a newborn child weighs twenty times as much in proportion to their total weight than the 
gland of an adult. The foetal zone, considerably wide in the foetus, is found in the place of the reticular zone, although 
it does not form in anencephali. Maternal cortisol transfers to the circulation of the foetus and affects feedback ACTH 
production in the foetus’s pituitary. Maternal hormones ensure the balance of electrolytes. Foetal zone involution be-
gins 3 to 4 days after birth and proceeds very fast, so the basic adrenal cortex remodelling is finished in the third week 
after delivery. The newborn child is able to maintain internal homeostasis in normal conditions, although the adrenal 
cortex undergoes rapid remodelling. Exceptions to this are inherited defects of steroidogenic enzymes in the adrenal 
cortex, which may lead to, for example, congenital adrenal hyperplasia.
From the histological point of view, the adrenal cortex is differentiated into three zones, which also differ in the 
gene expression of enzymes that take part in the synthesis of corticoids. Zona glomerulosa primarily produces aldoste-
rone (the zone does not have 11 beta-hydoxylase); zona fasciculata produces cortisol (the zone does not have P450-
-aldosynthase, i.e. 18-hydroxylase/18-oxidase); zona reticularis produces corticoids with an androgenic effect such as 
dehydroepiandrosterone (DHEA). DHEA levels are high at a young age and decrease with growing age. Foetal DHEA is 
converted into oestrogen in the placenta. Steroidogenic factor 1 (SF-1) is a special protein that takes part in corticoid 
synthesis. It is a transcription factor bound to the TGG CTA motif of the gene regulation domain. If absent, the adrenal 
gland and gonads are lost.
Figure 14.1. Synthesis of adrenal cortex hormones
The basic glucocorticoid is cortisol, whose secretion is regulated by corticoliberin or corticotropin-releasing hor-
mone (CRH) from the hypothalamus, and by adrenocorticotropin (ACTH) from the adenohypophysis. Approximate 
amounts excreted per day are: cortisol 10-20 mg, corticosterone 3 mg, aldosterone 0.3 mg. The biological half-life of 
cortisol is about 100 minutes. This process typically involves feedback through glucocorticoid receptors in the hypotha-
lamus and the pituitary gland. Disorders may also occur at a non-steroidogenic level: a gene defect for the glucocor-
ticoid receptor and a gene mutation for the ACTH receptor have been described (they lead to familial glucocorticoid 
deficiency syndrome).
Essential for hypothalamic-pituitary-adrenal axis function is the gene for the nuclear hormone receptor (DAX-1), 
mutations or deletions of which lead to congenital hypoplasia linked with the X chromosome. A high level of cortisol 
induces a drop in CRH and ACTH production within minutes. If the cortisol concentration is high for a long time, the 
pro-opiomelanocortin (POMC) precursor synthesis is also lower. An important stimulus for cortisol secretion increase 
is stress situations, including hypoglycaemia or anxious reactions (important in paediatrics). The pronounced circadian 
rhythm of cortisol is used in the laboratory diagnosis. Lowest concentrations are usually at 4 a.m., while maximum 
levels of cortisol and ACTH are at 8 a.m. Cortisol in the blood is bound to proteins (about 90%) transcortin (cortisol-
-binding globulin – CBG) and albumin. For the most part, cortisol is metabolized in hepatocytes to 17-hydroxysteroids 
eliminated in the urine. More than 95% of metabolites conjugate in the liver with glucuronic acid (3-alpha-hydroxy 
group), and a smaller part is sulfatized at the 21-hydroxy group. The transformation of cortisone (a biologically inactive 
form that does not bind to glucocorticoid receptors) to cortisol also takes place in the liver. Only a small part is excreted 
in the urine as free cortisol.
Cortisol affects the transformation of basic metabolites: it stimulates the conversion of amino acids into glucose 
(gluconeogenesis) in the liver, stimulates proteolysis in muscles, and lipolysis in fatty tissue (through hormone-sensi-
tive lipase). It has a significant effect on the immune reaction of the body, and has anti-allergic, anti-oedematous, 
anti-inflammatory and anti-exudative effects. Cortisol acts through nuclear steroid receptors. Cortisol or aldosterone 
first penetrates into the cytoplasma, binds to the steroid receptor, and releases the heat shock protein (Hsp90) that 
was previously bound to this structure at the carboxy-terminus. The receptor to which the hormone is not bound is 
prevented by hsp from translocation to the nucleus. Receptors for steroid hormones are dimeric transcription factors. 
After binding to the steroid, the complex penetrates into the nucleus, the conformation changes and the DNA binding 
site (with “zinc fingers”) is created together with the structure responsible for affecting promotor areas with negative 
and positive hormone response elements (HRE). These are short (15 bp) palindromic sequences.
14.2. Laboratory Diagnostics
14.2.1. Total Serum Cortisol
This test is used mainly to diagnose Cushing’s syndrome, in which the fluctuations in diurnal cortisol levels are 
suppressed. However, this test is less reliable than the 24-hr urinary free cortisol test. The test is made on serum or 
plasma collected between 8 and 9 a.m. or as a daily profile, always before meals, and haemolysis should be prevented. 
The patient must rest for at least 30 minutes before collection. The reference range depends on the method. The table 
shows guidance values only:
Cord blood Children 1-15 years Adults 15-60 years
138 - 773 nmol/l
8:00 a.m. 414 - 690 nmol/l 138 - 773 nmol/l
5:00 p.m. 138 - 276 nmol/l 55 - 386 nmol/l
8:00 p.m. Less than 50% of morning value Less than 50% of morning value
Conversion factor: ug/dl x 27.6 = nmol/l
Table 14.1. The reference ranges for serum cortisol
Heterophilic antibodies in the human serum may react with immunoglobulins in reagents and interfere; cross rea-
ctions have not been proved, however.
Elevated cortisol levels are tested for the following diagnoses: burns, Crohn’s diseases, Cushing’s disease, Cushing’s 
syndrome, ectopic ACTH production, eclampsia, severe hepatopathies, hyperpituitarism, hypertension, hyperthyroi-
dism, severe infections, obesity, osteoporosis, acute pancreatitis, pregnancy (elevated CBG, cortisol levels may be up 
to 2.5 times higher in the third trimester), severe renal diseases, shock conditions, increased stress (heat, cold, trau-
matic or mental stress), surgery, virilization. Cortisol levels increase following the administration of oestrogens, oral 
contraception, yohimbin, vasopressin, also after amphetamines, metamphetamines, nicotin, alcohol, spironolactone, 
interferon-gamma and metoclopramide.
Reduced cortisol levels are typical of the following diagnoses: Addison’s disease, adrenal insufficiency, adrenogeni-
tal syndrome (congenital adrenal hyperplasia), congenital adrenal hypoplasia, chromophobe adenoma, craniopharyn-
gioma, hypophysectomy, hypopituitarism, hypothyroidism, hepatopathy, rheumatoid arthritis, Waterhouse-Friedrich-
sen syndrome, and following administration of dexamethasone and derivative preparations, ketoconazole, morphine, 
the inhalation of glucocorticoids for asthma bronchiale treatment and grapefruit juice ingestion.
14.2.2. Urinary Free Cortisol
Free cortisol is unconjugated cortisol filtered through the glomeruli to the urine. Free cortisol represents only 
about 5% of the total circulating cortisol, but the amount filtered to the urine accurately follows the secretory pattern 
of the adrenal cortex. This test is important because 24-hour urine collection eliminates the influence of diurnal variati-
ons. The main indication for the assay is Cushing’s syndrome and the differential diagnosis of obesity; the assay is not 
suitable for a diagnosis of Addison’s disease. Cautious interpretation is required in patients with diminished glomerular 
filtration (renal insufficiency). The patient should not be subject to physical strain or stress. Urine should be collected in 
a glass or plastic container (refrigerated container), and urine preservation with boric acid (10 g in a 3-litre container) or 
acetic acid (33%) is advisable. If the patient is catheterized, the collection bag must be placed on ice and emptied into a 
refrigerated container every hour. The reference range depends on the method. The table shows guidance values only:
Children 1-12 years 6 - 74 nmol/24 hrs
Both sexes 12-60 years 6 - 138 nmol/24 hrs
Conversion factor: ug/24 hrs x 2.76 = nmol/24 hrs
Table 14.2. The reference ranges for Urinary Free Cortisol
14.2.3. Hydroxyprogesterone
17-hydroxyprogesterone is derived from progesterone and is a metabolic precursor of 11-deoxycortisol in the pa-
thway for the synthesis of cortisol. It has a pronounced diurnal rhythm (highest values in the morning). Elevated levels 
are usually due to steroid 21-hydoxylase or 11-hydroxylase deficiency. 17-hydroxyprogesterone is converted and excre-
ted as pregnantriol. The test is made on the serum or plasma, or a dried blood spot for neonatal screening. Collection 
should be made in the morning, women at the follicular phase. Very young children, particularly infants under 2-3 
months, have very high 17 OH-pregnenolone sulphate levels. Samples from infants should be tested after extraction. 
The test is used especially for the diagnosis of congenital adrenal hyperplasia. It is further used for the ACTH stimulati-
on test and to monitor patients on glucocorticoid substitution therapy. Elevated 17-hydroxyprogesterone is tested to 
prove diagnoses such as: Antley-Bixler syndrome, congenital adrenal hyperplasia (levels 120 – 700 nmol/l), germino-
ma, hirsutism, ovarian cysts and tumours, polycystic ovary syndrome, virilization, steroids and metformin. On the other 
hand, reduced levels are typical of congenital adrenal hypoplasia, male pseudohermaphroditism (17 beta-hydroxylase 
deficiency) and Addison’s disease. The reference range depends on the method. The table shows guidance values only:
Cord blood 27 – 150 nmol/l
0 – 6 weeks 0.2 – 21 nmol/l
6 weeks – 1 year 0.2 – 9.1 nmol/l
1 – 10 years 0.1 – 2.7 nmol/l
10 – 15 years 0.6 – 8.0 nmol/l
over 15 years Males Females
1.5 – 7.2 nmol/l 0.4 – 9.4 nmol/l
Follicular phase 0.45 – 3.3 nmol/l
Luteal phase 2.1 – 9.4 nmol/l
Pregnant 6 – 36 nmol/l
Post-menopausal 0.24 – 3.9 nmol/l
Conversion factor: ng/dl x 0.03 = nmol/l
Table 14.3. The reference ranges for 17-Hydroxyprogesterone
14.2.4. ACTH, Aldosterone, Renin
The ACTH test is intended to distinguish between a primary and secondary disorder of cortisol secretion. It is a 
special test made only by a few laboratories, and requires adherence to special pre-analytical conditions (e.g. sample 
delivered on ice and fast processing). Guidance reference limits are 5–41 ng/l (1–10 pmol/l). Tests for aldosterone and 
renin, which is closely related to hypoaldosteronism, for example, are dealt with in another chapter. Guidance referen-
ce limits for aldosterone are 0.08 – 0.61 mmol/l in the prone position, and 0.19 – 0.83 mmol/l in the sitting position.
14.3. Functional Tests
14.3.1. CRH Test
Indications: Cushing’s syndrome – to distinguish between a primary (peripheral) and a secondary (central) origin. 
To determine cortisol and ACTH, 1 ml of anticoagulated blood with K2EDTA is taken (the patient must rest for at least 
2 hours before sampling). Following the determination of basal values, 100 μg (human) CRH is administered intrave-
nously. Samples should then be taken at intervals of 15, 30, 45 and 60 minutes. Caution – flush symptoms may occur! 
Constant cortisol and ACTH levels are indicative of pituitary ACTH deficiency. An excessive rise in cortisol and ACTH 
points to hypothalamic-pituitary Cushing’s syndrome. (The elevated ACTH may persist if the hypothalamic cause has 
been present for a long time.) Elevated ACTH with normal cortisol levels is indicative of an adrenal tumour.
14.3.2. ACTH (Synacthen) Stimulation Test 
This is a diagnostic test to evaluate the adrenal cortex function used for suspected cortisol production deficiency. 
The administration of exogenous ACTH stimulates the adrenal cortex. The test points to the secretory capacity of the 
adrenal cortex. Contraindications include fresh ulcerative diseases of the stomach and duodenum, decompensated 
diabetes mellitus, acute infections, acute psychosis or acute glaucoma.
Short test:
A sample of non-anticoagulated venous blood for a serum cortisol level assay is taken at 7:00 a.m. fasting, before 
drug administration (S-cortisol “before”). Then 0.25 mg of a synthetic ACTH analogue such as Synacthen inj. Novartis; 
1 vial = 0.25 mg is applied i.v. The medication is administered under medical supervision due to the risk of anaphylactic 
shock. Additional samples of non-anticoagulated blood for the serum cortisol assay are taken 1 and 2 hours after the 
administration. Evaluation: 
• An increase in S-cortisol over 690 nmol/l rules out the diagnosis of insufficiency;
• A very pronounced rise is indicative of Cushing’s syndrome due to bilateral adrenal cortex hyperplasia;
• A normal or elevated response occurs in 50% of autonomous adrenal tumour cases; the other 50% of cases 
do not show any adrenal cortex response.
Prolonged test:
A sample of non-anticoagulated venous blood for a fasting serum cortisol assay is taken at 7:00 a.m. Thereupon 1 
mg of ACTH-depot is administered intramuscularly, and additional samples of non-anticoagulated blood (2 ml) for the 
serum cortisol level assay are taken in 1, 2, 4, 8, 12 and 24 hours.
Evaluation:
• Normal response – more than 900 nmol/l (maximum in 8 hours);
• Insufficient response at all phases after stimulation is indicative of the primary form of adrenal failure;
• Insufficient or no response in the first hour, then a slow rise in cortisol level with a peak in 24 hours, is 
indicative of secondary adrenal insufficiency.
14.3.3. Metyrapone Test (Metopirone Test)
The test indicates pituitary ACTH reserve and is indicated in the case of suspected primary or secondary hypocor-
ticism. Metyrapone inhibits 11-b-hydroxylase, thereby inducing the conversion of 11-deoxycortisol into cortisol and 
other metabolites. The decrease in cortisolaemia stimulates ACTH secretion. The increased ACTH level leads to an 
increased production of 11-deoxycortisol, which cannot be metabolized further, and its level rises.
Blood for the S-cortisol assay is taken at 8 a.m. Metyrapone (Metopirone 250 mg cps Novartis) is administered at 
12 p.m.: 2 g to patients under 70 g of body weight, 2.5 g to patients from 70 to 90 kg and 3 g to patients over 90 kg. 
Sometimes it is advisable to do the test with a lower inhibition dose of 750 mg. Evaluation: Normal response – decrease 
in S-cortisol under 222 noml/l.
14.3.4. Dexamethasone Suppression Test
This is a diagnostic test of the suppressibility of the hypothalamic-pituitary-adrenal axis used for suspected hyper-
cortisolism. The test determines the ability of the hypothalamic-pituitary system to decrease ACTH, and thereby also 
cortisol secretion following an increase in the amount of circulating glucocorticoids. Contraindications are the same as 
those for the ACTH test.
Standard test: The test starts by finding baseline levels of free cortisol in a sample from three 24-hour urine col-
lections. Then 0.5 mg dexamethasone (Dexamethazon tbl, 1 tbl. = 0.5 mg) is administered orally for two days every 6 
hours, starting at 6 a.m. (daily dose 2 mg). On the second day of administration, free cortisol is tested in the 24-hour 
urine collection. The test continues with an increased dose of 2 mg every 6 hours for the next two days (daily dose 
8 mg). On the second day of this stronger blockade, free cortisol is once again tested in the 24-hour urine collection.
Evaluation:
Weaker blockade (2 mg): Free cortisol excretion drops below 60 nmol/day in healthy people. Patients with Cushing’s 
syndrome do not show any decrease.
Stronger blockade (8 mg): Urinary free cortisol drops below 50% of the baseline concentration (average from 
three baseline values) in central Cushing’s syndrome. There is no decrease in patients with an adrenocortical tumour 
producing cortisol, or with paraneoplastic Cushing’s syndrome. Insufficient suppression of increased baseline values of 
urinary free cortisol at a weaker blockade is indicative of Cushing’s sydrome, and a stronger blockade differentiates the 
central Cushing’s syndrome from the other forms.
Fast (short, overnight) test: A 2-ml sample of non-anticoagulated venous blood for the fasting serum cortisol assay 
is taken before medication at 8 a.m. At 11 p.m. 1 mg (2 tbl) dexamethasone (Dexamethazon tbl.; 1 tbl. = 0.5 mg) is 
given p.o. The tablets are given with a small quantity of food. Dexamethasone is a synthetic fluorinated glucocortico-
id with a slight mineralocorticoid effect; the strongest hypothalamic-pituitary-adrenal axis inhibition activity occurs 
if dexamethasone is administered at night. A single administration of 1 mg dexamethasone at night will sufficiently 
suppress ACTH secretion for 24 hours in most healthy people. The next day, once again at 8 a.m. fasting, 2 ml of non-
-anticoagulated venous blood for a serum cortisol level assay are taken before medication. Evaluation: S-cortisol will 
drop below 100 nmol/l in fasting healthy people in the morning. Patients with Cushing’s syndrome will have insufficient 
suppression (over 100 nmol/l).
Stronger overnight dexamethasone test: 2 ml of non-anticoagulated blood are taken for the fasting serum cortisol 
assay at 8 a.m., and 8 mg dexamethasone is given at 11 p.m. A 2-ml sample is taken for the cortisolaemia on the next 
day at 8 a.m. Evaluation: A drop in cortisolaemia under 50% of the baseline concentration will occur in patients with 
central Cushing’s syndrome. Cortisolaemia will not drop to this extent in the case of adrenocortical tumours producing 
cortisol or paraneoplastic Cushing’s syndrome.
14.3.5. Renin-Aldosterone-Orthostatic Test
Indications for this test include a differential diagnosis of idiopathic primary hyperaldosteronism due to Conn’s 
disease (trias: hypokalaemia, hypernatraemia, hypertonia), or proof of isolated hypoaldosteronism. It is not indicated 
if adrenal adenoma has been confirmed.
Test procedure: The patient rests in bed from 12 p.m., baseline aldosterone and renin values are determined in the 
prone position at 8 a.m., and the collection is repeated after 2 hours of orthostasis.
Evaluation: An increase in the aldosterone and renin levels of between 0.5 times and twice is normal.
14.3.6. Insulin Test
Hypoglycaemia is a strong stress impulse for ACTH and STH secretion. Blood for blood sugar, cortisol, ACTH and STH 
assays is taken in the morning. I.v. insulin is administered: 0.05 – 0.1 U/kg of body weight for suspected hypothalamic-
-pituitary insufficiency, 0.15 U/kg for an anticipated normal response, 0.20 – 0.30 U/kg in obese patients with Cushing’s 
syndrome. Blood is taken in 30, 60, 90 and 120 minutes. Evaluation: Blood sugar in healthy people drops under 2.2 
mmol/l and cortisol rises over 320 nmol/l, or reaches a value 1.5 times higher than the baseline value. ACTH reaches at 
least twice as high against the baseline value. Contraindications for the test include ICHS, cerebrovascular alterations, 
gestosis or epilepsy.
14.4. Hypercorticalism
An overproduction of glucocorticoids manifests itself with clinical signs known as Cushing’s syndrome. The patients 
are obese, have hypertension and a loss of muscular tissue, they may sometimes have steroid diabetes (hyperglycae-
mia), hypernatraemia and hypokalaemia. Conn’s syndrome is a consequence and sign of isolated overproduction of 
aldosterone.
The primary cause is usually an adrenal cortex adenoma or adenocarcinoma. The circadian rhythm is missing, and 
the ACTH concentration is low. Cortisol secretion is autonomous; secretion does not rise following stimulation (ACTH 
or insulin test) and does not decrease following administration of suppressants (dexamethasone).
The secondary (central) cause is adenohypophyseal adenoma with higher ACTH concentrations (Cushing’s disea-
se). The adrenal cortex reacts to functional tests as expected (stimulation, suppression). If CRH overproduction in the 
hypothalamus is the cause, the condition is referred to as hypercorticalism.
Ectopic ACTH production is relatively frequent in some tumour diseases such as small-cell or bronchogenic lung 
cancer, sometimes with concurrent ADH production. The metabolic effects of mineralocorticoids may sometimes do-
minate the clinical picture. Cortisol does not react in functional stimulation and suppression tests.
Glucocorticoid therapy (long term, high doses) leads to the development of Cushing’s syndrome, i.e. hypokalae-
mia, hyperglycaemia, etc. CRH and ACTH production is suppressed and adrenal cortex atrophy occurs. Abrupt discon-
tinuation may be life-threatening. The most efficient artificial glucocorticoids such as dexamethasone do not interfere 
with the cortisol assay.
14.5. Hypocorticalism
The cause of primary hypocorticalism is the destruction of the adrenal cortex. Conditions include autoimmune 
adrenalitis (assay for autoantibodies against steroid 21-hydroxylase) and infectious adrenalitis (tuberculosis, menin-
gococcal infection, cytomegalovirus infection, HIV and other infections). Adrenal involvement in tumour metastases 
and congenital adrenal hypoplasia (AHC, DAX gene mutation or deletion, or microdeletion syndrome connected with 
glycerolkinase and the gene for dystrophin defect – DMD) in male patients are rare. If the glucocorticoid deficiency 
is accompanied by a mineralocorticoid deficiency, adrenal insufficiency (Addison’s disease) will develop (weakness, 
hypotension, hyponatraemia, hyperkalaemia) that may precipitate an Addisonian crisis. An increase in the ACTH con-
centration is confirmatory. The cortisol level is decreased or normal. The adrenal cortex does not react to stimulation 
tests. Increased pigmentation is the consequence of increased POMC (pro-opiomelanocortin) production.
The cause of secondary hypocorticalism is usually the inability of the pituitary to produce ACTH or damage to the 
hypothalamus. These conditions occur after traumas (of the brain), bleeding, radiotherapy, hypophysectomy, neuro-
surgical interventions, if a tumour is growing from the other cells (prolactinoma), after bleeding into the pituitary fol-
lowing birth, or because of infection (tuberculosis). The ACTH level is low. The adrenal cortex reacts to the stimulation 
test with ACTH, but not to CRH or hypoglycaemia (insulin test). Concomitant deficient production of other adenohy-
pophyseal hormones is common.
Adrenal insufficiency may also be caused by a long-term glucocorticoid therapy, which may lead to adrenal cortex 
atrophy. Abrupt discontinuation of therapy (or a dramatic dose reduction) exposes patients to risk of adrenal crisis.
Congenital adrenal hyperplasia (CAH) is a group of genetic diseases characterized by a hyperplastic growth of the 
adrenal cortex (influence of ACTH) and an impaired synthesis of adrenocortical hormones as a result of enzymatic de-
fects. Clinical signs are the consequence of deficient cortisol, or aldosterone in some cases, and excessive precursors 
synthesized prior to the defective enzymatic reaction. This is the most frequent autosomal recessive genetic disease 
(1:100) with a wide spectrum of phenotype signs, from life-threatening salt disorders (hyponatraemia, hyperkalaemia) 
with severe external genitalia malformations in newborns, to less conspicuous forms of hirsutism or virilization at an 
older age.
Figure 14.2. A newborn baby with CAH
Cornelius
27 June 1670 - 19 July 1670
“On 27 June 1670, a baby was born in Delft. Due to the malformation of the sex organs, the parents did not want 
to decide on a girl’s or boy’s name without expert advice. Experts concluded that it was a boy from the apparently 
perfect penis and a formation very similar to a scrotum. Therefore, the child was named Cornelius. Overcome by a 
serious disease, Cornelius departed this life on 19 July. The autopsy revealed, however, that Cornelius was a girl with 
an oversized clitoris.”
Regnier de Graaf (1672):
De mulierum organis generationi inservientibus tractatus novus
Laboratory findings of the severest forms are dominated by high ACTH, renin and 17-hydroxyprogesterone levels, 
hyponatraemia and hyperkalaemia.
Neonatal screening for CAH is based on the 17-hydroxyprogesterone assay on a dried blood spot. It is important 
for early corticoid substitution therapy. A prenatal diagnosis enables the use of intrauterine treatment that prevents, in 
particular, female foetus virilization. The commonest cause of CAH is mutations in the gene for steroid 21-hydroxylase 
(about 90% of cases).
Another cause of CAH (about 5%) is a deficiency of the mitochondrial enzyme 11-beta-hydroxylase. A 17-alpha-
-hydroxylase/17,20-lyase deficiency is special (it is one gene, one enzyme, but two enzyme activities dependent on 
post-translational modification). This enzyme deficiency is usually present in the adrenal gland and gonads and mani-
fests itself in CAH, hypertension, Biglieri syndrome in females, and New syndrome in males. Isolated 17,20-lyase defici-
ency has been observed in rare cases. Another enzyme the deficiency of which causes classical forms of CAH with salt 
losses is 3-beta-hydroxysteroid dehydrogenase. A final cause of CAH can be defects in the StAR protein (steroidogenic 
acute regulatory protein) co-responsible for the mitochondrial conversion of cholesterol to pregnenolone (this disease 
is sometimes referred to as lipoid congenital adrenal hyperplasia).
CHAPTER 15
15. Disorders of Acid-Base Balance
15.1. Metabolic and Respiratory Disorders of Acid-Base Balance
Authors: prof. MUDr. Jaroslav Racek, DrSc., MUDr. Daniel Rajdl, Ph.D.
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Acid-base balance (ABB) disorders are divided into two groups, depending on their cause: Metabolic and respira-
tory; acidosis and alkalosis is distinguished based on whether acids or bases are prevalent. From the above it follows 
that four main groups of ABB disorders can be distinguished:
• Metabolic acidosis (MAc);
• Metabolic alkalosis (MAI);
• Respiratory acidosis (RAc);
• Respiratory alkalosis (RAI).
The next paragraphs examine these basic disorders, taking note of their causes, clinical signs, laboratory alterations 
and means of compensation. Methods for their treatment will be mentioned in brief.
15.1.1. Metabolic Acid-Base Disorders
Metabolic acid-base disorders are characterized in laboratory results by changes in hydrogen carbonate concent-
ration. They are the commonest of all acid-base balance disorders.
15.1.1.1. Metabolic Acidosis
Metabolic acidosis (MAc) can be due to the accumulation of acidic metabolites or loss of hydrogen carbonates.
The clinical presentation of MAc is typified by deep acidotic Kussmaul breathing caused by stimulation of the re-
spiratory centre by a high concentration of hydrogen ions. The drop in cerebrospinal fluid pH is manifested in heada-
ches, vision disturbances, disorientation, somnolence or even coma. GIT manifestations take the form of nausea and 
vomiting.
In laboratory assays, MAc is manifested by negative BE value, reduced HCO
3
-, a drop in pH and later, as a result of 
lung compensation of the defect, by a drop in paCO2. The low paCO2 leads to mental state alterations or even coma. Uri-
ne is usually acidic, and the level of excretion of phosphates and ammonium ions is higher. HCO
3
- excretion decreases.
Metabolic Acidosis with Elevated AG Value
This type of MAc may be due to an accumulation of acidic endogenous metabolites or an intake of acids or substan-
ces transformed into acids in the body. This occurs in:
• Ketoacidosis found in decompensated diabetics, during fasting, in alcoholics, following prolonged physical 
strain;
• Lactate (lactic) acidosis due to, for example, insufficient oxygenation of the blood and perfusion of tissues 
when lactic acid accumulates in the body; similarly as in the case of a disorder affecting the elimination of 
this relatively strong acid – see below;
• Renal acidosis in patients with renal failure when endogenous anions (phosphates and sulphates) accu-
mulate;
• Accumulation of exogenous anions in intoxications where the toxic substance is an acid itself (e.g. salicylic 
acid) or it is metabolized to an acidic catabolite (lactate as a product of ethanol metabolism, glyoxylic and 
oxalic acids produced from ethylene glycol, formic acid from methanol, etc.);
• Inadequate parenteral nutrition, for example, following the fast administration of sorbitol, xylitol, fructose 
or protein hydrolysates; this is the reason that carbohydrates other than glucose are practically not used 
today in parenteral nutrition.
Lactic acidosis is probably the most frequent of the disorders listed above. It can be divided into types A and B 
based on the cause.
Type A lactic acidosis is connected with insufficient blood oxygenation and tissue hypoxia – hypoxic, anaemic, 
stagnant or histotoxic hypoxia.
Hypoxic hypoxia may be caused by low pO
2
 in the inhaled air, hypoventilation, pulmonary diseases connected with 
a limitation of the respiratory area, alveo - capillary blocks, etc.
Anaemic hypoxia is caused by a red blood cell or haemoglobin defect, or anaemia.
The cause of stagnant hypoxia can be the failure of the heart’s function as a pump, thrombosis, sepsis, a decrease 
in the circulating blood volume and even shock.
The cause of histotoxic hypoxia is usually damage to enzyme cell systems by radiation, heat, infection, hypoxia, 
carbon monoxide or cyanide poisoning, etc.
Type B lactic acidosis is not accompanied by tissue hypoxia. It is caused by impaired lactate elimination in hepatic 
and renal diseases, leukaemia, oral antidiabetic treatment (biguanide type – metformin), the fast administration of 
fructose, sorbitol or xylitol, in congenital metabolism disorders such as type I glycogenosis, methylmalonic aciduria etc. 
Lactate elimination disorder may also be due to insufficient supply of thiamine (vitamin B1) which is needed for the 
oxidative decarboxylation of α-keto acids (and pyruvic acid as well). In reality, however, both lactic acidosis types are 
often combined – for example, a rise in the lactate concentration from hypoxia in a patient in shock is potentiated by a 
lactate elimination disorder in the hypoxic liver.
A useful parameter for evaluating hypoxia in a certain organ is the determination of the difference in arterial and 
venous lactate levels. And finally, another option for hypoxia evaluation is establishing the lactate/pyruvate ratio, 
which varies with the supply of oxygen to tissues. Since glycolysis takes place in the cytoplasm, it is sometimes recom-
mended to use a similar β-hydroxybutyrate/acetoacetate ratio expressing the redox processes in mitochondria.
Lactic acidosis can also be seen physiologically when muscles work with an “oxygen debt”. This occurs during all 
sprinting-type physical activities, whereas extended physical exertion (endurance) must be performed in an aerobic 
mode.
The degree of physical training can be evaluated from the anaerobic threshold. Bicycle ergometrics compprises a 
gradual increase of physical exertion while the lactate level is monitored at regular intervals. Although the level incre-
ases slightly at first, a turning point then occurs after which the lactate concentration starts growing dramatically; the 
value of exertion at the turning point is called the anaerobic threshold (Figure 1).
Figure 15.1. Determination of the anaerobic threshold
The body is unable to do any more intensive exercise in the aerobic mode. Regular training can move the anaerobic 
threshold up to higher values – an individual can achieve better performance aerobically. This is important not only for 
sportspeople but also in patients after myocardial infarction. It is true, however, that the ability to cope with strain in 
the aerobic or anaerobic mode is to some degree innate, and is given by the ratio of white (anaerobic) to red (aerobic) 
muscle fibres.
Metabolic acidosis with normal AG value
This is caused by excessive loss of hydrogen carbonates. Such losses occur in:
• Severe diarrhoeas, losses of intestine content through GIT drains and fistulas distal to the duodenum;
• Hypoaldosteronism;
• Ureterosigmoidostomy (intestinal mucosa absorbs Cl-);
• Type 1 (distal) renal tubular acidoses, where distal tubule cells are not able to secrete H+);
• After NH
4
Cl and arginine hydrochloride administration in treatment for MAI;
• After acetazolamide (carbonic anhydrase inhibitor) administration;
• In dilutional acidosis with a relative loss of hydrogen carbonates following infusions lacking the buffer 
system (isotonic NaCl solution); the concentration of the bicarbonate buffer’s acid component is normal.
Metabolic acidosis is compensated by hyperventilation leading to a decrease in paCO2, and therefore an increase 
in pH. The maximum degree of compensation is reached 12 – 24 hrs from the occurrence of the disorder, and if the 
disorder is removed, the compensation persists for the same time. The compensation effect depends on respiratory 
apparatus efficiency: while it may be very effective in a young, otherwise healthy person, the effect will be limited in a 
person with severe emphysema.
The guiding principle when treating MAc (as well as other ABB disturbances) is that the underlying disease should 
be treated first: hypoxia by oxygen therapy, diabetic ketoacidosis by insulin, fasting ketoacidosis by glucose supply, etc. 
Alkali treatment should be used only in exceptional cases; the objective is to adjust the pH not the BE value.
Usually the 8.4% NaHCO
3
 or 10% KHCO
3 
solutions for coincident hypokalaemia are used; both solutions contain 1 
mmol HCO
3
- in 1 mL. Doses do not usually exceed 50 mL (20 mL of the solution are often sufficient). Administration of 
the NaHCO
3
 solution has its limitations too. The NaHCO
3
 solution is suitable only for non-hypoxic types of metabolic 
acidosis (uraemia, diabetes, diarrhoea). In lactic acidoses, it leads to an overproduction of CO
2 
in the ECF with the deve-
lopment of respiratory acidosis; at the same time, as a result of proton accumulation in cells, cell metabolism becomes 
impaired (further decrease in intracellular pH).
The sodium lactate solution is suitable only for acidoses with a good liver function, without the risk of lactic acid 
retention.
Organic acids (lactic acid, acetoacetic acid, β-hydroxybutyric acid) are metabolized to bicarbonate when the cause 
of their accumulation has been removed. Prior administration of NaHCO
3
 could therefore lead to a shift in blood pH to 
the alkaline side with all the disadvantages of alkalaemia.
Many unexplained lactic acidoses are caused by the depletion of thiamine (vitamin B
1
), needed for oxidative de-
carboxylation and also for aerobic glycolysis and the proper function of the Krebs cycle. This may occur in patients on 
long-term parenteral nutrition. The disturbance will quickly disappear following administration of vitamin B
1
.
15.1.1.2. Metabolic Alkalosis
This serious disorder is divided into two groups depending on the cause and method of treatment.
Metabolic alkalosis responding to chloride treatment
This type of MAI is caused by excessive loss of chlorides, either in the acidic gastric juice or urine. Such losses occur 
in:
• Loss of gastric juice;
• Prolonged vomiting (considerable amounts of Na+ and K+ are lost);
• Protracted diarrhoeas with a loss of chlorides (chloridorrhoea);
• Overdose of alkaligenous diuretics (furosemide); Cl- losses are greater than Na+ losses; in addition, a consi-
derable amount of K+ is excreted in the urine.
Figure 15.2. The pathogenesis of this MAI type involves a lack of chlorides in the proximal renal tubule, where they are 
normally absorbed together with Na+. Consequently, most Na+ ions come to the distal tubule where they are exchanged for 
K+ and H+: Characteristic for this type is a very low concentration of chlorides in the urine (U-Cl- < 20 mmol/L).
Metabolic alkalosis resistant to chloride treatment
Causes of this condition are diverse and may include:
• Primary hyperaldosteronism (Conn’s syndrome);
• Secondary hyperaldosteronism (in nephrotic syndrome, cardiac insufficiency, chronic hepatopathy or renal 
artery stenosis);
• Prolonged administration of corticoids with manifested mineralocorticoid effect;
• Excessive administration of antacids such as NaHCO
3
;
• Catabolism with K+ discharge from cells in exchange for H+ and Na+; the result is ICF acidosis and ECF alka-
losis;
• Fast correction of ketoacidosis when ketone bodies are metabolized to hydrogen carbonates;
• Dehydration with a concentration of the internal environment, a relative increase in HCO
3
- and secondary 
hyperaldosteronism (concentration alkalosis).
Na+ is absorbed in the distal renal tubule and excessive amounts of H+ and K+ are excreted in hyperaldosteronism, 
which is the commonest cause of this type of MAI; HCO
3
- is retained at the same time. The chloride concentration in 
urine, however, is usually higher than 20 mmol/L in this case.
In alkalaemia, the concentration of ionized calcium in the plasma decreases and neuromuscular irritability increa-
ses, while the tendency to spasms is increased. The drop in K+ in the plasma may lead to heart rhythm disorders. The 
release of oxygen from its bond to haemoglobin worsens and the haemoglobin dissociation curve shifts to the left. 
Additional signs are anoxia, vomiting, subileus, muscular weakness, paresthaesia and confusion.
Acidic urine reaction sometimes occurs in MAI – this is referred to as paradoxical aciduria. This is caused by hypo-
kalaemia, which often occurs with metabolic alkalosis: due to shortage of K+, Na+ has to be replaced with H+ in the distal 
renal tubule. The result is acidic urine formation. Since HCO
3
- ions are absorbed along with Na+, metabolic alkalosis is 
intensified. Circulus vitiosus should be interrupted by the supply of K+ (usually in the form of KCl, which also acidifies 
the internal environment).
The respiratory compensation of metabolic alkalosis (hypoventilation) is imperfect, and leads not only to hypercap-
nia but also to hypoxaemia. A drop in paO2 under 8.0 kPa is registered by chemoreceptors with subsequent stimulation 
of the respiratory centre. This mechanism does not allow paCO2 to rise over 8.0 kPa even if the disorder lasts for several 
days. An exception is those conditions when the last stimulus provoking escalation of the respiratory centre function is 
removed by increased paO2 during oxygen therapy.
While metabolic acidosis (due to fasting, physical strain, etc.) has been common in the course of human evoluti-
on, and humans can tolerate and compensate it quite well, metabolic alkalosis is compensated and thereby tolerated 
much worse; this underlines the need to distinguish the risk of alkalosis in time.
In laboratory results, MAI will manifest itself by an increase in HCO
3
-, BE and pH, and a compensatory increase in 
paCO2. Hypokalaemia and hypochloridaemia are concurrent; the ratio of ionized calcium to the total is reduced. The 
Cl- concentration in the urine varies depending on the cause of MAI (see above). As mentioned before, urine may be 
acidic in paradoxical aciduria.
Treatment for MAI depends on the type of disorder. Arginine hydrochloride is administered for MAI due to chlori-
de loss; NaCl and KCl solutions have lower acidification ability. Another option is to administer 0.1 mol/L hydrochloric 
acid using a slow infusion into the central vein. This type of MAI should not be considered cured until normalization of 
chloride losses in the urine occurs. When treating the second type of MAI, the objective is to affect the primary cause; 
lacking potassium is usually replenished in the form of KCl.
Threatening disorders may be optionally treated by haemodialysis, a fast and effective method for adjusting the 
metabolic ABB component.
When treating metabolic alkalosis and other acid-base disorders one should consider the dependence of K+ con-
centration in the extracellular fluid on the pH, and avoid violent kalaemia fluctuations with potential cardiac arrhy-
thmia as a result of changes in pH.
15.1.2. Respiratory Acid-Base Disorders
These disorders are characterized by primary changes in paCO2.
15.1.2.1. Respiratory Acidosis
Respiratory acidosis (RAc) is relatively rare in patients receiving intensive care, unless the acute disease or injury is 
preceded by chronic pulmonary disease.
Causes of respiratory acidosis may include:
• Central respiratory depression (injuries, inflammations, tumours in the region of the respiratory centre or 
as an effect of tranquilizers or hypnotic drugs, sleep apnoea syndrome, etc.);
• Ventilation disorder (chronic obstructive pulmonary disease, pulmonary oedema, extensive pneumonia, 
pneumothorax, extensive hydrothorax, status asthmaticus, chest deformities, chest injuries with breathing 
hampered by pain, extreme obesity [Pickwickian syndrome], etc.);
• Cardiac and respiratory arrest where RAc is combined with metabolic lactic acidosis.
Laboratory results will show RAc as an increase in paCO2 and a decrease in pH; decreased paO2 with increased lacta-
te concentration are indicative of RAc combined with MAc. Increased paCO2 (hypercapnia) normally forces the respira-
tory centre to increase respiratory activity. If paCO2 exceeds 8.0 kPa, the respiratory centre receptivity to this stimulus 
decreases, and low paO2 (hypoxaemia) remains the only stimulus. K
+ and Ca2+ concentrations in the blood increase. The 
haemoglobin dissociation curve shifts to the right. Vasodilatation occurs in the peripheries.
Figure 15.3. RAc compensation takes place in the kidneys. The exchange of Na+ for surplus H+ is accelerated in the tu-
bules. H+ and Cl- losses increase, while Na+ is retained. Hydrogen carbonates are also retained and their concentration in 
the blood increases.
Clinical signs of RAc include neurological symptoms of acidaemia and cerebral vasodilatation – headache, tremor, 
spasms, motor skills disorders, psychoses, sleep disorders, somnolence, fatigue or even coma.
The therapy for acute conditions of RAc consists in the removal of the cause in order to improve alveolar ventilati-
on. Medication can also be used (bronchodilatants, sympathomimetics). When using oxygen therapy for chronic condi-
tions, special caution should be exercised to ensure against removing the last stimulus, hypoxaemia, for the respiratory 
centre through a rapid increase in paO2. Chronic disorders are compensated by an increased concentration of hydrogen 
carbonates; if hypercapnia is removed by controlled ventilation, renal compensation will persist for many days, which 
would put the patient at risk of alkalaemia with all its adverse effects. Therefore, the rate of decrease in paCO2 should 
not exceed 0.3 – 0.7 kPa/hr during controlled ventilation.
Respiratory Insufficiency
The condition when the lungs are unable to ensure sufficient exchange of oxygen and carbon dioxide between 
atmospheric air and blood is referred to as respiratory insufficiency. In terms of laboratory results, it is characterized by 
pathological levels of blood gases (paO2 and paCO2).
A fall in paO2 and haemoglobin saturation with oxygen is typical of partial respiratory insufficiency (hypoxaemic 
failure). Initially it can be only found following exercise, later even in resting patients.
The laboratory picture of global respiratory insufficiency (hypercapnic failure) also shows a rise in paCO2, i.e. respi-
ratory acidosis. The later onset of hypercapnia is caused by the properties of carbon dioxide, which diffuses 30 times 
faster than oxygen.
Causes of respiratory insufficiency may be at the level of the respiratory centre, lungs and airways, or it involves a 
chest wall disease with the same causes as those of respiratory acidosis.
Hypoxaemia supports anaerobic tissue metabolism with lactate accumulation and the development of metabolic 
lactic acidosis.
The clinical presentation of respiratory insufficiency is given by the underlying disease and the combined effect of 
hypoxaemia, hypercapnia and RAc. A drop in paO2 under 6.7 kPa may lead to a manifestation of latent perfusion disor-
ders such as angina pectoris, intermittent claudication, transient ischemic attacks in the CNS, etc. The patient suffers 
from headaches, depression, anxiety, somnolence or, conversely, motor restlessness. Hypercapnia causes vasodilatati-
on and increased permeability of cerebral veins, short naps, insomnia at night, and somnolence during the day.
15.1.2.2. Respiratory Alkalosis
Respiratory alkalosis (RAl) develops in conditions accompanied by respiratory centre irritation with consequent 
hyperventilation. Respiratory centre irritation occurs in the following situations:
• Voluntary hyperventilation;
• Stress, and in hysterical patients;
• Respiratory centre disorders (ictus, trauma, tumour, inflammation);
• Metabolic disorders (fever, hepatic encephalopathy, effect of drugs – salicylates);
• Inappropriately set controlled ventilation parameters; a slight RAl may be deliberately induced in cont-
rolled ventilation to prevent cerebral oedema (a decrease in paCO2 causes cerebral vasoconstriction with 
decreased cerebral blood flow).
Respiratory centre irritation may also be caused by local acidosis in anaemia or cardiac failure, for example.
RAl is manifested in laboratory results as a fall in paCO2 and a rise in pH. Compensation takes place in the kidneys: 
decreased exchange of Na+ for H+ in renal tubules, hydrogen carbonates are lost, increased H+ and Cl- levels in the blood 
(Cl- ions replace the missing hydrogen carbonates in the anion column).
The clinical presentation of RAl is characterized by paraesthaesia, sweating, dizziness, weakness, fatigue and disor-
ders of consciousness (cerebral perfusion and function are considerably limited at paCO2 of 2.7 – 3.4 kPa). A decrease 
in the ratio of ionized calcium to the total calcium in plasma may occur with proneness to tetany.
The treatment for RAl should once again focus on the cause of the disorders. In psychogenic RAl, the patient should 
be sedated and the dead space in the lungs extended with a tube or bag so that the patient inhales part of the already 
exhaled carbon dioxide. The objective of controlled ventilation is to increase paCO2 gradually up to an optimum value 
of about 4.7 kPa.
Respiratory alkalosis may be the first sign of hypoxaemia (in latent cardiac failure, successive pulmonary artery 
embolism, in patients with severe anaemia, etc.).
15.1.3. Acid-Base Compensation (Diagnostic) Diagram
The acid-base compensation diagram allows for a fast, approximate evaluation of the acid-base balance status, and 
a classification of the disorder depending on paCO2 and BE. In addition, the diagram shows the estimated development 
of the disorder during compensation.
This only provides an initial outline. Patient history, clinical signs and the chronological characteristics of the di-
sease, the results of assays for basic minerals and other analytes in the serum or urine (lactate, ketone bodies) and 
other information, not only the results of laboratory examinations, must be known in order to establish an accurate 
diagnosis.
Figure 4 shows the acid-base compensation diagram. As is evident from the diagram, we can recognize within it 
not only acute and compensated acid-base disorders, but also mixed disorders; one exception to the latter group is 
combined MAc and MAl.
The involvement of metabolic disorders is usually assessed on the basis of the anion gap (AG). It can be calculated 
accordint to the formula: AG = (Na+ + K+) – (Cl- + HCO
3
-). AG usually ranges from 10 to 20 mmol/L, 15 mmol/L on average. 
Elevated AG values are usually in MAc due to the accumulation of anions other than chlorides, and reduced AG values 
in MAl are due to chloride losses.
Stewart and Fencl’s methods may also be used to assess MAc and MAl combinations. This method uses the fact 
that plasma cation and anion columns must be of equal height. These authors distinguish strong ions such as Na+, K+, 
Ca2+ and Mg2+ cations and the Cl- anion. Their difference is referred to as SID (strong ion difference) = (Na+ + K+ + Ca2+ 
+ Mg2+) – Cl-. Also involved are weak anions such as albumin and inorganic phosphate, and “unmeasured” anions such 
as lactate, β-hydroxybutyrate, anions produced by alcohol oxidation in intoxication, and, finally, bicarbonate, which 
plays a special role: it may be formed from CO
2
 in the body, or, in contrast, be decomposed and replaced with stronger 
acid anions, hence its being regarded as a dependent variable. It is the evaluation of this ion ratio that enables us to 
estimate the role of each metabolic disorder in acid-base alterations.
Figure 15.4. Acid-base compensation (diagnostic) diagram; the green area with waves shows the range of physiologi-
cal values; indexes in disorder abbreviations: a = acute, s = stabilized (maximum compensation)
15.1.4. Acid-Base Balance (and Blood Gases) Measurement
15.1.4.1. Collection of Blood 
Arterial blood, usually taken from a. brachialis or a. radialis, is best suited for partial blood gas pressure determi-
nation. Collection is made using a syringe with a plunger (Figure 5) or a special capillary collection system filled by the 
free flow of blood until the system is completely full.
Figure 15.5. Arterial blood collection for blood gas assay
For repeated sampling or acid-base level determination, arterialized blood is usually obtained from a hyperae-
mized earlobe, i.e. after it has been thoroughly warmed (heated in hot water or using hyperaemizing ointment). This 
will accelerate blood flow through the capillaries and the blood composition will be similar to that of arterial blood. In 
this case, blood is taken into a glass capillary tube, which is sealed with a plastic cap when full. Fingertip blood is less 
suitable. This is due to insufficient perfusion of peripheral parts of the body where pO
2
 is 2 – 3 kPa lower than pO
2
 in 
arterial blood. Blood taken from the earlobe is not suitable during blood circulation centralization or oxygen inhalation 
treatment.
All collection syringes or capillary tubes contain heparin as an anticoagulant, which is the reason blood should 
be thoroughly mixed after collection. Since many analyzers measure other analytes (minerals, lactate, glucose, urea, 
creatinine, etc.) in addition to pH and partial blood gas pressure, it is advisable to use collection syringes containing 
lithium salt of heparin which is saturated with calcium to avoid binding calcium and magnesium from the blood. A 
metal agitator (wire) is inserted into glass collection capillary tubes before sealing, and blood is mixed using a magnet 
applied to the outer surface of the capillary. Care should be taken to always ensure anaerobic collection. Blood must 
not flow down the finger, and no air bubble must be entrained in the syringe or capillary tube. Air would completely 
impair the oxygen assay; an air bubble is known to increase pO
2
 by up to several kPa! The syringe with the blood must 
be hermetically sealed.
Following collection, the syringe or capillary tube should be placed horizontally and the analysis should be made 
as soon as possible. Samples should be transported on melting ice, which prevents any decrease in pO
2
 that would 
otherwise occur due to metabolic processes in the collected blood (oxygen is consumed by white blood cells and 
thrombocytes, not red blood cells). The test should be made within 2 hours of collection, even when the blood is trea-
ted as described above.
15.1.4.2.  Acid-Base Balance and Blood Gases Measurement Procedure
Analyzers take measurements of acid-base balance and blood gases in a cell heated to 37°C; measured in this way 
are pH, paCO2 and always paO2. In addition to pH and partial blood gas pressure, these analyzers also offer all other 
related calculations, such as HCO3- and BE, that characterize the acid-base balance and oxygen metabolism. These 
instruments also measure haemoglobin concentration, and many of them measure oxygen saturation using the direct 
method (Figure 6) as well as the content of other haemoglobin derivatives. The instruments are sold by many manu-
facturers such as Radiometer, Roche, Instrumentation Laboratory, Nova Biomedical, Siemens, etc.
Special instruments measuring blood gases, acid-base balance and other acute parameters are designed to enable 
their use right at the patient’s bedside in intensive care units, departments of anaesthesiology and resuscitation, and 
operating theatres. Their small size ensures portability and ease of operation allows assays to be performed by trained 
clinical personnel. Examples: Instrumentation Laboratory, Roche, Radiometer or Abbott analyzers.
Figure 15.6. Measurement of blood gases, acid-base balance and some other analytes on the analyzer
15.2. Combined Metabolic Acid-Base Balance Disorders
Summary:
Combined acid-base balance disorders are caused by a combination of several simple disorders. Examples of com-
mon combinations:
• Vomiting (loss of chlorides → metabolic alkalosis) + fasting (accumulation of ketone bodies → metabolic 
acidosis)
• Diabetic ketoacidosis + dehydration (poor tissue perfusion → lactate formation → metabolic acidosis)
• Salicylate intoxication (organic acid → metabolic acidosis + respiratory centre irritation by salicylate → 
respiratory alkalosis)
• Respiratory insufficiency with hypercapnia (e.g. respiratory acidosis in COPD - Chronic obstructive pulmo-
nary disease) is also connected with hypoxia and lactic acidosis
The treatment for combined disorders focuses on removing the cause (all of the causes if there are more than one); 
the target laboratory parameter is pH (not BE).
If two or more simple disorders are present at the same time, the condition is referred to as a combined (mixed) 
acid-base balance disorder. The disorders either develop independently of each other, or one disorder conditions the 
other, which, however, never develops in order to compensate the former.
The disorders may counteract one another (a combination of acidosis and alkalosis), so the resulting pH does not 
deviate much from the norm and blood pH and other ABB parameters may even be in the physiological range. In other 
cases, both disorders shift the pH value in the same direction and potentiate each other. The paragraphs below descri-
be some examples of combined disorders.
15.2.1. Combination of Counteracting Disorders
15.2.1.1. Combined MAc and MAl
The patient vomits and develops hypochloraemic MAl. Since the patient is not taking in any food, another disorder, 
metabolic ketoacidosis, gradually develops as a result of fasting. One disorder may cancel out the other, so acid-base 
assays do not show any pathological deviation. In such instance it is very important to examine the basic ion concent-
ration in the serum (Figure 16.1).
The first column represents anions in healthy individual’s serum. The second column shows changes caused only by 
the loss of chlorides through vomiting. In the third column accumulating ketone bodies (included within unmeasured 
anions) will cause a decrease in HCO
3
- concentration to the normal level. The necessity to consider patient history and 
the clinical presentation of the disease is beyond dispute.
Another example of a MAc and MAl combination is a patient with uraemia (renal MAc) who vomits repeatedly 
(hypochloraemic MAl is developing).
Figure 15.7. The development of a combined acid-base balance disorder with concurrent vomiting and fasting as 
shown by serum anions; figures show ion concentration in mmol/l. Lost chlorides are replaced with hydrogen carbonates 
during vomiting (and there will be no change in the anion gap). An increase in ketone bodies (organic acids) during fas-
ting leads to a rise in unmeasured anions (and the anion gap) – refer to the preparation for the relevant calculations.
15.2.1.2. Combined MAc and RAl
In salicylate intoxication, the presence of relatively strong salicylic acid in the blood will induce MAc at first. As soon 
as the acid crosses the blood-brain barrier, RAl will develop as a result of respiratory centre irritation.
15.2.2. Combination of Disorders Acting in the Same Direction
15.2.2.1. Combination of Two Different MAcs
Example: A decompensated diabetic with ketoacidosis and hyperglycaemia; this will cause osmotic diuresis with 
polyuria and dehydration. Hypovolaemia will lead to tissue hypoxia and another MAc (this time lactic MAc) will deve-
lop.
15.2.2.2. Combined RAc and MAc
A typical example is the situation occurring in a patient with severe global respiratory insufficiency or even with 
cardiac and respiratory arrest. Carbon dioxide accumulates in the body (RAc) and tissues demanding oxygen produce a 
large amount of lactate (MAc). The result is a dramatic decrease in the internal environment pH.
Additional examples of the RAc and MAc combination, developing from a compensated simple disorder, are shown 
in the diagram in Figure 15.8.
Patient A is a diabetic with acute developing metabolic ketoacidosis (Position A
1
). As the disorder has lasted for 
some time, it is compensated by hyperventilation, at first partially (A
2
), later in full (A
3
). Subsequently, the condition 
was complicated by respiratory muscle fatigue, which not only prevented pulmonary compensation, but also led to the 
development of respiratory acidosis (A
4
).
The second patient B suffers from respiratory acidosis, at first acute (B
1
), later partially (B
2
) and fully compensated 
(B
3
) by renal function. Extensive pneumonia has led to further worsening of gas exchange in the lungs with a further 
increase in hypercapnia and hypoxaemia, resulting in hypoxic lactic MAc (B
4
).
Figure 15.8. The development of a combined disorder from the primary simple compensated disorder (see text for de-
tails); a = acute, s = stabilized.
15.2.3. Combination of Multiple Disorders
Perhaps the best example of the whole range of potential disorders is a patient with severe hepatic disease. The 
following acid-base disorders may occur in such patient:
• Lactic MAc as a result of impaired lactate elimination in the liver;
• Metabolic alkalosis in hypoalbuminaemia (a decrease in the anion column is compensated by a rise in 
hydrogen carbonate concentration); decreased oncotic pressure due to hypoalbuminaemia may lead to 
reduced blood stream with overproduction of renin and subsequently aldosterone, which supports the 
development of MAl;
• Respiratory alkalosis is the result of respiratory centre irritation by accumulating toxic substances;
• If the hepatic failure is complicated by hepato-renal syndrome, renal MAc will develop;
• Additional disorders may be induced by pharmacotherapy with diuretics (e.g. hypochloraemic metabolic 
alkalosis due to furosemide administration);
• Alcoholic ketoacidosis also exists – this occurs mainly in alcoholics or following a one-time ingestion of a 
large amount of ethanol. It is caused by a combination of fasting (increased elimination of fatty acids and 
formation of ketone bodies), dehydration from vomiting (reduced excretion of ketone bodies through the 
kidneys), and the metabolic effects of ethanol (mainly an increase in the NADH + H+/NAD+ ratio and the 
resulting decrease in gluconeogenesis and production of ketone bodies with prevalent β-hydroxybutyrate 
– undetectable by urine dip sticks).
15.2.4. Summary of Mixed Acid-Base Disorder Diagnostics
A simplified procedure that offers the fastest diagnosis of acid-base disorder is as follows:
1. Clinical approach – detailed patient history and physical examination often provide sufficient informati-
on for correct diagnosis. For example, information about vomiting, diarrhoea, polyuria, exposure to toxic 
noxa, alcoholism, use of diuretics, concomitant diseases or Kussmaul breathing, acetone breath or signs of 
cardiac failure can lead us to a correct diagnosis very fast.
2. Compensation (diagnostic) diagram – see Figures 2 and 3. A good tool since it allows us to easily identify 
the development of a disorder over time (compensation, correction), to differentiate the respiratory and 
metabolic components and to estimate therapeutic doses. The diagram does not work when used for 
mixed disorders (counteracting disorders in particular), nor does it allow the cause of the disorder to be 
revealed and the zone of compensated MAl is too broad (due to the limitation of hypoventilation com-
pensation by hypoxia).
3. Auxiliary calculations – based on the model of electroneutrality. Corrected chloride concentration and the 
anion gap (or unmeasured anions for greater precision) are particularly useful. The corrected chloride con-
centration helps reveal any effect of the change of chlorides on the acid-base balance, the anion gap helps 
in the case of increased production of acids (mainly in poisonings – methanol, ethylene glycol, ethanol, 
salicylates, less in lactic acidosis and ketoacidosis – the clinical picture is quite characteristic here).
15.2.5. Notes on Acid-Base Disorder Treatment
Treatment for acid-base disorders should always be based on patient history and the clinical presentation of the di-
sease. The objective is to remove or mitigate the root cause of the disease (vomiting in hypochloraemic MAl, tissue oxy-
genation disorders in lactic MAc, bronchopneumonia in RAc, diabetic decompensation in diabetic ketoacidosis, etc.).
If acidifying or alkalizing solutions are administered to treat for metabolic acid-base disorders, the aim is to reach 
the target pH; this is 7.2 in acidoses and 7.4 in alkaloses. Adjusting the BE value to zero is not advisable and will not 
normalize pH, which should be the ultimate goal of the treatment.
Care should be taken during infusion correction of metabolic acid-base disorders, in particular compensated acido-
ses or mixed disturbances with acidosis and alkalosis. Most disorders will resolve spontaneously if the underlying cause 
is eliminated. In any case, persistence of compensatory mechanisms following elimination of the cause of disorder 
has to be taken into account in compensated disorders. The same certainly holds true for compensated respiratory 
disorders, where renal compensation persists even for several days. The principle of concurrent treatment for both 
disorders must be adhered to in mixed disorders so that the other one does not become prevalent. Figure 3 shows 
several examples of inappropriate approach.
Figure 15.9. Examples of inappropriate treatment for compensated and combined acid-base balance disorders, leading 
to dangerous alkalaemia.
Patient A is a diabetic in ketoacidosis (A
1
), which is gradually compensated by hyperventilation (A
2
, A
3
). If the pri-
mary disorder, MAc, is eliminated by insulin administration, persisting hyperventilation will induce severe alkalaemia 
in the patient, albeit with BE = 0 (A
4
).
Patient B has chronic respiratory acidosis fully compensated by renal function (B
1
). If normocapnia is reached in 
the patient by controlled ventilation, persisting renal compensation of the respiratory disorder will once again induce 
alkalaemia (B
2
).
Position C
1
 represents a patient with hypochloraemic MAl (vomiting) combined with metabolic ketoacidosis 
(fasting). If only MAc is eliminated, for example by glucose infusion, this would lead to a shift back to the alkalaemia 
region (C
2
). Therefore, both disorders must be treated at the same time in combined disorders, i.e. to supply missing 
chlorides in the form of an isotonic NaCl solution infusion, for example, in addition to glucose.
In all cases mentioned above, the patients were at risk of alkalaemia, with all its adverse effects such as:
• Hypokalaemia;
• Decrease in ionized calcium and magnesium concentration with proneness to tetany;
• Oxyhaemoglobin dissociation curve shift to the left with decreased release of oxygen from the bond to 
haemoglobin;
• Increased toxicity of some drugs such as digoxin.
CHAPTER 16
16. Importance of Oxygen Assays
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16.1. Role of Oxygen in the Body
The role of oxygen in the energy metabolism is essential for all life. Electron pairs produced by the oxidation of 
NADH and FADH
2
 are transported to oxygen through respiratory chains in the mitochondria, by which energy is re-
leased for ATP synthesis by ADP phosphorylation. The resulting high-energy phosphate bonds are a direct source of 
energy for cell, tissue and organ functions in the body.
Because this source of energy is limited, the human body relies on a continuous inflow of oxygen from the atmo-
sphere and effective oxygen supply to cellular mitochondria.
Oxygen transport is greatly facilitated by the oxygen pressure gradient between the atmosphere and the intracel-
lular space.
There are some places on the oxygen pathway to cells that may adversely affect oxygen transport and have an 
ultimate impact on the development of tissue hypoxia.
16.2. Partial Oxygen Pressure along the Oxygen Pressure Gradient
kPa
Atmospheric air 19.9
Alveolar air 14.6
Arterial blood 13.3
Venous blood 5.7
Cell cytoplasm 2.7
Mitochondria 0.3
Table 16.1. Partial oxygen pressure
16.3. Monitored Parameters Related to Oxygen Metabolism (Guidance Values)
Partial oxygen pressure in arterial blood [10.0 - 13.3 kPa]
Partial pressure in mixed/central venous blood [4.5 - 5.5 kPa]
Haemoglobin [130 - 160 g/L; 8.0 - 10.0 mmol/L]
Carbonyl haemoglobin [< 0.03] *
Methaemoglobin [< 0.02] *
Haemoglobin saturation with oxygen [0.95 - 0.98] *
P50 [3.3 - 3.9 kPa]
FiO
2
 [0.21 atmosphere; 0.4 usually during pulmonary ventilation; 1.0 pure oxygen] *
Pulmonary shunts [0.02 - 0.05] *
Venous lactate-plasma [0.5 - 2.2 mmol/L]
Note: * [values are shown as a relative proportion]
16.4. Conditions for Adequate Oxygen Supply to Tissues and Possible Causes of Hypoxia
• Sufficient amount and partial oxygen pressure in the inhaled air
• Adequate ventilation – alveolar air exchange
• Optimal ventilation/perfusion ratio at the level of pulmonary parenchyma
• Efficient oxygen diffusion from alveolar air through the alveolar-capillary membrane to the blood
• (hypoxic hypoxia)
• Sufficient amount of functional (effective) haemoglobin in the blood
• Optimal oxygen affinity and bond to haemoglobin
• (anaemic/transport hypoxia)
• Adequate cardiac output per minute
• (circulatory/ischemic hypoxia)
• Effective oxygen release to tissues and cells
• (histotoxic hypoxia)
16.4.1. Sufficient amount and partial oxygen pressure in the inhaled air
The amount of oxygen available in the atmosphere depends on the barometric pressure.
The barometric pressure at the sea level is 760 mmHg ~ 760 Torr ~ 101 kPa (1 mmHg = 0.133 kPa).
According to Dalton’s law, barometric pressure is the sum of partial pressures of gasses contained in the atmosphe-
re.
The partial pressure of each atmospheric gas is calculated from the barometric pressure depending on their volu-
me concentration:
Oxygen 20.93%,
Nitrogen 78.1%,
CO
2
 0.03%,
Inert gases about 1%.
The percentage content of all atmospheric gases is the same at all altitudes.
Water vapour pressure [6.25 kPa] must be included in the partial pressure calculation.
A decrease in pO
2
 in atmospheric air occurs at high altitudes, on alpine hikes, during high-altitude flights, or if oxy-
gen is depleted by combustion in enclosed areas, or by oxygen displacement from the atmosphere by another gas such 
as CO
2
 in some caves where accumulated, heavier CO
2
 creates an oxygen-free zone at ground level.
16.4.2. Adequate ventilation – alveolar air exchange
Hypoventilation can be caused by a decreased tidal volume (shallow breathing) or decreased respiratory rate (hy-
popnoea). Since pulmonary ventilation is ensured by atmospheric gas inspiration by volume changes in the thorax 
(through the activity of respiratory muscles, including the diaphragm), painful respiratory movements (chest injuries, 
pleuritis) lead to a reduced tidal volume. Respiratory centre inhibition may lead to an extreme decrease in the respi-
ratory rate down to a few breaths per minute (e.g. morphine poisoning). Also, exhaustion of critically ill patients with 
signs of muscle weakness may be a cause of considerable hypoventilation and indications for artificial pulmonary 
ventilation.
The importance of dead space, the volume of air that remains in the lungs and airways after maximum expiration, 
increases during shallow breathing (low tidal volume). Dead space has a lower pO
2
 and a higher pCO
2
, which means it 
„dilutes“ the inspired atmospheric air; the greater the ratio of relative dead space to tidal volume, the greater is such 
dilution.
The alveolar air pO
2
 is about 14.6 kPa as compared with atmospheric air pO
2
 of 19.9 kPa.
16.4.3. Optimal ventilation/perfusion ratio at the level of pulmonary parenchyma
Even in physiological situations, perfused but non-ventilated areas occur in the pulmonary parenchyma. Their 
proportion may increase considerably in pathological situations. Causes may include conditions leading to atelectasis. 
Blood flowing through these areas keeps its venous character and decreases haemoglobin saturation with oxygen in 
arterialized blood. This increases the value of pulmonary shunts, non-oxygenated blood after passage through the 
lungs (normally under 0.05; 5%). In character, pulmonary shunts correspond to the haemodynamic right-to-left cardiac 
shunt. Depending on the extent of the disorder, the pulmonary shunt area may reach tens of percent with highest va-
lues of up to 80%; 0.8 in ARDS with a shock lung.
16.4.4. Oxygen diffusion from alveolar air through the alveolar-capillary membrane to the blood
Oxygen diffusion is 20 times more difficult/slower than CO
2
, which is why it is more sensitive to conditions ham-
pering gas diffusion in the lungs. Structural or pathophysiological (alveolar/capillary) diffusion disorders alter oxygen 
transport considerably but have a minimal effect on the diffusion/excretion of CO
2
.
Disorders of oxygen diffusion in the lungs may be caused by:
failure/destruction of alveoli
The normal surface area of alveoli is about the size of a tennis court. This area may decrease critically in emphyse-
ma, for example. Diffusion is considerably impaired by fibrotic processes such as interstitial pulmonary fibrosis.
pulmonary oedema
Oxygen diffuses from alveoli to pulmonary capillaries through a very thin space. The fluid accumulated in this space 
during pulmonary oedema extends the diffusion path and hampers the diffusion.
insufficient pulmonary perfusion
Reduced perfusion → embolism, pulmonary hypertension, cardiac failure
16.4.5. Sufficient amount of functional (effective) haemoglobin in the blood
A normal value of „effective haemoglobin“ in fully grown red blood cells is essential for ensuring sufficient oxygen 
supply to tissues according to their current requirement. This haemoglobin represents the oxygen-carrying capacity of 
blood; 1 g of haemoglobin can bind 1.39 ml (0.062 mmol) of oxygen (O
2
). A lowered effective haemoglobin concentra-
tion may cause anaemic hypoxia.
Apart from adult haemoglobin A, blood also contains variants of haemoglobin incapable of reversible oxygen bin-
ding, and that do not take part in oxygen transport within the body. They are called dyshaemoglobins, one of them 
being carbonyl haemoglobin (COHb – town dwellers under 5%, smokers up to 10%) with a reversible CO bond, which is 
200 times stronger than the oxygen bond, and methaemoglobin (MetHb – under 3%), unable to bind oxygen because 
the Fe in its molecule is irreversibly oxidized to Fe3+.
Sulphaemoglobin and cyanhaemoglobin also do not participate in the oxygen transport.
These forms of haemoglobin gain pathophysiological importance if their level (%) in the blood increases to such 
extent that they may cause hypoxia (CO intoxication, effect of nitrites, iatrogenic action of drugs such as sulphones – 
organic sulphur compounds used in dermatology, etc.).
A special variant is foetal haemoglobin. With its higher oxygen affinity, it supplies the foetus with oxygen in specific 
intrauterine conditions, and is replaced with adult haemoglobin A following birth.
Forms of haemoglobin with genetically determined alterations to their primary structure (composition and the 
order of amino acids) that also alter the oxygen bond are called haemoglobin variants or haemoglobinopathies.
16.4.6. Optimal oxygen affinity and bond to haemoglobin
The saturation/dissociation curve shows haemoglobin’s affinity for oxygen. Partial oxygen pressure is the indepen-
dent variable (x-axis), and haemoglobin saturation with oxygen is the dependent variable (y-axis). Oxygen does not 
bind to haemoglobin uniformly – the bond is difficult and energy-consuming at first, because most electrostatic bonds 
between the alpha and beta subunits have to be broken. The easier bonding of additional oxygen molecules is repre-
sented by the shape (slope) of the haemoglobin dissociation curve.
The typical S-shaped form of the saturation/dissociation curve conceals important advantages to oxygen transport 
within the body.
The end part of the curve on the right with high partial oxygen pressure and saturation values reflects the situati-
on in the lungs. The curve shows that even a relatively large drop in partial oxygen pressure will cause an insignificant 
decrease in haemoglobin saturation with oxygen (a 3 kPa drop in pO
2
 leads to a 2 % drop in saturation).
On the contrary, the left part of the curve with low pO
2
 values describes the situation in tissues. The same drop in 
pO
2
 will cause a significant drop in haemoglobin saturation, and therefore a large amount of released oxygen available 
for diffusion into tissues and cells.
Haemoglobin’s affinity for oxygen is not constant. It changes (increases and decreases) in response to changes 
in certain physical and chemical parameters (temperature, pH, pCO
2
, 2,3-bisphosphoglycerate). This phenomenon is 
referred to as the Bohr effect.
Figure 16.1. The effect of blood pH on the position of the haemoglobin dissociation/saturation curve. The position of 
the curve on the graph is characterized mathematically by the p50 value (3.0 << 3.6 >> 4.4 [kPa])
Haemoglobin’s affinity for oxygen is increased by the following parameters:
Alkaline pH
Decreased temperature
Decreased pCO
2
Decreased 2,3-bisphosphoglycerate level
Haemoglobin’s affinity for oxygen is decreased by the following parameters:
Acidic pH
Increased temperature
Increased pCO
2
Increased 2,3-bisphosphoglycerate level
Given the big functional reserve of the oxygen bond to haemoglobin in the lungs (see the haemoglobin saturation 
curve), the benefit of this phenomenon clearly points to oxygen metabolism in tissues (in terms of easier oxygen rele-
ase).
The effect of the increased 2,3-bisphosphoglycerate level also manifests itself as a compensatory mechanism in 
developing anaemia, where it acts as a compensation for a potential hypoxic condition. By linking to the Hb molecule 
it decreases Hb’s affinity for oxygen.
Patients with gradual/slow development of anaemia have an elevated 2,3-BPG concentration, which can partially 
explain why even patients with an extremely low Hb level are capable of ordinary activities.
There is also an increase in 2,3-BPG as part of the body’s adaptation to high altitudes.
P50 value
P50 indicates the partial oxygen pressure at which haemoglobin, in a patient’s current situation, is 50% saturated 
with oxygen.
An increase in haemoglobin’s affinity for oxygen is graphically represented by a shift of the saturation/dissociation 
curve to the left; a decrease in affinity will shift the curve to the right.
The central position of the saturation/dissociation curve, or the range of its shift to the left or right, is expressed 
by the p50 value.
The p50 reference interval for pH 7.4 and T 37°C is 3.3 - 3.9 kPa. P50 differs from the standard value if pH deviates 
from 7.40, pCO
2
 from 5.3 kPa, temperature from 37°C or 2,3-BPG concentration from 5.0 mmol/L. P50 for newborns is 
2.4 - 3.2 kPa due to foetal Hb.
Increased P50 points to a shift of the Hb dissociation curve to the right, i.e. a lower Hb affinity for oxygen. Causes 
may include: hyperthermia, acidaemia, hypercapnia, elevated 2,3-BPG or a combination thereof.
Decreased P50 points to a shift of the dissociation curve to the left, and a higher oxygen affinity for Hb. Main cau-
ses include: hypothermia, acute alkalaemia, hypocapnia and low 2,3-BPG concentration. A pathophysiological impact 
of the elevated oxygen affinity for haemoglobin is less effective oxygen release from oxyhaemoglobin in peripheral 
tissues, and therefore a low tissue pO
2
.
16.4.7. Adequate cardiac output per minute
Cardiac output per minute represents the volume of blood ejected by the cardiac function to the blood circulation 
(systolic volume x heart rate) per minute, and reacts to the current requirement for oxygen supply to tissues. A de-
crease in the minute output due to cardiac insufficiency or heart rhythm disorder leads to insufficient oxygen supply 
to tissues and hypoxia. In contrast, when there is insufficient oxygen supply to tissues, increased cardiac output will 
increase the oxygen supply to tissues, if the myocardium capacity allows it.
The cardiovascular system’s adaptation reactions to hypovolaemia or shock with circulation centralization dramati-
cally decrease the oxygen supply to hypoperfused tissues with subsequent signs of their ischaemia/hypoxia.
In severe sepsis, septic shock and other critical conditions, when the blood flow through the splanchnic region and 
the kidneys decreases, blood flow through the myocardium and brain is maintained.
16.4.8. Oxygen release to tissues and cells
Oxygen is released from the bond into tissues as a result of the large pressure gradient between the blood pO
2
 and 
tissue cells, and the easy dissociation of the oxygen-haemoglobin bond at low pO
2
 at the interface of the blood and 
tissue cell surface.
The pO
2
 at the venous end of the capillary is about 5.0 kPa, so the normal arteriovenous pO
2
 difference ranges 
between 5.0 and 8.3 kPa.
Arteriovenous difference
The a-v difference in the oxygen content shows the current amount of oxygen supplied by the blood to tissues.
Arterial blood Mixed venous blood
Haemoglobin concentration [mmol/L] 9.0 9.0
Haemoglobin saturation [0.00] 0.98 0.68
pO2 [kPa] 10.6 5.0
ctO2 [mmol/L] 9.0 6.7
A-v O2 difference [mmol/L] 2.3
A-v O2 difference [mL/L] 51
Table 16.2. shows an example of the a-v difference with different oxygen metabolism parameters.
ctO
2
 – total oxygen content in the blood; 1 mol of haemoglobin binds 1 mol of oxygen.
An a-v difference of 51 mL O
2
/L of blood is required to cover a rest oxygen consumption of about 250 mL/min (70 
kg weight) and rest cardiac output per minute (5 L/min.).
Figure 16.2. The values shown in the table are derived from the saturation/dissociation curve.
In addition to reaffirming the benefits of the S-shaped haemoglobin saturation/dissociation curve, the critical im-
portance of a sufficient pressure gradient for the transport of oxygen must also be kept in mind. At a low paO2 in the 
artery, a release of 2.3 mmol/L (51 mL/L) of oxygen has to be accompanied by a drop in pvO2 in mixed venous blood. 
Values under 4.0 kPa may lead to hypoxia. The critical value for pvO2 in mixed venous blood is < 2.5 kPa, which is when 
hypoxic brain damage occurs.
The total oxygen content ctO
2
 is shown on the y-axis instead of oxygen saturation sO
2
.
There is an assumption that 1 mol of haemoglobin binds 1 mol of oxygen. ctO
2
 is 9.1 mmol/L at 100% Hb saturation 
(150g/L = 9.1 mmol/L). ctO
2
 decreases in proportion to decreasing saturation.
16.5. Respiratory Insufficiency
Chronic respiratory insufficiency as a result of a chronic pathological process in the lungs is divided into partial, 
affecting the oxygen supply (hypoxia), and global, which is also associated with carbon dioxide retention (hypercapnia 
and respiratory acidosis).
Acute respiratory insufficiency – acute respiratory distress syndrome (ARDS) is a serious condition connected with 
high mortality. This condition is often connected with shock (shock lung), also as part of multiple organ dysfunction 
with different aetiologies.
16.6. Lactate
Lactate is the product of anaerobic glycolysis. Elevated lactate concentration in the plasma (> 2.2 mmol/L) may 
be caused by increased production or reduced elimination. In connection with oxygen metabolism, an increasing la-
ctate concentration, lactate acidosis, goes together with tissue hypoxia (type A). Lactate acidosis may also occur as a 
consequence of lactate elimination disorder in renal and hepatic failure, due to nutritional and iatrogenic effects such 
as complications in biguanide treatment, realimentation in thiamine deficiency, and ethanol, salicylate or methanol 
intoxications, including congenital carbohydrate metabolism disorders (type B).
A rise in lactate concentration in critically ill patients is an alarming symptom, which often precedes and accompa-
nies shock conditions. Continuous monitoring of the plasma lactate level and its trends is fully indicated to see whether 
therapeutic actions have been successful. A permanently elevated or increasing value is associated with a worsening 
prognosis and high mortality.
In general, 18 - 22% mortality is reported for shock, non-septic conditions with lactatemia 1.3 - 4.4 mmol/L, 73% 
mortality for hyperlactatemia 4.5 – 8.9 mmol/L, and 100% for values over 13 mmol/L. Values as low as 3.0 - 3.5 mmol/L 
suggest a poor prognosis for septic conditions. A rise in lactate is a signal that sepsis has transferred from a metabo-
lically compensated into a decompensated stage, where tissues consume less oxygen even if the supply is sufficient.
16.7. Perinatal Asphyxia
Asphyxia is one of the commonest causes of death or severe damage to the foetus. Causes can be on the side of the 
mother (cardiac or pulmonary diseases, disturbed blood flow through the placenta, abnormal uterine contractions), 
or else asphyxia may be induced by umbilical cord compression or knotting, premature separation of the placenta, or 
pathology of the foetus (congenital heart defects, heart rhythm disorders, severe anaemia, sepsis, pneumonia, etc.). 
Respiratory distress syndrome (RDS) in newborn infants is a separate condition. It occurs in premature infants in par-
ticular, and is caused by insufficient pulmonary surfactant in the immature lungs, which prevents alveolar collapse in 
the expiratory phase and avoids functional atelectases. The degree of perinatal asphyxia is clinically evaluated using 
the Apgar score (the international system for rating a newborn’s neonatal adaptation; the criteria are Appearance (skin 
colour), Pulse (pulse rate), Grimace (reflex irritability), Activity (muscle tone) and Respiration; the infant receives 0 - 2 
points for each function, with 10 points as a maximum). A score of 0 - 3 at the 5th, 10th, 15th and 20th minute from birth 
is considered deeply pathological. Laboratory measurement of pH in the cord blood collected during delivery is used 
to evaluate the seriousness of foetal hypoxia; pH values < 7.0 are indicative of hypoxia.
16.8. High Altitude Effect
The composition of atmospheric air at sea level and on top of Mount Everest is the same; only the barometric pres-
sure, and thus the partial pressure of oxygen, is different. Lower pO
2
 causes hypoxia, which induces many adaptation 
reactions. Spending extended periods at high altitude often induces an increased production of erythropoietin (EPO) in 
the kidneys with subsequent stimulation of haemoglobin and red blood cell production and a resulting increase in the 
oxygen-carrying capacity of blood. There is also a rise in 2,3-bisphosphoglycerate, which facilitates oxygen release into 
tissues. These adaptation mechanisms are used to prepare mountaineers for high altitudes and often also to increase 
the oxygen-carrying capacity in different high-performance sports disciplines.
16.9. Diving
Divers face the opposite problem. As the immersion depth grows, the pressure and paO2 of inhaled air increases 
dramatically up to toxic levels. There is a risk of hyperoxia if air of the same composition as atmospheric air is inhaled. 
A gas mixture containing less oxygen (Trimix) is therefore used for deep diving. Surplus nitrogen and oxygen is replaced 
with an inert gas (helium).
16.10. Measured and Counted Oxygen Metabolism Parameters
• paO2, Hb saturation, haemoglobin fractions, lactate, (pH, paCO2, FiO2, etc.)
• Pulmonary shunts, oxygen consumption, a-v difference
Anticoagulated (heparinized) arterial blood or arterialized capillary blood from the hyperaemized adult’s earlobe 
or newborn’s heel is most suitable to determine oxygen metabolism parameters.
Blood paO2 is measured using the Clark-type electrode on the amperometric principle. The electrode is a standard 
part of acid-base and blood gas parameter analyzers, together with the pH electrode and Severinghaus electrode to 
determine pCO
2
. In addition to analyzers intended for clinical and biochemical laboratories, there are also instruments 
with very simple operation and maintenance for clinical use at the patient’s bedside – Point Of Care Testing (POCT).
Haemoglobin oxygen saturation (SO
2
) is usually derived in these instruments empirically from paO2, pH and hae-
moglobin, from the normal shape and position of the Hb dissociation curve.
A correct result is conditioned by normal oxygen affinity for Hb, a normal 2,3-BPG concentration and the absence 
of dyshaemoglobins.
The drawbacks and limitations of the approximative method mentioned above are eliminated by direct measu-
rement of all haemoglobin type contents in the blood based on their different absorption spectra (oxyhaemoglobin, 
reduced haemoglobin, carbonyl haemoglobin, methaemoglobin, sulphaemoglobin, foetal haemoglobin, oxygen satu-
ration and total oxygen content ctO
2
). Following ultrasonic red blood cell haemolysis, the haemolyzate is measured by 
spectrophotometry, and the haemoglobin levels present are computed from their maximum absorptions. The oxyhae-
moglobin to total haemoglobin ratio is the usual result of the saturation calculation.
A CO-oximeter is a standard part of the advanced acid-base analyzers used today.
Pulse oximeters are used to monitor haemoglobin oxygen saturation.
The method is based on the principle of different absorption of red (or infrared) light by haemoglobin and oxyhae-
moglobin. A sensor emitting radiation with wavelength of 660 nm (red light) and 940 nm (infrared light) is applied to an 
acral part of the body, usually a finger or earlobe. Light is passed through this part of the body and the transmitted light 
is measured. The light is absorbed by the tissue and venous, capillary and arterial blood, of which only the arterial com-
ponent has a pulsing character. The absorption of light of the two wavelengths by pulsing and non-pulsing components 
is used to estimate haemoglobin oxygen saturation in arterial blood (SaO
2
) in percent. Naturally, if the patient’s blood 
contains other haemoglobin derivatives (COHb, MetHb), the method gives falsely high results of saturation. Neither is 
it suitable in the case of disturbances of peripheral circulation: the measured result will correspond to the value in the 
poorly perfused periphery, and not to arterial blood.
Pulse oxymetry is used for its simple and quick application when estimating a patient’s blood oxygenation during 
anaesthesia in intensive care units and emergency wards, where patients are at risk of rapid development of respira-
tory insufficiency.
Pulmonary shunts are usually computed automatically from measured blood gas values in arterial and mixed/cen-
tral venous blood, measured oxygen saturation, the FiO
2 
value, temperature and barometric pressure.
The arteriovenous paO2 difference and the position of the haemoglobin dissociation curve are used to derive the 
a-v difference in oxygen content, i.e. the content of oxygen available to tissues in that specific situation.
Information on current oxygen consumption can be obtained using instruments continuously analyzing oxygen 
content in inspired and expired air. Modern calorimeters work on the same principle to determine energy output/ener-
gy requirement using indirect calorimetry; 1.0 litre of consumed oxygen is equivalent to energy of 4.8 kcal (20.2 kJ).
In basal condition, the oxygen consumption of an adult is about 3.5 mL.kg-1.min-1. Cardiopulmonary system per-
formance is expressed by the maximum oxygen consumption reached under an increasing dynamic load. This corre-
sponds to about ten times the basal oxygen consumption in middle-aged men who do not take regular exercise.
16.11. Treatment for Hypoxia
Spontaneous breathing – oxygen therapy using oxygen-enriched air
Artificial pulmonary ventilation (ventilation modes)
At constant pressure – pressure-controlled ventilation
At constant volume – volume-controlled ventilation
PEEP – positive end-expiratory pressure
High-frequency ventilation
ECMO – extracorporeal membrane oxygenation
Hyperbaric oxygen therapy
(CO intoxication, caisson disease, Clostridium infections, risk of transplanted grafts/skin flap rejection)
Indications for oxygen therapy and controlled breathing
The following biochemical values are indications for oxygen therapy and controlled breathing:
paO
2
 < 9.3 kPa and paCO2 > 6.6 kPa in unventilated patient in acute condition; these are arterial blood values.
The aim of oxygen therapy is to increase haemoglobin oxygen saturation to 0.85 - 0.90 with subsequent normali-
zation of blood gas values. It is advisable to select the lowest effective oxygen concentration in the inhaled mix (FiO
2
) 
to prevent the toxic effects of oxygen on lung tissue. Oxygen concentrations under 60% are well tolerated over long 
periods of time. A permanent increase in FiO
2
 over 60% will lead to the development of inflammatory alterations and 
infiltration of alveoli with subsequent fibrosis. If oxygen concentrations over 60 – 80% have to be supplied, controlled 
ventilation should be used.
Pure, 100% oxygen is supplied during emergency resuscitation; 100% oxygen inhalation is safe for at least 6 hours. 
Toxic effects start to develop after 48 hours.
Increased attention should be paid to oxygen therapy of chronic hypercapnia conditions; the reason is that the only 
stimulus for the respiratory centre is the low paO2. If this last ventilation stimulus is removed, further paCO2 increase 
may occur with depression or even arrest of ventilation.
Also, controlled ventilation leading to a paCO2 decrease must be slow – the decrease rate should not be faster than 
0.3 – 0.7 kPa/hr. Always keep in mind the persistence of the renal compensation of the disorder and the risk of transi-
tion to alkalaemia. Progress should be monitored by repeated blood gas analyses – before ventilation, 20 – 30 minutes 
after the start of controlled ventilation, and following each change in the ventilator set-up.
Pre-analytical phase
The essential pre-analytical requirement is to ensure an anaerobic method of blood collection and fast transport 
for the analysis. Anaerobic collection means the shortest possible contact of the collected blood with atmospheric air 
(capillary collection), and absolute prevention of air bubbles in the capillary tube or collection syringe. Failure to ad-
here to this principle may degrade the test completely and produce false results. The collected blood must be mixed 
perfectly with the anticoagulant (heparin) in order to prevent the formation of blood clots (collection syringe rotation, 
mixing the content of the capillary tube with a wire and magnet) that make the assay impossible and may clog up the 
analyzer and put it out of order.
Figure 16.3. Anaerobic blood collected in a heparinized syringe and capillary tube; wire and magnet to mix anticoagu-
lated blood; microstrainer to capture microclots during aspiration into the instrument.
CHAPTER 17
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17.1. Osmolality and Water Metabolism
Water accounts for 60 percent of average human body weight. A uniform and constant distribution of water, and 
the substances dissolved in water, in different body compartments is one of the essential requirements for all vital 
functions of the organism.
The essential importance of water for the metabolism and proper function of cells, tissues, organs and the body 
as a whole is reflected in the perfect mechanism which regulates the volume, composition and distribution of water 
to each body compartment. Body water in cells provides an environment for all enzymatic and other physical and 
chemical reactions, the transport of substrates and products, and for maintaining the optimum volume of intracellular 
structures, cells and tissues. On the macro-scale of the body, water is essential for effective blood circulation with op-
timum tissue perfusion.
Water volume and water transfers within the body are regulated by systems equipped with sensitive osmorecep-
tors, volume receptors and baroreceptors. The sodium cation (Na+), which is accountable for 90% of extracellular fluid 
osmolality, lies at the centre of regulation loops, the purpose of which is to maintain (preserve) the optimum content 
and distribution of water in the body.
The effects of mechanisms regulating osmolality, Na+ and water therefore interact and affect each other see also 
the chapter Importance of Na, K, Cl Assays.
17.1.1. Water Balance
In evaluation of water balance the intake means the water added to the body (food and beverages) and metabolic 
water (about 0.2 L per day). Water output, meanwhile, includes losses in urine, stool (usually 0.1 L/day, up to several 
litres during diarrhoea), sweat (0.1 L), by evaporation through the skin in thermoregulation (0.35 L) and losses in air 
exhaled from the lungs (0.35 L). Losses through the skin, in sweat and lungs, and metabolic gain, are referred to as 
insensible (unquantifiable when determining water balance), yet must be taken into account. Immeasurable losses are 
about 700 mL/day in normal circumstances, but they increase during fever and enhanced sweating, and, conversely, 
may decrease when artificial ventilation is applied.
The regulation of the volume, osmolality and composition of water in different body compartments serves prima-
rily for ensuring optimum conditions in the intracellular space in reaction to changes in the ECF.
The unique function of the individual parts of nephrons ensures that about 99% of the daily volume of about 180 
litres of glomerular filtrate (primary urine) is reabsorbed to produce definitive urine with osmolality from 50 to 1400 
mmol/kg, depending on the extremes of variation in water intake.
Daily osmotic load excretion in the urine may fluctuate considerably even in physiological circumstances. Excreted 
osmotic loads may exceed 1500 mmol/24 hrs in healthy people with a high intake of salt and proteins, and who are 
highly physically active. In contrast, daily excretion of the osmotic load falls below 600 mmol if the protein intake is low 
and in resting non-catabolic patients.
Osmotic load excretion increases significantly in critical conditions. A major role in this excretion is played by high 
urea, ions and frequent glycosurias with a diminished tolerance for glucose, osmotherapy solutions, or low-molecular 
substances excreted during catabolism and intoxications. Losses over 1500 mmol/day occur in more than 1/3 of hyper-
catabolic patients, and even losses reaching 3000 mmol/day and more are not exceptional.
Excreting such a high osmotic load is very burdensome on the kidneys. If their renal concentrating ability is im-
paired following hypoxic accidents, intensive diuretic treatment or potassium depletion, for example, patients must 
be sufficiently hydrated to be able to excrete such high osmotic load and prevent the retention of osmotically active 
catabolites in the body.
17.1.2. Osmolality
Osmolality is a physical property of solutions based on the solute concentration expressed as mmol/kg (w/w). Os-
molality is related to changes in many properties of the solution relative to solute-free water, such as decreasing the 
freezing point and water vapour depression. These properties are referred to as colligative properties (dependent on 
the number of molecules) and also form the basis of routine measurement of osmolality in biological samples.
The term osmolarity is an expression of osmolality in mmol/l (w/v = weight/volume). It is imprecise (unsuitable) 
for hyperlipidaemia and hyperproteinaemia, for urine measurements, and in the presence of some osmotically active 
substances such as alcohol or mannitol. In addition, it is related to the volume of the solution, which depends on tem-
perature.
17.1.3. Osmolality and Body Water Regulation
17.1.3.1. Systemic Regulation of Osmolality
The maintenance of water and ion balance is based on the regulation of osmolality and extracellular fluid volume. 
Although this regulation is controlled by different mechanisms, both regulation systems have in common a relationship 
to plasma Na+ ion concentration. Osmolality (affected mainly by Na+ concentration) is regulated by changes in water 
balance, and intravasal volume is regulated by changes in Na+ concentration.
The essential hormone for osmolality regulation is the antidiuretic hormone (ADH). ADH is a nonapeptide synthe-
sized in the hypothalamus (nucleus supraopticus and paraventricularis). Secretory granules with ADH are stored in the 
posterior pituitary gland. ADH half-life is 15 - 20 minutes.
The hypothalamus reacts to an increase in blood osmolality, recorded by osmoreceptors in the hypothalamus, by 
an impulse to raise antidiuretic hormone (ADH) secretion and by inducing a sense of thirst.
The natural response to the sense of thirst is increased fluid intake, which leads to an increase in water content in 
the extracellular space, dilution of the elevated Na+ concentration and a subsequent decrease in plasma osmolality. 
Thirst is the decisive feature in fluid intake regulation in relation to plasma osmolality. Thirst is stimulated by a 2% and 
greater increase in osmolality.
ADH is responsible for the hormonal regulation of osmolality by controlled water excretion through the kidneys. 
ADH is transported by blood into the kidneys where it activates aquaporins by acting on V2 receptors in the distal tubu-
le and the connecting segment. This increases water absorption in the distal part of the kidneys. Water retained in the 
kidneys decreases plasma osmolality with the subsequent damping of ADH secretion. To keep osmolality at 285 ± 10 
mmol/kg, osmoreceptors in the hypothalamus react very fast even to small changes in plasma osmolality. A 1-2% rise 
in osmolality will lead to a four times higher ADH concentration in the circulation. Conversely, a 1-2% drop in osmolality 
will stop ADH secretion. The response is fast.
There are also other factors that participate in ADH secretion. Aortal and carotid baroreceptors and arterial volume 
receptors stimulate ADH secretion when blood pressure drops by 10%. As pressure drops, the activity of sympathetic 
nerves in the heart and veins simultaneously increases, and the effect of ADH and the sense of thirst are supported by 
feedback. The ADH circulating in the blood acts on arterioles and induces their constriction. The decrease in blood flow 
through the kidneys induces the release of renin, which leads to a higher production of angiotensin II. Angiotensin II 
acts in the brain and induces the release of the ADH.
Renal regulation plays a major role in excess water management in the body, while thirst is a more important regu-
lator preventing water deficiency and dehydration.
17.1.3.2. Osmolality Regulation at Cellular Level
The effective osmolality of fluids is decisive for water distribution and transfers between cells and extracellular 
spaces. The level of effective osmolality is influenced by substances that accumulate only in some spaces, and cannot 
spontaneously pass through the capillary wall or cell membrane. Typically these are sodium ions and glucose. If their 
concentration in the ECF increases, this fluid becomes hypertonic compared to ICF (ECF has a higher effective osmo-
lality), whereas if their concentration decreases, effective osmotic ECF pressure will decrease. Changes in effective 
osmolality lead to the transfer of water to areas with higher effective osmolality. This process continues until osmotic 
balance is achieved. Urea, which freely passes through cell membranes, has no influence on effective osmolality or 
water transfers.
If the cell is in a hypertonic environment, typically in hypernatraemia, the cell starts to quickly lose water. The de-
creased intracellular volume activates processes that increase the volume of osmotically active substances, followed 
by the entry of water into the cell and adjustment to the cell volume. In particular, an influx of Na+ ions occurs due to 
the mechanism of Na+ Cl- symport, Na+ K+ 2Cl- symport and Na+/H+ antiport. These mechanisms, based on an increase in 
intracellular sodium ion concentration, are effective only for a short time because an increase in the Na+/K+ pump acti-
vity follows very quickly. This is the reason cells in regular contact with a hypertonic extracellular environment, brain 
cells in particular, have other secondary mechanisms at their disposal to maintain an optimum volume. They can start 
synthesizing special osmotically active organic compounds in a few hours. The nature of these molecules was unknown 
for a long time, and they were called idiogenic osmoles. Recent findings have shown they consist of multiple organic 
compounds (polyols, amino acids, amines, choline compounds, creatinine phosphate). As a consequence, patients 
with chronic hypernatremia or diabetic hyperglycaemia are able to tolerate high plasma osmolality levels without any 
damage to brain cells.
If the cell is in a hypotonic environment, the cell’s volume will start to increase due to the transport of water. In 
reaction to this effort to maintain cell volume, transport processes become activated leading to a decrease in the vo-
lume of osmotically active substances in the cell, the balancing of osmolality and the maintenance of the cell volume. 
Different cells employ different regulation mechanisms, most often the enhanced release of K+ through the stimulation 
of channels for K+. The content of organic compounds (idiogenic osmoles) in brain cells decreases.
17.1.3.3. Intravasal Volume Regulation
Adequate intravasal volume is required to maintain blood pressure and to maintain the necessary perfusion of 
tissues and organs. The regulation of the content (amount) of Na+ and water take part in the intravasal volume control.
The renin – angiotensin - aldosterone system has primary responsibility for decreases in intravasal volume.
Renin is excreted by juxtaglomerular cells in afferent renal arterioles close to renal glomeruli in reaction to reduced 
perfusion of the kidneys.
Renin converts angiotensinogen to angiotensin I, which transforms into angiotensin II at a later stage. Angiotensin 
II causes vasoconstriction, which quickly increases blood pressure as well as aldosterone secretion, which then increa-
ses the retention of Na+ and the water accompanying it.
Figure 17.1. The effects of changes in osmolality and intravasal volume on Na+ and water metabolism. (Clinical Che-
mistry: Techniques, Principles, Correlations. Sixth edition. M.L. Bishop, E.P. Fody, L.E. Schoeff. Wolters Kluwer/Lippincott 
Williams&Wilkins, 2010)
Intravasal volume changes are primarily detected by a series of tension receptors located at various points of the 
cardiopulmonary circulation, carotid sinus, aortic arch and glomerular arterioles. Signals from these receptors activate 
many responses aimed at adjusting intravasal volume through the adjustment of vascular resistance, cardiac output 
and renal retention or excretion of Na+ and water.
• Additional factors affecting intravasal volume:
Natriuretic peptides: atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) released from the atria 
and ventricles of the heart in response to the expansion of intravasal volume support Na+ excretion in the kidneys; BNP 
and ANP co-act in regulating blood pressure and water balance.
Volume receptors also stimulate the release of the ADH independently of osmolality, which saves water through 
renal re-absorption.
Glomerular filtration increases and decreases with increasing or decreasing intravasal volume.
A 1 - 2% decrease in tubular re-absorption of Na+ may increase water losses by litres per day.
Urine osmolality has a broad range depending on water intake and the status of body hydration.
17.1.4. Water Deficit – Dehydration
Water deficit caused by insufficient intake or excessive losses leads to increased plasma osmolality. Both regu-
lators, thirst and ADH, become activated. While ADH minimizes water losses, thirst is the major correcting factor. It 
is, however, inactive in unconscious people and may fail in elderly people, children, or in cases where drinking is im-
possible or it is otherwise impossible to secure access to water. The osmotic stimulation of thirst decreases considera-
bly in people over 70.
Water deficiency, dehydration, leads to a more concentrated internal environment, reflected in the plasma by 
haemoconcentration, i.e. an increase in the concentration of haemoglobin, proteins and urea, and an increase in the 
haematocrit level (an increase above the reference limits occurs only if baseline levels were within the reference limits; 
previously decreased levels can only be „adjusted“). Isotonic, hypertonic and hypotonic dehydration are distinguished 
based on the osmolality level.
17.1.4.1. Isotonic Dehydration
Isotonic dehydration is caused by a loss of a fluid that is isotonic with blood plasma (vomiting, diarrhoea, burns). 
This loss is not accompanied by a rise in ECF osmolality, and so the compensatory transfer of water from the ICF does 
not occur. There are signs of haemoconcentration, and skin turgor and diuresis are reduced. Lowered blood volume 
stimulates renin and aldosterone secretion. This increases sodium absorption from the distal tubule, which causes low 
sodium concentration in the urine. Given the relatively low ECF volume, hypovolaemia and the centralization of blood 
circulation and its failure may occur rapidly.
17.1.4.2. Hypertonic Dehydration
Hypertonic dehydration is caused by a lack/loss of fresh water. The most common cause is a reduced supply of 
water (unconsciousness, reduced sense of thirst, inability to swallow) or inadequately compensated losses (polyuric 
phase of renal failure, central or nephrogenic diabetes insipidus). Osmolality and Na+ concentration in the ECF increase 
in addition to signs of haemoconcentration. Hyperosmolality of the ECF leads to the transfer of water from the ICF in 
an effort to correct the disturbed osmotic balance. Due to double the content of water in the ICF, the disorder may be 
corrected at first in the ECF, thereby delaying the clinical signs of hypovolaemia.
17.1.4.3. Hypotonic Dehydration
Hypotonic dehydration is less frequent. It occurs if fluids with relatively higher Na+ content than that in the ECF are 
lost (pancreatic fistula, some types of diarrhoea). Relative hyperosmolality of the ICF leads to the transfer of water to 
this space and a deepening of existing hypovolaemia.
17.1.5. Excess of Water – Hyperhydration
Excessive intake or insufficient excretion of water leads to a decrease in osmolality.
Both regulators (thirst and ADH) are dampened. In the absence of ADH, water is not reabsorbed from the primary 
urine, and a large amount of diluted urine is produced. Normally functioning kidneys are so effective that even hypo-
osmolality and hyponatraemia need not necessarily occur (beer drinkers).
In pathological situations, isotonic, hypotonic or hypertonic hyperhydration may occur.
17.1.5.1. Isotonic Hyperhydration
Isotonic hyperhydration occurs due to the accumulation of isotonic fluid leading to an increase in the ECF volume 
without a change in its osmolality. This disorder occurs in patients with cardiac failure, decompensated cirrhosis and 
nephrotic syndrome. These conditions are accompanied by secondary hyperaldosteronism with sodium and water 
retention. Signs of haemodilution (a drop in proteinaemia, haemoglobin and haematocrit) are present, osmolality and 
Na+ concentration are in the reference range, and the Na+ reserve is usually increased. Oedemas or ascites are present.
17.1.5.2. Hypotonic Hyperhydration
Hypotonic hyperhydration accompanies conditions where the ability to excrete excessive intake of water is limited, 
for example in renal failure and in cardiac patients. Capillary leakage of water leading to secondary hyperaldosteronism 
sometimes occurs in polytraumas, and so it is easy to hyperhydrate patients at the beginning of the therapy.
The laboratory signs of haemodilution, hyponatraemia and hypoosmolality are present.
Patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) form a special group. SIADH 
may accompany some inflammatory and tumour diseases of the lungs and CNS, post-traumatic and post-operative 
conditions. These conditions feature increased ADH production not induced by increased osmolality or hypovolaemia.
A similar clinical and laboratory presentation is typical of the cerebral salt wasting syndrome (CSWS), caused by 
the pathological overproduction of natriuretic peptide. Hyponatraemia and hypoosmolality are present in both cases.
While signs of dehydration can be found in CSWS, in SIADH the intravascular volume is normal or only slightly ele-
vated.
17.1.5.3. Hypertonic Hyperhydration
Hypertonic hyperhydration tends to be iatrogenic in origin, and develops by making up for pure water losses with 
saline (154 mmol Na+/L), by administering a hypertonic solution, drinking seawater, etc.
The kidneys are forced to react to extreme situations in the water balance, which is made possible by their ability 
to produce urine in a broad range of osmolality (50 – 1500 mmol/kg).
17.1.6. Causes of hyperosmolality
• Hypertonic dehydration (thirst, central or nephrogenic diabetes insipidus)
• Hyperglycaemia → hyperosmolar diabetic coma
• Low-molecular substance poisoning (e.g. 1‰ ethyl alcohol = 23 mmol/kg, methanol, ethylene glycol)
During therapy for effective ECF osmolality disorders, the principle of carefully controlled, gradual adjustment 
should be adhered to (a maximum change in serum osmolality by 2 - 4 mmol/kg per hour), in particular with respect 
to the risk of damage to the CNS.
Hypoosmolality of the ECF leads to the penetration of water into the relatively hyperosmolar environment in the 
CNS to form cerebral oedema and an increase in intracranial pressure with neurological symptoms (headaches, diso-
rientation, lethargy, vomiting) and a risk of brainstem herniation. To compensate this, the Na+ and K+ content in brain 
cells decreases within 24 hours, and the content of organic substances (polyols) decreases within 48 hours, with a drop 
in effective osmolality.
ECF hyperosmolality and too fast an adjustment to previous ECF hypoosmolality leads to brain dehydration with 
a dramatic reduction in brain cell volume, and demyelization and damage to brain capillaries. Clinical signs are also 
neurological.
17.1.7. Measurement of Osmolality
Blood plasma osmolality is determined using osmometers mostly based on freezing point depression measure-
ment. Osmometers based on the cryoscopic principle are equipped with highly sensitive thermistors which measure 
with an accuracy of one thousandth of a degree centigrade. A -1.86°C drop in the freezing point is caused by 1 mol 
dissolved undissociated substance.
The range of blood serum osmolality in healthy people is 285 ± 10 mmol/kg. More than 90% of total plasma os-
molality is attributable to the Na+ cation and its associated Cl- and HCO3- anions. The contribution of other cations and 
anions is low. As regards non-electrolytes, a major contribution is made by glucose and urea. Since urea readily pene-
trates the intracellular space and does not cause an osmotic gradient between the ECF and the ICF, it is not regarded 
as a substance with any effective influence on osmolality intended for therapeutic correction.
In clinical practice, blood plasma osmolality is also estimated by calculating from molar concentrations (mmol/L) of 
osmotically important components of the plasma. The concentration of Na+ and the corresponding anions, urea, glu-
cose and to a small extent proteins, are decisive for the value of plasma (serum) osmolality. There are many empirical 
formulas, such as:
These calculations are made even if the value of osmolality has been found by measurement. The measured os-
molality value is usually about 5 - 10 mmol/kg higher than the calculated value. Where the difference between the ap-
proximate calculation and the measured value (osmolal gap) is larger, it warns of the presence of an increased amount 
of low-molecular substances that normally do not occur in the plasma, such as alcohol, acetone or ethylene glycol. If 
the difference between the measured and the estimated osmolality is greater than 10 mmol/kg, the presence of these 
substances in the plasma is highly probable. For example, 1‰ alcohol will increase osmolality by 23 mmol/kg. The 
presence of volatile artificial substances can be proved only by the cryoscopic measurement method, not by measure-
ment on the principle of water vapour depression. One should keep in mind when evaluating the osmolal gap that the 
administration of osmotically active substances such as mannitol will also increase plasma osmolality.
Percentage - wise, a small but important contribution (~0.5% of the total osmotic pressure) is made by the mole-
cules of proteins, albumin in particular. This property of proteins is referred to as colloid osmotic (oncotic) pressure, 
and this pressure is important for transfers of water between the plasma and the interstitium. High-molecular sub-
stances do not penetrate from the venous space to the interstitium in normal circumstances, thus they act against 
hydrostatic pressure and contribute to the maintenance of intravasal volume. A dramatic worsening of this function 
accompanies shock conditions with permeability disorder and albumin leakage into the interstitium.
Values < 250 mmol/kg and > 325 mmol/kg are regarded as critical serum osmolality values.
17.1.8. Importance of Osmolality Determination
17.1.8.1. Serum
• Differential diagnostics of water and ion balance system disorders
• Establishing the seriousness and level of hyperosmolal conditions
• Control and monitoring the decrease in osmolality in treatment for hyperosmotic conditions
• Finding the osmolal gap from the difference between measured and calculated osmolality
17.1.8.2. Urine
• Monitoring osmotic load excretion in hypercatabolic conditions
• Determining renal concentrating ability in the concentrating experiment (adiuretin test)
17.1.8.3. Serum/urine
• Determining the osmolal index (UOsm / SOsm) in the differential diagnosis of renal and prerenal disorders
• Calculation of osmolal clearance (ClOsm) and solute-free water clearance (ClH2O)
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18.1. Lipids
Lipids include hydrophobic substances (Tg, FAs, esterified cholesterol) and substances simultaneously both hyd-
rophobic and hydrophilic (phospholipids, free cholesterol). They can be divided into four groups: FAs, simple lipids, 
complex lipids and isoprenoid lipids.
18.1.1. Fatty Acids (FAs)
Fatty acids are substances with a simple carbon chain whose molecule may contain one or more double bonds. 
FAs in animal tissues only have an even number of carbons, usually 16 - 22 carbons. They are supplied from food and 
are also synthesized in the liver. In the blood they are transported while bound to albumin (free FAs) or in the form of 
complex lipids in lipoproteins. They are the main source of energy for cardiac and skeletal muscles. They are cleaved 
(beta-oxidation) in mitochondria, to which they are transported while bound to carnitine. Beta-oxidation may produce 
ketone bodies, an important source of energy. Free FAs in the blood have a very short biological half-life (about 2 mi-
nutes); they are taken up in the liver and re-esterified to Tg.
18.1.1.1. Saturated FAs
Saturated FAs do not have any double bond in the chain, and are primarily a ready source of energy. They can 
be synthesized in the liver from other energy substrates such as glucose, amino acids and alcohol, and can be stored 
in the form of Tg as an energy reserve. Physiologically important saturated FAs are lauric acid (C12:0), myristic acid 
(C14:0), palmitic acid (C16:0), stearic acid (C18:0) and arachidic acid (C20:0). Their primary source is animal fats (they 
are accompanied by cholesterol) and also some vegetable fats such as palm oil. They are relatively stable even at high 
temperatures and do not oxidize easily.
Relation to atherosclerosis: they are a rich source of energy and an increased intake of FAs supports the develop-
ment of obesity. In addition, a high consumption has proatherogenic effects, leading to an increase of LDL cholesterol 
level in the blood (probably through the induction of elevated cholesterol synthesis in the liver). An exception here is 
stearic acid, which can be changed in the body into unsaturated oleic acid. It is recommended to reduce saturated FAs 
consumption to prevent atherosclerosis.
Figure 18.1. Saturated FA structure
18.1.1.2. Unsaturated fatty acids
These FAs contain 1 or more double bonds in their chains, physiologically usually in the cis configuration. They are 
contained mainly in vegetable fats and fish oils.
18.1.1.3. Monounsaturated fatty acids
The main representatives are palmitoleic acid (C16:1, ω-7) and oleic acid (C18:1, ω-9). They can be synthesized in 
the liver and so are not essential; nonetheless, an exogenous supply of oleic acid is recommended, because oleic acid 
synthesis in the body is usually insufficient. Relation to atherosclerosis: if supplied sufficiently, oleic acid can lower the 
LDL-cholesterol level and is considered a part of the Mediterranean diet reducing the risk of atherosclerosis develop-
ment.
Figure 18.2. Example of monounsaturated FAs structure
18.1.1.4. Polyunsaturated fatty acids
They have multiple double bonds. The first bond is usually on the third (ω-3) or sixth (ω-6) carbon from the carbo-
xylic tail. Among other things, they are used as a source for the synthesis of prostaglandins, leukotrienes and thrombo-
xanes. They are less stable than saturated FAs and oxidize more easily.
Figure 20.3. Some examples of the most important fatty acids
ω-6 fatty acids
The main representatives are linoleic acid 18:2 (9,12), γ-linolenic acid 18:3 (6,12,12) and arachidonic acid 20:4 (5, 
8, 11, 14). They are a source for the synthesis of those eicosanoids which have pro-inflammatory and vasoconstrictive 
effects and increase thrombocyte aggregability. A high consumption may reduce the HDL-cholesterol level.
ω-3 fatty acids
Their main representatives are linolenic acid 18:3 (9,12,15), eicosapentaenoic acid 20:5 (5,8,11,14,18) and docosa-
hexaenoic acid 22:6 (4,7,10,13,16,19). They are a source for the synthesis of those eicosanoids which have vasodilative 
and anti-inflammatory effects and decrease thrombocyte aggregability. If supplied in sufficient amounts, they lower 
the Tg level and act in preventing the development of atherosclerosis complications. They are contained primarily in 
fish oils, and to a lesser extent in vegetable oils.
18.1.1.5. Trans fatty acids
These are isomers of unsaturated FAs and their spatial arrangement is similar to saturated FAs (straight chain). 
They are produced from cis isomers FAs by the action of bacteria in the bowels of ruminants, from where they arrive 
at all meat and milk products. They can also be formed during the hydrogenation of unsaturated FAs (the producti-
on of “hard” margarines for baking and frying; soft margarines for direct consumption are produced using different 
technologies and do not contain trans isomers of FAs). They are also produced if unsaturated FAs are exposed to high 
temperatures for an extended period, during frying, for example.
Therefore, normally consumed foodstuffs of animal origin, bread and pastry, and various “delicacies” with icing 
and chocolate substitutes are the main source of trans FAs from food. Trans FAs may have pro-atherogenic effects – an 
increased intake may accelerate atherosclerosis and raise the LDL-cholesterol level.
Figure 18.3. Trans and cis FAs structure
18.1.2. Simple Lipids
The group of simple lipids includes acylglycerols and waxes. Acylglycerols are produced by FAs bonding to trihydric 
alcohol glycerol, and waxes are produced by FAs bonding to primary or secondary aliphatic alcohol.
18.1.2.1. Triacylglycerols (Tg)
Triacylglycerols are produced by bonding 3 FAs to trihydric alcohol – glycerol (glycerol triesters). The first Tg carbon 
preferentially binds palmitic acid, the second carbon linoleic acid and the third carbon oleic acid (if these FAs are avai-
lable). Tg are of exogenous (about 80 – 170 mmol/day are consumed in food) and endogenous origin (synthesis in the 
liver). Tg are cleaved in the fatty tissue by the action of hormone-sensitive lipase. This enzyme is inhibited by insulin, 
and so it is active only if insulinaemia decreases (during fasting). Increased Tg synthesis in the liver (an increased fasting 
concentration of Tg in the blood) is usually caused by an excessive intake of energy (carbohydrates, fats, alcohol) in 
food. Tg are the main reserve form of energy: a non-obese adult has about 15 kg of Tg. With a content of about 38 kJ 
of energy per gram of weight, this corresponds to about 570,000 kJ, which is a reserve of energy for almost 3 months 
of fasting. Tg are transported in the blood in all lipoproteins, but their highest content is in the VLDL and chylomicrons.
The physiological concentration of Tg in the blood is under 1.7 mmol/L, provided the patient has been fasting for 
10 - 12 hours prior to blood collection. An elevated Tg concentration in the blood is a marker of increased risk of athe-
rosclerosis and cardiovascular diseases. A very frequent cause of an elevated Tg level is excessive alcohol consumption. 
A decrease of Tg concentration in the blood can, in most cases, be simply achieved by limiting the energy (and alcohol) 
intake, irrespective of the food composition, and also by increased physical activity. Hyperinsulinaemia (e.g. in patients 
with type 2 diabetes mellitus or obese people) inhibits hormone-sensitive lipase in the fatty tissue, thus inhibits the 
splitting of Tg. This hormone becomes activated only if insulinaemia decreases – when restricting energy intake.
18.1.3. Complex Lipids
Complex lipids, which consist of polyhydric alcohol with the bound FAs and other components, and one of the basic 
structural substances of the body. Their molecules have hydrophobic and hydrophilic tails, which is decisive for their 
physiological functions – they are the basic building blocks of all cell membranes. Cell membranes are characterized 
by their double layer, with the outer layer consisting of choline phospholipids and glycolipids, and the inner layer con-
sisting of aminophospholipids. Assays for measurement of phospholipids or glycolipids in the blood are not available, 
as their blood levels are not related to atherogenesis.
18.1.3.1. Phospholipids
They are a basic component of all cell membranes at the cellular and sub-cellular level, and also form the surface 
structure of blood lipoproteins. All cells are able to synthesize phospholipids. They are divided into glycerophospholi-
pids and sphingophospholipids.
Figure 18.4. Structure of phospholipids
Glycerophospholipids
They are derived from Tg, where one fatty acid is replaced with phosphoric acid residue and another substance 
(choline, ethanolamine, serine). One representative phospholipid in the outer cell membrane layer is phosphatidylcho-
line (sometimes also called „lecithin“), while the inner layer of cell membranes is formed usually by phosphatidylserine.
Relation to atherogenesis: has not been conclusively proved.
Figure 18.5. Structure of glycerophospholipids
Sphingophospholipids
A typical representative is sphingomyelin, which contains the amino alcohol sphingosine, 2 FAs, phosphoric acid 
residue and choline. Sphingosine is the main membrane phospholipid at the sub-cellular level and is also a dominant 
phospholipid in the nerve fibre myelin. It is also part of surface structures of lipoproteins.
18.1.3.2. Glycolipids
Glycolipids contain sphingosine to which is bound FAs and a saccharide component. They are components of cyto-
plasmatic membranes, neuron sheaths and many other organic structures.
18.1.4. Isoprenoid Lipids
18.1.4.1. Cholesterol
Cholesterol is one of the basic biological compounds: it has a key role in the structure of membranes at the cellular 
and sub-cellular levels; it is a starting substance for the synthesis of steroid hormones, bile acids and vitamin D; and, 
it is required for the absorption and transport of Tg and fat-soluble vitamins. Practically all cells in the body are able 
to synthesize it; intensive synthesis takes place in hepatocytes, enterocytes, neurons and steroid hormone-producing 
endocrine glands. The enzyme 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase is crucial for the regulation of 
cholesterol synthesis as it catalyzes the conversion of hydroxy-methyl-glutaryl-CoA to mevalonate. The activity of this 
enzyme is inhibited by statins – blood cholesterol-lowering drugs. The intensity of cholesterol synthesis in the cell is 
regulated by feedback at the HMG-CoA reductase level: a sufficient reserve of intracellular cholesterol inhibits this 
enzyme, while a lack of cholesterol activates it. This enzyme’s activity is also stimulated by insulin, for example, and 
inhibited by glucagon. Another mechanism regulating intracellular reserves of cholesterol is the regulation of LDL-
-receptor synthesis: if supply of cholesterol is deficient, the synthesis of receptors increases (increased uptake of LDL 
lipoproteins from the blood), while high supply of cholesterol inhibits LDL-receptor synthesis. Cholesterol synthesis in 
the liver is often increased in obese people and following an increased intake of unsaturated FAs from food. Cholesterol 
in the blood is transported in lipoproteins, eliminated from the body in bile (both in an unchanged form and in the form 
of bile acids), and about 50% of this excreted cholesterol and about 95% of bile acids are re-absorbed in the intestine.
Free Cholesterol
Free cholesterol is partly hydrophilic and is a basic component of cell membranes at the cellular and sub-cellular 
levels. It is transported in the blood on the surface of lipoproteins.
Figure 18.6. Structure of free cholesterol
Esterified Cholesterol
Esterified cholesterol has a bound fatty acid, and it is a reserve form of cholesterol in cells. Cholesterol esterifi-
cation takes place intracellularly by the catalysis effect od acetyl-CoA cholesterol acetyltransferase, whose activity 
increases when cholesterol supply is sufficient and decreases when cells are lacking cholesterol reserves. In addition, 
cholesterol esterification takes place also in blood lipoproteins under catalysis of lecithin-cholesterol acyltransferase. 
Linoleic and linolenic acids are preferentially bound to cholesterol in lipoproteins, and oleic and palmitoleic acids pre-
ferentially within cells.
Figure 18.7. Structure of esterified cholesterol
Relation of Cholesterol to Atherogenesis
An elevated blood cholesterol level is a main risk factor for the development of atherosclerosis and cardiovascular 
diseases. Cholesterol is always a basic part of the atherosclerotic plaque (there is no atherosclerosis without choleste-
rol). As the cholesterol level grows, starting from a total cholesterol concentration as low as 3.9 mmol/L, so the risk of 
cardiovascular complication also rises. Average cholesterol levels in the adult Czech population range from 5.6 to 5.8 
mmol/L. Total cholesterol level values under 5.0 mmol/L are considered optimal for the general population, and this 
value should also be indicated as the “physiological” upper limit for cholesterolaemia in laboratory results of choleste-
rol level measurement. Lower cholesterol levels are recommended for people with a high risk of cardiovascular com-
plications under primary prevention (under 4.5 mmol/L). The optimum total cholesterol level in the blood for patients 
with cardiovascular diseases is under 4.0 mmol/L. Intervention studies have shown that a 1% decrease in the blood 
cholesterol level leads to about a 2% decrease in the incidence of ischaemic heart disease. A dramatic decrease in the 
cholesterol level may even lead to the regression of atherosclerosis.
18.2. Lipoproteins
Lipoproteins are spherical particles transporting lipids in the blood. Table 1 shows an overview of the basic lipopro-
tein classes. Chylomicrons and VLDL are synthesized de novo. IDL and LDL are products of VLDL catabolism. HDL pro-
duction and metabolism are described in the relevant section of this chapter. An intensive metabolism of lipoproteins 
takes place in the blood, where besides their degradation, practically all their components (cholesterol, Tg, phospholi-
pids, apolipoproteins) are exchanged and transferred between the lipoprotein types. Lipoprotein(a) is an atypical lipo-
protein. It takes part in the fibrinolysis process and is described in the chapter Laboratory Markers of Atherosclerosis. 
Table 1 shows the relation of each lipoprotein class to atherosclerosis.
Figure 18.8. Shape and structure of lipoproteins
Table 18.1. Relation of lipoproteins to atherosclerosis
18.2.1. Chylomicrons
Chylomicrons are synthesized in enterocytes (along with apolipoprotein B48). Their physiological function is to 
transport Tg from the intestine to peripheral tissues (fatty tissue in particular) and transport cholesterol from the in-
testine to the liver. They are partially degraded in blood capillaries of the peripheral tissues (fatty and muscle tissues 
in particular), and released Tg are hydrolyzed by lipoprotein lipase effect. This enzyme is localized on the blood ca-
pillary endothelium, mostly in skeletal muscles, myocardium, fatty tissue and the mammary gland during lactation. 
The particle gradually diminishes, and when about 70% of Tg have been split off, chylomicrons become „chylomicron 
remnants“ which are relatively rich in cholesterol. They are bound very rapidly, mainly in the liver, through the pathway 
of receptors for apolipoprotein E. The remnant particles are a source of exogenous cholesterol for hepatocytes. The 
highest concentration of chylomicrons in the blood is usually 3 - 6 hours after a meal, and they should not be present 
in the blood after about 9 hours of fasting.
Atherogenicity: chylomicrons do not have any atherogenic potential; their remnants, however, are strongly athero-
genic (but they have a very short biological half-life in physiological circumstances).
18.2.2. VLDLs
VLDLs are synthesized in hepatocytes. The rate of apolipoprotein B100 synthesis is a limiting factor for their secre-
tion into the blood. VLDLs transport endogenous Tg (synthesized in the liver) to peripheral tissues (fatty and muscle 
tissues in particular). While in the blood, VLDLs take over additional apolipoproteins (apo E, apo C) from HDL particles. 
In the blood capillaries of peripheral tissues (muscle and fatty tissues in particular) are VLDLs partially degraded during 
the hydrolysis of Tg by the action of lipoprotein lipase, that is localized on the endothelium of capillary vessel in the 
tissue with a high consumption of FAs. Lipoprotein lipase is activated by apolipoprotein C-II and also by insulin. The 
VLDL particle takes over esterified cholesterol from the HDL particles in exchange for Tg. The VLDL particle is thereby 
depleted of Tg and enriched with cholesterol esters, they decrease and becomes the IDL particle (VLDL remnant). The 
biological half-life of VLDL is about 2 - 4 hours.
Atherogenicity: increased VLDL concentration slightly increases the risk of cardiovascular diseases. Their presence 
in the blood (along with chylomicron remnants) is involved to elevated Tg level.
18.2.3. IDLs
IDLs are a product of VLDL catabolism and contain approximately the same molar content of both cholesterol and 
Tg. They may be metabolised in two ways: a) when flowing through the liver, they are taken up by hepatocytes using 
the receptor for apolipoprotein E (carried on the IDL surface) and degraded in the liver; b) when flowing through the 
liver, they are exposed to the effect of hepatic lipase, which hydrolyzes most of Tg remaining in them to form the LDL 
particle. In physiological circumstances, IDLs have a very short biological half-life and their concentration normally does 
not exceed 1/10 of the LDL concentration.
Atherogenicity: IDLs are highly atherogenic and may markedly accelerate the development of atherosclerosis.
18.2.4. LDLs
LDLs are a product of VLDL and IDL catabolism in the blood and carry apolipoprotein B100 on their surface, which is 
required for the LDL bond to the LDL-receptor on the surface of cells. Their function is to supply cholesterol to all peri-
pheral tissues – practically all cells express the LDL-receptor on their surface. The entry of cholesterol into cells through 
the pathway of LDL-receptors is regulated by feedback. LDLs are the main source of cholesterol, that is primarily used 
for cell membrane synthesis. About 30 – 40% of LDL particles are usually catabolized within 24 hours, about 80% of 
these through the LDL-receptor pathway. LDLs have a long biological half-life and a part of them is subject to chemical 
modification such as glycosylation and/or oxidation. Such modified LDLs lose their ability to bind to LDL-receptors and 
are catabolized through the pathway of scavenger receptors, particularly by macrophages in sub-endothelial spaces. 
The entry of modified LDLs into cells through the pathway of scavenger receptors is not regulated by feedback; ma-
crophages in sub-endothelial spaces therefore accumulate cholesterol uncontrollably and gradually change into foam 
cells that form the basis of the atherosclerotic plaque. There are several LDL subtypes, differing in size, density and 
composition (content of cholesterol and Tg): large LDL
1
, medium-sized LDL
2
 and small LDL
3
. The small LDL
3
 are produced 
in the blood of patients with high level of Tg a result of the degradation of originally very large (atypical) VLDL particles. 
These are synthesized in the liver due to excess energy intake (obesity) in type 2 diabetes mellitus and in patients with 
metabolic syndrome.
Atherogenicity: LDLs are highly atherogenic; LDL atherogenicity increases with diminishing size (the most athero-
genic LDLs are the small LDL
3
).
18.2.5. HDLs
These smallest lipoproteins have a high content of proteins (apolipoproteins and other proteins and enzymes). The 
main function of HDLs is the reverse transport of cholesterol from peripheral tissues and other lipoproteins back to the 
liver. Precursor of HDL is apolipoprotein A1, which is secreted from the liver into blood. Apolipoprotein A1 binds in the 
blood free cholesterol, phospholipids, and other apolipoproteins and enzymes to form discoid (nascent) HDL particles. 
Cholesterol in HDL particles is esterified by the action of LCAT (lecithin-cholesterol acyltransferase); esterified choleste-
rol is transported inside HDL particles to form larger, spherical HDL particle is then formed. This esterified cholesterol is 
exchanged at the same time for Tg between HDLs and Tg-rich lipoproteins (VLDLs, chylomicrons) by the action of CETP 
(the cholesterol-ester transfer protein). The HDL particles may have two potential fates:
• they are taken up by hepatocytes through the pathway of the HDL-receptor and hepatocytes excrete cho-
lesterol from the HDL into the bile;
• Tg in the HDL are hydrolyzed by the action of hepatic lipase to form a smaller HDL particle, which returns 
to the process of reverse cholesterol transport.
Atherogenicity: HDLs protect against the development of atherosclerosis – they transfer excess cholesterol from 
the vessel wall (and from peripheral tissues and other lipoproteins) back into the liver. In addition, HDLs have many 
other „anti-atherogenic“ effects. For example, they protect LDL particles from oxidative modification (by the action of 
the enzyme paraoxonase on their surface), they stimulate nitric oxide synthesis in the endothelium and thus protect 
the vessel endothelium.
18.3. Apolipoproteins
Apolipoproteins are proteins which are part of the lipoprotein particle and have many functions in the lipoprotein 
metabolism: they are enzyme cofactors, ligands for receptors, they take part in the transport and exchange of substan-
ces between lipoprotein particles (cholesterol, Tg, phospholipids), and are the structural proteins of lipoproteins. Table 
2 shows the characteristics of some main lipoproteins. Clinically significant lipoproteins which are determined and are 
most important for the diagnosis and treatment of patients with hyperlipoproteinaemia are apolipoprotein B100 and 
apolipoprotein A-I.
Apolipoprotein Site of Synthesis Contained in Lipoproteins: Function
A I Liver, intestine HDL, CL LCAT activator
A IV Liver, intestine HDL, CL LCAT activator
B 48 Intestine CL Structural lipoprotein
B 100 Liver VLDL, IDL, LDL Ligands for LDL receptors
C I Liver, adrenal gland HDL, VLDL, CL LCAT activator
C II Liver, intestine HDL, IDL, VLDL, CL LPL activator
C III Liver, intestine HDL, IDL, VLDL, CL LPL and hepatic lipase inhibitor
E Liver, peripheral tissue HDL, IDL, VLDL, CL Ligands for LDL and apo E receptors
CL - chylomidrons; LCAT – lecithin-cholesterol acyltransferase; LPL - lipoprotein lipase 
Table 18.2. Some important apolipoproteins and their functions
18.3.1. Apolipoprotein A-I (Apo A-I)
This polypeptide is bound reversibly to the surface of HDL and chylomicrons. When chylomicrons are metabolized 
in the blood stream, apo A-I is transported to HDL where it accumulates. It is a structural HDL apolipoprotein and LCAT 
(lecithin-cholesterol acyltransferase) enzyme cofactor, which is required for cholesterol esterification in HDL particles 
and thereby for reverse cholesterol transport. Apo A-I is also a ligand for the HDL receptors in hepatocytes. Apo A-I 
level is routine measured in biochemical laboratories. This assay is important to evaluate cardiovascular risks because 
it provides information about the amount of anti-atherogenic HDL particles in the blood (unless the blood also contains 
chylomicrons, i. e. unless the serum is chylous).
Atherogenicity: increased Apo A-I concentration reduces the risk of atherosclerosis.
18.3.2. Apolipoprotein B100 (Apo B)
This is the largest apolipoprotein (4536 amino acids). It is synthesized in hepatocytes (about 10 mg per day) and it 
is a structural component of VLDLs, IDLs and LDLs. It also serves as a ligand for the bond of LDL particle to LDL-receptor 
on the surface of all cells. Apo B synthesis is decisive for the rate of VLDL secretion from hepatocytes into the blood. 
Following VLDL secretion into the blood, the active part of the apo B100 chain is masked, so VLDL and IDL particles 
are not bound to the LDL-receptor. Only after the hydrolysis of Tg from VLDLs and IDLs (when the LDL particle is for-
med) the specific parts of the apo B100 chain are unmasked and the LDL particle can bind to LDL-receptors. Following 
internalization of the receptor - LDL complex, apo B100 is degraded in lysozymes. A mutation in the apo B100 gene 
(like mutations in the LDL-receptor gene) leads to a disease called „familial hypercholesterolaemia“. In both cases, LDL 
particles are not sufficiently taken up from the blood and a marked increase occurs in the LDL-cholesterol level in the 
blood. This causes a very early ischaemic heart disease. Concentration of Apo B100 is routine measured in biochemical 
laboratories.
Atherogenicity: apo B100 concentration is an indicator of the sum of the main atherogenic lipoproteins (LDLs, IDLs 
and VLDLs) in the blood. Therefore, an increased apo B100 level is a risk factor for cardiovascular diseases.
CHAPTER 19
19. Risk Factors for Atherosclerosis (Except Lipids)
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19.1. Markers of Inflammation
Atherosclerosis is characterized by chronic inflammatory process in the vessel wall and therefore it is not surprising 
that inflammatory markers are related to complications of atherosclerosis
19.1.1. C-Reactive Protein (CRP)
CRP is a clinically significant „acute phase protein”, whose level increases particularly in systemic bacterial, infec-
tious and tumour diseases. CRP levels in tens and often hundreds of mg/L are typical of systemic bacterial infections.
Clinical studies have shown, however, that a slightly increased CRP level in the range of 3 - 10 mg/L is associated 
with an increased risk of the manifestation of cardiovascular complications. Primarily, there is an increased risk of 
ischaemic heart disease, but the risk of ischaemic cerebrovascular accident and atherosclerosis in other locations also 
rises. Clinical studies performed on large sets have proved that people with slightly increased CRPs had higher cardio-
vascular morbidity and mortality rates. This relationship is valid not only for previously healthy people without cardio-
vascular complications (primary prevention), but also for patients with cardiovascular diseases (secondary prevention). 
CRP values under 3 mg/L are currently considered physiological, 3 - 6 mg/L indicate a borderline risk, and 7 - 10 mg/L 
indicate a elevated risk of cardiovascular diseases.
However, CRP is not a risk factor that induces atherosclerosis, it is just an indicator of risk (like other inflammatory 
markers). The CRP level is increased in people with major causal risk factors such as smoking, hypertension, obesity, 
metabolic syndrome, diabetes mellitus, etc. The CRP level decreases if a person manages to reduce the cholesterol 
level, lose weight, induce a regression of diabetes (overweight or obesity reduction), etc. In addition, a slight increase 
in CRP may not always be associated with an elevated risk of cardiovascular complications: the interpretation of a CRP 
result between 3 and 10 mg/L should be with cousion and individually, as a slight increase in CRP may be due to any 
inflammation in the body and may not have relationship to cardiovascular diseases (chronic diseases of the intestine, 
lungs, joints, etc.), or can be the result of a starting or subsiding acute inflammation.
19.1.2. Interleukin 6 (IL-6)
IL-6 is a cytokine which stimulates the synthesis of acute phase proteins in the liver, including CRP. IL-6 is also 
produced in atherosclerotic vessel wall lesions, particularly in macrophages and smooth muscle cells. Therefore, in-
flammatory (atherosclerotic) activity in the vessel wall is connected with an increased IL-6 level in the blood. Clinical 
prospective studies dealing with the risk of cardiovascular diseases have proved that an increasing IL-6 level also incre-
ases the risk of morbidity and mortality from cardiovascular diseases, particularly ischaemic heart disease. However, it 
is not yet clear yet whether there is a causal or only a mediating relationship between IL-6 and atherosclerosis. There 
are probably two mechanisms by which IL-6 may influence cardiovascular risk:
a) the process mediated by other cytokines and acute phase proteins (CRP, SAA, lipoprotein modifications);
b) the direct effect of IL-6 on endothelial cells.
Elevated levels of IL-6, however, should be interpreted (like CRP) very carefully, because it need not be related 
to cardiovascular complications, but to any other inflammatory diseases. In addition, the IL-6 level is often increased 
(like CRP) in patients with diabetes, dyslipidaemia and in smokers. Values ranging from 1.5 to 7.0 ng/L are considered 
physiological.
19.1.3. Serum Amyloid A (SAA)
SAA is the common name for several proteins belonging to the family of acute phase reactants. It is also closely 
related to blood lipoproteins, particularly high-density lipoproteins (HDL). SAA is frequently associated with them – it 
is bound to their surface, most often to HDL
3 
particles. In a chronic inflammatory condition, SAA increasingly binds to 
the HDL surface and displaces from binding to HDL enzyme paraoxonase-1. This enzyme provides HDL with antioxidant 
properties, which are required in preventing the development of atherosclerosis. The HDL particle loses its antioxidant 
properties becomes dysfunctional and may even acquire pro-atherogenic properties. Increased SAA levels are often 
found in people with obesity, insulinresistance, metabolic syndrome and diabetes mellitus. According to the results of 
clinical studies, increased SAA as a marker of cardiovascular risk is concurrent with an increase in another inflammatory 
marker of atherosclerosis, namely CRP.
19.1.4. Myeloperoxidase
Myeloperoxidase is an enzyme (haemoprotein) from the group of peroxidases produced by monocytes and ne-
utrophils at the site of inflammation. When the inflammatory process in atherosclerotic plaques is active, the originally 
stable plaque is transformed by myeloperoxidase action into an unstable (vulnerable) plaque with a risk of plaque rup-
ture and thrombus formation, causing artery lumen occlusion. Therefore, increased MPO activity in the blood is a sign 
of the risk of atherosclerotic plaque instability and also the risk of acute cardiovascular accident.
19.2. Markers of Haemostasis and Thrombosis
Acute complications of atherosclerosis (myocardial infarction, cerebrovascular accident) usually develop as a result 
of a thrombus adhering to a artery wall damaged by atherosclerosis. That is why the relationship between markers of 
haemostasis and thrombosis to atherosclerosis and its complications has been studied intensively. In addition to the 
factors listed below - lipoprotein (a), fibrinogen, factor VII, plasminogen activator inhibitor - other coagulation and 
prothrombotic factors may also take part in the atherogenesis process.
19.2.1. Lipoprotein(a) [Lp(a)]
Lp(a) is essentially the LDL particle, on which the surface of the addition of apolipoprotein B100 is bound one more 
protein - apolipoprotein(a). Apolipoprotein(a) is highly homologous with plasminogen; it competes with plasminogen 
for binding sites on plasmin, but does not activate it. Higher concentrations may thus block the fibrinolysis process. In 
addition, unlike the LDL particle, the Lp(a) particle is not catabolized through the LDL-receptor pathway. The Lp(a) level 
is usually genetically determined. It is often increased in patients with familial hypercholesterolaemia, but it is also 
increased in patients with chronic renal failure, nephrotic syndrome and post-menopausal women. Concentrations 
under 0.3 g/L (sometimes under 0.5 g/L) are usually considered physiological, but a part of the population has a very 
low or even non-measurable Lp(a) concentration.
Increased Lp(a) concentration is connected with an increased risk of arterial thrombosis. Epidemiological studies 
have shown that an increased Lp(a) concentration is an independent risk factor primarily for the development of early 
ischaemic heart disease. But it is very difficult to lower the Lp(a) level; most hypolipidemic agents (statins, fibrates, 
resins, ezetimibe) have practically no effect on the Lp(a) level. The only hypolipidemic agent which may lower the Lp(a) 
level is niacin (nicotinic acid). The measurement of Lp(a) concentration has not yet been standardized; the main pro-
blem is the existence of several tens of Lp(a) chain variants with different binding capacities for the antibodies used in 
diagnostic sets. With immunonephelometry method it is possible to measure even very low concentrations of Lp(a).
19.2.2. Fibrinogen
Fibrinogen is a coagulation factor: it is changed into fibrin by the action of thrombin, which is a key step in blood 
clotting. Commonly reported physiological concentrations are 2 - 4 g/L, but recent opinions suggest that the upper 
limit is only 3.5 g/L or thereabouts (levels around 4 g/L may be connected with a slight increased thrombophilic risk). 
Epidemiological studies have shown that elevated fibrinogen concentration is a risk factor for cardiovascular diseases, 
in particular for ischaemic heart disease and cerebrovascular accidents, but also for peripheral forms of atherosclero-
sis. Fibrinogen predicts the risk of these complications. The mechanism through which fibrinogen interferes with the 
atherogenesis process is still under discussion and it is expected a few options:
a) increasing platelet aggregation, and thus an increased risk of a thrombus on the atherosclerotic plaque
b) increasing blood viscosity
c) infiltration through the arterial wall and cell proliferation stimulation
The blood fibrinogen level is reduced by some hypolipidemic agents, in particular fibrates and nicotinic acid. Fib-
rinogen is an indicator of cardiovascular diseases risk (such as inflammatory markers), but it is probably not a causal 
risk factor: a decrease in fibrinogen concentration in the blood did not lead to any decrease in the incidence of cardio-
vascular diseases in the interventional studies. Elevated fibrinogen concentrations are often associated with other risk 
factors: smoking, diabetes mellitus, obesity, metabolic syndrome, and it also increases during physical inactivity.
19.2.2.1. Factor VII
Factor VII is another coagulation factor. its physiological level in the blood is usually given as 70 to 120% of the 
standard activity. A raised factor VII concentration is associated with an increased risk of a thrombus in the artery wall 
that id damaged by atherosclerotic plaque. Results of epidemiological studies show that increased factor VII levels are 
associated with an increased risk of cardiovascular diseases. Raised factor VII levels (together with increased PAI-1) can 
be often found in people with metabolic syndrome.
19.2.2.2. Plasminogen Activator Inhibitor 1 (PAI-1)
Under the name of PAI-1 are included natural inhibitor of tissue plasminogen activator. An increased PAI-1 level 
leads to impaired fibrinolysis and that is why PAI-1 is considered a risk factor for atherosclerosis. Among other places, 
it is synthesized in the vessel endothelium, where the synthesis of PAI-1 may be increased either by hypertriglyceridae-
mia or an increase very low-density lipoproteins level. Elevated PAI-1 can be typically found (together with elevated 
factor VII) in people with metabolic syndrome. An increase in PAI-1 correlates with insulinaemia, and its synthesis in 
adipocytes (in intra-abdominal fat) may be induced by insulin. Decrease in PAI-1 levels in diabetic patients treated with 
metformin suggests that there is a relationship between the increase in PAI-1 and hyperinsulinemia.
19.2.2.3. Homocysteine
An elevated level of this non-essential amino acid in the blood is called hyperhomocysteinaemia (hHCy). Mild hHCy 
(16 - 30 μmol/L), intermediate hHCy (31 - 100 μmol/L) and severe hHCy (over 100 μmol/L) are distinguished. Severe 
hHCy is determined genetically and it is accompanied by thrombosis of the venous and arterial systems, thromboem-
bolic disease and atherosclerosis complications. Fortunately, the incidence of severe hHCy in the population is very 
rare. In the context of atherosclerosis, is addressed primarily mild hHCy, which is relatively frequent in the population 
(prevalence of about 1:70). It has been proved that mild hHCy is associated with an increased risk of cardiovascular 
complications. A weak association between mild hHCy and CVD has been proved in healthy people; on the other hand, 
in patients with ischaemic heart disease, thromboembolic disease, diabetes mellitus and renal failure, mild hHCy is a 
strong predictor of future cardiovascular accidents.
The commonest cause of mild hHCy is polymorphism in the methylenetetrahydrofolate reductase gene, mani-
fested particularly as a result of insufficient folic acid intake from food. In addition the homocysteine level increases 
also as a result of renal failure and smoking; it rises also with age and in post-menopausal women. Elevated homocys-
teine concentrations are frequent in patients with premature manifestation of atherosclerosis. The mechanism of the 
pro-atherogenic action of homocysteine is not yet clear. It was expected that homocysteine directly affects the vessel 
endothelium, dampens fibrinolysis, affects oxidative stress (increased production of free radicals) and may developed 
endothelial dysfunction with subsequent platelet activation and the formation of platelet-rich thrombi. The homocy-
steine level in mild hHCy can usually be easily decreased by the administration of B vitamins, in particular pyridoxine, 
B12 and folic acid. However, homocysteine is most probably not a causal risk factor: although there was a decrease in 
homocysteine concentration in practically all clinical interventional studies of folic acid and B-group vitamin adminis-
tration, there was no any decrease of the incidence of cardiovascular events.
19.2.2.4. Lp-PLA2 (Lipoprotein-Associated Phospholipase A2)
Lp-PLA2 is synthesized primarily in macrophages (partially also in T-cells and hepatocytes), and it is bound to lipo-
proteins in the blood (mostly to LDLs, and to a small extent to HDLs). Lp-PLA2 in the blood catalyzes the transformation 
of phosphatidylcholine into free fatty acids and lysophosphatidylcholine. Theis process may accelerate inflammation 
and atherogenesis. Lysophosphatidylcholine is a chemoattractant of monocytes and T-cells, and may activate the deve-
lopment of vessel endothelium dysfunction, the induction of endothelial adhesive molecule expression, the prolifera-
tion of smooth muscle cells and macrophages in the vessel wall, and the expression of PDGF (platelet-derived growth 
factor). Oxidized free fatty acids are chemoattractants for monocytes and increase both adhesive molecule (VCAM-1) 
expression and cell membrane permeability. Lp-PLA2 is also present in atherosclerotic plaques, where it is produced 
by inflammatory cells.
It has been proved that an increased Lp-PLA2 concentration in the blood is associated with an increased risk of 
myocardial infarction and cerebrovascular accidents. It is due to fact that Lp-PLA2 is expressed primarily in unstable 
atherosclerotic plaques with a thin fibrous cover, so increased Lp-PLA2 concentration in the blood points to the risk of 
plaque rupture with consequent acute myocardial infarction or a cerebrovascular accident. The association between 
an increased blood Lp-PLA2 level and increased risk of cardiovascular diseases has been proved in many epidemiolo-
gical studies. Results of these studies indicate that increased Lp-PLA2 concentration is a predictor of cardiovascular 
risk independent of the presence of other risk factors. Nevertheless, the Lp-PLA2 level also increases due to smoking, 
diabetes mellitus, obesity and metabolic syndrome. Concentrations over 200 - 235 ng/mL are considered elevated.
19.2.2.5. Microalbuminuria
Albumin excretion to the urine in the ranges 30 to 300 mg/24 hrs in is called “microalbuminuria”. This assay is 
performed especially in patients with diabetes mellitus, as it is an early indicator of diabetic nephropathy. Clinical stu-
dies have shown, however, that microalbuminuria is also associated with the risk of cardiovascular complications, not 
only in patients with diabetes mellitus but also in non diabetic population. Microalbuminuria is therefore a predictor 
of cardiovascular morbidity and mortality in diabetic and hypertonic patients as well as in the general population. It 
is supposed that microalbuminuria is not only the indicator of glomerular damage, but also generally a marker of the 
damaged vessel permeability that is present in endothelial dysfunction. Vessel endothelium dysfunction is one of the 
key steps in the development of atherosclerotic focus.
19.2.2.6. Disorder of Glucose Homeostasis
Practically all disorders of glucose homeostasis (insulinoresistance with hyperinsulinaemia, impaired fasting glycae-
mia, impaired glucose tolerance, type 2 DM) are risk factors for the premature atherosclerosis and the development 
of cardiovascular complications. Cardiovascular diseases are also the main cause of mortality of patients with diabetes 
mellitus. The incidence of ischaemic heart disease is 2-4 times higher in diabetics; the risk of stroke is 3-5 times higher; 
and the risk of lower-extremity ischaemia is even up to 30 times higher compared with non-diabetics. Mechanisms 
accelerating atherogenesis in diabetis subjects have not yet been fully clarified. Diabetes mellitus is usually accompa-
nied by dyslipidaemia hypertension and obesity (obesity is the main cause of type 2 diabetes mellitus). Besides the risk 
factors mentioned above, many other pathophysiological processes take part in atherosclerosis acceleration in diabetic 
subjects: endothelial dysfunction, platelet hyperreactivity, impaired fibrinolytic balance, impaired blood flow, and chro-
nic inflammation. Platelets in patients with diabetes mellitus increasingly adhere to the vessel endothelium and their 
aggregability is increased; enhanced von Willebrand factor production in the damaged endothelium also contributes 
to their activation. The concentration of other coagulation factors (fibrinogen, factor VII, VIII, XI, XII, kallikrein) is also 
increased with concurrent inhibition of the fibrinolysis system (increase in PAI-1). The permeability of cell membranes 
is impaired. Type 2 diabetes mellitus is commonly accompanied by dyslipidaemia, characterized by the presence of 
small LDL
3
 particles, a decrease in HDL-cholesterol and increased triglycerides. The atherosclerotic process becomes 
accelerated in the period before diabetes manifests itself, when hyperinsulinaemia and insulinoresistance are present, 
and they initiate the development of vessel endothelium dysfunction as the first step in the atherosclerotic process.
CHAPTER 20
20. Free Radicals, Relation to Diseases and Protection against Them
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20.1. What Is Oxidative Stress?
Oxidative stress is a mechanism of damage to the body which co-participates in the pathogenesis of many diseases 
and their complications, such as atherosclerosis, diabetes mellitus, renal disease, ischaemia-reperfusion injury, neuro-
degenerative diseases, carcinogenesis and inflammatory diseases.
Oxidative stress is defined as an imbalance between the increased production of oxidants and insufficient antioxi-
dant defence mechanisms, which results in damage to tissues.
20.2. Oxidants – Free Radicals and Reactive Forms of Oxygen and Nitrogen
Oxidants are free radicals and other reactive forms of oxygen and nitrogen which are closely related to radical 
reactions. Free radicals are atoms, molecules or ions containing one or more unpaired electrons in the bonding orbi-
tal. They are unstable, highly reactive and tend to make chain reactions. Examples of important oxidants include the 
hydroxyl radical OH˙, superoxide O
2
˙-, singlet oxygen 1O
2
, hydrogen peroxide H
2
O
2
, nitric oxide NO˙, hypochlorous acid 
HClO, and the peroxyl and alkoxyl radicals ROO˙ and RO˙. Figure 1 shows the reactions leading to oxidant generation.
Figure 20.1. Oxidant generation and oxidant inter-reactions
The most important source of free radicals in the body is the mitochondrial respiratory chain. Oxygen commonly 
accepts 4 electrons and is transformed into water. This reaction, however, takes place in successive steps: oxygen → 
superoxide → hydrogen peroxide → hydroxyl radical → water. Another important producer of oxidants is phagocytes 
(neutrophils and monocytes-macrophages), specifically their NADPH oxidase and myeloperoxidase. In the respiratory 
burst (Figure 21.2), following activation by inflammatory stimuli, NADPH oxidase reduces molecular oxygen to super-
oxide, which is subsequently converted to hydrogen peroxide. These substances can be another source of oxidants – 
nitric oxide, peroxynitrite and hydroxyl radical. In the presence of chloride ions, hydrogen peroxide is also metabolized 
by myeloperoxidase to hypochlorous acid, which may subsequently react with endogenous amines to form chlora-
mines. Free radicals are also generated during xenobiotic detoxification and in many other chemical reactions, such 
as reactions catalyzed by cytochrome P450, xanthine oxidase, lipoperoxidase or cyclooxygenase. Their generation is 
accelerated by transition metals - iron, copper – Fenton’s reaction:
Nitric oxide (NO˙) is generated from L-arginine by the action of NO synthase (NOS). Constitutive NOS is found pri-
marily in the endothelium and neurons, and inducible NOS primarily in macrophages.
Figure 20.2. Respiratory burst of neutrophils
20.3. Antioxidants – Substances Acting against Oxidants
Antioxidants are substances working against the generation and effect of free radicals – as scavengers (intercep-
tors) of free radicals, as free radical generation inhibitors through the bond to transition metals, for example, or else 
they eliminate hydroperoxides and repair damage. Antioxidants in the human body can be divided into two groups:
Enzymes and enzyme cofactors = trace elements (superoxide dismutase – copper, zinc, manganese; glutathione 
peroxidase – selenium; catalase – iron; cytochrome P450, lactoperoxidase;
Substrates – lipophilic (tocopherols and carotenoids) and hydrophilic (ascorbic acid, glutathione, thiols, caerulo-
plasmin, transferrin, ferritin, albumin, bilirubin, uric acid and others).
Antioxidant properties can also be found in many synthetic compounds such as the iron and copper chelates de-
ferroxamine and penicillamine, the xanthine oxidase inhibitors allopurinol and oxypurinol, probucol, lazaroids, angio-
tensin-converting-enzyme inhibitors and statins.
20.4. Compounds Generated Due to Oxidative Stress – Radical Reaction Products and 
Their Importance in Tissue Damage
Oxidative stress modifies biologically important compounds. It changes their structure by fragmentation, aggre-
gation, cross-linking; and, it changes their properties – hydrophobicity, proneness to proteolysis and function, as well 
as their immunological properties. These changes depend on the chemical nature of the agent and the intensity of 
attack. The damage affects lipids, proteins, carbohydrates and nucleic acids. Fatty acids with multiple double bonds – 
polyunsaturated fatty acids – are most prone to radical reactions in lipids, and the process is referred to as lipid peroxi-
dation. Their structure is gradually rearranged; conjugated dienes, peroxyl and alkoxyl radicals and hydroperoxides are 
generated, and the modified molecule may also cleave into shorter products to form malondialdehyde or 4-hydroxyno-
nenal. Membrane lipids as well as lipoproteins may become damaged. The amino acids tyrosine, methionine, cysteine 
and tryptophane are subject to damage in proteins by oxidation, nitration, chlorination and dimer formation. Proteins 
may then aggregate and cross-link to generate advanced oxidation protein products (AOPP). Advanced glycation end 
products (AGEs) are generated with the help of carbohydrates and also due to carbonyl stress. Proteins can also be mo-
dified through the action of lipid peroxidation products (malondialdehyde lysine, hydroxynonenal and acrolein-protein 
adduct) to form advanced lipid peroxidation end products (ALEs). DNA damage affects deoxyribose and bases, which 
results in DNA chain breaks and chain cross-linking. Figure 3 shows damage to biological structures and its effects.
Figure 20.3. Effects of oxidative stress
Oxidative stress is closely related to carbonyl stress, which is characterized as an increase in reactive carbonyl 
compounds caused by their reduced production and/or reduced elimination and excretion. These are compounds 
containing a carbonyl group such as glyoxal and methylglyoxal, or products of lipid peroxidation, malondialdehyde 
and 4-hydroxynonenal. Reactive carbonyl compounds may also be generated from carbohydrates, lipids and amino 
acids in oxidative and non-oxidative reactions, and may give rise to ALEs and AGEs. AGEs, a heterogeneous group of 
compounds such as carboxymethyllysine, pentosidine, glyoxal-lysine dimer and methylglyoxal-lysine dimer, have been 
characterized the best; they are generated spontaneously by non-enzymatic glycation, but also due to oxidative and 
carbonyl stress. Apart from structural damage and change in the biological properties of important substances, the end 
products of advanced damage by oxidative and carbonyl stress (AGEs, ALEs, AOPP) have many other effects mediated 
through specific receptors, of which RAGE (receptor for AGEs, with AGE-R1, R2 and R3 being essential) was the first to 
be described.
RAGE is a multiligand receptor, and AGEs were described as the first ligands. β-amyloid, S100-proteins/kalgranulins 
or HMGB1 (high mobility box group protein 1) bind to RAGE. Ligand-RAGE interactions trigger a signalling cascade in-
volving p21ras, MAP-kinase, ERKs and JNKs; in addition, the nuclear factor κB becomes activated, which is also connec-
ted with oxidative stress. This is followed by the stimulation of gene transcription of cytokine and growth factors (TNF, 
IL-1, PDGF, IGF-1, interferon γ) and of adhesion molecules (ICAM-1, VCAM-1), the stimulation of cell proliferation, an 
increase in vascular permeability, the induction of macrophage migration, etc. The AGE-RAGE interactions, subsequent 
oxidative stress and AGEs also directly damage DNA. In addition, the RAGE activation affects the expression and activity 
of glyoxalase I, which is an enzyme detoxifying the AGE precursors methylglyoxal and glyoxal. RAGE plays a role in the 
pathogenesis of many diseases and their complications, such as diabetes mellitus, atherosclerosis, Alzheimer’s disease, 
rheumatoid arthritis, inflammatory diseases and tumour metastasizing.
20.5. Physiological and Pathological Role of the Reactive Forms of Oxygen and Nitrogen, 
Importance in Pathogenesis
When discussing oxidative stress, its definition must include not only the imbalance between oxidants and antioxi-
dants in favour of oxidants, but also take into account the subsequent damage to the body, since oxidants, i.e. free ra-
dicals and other reactive forms of oxygen and nitrogen, have many important biological functions in the inflammatory 
response, xenobiotic metabolism, vascular tonus, or as second messengers in signal transduction (Table 1).
Physiological role Specific function
Inflammatory reaction Respiratory burst of phagocytes
Signal transduction Intracellular signalling – second messenger role
Monooxygenase reactions
Steroid hydroxylation
Xenobiotic metabolism
Vascular tonus regulation
NO – relaxation
superoxide – constriction
Mediators NO – CNS neuromodulator
Table 20.1. Physiological roles of free radicals
In contrast to this, the pathological effect of radicals and radical reaction products involves extensive damage 
to biological structures, damage signalling through receptors with the subsequent triggering of many cascade reacti-
ons depending on the cell type – pro-inflammatory responses, cell proliferation or apoptosis, and the effect on other 
structures by the chemical compounds thus produced. Therefore, oxidative stress plays a role and co-acts in the pa-
thogenesis of many diseases and their complications, from inflammatory diseases (sepsis, chronic inflammatory disea-
ses), through cardiovascular diseases (hypertension, atherosclerosis, ischaemia-reperfusion), diabetes mellitus and its 
complications, renal impairment and its effects, neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis) 
through to tumour diseases and their treatment, or pregnancy, and especially to pathological conditions in pregnancy 
(pre-eclampsia).
Pathological role Specific function
Damage to biological structures
Lipid peroxidation
Glycoxidation
Protein modification
DNA modification
Role in the pathogenesis of many diseases and their 
complications
Atherosclerosis
Diabetes mellitus 
Renal diseases 
Tumour diseases
Inflammatory diseases
Neurodegenerative diseases
Table 20.2. Pathological roles of free radicals
20.6. Laboratory Diagnostics
The determination of free radicals in body fluids is problematic due to their short biological half-life. It is therefo-
re more appropriate to measure levels of compounds generated due to oxidative stress or antioxidation protection. 
Assays can be made on various biological materials such as serum, plasma, urine, whole blood, blood elements or 
exhaled air. Laboratory diagnosis must always be comprehensive and the results of regular tests may often point to the 
probable presence of oxidative stress. Laboratory results must be evaluated on an individual basis in relation to the 
patient’s clinical condition. Laboratory assays for oxidative stress and antioxidant parameters are used mainly to study 
the cause and course of a disease; they are not used in normal clinical practice.
Direct measurements include assays for generating radicals and the reactive forms of oxygen and nitrogen using 
methods such as pulse radiolysis, electron spin resonance and chemiluminescence. These methods are used especially 
in basic research and are not commonly available.
Indirect measurements determine substances generated in radical reactions, antioxidants and autoantibodies. It is 
also possible to determine degradation products in NO generation (nitrites, nitrates) or use an immunochemical assay 
(ELISA) for enzymes generating radicals – myeloperoxidases or xanthine oxidase.
It is possible to determine many substances generated in radical reactions (classic oxidative stress markers); for 
example, lipid peroxidation is characterized by malondialdehyde, oxidized LDLs or 8-isoprostane as an arachidonic acid 
metabolite. Protein impairment can be mapped by measuring modified amino acids or as AOPP; AGEs or sRAGE (so-
luble receptor for AGEs) are typical for the effects of carbohydrates. 8-hydroxy-2´-deoxyguanosine is a marker of DNA 
damage. ELISA, high-performance liquid chromatography (HPLC) and gas chromatography with mass spectrometry 
(GC/MS) are the most commonly applied methods.
Assays for selected antioxidants are more available: vitamins A and E (HPLC), trace elements, zinc and selenium in 
particular (atomic absorption spectrometry); it is also possible to determine the activity of antioxidant enzymes or total 
antioxidant capacity using spectrophotometry.
Another possibility, again more used for research, is the assay for autoantibodies generated in reaction to the mo-
dification of biological structures. The oxidative stress process involves the generation of compounds that are immu-
nogenic and the body produces antibodies against them. Another system (immune system) thereby becomes involved 
and may be impaired by oxidative stress; an example would be antibodies against oxidized LDL determined by ELISA.
Molecular biology techniques are able to determine a genetic predisposition to tissue damage (e.g. polymorphism 
of genes for antioxidant enzymes or enzymes degrading reactive carbonyl compounds, or genes for receptors media-
ting tissue damage such as RAGE – receptor for AGEs).
Basic laboratory assays can point to various pathologies and signal the probable presence of oxidative stress. The 
function of kidneys is examined routinely, and it is known that oxidative stress is present in patients with impaired renal 
function. Oxidative stress also has an important connection with inflammatory reaction (indicators such as C-reactive 
protein, orosomucoid) and the atherogenesis process (modified LDL particles, myeloperoxidase). An elevated glucose 
or lipid level means more substrates for the production of reactive carbonyl compounds. On the other hand, albumin 
and bilirubin (higher levels without hepatic involvement, e.g. Gilbert’s syndrome) and also glucose have antioxidant 
effects. Erythrocytes contain another important antioxidant, glutathione, and so a drop in total glutathione is expected 
in anaemia.
Table 21.3 summarizes selected assays for detecting oxidative stress. The methods listed below describe the reacti-
ons and processes that take place in the human body during oxidative stress. Individual analytes should be considered 
in context of their mutual relations before evaluating the degree of damage to the body by oxidative stress.
Group of Assays Parameters
Direct measurement – determination of generated 
radicals Pulse radiolysis, electron spin resonance, chemiluminescence
Oxidative stress damage markers
Lipid peroxidation – malondialdehyde, conjugated dienes, 
oxLDL, ALEs, 8-isoprostane
Amino acid and protein oxidation – modified amino acids 
(3-chlorotyrosine, 3-nitrotyrosine, dichlorotyrosine), AOPP
Glycoxidation – AGEs, sRAGE
Oxidative DNA damage – 8-hydroxy 2´deoxyguanosine
Degradation products in NO generation (nitrites, nitrates)
Radical-generating enzymes – xanthine oxidase, myelopero-
xidase
Antioxidants
Vitamins A and E
Trace elements – Se, Zn
Albumin, bilirubin
Glucose, uric acid
Antioxidant enzymes – superoxide dismutase, glutathione 
peroxidase, catalase
Total antioxidant capacity
Autoantibodies Antibodies against oxidized LDL
Molecular biology techniques
Polymorphism of genes for antioxidant enzymes and enzy-
mes degrading reactive carbonyl compounds, or genes for 
receptors mediating tissue damage such as RAGE – receptor 
for AGEs
Basic laboratory assays
Renal function – estimated glomerular filtration, serum crea-
tinine
C-reactive protein, albumin, glucose level, HbA1c, microalbu-
minuria, lipids, bilirubin, blood count
Table 20.3. Selected assays for detecting oxidative stress
20.7. Possible Therapies
There are no standard recommendations for oxidative stress therapy at present. However, many studies have 
shown the positive effect of administering some antioxidants, and it is also known that some drugs which are frequent-
ly administered for different indications have antioxidant properties (angiotensin-converting-enzyme inhibitors, angi-
otensin II AT
1
 receptor blockers or statins). The physiological balance between oxidants and antioxidants and potential 
adverse effects should always be taken into account when considering therapy. For example, some antioxidants may 
also have pro-oxidizing effects. The administration of antioxidants is not currently part of the recommendations for 
therapy or prevention of diseases, except for some rare diseases. On the contrary, the unsuitable administration of 
antioxidants (e.g. beta-carotene in smokers) may even lead to damage to the body. Antioxidants are administered as a 
supportive or complementary treatment, not as a causal therapy.
CHAPTER 21
21. Biochemical Tests for Liver Diseases
Authors: Prof. MUDr. Libor Vítek, PhD., Doc. MUDr. Milan Jirsa CSc.
Reviewer: MUDr. Milan Dastych
A standard set of biochemistry assays sometimes referred to as “liver tests” or “liver function tests” has been put 
together over the years. These assays are not reflecting liver function tests in the real sense of the word; rather, they 
are tests for markers substituting specific liver function tests. Biochemical tests can be divided into several groups 
based on different points of view (see the table below):
Tests indicative of hepatocyte integrity ALT, AST
Tests indicative of disorders at the level of bile duct sys-
tem and the canalicular pole of hepatocytes
ALP, GT (GGT)
Tests measuring protein synthesis by the liver Albumin, prealbumin, cholinesterase, prothrombin com-
plex/coagulation factors
Tests measuring liver capacity to transport organic ani-
ons and eliminate endogenous and exogenous substan-
ces from circulation
Bilirubin, bile acids
Tests measuring the liver’s ability and capacity to meta-
bolize xenobiotics or endogenous substances
Ammonia, CDT, lidocaine, aminopyrin
Laboratory tests for the diagnosis of specific hepatic 
diseases
Viral hepatitis, haemochromatosis, Wilson’s disease, por-
phyric diseases, autoimmune hepatic diseases, etc.
Table 21.1. Summary of biochemical tests of liver function
21.1. Tests indicative of impairment of hepatocyte integrity
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
Serum AST and ALT activities are elevated in most hepatic diseases. The highest values can be seen in fulminant 
viral hepatitis, drug-induced liver injury and toxicity, and circulatory shock. The magnitude of the increase reflects the 
extent of liver injury, but does not correlate with the prognosis. A decrease in values may reflect both declining disease 
and massive necrosis.
The AST/ALT ratio (de Ritis index) is particularly useful in alcoholic liver injury, where it is often higher than 2. The 
activities of both enzymes is affected by many factors; there is a correlation between body weight and AST/ALT activi-
ty – the both enzymes have up to 40% higher activities in obese people, most often as a result of the development of 
non-alcoholic steatohepatitis (NASH). This is also related to the fact that the asymptotic elevation of aminotransferase 
activity correlates with total mortality (similar association has been reported for elevation of gamma-glutamyl transfe-
rase (GT) activity, see below). At the same time, the asymptomatic elevation of aminotransferase activities is highly 
prevalent; 10-20% of the total population is afflicted due to alcoholic injury and/or non-alcoholic fatty liver.
21.2. Tests indicative of disorders at the level of bile duct system and the canalicular 
pole of hepatocytes
• Alkaline phosphatase (ALP)
Among liver diseases, the highest values can be seen in cholestatic diseases. This is caused by the localization of 
ALP (and also GT) at the canalicular pole of hepatocytes and in the apical membrane of the bile duct epithelium. ALP 
activity increases in extrahepatic and intrahepatic cholestasis; some patients with malignant tumours have an incre-
ased ALP activity as a result of ectopic ALP production in the malignant tissue (Regan isoenzyme). Other extrahepatic 
causes of higher ALP activity include bone diseases, some rheumatological diseases, vasculitis, hyperparathyroidism, 
hyperthyroidism, or acromegaly.
•  Gamma-glutamyl transferase
GT is a non-specific marker of cholestasis, but it also increases following the administration of some drugs and al-
cohol abuse as a result of microsomal isoform induction. The half-life of the GT elevation after alcohol consumption has 
been discontinued is long (26 days). In this case, a combination of assays for GT activity and the carbohydrate-deficient 
transferrin (CDT) level are very useful in confirming alcohol abuse. CDT is a transferrin lacking the usual carbohydrate 
component in the side chain. Transferrin glycosylation is post-translational and is adversely affected by alcohol abuse.
The GT value correlates with ALP in liver diseases. It is considered a more sensitive test for hepatobiliary disease 
than ALP. The diagnostic value of GT is limited by low organ specificity – GT activity also rises in many extrahepatic di-
seases such as cardiac infarction, renal insufficiency, obstructive bronchopulmonary disease, diabetes and pancreatic 
diseases. In addition, marked overweight may increase GT by up to 50%, so it is no surprise that higher GT activity is 
associated with higher cardiovascular morbidity and mortality.
21.3. Tests measuring protein synthesis by the liver
The liver synthesizes practically all plasma proteins except immunoglobulins. Serum level measurement allows for 
a rough estimate of protein synthetic capacity of the liver.
• Albumin
Albumin is quantitatively the most important serum protein synthesized in the liver. The half-life of albumin is 19 
- 21 days, and so albumin is not a suitable parameter for evaluating protein synthesis in acute hepatic diseases. Serum 
albumin level is not only influenced by albumin synthesis, but also by the nutritional status, distribution space and 
catabolism of albumin.
Serum albumin is typically reduced in patients with alcoholic liver cirrhosis and ascites. Other possible causes of 
reduction include nephrotic syndrome, protein losing enteropathy, burns, catabolic conditions and corticosteroid trea-
tment. The serum level correlates very well with the prognosis, which is why it is one of the criteria for the Child - Pugh 
score. The serum level in patients with ascites may be decreased considerably due to albumin leakage into the perito-
neal cavity. A rise in albumin level is typical of haemoconcentration in dehydration and diuretic therapy.
Figure 21.1. The Child-Pugh score (sometimes the Child-Turcotte-Pugh score) is used to assess the prognosis of chronic 
liver disease, mainly cirrhosis. Although it was originally used to predict mortality during surgery, it is now used to deter-
mine the prognosis, as well as the required strength of treatment and the necessity of liver transplantation.
• Prealbumin
The half-life of prealbumin is only 1.9 days, so the prealbumin level is used to evaluate proteosynthesis in the liver 
parenchyma in acute liver lesions.
• Changes in γ-globulins
Polyclonal gammapathy is a standard finding in patients with hepatic cirrhosis. An increase in each -globulin group 
is typical of some hepatic diseases; elevated IgM is typical of primary biliary cirrhosis, IgG of autoimmune and crypto-
genic liver cirrhosis, and IgA of alcoholic cirrhosis.
• Coagulation factors
Many coagulation factors such as factor I (fibrinogen), II (prothrombin), V, VII, IX and X are synthesized in the liver. 
The synthesis of coagulation factors II, VII, IX and X depends on vitamin K. Most of these factors are abundant in the 
serum, and decrease only if the proteosynthetic function of the liver is considerably impaired. Coagulation disorders 
commonly occur in hepatic diseases, most often due to disorders of the proteosynthetic functions of the liver paren-
chyma or cholestatic liver lesions, when the absorption of fat-soluble vitamins, including vitamin K, is impaired.
The prothrombin time test (Quick test) is used most often to evaluate the synthesis of coagulation factors produced 
by the liver. The test reflects external coagulation system activity by measuring prothrombin-to-thrombin conversion in 
the presence of Ca2+ ions and tissue thromboplastin. Given the short half-life of prothrombin, the test reflects changes 
very fast and is highly responsive. It is therefore an important test for acute liver conditions or the progression from 
chronic hepatic disease to hepatic failure. The measurement result is commonly referred to as the INR (International 
Normalized Ratio), the ratio of tested to control prothrombin time. Values within the range of 0.75 - 1.25 are conside-
red normal; an INR over 1.5 is accompanied by an increased risk of bleeding.
The prothrombin time is one of components for rating liver function capacity according to the Child-Pugh score.
21.4. Analytes measuring the transport and excretory capacity of the liver
a), b) Bilirubin and urobilinogen – [refer to Chapter 24]
• Bile acids
The determination of serum bile acids is a sensitive test of cholestatic liver lesions. Patients with cholestatic liver 
lesions are often treated with ursodeoxycholic acid; this treatment has to be discontinued at least one week before 
scheduled blood collection for the bile acid assay. The highest levels can be seen in primary biliary cirrhosis, primary 
sclerosing cholangitis and congenital defects in the bile acid biosynthesis pathway or bile pigment transport by the 
hepatocyte. Very important is the assay for serum bile acids in women with suspected intrahepatic cholestasis of preg-
nancy, where a relatively slight increase in the bile acid level (over 40 μmol/L, with normal levels under 7 μmol/L) poses 
a serious risk of cardiodepression for the foetus.
21.5. Tests measuring the liver’s ability and capacity to metabolize endogenous and xe-
nogenous substances
• Ammonia
An increase in the ammonia level can be seen in hepatic diseases, particularly at the phase of hepatic insufficiency. 
High levels are also present in urea cycle enzyme deficiency, Reye’s syndrome, acute and chronic hepatic encephalopa-
thy, and in bleeding into the digestive tract accompanied by increased production of ammonia by the gut flora.
Ammonia determination has many pre-analytic limitations. The correlation is better if arterial blood is taken inste-
ad of venous blood. The plasma has to be separated from red blood cells within 1 hour, ideally within 15 minutes in 
patients with cirrhosis.
•  Carbohydrate-deficient transferrin – see above
•  Dynamic tests
These tests measure the liver’s capacity to metabolize foreign substances. Non-toxic substances metabolized only 
by the liver are used. Most of these substances are metabolized by microsomal enzymes, and the tests therefore pro-
vide a good illustration of the microsomal functions of the liver. The best-known are the antipyrine and aminopyrine 
breath tests, either with direct measurement of the metabolized substance, or the method using a stable isotope 13C-
-labelled substrate to measure exhaled labelled CO
2
. Despite their relatively high diagnostic value, these tests are not 
widely used in practice, in particular due to the difficulty of determining stable isotopes in the exhaled air. Chromo-
-excretion tests are also available, but they pose a potential risk of serious anaphylactic reactions.
21.6. Laboratory assays for the diagnosis of specific liver diseases
• Laboratory assays for suspected haemochromatosis
• Transferrin saturation: physiological range 19 - 49%, a more than 60% increase is indicative of haemochro-
matosis in men and 50% in women.
• Plasma/serum iron: physiological range 6 - 29 µmol/L, values > 30 µmol/L are suggestive of haemochro-
matosis.
• Serum ferritin: physiological range 30 - 400 µg/L, values > 1.000 mg/L are usually suggestive of haemochro-
matosis.
• Iron content in liver dry matter: physiological range 0 - 2.000 µg/g dry matter, > 2000 µg/g dry matter is 
indicative of haemochromatosis.
• Gene testing: Mutations of the haemochromatosis gene on the short arm of chromosome 6; homozygous 
C282Y gene mutations or heterozygous C282Y mutations in combination with H63D in 80% of afflicted 
patients.
• Laboratory assays for suspected Wilson’s disease
• Serum caeruloplasmin: physiological range 0.2 - 0.6 g/L, levels under 0.2 g/L are suggestive of Wilson’s 
disease – this reduction is present in 90% of afflicted patients.
• Serum copper level: physiological range 12 - 24 µmol/l, levels > 24 µmol/L are suggestive of Wilson’s disea-
se, but levels may also be normal.
• Free copper in serum: physiological range 0 - 1.6 µmol/L, an increase in the fraction over 2.0 µmol/L is 
suggestive of Wilson’s disease.
• Urinary copper excretion: physiological range 0.03 - 1.26 µmol/L, an increase over 1.5 µmol/L is indicative 
of Wilson’s disease; the penicillamine challenge test is also available.
• Copper content in liver dry matter: physiological range under 50 µg/g dry liver tissue; an increase over 250 
µg/g liver tissue is found in patients with Wilson’s disease, and high levels can be found also in cholestasis 
of any aetiologies.
• Gene testing: the commonest H1069Q gene mutation is present in 40 - 50% of afflicted patients.
• Laboratory assays for suspected porphyria
Porphyrias belong to a group of haem biosynthesis disorders characterized by considerable variability in the clinical 
presentation. Clinically, porphyrias can be divided into acute and chronic types. The commonest chronic porphyria in 
the Czech Republic is porphyria cutanea tarda (PCT), and the commonest acute porphyria is acute intermittent por-
phyria (AIP).
• Porphobilinogen test on fresh morning urine
Importance: acute porphyric attack marker, more sensitive than δ-aminolevulic acid (ALA)
Reference range: < 0.25 mg/dL
• D-aminolevulic acid test on fresh morning urine
Importance: like porphobilinogen (PBG), ALA is also a marker for acute porphyric attack. The urinary ALA assay is 
important for lead poisoning diagnosis (lead reversibly inhibits the ALA-dehydratase enzyme) and porphyrias due to 
congenital ALA-dehydratase deficiency (incorrectly plumboporphyria).
Reference range: < 0.45 mg/dL
Both analytes are tested in 10 mL of fresh urine. PBG and ALA are both sensitive to light, heat, storage time and pH 
fluctuations. The PBG test has fewer interferences than ALA.
• Total porphyrin test on collected urine and stool
Importance: total porphyrin output in the urine is a marker for acute and chronic porphyria, as it is for secondary 
coproporphyrinuria (typically ranging from 200 to 500 µg/24 hours).
Reference range: < 200 µg/24 hours
The test for total porphyrin in faeces (sample of about 5 g stool) is similar.
Reference range: < 200 ng/g dry mass
There is also a set of special methods available in the CR at the Hepatology Laboratory, Institute of Medical Bio-
chemistry and Laboratory Diagnostics of the General University Hospital and of the First Faculty of Medicine, Charles 
University in Prague (affiliation of the author – LV). These methods include the tests for plasma porphyrin emission 
maximum, urine and faeces porphyrin fractionation, a test for the activities of some haem biosynthetic pathway enzy-
mes, or molecular diagnostics (provided in the CR by Prof. Martásek’s site at the Paediatric Clinic of the First Faculty of 
Medicine, Charles University in Prague).
Figure 21.2. Porphyria cutanea tarda (commonly referred to as PCT). Typically, patients who are ultimately diagnosed 
with PCT first seek treatment following the development photosensitivities in the form of blisters and erosions on common-
ly exposed areas of the skin. This is usually observed in the face, hands, forearms, and lower legs. It heals slowly and with 
scarring. Other skin manifestations like hyperpigmentation (as if they are getting a tan) and hypertrichosis (mainly on top 
of the cheeks) also occur.
• Laboratory assays for suspected hepatocellular carcinoma
• α
1
-fetoprotein (AFP)
This is a glycoprotein synthesized in the yolk sac, foetal liver and malignant epithelial hepatic carcinomas. An in-
crease is associated with hepatocellular carcinoma, but also embryonal carcinomas, germinal tumours and cleft neural 
plate.
• Serological laboratory tests for liver diseases
Serological hepatological assays play a major role in the diagnosis of viral hepatitis. Nowadays, they represent one 
of the main causes of acute and chronic hepatic diseases. The diagnosis currently relies on a combination of serological 
and molecular genetics methods.
Hepatitis A
The diagnosis relies on the presence of antibodies against the hepatitis A virus (anti-HAV)
• In the IgM class = acute hepatitis A
• In the IgG class (anamnestic antibodies) = history of hepatitis A, HAV vaccination
Hepatitis B
Acute hepatitis B
• Acute hepatitis B may be diagnosed based on serological findings only if basic patient history is known, 
because serological findings can be identical with findings for an acute hepatitis B virus infection at certain 
stages of chronic infection.
• Positive hepatitis B surface antigen (HBsAg) and antibodies against hepatitis B core antigen (anti-HBc) of 
the IgM class
• Secretory antigen (HBeAg) – persists for more than 10 weeks, probable transition to chronicity
• Occurrence of anti-HBs antibodies means recovery from acute infection and, with titre over 100 IU/mL, 
also permanent immunity. HBsAg may disappear in acute infection several weeks before anti-HBs antibo-
dies appear (the period called diagnostic gap or window) – the only serological sign of HBV infection is the 
presence of anti-HBc antibodies.
Chronic hepatitis B
• Positive HBsAg, specific and sensitive test
• Anti-HBs antibodies persist permanently in most people with a history of hepatitis B, and are also a sign of 
successful HBV vaccination.
• HBe antigen – can be proved only if HBsAg is present at the same time. The presence of HBeAg reflects 
active replication. It is negative in pre-core HBV mutations. In such case, replication should be confirmed 
by the HBV DNA test.
• Transition to chronicity is characterized by the presence of HBsAg > 6 months, HBeAg (±) and HBV DNA (±) 
in the serum.
• The occurrence of anti-HBe antibodies and the disappearance of HBeAg is referred to as seroconversion in 
the HBe system and means the end of viral replication.
• HBV DNA test using PCR
Hepatitis C
Demonstration of infection:
• Serological tests demonstrating anti-HCV antibodies
• Molecular genetics tests – demonstrate HCV RNA in the blood, enable the quantification of viraemia, and 
determine the genotype of virus
Serological tests to demonstrate rarer hepatitis D and E virus infection are also available.
• Immunological tests in diagnosing liverdiseases
Assays for autoantibodies are performed for all diseases where a certain amount of autoimmunity is expected, 
particularly for suspected autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Autoan-
tibodies are also present in a high number of patients with chronic HCV infection, however. The antibodies are type-
-nonspecific and may occur temporarily in healthy people as well. Autoimmune hepatitis is characterized primarily by 
elevated aminotransferase activity in laboratory results, with marked hypergammaglobulinaemia being typical.
Autoimmune hepatitis is divided into types I, II and III depending on the prevailing type of autoantibodies.
Antibody AIH type I AIH type II AIH type III
ANA +  ±
ASMA +  ±
AAA +   
pANCA +   
LKM1  +  
LKM2  ±  
LKM3  ±  
AMA ±   
LCA  ±  
SLA   +
dsDNA +   
Table 21.2. The basic types of antibodies
Positive antimitochondrial antibodies (AMA, type M2) are typical of primary biliary cirrhosis and occur in up to 
95% of all patients with this disease. Some patients also have anti-nuclear antibodies (ANA), which correlate with the 
prognosis of the disease. Perinuclear antibodies ANCA (pANCA) together with anti-nuclear antibodies (ANA) and anti-
-smooth muscle antibodies (ASMA) occur in patients with primary sclerosing cholangitis.
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22.1. Classification of Hyperbilirubinaemias
Hyperbilirubinaemia may be caused by either a predominantly unconjugated or predominantly conjugated type of 
bilirubin, depending on the aetiology and pathogenesis of the disease. Predominantly unconjugated hyperbilirubinae-
mias - pre-microsomal and microsomal types (see Figure 1) – pre-hepatic jaundice according to former classification, 
where the proportion of conjugated bilirubin does not exceed 20% of total bilirubin, are caused by an excessive influx 
of unconjugated bilirubin to the liver, insufficient unconjugated bilirubin uptake, or reduced conjugation capacity. The 
impairment of conjugation can be congenital or acquired.
Figure 22.1. Diagram of bilirubin conjugation and secretion in the liver and classification of jaundice. From the bio-
chemical point of view, jaundice can be classified into predominantly unconjugated (direct bilirubin does not exceed 20% 
of total bilirubin) and predominantly conjugated types (direct bilirubin exceeds 20% of total bilirubin). Mixed jaundice 
with direct bilirubin from 20 - 50% of total bilirubin is sometimes classified as a separate type. ER – smooth endoplasmic 
reticulum
The cause of predominantly conjugated hyperbilirubinaemias (post-microsomal type, Figure 1, includes hepatic 
and post-hepatic jaundice according to the former classification), where the proportion of direct bilirubin exceeds 
50% of total bilirubin, is the inability to secrete conjugated bilirubin from the liver to the bile, or an obstacle in the bile 
drainage. Besides congenital disorders of bilirubin metabolism, most predominantly conjugated and mixed hyperbili-
rubinaemias, where the proportion of bilirubin is 20 – 50% of total bilirubin, are subject to a combination of multiple 
mechanisms resulting in a variable ratio of conjugated to unconjugated bilirubin.
22.2. Predominantly Unconjugated Hyperbilirubinaemias
22.2.1. Hyperbilirubinaemia due to unconjugated bilirubin overproduction (pre-microsomal pre-hepa-
tic jaundice)
The common causes of predominantly unconjugated hyperbilirubinaemia are conditions associated with haemoly-
sis. The liver capacity in adults for the uptake, conjugation and secretion of bilirubin is substantial. Therefore, haemoly-
tic icterus occurs at an adult age only due to massive and prolonged haemolysis, and the concentration of unconjuga-
ted blood bilirubin usually does not exceed 70 - 100 μmol/L. An exception is acute haemolytic crisis which accompanies 
some types of haemolytic anaemias, where bilirubin levels can be significantly higher. Bilirubin overproduction based 
on haemolysis can be found in sickle cell anaemia, hereditary spherocytosis, toxic or allergic reactions to xenobiotics, 
conditions connected with ineffective erythropoiesis (thalassaemia) and other haematological diseases.
The situation is different in newborn infants. The lower conjugation capacity of the liver and the absence of gut 
flora catabolizing bilirubin to non-toxic urobilinoids play a role here, in addition to haemolysis. Physiological neonatal 
jaundice, icterus neonatorum, occupies the boundary between haemolytic icterus and hyperbilirubinaemia based on 
insufficient bilirubin conjugation. This jaundice afflicts almost one half of all healthy, full-term newborns in the first 5 
days of life. It is associated with unconjugated bilirubin levels of around 70 to 80 μmol/L, only rarely with higher levels 
of up to 220 μmol/L. These values revert to normal within 8 to 10 days, although normal neonatal levels are higher 
than levels in the adult population. Pathological neonatal hyperbilirubinaemia is characterized by its development in 
the first 24 hours after the birth, where hyperbilirubinaemia is over 220 μmol/L in full-term or over 256 μmol/L in pre-
mature infants, by bilirubinaemia rising by about 85 μmol/L a day, by the proportion of conjugated bilirubin being over 
10%, and by the persistence of icterus for one (full-term infants) or two weeks (premature infants). Pathological neona-
tal hyperbilirubinaemia is an indication for phototherapy, or exsanguination transfusion in extreme cases. The criteria 
for starting a therapeutic intervention are shown in the Hodr-Poláček graph (Figure 2); similar recommendations given 
by the American Academy of Pediatrics and the UK National Institute for Health and Clinical Excellence are available. 
Pathological neonatal jaundice is caused mainly by haemolytic conditions induced by Rh incompatibility between the 
mother and the foetus, and incompatibility in the AB0 system. In addition to which, haemolytic neonatal jaundice may 
be a sign of a congenital disorder such as spherocytosis or sickle cell anaemia, or result from a toxic or allergic reaction.
The principle of phototherapy consists in the isomerization of bilirubin present in the skin and subcutis by exposure 
to 425 - 475 nm blue light. The radiation leads to the generation of cis-trans isomers on double bonds in the methylene 
bridges, which results in breaking the intramolecular hydrogen bonds between propionyl side chains and pyrrole nit-
rogens, and to the cyclization between rings A and B (Figure 4). Photoisomers have a polar character; they are water-
-soluble and are excreted in the bile in an unconjugated state. Due to their polar character, photoisomers do not pass 
the blood-brain barrier and are non-toxic for the newborn’s central nervous system. In laboratory assays it is important 
that, unlike cyclobilirubins, configurational isomers are diazo reactive in common tests for bilirubin. Therefore, serum 
bilirubin assays may be biased due to phototherapy.
Breast-fed newborns generally have higher serum bilirubin concentrations. This is caused by the presence of UG-
T1A1 enzyme inhibitor in the breast milk. 
Figure 22.2. Hodr-Poláček graph. The nomogram on the left divides postnatal bilirubin level development into five 
zones. The table on the right shows the therapeutic intervention indications or the frequency of bilirubin assays depending 
on the zone, age and cause of jaundice. Key: ET – exchange transfusion, PhT – phototherapy, B1x, B2x – bilirubin assays 
once or twice a day
The effect of this enzyme can be eliminated by heating milk to 56°C. Serum bilirubin levels may reach 250 to 450 
μmol/L in the first 10 to 19 days of life. This temporary non-haemolytic unconjugated hyperbilirubinaemia is usually 
not connected with neurological damage; nevertheless, every hyperbilirubinaemia over 340 μmol/L is considered po-
tentially very dangerous.
22.2.2. Hyperbilirubinaemia due to insufficient unconjugated bilirubin uptake (pre-microsomal hepa-
tic jaundice)
Hyperbilirubinaemia of the predominantly unconjugated type also occurs in toxic and viral hepatocellular injury 
when hepatocellular icterus develops. This is caused by many hepatocellular noxae such as alcohol, chloroform, tetrac-
hloromethane, acetaminophen, etc. Some types of intoxication involve a combination of the conjugation disorder with 
cholestasis. Mixed unconjugated and conjugated hyperbilirubinaemia develops in these cases (see below). Depending 
on the type and extent of liver parenchyma injury, the corresponding response can be seen in liver tests and acute 
phase reactants.
Figure 22.3. Chemical structures of bilirubin IXα, its photoisomers and their photochemical interconversion. Adopted 
from McDonagh AF et al. Pediatrics 2009;123:67-79
22.2.3. Hyperbilirubinaemia due to unconjugated bilirubin conjugation disorders (microsomal hepatic 
jaundice)
Gilbert’s syndrome (icterus intermittens juvenilis) is characterized by chronic, fluctuating icterus and a slight in-
crease in unconjugated serum bilirubin. Serum bilirubin usually does not exceed 85 μmol/L (exceptionally over 100 
μmol/L). The syndrome is caused by reduced activity of hepatic UGT1A1, either due to the reduced expression of the 
enzyme as a result of gene UGTA1 TATA box promoter prolongation (motif allowing the recognition of the start of trans-
cription) from sequence A(TA)6TAA) to A(TA)7TAA, or directly by mutations in UGT1A1 gene coding regions, resulting in 
decreased activity of the normally expressed enzyme (Figure 4). Gilbert´s syndrome is an autosomal recessive disorder 
with incomplete penetration and afflicts about 10% of Europeans. Concurrent UGT1A1 defect with slight haemolysis 
has also been described. Given the indistinct clinical presentation, the syndrome is often diagnosed by accident based 
on a biochemical assay where all liver test results except unconjugated bilirubin are repeatedly normal for at least two 
years.
Crigler–Najjar syndrome is a familial non-haemolytic icterus, an autosomal recessive inherited disorder associated 
with the total (type I) or partial (type II) defect of enzyme UGT1A1. The type I syndrome is completely lacking conjuga-
ted bilirubin excretion, and non-conjugated blood bilirubin levels reach 300 to 800 μmol/L. The defect manifests itself 
from birth, and afflicted newborns without intensive phototherapy die early due to the involvement of the central 
nervous system. The administration of conjugation inductors is not therapeutically effective in this type of disorder.
Figure 22.4. Mutations in UGT1A1 gene associated with Gilbert’s syndrome. In Europe, by far the most common is the 
TA insertion in the TATA-box of the UGT1A1 promoter, shown in the chart below.
The defect of conjugation in type II is incomplete, and as a result the progress of the disease is milder, with uncon-
jugated bilirubin concentrations in the blood of 100 - 350 μmol/L. Bilirubin-monoglucosiduronate is found in the bile of 
patients suffering from this disorder. Reduced conjugation can be induced and the progress of the disease favourably 
affected by the administration of phenobarbital. Both forms are subject to mutations in the UGT1A1 gene.
22.3. Predominantly Conjugated Hyperbilirubinaemias
22.3.1. Mixed hyperbilirubinaemia due to hepatic parenchyma involvement (post-microsomal hepatic 
jaundice)
Mixed-type jaundice often accompanies acute and chronic liver diseases such as viral hepatitis, bacterial infections, 
toxic liver damage, autoimmune hepatitis, metabolic liver diseases and cirrhosis of any aetiology. Jaundice is caused 
by the concurrent inability of damaged hepatocytes to take up unconjugated and conjugated bilirubin from the blood, 
conjugate unconjugated bilirubin or excrete it into the bile. It is not rare for jaundice to be accompanied by intrahe-
patic bile duct involvement. However, jaundice cannot be equated with liver and bile duct diseases. A serious liver 
disease - hepatitis or advanced cirrhosis - may develop surreptitiously, without manifested jaundice, and the disease is 
not discovered until detailed laboratory testing is made. In contrast, a rise in bilirubin in patients with hepatic cirrhosis 
signals the progression of a liver dysfunction. That is why bilirubin, alongside other analytes, was included in scoring 
systems (Child-Pugh and MELD) (Figure 5) used to evaluate liver function and predict the survival rates of patients with 
advanced liver diseases.
Focal liver diseases usually do not induce jaundice. If present, it is mostly a late trait signalling an advanced disease. 
The mechanism of jaundice is complex, and it also often involves bile duct obstruction.
Figure 22.5. Child-Pugh (down) and MELD (up) scoring systems.
22.3.2. Hyperbilirubinaemia due to conjugated bilirubin secretion disorders (post-microsomal hepatic 
jaundice)
Dubin-Johnson syndrome is a benign, autosomally and recessively inherited, predominantly conjugated hyper-
bilirubinaemia. Apart from jaundice, its symptoms are indistinct, which is why laboratory testing is primarily used 
for diagnosis. The serum exhibits distinctive hyperbilirubinaemia (usually 35 to 85 μmol/L, exceptionally 350 to 400 
μmol/L), 50% of which is conjugated bilirubin. Increased excretion of coproporphyrin I in the urine is also typical, but 
total porphyrin output is not increased. Other laboratory findings are within the normal range. Patients’ livers are ma-
croscopically dark and the presence of black pigment, probably related to melanin, is demonstrated histologically in 
hepatocyte lysosomes.
Dubin-Johnson syndrome is caused by a defect in conjugated bilirubin secretion from the hepatocyte into the bile 
due to mutations in the ABCC2 gene. The secretion of glutathione bromosulphophthalein conjugates and other anion 
pigments used previously for liver function tests are affected in a similar way. Today, they are substituted by cholescin-
tigraphy with radiopharmaceuticals as excreted anions. The secretion of bile acids is unaffected.
Another rare chronic benign, predominantly conjugated, hyperbilirubinaemia is Rotor syndrome. In this syndrome, 
too, the other common haematology and biochemistry tests are in the normal range. However, the liver lacks any pig-
mentation and up to five times the normal amount of coproporphyrin is excreted in the urine, of which more than 65% 
is coproporphyrin I. Cholephilic anion pigments are excreted from the blood very slowly (Figure 6). Again, the disease 
is familial, with autosomal recessive trait of inheritance. The disease is subject to the concurrent presence of mutations 
in the genes for OATP1B1 and OATP1B3, and consists in the absence of conjugated bilirubin and other organic anion 
uptake by the liver; the secretion of conjugated bile salts is maintained, however.
Figure 22.6. Cholescintigram: Rotor syndrome (A). Panel B shows a normal finding without signs of hepatic chromose-
cretion disorder. Adopted from Hřebíček M, et al. Liver Int 2007;27:485-91.
22.3.3. Hyperbilirubinaemia due to intrahepatic and extrahepatic bile drainage disorders (post-hepa-
tic jaundice)
Obstacles in the bile drainage may be caused by mechanical obstructions or inflammation of hepatic or extrahepa-
tic bile ducts. Bile accumulation is often connected with hyperbilirubinaemia and obstructive icterus.
Intrahepatic cholestasis is caused through different mechanisms by many pharmaceuticals, therapeutic hormones, 
natural substances and other noxae: oestrogens and C-17 alkylated steroids (ethinyl oestradiol), tauro and glycolitho-
cholate, chlorpromazine, cyclosporin, colchicine, phalloidin and others. Oestrogens and progesterone take part in the 
pathogenesis of intrahepatic cholestasis of pregnancy. These substances affect the expression, localization and activity 
of each canalicular transporter. The cholestatic effect of many substances is subject to their genetic predisposition.
Conjugated bilirubin, conjugated bile acids, enzymes and other hepatocyte proteins are transferred to the blood in 
intrahepatic cholestasis or biliary obstruction. Continuous, although limited, transfer of these substances to the blood, 
mediated by carriers localized in the basolateral membrane of hepatocyte, takes place in physiological conditions as 
well. During cholestasis, other carriers that also take the role of canalicular transporters (e.g. MRP3 relative to cana-
licular MRP2 with decreasing expression) are expressed in the basolateral membrane, and the cell loses its original 
transporting polarity. The basolateral carriers then intensively take away toxic metabolites from the hepatocyte and 
transfer them to the blood.
The transfer of membrane proteins and enzymes such as alkaline phosphatase (ALP), gamma-glutamyl transferase 
(GGT) and 5´-nucleotidase to the blood in intrahepatic or extrahepatic cholestasis is explained by damage of bile duct 
epithelium due to the detergent effect of bile acids and subsequent regurgitation of bile into the blood circulation 
through chemically and mechanically (by compression) damaged cell junctions. The mode of cytosolic and mitochon-
drial protein and enzyme transfer from the hepatocyte to the blood is even less clear. Increased permeability of cell 
membranes caused by the primary pathological process probably plays a part.
Familial benign recurrent intrahepatic cholestasis is a disease diagnosed most often in adolescence. Nevertheless, 
it afflicts all age categories and is characterized by attacks of cholestasis with jaundices and intermittent asymptomatic 
periods. At the preicteric phase, the bile acid concentration in the blood rises and alkaline phosphatase activity also 
increases. Increased conjugated bilirubin is tested in the serum at the icteric phase, aminotransferase activity may be 
slightly increased and the prothrombin time is prolonged due to vitamin K malabsorption. Unlike most other cholesta-
tic liver diseases, GGT activity is normal as a result of reduced bile salt secretion. Laboratory findings between attacks 
are within the normal range. In most patients the disease is caused by mutations in the FIC1 gene (familial intrahepatic 
cholestasis type 1), whose role in the mechanism of bile salt and bile pigment secretion is not yet known.
Extrahepatic cholestasis (obstructive icterus) in adults is most commonly caused by a stone stuck in the bile duct 
or a tumour. Other causes include strictures (strictures due to primary or secondary sclerosis cholangitis, caused by 
inflammation around the bile duct and in the ampulla of Vater region, post-operative or iatrogenic strictures) and 
compression of the bile duct (by tumour, node, etc.). Biliary atresia should be considered at neonatal age and infancy.
22.4. Laboratory assays for differential diagnosis of jaundices
Basic biochemistry testing, including direct and total serum bilirubin, urinary bilirubin and urobilinogen, and the 
activity of aminotransferases (ALT and AST) and cholestatic enzymes (ALP and GGT) in the serum, is usually the first step 
in the differential diagnosis of jaundice following the patient history and physical examination. In the case of predomi-
nantly unconjugated isolated hyperbilirubinaemia, where ALT, AST, ALP and GGT levels are normal, haemolysis should 
be confirmed or ruled out. Blood count and reticulocyte count are used for this purpose. The differential diagnosis of 
haemolytic anaemias is then the domain of haematology. The diagnosis of inherited bilirubin conjugation disorders 
can be confirmed by molecular genetic tests. A result testifying to obstruction of the bile duct is followed by ultrasonic 
examination and other imaging (CT, MRCP) or endoscopic (ERCP) techniques focused on diagnosing and/or treating bile 
duct disease. Ultrasonography of the bile duct is also used for hepatic parenchyma diseases. If the ultrasound finding 
is normal, tests focused on liver disease aetiology follow. The basic differential diagnosis chart for jaundice based on 
biochemistry findings is shown in Figure 7.
Figure 22.7. Laboratory findings in each type of jaundice.
CHAPTER 23
23. Bone Metabolism
23.1. Bone Metabolism – Preparation
Author: MUDr. Richard Pikner, Ph.D.
23.1.1. Introduction
This chapter provides an overview of the bone structure, bone remodelling process, bone remodelling regulation 
factors and options for bone metabolism laboratory tests. The key information offers a summary of the basic knowled-
ge from this chapter.
23.1.2. Function and Structure of Bones
The human body is made up of 220 bones, which constitute about 15% of the body weight. Bone is not only the 
basis of the musculoskeletal system, but it is also a highly metabolically active tissue, permanently degrading (osteore-
sorption) and recreating (osteoformation). This process is called bone remodelling.
Bone remodelling provides a replacement for and repairing of damaged bone parts (microfractures and ma-
crofractures) as well as adjustment of the bone shape to long-term mechanical load, to which athletes are exposed to, 
for example.
The bone has the following 3 basic functions in the human body:
Structural – biomechanical support of the limbs and protecting cavities in the body, points of attachment for 
muscles and tendons
Haematopoietic – the bone provides a spatial matrix for haematopoietic cells.
Metabolic – as a deposit for calcium, magnesium, sodium and phosphates, the bone contributes to regulating cal-
cium and phosphate homeostasis and phosphate buffer systems
Figure 23.1. The skeleton consists of cortical and trabecular bones
There are two basic types of bone:
1. cortical bone
2. trabecular bone
The cortical (compact) bone makes up about 80% of overall bone mass, consists of dense layers of mineralised 
collagen (mineralisation is up to 90%), whose main function it is to provide biomechanical support and structure. 
Microscopically, the cortical bone consists of regular lamellae arranged concentrically around blood vessels, referred 
to as the Haversian lamellae. The Haversian canal with a vascular bundle is found in the middle. The lamellae with the 
canal form the basic structural unit, the osteon. Osteocytes, mutually interconnected bone cells, lie between osteons. 
The cortical bone is the main component of long bones and forms a protective coating for the other bones. The cortical 
bone’s remodelling activity is 10 times less than that of the trabecular bone. About 25% of trabecular and only 3% of 
the cortical bone is remodelled annually in the human body.
The trabecular (cancellous) bone, conversely, makes up less than 20% of the bone mass, yet assumes a prevailing 
part in the overall metabolic activity of bones due to its much greater surface. Mineralisation is from 5 to 20%. Micro-
scopically it is formed from a spongy structure consisting of individual interconnected trabeculae. The orientation and 
thickness of trabeculae depends on the long-term mechanical load of the given site. The trabecular structure markedly 
enlarges the overall surface, thus allowing a relatively fast metabolic exchange.
Different bones have different contents of bone types. Lumbar vertebrae contain 70% of trabecular bone, the heel 
75%, proximal femur 50 - 75%, and the distal radius 25% of the trabecular bone. As corticoids primarily suppress the 
trabecular bone’s remodelling activity, the vertebrae suffer from pathological compression. Primary hyperparathyro-
idism causes considerable demineralisation of the cortical bone, which can be documented in an X-ray image of the 
distal radius.
Figure 23.2. The stucture of cortical and trabecular bone
23.1.2.1. Composition of Bone
Bone is made up of water (8%), and inorganic (70%) and organic (22%) components. The basic part of the inorganic 
component is hydroxyapatite Ca
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and mineral salts such as calcium phosphate, calcium carbonate, mag-
nesium phosphate and magnesium carbonate, zinc, fluoride and strontium. 90% of the organic component (osteoid) 
is made up of collagen I, however it also contains collagen V, VI, VIII and XII and other non-collagen molecules, 20% of 
which is made up of osteocalcin and the rest osteopontin, vitronectin, sialoprotein, heparan and chondroitin sulphates, 
etc.
• Collagen I
Collagen I contains two identical 1-chains, and the third, different 2-chain. It is produced by osteoblasts in the form 
of individual pro-chains (procollagens); the C and N-terminal ends are cleaved off extracellularly and the typical triple 
helix stabilised by many cross-linking connections of pyridinoline and deoxypyridinole is formed. These links form by 
combining hydroxylysine or lysine residues from chains, and provide stability to the triple helix. The cleaved-off N and 
C-terminal ends are released to the serum and can be detected here as PICP or PINP (new bone formation markers). 
Collagen I is degraded from the bone using proteolytic enzymes: cathepsin K (osteoclasts) or matrix metalloproteinase 
9 (MMP9 from tumour cells). The product of degradation is collagen fibres, released into the circulation. They can be 
detected in the plasma or serum as CTX, NTX or ICTP (bone resorption markers).
• The bone tissue contains 3 types of cells:
3. Osteoblasts
4. Osteocytes
5. Osteoclasts
Figure 23.3. Osteoblasts, osteoclasts and osteocytes view in microscope
6. Osteoblast is the basic cell for new bone formation. Osteoblasts form in precursor mesenchymal cells 
(common stem cell for the myoblast, myocyte, adipocyte, chondrocytes and osteoblasts) in bone marrow. 
Differentiated osteoblasts produce a new bone matrix (osteoid) and initiate its mineralisation. A part of 
osteoblasts caught up in the newly formed bone stays here and creates osteocytes. The osteoblast is the 
basic cell for bone remodelling regulation and produces local regulation cytokines RANKL and osteoprote-
gerin (OPG). Its surface bears receptors for most systemic hormones (PTH, oestrogens, androgens, cortisol, 
etc.). Hormonal stimulation and local regulation factors result in regulation of the bone remodelling level.
7. Osteocytes are formed from osteoblasts located between cortical lamellae and inside trabeculae. Osteo-
cytes have minimal synthetic activity, however they use cytoplasmic projections to create a cross-linked 
spatial network. They act as mechanosensors in the bone. Osteocytes are activated by a permanent load 
change or microdamage to their mutual links. They are a source of local signalling molecules which activate 
or inhibit the bone remodelling process in the given area. A good example is long-term inactivity. Mecha-
nical load in bedridden patients is reduced, which results in a very fast osteoresorption in the unloaded 
bones, while regular physical strain leads to local remodelling resulting in increased new bone formation 
(gain) and altered orientation of the trabeculae in the direction of the mechanical load.
8. Osteoclasts come from the hematopoietic myeloid stem cell (common stem cell for erythrocytes, mega-
karyocytes, monocytes and granulocytes). Osteoclast comes from the monocytic line and is a specialised 
macrophage. The osteoclast is a multinucleate cell formed by fusing pre-osteoclasts from monocytic cells. 
Following contact with the bone surface, osteoclasts create a specially structured part of the plasma mem-
brane called a ruffled border. This ruffled part of the membrane creates a space where H-K-ATPase secretes 
hydrogen protons. Together with other enzymes (cathepsin K), this acidic environment with a pH of about 
4 creates the extracellular lysosome which degrades the adjoining bone. The result is the resorption lacuna 
- a space left after the completely resorbed bone. Osteoclasts bear receptors for local signalling molecules 
on their body. The only systemic hormonal receptor they have on their surface is the receptor for calcito-
nin. Therefore, calcitonin directly inhibits osteoclast activity.
23.1.2.2. Bone Remodelling
Bone remodelling is a continuous process of activation of bone resorption and new bone formation involving all of 
the three bone cell types. This results in a new bone protein matrix (osteoid), which is subsequently passively mine-
ralised. In bone remodelling, osteocytes play the role of mechanosensors and also trigger the bone remodelling cycle. 
Any mechanical damage to osteocytes activates the remodelling cycle at the site of injury (osteoresorption) followed 
by new bone formation activation. The balance between osteoresorption and new bone formation is controlled by 
osteoblasts.
One site in the bone where the remodelling cycle takes place is referred to as the bone metabolic unit (BMU). Mil-
lions of BMUs at different stages of activity are concurrently present in the human body.
Figure 23.4. Bone remodelling cycle
• The remodelling process lasts about 180 days and may be divided into several phases:
Activation phase – bone cells are in the idle state. Osteocytes become activated through the action of different 
stimuli (load, damage, hormonal signals). Osteocytes reduce osteoblast activity by means of sclerostin and, conversely, 
begin to stimulate the formation of osteoclasts by M-CSF and RANKL cytokines. The formation of active osteoclasts is 
supported and induced by the production of RANKL in osteoblasts, concurrently decreasing the production of its natu-
ral inhibitor, OPG. This effect is the result of sclerostin activity and other hormonal influences.
The osteoresorption phase lasts about 10 – 14 days; M-CSF and RANKL activate the differentiation of monocytic 
cells into pre-osteoclasts and osteoclasts, and the bone in resorbed. OPG (osteoprotegerin) is the regulator of the de-
gree of osteoresorption; it is a natural competitive inhibitor of RANKL. Bone resorption is further stimulated by TNF-1, 
IL-1, interferons-gamma and prostaglandins. Proteolysis of the bone matrix as well as the release and activation of TGF-
-ß1 take place during bone resorption. TGF-ß1 activates osteoblasts and the transition to the next phase.
New bone formation phase - Osteoblasts producing the bone protein matrix (osteoid) are responsible for new bone 
formation followed by the passive process of primary osteoid (50% of minerals) mineralisation. This process lasts for 
around 150 days.
Resting phase – after the primary mineralisation phase, the newly formed bone further mineralises (the percen-
tage of crystals increases) provided there is a sufficient supply of minerals and vitamins. This process is called secon-
dary mineralisation, and the time required for reaching 100% absorption capacity of the bone protein matrix is not 
known. The bone remains in the resting phase until the remodelling cycle in the give place has been activated.
Figure 23.5. Bone remodelling phases
23.1.2.3. Bone Remodelling Regulation 
• The remodelling process is regulated by:
Systemic hormones: parathormone, calcitriol, calcitonin, FGF23, oestrogens, IGF1, leptin, thyroid hormones, cor-
tisol
Systemic cytokines: IL-1, IL-6, TNF, OPG, RANKL, prostaglandins, etc.
Local cytokines: signalling molecules identical to systemic and specific molecules such as sclerostin, BMPs (bone 
morphogenetic proteins)
Intercellular communication between osteoclasts and osteoblasts
Minerals (calcium, magnesium, zinc) and vitamins (K, C, B6, A): sufficient amounts are essential for correct osteoid 
mineralisation
Osteocytes trigger the remodelling cycle by RANKL and sclerostin production. RANKL activates osteoclasts and 
sclerostin inhibits osteoblast activity. However, the main regulator is osteoblasts mediating the action of osteocytes 
and other hormones.
Figure 23.6. The interaction of cells and sclerostin in the bone formation
Osteoblasts and osteoclasts are key players in bone remodelling. The result of remodelling depends on their co-
ordinated interaction. If the regulation favours osteoclast activity, bone tissue is lost. This happens in osteoporosis. 
Conversely, if the regulation favours new bone formation, bone tissue increases. This is physiological in the period 
of growth. The peak bone mass is subsequently the result of nutritional, genetic and hormonal factors together with 
mechanical load during the growth period with subsequent secondary mineralisation. The human body reaches peak 
bone mass between 25 and 30 years of age.
Osteoblasts are superior to osteoclasts in regulation. Their interaction is coordinated through osteoblasts. Oste-
oblasts and osteoclasts are located close to each other in the bone. Their coordination is based on:
Intercellular communication – this close intercellular communication is provided by epinephrines.
The RANKL-OPG-RANK system is the key regulatory mechanism for the remodelling unit’s activity. The system 
consists of the RANK receptor on osteoclasts. When the receptor is stimulated, pre-osteoclasts differentiate into os-
teoclasts and their metabolic activity is maintained. RANKL stimulates its activity, while OPG is a competitive inhibitor. 
Both RANKL and OPG are produced by osteoblasts, and their proportion is decisive for the activation or inhibition of 
osteoclasts. Systemic hormones transfer their signal to the bone by inducing the production of RANKL and OPG in diffe-
rent ways. Oestrogens increase the production of OPG and inhibit the production of RANKL, meaning they have an ana-
bolic effect on the bone. Corticoids increase the production of RANKL, decrease the production of OPG, and increase 
bone resorption. M-CSF triggering and maintaining the production of osteoclast precursors is also an important factor.
Figure 23.7. Regulation of the osteoblasts activity – systém OPG-RANKL
Apart from osteoblasts, RANKL and OPG are also produced by immune system cells, which confirm the connection 
between bone remodelling and immune system activity.
In addition to the low sclerostin level, osteoblasts are stimulated by TGF-ß1 released by osteoresorption activity 
of osteoclasts from the bone matrix. Bone remodelling is the result of a multifactorial effect of hormones, cytokines 
and other agents which finely balance the system to maintain stable bone mass while enabling an intense exchange of 
mineral components (Ca, Mg, phosphates) with the extracellular fluid as well as repair processes.
23.1.2.4. Hormonal Factors in Regulating Bone Remodelling
Parathyroid hormone – has an indirect effect on osteoclasts through receptors for the PTH on osteoblasts; this 
results in increased production of RANKL and decreased OPG followed by increased osteoresorption, all this assuming 
continuous stimulation of PTH like in primary hyperparathyroidism.
Intermittent administration of the PTH once daily not only induces the stimulation of osteoresorption but above 
all leads to greater stimulation of osteoblast differentiation. This results in an anabolic effect on the bone, where new 
bone formation is stimulated more than osteoresorption.
Sex hormones:
• Oestrogens – also act through osteoblasts; suppress RANKL production and stimulate OPG secretion, acting 
on mesenchymal cells at the same time, thus suppressing the production of other osteoclast-stimulating 
cytokines such as M-CSF, IL-1, IL-6 and TNF-α, meaning they act at the new bone formation phase – during 
matrix formation.
Figure 23.8. Mechanisms of oestrogen action on the bone
• Androgens primarily act on bone mineralisation and support periostal bone apposition. Differences in hor-
mone concentrations between genders lead to different bone shape remodelling. Through the action of 
androgens, men have a larger diameter of supporting bones and a thinner cortical bone with predominant 
periostal apposition than women.
• IGF1 stimulates osteoblast differentiation.
• Thyroid hormones stimulate bone remodelling with a stronger effect on osteoresorption.
• Corticoids – stimulate osteoresorption through increased RANKL production and decreased OPG producti-
on and decrease collagen I formation at the same time.
• Calcitonin – as the only hormone directly inhibits osteoclast activity and induces their apoptosis.
23.1.3. Summary – Key Information
The bone has the following 3 basic functions in the human body: structural – biomechanical support of the limbs 
and the protection of body cavities, points of attachment for muscles and tendons; haematopoietic – the bone pro-
vides a spatial matrix for haematopoietic cells, and metabolic – as a deposit for calcium, magnesium, sodium and 
phosphates, the contributes to regulating calcium and phosphate homeostasis and phosphate buffer systems.
• The cortical (compact) bone makes up roughly 80% of overall bone mass and less than 50% of metabolic 
activity, while the trabecular (cancellous) bone makes up less than 20% of the bone mass, but more than 
50% of metabolic activity.
Bone is made up of water (8%), and inorganic (70%) and organic (22%) components. The basic part of the inorganic 
component is hydroxyapatite Ca
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and mineral salts of Ca, Mg, Sr, F and Zn. 90% of the organic component 
(osteoid) is made up of collagen I, however also contains other non-collagen molecules such as osteocalcin (20%).
The bone tissue contains 3 cell types: 1. Osteoblasts, 2. Osteocytes, 3. Osteoclasts.
• The osteoblast is the basic cell for new bone formation and a cell regulating the bone remodelling process. 
The osteoblast produces osteoclast-stimulating cytokines (RANKL) and its natural inhibitor, OPG. Most sys-
temic hormones (PTH, oestrogens, androgens, cortisol etc.) control bone remodelling by influencing on the 
production of RANKL and OPG in osteoblasts.
• Osteocytes are formed from osteoblasts located between cortical lamellae and inside trabeculae. They 
create a cross-linked spatial network acting as mechanosensors. Osteocytes are the source of signals trig-
gering the bone remodelling process in the given area.
• Osteoclasts come from the monocytic line and are actually specialised macrophages. The osteoclast is a 
multinucleate cell able to adhere to the bone surface and degrade bone tissue beneath the membrane. 
The osteoclast needs RANKL for its activity; conversely it is inhibited by OPG or calcitonin as the only sys-
temic hormone.
• Bone remodelling is a continuous process of activation of bone resorption and new bone formation invol-
ving all the three bone cell types. This results in a new bone protein matrix (osteoid), which is subsequently 
mineralised secondarily.
• The remodelling process lasts about 180 days and can be divided into some phases:
Activation phase – the action of stimuli activates osteocytes, and subsequently osteoclasts and osteoblasts.
Osteoresorption phase – lasts around 10 – 14 days, osteoclasts resorb the bone.
New bone formation phase - active osteoblasts produce the bone protein matrix (osteoid); this is followed by the 
passive process of primary osteoid mineralisation (50% of minerals). This process lasts for around 150 days.
Resting phase – the newly formed bone further mineralises. This is a secondary mineralisation process with an 
unknown duration.
One site in the bone where the remodelling cycle takes place is referred to as the bone remodelation unit (BRU). 
Millions of BRUs at different stages of activity are concurrently present in the human body.
• Bone remodelling regulation: Osteocytes activate bone remodelling and osteoblasts control it using the 
RANKL/OPG-RANK system. The RANKL – OPG - RANK system is the key regulatory mechanism of the re-
modelling unit’s activity. The system consists of the RANK receptor on osteoclasts. When the receptor is 
stimulated, pre-osteoclasts differentiate into osteoclasts and their metabolic activity is maintained. RANKL 
stimulates its activity, while OPG is a competitive inhibitor. Both RANKL and OPG are produced by oste-
oblasts, and their proportion is decisive for the activation or inhibition of osteoclasts.
Systemic hormones transfer their signal to the bone by inducing the production of RANKL and OPG in different 
ways.
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23.3.1. Options for Laboratory Detection of Bone Remodelling – Bone Markers
Laboratory methods offer many possibilities of testing the state of bone remodelling. In addition to the genetic 
analysis which helps confirm some congenital diseases such as osteogenesis imperfecta, Ehlers-Danlos syndrome and 
other diseases, such methods primarily include tests for molecules circulating in the plasma (serum). Their concentra-
tions are subsequently proportional to bone cell activity. Bone remodelling tests are usually performed together with 
tests for calcium-phosphate metabolism parameters (PTH, 25 OH vitamin D, calcitonin) which have a major impact on 
the rate of bone remodelling. The body prefers to maintain normocalcaemia and normophosphataemia to maintaining 
bone integrity. The differential diagnosis also employs tests for systemic hormones (thyroid hormones, cortisol, oest-
rogens, androgens, IGF-1, etc.).
Commonly used or research methods are used to assess bone remodelling. Research methods include determining 
local regulation molecule concentrations (RANKL, OPG, sclerostin). Commonly used bone remodelling parameters are 
divided into osteoresorption markers or new bone formation markers, and are discussed in this chapter.
23.3.2. Nomenclature for Routinely Used Bone Markers (Abbreviations)
• New bone formation markers:
→	 Osteocalcin (OC)
→	 Bone alkaline phosphatase isoenzyme (bone ALP or bALP)
→	 Procollagen type I N-terminal propeptide (PINP)
• Bone resorption markers:
Collagen type I telopeptides (products of type I collagen degradation in the bone)
→	 N-terminal cross-linking telopeptide of type I collagen (NTX-I) 
→	 C-terminal cross-linking telopeptide of type I collagen (CTX-I b, Crosslaps)
o Type I collagen telopeptide (ICTP)
o Tartrate-resistant acid phosphatase 5b (TRACP 5b)
Figure 23.9. Bone Turnover Markers – Graphical summary
23.3.2.1. NEW BONE FORMATION MARKERS
Osteocalcin
Osteocalcin is the most abundant non-collagen protein in the bone matrix (osteoid). It is synthesized in osteoblasts 
and its subsequent carboxylation is dependent on vitamin K. Osteocalcin deposited in the bone tissue has a high affini-
ty to calcium and contributes to bone matrix mineralisation. Serum osteocalcin levels are proportional to its production 
by osteoblasts. The latest research has revealed information about osteocalcin as a systemic hormone released from 
the bones, which contributes to regulating the leptin-adiponectin system and androgen synthesis.
Bone alkaline phosphatase isoenzyme (bone ALP, ostase)
Alkaline phosphatase comprises 4 isoenzymes: placental, carcinoplacental, intestinal, and the hepatic/renal/bone 
group. These isoenzymes differ in their primary structure and are coded by different genes. In an adult the bone isoen-
zyme produces less than a half of the total ALP activity (most of it is produced by the hepatic isoenzyme). The bone 
isoenzyme is a product of osteoblasts, and its quantitative test is a function of their activity.
N-terminal type I procollagen (PINP)
It is released to circulation during type I collagen production. Osteoblasts produce procollagen, which releases the 
N and C-terminal ends (PINP, PICP) by extracellular proteolysis. The circulating N and C-terminal ends are subsequently 
quantified. The PINP or PICP values provide information about the level of type I collagen production not only in the 
bones but also in all tissues producing collagen I (skin, connective tissue, blood vessels). Cartilage contains type II col-
lagen.
23.3.2.2. BONE OSTEORESORPTION MARKERS
N-terminal cross-linking telopeptide of type I collagen (NTX-I), C-terminal cross-linking telopeptide of 
type I collagen (CTX-I)
Type I collagen is degraded by the action of proteolytic enzymes osteoclasts. The main proteolytic enzyme is ca-
thepsin K, which cleaves collagen fibre into various fragments. The fragments cleave off from both the C and N-terminal 
ends of the type I collagen molecule. In the circulation they are detected as the N-terminal cross-linking telopeptide 
of type I collagen (NTX-I) or C-terminal cross-linking telopeptide of type I collagen (CTX-I). They are finally excreted in 
the urine (accumulation in patients with chronic kidney failure). Their concentrations then indicate the degree of type 
I collagen degradation.
Type I collagen telopeptide (ICTP)
Another kind of type I collagen degradation prevails in some pathological situations – degradation by matrix metal-
loproteinases (MMPs), MMP-9 in this case. MMP-9 is produced mainly by tumour cells of bone metastases and causes 
local pathological degradation of type I collagen, and a fragment other than CTX or NTX is formed, type I collagen telo-
peptide (ICTP). ICTP concentrations are an indicator of the degree of pathological bone degradation by MMP-9. In the 
serum, ICTP is subsequently degraded to smaller fragments excreted through the kidneys; ICTP accumulates in chronic 
kidney failure.
Figure 23.10. Collagen degradation and Markers of Resorption CTx, NTx, ICTP
Tartrate-resistant acid phosphatase 5b isoenzyme (TRACP 5b)
It is one of the 6 ACP isoenzymes. It is abundant in osteoclasts. Quantitative tests of serum TRACP 5b indicates the 
degree of osteoclast activity.
23.3.3. Indications for Bone Marker Tests
The aim is to assess the rate of bone remodelling. It should be kept in mind, however, that the plasma or serum 
parameters tested provide a picture of the overall activity of all bone remodelling units in the whole body. They are in 
various phases of bone remodelling. This results in an average activity of all bone remodelling units. It is thus logical for 
minor local processes (solitary metastasis) not to reflect in the values until their activity has significantly exceeded the 
average activity of other remodelling units (BMUs).
A big advantage of bone markers is that sampling is minimally stressful for patients as they only give a normal blood 
sample.
Figure 23.11. Bone Turnover Changes – Balance between the bone resoption and formation
Bone markers are used for:
1. Monitoring the effect of metabolic bone disease therapy
2. Predicting the risk of fractures and bone metastases
3. Differential diagnosis
4. Personalized therapy???
23.3.4. Monitoring the effect of metabolic bone disease therapy
This is probably the most common indication for bone marker tests in post-menopausal osteoporosis. Bone mar-
kers practically react immediately to the therapy applied, while the imaging methods (densitometry) are able to detect 
a change after about 12 months. The effect on bone markers can be expected depending on the therapy selected:
• Bisphosphonates (alendronate, ibandronate, risedronate, zolendronate, pamidronate) reduce bone remo-
delling – both resorption and new bone formation, and support secondary mineralisation.
• SERMs (selective oestrogen-receptor modulators – raloxifene, tamoxifene) induce the pre-menopausal 
state of bone remodelling. They are useful for treating early post-menopausal osteoporosis with increased 
osteoresorption, which is normalised by SERMs; SERMs also reduce the risk of hormone-positive breast 
cancer.
• Calcitonin considerably inhibits osteoporosis for not longer than about 8 – 12 hours; 1/3 of patients are 
non-responders, whose bone marker levels do not respond to the administering of calcitonin.
• Intermittent administration of parathormone (once daily, s.c.) – intermittent PTH administration leads to 
a different profile of RANKL: OPG production than the profile typical of a continuously elevated PTH level. 
Both new bone formation and osteoresorption are stimulated. New bone formation is, however stimula-
ted more (a higher percentage of change in the markers as compared with their level before treatment). 
The treatment has an anabolic effect on the bone.
• Denosumab is a subcutaneously administered human antibody with the same effect as OPG, leading to 
considerable suppression of bone resorption followed by a decrease in new bone formation. It has a simi-
lar effect on bone remodelling as bisphosphonates.
• Strontium ranelate is a drug, which presents another option for treating osteoporosis, however adminis-
tration of strontium does not markedly change bone remodelling. Its effect probably uses another mecha-
nism through the calcium-sensing receptor.
• The human antibody against sclerostin is only in the phase of clinical testing: New bone formation prevai-
ling over osteoresorption, i.e. a considerable anabolic effect on the bone, can be expected.
Similarly, changes in bone remodelling can be monitored through successful therapy of other metabolic skeleton 
diseases (osteomalacia, Paget’s disease, bone metastases, etc.).
In some cases it is helpful to assess the degree of patient’s non-compliance, the site of the expected decrease/
drop, or bone remodelling parameters changed/unchanged against expected values.
Figure 23.12. CTX levels in serum before and 7 days after the dose during the 12 – months MOTION study
23.3.5. Predictive Value of Bone Markers
The determination of bone remodelling markers is used to estimate the risk of osteoporotic fracture or bone 
metastases. The evidence shows that the higher bone markers, the higher risk of complications (fracture, metastasis, 
progression or relapse). Breast cancer patients show a negative correlation of bone resorption markers and survival 
time (the higher osteoresorption, the shorter time of survival).
Figure 23.13. Predictive value of osteoresorption markers
23.3.6. Bone Markers in Differential Diagnosis
Bone remodelling markers are not very useful for differential diagnosis. This is determined by their non-specific 
character. Metabolic skeleton diseases affect bone remodelling, yet the inciting causes are different and changes are 
only quantitative.
Osteomalacia, for example, causes increased bone remodelling very similar to multiple bone metastases of a mixed 
character, as well as primary hyperparathyroidism and the condition after healing fractures.
Increased bone resorption alone cannot be interpreted as post-menopausal osteoporosis as it can have several 
causes such as osteolytic metastases or primary hyperparathyroidism.
However, some laboratory findings are quite typical and may speed up the diagnostic process.
• A sporadically elevated bone ALP value with hyper or normocalcaemia is typical of Paget’s disease
• Elevated ICTP values are suspected to be caused by osteolytic or mixed metastases or osteomalacia
• Elevated CTX (NTX) and decreased PINP are typical of corticoid treatment.
23.3.7. Personalized Therapy
The issue of personalized therapy is very questionable. The main method of checking the effect of osteoporosis 
treatment at present is treatment based on evidence-based, multicenter, prospective, placebo-controlled studies. The-
re is no space for personalized therapy here, though. Most of these studies are performed in patients with normal or 
slightly deficient vitamin D level. Is it therefore possible to start treatment in patients with severe vitamin D deficiency? 
Severe vitamin D deficiency is found in around 30 – 40% of the normal population with osteoporosis.
The point of personalisation is finding an optimum therapy model for a specific patient on the basis of known me-
dical history, and an analysis of risk factors and laboratory tests, of course.
Personalized therapy is used for Paget’s disease where the ALP level is decisive. Therapeutic bisphosphonates 
(zolendronate) are administered to normalize the ALP. An additional zolendronate dose is pointless until the level in-
creases.
Another example is individual dosing of vitamin D based on initial and target vitamin D levels, body weight %, sun-
bathing, etc.
23.3.8. Test Methods
Bone remodelling parameters are measured almost exclusively using immunoassays. Except for TRAP5b and ICTP, 
most methods are currently available on fully automated instruments. TRAP5b and ICTP are measured using enzyme 
immunoassay on plates, or using radioisotope detection kits.
When measuring osteocalcin, it is important to use methods testing the intact form and N-MID fragment to ensure 
a lower variability of results.
23.3.8.1. Pre-Analytical Phase – Sample Stability, Diurnal Rhythms, Diet, Method Selection
Bone markers show significant variability depending on the age, gender, sampling time, food consumed and use 
of some drugs (corticoids), and also depending on the test method used. Bone markers should therefore be tested in 
one laboratory, if possible.
Changes can be in the order of tens to hundreds of %.
This means it is essential to take samples under standardized conditions and follow age, gender and race-specific 
reference limits.
TRAP5B is the least affected method of all methods (diurnal rhythm, diet, renal functions).
Standard sampling is in the morning between 08:00 and 11:00, fasting patient.
Sources of biological variability of bone markers
Uncontrollable sources:
Age – bone remodelling is age-dependent primarily in children. Bone remodelling should be assessed in correlati-
on with the individual patient’s growth phases (growth curve); levels are more or less stable in middle age; the same 
holds true for bone mass and mineralisation. Old-age changes (first a rise in osteoresorption and also reduced bone 
formation from 70 years) are not physiological and are very individual.
Diurnal rhythm – PTH is the main systemic hormone regulating bone metabolism. The PTH has a biphasic circadian 
rhythm with a slight increase between 4:00 and 7:00 p.m., peak values between 2:00 and 6:00 a.m. and lowest levels 
between 10:00 and 11:00 a.m. The bone remodelling markers follow the same diurnal rhythm.
Gender – bone remodelling values vary with the gender as they reflect different oestrogen and androgen levels.
Race – bone remodelling parameters are race-dependent.
Figure 23.14. Diurnal rhythm of osteocalcin and CTx
Controllable sources
Physical strain – exertion impacts bone remodelling regulation by suppressing sclerostin production. Physical strain 
has to be prolonged and repeated; an extreme one-off load does not significantly affect the values.
Diet – ingestion of food leads to a dramatic drop in bone resorption and a slight increase in bone formation. Fasting 
samples are recommended. 
The use of chondroprotective agents containing type I collagen affects collagen degradation marker CTX and NTX 
levels.
23.3.8.2. Sample Stability following Collection:
Bone markers such as osteocalcin, CTx, PINP, ICTP, bone ALP and TRAP5b are measured in the serum. If the serum is 
separated from blood elements within 8 hours from sampling, they are stable at 4 – 8 °C for at least 72 hours. Repeated 
freezing and thawing is not good for osteocalcin, but is possible for the other parameters.
23.3.8.3. Interpretation of Results
Reference Limits
Reference limits depend on the age, race and gender.
They are method-specific, so are not listed.
23.3.9. Specific Metabolic Bone Diseases
23.3.9.1. Bone mineralisation and age
Both sexes reach peak bone mass levels around the 2nd or 3rd decade of life. In the following period until 50 years of 
age, the bone mass is relatively constant on the provision of the „physiological state“: normal calcium intake, adequate 
physical activity, normal reproductive state and absence of diseases or influences causing secondary osteoporosis. Old 
age brings hormonal changes affecting bone mineralisation. In addition the prevalence of secondary hyperparathyro-
idism due to deficient vitamin D and calcium increases. This is followed by involutional changes such as decreases to 
physical activity, reduced hormone production etc. A disease called osteoporosis occurs.
Figure 23.15. The loss of bone mas sis quick with the onset of menopause
WHO defines osteoporosis as a systemic bone disease characterised by a decrease in bone mass and damage to 
the bone tissue microarchitecture, with a subsequent increase in bone fragility and proneness to fractures. The loss of 
minerals and the osteoid is proportional.
Bone mineral density (BMD) is most commonly measured by dual-energy X-ray absorptiometry (DXA). Measured 
bone mineral density is then compared with the average value found in young, healthy individuals of the same sex (T-
-score) and with the average value in the same age category (Z-score).
Osteoporosis in post-menopausal women and men over 50 is defined as a T-score less than 2.5 SD (standard devi-
ation minus average density).
Reduced bone mass corresponds to the T-score -2.4 to -1.0 SD, and normal bone density is defined as the T-score 
between -1.0 and +1.0 SD.
Figure 23.16. Osteoporosis is a common disease with a high risk of fractures throughout the skeleton
Post-menopausal osteoporosis due to deficient oestrogens
Oestrogen deficiency caused by the menopause leads to reduced secretion of OPG and increased production of 
cytokines (RANKL, M-CSF, IL6, IL-11). This leads to increased activation of osteoclasts and reduced activity of oste-
oblasts. Bone remodelling thus increases, osteoresorption in particular. Increased amounts of calcium released from 
bones leads to reduced secretion of PTH, thus increasing calciuria and reducing the production of 1.25 (OH)
2
 vitamin 
D. The total daily loss of calcium rises about threefold. Administration of oestrogens normalizes the pathophysiological 
mechanism and prevents loss of bone mass. This problem afflicts women around 10 years after the menopause.
Lab: Increased osteoresorption and normal or decreased new bone formation
Involutional (senile) osteoporosis
Multifactorial aetiology: secondary hyperparathyroidism occurs due to vitamin D deficiency and conversion in the 
kidneys, decreased physical activity, lack of androgens and oestrogens and other anabolic hormones (IFG1); commonly 
due to poor diet – protein malnutrition, and coinciding drugs and diseases.
Lab: Osteoresorption and new bone formation are decreased in the lower quartile of reference limits
Glucocorticoid-induced osteoporosis (GIOP)
Chronic oral or intravenous administration of glucocorticoids (does not apply to replacement therapy for adrenal 
insufficiency) leads to a fast induction of osteoporosis. Major losses are in the trabecular bone (most frequent fractures 
in the axial skeleton – vertebrae); peak loss in the first 12 months of treatment. The loss depends on the dose, drug 
type, age, gender, BMD and individual sensitivity.
Mechanism of osteoporosis induction:
1. Direct effect
• Reduced new bone formation
• Number and differentiation of osteoblasts and apoptosis of osteoblasts
• Reduced synthesis of osteoid (collagen I)
• Increased bone resorption
2. Indirect effect
• Induced deficiency of calcium
• Reduced calcium resorption in the intestine and increased degradation of 1,25 (OH)2 D
• Reduced renal tubular reabsorption - hypercalciuria
• Reduced secretion of GH and IGF-1 (anabolic effect)
• Reduced secretion of sex hormones
Lab: Increased osteoresorption, reduced new bone formation (PINP in particular), secondary hyperparathyroi-
dism
Figure 23.17. Mechanisms of glucocorticoid effect on bone
Thyrotoxicosis-induced osteoporosis
Excess thyroid hormones lead to increased bone turnover, negative calcium balance and loss of trabecular bone.
Lab: Osteoresorption is increased more than new bone formation
Immobility-induced osteoporosis
Increased sclerostin levels lead to increased osteoresorption on negative calcium balance, and new bone formati-
on decreases.
Lab: Osteoresorption is increased much more than new bone formation, hypercalciuria
23.3.9.2. Osteomalacia, rickets (rachitis)
Osteomalacia is also a systemic bone disease, but this one afflicts osteoid mineralisation. This disorder is referred 
to as rickets (rachitis - missing mineral and normal osteoid mass) in children with open epiphyseal cartilages.
The most common cause is deficient vitamin D with subsequent malabsorption of minerals in the small intestine. 
This fact leads to abnormal mineralisation of the newly formed osteoid, increased formation and insufficient ossificati-
on. In addition to the bone, also the epiphyseal cartilage is afflicted in children, which leads to bone deformities.
Causes of osteomalacia
1. Vitamin D deficiency
2. Disorders of vitamin D metabolism (hereditary, anticonvulsant-induced)
3. Malabsorption syndrome
4. Renal acidosis (primary and secondary)
5. Depletion of phosphates
Lab: Highly increased bone remodelling (new bone formation and osteoresorption). In addition, calcium and 
phosphate metabolism disorder is present depending on the cause (low vitamin D, low or normal calcium, low 
phosphorus, increased PTH)
23.3.9.3. Other selected common osteopathies
Hyperparathyroidism, hypoparathyroidism see chapter Calcium, Phosphate and Magnesium Metabolism
Chronic kidney disease - mineral and bone disorder (CKD-MBD) – formerly renal osteodystrophy, renal 
bone disease
It is now defined as a disorder of 1 of the following 3 clinical components:
1. Laboratory component = impaired calcium-phosphate metabolism and bone remodelling
2. Bone component = histological bone tissue alterations
3. Calcification component = presence of off-skeleton calcifications
In its initial phase renal failure leads to increased requirements for phosphate excretion. The production of FGF23 
increases, which leads to reduced production of active calcitriol in the kidneys and subsequently to reduced calcium 
absorption (hypocalcaemia or the lower quartile of standard values). This results in secondary hyperparathyroidism. 
This finding is typical of the histological presentation of high-turnover osteopathy (osteitis fibrosa).
On the other hand, around a half-sized group of patients present with adynamic bone disease. It is characterized 
by low PTH levels, low bone remodelling, while histology samples show a cell-deficient bone without signs of remo-
delling.
The remaining 10% is mixed-type, high-turnover and low-turnover bone disease. Osteomalacia due to deficient 
vitamin D with typically low bone remodelling is very rare today.
Prevalence of CKD-MBD in patients with CKD stages 3-5:
1. 32% ... Osteitis fibrosa
2. 20% … Mixed disease
3. 18% … Adynamic bone disease
4. 16% … Normal bone remodelling
5. 8% … Osteomalacia
6. 6% … Mild disease
Lab:
• Osteitis fibrosa: High bone remodelling, 2nd generation PTH often over 300 pg/mL, normal bone mine-
ralisation
• Adynamic bone disease and osteomalacia: Low bone remodelling, 2nd generation PTH is decreased 
or corresponds to healthy values, impaired bone mineralisation
• Mixed bone disease: Normal or slightly increased bone remodelling, medium-increased 2nd generation 
PTH, impaired bone mineralisation
Hypercalcaemia in tumour diseases
Bone metastases are most common in breast (73%), prostate (68%), thyroid (42%), kidney (35%) and lung (36%) 
cancer. Primary bone marrow impairment is typical of multiple myeloma.
The most common cause of hypercalcaemia in tumour diseases is the overproduction of PTHrP (parathormone-re-
lated protein), permanently elevated levels of which, similar to the PTH, lead to osteoresorption and hypercalcaemia.
The formation of metastases is connected with the primary tumour’s ability to create and release micrometastases 
into the blood stream. The bone then provides a suitable environment full of growth factors. Metastasizing tumour 
cells are able to stimulate osteoclasts or osteoblasts by means of cytokines produced by them. This results in increased 
osteoresorption leading to osteolytic metastases, or new bone formation leading to osteoplastic metastases. On the 
other hand, stimulated bone cells release many growth factors, which retroactively support tumour growth (vicious 
circle – circulus vitiosus).
Tumour micrometastases are not always histologically homogeneous. Mixed metastases consisting of osteolytic 
and osteoplastic foci are common.
Lab: The rate of bone remodelling is directly proportional to the scope of metastases and, of course, to the activity 
of tumour and bone cells. (Small solitary metastases do not usually affect bone markers.)
Osteolytic metastases – increased osteoresorption of ICTP and CTX in particular. ICTP is more specific for bone 
metastases as tumour cells more often eliminate bone collagen I by means of MMP-9, which produce ICTP.
Osteoplastic metastases – increased PINP, less bone ALP
Mixed metastases – increased bone remodelling (osteoresorption and new bone formation)
Figure 23.18. Interaction of osteoblasts, osteocytes and bone metastases – „vicious circle“
Paget’s disease
Paget’s disease is a localised bone disease with impaired bone remodelling regulation. The function of osteoclasts 
is impaired. Osteoclasts begin to resorb the bone locally and permanently, and a compensatory increase in new bone 
formation follows. This results in the formation of a disorganised mixture of trabecular and lamellar bone. This causes 
deformities and increases proneness to pathological fractures.
Lab: Increased bone remodelling, ALP in particular; calcium-phosphate metabolism is usually normal.
23.3.10. Summary – Key Information
• New bone formation markers are proportional to osteoblast (OB) activity: bone ALP, or type I collagen 
synthesis (PINP).
• Bone resorption markers are proportional to the amount of degraded type I collagen (CTx, NTx, ICTP) or 
proportional to osteoclast activity (TRACP5b).
• Measured plasma or serum bone remodelling parameters provide a picture of the overall activity of all 
bone remodelling units (BMUs) in the whole body. BMUs are found in various phases of bone remodelling. 
The result of the bone marker test is total average activity of all BMUs.
• Bone markers react practically immediately when the effect of therapy is checked, while the imaging met-
hods (densitometry) are able to detect a change after about 12 months. The corresponding effect on bone 
markers can be expected depending on the therapy selected:
→	 bisphosphonates, denosumab and calcitonin decrease bone remodelling
→	 PTH increases bone remodelling
→	 SERMs (selective oestrogen-receptor modulators) normalize bone remodelling
• Predictive value – bone remodelling markers are used to estimate the risk of osteoporotic fracture or bone 
metastases. The higher the bone resorption marker value outside the reference range, the higher the risk 
of accident. The higher the PINP values in patients with prostate cancer, the higher the likelihood of oste-
oplastic metastases.
• Bone remodelling markers are not very useful for differential diagnosis. It is due to their non-specificity, 
since metabolic skeleton diseases cause quantitative rather than qualitative changes in bone remodelling.
• Bone remodelling parameters are measured almost exclusively using immunoassays.
• Bone markers show significant variability depending on the age, gender, sampling time, food consumed, 
the use of some drugs (corticoids), and also depending on the specific immunoassay used. Changes can 
be in the order of tens to hundreds of %. Standard sampling is in the morning between 
08:00 and 11:00, fasting patient. Following blood cell separation, most parameters are sta-
ble at 4–8 °C for 24 hours.
• Osteoporosis is a systemic bone disease characterised by a low bone mass and damage to the bone 
microarchitecture (the loss of minerals and the osteoid is proportional).
• Typical laboratory findings – osteoporosis:
o Post-menopausal osteoporosis due to deficient oestrogens – bone markers: Increased osteoresorp-
tion and normal or decreased new bone formation
o Involutional (senile) osteoporosis - Osteoresorption and new bone formation are decreased in the 
lower quartile of reference limits.
o Glucocorticoid-induced osteoporosis – Bone markers: Increased osteoresorption, reduced new 
bone formation (PINP in particular), secondary hyperparathyroidism
o Thyrotoxicosis-induced osteoporosis – Bone markers: Osteoresorption is increased more than new 
bone formation
o Immobility-induced osteoporosis – Bone markers: Osteoresorption is increased much more than 
new bone formation, hypercalciuria
• Osteomalacia is impaired osteoid mineralisation in adults; this disease is referred to as rickets (rachitis) in 
children with open epiphyseal cartilages. Osteomalacia is characterised by insufficient minerali-
sation, however the osteoid amount is normal.
• Osteomalacia – Highly increased bone remodelling (new bone formation and osteoresorption). In additi-
on, calcium and phosphate metabolism disorders are present depending on the cause (low vitamin D, low 
or normal calcium, low phosphorus, increased PTH).
• Chronic kidney disease-mineral and bone disorder (CKD-MBD) – formerly renal osteo-
dystrophy, renal bone disease:
o Osteitis fibrosa: High bone remodelling, 2nd generation PTH often over 300 pg/mL, normal bone mi-
neralisation
o Adynamic bone disease and osteomalacia: Low bone remodelling, 2nd generation PTH is decreased 
or corresponds to healthy values, impaired bone mineralisation
Mixed bone disease: Normal or slightly increased bone remodelling, medium-increased 2nd generation PTH, im-
paired bone mineralisation
• Hypercalcaemia in tumour diseases – Bone markers: The rate of bone remodelling is directly propor-
tional to the scope of metastases and, of course, to the activity of tumour and bone cells.
o Hypercalcaemia is caused by PTHrP (PTH-related protein) overproduction
o Osteolytic metastases – increased osteoresorption of ICTP and CTX in particular. ICTP is more specific 
for bone metastases than CTx.
o Osteoplastic metastases – increased PINP, less bone ALP
Mixed metastases – increased bone remodelling – osteoresorption and new bone formation
• Paget’s disease – Bone markers: Increased bone remodelling, ALP in particular; calcium-phosphate 
metabolism is usually normal.
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24. Laboratory Diagnostics in Gastroenterology
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Laboratory diagnostics in gastroenterology includes targeted diagnostic methods, specific screening programmes 
and non-invasive function test programmes employing modern methods of analyte detection in faeces or using breath 
tests.
24.1. Screening programmes
Screening programmes focus on early diagnosis of diseases which would otherwise remain unrecognized at this 
early stage. Screening programmes are carried out in asymptomatic individuals (i.e. individuals without signs or sym-
ptoms of the disease). Defined high-risk groups are subject to preventive medical care programmes. Gastroenterology 
screening currently includes two basic programmes: screening for celiac disease and screening for colorectal tumours.
24.2. Function tests
They form an important part of the clinical and diagnostic process in gastroenterology. They supplement imaging 
examination results with an essential piece of information, namely, how the organ is functioning, i.e. its ability to react 
to stimulation. Function tests include precisely defined stimulation and the result is interpreted as the organ’s response 
to such stimulation, taking baseline analyte values prior to stimulation into account. In addition, the interpretation of 
indirect function test results must also consider the function of other organs or systems that take part in the process.
24.2.1. Modern, non-invasive function diagnostics
Modern diagnostics focuses on breath tests based on measuring hydrogen or carbon 13C concentrations in exhaled 
air. H
2
-breath test applications cover a wide area, from differential diagnostics of malabsorption syndrome, syndrome 
of small intestinal bacterial overgrowth (SIBO) and gastrointestinal motility testing, to oral-caecal transit time (OCTT) 
or the quality of colon preparation before endoscopy. The time of transit through the gastrointestinal tract is an impor-
tant piece of information for evaluating and interpreting other function tests, and it is therefore often combined with 
additional breath tests such as the 13C/H
2
 - lactose test, where enzymatic cleavage of lactose is evaluated (the marker 
is carbon 13C), and at the same time bacterial cleavage in the colon is used to correct motility and transit (the marker is 
H
2
). The reliability and evaluation of H
2
 breath tests are increased not only by hydrogen assays, but also combinations 
with methane assays, enabled by GC (Gas Chromatography) analyzers and NDIRS (Nondispersive Isotope-Selective 
Infrared Spectroscopy) technologies.
24.3. Laboratory diagnostics of gastric pathologies
This domain includes serological tests of the gastric mucosa: gastrin-17 level, pepsinogens I and II (pepsinogens A 
and C) ratio, Helicobacter pylori infection, Hp-antibodies, CagA and VacA antigens, the gastric acidity (HCl) function test 
and the gastric motility breath test (OABT).
24.3.1. The diagnosis of Helicobacter pylori infection
The diagnosis of HP includes invasive tests, requiring the collection of gastric or duodenal mucosa biopsy spe-
cimens, or non-invasive tests. The culture test has the highest sensitivity and specificity. However, the considerable 
sensitivity of the Helicobacter pylori bacterium to oxygen is a drawback since the test requires special conditions for 
collection and transport. The rapid urease test (CLO) is based on the chromogenic detection of urease activity (the 
surface marker of Helicobacter pylori), and is a routine test performed at the time of endoscopy. More recent tests 
determine Helicobacter pylori in biopsy specimens by immunological detection – the iRUT method. Molecular biology 
and PCR methods are facilitating other modern methods of detecting Helicobacter pylori in biopsies and stool sam-
ples. The breath test with 13C - labelled urea (UBT) is the gold standard of Helicobacter pylori infection diagnostics; the 
test can also be performed by endoscopy with the administration of 20 mg labelled urea and the collection of gastric 
gas content using the bioptic channel of the endoscope. A reliable variant of Hp detection is non-invasive Hp antigen 
detection in the stool.
24.3.2. Gastric acidity tests
Gastric acidity tests are based on the stimulation of parietal cells, withdrawal of gastric juice and the determination 
of free and total HCl. Pentagastrin is optimal for stimulation, but also histamine (Lambling test) and insulin can be used. 
Functional test evaluation depends on the type of stimulation, which means that results vary depending on gastrin, 
histamine or insulin administration. Hypochlorhydria (hypoacidity) or even achlorhydria (anacidity) is a significant sym-
ptom of pernicious anaemia or suspected malignancies (gastric carcinoma at the early stages exhibits hyperacidity or 
normal acidity, however). The gastric acidity test is important for diagnosing Zollinger-Ellison syndrome, where high 
basal and maximum secretion is determined (BAO > 15, MAO > 60); a BAO/MAO index > 0.60 is found in more than 50% 
of Zollinger-Ellison syndrome cases. Pentagastrin stimulation in the test can also be used for mucin analysis. Latest stu-
dies use the bQRT test (Blood Quininium Resin Test) to detect hypochlorhydria. An endoscopic variant of the function 
test is stimulation by 4 µg tetragastrin/kg body weight subcutaneously with a 10 - minute secretion collection (20 - 30 
minutes after stimulation), and theacidity in mEq/10 minutes is measured by titration. The correlation with MAO-BAO 
is r = 0.92 and the reproducibility of the test is CV = 5.6%. A breath test with labelled calcium carbonate was the latest 
development in 2009.
24.3.3. Serum gastrin level
Gastrin level determined by RIA or ELISA immunochemical detection is 25 - 100 ng/L. A 10 to 1000 - fold increase 
in gastrin level is detected in Zollinger - Ellison syndrome (gastrinoma, pancreatic tumour with gastrin overproduction); 
however, this level fluctuates widely even during the day; normal gastrin level can be found in 20 - 40% of cases. As 
there are three forms of gastrin, the test result depends on the type of antibody used in the test. Gastrin test methods 
have been standardized to synthetic gastrin G-17; G-34 and G-13 tests depend on cross-reactivity with the relevant an-
tibody. The normal proportion of the forms G-13:G-17:G-34 is 8:2:1; G-34 is higher in a fasted state, and G-17 and G-13 
are higher after meals. The gastrin test is part of the gastrin stimulation test, where a 90 - minute profile is determined 
(in 9 serum specimens) following insulin, secretin or Ca-gluconate stimulation.
24.3.4. Pepsinogen A
Pepsinogen A is a mucosal atrophy marker and is used in genetic studies as a subclinical marker of duodenal ulcer 
disease. Pepsinogen C is used as a marker for the state of gastric mucosa (or the PG-A/PG-C ratio), and also as a mar-
ker of Helicobacter pylori infection eradication. Electrophoresis permits the separation of 8 gastric mucosa proteases 
in agar gel: pepsinogens PG1 - PG5 form a group of immunologically identical proteins – pepsinogen I (PG-I, PGA), 
pepsinogens PG6 and PG7 form a group of pepsinogen II (PG-II, PGC), and the last protein is cathepsin E (SMP, Slow 
Moving Proteinase). A decrease in the pepsinogen A level is tested in patients with achlorhydria, for example in perni-
cious anaemia. The latest studies have proven a significant decrease in pepsinogen-I with a concurrent increase in IgA 
antibodies against Helicobacter pylori in gastric carcinoma. The detection of pepsin in saliva/sputum is also indicated 
as a simple screening for gastroesophageal reflux disease (GERD) with extra-gastric signs of the disease. The PG-I/PG-II 
ratio decreases significantly depending on the histological risk or the presence of a vacA+ positive Helicobacter pylori 
infection. The combination of pepsinogen-I/II, gastrin-17 and Helicobacter pylori antibody tests is used as a „serological 
biopsy”, referred to as the GastroPanel, in the differential diagnosis of gastritis. Screening testing of the risk of atrophic 
gastritis or gastric carcinoma in connection with positive Helicobacter pylori is another area of screening for gastroin-
testinal tract tumours. Pepsin determination in the insulin test is also clinically important.
24.3.5. The 13C-octanoic acid breath test
The acid breath test is a non-invasive test of gastric evacuation, which can be used for a differential diagnosis of 
functional dyspepsias, reflux diseases and for the indication of some modern drugs (prokinetics). Octanoic acid does 
not absorb in the stomach, but is absorbed quite quickly in the duodenal mucosa. Metabolic activity in the liver tissue 
produces 13CO
2
, which is then determined in exhaled air. The range of normal values is 110 - 160 minutes for solid food 
and 91 - 155 minutes for semi-solid food. Gastric evacuation rate assessment using the 13C-octanoate breath test exhi-
bits a high correlation with the scintigraphic method.
Figure 24.1. A positive answer offers conclusive evidence that the patient is infected with Helicobacter pylori. In the 
absence of Helicobacter pylori, the administered urea is absorbed from the gastrointestinal tract and subsequently voided.
24.4. The laboratory diagnostics of malabsorption syndrome
The diagnostics of malabsorption includes function tests aimed at clarifying the cause and degree of malabsorp-
tion (primary and secondary malabsorption syndrome), and serological tests in connection with the screening and 
long-term monitoring of patients with celiac disease. Function tests include challenge/tolerance tests with oral admi-
nistration of D-xylose or vitamin A, and intestinal permeability tests such as the lactulose/mannitol (LA/MA) test. The 
lactulose/mannitol test can also be combined with the administration of D-xylose, sucralose and other sugars. Each 
sugar is analyzed using gas chromatography for relative indices of permeability. The average LA/MA index value is 0.016 
± 0.008 and LA/XY 0.013 ± 0.009. The intestinal permeability LA/MA test can be used for monitoring post-operative 
chemotherapy.
Function tests may also use other substances such as iron and vitamin B12 (Schilling test) or secretion function tests 
with labelled albumin (51Cr-albumin test). When collecting samples following the administration of tested substances 
and interpreting results, one should consider not only the transit time but also the different locations in the small in-
testine (from the duodenum to the terminal ileum) where the tested substrate is absorbed. Non-invasive breath tests 
include the H
2
-lactose breath test or 13C-xylose breath test suitable for detecting small intestinal bacterial overgrowth.
24.4.1. A comprehensive stool analysis
Stool analysis from macroscopic evaluation, determination of volume, structure and pH to an analytical determi-
nation of laboratory markers, is considered the basic testing process if malabsorption syndrome is suspected. The qua-
litative determination of undigested sugars, fats and proteins – a microscopic evaluation of stained faeces is presented 
by the latest publications of internal medicine, gastroenterology and clinical biochemistry.
24.4.2. ß-carotene and vitamin A
Carotene and vitamin A are fat-soluble; ß-carotene is a retinoid – a vitamin A precursor, and their serum level 
therefore depends on lipid digestion and absorption. Of the ß-carotene in the circulation, 80% is bound to LDL, 8% to 
HDL and 12% to VLDL. ß-carotene represents about 25% of serum carotenoids. The very short half-life of ß-carotene, 
i.e. its rapid conversion into vitamin A, is important from the clinical point of view. The determination of ß-carotene is 
clinically important primarily as a screening test if malabsorption syndrome is suspected. Increased ß-carotene levels 
have been described in hypothyroidism, diabetes mellitus, myxoedema, nephrotic syndrome, hyperlipoproteinaemia 
and pregnant women. Reference values depend on the test procedure; the range commonly specified for the extrac-
tion method (i.e. total serum carotenoid assessment) is 0.90 - 4.60 µmol/L, the narrower range of reference values is 
1.12 - 3.72 µmol/L. Only the lower limit 0.93 µmol/L is specified for malabsorption syndrome screening in adults, and 
the reference range 0.37 - 74 µmol/L is described for the HPLC technique specifically assessing ß-carotene. The challen-
ge/tolerance test with vitamin A is evaluated based on serum level increase 3 and 5 hours after administering the test 
challenge. Normal values 3 hours later are within the range of 3.6 - 12.6 µmol/L, and 7.2 - 24.6 µmol/L 5 hours later. 
Values < 3.6 µmol/L 3 hours later, or < 7.2 µmol/L 5 hours later indicate a pathological test result.
24.4.3. The D-xylose tolerance test
This test is usually indicated to confirm intestinal malabsorption in gluten-sensitive enteropathy (celiac sprue) and 
tropical sprue. The urine output result depends on the renal function. A falsely positive result may be found in conditi-
ons such as vomiting, dehydration, myxoedema, ascites or oedema. Many drugs such as aminosalicylic acid, acetylsa-
licylic acid, digitalis, indomethacin and neomycin decrease D-xylose excretion by the kidneys. The 14C-D-xylose breath 
test and the 13C-D-xylose breath test are variants of the xylose absorption test, and have been used more commonly 
than urine xylose determination for diagnosing intestinal malabsorption over the last few years. The serum level is 
1.40 - 3.80 mmol/L 1 hour after D-xylose administration, 2.13 - 3.86 mmol/L in 2 hours, 1.27 - 2.80 mmol/L in 3 hours, 
0.73 - 1.93 mmol/L in 4 hours and 0.40 - 1.20 mmol/L in 5 hours. Values < 1.67 mmol/L 2 hours after the administration 
of 25 g to adults, and < 1.33 mmol/L after the administration of 5 g to children, indicate a pathological result. In 5-hour 
urine collection, pathological values after the administration of 5 g D-xylose to children aged 5-12 are < 0.8 g/5 hrs (the 
broader range of normal values is 0.5 - 1.65 g/5 hrs), and < 4 g/5 hrs after the administration of 25 g to adults (some 
authors find results < 5 g/5 hrs pathological). The threshold drops to 3.5 g/5 hrs in individuals over 65. If D-xylose is 
administered based on weight (to small children in particular), the normal range of xylose excreted in the urine over 5 
hours is 10 - 33% of the administered amount.
24.4.4. Celiac sprue (CS)
Celiac disease – gluten-sensitive enteropathy, is the primary malabsorption syndrome. Celiac disease is an au-
toimmune disorder with a genetic predisposition (HLA-DQ2/DQ8) and a specific humoral response to the triggering 
factor – wheat gliadin (gluten) peptides or storage proteins (prolamins) of the related cereals barley, rye and oats. The 
diagnosis of celiac disease is based on the histological or histochemical assessment of small intestinal mucosal biopsy 
specimens. Parameters assessed in celiac disease include inflammatory mucosa alterations, raised intraepithelial lym-
phocyte count, small intestine mucosa lesions with reduced or lost intestinal villi, hypertrophy of Lieberkühn’s crypts, 
abnormal enterocyte maturation, and a remission of these alterations when on a gluten-free diet.
 
Figure 24.2. Damage to the intestine is due to a specific immune response triggered by certain peptides derived from 
gluten proteins in wheat, rye and barley, and sometimes oats. Damage to the intestine generally disappears over months to 
years after the harmful gluten proteins are completely excluded from the diet. If gluten is accidentally or deliberately rein-
troduced into the diet, the immune response to gluten is reactivated; many patients experience acute food poisoning and 
the intestine can be injured if gluten exposure continues.
Diagnostic tests for celiac disease focus primarily on celiac disease screening and include IgA and IgG class anti-gli-
adin antibodies (AGA-A, AGA-G), IgA and IgG class anti-endomysial antibodies (EmA) and IgA and IgG class anti-tissue 
transglutaminase antibodies (atTG-A, atTG-G). Tissue transglutaminase is an enzyme that plays a key role not only in 
the diagnosis but also in the pathogenesis of the disease itself. Gliadin, gliadin fragments and peptides contain a very 
high percentage of glutamine (glutamine and proline constitute 30 - 40%), and so gliadin is a very good substrate for 
the tissue transglutaminase enzyme, which creates a bond to the substrate (gliadin), modifies these peptides, and 
the neoepitopes that are produced then bind to surface glycoproteins of HLA-DQ2/DQ8-positive immunocompetent 
cells and induce an immune response in the small intestine mucosa. Studies from 2008 - 2010 recommend detecting 
antibodies against synthetic gliadin-specific nonapeptides or deamidated gliadin peptides. The sensitivity and specifi-
city of ELISA tests for deamidated gliadin peptides (DGP) is comparable to the reliability of anti-transglutaminase an-
tibodies; DGP antibodies in combination with IgA and IgG are even more reliable. The latest studies recommend tests 
in combination with IgA atTG and IgG DGP. Molecular biology methods such as PCR permit the detection of specific 
HLA-DQ2/DQ8 markers. Screening is particularly important in patients with another autoimmune disease. The risk of 
asymptomatic celiac disease (without clinical signs) in patients with type 1 diabetes is 10 times as high as the risk in the 
normal population, i.e. the incidence is not 1:200 but 1:20. The increased risk is similar for other autoimmune diseases 
(autoimmune thyreopathy, hepatitis, rheumatoid arthritis and others).
Figure 24.3. Gluten is degraded by gastrointestinal enzymes to a 33 amino acid (33-mer) peptide. The 33-mer peptide 
is absorbed across the small bowel epithelium to the subepithelial layer in the lamina propria. Tissue transglutaminase 
deaminates the 33-mer peptide. The deaminated peptides are processed by APC to three epitopes that bind to the HLA-
DQ2 or DQ8 molecules. The T-cell receptor on T-cells then cross-react with the HLA molecule leading to the initiation of 
an autoreactive immune response with subsequent activation of B-cells, CD4+ Th1 cells and NK cells. The resultant proin-
flammatory environment results in further immune activation and migration of lymphocytes resulting in the characteristic 
pathological finding of increased intraepithelial lymphocytes and villous atrophy.
24.4.5. The lactose tolerance test
The lactose tolerance test is an indirect measurement of intestinal lactase activity for the differential diagnosis of 
the malabsorption syndrome lactose intolerance. The traditional test is blood sugar measurement 15, 30, 60 and 90 
minutes after oral administration of 50 g of lactose. Lactase deficiency is demonstrated by a rise in blood sugar of less 
than 1 mmol/L. A newer lactose test consists in breath tests such as the H
2
 test, measuring a rise in hydrogen con-
centration in exhaled air as a result of bacterial decomposition of unsplit lactose in the colon, or carbon 13C detection 
after the administration of 13C-labelled lactose. Very accurate results are provided by the combined 13C/H
2
-lactose test. 
The lactose intolerance diagnosis can be supplemented by specific DNA genotyping – the 13910 T/C variant. Lactose 
intolerance can also be diagnosed by a duodenal biopsy-based rapid test, which is similar to the CLO rapid test for He-
licobacter pylori diagnosis. The incubation medium in the cell for biopsy includes the glucose-oxidase and peroxidase 
enzymes and the chromogenic oxidation-reduction substrate. The test takes 20 minutes.
24.4.6. Acute pancreatitis (AP)
Acute pancreatitis is a disease with variable clinical symptoms. Important issues in diagnosis are early diagnosis, 
severity of the disease, prognosis and monitoring the therapy process. Two stages can be distinguished in severe AP. 
The first is an extensive, sometimes necrotising inflammation of the pancreas with subsequent development of the 
Systemic Inflammatory Response Syndrome (SIRS), which may lead to Multiple Organ Dysfunction Syndrome (MODS). 
The next stage involves bacterial infection of the pancreatic necrosis and a deepening of systemic complications, renal 
failure, coagulation disorders and other manifestations. Laboratory diagnostics includes the assessment of many spe-
cific and non-specific markers, pancreatic enzymes and their precursors in the serum or urine, inflammatory markers 
and immune reaction markers such as cytokines, interleukins and TNF. The most commonly used parameter is the 
serum total α-amylase level, elevated values of which may revert to normal 3 - 5 days from the onset of the disease. 
The total α-amylase level is reliably elevated in 100% of acute pancreatitis cases, but it is also elevated in 80% of all 
acute abdomen pain cases. Diagnostically much more valuable is the pancreatic isoenzyme assay (P-type, P-AMS), 
whose level is also increased in 100% of acute pancreatitis cases, but only in 10% of acute abdomen pains. The di-
agnostic value of a serum pancreatic lipase assay is considerably higher than the α-amylase assay. The serum lipase 
level remains increased after an acute pancreatitis attack considerably longer than the amylase level (increased lipase 
activity 14 days later has been described). As serum lipase originates primarily in pancreatic cells, the assay provides 
considerably higher specificity, comparable with the specificity of the pancreatic α-amylase isoenzyme. A reliable early 
marker for acute pancreatitis is the pancreatic elastase-1 level post-ERCP and pancreatic carcinoma, where elastase-1 
(determined by ELISA techniques) has the highest specificity and sensitivity to pancreatic carcinoma of all pancreatic 
enzymes. The earliest markers for rapid diagnosis of acute pancreatitis are the detection of TAP and CAPAP activation 
peptides in the urine. Serum procalcitonin has been studied over the last few years as a marker of bacterial infection 
of pancreatic necrosis and sepsis.
24.4.6.1. Trypsinogen, trypsinogen activation peptide (TAP) & carboxypeptidase activation peptide (CA-
PAP)
TAP can be detected in the serum and urine. Clinically, the most commonly used is the urinary trypsinogen-2 level; 
values 5600 – 10,000 µg/L correspond to a severe, serious form of acute pancreatitis and values 130 – 890 µg/L to a 
medium to mild form of AP. The product of trypsinogen conversion to active trypsin, trypsinogen activation peptide 
(TAP), is also determined in the urine. Increased TAP levels are clinically significant for evaluating the seriousness of 
acute pancreatis: urinary TAP values over 15 nmol/L detect medium pancreatitis, and values over 40 nmol/L a severe 
form of the disease. The CAPAP is longer than the other peptides released in pancreatic proenzyme activation. It is 
therefore more stable and more useful for laboratory diagnosis. The normal serum CAPAP level measured by the RIA 
is 0.8 nmol/L.
24.4.7. Chronic pancreatitis (CP)
CP is defined as a continuing inflammatory process of the pancreas, characterized by irreversible morphologic 
changes, causing characteristic pain and permanent loss of pancreatic function. The gold standard of functional dia-
gnosis is the secretin-pancreozymin (secretin-CCK) test. Quantitative determination of faecal fat in a 72 - hour collec-
tion period is also used as a reference test. Of all the tests available, the secretin-CCK test provides the most accurate 
information about the secretory activity of the pancreas. Despite the non-standard arrangement, it is considered the 
“gold standard” of pancreatic function tests, in particular for pancreatic insufficiency assessment. Normal values de-
pend on the method of stimulation, collection and analysis of the duodenum content. The values listed below are 
just one of the variants: secretin-stimulated secretion volume 165 - 536 mL/hr, HCO
3
- concentration 9.8 - 39.7 mmol/
hr, trypsin activity 9.3 - 171 U/20 minutes, amylase activity 34 - 204 U/20 minutes. Foreign literature describes one 
variant, the Lundh test, in which the pancreas is stimulated by a standardized Lundh meal. The latest studies combine 
endoscopy, stimulation by CCK or secretin, and the analysis of lipase, bicarbonate and other enzyme concentrations in 
the pancreatic juice collected at endoscopy, or they recommend assays for other markers such as zinc, which is a more 
stable analyte compared with pancreatic enzymes. The technological advances made in imaging methods in gastroen-
terology today offer a combination of morphological imaging with the simultaneous evaluation of some aspects of the 
tested organ function. The ERCP and MRCP methods can be performed with concurrent stimulation by i.v. administered 
secretin or cholecystokinin, and are the originators of modern combined testing procedures such as S-MRCP, MRCPQ 
or ePFT (endoscopic pancreatic function test).
24.4.7.1. Human pancreatic elastase-1
Elastase-1 is synthesized by pancreatic acinar cells. The enzyme is secreted by pancreatic juice to the duodenum, 
and the protein sequence selected for immunochemical detection is not degraded during intestinal transit. Elastase-1 
assessment therefore exhibits greater diagnostic benefit compared to a chromogenic assay for chymotrypsin in stool. 
The reference range is 200 - 500 µg/g of stool, the borderline range is 100 - 200 µg/g, and serious pancreatic insuffi-
ciency is found if values are < 100 µg/g of stool. The immunochemical assay for elastase-1 is not affected by transit 
through the colon, substitution therapy or other factors affecting the enzyme assay for chymotrypsin in stool. The 
specificity of the method is 93%, sensitivity is 100% for severe pancreatic insufficiency and 87% for medium and mild 
forms. This test is commonly used in paediatrics to demonstrate cystic fibrosis with almost 100% specificity and sensi-
tivity. Falsely reduced values can be caused by dilution (water content) during diarrhoea.
24.4.7.2. The breath test with 13C-mixed triglycerides
The principle is the cleavage of this substrate by pancreatic lipase. The 13C-MTG substrate is a triglyceride with 
13C - labelled octanoate in position 2 and stearate in positions 1 and 3. Pancreatic lipase cleaves triglyceride, and 13C-
-octanoate is further oxidized in the liver (beta-oxidation of fats). The amount of 13CO
2
 in exhaled air is measured with 
a breath test analyzer. The 13C-MTG test is clinically important in the differential diagnosis of malabsorption syndrome, 
as a function test of exocrine function of the pancreas, and for the long-term monitoring of patients with chronic pan-
creatitis. 13C breath tests with mixed triglycerides (MTG) or hiolein are indirect function tests of exocrine pancreatic 
function, and can be used to monitor the success of pancreatic substitution therapy.
24.4.8. Colonic pathologies
Laboratory diagnostics of colonic pathologies focuses primarily on screening for colorectal tumours (CRCA), faecal 
occult blood tests, the haemoccult guaiac screening test (gFOBT), the more sensitive immunochemical test (iFOBT), 
and the quantitative faecal occult blood test (qi-FOBT). The activity of inflammatory diseases and tumours can be moni-
tored by many faecal markers, the detection of calprotectin, lactoferrin, pyruvate kinase M2 and the protein S100A12. 
Progress in molecular biology allows the isolation of DNA from a stool specimen and the assessment of many genetic 
markers.
The risk of colon carcinoma in the Czech population continues to rise, with 80 cases per 100,000 inhabitants in 
2010, which is the highest incidence in Europe. Colorectal carcinoma (CRCA) develops as an adenoma malignization 
by a sequence of gene mutations over the course of ten years (on average) and most of the tumour tissue is localized 
intraluminally, at least at the initial stage of the disease. A small proportion of colorectal carcinomas develop in the 
presence of risk factors such as non-specific inflammatory bowel diseases, familial adenomatous polyposis, hereditary 
nonpolyposis colorectal cancer and other hereditary syndromes. The carcinoma (and the adenomatous polyp) already 
intermittently bleeds at the asymptomatic stage of the disease. Screening programmes include primarily laboratory 
methods of occult blood detection such as faecal occult blood test (FOBT) (test okultního krvácení ve stolici – TOKS – 
in Czech), the detection of genetic markers, and imaging methods such as sigmoidoscopy, colonoscopy, irrigography, 
virtual computer-aided colonography using computed tomography (CT) or magnetic resonance (MR). Progress in mo-
lecular biology and the application of PCR in routine diagnosis are also opening up brand new avenues in GIT tumour 
screening. The latest screening methods are based on the detection of specific mutations of the DNA isolated from 
a stool specimen using PCR methods or biochip array technology. APC, K-ras, p53, microsatellite instability (MSI) and 
other genetic markers can be assessed for the detection of colon tumours from stool specimens. Detection of specific 
protein (vimentin) methylation may also be used as molecular markers of colorectal cancer, and these DNA alterations 
can be monitored in the stool and serum of patients with CRCA.
For many years, the only test recommended for screening was the Haemoccult - guaiac test. The test is based on 
the pseudoperoxidase reaction of haemoglobin and contains a test medium (strip) impregnated with guaiac resin or, 
in former tests, a derivative of benzidine such as dimethylbenzidine (o-tolidine). Given the chemical principle of the 
oxidation reaction, tests are affected by the presence of other oxidizers (vitamin C), the presence of haemoglobin from 
food (meat, blood), and a falsely positive result may also be caused by the presence of vegetable peroxidases (some 
root vegetables). Defined dietary limitations are therefore recommended depending on how the test is arranged. The 
sensitivity of first generation gFOBTs is very low, 26 - 30% for cancer detection; however, gFOBTs have almost zero false 
positivity. Qualitative immunochemical tests (iFOBT) of the second generation are almost twice as sensitive, but their 
specificity is considerably lower and false positivity is almost 25% for some tests. The third generation of FOBTs, qiFOBT 
with quantitative faecal Hb detection, provide 90 - 95% sensitivity and specificity by optimizing cut-off values. This is 
why quantitative immunochemical tests, qiFOBT, are recommended specifically for CRCA screening at present.
24.4.8.1. Calprotectin
Calprotectin is a 36.5 kDa calcium binding protein with antimicrobial activity; it is composed of two heavy chains 
and one light chain, and is primarily derived from monocytes and neutrophils. Calprotectin as a marker detected in the 
stool exhibits lower variability than haemoglobin and is a suitable indicator in the diagnosis and monitoring of therapy 
for inflammatory bowel diseases, ulcerative colitis and Crohn’s disease, or necrotising enterocolitis in children. The de-
termination of concentration in a stool specimen with a cut-off of 30 mg/L exhibits 97% specificity and 100% sensitivity 
for the differential diagnosis between acute Crohn’s disease and irritable bowel syndrome (IBS). Faecal calprotectin is 
also tested as a colorectal cancer marker. Another inflammatory disease marker measured in the stool is lactoferrin, 
which has a superior sensitivity to calprotectin.
For more detailed information about each laboratory method, test procedures, links to current NLM Medline abs-
tracts and 100 colour diagrams and photos, refer to the up-to-date on-line GastroLab at the First Faculty of Medicine 
website - http://glab.zde.cz.
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25.1. Definition and Incidence of the Disease
Diabetes mellitus is a metabolic disease with two major causes:
• Absolute deficiency of insulin
• Resistance to insulin (i.e. tissues do not respond to the action of insulin)
The incidence of diabetes has an ever growing tendency in developed as well as developing countries. While Cze-
choslovakia had about 4% of diabetics 30 years ago, the incidence in the Czech population is almost 8% today; another 
few percent of people have diabetes without knowing it. The number of diabetics in developed countries is expected to 
rise by another 20% and in developing countries by up to 70% in the next 20 years. With the present trend unchanged, 
about 33% of the US population will suffer from diabetes in 2050. This is especially due to unhealthy lifestyle and a 
growing number of obese people. Figure 1 illustrates the trend in the worldwide incidence of diabetes in absolute and 
relative figures and its approximation to 2030.
Figure 25.1. Trend in worldwide incidence of diabetes
Diabetes mellitus is a very serious disease due to potential complications that shorten the patient’s life and are 
exceedingly expensive for the healthcare system. Early diagnosis of the disease is of paramount importance: 20 - 30% 
of newly diagnosed patients are estimated to have late diabetic complications. As complications develop slowly, over 
seven or more years of the disease, diabetes could have been identified in these people and adequately treated years 
before.
25.2. Clinical and Laboratory Signs of Diabetes
Clinical signs of diabetes are based primarily on glucose losses in urine accompanied by osmotic diuresis. The pati-
ent then has polyuria (increased volume of urine) followed by polydipsia (excessive drinking) and a loss of weight due 
to a loss of energy - rich substances (glucose and often ketone bodies) in the urine.
Laboratory signs of diabetes can be derived very easily from the knowledge of insulin effects (or the absence of it):
Hyperglycaemia (glucose is unable to penetrate into cells due to the lack of insulin or insulin resistance);
Glycosuria (when the renal threshold for glucose is exceeded, the offer of glucose to renal proximal tubular cells 
exceeds their maximum absorptive capacity and glucose gets into the definitive urine);
Ketonemia and ketonuria (cells lack glucose, so they have to get energy by cleaving fats or fatty acids, which the 
human body is unable to burn completely without concurrent metabolism of glucose. This results in the production 
of ketone bodies – acetoacetic acid, β-hydroxybutyric acid and acetone.) These acids cause metabolic (keto)acidosis.
25.3. Blood Glucose (Glycaemia) Testing
Blood sugar (glucose) testing is one of the basic diabetes tests used to diagnose and monitor treatment. Generally, 
two biological materials are used:
Venous blood; an addition of anticoagulant (K
3
EDTA, Na
2
EDTA) prevents blood clotting, while sodium fluoride 
(NaF) is used as a glycolysis inhibitor and provides a stable glucose concentration for at least 24 hours. As fluoride inhi-
bits final glycolysis reactions, initially we see a slight decrease in glycaemia; this is not observed, though, if the blood 
is acidified by citrate at the same time. Venous blood plasma is necessary for the diagnosis of diabetes. The glucose 
concentration is sometimes measured in venous blood serum – usually when additional laboratory tests are required. 
This method requires timely separation of the serum from red blood cells;
Capillary blood (usually from the fingertip) is used for monitoring diabetes management. Patients may measure 
blood sugar by themselves with their own glucose meter; the same method is used for POCT blood sugar measurement 
in ICUs, operation theatres or acute admission units in hospitals. Capillary blood can also be sent for laboratory testing 
or collected at home for glucose profile monitoring; in this case, blood is collected in plastic „pointed” micro test tubes 
containing anticoagulant and NaF; a volume of blood adequate to the added preservative has to be taken and then mi-
xed in the test tube. Another option is collecting an exact amount of capillary blood (usually 20 μL) in a short capillary 
tube and transferring the blood to a little test tube with a lysis buffer; this ensures a stable glucose level while being 
transported to the laboratory.
Needle-free transdermal glucose monitoring is in the phase of clinical studies; this facilitates patient care in in-
tensive care units where repeated measurement of blood glucose level is required.
25.4. Diagnosis of Diabetes
As mentioned in the preceding chapter, the only acceptable biological material recommended for the diagnosis of 
diabetes by the Czech Diabetes Society and the Czech Society of Clinical Biochemistry is venous blood plasma.
The following glucose levels in the venous blood plasma are indicative of diabetes mellitus:
> 7.0 mmol/L, if the patient was fasting
> 11.0 mmol/L, if it is unsure whether the patient was fasting
However, this value has to be confirmed by a new blood sample collected on another day. If the result above is 
found only once, typical clinical signs of diabetes have to be present to establish the diagnosis.
If the above glucose level is found only once and the patient does not have clinical signs of diabetes, or if fasting 
venous blood plasma glucose is within the range of 5.6 – 7.0 mmol/L (slightly elevated), the diagnosis of diabetes has 
to be confirmed (or ruled out) using a challenge test – oral glucose tolerance test (oGTT).
25.4.1. Glucose Tolerance Test (oGTT)
Indications for oGTT have been listed in the paragraphs above. The patient has to be instructed about preparations 
for the test. At least three days before the test, the patient should eat normal food without carbohydrate limitations 
and be fasting from the evening.
The test itself consists of challenging the patient by 75 g of glucose administered per os. The patient has one mi-
nute to drink a solution with 75 g of glucose, usually flavoured with lemon or citric acid. The patient then rests and 
another venous blood sample is taken two hours later. The tested individuals are classified into the following groups 
based on the venous blood plasma glucose level:
Glucose level < 7.8 mmol/L: normal glucose tolerance
Glucose level > 11.0 mmol/L: diabetes mellitus
Glucose level 7.8 – 11.0 mmol/L: impaired glucose tolerance; repeating the oGTT is recommended in a few months
Figure 25.2. Diabetes diagnosis algorithm
Notes:
oGTT is less common in the USA. The condition, which is an indication for the oGTT in the CR (i.e. fasting venous 
blood plasma glucose > 7.0 mmol/L found once in an individual without signs of diabetes or with glucose level within 
5.6 – 7.0 mmol/L), is called impaired fasting glucose. Together with impaired glucose tolerance (i.e. venous blood plas-
ma glucose level within 7.8 – 11.0 mmol/L 2 hours after the oGTT), it is sometimes referred to as prediabetes. There is 
no doubt that these individuals are at high risk of developing diabetes but also cardiovascular diseases and even some 
malignant tumours.
The criteria for diagnosing diabetes have changed, or rather tightened over the years. Original fasting venous blood 
plasma glucose for the diagnosis of diabetes was 7.8 mmol/L. Based on the finding that diabetic retinopathy develops 
in a significant percentage of people with levels under 7.8 mmol/L, the decision limit was lowered to 7.0 mmol/L in 
1997. Similarly, the lower decision limit for fasting hyperglycaemia was lowered from 6.1 to 5.6 a few years ago. These 
changes are aimed at timely capturing patients at risk of developing future diabetes and, in particular, late diabetic 
complications.
The oGTT procedure for pregnant and non-pregnant women is the same (challenge with 75 g of p.o. glucose) but 
the evaluation of results is different, being more stringent. The fasting glucose level should not exceed 5.5 mmol/L, and 
7.7 mmol/L 2 hours after the challenge. The glucose level may optionally be evaluated 60 minutes after the challenge 
and should not exceed 8.8 mmol/L. Gestational diabetes has been described in greater detail chapter Laboratory exa-
minations during pregnancy.
25.5. Laboratory Monitoring of Diabetes
If a patient is diagnosed diabetes mellitus, laboratory tests are required. Three levels of laboratory monitoring are 
distinguished depending on the time covered by the laboratory testing:
25.5.1.1. One-off glucose test
The test shows current blood glucose concentration at the time of collection. It is important especially if serious 
hyper or hypoglycaemia is suspected. The patient can make a self-test on fingertip blood using diagnostic strips and 
read the result on the personal glucose meter; an immediate reaction (i.e. taking insulin or conversely carbohydrates) 
is possible based on the result.
25.5.1.2. Blood glucose profile
The blood glucose profile reports blood glucose changes during a period of 24 hours. Fingertip blood is taken at 
predefined times (5 to 11 collections per day). Blood is taken before and after meals and, in indicated cases, also at 2 
a.m. to reveal potential night-time (nocturnal) hypoglycaemia that could be masked by consequent reactive hypergly-
caemia in the morning; this is sometimes referred to as the „dawn phenomenon”.
This is not an acute test; adequately preserved samples (with sodium fluoride) can be stored and sent to the labo-
ratory all at once. Insulin therapy is managed depending on the levels found (insulin type, intervals, doses).
25.5.1.3. Long-term diabetes compensation – glycated haemoglobin
The attending physician needs to know what the patient’s compensation has been over a longer period of time. 
The glycated haemoglobin test is typically used for this purpose.
25.5.1.4. Glycation – explanation and principle
Glycation is a non-enzymatic bonding process of carbohydrate molecules to free amino groups in biomolecules. 
The molecule of glucose most often binds by its aldehyde group to a free amino group in a protein, ε-amino group of 
lysine in particular. The Schiff base (chemical name: aldimine) is formed in the condensation reaction. The reaction is 
fully reversible: the reaction goes from the left to the right during hyperglycaemia; if the glucose level drops, the glu-
cose molecule cleaves off again and the reaction proceeds in the opposite direction.
However, this holds true only if hyperglycaemia is temporary. In the case of long-term hyperglycaemia, the aldi-
mine molecule is restructured in a process called intramolecular rearrangement (called Amadori rearrangement after 
the person who discovered it). This reaction is irreversible and gives rise to ketoamine, a derivative of fructosamine. 
Fructosamine remains bound to the protein molecule until the molecule has been entirely degraded and eliminated 
from the body. Figure 3 shows the glycation diagram.
Figure 25.3. Diagram of protein glycation (explained in the text)
25.5.1.5. Glycated haemoglobin as an indicator of long-term compensation of diabetes
If suitable protein is chosen, protein glycation intensity may be indicative of long-term average glucose level, i.e. 
diabetes compensation. Such a molecule is a molecule of haemoglobin. The beta-chain in haemoglobin A is readily gly-
cated; the biological half-life of haemoglobin is very long, and although enclosed inside red blood cells, it is available to 
glycation in diabetics – glucose penetrates red blood cells even without the effect of insulin. The measured parameter 
is then glycated haemoglobin, usually referred to as HbA
1c
 or only A1c for short.
Glycated haemoglobin shows the patient’s compensation (i.e. average glucose level) for about 2 – 3 months before 
blood collection. It is usually expressed as a total haemoglobin percentage, with an upper reference limit of 4% for 
healthy individuals. In a well-compensated diabetic, the glycated haemoglobin ratio should not exceed 4.5%; compens-
ation levels under 6% are satisfactory, and higher levels are unsatisfactory.
The figures above apply to glycated haemoglobin test calibration using IFCC-certified calibration, applicable in the 
CR since 2004. Many other countries (e.g. USA and many European countries) use the former National Glycohemoglo-
bin Standardization Program (NGSP) certified calibration with resulting figures of around 2% higher. Lately there has 
been a tendency to express the glycated haemoglobin concentration in SI units indicating the amount of fructosamine 
molecules bound to haemoglobin. The unit is mmol/mol. The relationship is roughly as follows: HbA
1c
 4.75% (IFCC) = 
6.5 (NGSP) = 47.5 mmol/mol (SI units).
The calculation of estimated average glucose (eAG) sometimes recommended in the USA is not used in the CR. Gly-
cated haemoglobin is converted using a simple formula to a kind of average glucose level, which is easier to understand 
for the patient; this, however, does not allow for individual differences in the glycation rate.
25.5.1.6. Glycated haemoglobin in the diagnosis of diabetes
As recommended by the Czech Diabetes Society and the Czech Society of Clinical Biochemistry (2012), the glucose 
tolerance test (oGTT) result is decisive for the diagnosis of diabetes in cases of doubt. The glycated haemoglobin test is 
used only to evaluate long-term diabetes compensation.
Lately there have been efforts in the US to employ glycated haemoglobin concentration also for the diagnosis of 
diabetes. There are several reasons for this:
• Better analytical parameters
• Higher stability of the analyte in biological material specimens
• Lower biological variability of HbA
1c
 (under 2 %)
• Higher comfort for the patient (fasting and drinking the glucose solution is not required);
• Minimal influence of stress on the result
• Use of the same test for the diagnosis and monitoring therapy
A group of experts from the American Diabetes Association (ADA), European Association for the Study of Diabetes 
(EASD) and the International Diabetes Federation (IDF) recommends using 6.5% as a glycated haemoglobin cut-off for 
diagnosing diabetes (NGSP); the corresponding IFCC-calibrated cut-off is 4.75%, i. e. 47.5 mmol/mol in SI units. Accor-
ding to the NGSP, values from 5.7 to 6.5% are subsequently indicative of an increased risk of developing diabetes or 
late diabetic complications. Glycated haemoglobin and the risk of late complications, diabetic retinopathy in particular, 
have been found to correlate fairly well. As this is a continuous function and it is impossible to find a value from which 
the increase in the risk is steeper, 5.7% was chosen by agreement in order to find a sufficient number of patients to 
whom qualified care could be provided.
The diagnosis of diabetes was repeatedly compared based on the classical criteria (fasting and postprandial gluco-
se level, oGTT result) and based on the newly introduced criterion – the glycated haemoglobin level. That is to say that 
each of the criteria covers a somewhat different part of the population and the overlap is only partial (see Figure 4), 
while the glucose tolerance test seems to be more sensitive than the glycated haemoglobin test in detecting diabetes. 
Glycated haemoglobin should be used particularly in people who cannot guarantee proper preparation for the oGTT.
As recommended by the Czech Diabetes Society, glycated haemoglobin may be used in the screening of glucose 
homeostasis disorder, in respect of prediabetes in particular, but not for the diagnosis of diabetes.
Figure 25.4. The diagnostic criteria for diabetes do not cover the same individuals (based on Škrha)
25.5.1.7. Glycated albumin
Glycated protein was once used as an indicator of medium-term diabetes compensation; the test was known as 
fructosamine. The test predominantly measured the glycated molecule of albumin. As the method was non-specific 
and had many interfering influences, it was gradually abandoned.
Several specific methods have been developed recently to determine solely glycated albumin. Glycated albumin is 
used as a patient’s compensation indicator 2 - 4 weeks before blood collection and can be used in cases where glycated 
haemoglobin does not reliably indicate long-term diabetes compensation (shorter red blood cell survival, haemoglo-
binopathy etc.).
25.5.1.8. Point-of-care testing (POCT) and self-monitoring of diabetics
There is a possibility of testing the diabetic in the physician’s office, in the operating theatre or at home by patients 
themselves. It is currently unimaginable to think of caring for a diabetic without being able to monitor the glucose level 
and immediate reaction to the reading.
Personal glucose meters providing an objective glucose evaluation using a diagnostic strip have been available for 
decades. State-of-the-art instruments work on the electrochemical principle and are able to store many results in the 
memory. Patient (or non-laboratory healthcare staff) instruction and external quality assessment of the glucose meter 
are required to ensure proper measurement. I deem it necessary to emphasize that glucose meters are used for moni-
toring diabetes and not to diagnose the disease; this test exhibits significantly worse reproducibility as compared with 
sophisticated methods for measuring the glucose level in clinical laboratories.
Additional options of POCT have recently been offered to diabetics. These mainly involve glycated haemoglobin. 
Unfortunately, many instruments manufactured for this purpose fail to show acceptable analytical parameters. The 
microalbuminuria test using a special strip (not a strip for a proteinuria demonstration!) is also possible; as this is by no 
means an acute test, it is more suitable to refer the test to the relevant clinical laboratory.
25.6. Other Laboratory Tests of Diabetic Patients
25.6.1. Microalbuminuria
Only a minimum amount of albumin and a certain amount of microproteins penetrate a healthy glomerulus (the 
glomerular membrane has a physiologically negative charge like albumin, which prevents a greater amount of albumin 
from penetrating it). These proteins are almost completely taken up by proximal tubule cells and are metabolized. 
However, the re-absorption capacity of the proximal tubule does not have a big functional reserve, and should the 
penetration of proteins through the glomerular membrane increase, non-absorbed proteins can be demonstrated in 
urine. This is also the case for the initial phase of diabetes, when temporary glomerular hyperfiltration may be seen; 
this is also partly due to the increased permeability of the glomerulus as a result of glycation or aseptic inflammation. 
An increased (greater than physiological) amount of albumin is then found in urine, although indemonstrable from 
protein test strips. This condition is referred to as microalbuminuria and the demonstration requires a more sensitive, 
immunochemical method. The diagram in Figure 5 explains the concept of microalbuminuria; as the albumin concen-
tration in urine depends on the patient’s hydration, in practice the result is not given in mg/L but in units taking this 
fact into account (see below).
Figure 25.5. Explanation of microalbuminuria
The microalbuminuria test is used for early prediction of diabetic nephropathy in diabetics. Patients with diabetes 
should be tested for diabetic kidney disease on an annual basis. In type 1 diabetic patients, the screening should start 5 
years upon being diagnosed with diabetes, and immediately after diagnosis in the case of type 2 diabetic patients. The 
screening includes an albumin/creatinine ratio test in the first morning urine specimen. A 24 - hr urinary albumin test 
is not recommended but albuminuria can be tested in a sample of urine collected while resting on the bed overnight; 
the result is then given in μg/min. One-off urine tests are preferred in practice, though; the result is related to the 
urinary creatinine concentration (ACR = albumin/creatinine ratio; the result is given in mg/mmol creatinine); Table 1 
shows the criteria for microalbuminuria. Given the high intraindividual variability (up to 30%), at least 2 out of 3 urine 
samples taken over 3 - 6 months should be positive to diagnose microalbuminuria; the test should not be carried out 
while concurrent urinary tract infection is present, after enduring higher physical stress and during menses. Diabetic 
kidney disease is always present in the form of incipient diabetic nephropathy if microalbuminuria is demonstrated.
Improved metabolic compensation of diabetes, satisfactory correction of hypertension and treatment with angio-
tensin-converting-enzyme inhibitors (ACEI) reduce the risk of renal injury progression. Patients with microalbuminuria 
(also non-diabetic patients) have a considerably increased cardiovascular risk. Microalbuminuria seems to be a marker 
for generalized endothelium dysfunction in these patients. Recently it has transpired that people with „high normal 
albuminuria” are also at increased renal and cardiovascular risk.
Urinary albumin concentration testing is also important in patients with arterial hypertension, where it may signa-
lize incipient kidney injury.
Table 25.1. Criteria for microalbuminuria
Type of Sample Microalbuminuria
Random specimen 2.6 – 29.9 mg/mmol creatinine (males)
3.6 – 29.9 mg/mmol creatinine (females)
Collected urine 30 – 299 mg/24 hrs
20 – 199 μg/min
Note: The preferred criterion is ACR (mg/mmol creatinine)
25.6.2. Autoantibody Tests
Type 1 diabetes mellitus is an autoimmune disease caused by β-cell destruction by cytotoxic T-lymphocytes. In 
addition, different types of diabetes-associated autoantibodies can be demonstrated in the blood serum of these pati-
ents; these do not have cytotoxic effects but they do signalize an ongoing autoimmune process. The effect of cytotoxic 
lymphocytes is very adequately compared to fire; autoantibodies form only smoke, which is produced by fire but does 
not have destructive effects itself.
Autoantibodies can be demonstrated months to years before the onset of clinical symptoms: More than 80 - 90% 
of β-cells have to be destroyed to have insulin production so low to induce symptoms of diabetes. Autoantibodies often 
fade away as diabetes proceeds.
The following DM1-related autoantibodies are demonstrated in practice:
• Islet cells autoantibodies (ICA)
• Insulin autoantibodies (IA)
• Glutamic acid dexarboxylase autoantibodies (GADA)
• Insulinoma 2-associated autoantibodies (IA-2A)
• Zinc transporter 8 protein islet autoantibodies (ZnT8A)
Except for insulin, all antigens, against which the autoantibodies are produced, are localized intracellularly; that is 
why β-cells have to be destroyed to make antigens accessible to immunocompetent cells.
ICA and GADA can be identified in 70 - 80% of people with DM1 at the onset of the disease; other types of au-
toantibodies have a slightly lower sensitivity. The detection of autoantibodies signalizes an increased risk of DM1 
development in the future; the risk rises with the number of detected antibody types. About 3 – 16 – 40 and 50% risk 
is described in 1 – 2 – 3 and 4 types of autoantibodies found. The risk further increases if relatives have DM1 or if a 
high-risk HLA genotype is present.
It is to be expected that assays for autoantibodies in relatives with DM1 will be very important at the time when 
we are able to delay the onset of the disease by dampening the autoimmune process through preventive treatment.
As mentioned above, type 1 diabetes mellitus is an autoimmune disease. As autoimmune diseases often group to-
gether, considering DM1 is recommended also in people with another diagnosed autoimmune disease (celiac disease, 
autoimmune thyroiditis, etc.). And vice versa, the possibility of other autoimmune diseases should be considered in 
patients with DM1.
25.6.3. Insulin Resistance Quantification
Insulin resistance is typical not only of type 2 diabetes mellitus, but also of metabolic syndrome. Insulin resistance 
should sometimes be objectified and its grade evaluated to assess therapeutic measures. This is, however, carried out 
using several methods that are not performed on a routine basis.
The HOMA (Homeostatic Model Assessment) index is computed from the serum glucose concentration and fasting 
insulin: HOMA = (glucose x insulin)/22.5. Normal values are under 1, probable insulin resistance is over 2, and very 
probable over 2.5.
Insulin curve – it is actually an oral glucose tolerance test prolonged to three hours after the oral administration of 
glucose. Insulin resistance will manifest itself by insulin overproduction, i.e. hyperinsulinism.
The hyperinsulinemic-euglycemic clamp is the most complex test to perform. The tested person is administered an 
i.v. infusion of insulin at the same time with concurrent glucose infusion. The glucose infusion rate is changed to have 
the glucose level within 5 – 5.5 mmol/L. Insulin resistance will manifest itself by lowered amount of glucose which 
should be administered to maintain euglycaemia.
25.6.4. Insulin and C-Peptide Test
Both insulin and C-peptide can be tested by immunochemical techniques using specific antibodies, but the tests 
are not commonly used in practice. As β-cells of the pancreas secrete insulin and C-peptide in equimolar amounts, C-
-peptide can be considered to be an indicator of endogenous insulin secretion. Unlike the insulin test, the C-peptide 
level is not affected by exogenous insulin or present anti-insulin antibodies. The C-peptide test is therefore important 
for the evaluation of residual insulin secretion in patients with type 1 diabetes, and for patients with hypoglycaemia of 
unclear aetiology. Figure 6 shows C-peptide and insulin generation from proinsulin.
Figure 25.6. Diagram of proinsulin splitting into insulin and C-peptide molecules
25.7. Complications of Diabetes
Diabetes mellitus is serious primarily due to its complications which can be even life threatening. They can appear 
quickly and develop within hours to days, sometimes even tens of minutes (acute complications of diabetes); in other 
cases the disease lasts for decades before complications manifest themselves (late/chronic complications). We cover 
these complications in brief with respect to their relation to laboratory tests in the following paragraphs. Refer to In-
ternal Medicine for details.
25.7.1. Acute Complications of Diabetes
These complications occur suddenly and may present an immediate danger to the patient’s life. In general terms 
we can distinguish two acute complications of diabetes.
25.7.1.1. Hyperglycaemic Coma
Hyperglycaemic coma is caused by an insulin deficiency. Type 1 diabetics with absolute insulin deficiency are afflic-
ted more often, but type 2 diabetics are not spared either. The patient has considerable hyperglycaemia and loses high 
amounts of fluids and minerals (osmotic diuresis) through urine, which may even lead to a shock. Plasma osmolality 
grows. The incapacity of cells to metabolize glucose leads to fatty acid oxidation and ketone body production. This is 
why hyperglycaemic coma is often accompanied by diabetic ketoacidosis with a considerable decrease in blood pH, 
which is the main cause of loss of consciousness. Ketone bodies are tested in urine. Tissue hypoxia in patients in shock 
may lead to the reduction of acetoacetic acid to β-hydroxybutyric acid, which does not react with the diagnostic strip 
for the ketone body test; the results are then falsely negative.
The compensation for ketoacidosis manifests itself by deep Kussmaul breathing; the patient’s breath may smell of 
acetone. Lactate overproduction in hypoxic tissues also plays a role in the development of acidosis in patients experi-
encing shock. On rare occasions lactate acidosis may complicate diabetes treatment with biguanides, and also occurs 
in severe deficiency of vitamin B
1
 (thiamine).
Following insulin treatment, ketone bodies are metabolized to hydrogencarbonate (bicarbonate); which is why the 
patient is usually not given alkaline infusions – this could consequently lead to alkalaemia.
25.7.1.2. Hypoglycaemic Coma
Hypoglycaemic coma is usually caused by overdosing on insulin (i.e. the administration of an excess dose, insuffi-
cient supply of carbohydrates or unusual physical strain with a normal dose of insulin). The higher the rate of glucose 
decline, the more severe the signs are. Sweating is induced by sympathetic nerve activation and is followed by the loss 
of consciousness or even coma – CNS cells need glucose in order to work. The condition is treated by means of an oral 
or i.v. (if the patient is unconscious) supply of glucose.
In rare cases, severe hypoglycaemia may be the result of overdosing on oral antidiabetic drugs from the group of 
sulphonylurea derivatives.
25.7.2. Late (Chronic) Complications of Diabetes
Late complications endanger both type 1 and 2 diabetics. They develop slowly, over decades, manifesting no signs 
to begin with. As mentioned in the introduction, 20 – 30% of newly diagnosed patients have already developed late 
complications. As the prevention of late complications is of paramount importance, it is clear that the earliest possible 
diagnosis of diabetes is desirable.
Late complications involve primarily blood vessels but also the eye lens (cataract); blood vessel complications are 
distinguished into two main types.
25.7.2.1. Diabetic Macroangiopathy
This complication involves large arteries and the disease does not differ from atherosclerosis in people who do not 
have diabetes. The only difference is that diabetics are about three times more endangered than people without dia-
betes. The patient is at risk of developing all the known complications of atherosclerosis: different forms of ischaemic 
heart disease including myocardial infarction, cerebrovascular accident and lower extremity arterial disease compli-
cations.
Oxidative stress is the main factor for aetiopathogenesis of the atherosclerosis; hyperglycaemia in diabetics is ac-
companied by overproduction of free radicals, glycation of LDLs facilitates their oxidation with the following inability 
to bind to LDL receptors.
25.7.2.2. Diabetic Microangiopathy
This complication is typical of diabetes. This affects the small arterioles – their wall grows thicker, leading to tissue 
oxygenation disorders. The most serious condition involves the eye ground blood vessels (i.e. diabetic retinopathy even 
leading to blindness), glomeruli (i.e. diabetic nephropathy with ultimate renal failure), and lower extremity blood ves-
sels with consequent gangrenes. The involvement of vessels supplying blood to the nerves contributes to the develop-
ment of diabetic neuropathy. At least 40% of patients are included in chronic dialysis programmes due to renal failure 
caused by diabetic nephropathy; diabetic retinopathy is the most common cause of blindness in people of working age.
The aetiopathogenesis of this complication includes glycation of proteins with a long biological half-life and sub-
sequent oxidation of the compounds produced. The result is the production of highly reactive aldehydes called advan-
ced glycation end-products (AGEs). AGEs react with other proteins and the glucose forms bridges between protein 
molecules. Cross-linked proteins stimulate the production of cytokines with inflammatory and proliferative effects; the 
vessel wall character and thickness change due to their activity, and diabetic microangiopathy develops.
The aetiopathogenesis of the process clearly shows that the most effective prevention means the best possible 
compensation of the diabetic to avoid excessive glycation and overproduction of free radicals.
25.8. Diabetes Management Options
These paragraphs do not strive to substitute the internal medicine textbook; they rather provide a brief outline of 
options for managing diabetes, emphasizing each drug’s mechanism of action.
25.8.1. Diet
Diabetics at the initial stages of DM2 have to live on a diet with a certain restriction to carbohydrates. Weight-loss 
diet in patients with central obesity considerably increases sensitivity to insulin through the reduced cytokine overpro-
duction by the fatty tissue. Increased physical exercise is a matter of course in the therapy.
Food containing carbohydrates can be divided by their glycaemic index reflecting the glucose growth rate and the 
time of glucose level persistence following consumption of the food. Glucose levels are measured within two hours 
from eating food containing 50 g of carbohydrates (in any form) and administering 50 g of per os glucose. The ratio of 
areas under the curve for the tested food relative to the pure glucose solution in percent equates to the glycaemic in-
dex. Foodstuffs with a high glycaemic index (fruit, honey, white bread) cause a rapid increase of glycaemia and increase 
the secretion of insulin, tissue resistance to insulin and the triacylglycerol concentration. By contrast, low-glycaemic 
index foodstuffs (rice, brown bread) do not have the metabolic effects listed above and seem to be more appropriate 
for a diabetic diet.
25.8.2. Pharmacotherapy
Many drugs with different indications and different mechanisms of action are available.
25.8.2.1. Insulin
Human insulin produced using biotechnology methods is the only form of insulin used today. It is indicated to pa-
tients with DM1 and patients with more advanced stages and complications of DM2. Many preparations differing by 
the onset rapidity and duration of action are available. One common method of administration is subcutaneous, often 
using insulin pens or insulin pumps, if necessary.
A preparation for inhalation is also available but is not used in practice due to its high cost and many limitations.
25.8.2.2. Insulin Analogues
This refers to an altered form of insulin whose molecules differ from human insulin by the amino acid sequence. 
The changed insulin structure leads to a changed rapidity and duration of insulin action. Short-acting insulin analogues 
last for a shorter period of time and have a more rapid onset than regular human insulin. They are not only used for 
injections but also for insulin pumps. The benefit of long-acting analogues is their long effect (up to 24 hours).
25.8.2.3. Biguanides
Biguanides are used for all patients with DM2 who do not have contraindications and tolerate them. They increase 
insulin sensitivity of the liver and muscle tissue, and damp gluconeogenesis and glucose absorption in the small intes-
tine. They can induce lactate acidosis through the stimulation of glycolysis. Metformin is the main type in this group.
25.8.2.4. Sulphonylurea Derivatives
Sulphonylurea derivatives belong to secretagogues – they increase the secretion of insulin from β-cells in the is-
lets of Langerhans. The basic mechanism of action is the blockade of ATP-sensitive potassium channels leading to cell 
membrane depolarization. If overdosed, they may induce hypoglycaemia, increase appetite and sometimes lead to 
increased weight. Glipizide and glimepiride are examples of sulphonylurea derivatives used in practice.
25.8.2.5. Inhibition of glucose production from starch in the small intestine
The main type is acarbose, an intestinal α-glucosidase inhibitor. This enzyme continues the action of α-amylase and 
finishes starch break-down into glucose. Acarbose therefore slows down the production of glucose from polysacchari-
des in the food and reduces postprandial hyperglycaemia.
25.8.2.6. Glitazones
Glitazones (thiazolidinediones) through PPAR-γ nuclear receptors activate the transcription of genes responsible 
for metabolic effects of insulin (i.e. reduce insulin resistance). Only pioglitazone is used.
25.8.2.7. Glinides
Glinides as well as sulphonylurea derivatives block the ATP-sensitive potassium channel in β-cell membranes. They 
act quickly, so are ideal to be used together with food to compensate postprandial hyperglycaemia. Repaglinide and 
nateglinide are examples of these substances.
25.8.2.8. Incretin-Modulating Drugs
Incretins are peptides released from the digestive tract, which facilitate maintaining glucose homeostasis. The 
main incretin hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). 
GLP-1 stimulates insulin secretion in response to eating food, inhibits glucagon secretion and slows down the emptying 
of stomach. This leads to a marked decrease in postprandial glycaemia fluctuations.
Synthetic GLP-1 analogues such as exenatide are used in practice. Another possible way of increasing the GLP-1 
level is to slow down its elimination by the dipeptidyl peptidase-4 (DPP4) enzyme. The benefit of DPP4 inhibitors (glip-
tins) consists of their oral administration while GLP-1 analogues have to be injected. Examples of gliptins are sitagliptin 
and vildagliptin.
25.8.2.9. Biological therapy of type 1 diabetes mellitus
The aim of this treatment is to slow down the autoimmune process and thus also β-cell death in patients with type 
1 diabetes mellitus. There are two monoclonal antibodies in the phase of clinical trials: anti-CD3 antibodies (modulate 
T-lymphocyte response) and anti CD20 antibodies (influence β-lymphocyte maturation and thus reduce presentation 
of antigens to T-lymphocytes). Certainly it would be best to influence the autoimmune process as soon as possible, 
when diabetic symptoms are still not present; nevertheless, it is still a long way for scientific research teams.
25.8.3. Islet Cell Transplantation
In general, transplantation options include the pancreas itself (in rare cases), combined transplantation of the kid-
ney and pancreas in patients with diabetes and renal failure, or islet cell transplantation. This is preceded by complex 
separation, purification and multiplication of these cells in the tissue culture. The transplantation itself is simpler – the 
cells are injected to the portal vein of the liver, so no operation is required.
In an experiment, laboratory animals received an intraperitoneal implant of β-cells encapsulated in a polymer al-
lowing the penetration of small (glucose) and medium-sized molecules (insulin), but preventing the entry of antibodies 
and immunocompetent cells. Experimentally induced diabetes mellitus was thereby compensated for many months.
25.9. Stress-Induced Hyperglycaemia
Insulin is the only hormone that lowers blood glucose. Contrary to that, there are many hormones with the opposi-
te, hyperglycaemic effects. When these hormones prevail over insulin, hyperglycaemia occurs. Hyperglycaemia can be 
seen in hyperthyroidism or Cushing’s syndrome, although hyperglycaemia induced by stress hormone overproduction 
is most common.
A stressed body requires the abundance of readily usable energy for muscle and other cells, i.e. the abundance of 
glucose. This is ensured by catecholamines (adrenalin), which supports glycogen breaking down in the liver, and gluco-
corticoids (cortisol), which also stimulate gluconeogenesis. Every patient in a severe condition (patients after undergo-
ing surgery, sustaining an injury, in intensive care units, after myocardial infarction or ictus, with severe inflammatory 
disease) is stressed. Therefore, hyperglycaemia can be expected in all of these patients. Glucose tolerance tests should 
be performed at least 6 weeks once the acute condition has subsided.
A positive effect of blood glucose control aimed at reaching a glucose level of 6 - 10 mmol/L has been proven in 
patients in a severe condition with stress-induced hyperglycaemia. Efforts to reach lower glucose levels lead to an in-
creased occurrence of hypoglycaemia, which increases patient mortality rates.
25.10. Causes of Hypoglycaemia
In conclusion and for the sake of completeness, there is a chapter which is only partially relevant to diabetes; the 
chapter deals with potential causes of hypoglycaemia. The most common causes of this condition include:
Prolonged fasting, particularly in people with reduced glycogen reserve in the liver; the condition often occurs in 
newborn infants (premature infants in particular) and cirrhotic patients, of course.
Insulin overdosing, either due to an excessive dose relative to the carbohydrate intake, or due to unusual physical 
strain which lowers the requirement for insulin.
Oral antidiabetic drug overdosing, namely sulphonylurea derivatives.
Alcohol intoxication – reduced form of the NADH coenzyme produced by alcohol metabolism inhibits gluconeoge-
nesis, which ultimately leads to hypoglycaemia.
Nesidioma of the pancreas (= insulinoma) is an insulin-producing tumour of β-cells. The release of insulin may be 
sudden and paroxysmal, which manifests itself by sudden hypoglycaemia. High levels of insulin and C-peptide prevail 
in laboratory test results.
Hereditary disease such as some types of glycogenosis, monosaccharide metabolism disorders, gluconeogenesis 
disorders and fatty acid oxidation disorders. Patients with type 1 glycogenosis have severe fasting hypoglycaemia, be-
cause they are unable to break down glycogen in the liver due to a glucose-6-phosphatase deficiency. Contrary to that, 
patients with galactosaemia and fructose intolerance experience hypoglycaemia after eating the relevant sugar (after 
ingesting milk containing lactose in the former case, and after ingesting saccharose containing fructose in the latter). 
The most common cause of galactosaemia is a galactose-1-phosphate uridyltransferase deficiency; accumulating galac-
tose-1-phosphate inhibits glycogenolysis, among others glycogen phosphorylase and glucose-6-phosphatase enzymes. 
Hereditary fructose intolerance features fructose-1-phosphate accumulation in the body (for a fructose-1-phosphate 
aldolase deficiency); this reduces the activation of hepatic phosphorylase and gluconeogenesis at the level of fructo-
se-1,6-bisphosphate.
CHAPTER 26
26. Cardiac Markers
26.1. Cardiac Markers – Preparation
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26.1.1. Ischaemic Heart Disease
Ischaemic heart disease (IHD) is an acute or chronic disease of the heart muscle caused by insufficient blood sup-
ply in coronary artery disease. The involvement of coronary arteries can be organic (narrowing), functional (spasm) or 
thrombotic (mural or obturating thrombus). Combinations of all these components can be seen in practice.
IHD is the most common cause of death in the Czech Republic.
26.1.1.1. Aetiology and Pathogenesis of IHD
The most common cause of IHD is atherosclerosis of the coronary arteries. At the beginning, atherosclerotic plaque 
build-up is usually associated with an enlarged arterial diameter (arterial remodelling), and the disease may be present 
without clinical symptoms for decades.
Only when the plaque narrows the arterial lumen to more than 70 %, does stenosis start to obstruct increased 
coronary flow under physical strain. This is how ischaemia is formed downstream the obstruction with its clinical sym-
ptoms in the form of exertional angina pectoris (chest pain on physical exertion). Another mechanism for initiating 
ischaemia is a spasm of the smooth muscle of the arterial wall. It is based on endothelial dysfunction induced by stimuli 
such as cold, tobacco smoke, physical and mental strain.
Should the plaque rupture, the thrombogenic (subendothelial) structures of the vessel wall become exposed, 
which leads to platelet activation and blood clotting which may even cause a sudden closure of the coronary artery. 
Bleeding in the plaque may also lead to a sudden arterial narrowing and a dramatic decrease in the blood flow. These 
conditions cause acute coronary syndromes (see chapter Acute Coronary Syndromes).
Atherosclerosis may affect all of the three major arteries evenly, however prevailing involvement of one of them 
is more common.
Heart arteries most commonly affected by atherosclerosis:
• RIA, ramus interventricularis anterior (ventralis) arteriae coronariae cordis sinistrae (ACS);
• RCx, ramus circumflexus arteriae coronariae cordis sinistrae;
• ACD, arteria coronaria cordis dextra.
Coronary atherosclerosis may build up evenly (concentrically) around the arterial perimeter, followed by the resi-
dual lumen is in the middle of the artery. However, the plaque may also be asymmetric (eccentric), outside the centre. 
The grade of atherosclerosis is assessed depending on the percentage of arterial lumen narrowing by sclerotic plaques, 
see Table 29p.1, measured by coronarography, intravascular ultrasound (IVUS) or found in the autopsy report.
Arterial Lumen Narrowing Grade of Coronary Atherosclerosis
25 % Grade I
50 % Grade II
75 % Grade III
over 75 % Grade IV
Table 26.1. Grading atherosclerosis
Coronary artery diseases other than atherosclerosis are rare (e.g. Wegener’s granulomatosis, syphilis).
The risk factors for coronary atherosclerosis are the same as the risks for atherosclerosis in general. They do not 
exactly explain the cause of atherosclerosis however do help estimate the risk of complications associated with athe-
rosclerosis (cardiovascular risk). Therapy is used for prevention.
The most common cause of IHD is atherosclerosis of the coronary arteries.
26.1.1.2. Atherosclerosis
Atherosclerosis is a degenerative involvement of arterial walls characterized by the accumulation of lipids, inflam-
matory infiltration of the vessel wall and fibrous tissue proliferation. After birth, human arteries are smooth, elastic and 
not very resistant to the blood flow.
Aetiology and Pathogenesis of Atherosclerosis
For many years, atherosclerosis was regarded as a mechanical process typical of lipid accumulation in the vessel 
wall, and calcium incrustation at a later phase. Multifactorial aetiology of atherosclerosis is accepted at present. Risk 
factors have been shown to contribute to atherosclerosis. Literature mentions hundreds of them, however about ten 
are important in practice. Table 29p.2 lists the most commonly mentioned risk factors.
The first stages of atherosclerosis are known to be caused by increased penetration and infiltration of atherogenic 
lipoproteins and inflammatory cells from the blood through the endothelium, followed by their accumulation in the 
subendothelial space. At later stages, fibroproductive processes join the process of atherogenesis in reaction to depo-
siting lipids and the inflammatory infiltration of the vessel wall. Endothelial damage, inflammatory mechanisms and 
atherogenic lipoproteins are involved to varying degrees in the development of these lesions. All of these factors are in 
complicated interactions and potentiate each other.
Uncontrollable Risk Factors Controllable Risk Factors
Age (men over 45, postmenopausal women or over 55) Smoking
Male gender Dyslipidaemia, increased total plasma cholesterol (LDL-
-cholesterol in particular), increased triacylglycerols, 
decreased HDL-cholesterol)
Family history of premature IHD (manifested in men 
under 55 and women under 65), or other clinical mani-
festations in first-degree relatives (parents, siblings and 
children)
Hypertension
Glucose metabolism disorders (diabetes mellitus, boun-
dary fasting blood glucose, impaired glucose tolerance)
Obesity (android type)
Table 26.2. Risk factors of atherosclerosis
26.1.1.3. Clinical Presentation of IHD
The clinical forms of IHD are shown in Table 29p.3 below.
Acute Forms Chronic Forms
Unstable angina pectoris Asymptomatic IHD
Myocardial infarction Angina pectoris (exertional, mixed, variant)
Sudden cardiac death Condition after myocardial infarction
Dysrhythmic IHD
Chronic heart failure
Table 26.3. Clinical forms of ischaemic heart disease
26.1.1.4. Acute Coronary Syndromes
Acute coronary syndrome is the clinical manifestation of a critical phase in IHD development, when the imbalance 
between the oxygen supply and requirements of the myocardium for the supply and removal of metabolic waste pro-
ducts becomes manifested.
The most common pathophysiological background for these conditions is an atherosclerotic plaque rupture and a 
blood clot formation in the coronary artery with potential presence of coronary spasm. The blood clot leads to a nar-
rowing or closure of the coronary artery with varying degrees of seriousness, and embolism in its peripheral branches.
Acute coronary syndromes:
• ST-segment elevation myocardial infarction (STEMI);
• Non-ST-segment elevation myocardial infarction (NSTEMI);
• Unstable angina pectoris.
Clinical presentation
Sudden blockage or critical narrowing of the coronary artery causes ischaemia, manifested in most cases by chest 
pain while at rest. In typical cases, the pain is constricting or burning, affects a wide area, may radiate to the neck, lower 
jaw or the upper left extremity, and lasts more than 20 minutes. Patients may sometimes feel back pain or epigastric 
pain. The pain is usually accompanied by dyspnoea, sweating and nausea, and the patient has to stop working and wait 
for relief. In a small part of patients (about 20 %), myocardial infarction manifests itself only as dyspnoea, not pain. 
There can be a rise in blood pressure and heart failure may develop.
Patients with acute coronary syndrome have alternating pain attacks, are restless, anxious, have pale, sweaty and 
cyanotic skin, while the heart rate may be increased, normal or decreased.
Myocardial Infarction
According to the definition of the European Society of Cardiology of 2007, the term myocardial infarction is reser-
ved for conditions with evidence of myocardial necrosis in a clinical setting consistent with myocardial ischaemia. Ne-
crosis assumes a coagulative character, caused by high protein content. Around 20 hours from the start of ischaemia, 
the colour of the tissue turns to yellowish, and water loss shrinks the necrotic tissue volume. Fully developed necrosis 
is evident after 3 days.
Diagnostic criteria of myocardial infarction
Evidence of a rise and/or drop in laboratory markers of necrosis (troponin in the first place) with at least one value 
above the 99th percentile of the upper limit of the normal range with evidence of myocardial ischaemia with at least 
one of the symptoms of ischaemia listed below:
• Laboratory tests help establish diagnosis of acute MI;
• Symptoms of ischaemia;
• ECG alterations are indicative of new ischaemia (ST-T segment alterations or a new left bundle branch 
block);
• Development of pathological Q waves on the ECG;
• New loss of viable myocardium or new local disorders of myocardial kinetics evidenced by an imaging 
method.
Sudden and unexpected cardiac death including cardiac arrest, frequently with symptoms indicative of myocardial 
ischaemia, very often accompanied by new ST segment elevations. Sometimes a fresh thrombus is proved by a coro-
narography and/or section, when death occurred before blood could be taken and before a rise in laboratory markers 
of necrosis.
In patients with percutaneous coronary intervention and normal baseline values of laboratory markers of necrosis, 
their increase over the 99th percentile of the upper limit of the normal range is a sign of periprocedural myocardial ne-
crosis. By consensus, periprocedural myocardial infarction is defined as a rise in laboratory markers of necrosis more 
than three times the upper limit of the normal range with the presence of one of the signs listed below:
• Newly developed pathological Q waves;
• Left bundle branch block;
• Development of a new bypass or coronary artery closure proved by angiography;
• Evidence of a new loss of viable myocardium using an imaging method.
Myocardial infarction is currently classified in clinical practice into ST-segment elevation and non-ST-segment ele-
vation myocardial infarction.
ST-elevation (STEMI) is indicative of necrosis of all myocardial wall layers; so this type of infarction is referred to as 
transmural MI. As a Q wave development can be seen on the ECG, also Q-infarction is used.
The extent of non-ST elevation MI is usually smaller, it affects subendocardial myocardial levels, and there is no ST-
-segment elevation or pathological Q-wave development. This is why it is called non-Q infarction or NSTEMI.
This classification is especially used on patient hospitalisation for rapid patient stratification. While STEMI patients 
go right to the operation theatre (without waiting for further test results), NSTEMI patients are examined in more detail 
to decide (taking other test results into account) whether or not myocardial infarction is involved.
Feature High probability
Whichever of following:
Intermediate probability
Absence of highly proba-
ble features and presence 
of whichever of following:
Low probability
Absence of highly or 
intermediate probable 
features, but patient can 
show:
Anamnesis Thorax or left arm pain or 
dyscomfort as a main sign 
of before known angina 
pectoris
Known anamnesis of ICHS 
including myocardial in-
farction
Thorax or left arm pain or 
discomfort as a main sign
Age ≥ 70 years
Masculine gender
Diabetes mellitus
Probable ischemic signs 
and absence of whichever 
intermediate probable 
features
Ancient cocain abuse
Examination Transient murmur cor-
responding with MR, 
hypotension, excessive 
sweating, lungs oedema 
or crackles 
Extracardial vascular di-
sease
Thorax discomfort repro-
duced on palpation
ECG New or most probably 
new transient ST part de-
nivelation (≥ 1 mm) or T 
wave inversion in multiple 
precordial leads
Fix Q waves
ST segment depression 
(0.5 – 1.0 mm) or T wave 
inversion > 1.0 mm
T wave flatteningor inver-
sion < 1 mm in leads with 
dominant T waves
Normal ECG
Cardiomarkers Increase of cardial TnI, TnT 
concentration or CK-MB 
concentration
Normal Normal
Figure 26.1. Marks and signs and probability of ACS
Unstable Angina Pectoris
Unstable angina pectoris is not a homogeneous nosological entity, but rather a syndrome with a name describing 
the acute condition.
Clinical definition of unstable angina pectoris – criteria:
• Newly developed angina pectoris; or
• Sudden worsening of existing angina pectoris; or
• Development of stenocardia in the subacute MI phase.
Worsening means more frequent anginous attacks (frequent stenocardia), more intense pain or change in the na-
ture of attacks, stenocardia while at rest or protracted stenocardia. The difference from non-ST elevation MI consists 
in the absence of laboratory markers of myocardial necrosis. The ECG only shows signs indicative of subendocardial 
ischaemia.
Chronic Forms of Ischaemic Heart Disease
Exertional (Stable) Angina Pectoris
The typical clinical symptom is pain behind the breastbone in situations connected to increased oxygen consump-
tion in the myocardium. Stenocardia usually lasts less than 20 minutes, radiates to the left arm, neck and back, and is 
usually not accompanied by vegetative symptoms. There is also a painless form of stable angina pectoris, most often 
manifested by dyspnoea.
Precipitating moments include physical exertion, heavy food or emotions. Discomfort is more pronounced in cold 
weather, or in the morning in some patients (quite typically when coming out from a warm environment to the freezing 
air). Discontinued exertion or nitrate administration lead to relief within minutes.
Variant Angina Pectoris (Prinzmetal’s Vasospastic Angina)
Variant angina pectoris is a nosological entity, the pathophysiological background of which is spasms of epicardial 
coronary arteries caused by endothelial dysfunction.
The typical clinical symptom is stenocardia while at rest accompanied by transient ST-segment elevations and heart 
rhythm disorders. The spasms can be induced during coronarography examination by provocation tests. If no spasm 
is present on physical exertion, the patient is usually asymptomatic. Variant angina typically affects women at an age 
between 40–50 years with some risk factors of ischaemic heart disease.
Cardiac Syndrome X
This name includes a heterogeneous group of patients with typical exertional stenocardia and evidence of ischae-
mia on a stress ECG or thallium myocardial scintigraphy, but without the presence of stenotic alterations or spasm on 
coronary arteries. Microvascular dysfunction at the level of prearterioles with the impossibility to increase coronary 
perfusion on exertion is being considered as one of causes.
26.1.2. Heart Failure
26.1.2.1. Acute Heart Failure
Acute heart failure is a sudden severe heart disorder or a sudden worsening of the heart’s function where the heart 
is unable to pump blood from the venous circulation to the lungs, or from the lungs to the arterial circulation. This 
results in congestion of the blood in some organs and insufficient tissue oxygenation.
Aetiology and pathogenesis
Many cardiovascular diseases present themselves as acute heart failure.
Acute heart failure is a syndrome and should never be a diagnosis in itself!
Depending on the dominant clinical symptoms, heart failure may be right-sided or left-sided.
Acute Right-Sided Heart Failure
Volume Overload Pressure Overload Lower Contractility
Tricuspid regurgitation Pulmonary embolism Right ventricular infarction
Pulmonic regurgitation Left-sided heart failure Right ventricular cardiomyopathy
Defects which cause shunting Pulmonary artery stenosis Perioperative right heart injury
Acute ventricular septal defect Mechanical ventilation, pulmonary 
hypertension, chronic obstructive 
pulmonary disease, pulmonary em-
bolism
Table 26.4. Most common causes of right-sided heart failure
Clinical presentation
Typical subjective symptoms of acute right-sided heart failure include dyspnoea, reduced tolerance to exercise, 
fatigue and chest pain.
Acute left-sided heart failure
Aetiology and pathogenesis
Acute left-sided heart failure occurs as a result of sudden injury to the left ventricle by mechanical influences, di-
rect injury or impaired diastolic filling.
This failure leads to sudden left ventricular pulmonary hypertension, which transmits back to the left atrium and 
pulmonary circulation. This leads to acute pulmonary hypertension and the amount of blood in the lungs rises. If 
pulmonary capillary pressure exceeds colloid osmotic pressure in the plasma, liquid penetrates into the interstitium 
followed by to the alveoli. This is why interstitial and intra-alveolar pulmonary oedemas are recognized.
Mechanical Influences Direct Injury Impaired Diastolic Filling
Pressure (hypertension, aortic ste-
nosis)
Ischaemic heart disease Cardiac tamponade
Volume (valvular regurgitation) Cardiomyopathy Arrhythmia
Myocarditis Exudative pericarditis
Table 26.5. Causes of acute left ventricular failure
Clinical presentation
Typical symptoms of acute left ventricular failure include dyspnoea and pulmonary oedema. Pulmonary oedema 
is a symptom of acute left-sided heart failure. The patient is extremely dyspnoeic even at rest, tachypnoic, anxious, 
restless, pale, perspiring and coughs up frothy sputum.
Cardiac asthma (asthma cardiale) is a condition of severe dyspnoea usually occurring at night when it wakes up the 
patient, who is first urged to sit up, then stand up and breathe while employing accessory muscles.
26.1.2.2. Chronic Heart Failure
Chronic heart failure is a disorder of the heart’s performance, whereby the minute cardiac output decreases despi-
te sufficient filling of the ventricles, and the heart is unable to cover the metabolic requirements of peripheral tissues. 
Depending on whether congestion prevails in the pulmonary or systemic bloodstream, heart failure is sometimes clas-
sified as right-sided and left-sided. This does not indicate, however, which of the ventricles is affected more.
Aetiology and pathogenesis
Chronic heart failure develops as a result of systolic and/or diastolic myocardial dysfunction. The most common 
cause is IHD, less frequently cardiomyopathies, myocarditis and toxic myocardial injuries. Worsening factors include 
hypertension, some arrhythmias, anaemia, hyperthyroidism or the iatrogenic effects of some drugs (antidepressants).
The basic pathophysiological cause of chronic heart failure development is a disorder of systolic or diastolic func-
tion of the ventricles with a subsequent drop in tissue perfusion, which induces the activation of sympathetic nerves, 
the renin-angiotensin-aldosterone system and the secretion of endothelin and vasopressin.
The myocardium undergoes remodelling (presented as dilation at the ventricular level) which worsens contractility 
and relaxation of cardiomyocytes, and ligament restructuring and collagen proliferation in the interstitium. Disorders 
of endothelial functions and microvascular fibrosis occur in the vascular blood stream. The heart is no longer able to 
increase its performance on exertion despite the fact that the ventricular dilation allows the stroke volume to be kept 
with an even lower ejection fraction (EF is less than 45 %).
Clinical presentation
Dominating clinical symptoms and objective pronounced signs allowing for right-sided and left-sided heart failure 
to be distinguished.
Left-sided heart failure
Most signs and symptoms occur as a result of blood congesting in the lungs, namely exertional dyspnoea, paro-
xysmal nocturnal dyspnoea (cardiac asthma), and pulmonary oedema. Objective signs include wet inspiratory crackles 
not changing their character after coughing, and also a one-sided or two-sided effusion.
Right-sided heart failure
Most symptoms occur as a result of blood congesting before the right ventricle, increased filling of the jugular ve-
ins, positive hepatojugular reflux, hepatomegaly and peripheral oedemas. Oedemas first develop around the ankles, 
form during the day and release at night (nocturia). They signal a 3–5-litre increase in the volume of extracellular fluid. 
Extreme retention of fluids manifests itself as hydrothorax, ascites, anasarca, and hydropericardium.
26.2. Laboratory Diagnosis of Acute Myocardial Infarction and Heart Failure – Use of 
Cardiac Markers
Authors: MUDr. Věra Ploticová; RNDr. Zdeněk Švagera, Ph.D.
Reviewer: MUDr. Roman Cibulka, Ph.D.
26.2.1. Laboratory Assays Used in Diagnosing Ischaemic Heart Disease
Myocardial infarction was very scarce in the nineteenth century. Each case was seen as a rarity. However the situ-
ation has considerably changed over the years. Dr. James Herrick published a study about the effects of coronary artery 
blockage in 1912. That was the time when symptoms of cardiac infarction were first mentioned in addition to sudden 
death and angina pectoris. Several years later, Dr. Herold Pardee first described and characterised the ECG record of 
acute myocardial infarction. After the Second World War, myocardial infarction became one of the most common 
causes of adult mortality. This was when people got interested about this disease and its causes. The Framingham 
study was published in 1960 and described the major causes of this disease. Even in the 1980s, the first attack of acu-
te myocardial infarction (AMI) was regarded as waiting for the second AMI attack, the second as waiting for the third 
attack, and the third attack usually ended by death. The development of laboratory diagnosis and intense therapy in 
cardiology have led to a marked decrease in AMI mortality.
In general, diagnosing acute coronary syndrome (ACS) is based on an assay for intracellular proteins released from 
the ischaemic focus in the myocardium to the blood stream. Finding a sufficiently sensitive as well as specific parame-
ter for the myocardium, which could point to the ACS fast, specifically and sensitively, has always been problematic.
Different, though not sufficiently cardiospecific parameters were used in the past. A change in aspartate ami-
notransferase (AST) concentration in acute myocardial infarction was described in the 1950s. Consequently, lactate-
-dehydrogenase (LD), creatine phosphokinase (CK), myoglobin and LD and CK isoenzyme tests were first used. In the 
1980s, the “gold standard” for diagnosing AMI was the assay for creatine phosphokinase cardiac isoenzyme activity 
(CK-MB), which had its limitations (inadequate sensitivity, loss of activity in the circulation) and is no more satisfactory 
for practical use today.
As these assays were not specific enough for diagnosing cardiac muscle injury, new markers were sought, and in 
1990 attention turned to structural proteins of the cardiac muscle, cardiac troponins, which have become the „gold 
standard“ of today, and are currently firmly established in all recommendations of societies of cardiology with regard 
to diagnosing acute coronary syndrome (ACS)
26.2.1.1. Diagnosis of Acute Myocardial Infarction
According to the definition of acute myocardial infarction (2009), acute (developing or recent) myocardial infarcti-
on is defined as a typical increase and/or decrease in biochemical markers of myocardial necrosis (cardiac troponin T 
or I, or CK-MB) with concurrent presence of at least one of the following criteria:
a)	 Clinical symptoms of ischaemia;
b)	 Development of pathological Q waves on the ECG;
c)	 ECG alterations indicative of ischaemia (ST elevation or depression);
d)	 Relation to coronary revascularization (PCI, bypass);
e)	 Evidence of a new regional disorder of kinetics (echocardiogram), or imaging evidence of a new loss of viable 
myocardium.
This recommendation clearly shows the importance of troponin assays as markers of myocardial necrosis.
26.2.1.2. Cardiac Troponins
Troponins are structural proteins of striated muscles, which means they can be found both in skeletal muscles and 
the myocardium. Troponin T (TnT) provides the bond of troponins C and I to tropomyosin; troponin I (TnI) inhibits acti-
nomyosin-ATPase, which depends on the amount of calcium bound to troponin C. Troponins with tropomyosin create 
the troponin-tropomyosin complex, which performs a regulatory and structural role in the contractile apparatus of 
striated muscles (see the animation) Animation – contractions!!!
http://translate.google.cz/translate?hl=cs&langpair=en|cs&u=http://highered.mcgraw-hill.com/si-
tes/0072495855/student_view0/chapter10/animation__action_potentials_and_muscle_contraction.html
Methods of molecular genetics helped reveal that troponins T and I in the skeletal muscle and myocardium have 
different primary structures and can be distinguished by immunoassays. This fulfilled the requirement for a cardiospe-
cific method allowing for only cardiac troponins T (cTnT) and I (cTnI) to be determined, thus distinguishing myocardial 
involvement from damage to the skeletal muscle.
Troponin I (cTnI) Troponin T (cTnT)
Origin Myocardium Myocardium
Molecular weight (Da) 23,876 37,000
Biological half-life (minutes) <120 120
Rise after AMI (hours) 3-5 3-4
Maximum concentration in blood 
(hours)
12-30 12-75
Persistence in blood (days) 4-7 4-12
Practicability for ACS diagnosis Comparable Comparable
Efficiency in cardiovascular risk stra-
tification
Comparable Comparable
Biphasic waveform during 
successful and early reperfusion
Less distinct Distinct
Practicability for reperfusion evalu-
ation
Yes Yes
Diagnosis of reinfarction Limited use due to long persistence 
in the blood
Limited use due to long persistence 
in the blood
Elimination through the kidneys Yes Yes
Rise in patients with stage 5 chronic 
renal disease (according to the Nati-
onal Kidney Foundation)
Less pronounced  Pronounced
Multiple of the upper reference 
limit at maximum
300x 300x 
Estimate of AMI focus size Yes Yes
Timing of sampling for diagnosing 
AMI (CSKB recommendation, 2008)
On admission, 6–9 hours, if negati-
ve then 12–24 hours
On admission, 6–9 hours, if negati-
ve then 12–24 hours
Table 26.6. Summarizes some properties of cardiac troponins T and I
Advantages of Determining Cardiac Troponins (cTn) in ACS (AMI) Diagnosis
• Very high specificity for the myocardium – a rise in cTn concentrations always relates to myocardial injury;
• High diagnostic sensitivity (ability of the method to detect the disease);
• Multifold increase in concentrations in acute myocardial infarction;
• High sensitivity allows for even the slightest myocardial damage to be detected;
• Possible to estimate the focus size from the rise in concentration;
• Late diagnosis of MI due to the long persistence of increased values.
Disadvantages of Determining Cardiac Troponins in ACS (AMI) Diagnosis
A relatively slow increase after AMI – 3–4 hours on average (this drawback will be eliminated in the near future by 
the introduction of new, ultrasensitive methods for determining troponin).
Limited use in diagnosing reinfarction due to long persistence in the blood (this drawback should be eliminated by 
introducing ultrasensitive methods).
Different TnI cut-offs between laboratories – there are multiple manufacturers of TnI test kits using different anti-
bodies, and therefore different cut-off values. TnT test kits are supplied by only one manufacturer, which guarantees 
uniform cut-off values and comparability between laboratories.
Literature describes the existence of a disease with an increased serum troponin level due to non-cardiac causes 
(renal failure, sarcoidosis, amyloidosis, critically ill patients with respiratory failure or diabetes, acute neurological 
diseases, burns, toxins, hypothyroidism, etc.). The increase in troponin in such diseases has different dynamics than 
those typical of AMI. In addition to this, the patient’s clinical condition and other examination methods do not confirm 
AMI diagnosis.
Clinical Importance of Cardiac Troponin Assays
Cardiac troponins have been used in clinical diagnosis as organ-specific (cardiospecific) markers of ischaemic myo-
cardial injury in acute coronary syndromes (ACS) and also myocardial injury with different aetiology and pathogenesis.
List of causes which may increase serum troponin levels:
• The most common cause is ischaemic necrosis due to limited or blocked perfusion by mural or occlusive 
thrombus in a coronary artery;
• However, elevated cTn concentration in the blood may also be a symptom of ischaemic and/or non-ischa-
emic myocardial injury not caused by atherothrombosis such as mechanical disruptions of cardiomyocytes 
due to myocardial injury, the cumulative effect of potentially cardiotoxic drugs, action of bacterial toxins, 
or as a result of a neurohumoral reaction;
• Other causes include cardiac muscle inflammations, circulatory collapse of varied aetiology (e.g. following 
polytraumas, sepsis with multi-organ failure, severe burns, etc.), when systemic hypotension may lead to 
myocardial ischaemia, a rise in troponin, and renal failure with slightly increased cTn (cTnT in particular) 
levels not indicative of infarction. Intoxications should also be mentioned (carbon monoxide poisoning is 
quite frequent: the reduced oxygen-carrying capacity of haemoglobin may lead to myocardial hypoxia and 
a rise in troponin);
• Doubtless and sometimes prognostically serious myocardial injuries with increased cTn concentrations in 
the blood occur for iatrogenic causes, during diagnostic or therapeutic procedures associated with corona-
ry blood stream catheterisation and all cardiosurgeries;
• With corresponding clinical symptomatology, a rise in cTn concentration is considered a result of irrever-
sible (definitive) myocardial necrosis, and should always be assessed in relation to diagnosing the disease 
and also in order to stratify the risk of further development of cardiovascular diseases;
• Long and permanently increased levels of cTn, cTnT in particular, are frequent (without clinical symptoma-
tology of the ACS) in patients in the terminal stage of renal failure, and correlate significantly with the risk 
of their overall mortality; they should be continually monitored for cTn levels.
Other Tests for Diagnosing AMI
AMI diagnosis also employs other auxiliary tests which may supplement information obtained from cardiac tropo-
nin assays. These tests include the myoglobin assay and the creatine phosphokinase cardiac isoenzyme mass (CK-MB 
mass).
Parameter Myoglobin CK-MB mass
Origin Striated muscle – skeletal muscle 
and myocardium
Myocardium-specific isoenzyme, 
below 5 % of total CK in skeletal 
muscle
Molecular weight (Da) 18,000 85,000
Biological half-life (minutes) 10 – 20 11 – 12
Rise after AMI (hours) 1 – 2 3 – 10
Maximum concentration in the blo-
od (hours)
4 – 10 12
Persistence in the blood (hours) 24 48 – 72
Practicability for diagnosing ACS For early phase after AMI Where cTn cannot be determined
Practicability for reperfusion evalu-
ation
Yes Yes
Diagnosis of reinfarction Yes Yes
Elimination through the kidneys Yes No
Rise in patients with stage 5 chronic 
renal disease (according to the Nati-
onal Kidney Foundation)
Pronounced Less pronounced
Estimate of AMI focus size --- ---
Timing of sampling for AMI diagno-
sis (CSKB recommendation, 2008)
2–6 hours from onset of disease, 
pointless after 12 hours
On admission, 6–9 hours, if negati-
ve then 12–24 hours
Table 26.7. Summarizes some properties of myoglobin and CK-MB mass
Clinical Importance of Myoglobin and CK-MB Mass Assays
Myoglobin is an early, yet organ non-specific marker of AMI. Myoglobin levels increase as a result of muscle injury 
of varied aetiology, when myoglobin is released into the blood. This parameter can be used at a very early stage after 
displaying ACS symptoms (3–6 hours) in order to rule out ACS diagnosis. Serum myoglobin levels have a very high 
negative predictive value (the probability that a person with the negative test is actually healthy – does not have the 
suspected disease). In practice this means that if this parameter is elevated, AMI cannot be ruled out (patient hospita-
lisation). Conversely, increased myoglobin does not mean that AMI is present since the elevation may be due to muscle 
damage with another aetiology.
The CK-MB mass assay is currently an alternative assay for the AMI diagnosis where the cTn assay is not available. 
This cardiac marker is still recommended, and is used to detect the myocardium (reinfarction) extent when high cTn 
levels persist in the blood. Elevated CK and CK-MB may also occur in non-cardiac conditions where AMI is not present. 
Examples include muscular dystrophy, surgery, trauma, intramuscular injections, collagenosis, hypothyroidism, hyper-
thermia, spasms, enormous physical strain, etc.
26.2.1.3. Less Common Cardiac Markers
Other parameters especially useful for detecting very early cardiac damage are being sought. One big goal in 
today’s cardiology is to identify a patient with vulnerable plaque(s) in the coronary arteries prior to rupturing, and early 
identification of LV remodelling and dysfunction.
Present knowledge and basic characteristics of some new biomarkers in acute cardiology are potential candidates 
for clinical use for risk stratification of patients with ACS, early detection of left ventricular (LV) dysfunction develop-
ment and possible monitoring of treatment.
These parameters can thus be divided based on the cause of their origin into:
• Markers of the vessel wall inflammation (interleukin 6, interleukin 10, highly sensitive CRP, lipoprotein-as-
sociated phospoholipase A2, etc.);
• Markers of destabilization or rupture of atheromatous plaque (soluble CD40 ligand, myeloperoxidases, 
etc.);
• Myocardial ischaemia markers (ischaemia modified albumin, free fatty acids, etc.);
• Cardiomyocyte necrosis markers (binding protein for fatty acids, glycogen phosphorylase).
26.2.2. Laboratory Assays Used for Heart Failure
Laboratory assays are also used to diagnose heart failure. Just like troponins reveal information about damaged 
cardiomyocyte (damaged structure), natriuretic peptides reveal information about overloaded myocardial cells (mal-
function). In addition to standard patient history data, physical examination, cardiac and pulmonary X-ray, and above 
all echocardiography, natriuretic peptides have become an integral part of heart failure diagnosis.
26.2.2.1. Natriuretic peptides
Natriuretic peptides are hormones of a protein nature excreted mainly through the myocardium, also through the 
endothelium and kidneys. They have a protective function in the body – protecting the cardiovascular system against 
pressure and volume overloading (pressure and volume overloading of the myocardium lead to increased BNP levels).
The main target organ of natriuretic peptides is the distal renal tubule where they inhibit reverse sodium trans-
port (induce natriuresis, increased diuresis and the renin-angiotensin-aldosterone system inhibition). The history of 
natriuretic peptides dates back to 1981 when the extract from the atria was portrayed to cause natriuresis and vaso-
dilatation. The chemical structure of atrial natriuretic peptide (ANP) was described in 1984, with the brain natriuretic 
peptide (BNP) being isolated from the swine brain in 1988, and with the central nervous system natriuretic peptide 
(C-natriuretic peptide, CNP) being isolated in 1990.
ANP is stored in the form of secretory granules in the cytosol of atrial cardiomyocytes; its release is immediate, in 
the order of tens of seconds to minutes.
BNP is not stored correspondingly, and an increase in its concentration in the blood is determined by the fast ac-
tivation of its synthesis in ventricular cardiocytes. A rise in BNP concentration in the blood is very fast – in the order 
of minutes to tens of minutes.The N-terminal part of the propeptide of BNP (NT-proBNP), which is also present in the 
blood, is cleaved off in the metabolic activation of pre-prohormone proBNP with a concurrent release of BNP.
Routine tests exist for the active hormone BNP and the NT-proBNP. Advantages of the BNP or NT-proBNP assays 
have not been clearly defined. According to international recommendations published so far, the BNP and NTproBNP 
assay provide equal clinical information both in patients with dominating clinical symptoms of dyspnoea to differentia-
te between cardiac and extra-cardiac aetiology, and patients with suspected ACS for the stratification of risk of further 
cardiovascular complications. An advantage of NT-proBNP as compared with BNP can be longer stability in the blood 
against BNP.
The Clinical Importance of Natriuretic Peptide Assays
In clinical practice, natriuretic peptide assays, BNP and NT-proBNP assays in particular, are used as indicators of the 
heart’s failure to work as a pump (regardless of etiology) and as a sign of activation of one of the basic neurohumoral 
systems regulating cardiac performance. The main areas where natriuretic peptides are used are:
• Differential diagnosis of acute dyspnoea with an unclear proportion of cardiac failure;
• Stratification of the risk of cardiovascular complications in patients with suspected ACS.
Differential Diagnosis of Acute Dyspnoea with an Unclear Proportion of Heart Failure
Samples are taken from patients with dominating dyspnoea immediately on being admitted. The result of the exa-
mination helps establish diagnosis of cardiac and extra-cardiac aetiology of dyspnoea (see the diagram below).
Figure 26.2. Acute dyspnoea and natriuretic peptides levels – scheme
The diagram shows that low natriuretic peptide levels indicate dyspnoea of non-cardiac origin, and pulmonary or 
other disease should be ruled out. Medium increased concentrations point to probable heart failure, however septic 
shock, pulmonary hypertension, ARDS, acute embolism or renal failure should be ruled out. Heart failure is very proba-
ble if natriuretic peptide concentrations are high; however, conditions such as septic shock, where high BNP levels are 
also detected, have to be ruled out.
Stratification of the Risk of Other Cardiovascular Complications in Patients with Suspected ACS
The recommended time of sample collection in patients with clinical symptoms of heart failure (primarily patients 
with suspected or diagnosed ACS) is 2 to 3 days upon being admitted , and a follow-up test after 1 to 2 weeks; the test 
results help stratify the risk of developing cardiac dysfunction and/or heart failure.
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27. Laboratory Signs of Malignant Tumours
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Laboratory tests in patients with tumours include both routine tests as in other groups of patients as well as spe-
cial examinations. Routine laboratory tests provide basic information about the patient’s condition, nutrition, organ 
involvement due to the tumour growth or metastasizing of the tumour with consequent impairment of organ function, 
about any ongoing inflammatory reaction or change in condition following the use of effective therapy. Special labo-
ratory tests are also called “tumour markers” (note: the name is not entirely accurate as an increased tumour marker 
value does not always mean the presence of a tumour). Results may vary with time, either as a result of a curative 
action, tumour disease progression or the adverse effects of treatment.
Basic tests should always include blood count, basic urine tests and routine biochemical serum analysis. Cancer 
screening in patients over 50 includes blood in the faeces (faecal occult blood test) as part of the preventive medical 
check-up. Many alterations may already be seen in routine laboratory test results.
• The blood count may exhibit signs of anaemia as a result of bleeding, chronic disease, malnutrition, iron 
or other factor deficiency, or bone marrow suppression after chemo and radiotherapy. Leukocytes may be 
increased not only in blood cell tumours (leukaemias) but also as a result of consequent infection or non-
-specifically as a reaction to the tumour, or, conversely, may be decreased if bone marrow is suppressed.
• The basic biochemical serum analysis may also show various alterations:
o Elevated inflammatory parameters due to infection or as a non-specific reaction to the cancer process
o Signs of malnutrition – lowered albumin, prealbumin and cholinesterase
o Elevated hepatic enzymes (ALT, AST, ALP, GGT) and bilirubin in liver injury, liver metastases and bile 
duct obstruction
o Elevated urea, creatinine and potassium in kidney injury or as a result of urinary tract obstruction whe-
re the tract is compressed by the tumour
o Elevated calcium in multiple myeloma or metastatic bone lesions
o Elevated uric acid as a sign of tumour disintegration
o Acid-base disorders in renal or pulmonary injury
o Results of hormonal activity in endocrine-active tumours
o and others
The urine test may show haematuria that may accompany kidney and bladder cancer or glomerulopathies and 
urinary tract infections, or the presence of a protein as in myeloma (paraprotein). Non-typical tumour cells may be 
detected in the urine sediment.
27.1. Tumour Markers – Definition and Classification
A tumour marker is a substance present in or produced by the tumour, or the host, in response to the presence of 
the tumour. The substance provides information about the biological properties and behaviour of the tumour.
Tests are either qualitative, i.e. histopathological tests for markers in the tumour tissue (i.e. cellular tumour mar-
kers), or quantitative, most commonly measuring the concentration of serum markers (i.e. humoral tumour markers), 
which is suitable for dynamic monitoring.
The history of tumour markers dates back to the 1930s, when human chorionic gonadotropin (hCG), physiologi-
cally produced by the placenta, was discovered in young men with seminoma (Zondek). α
1
-foetoprotein, also physio-
logically produced by the placenta, was first described in mice with liver cancer (Tatarinov) in the 1970s, and in human 
hepatomas shortly after. Intensive research into these markers followed, and they were subsequently used in oncology 
and prenatal diagnosis. Based on existing knowledge, local and international expert associations provide recommen-
dations for the rational use of tumour markers in clinical practice.
Tumour markers include:
• Soluble markers – traditional tumour markers tested in clinical biochemistry. These are substances of 
various chemical nature - enzymes, immunoglobulins, hormones, cytokeratins, glycolipids, glycoproteins, 
carbohydrates and receptor-type molecules.
• Cellular markers – receptor-type molecules, usually demonstrated histochemically directly in the tumour 
tissue. They are important for the selection and control of therapy and for the prognosis of the disease.
• Circulating cellular elements – circulating tumour cells, circulating endothelial cells and their precursors.
• Genetic abnormalities – oncogene and tumour suppressor gene mutations, protein products of oncoge-
nes and other alterations.
Classical tumour markers can be divided into three groups:
• Oncofoetal antigens – substances produced physiologically by the foetoplacental unit (foetus or placenta) 
in the prenatal period; postnatally they are produced only in connection with certain diseases, usual-
ly cancer. Antigens appearing early in the postnatal ontogenesis are characteristic of less differentiated 
(i.e. more malignant) tumours. This group includes α
1
-foetoprotein (AFP), human chorionic gonadotropin 
(hCG), carcinoembryonal antigen (CEA), placental alkaline phosphatase (PLAP) and several other substan-
ces currently of limited use in onkology.
• Tissue or organ-specific antigens – substances physiologically occurring inside healthy tissue or organs, 
outside they are released only in minimal amounts. Increased release is connected with pathological con-
ditions (most often in a tumour disease but sometimes during inflammation or following trauma).Exam-
ples include prostate-specific antigen (PSA), neuron-specific enolase (NSE), S-100 protein, soluble cyto-
keratin fragments (TPA, TPS, CYFRA 21-1), most CA antigens defined using monoclonal antibodies (MAb), 
squamous cell carcinoma (SCC) antigens, thyreoglobulin (TG) and hormones, and hormone precursors, in 
tumours of glands physiologically producing them (such as C-peptide in insulinoma, vanilmandelic acid in 
urine in pheochromocytoma – tumour of the medulla of the adrenal glands).
• Non-specific antigens are enzymes and hormones produced by tumours (tumours of organs that do not 
produce them physiologically – paraneoplastic syndrome), or substances related to the presence of the 
tumour – markers of cellular proliferation, metabolism or a non-specific reaction of the body. This group 
includes ferritin, lactate dehydrogenase (LD), thymidine kinase (TK), β
2
-microglobulin (ß-2M), some acute 
phase reactants (APR), lipid-associated sialic acid (LASA), and many other, less frequently used markers. 
Paraneoplastic hormone production is characteristic primarily of small-cell lung cancer. Various endocri-
ne and metabolic syndromes occur with a corresponding manifestation typical of the relevant hormone 
(ACTH, parathormone, antidiuretic hormone, etc.).
27.1.1. Basic characteristics of selected tumour markers; use of markers depending on tumour site and 
type
AFP (α1- foetoprotein): AFP is an albumin-like glycoprotein. At first it is produced physiologically by the yolk sac 
and later by the foetal liver. AFP is used during pregnancy for prenatal screening for congenital developmental defects 
in the 2nd trimester. The pathological occurrence of AFP is seen in tumours containing structures that produce AFP in 
the foetal period, such as hepatocellular carcinoma (but not cholangiocellular carcinoma), hepatoblastoma in children, 
and germ-cell tumours of the testicle (non-seminomas) and ovary. AFP may also be elevated in patients with hepatic 
cirrhosis (look out for the transition of cirrhosis to hepatocellular carcinoma!), in acute or chronic active hepatitis, 
where the maximum elevation is usually in the period of regeneration, in toxic liver injury, etc.
CEA (carcinoembryonic antigen): CEA is a glycoprotein (molecular weight: 180,000) with a high carbohydrate con-
tent. CEA can be found both in the embryonic tissue (foetal gut) and in adult epithelial tissue. It is used for monitoring 
colorectal carcinoma and also tumours in other locations (gastrointestinal tract, breast, lungs). CEA levels are higher in 
smokers and frequently in non-malignant diseases (elderly people, decreased kidney function, inflammatory diseases 
of the intestine and lungs).
hCG, β-hCG (human chorionic gonadotropin): hCG is a glycoprotein consisting of two noncovalently bound sub-
units, alpha and beta. The α-subunit is identical to the α -subunit of other hormones (LH, FSH and TSH), which enables 
cross-reactivity. The whole molecule or only the β-subunit is then tested depending on the indication. To be able to use 
hCG as a tumour marker, the antibody used must not cross-react with the other peptide hormones of similar structure. 
This is why the β-subunit is tested (specific hCG). hCG is used to monitor germ-cell testicular tumours, choriocarcino-
mas and hydatidiform mole. In addition to the pregnancy test, it is used for the screening for congenital developmental 
defects in the 1st and 2nd trimesters of pregnancy.
CA 125: This is an antigen characterized by means of monoclonal antibodies. It is suitable for monitoring ovarian 
carcinomas. Elevated CA 125 levels may be found in ovarian cysts, inflammation of the adnexa, damage to serous mem-
branes, ascites and pleural effusion.
CA 15-3: A glycoprotein from the mucin family, it is used primarily to monitor patients with metastasizing breast 
cancer.
CA 72-4: An antigen characterized by means of monoclonal antibodies and used to monitor stomach cancer.
CA 19-9: This is a glycolipid carrying the blood group Lewis(a) determinant (about 5% of the population does not 
produce CA 19-9). CA 19-9 plays a major role in monitoring patients with gastrointestinal tumours, pancreatic and bile 
duct cancer in particular.
CYFRA 21-1: A tissue-nonspecific soluble fragment of cytokeratin 19, CYFRA 21-1 is suitable for monitoring patients 
with non-small-cell lung carcinomas and patients with urinary bladder cancer.
NSE (neuron-specific enolase): NSE is an enzyme characteristic of nerve and neuroendocrine cells (APUD cells). 
Indications for the NSE test include neuroendocrine tumours, small-cell lung carcinomas and neuroblastomas. Elevated 
levels may also be found in metastasizing renal carcinomas. NSE is also increased in patients with CNS injury, and rising 
levels mean a poor prognosis for patients. Moreover, NSE is present in red blood cells and platelets, and may release 
from them; this is why blood should be processed as early as possible after collection in order to separate serum or 
plasma to avoid platelet haemolysis and disintegration, which would lead to an artificial increase in NSE.
PSA and fPSA (total and free prostate-specific antigen): PSA is a glycoprotein with enzymatic activity (serine pro-
tease) and is a physiological component of seminal plasma. If released to the blood, it quickly binds to antiproteases 
(antichymotrypsin in particular). Total PSA (free PSA plus PSA bound to antichymotrypsin) and free PSA can be tested. 
Prostatic cancer is an indication for the PSA test. PSA may also be elevated in benign hyperplasia or inflammation of 
the prostatic gland. The fPSA/PSA ratio, expressed as a percentage, can be assessed in addition to total PSA. In healthy 
individuals, fPSA represents more than 25% of total detectable PSA, and decreases in prostate carcinoma, often under 
10%. Other tests include PSA velocity (PSA growth rate) and PSA density (PSA concentration relative to gland volume). 
Per-rectal examination, sexual activity, contusion of the prostate from cycling or horseback riding may release PSA from 
the prostate and increase serum PSA concentration. The histopathological examination of specimens from prostate 
biopsy is decisive for the diagnosis.
SCC antigen: A squamous cell carcinoma antigen, it is not very specific but is adequate enough for monitoring 
different types of squamous cell carcinomas, in particular of the head and neck, external genitalia and oesophagus 
carcinomas.
TPA (tissue polypeptide antigen) and TPS (tissue polypeptide-specific antigen): These are cytokeratins, closely 
related to CYFRA 21-1. TPA is a mixture of soluble cytokeratins 8, 18 and 19, and TPS is a soluble fragment of cytokeratin 
18. They are classified as non-specific markers. Elevated values can be found in patients with advanced carcinomas of 
the breast, lung, colorectum, cervix, ovary and urinary bladder. TPS seems to be more specific for monitoring metasta-
sizing breast carcinoma.
Thymidine kinase (TK): TK is an enzyme of DNA synthesis and therefore a cellular proliferation indicator. Extreme 
elevation is typical of leukaemia, where TK correlates with the severity of the disease. A certain increase can also be 
seen in solid tumours.
β2-microglobulin: Exhibiting considerable sequence homology with immunoglobulins, β2-microglobulin is identical 
to the light chain in HLAs. It is suitable for monitoring patients with multiple myeloma, non-Hodgkin lymphomas and 
B-cell chronic lymphocytic leukaemia. Increased β
2
-microglobulin can also be seen in patients with chronic inflamma-
tory and autoimmune diseases, acquired immunodeficiency syndrome (AIDS) and after organ transplantations. Re-
nal function must be considered while interpreting results because β
2
-microglobulin is excreted mainly through the 
kidneys (increase in serum due to lower glomerular filtration, and increase in urine due to tubular impairment when 
reabsorption worsens).
Ferritin: This is a high-molecular protein used to store iron, which is toxic in its free form. Indications for the ferritin 
test include haematological malignancies, in particular myeloblastic leukaemia and Hodgkin’s disease. Ferritin is also 
elevated in iron metabolism disorders and non-specifically in many tumours such as hepatomas, pancreatic carcinoma, 
germ-cell tumours, as well as mammary gland and lung carcinomas.
Calcitonin (CT): CT is a peptide consisting of 32 amino acids and is secreted by the parafollicular C-cells of the thy-
roid. It is suitable for monitoring medullary thyroid cancer and for screening in families with medullary thyroid cancer 
(multiple endocrine neoplasia - MEN syndrome).
Thyroglobulin (TG): TG is produced by the thyroid and used for the synthesis and storage of hormones. It is used 
to monitor patients with well-differentiated thyroid cancer. It is not used for diagnosis as TG may also be increased in 
patients with goitre.
Chromogranin A (CgA): An acid glycoprotein found in secretory granules of normal and neoplastic neuroendocrine 
tissues, CgA is used in patients with neuroendocrine tumours.
Paraproteins: There are immunoglobulins and immunoglobulin components produced by a single proliferating 
plasma cell clone. Free light chains are filtered by the kidneys and transfered to urine (Bence Jones protein). Regret-
tably, test strips employing the protein error of acid-base indicators do not capture these globulins; this means that 
the protein found in urine is negative. Paraprotein is found in multiple myeloma, Waldenström’s macroglobulinaemia, 
amyloidosis, monoclonal gammopathy of undetermined significance and various lymphoproliferative disorders.
S-100B (S-100B protein): This occurs physiologically in the nervous tissue. It is used to monitor patients with ma-
lignant melanoma.
Oestrogenic and progesterone receptors: These tumour tissue markers are tested in the breast cancer tissue, usu-
ally by immunohistochemical techniques, and help determine the tumour’s reaction to hormonal therapy and estimate 
prognosis of the disease.
HER2/neu: The HER2/neu gene product is a transmembrane receptor possessing tyrosine kinase activity. It can be 
determined in a tissue specimen immunohistochemically or by using molecular genetics methods (fluorescence in situ 
hybridization, FISH) as a HER2/neu gene copy number. It is an important marker for invasive mammary gland cancer, 
where it is associated with a poor prognosis. If HER2/neu gene amplification is proved, the monoclonal antibody aga-
inst the extracellular domain of this receptor (trastuzumab - HERCEPTIN) can be used for treatment.
In addition to the most common tumour markers listed above, many other markers do exist. Examples of less 
common tumour markers include vanilmandelic acid, which is gradually being substituted by catecholamines and me-
tanephrines (markers for pheochromocytoma), or the test of the 5-hydroxyindoleacetic acid level for carcinoid. Newer 
soluble markers include proGRP (pro-gastrin-releasing peptide) for small-cell lung cancer and HE4 (human epididymis 
protein 4) for ovarian cancer monitoring.
Potential new tumour markers are proteins and oncoproteins – mutant gene products important for cell survival, 
division, differentiation, and metastasizing. Specifically, they interfere with cell cycle regulation (cyclins), apoptosis 
(e.g. the mutant gene p53 product), signal transduction (HER2/neu, epidermal growth factor), adhesion (adhesion mo-
lecules ICAM-1 and VCAM-1), angiogenesis (angiogenesis inhibitors – angiostatin, angiogenin and thrombospondin), or 
are associated with specific tumour cell properties (matrix metalloproteinases, urokinase-type plasminogen activator 
uPA and uPA inhibitor PAI-1).
Overview of tumour markers suitable for each cancer type
Gastrointestinal tract • Oesophagus – superior third – ;  – CA 72-4, CEA, CA 19-9
• Stomach – 
• Colon – 
• Liver - hepatocellular - ; cholangiocellular - 
• Pancreas – 
Lungs • small-cell cancer – NSE
•  CYFRA 21-1, CEA, SCC
Gynaecological region • Mammary gland – CA 15-3, CEA, TPA/S, steroid receptors
• Ovary – non-mucinous - ; mucinous – ; germinal – AFP, hCG
• Cervix uteri – epidermoid - SCCA, CYFRA 21-1; adenocarcinomas – CEA
• Corpus uteri – 
• Vulva – 
• Chorion (choriocarcinoma, mola hydatidosa) – hCG
Urogenital region • Kidneys – TPA/S, CEA, NSE
• Urinary bladder – TPA/S, CYFRA 21-1
• Prostate – PSA, fPSA, chromogranin
• Testes – seminomas - hCG, AFP, NSE; non-seminomas – hCG, AFP
Haematological malignancies  – thymidine kinase, ferritin, lactate dehydrogenase
 – Hodgkin – β2-microglobulin, ferritin, lactate dehydrogenase; non-Hod-
gkin – thymidine kinase, β2-microglobulin, lactate dehydrogenase
 – β2-microglobulin, paraproteins
Other • Head, neck – SCCA, CYFRA 21-1
• Carcinoid – 5-hydroxy, 3-indoleacetic acid, NSE
• Thyroid gland – differentiated carcinoma – thyroglobulin, CEA; medul-
lary - CT, CEA (NSE); anaplastic TPA/S
• Melanoma – S-100B, NSE, thymidine kinase
• CNS – neuroblastomas – NSE; gliomas – CEA; astrocytomas – thymidine 
kinase
Table 27.1. Overview of tumour markers suitable for each cancer type
Cancer type Marker
Gynaecological region
• Mammary gland – CA 15-3, CEA, TPA/S, steroid receptors
• Ovary 1
– non-mucinous - CA 125
; mucinous – CA 19-9, CA 72-4
germinal AFP, Hcg
• Cervix uteri
; epidermoid ; SCCA, CYFRA 21-1
adenocarcinomas CEA
Gastrointestinal tract Oesophagus – superior third – SCCA, CYFRA 21-1; inferior 
third – CA 72-4, CEA, CA 19-9
Stomach – CA 72-4, CEA
Colon – CEA, CA 19-9
Liver - hepatocellular - AFP, CEA; cholangiocellular - CA 19-9
Pancreas – CA 19-9, CEA
Lungs small-cell cancer - NSE; non-small-cell cancer - CYFRA 21-1, 
CEA, SCC
Gynaecological regio • Mammary gland – CA 15-3, CEA, TPA/S, steroid receptors
• Ovary – non-mucinous - CA 125; mucinous – CA 19-9, CA 
72-4; germinal – AFP, hCG
• Cervix uteri – epidermoid - SCCA, CYFRA 21-1; adenocarci-
nomas – CEA
• Corpus uteri – CA 125, CEA
• Vulva – SCCA
• Chorion (choriocarcinoma, mola hydatidosa) – hCG
Urogenital region
• Kidneys – TPA/S, CEA, NSE
• Urinary bladder – TPA/S, CYFRA 21-1
• Prostate – PSA, fPSA, chromogranin
• Testes – seminomas - hCG, AFP, NSE; non-seminomas – 
hCG, AFP
Haematological malignancies
• Leukaemia – thymidine kinase, ferritin, lactate dehydroge-
nase
• Lymphoma – Hodgkin – β2-microglobulin, ferritin, lacta-
te dehydrogenase; non-Hodgkin – thymidine kinase, β2-
microglobulin, lactate dehydrogenase
• Multiple myeloma – β2-microglobulin, paraproteins
Urogenital region • Kidneys – TPA/S, CEA, NSE
• Urinary bladder – TPA/S, CYFRA 21-1
• Prostate – PSA, fPSA, chromogranin
• Testes – seminomas - hCG, AFP, NSE; non-seminomas – 
hCG, AFP
Haematological malignancies • Leukaemia – thymidine kinase, ferritin, lactate dehydroge-
nase
• Lymphoma – Hodgkin – β2-microglobulin, ferritin, lacta-
te dehydrogenase; non-Hodgkin – thymidine kinase, β2-
microglobulin, lactate dehydrogenase
• Multiple myeloma – β2-microglobulin, paraproteins
Other • Head, neck – SCCA, CYFRA 21-1
• Carcinoid – 5-hydroxy, 3-indoleacetic acid, NSE
• Thyroid gland – differentiated carcinoma – thyroglobulin, 
CEA; medullary - CT, CEA (NSE); anaplastic TPA/S
• Melanoma – S-100B, NSE, thymidine kinase
• CNS – neuroblastomas – NSE; gliomas – CEA; astrocytomas 
– thymidine kinase
Gastrointestinal tract
Oesophagus – superior third – SCCA, CYFRA 21-1; inferior third – CA 72-4, CEA, CA 19-9
Stomach – CA 72-4, CEA
Colon – CEA, CA 19-9
Liver - hepatocellular - AFP, CEA; cholangiocellular - CA 19-9
Pancreas – CA 19-9, CEA
Lungs – small-cell cancer - NSE; non-small-cell cancer - CYFRA 21-1, CEA, SCC
Gynaecological region
• Mammary gland – CA 15-3, CEA, TPA/S, steroid receptors
• Ovary – non-mucinous - CA 125; mucinous – CA 19-9, CA 72-4; germinal – AFP, hCG
• Cervix uteri – epidermoid - SCCA, CYFRA 21-1; adenocarcinomas – CEA
• Corpus uteri – CA 125, CEA
• Vulva – SCCA
• Chorion (choriocarcinoma, mola hydatidosa) – hCG
Urogenital region
• Kidneys – TPA/S, CEA, NSE
• Urinary bladder – TPA/S, CYFRA 21-1
• Prostate – PSA, fPSA, chromogranin
• Testes – seminomas - hCG, AFP, NSE; non-seminomas – hCG, AFP
Haematological malignancies
• Leukaemia – thymidine kinase, ferritin, lactate dehydrogenase
• Lymphoma – Hodgkin – β2-microglobulin, ferritin, lactate dehydrogenase; non-Hodgkin – thymidine kina-
se, β2-microglobulin, lactate dehydrogenase
• Multiple myeloma – β2-microglobulin, paraproteins
Other
• Head, neck – SCCA, CYFRA 21-1
• Carcinoid – 5-hydroxy, 3-indoleacetic acid, NSE
• Thyroid gland – differentiated carcinoma – thyroglobulin, CEA; medullary - CT, CEA (NSE); anaplastic TPA/S
• Melanoma – S-100B, NSE, thymidine kinase
• CNS – neuroblastomas – NSE; gliomas – CEA; astrocytomas – thymidine kinase
27.2. Tests for Tumour Markers, Indication and Interpretation
The process of tumour marker testing includes the indication for the test, the pre-analytical phase, the test itself 
and the proper interpretation of results.
In terms of pre-analytics, the specific features of some tumour markers (see above) have to be considered in addi-
tion to generally accepted principles, in particular the effect of prostate agitation on the PSA, effect of haemolysis on 
NSE and the effect of secretions (saliva) on the SCC level.
Tumour markers are predominantly protein in nature and are determined by immunoassays with different types 
of labelling (radioimmunoassay, enzymoimmunoassay, fluorescence analysis, chemiluminiscence). The same method 
and diagnostic set from the same manufacturer should be used because results acquired using different techniques 
may vary; otherwise, re-baselining is required. In terms of analysis, problems may be caused by the cross reactivity 
of molecules with a similar structure, the hook effect caused by a high marker concentration or by interference from 
heterophilic antibodies and human anti-mouse antibodies (HAMA), which may be produced during biological therapy, 
for example.
As regards to the indication and interpretation of tumour markers, it is important to know that they are inten-
ded primarily for monitoring patients with cancer, i.e. the test is usually indicated by the oncologist. The dynamics of 
change is important. First, the individual level should be determined, i.e. the concentration in the stabilized condition 
following surgery, i.e. removal the tumour mass. The next step is repeated follow-up monitoring, frequent at the be-
ginning, and later at intervals of about 3-6 months. A rise in 3 consecutive samples and a rise in the marker by more 
than 25 % are considered significant. Such increased marker level, although in the reference range, may provide an 
earlier warning of relapse than imaging methods, and suggests the indication of additional diagnostic and therapeutic 
procedures. Several markers should be monitored at the same time because this increases the chance that a relapse is 
detected (usually the 2 markers most suitable for the region are chosen).
Tumour markers are not directly suitable for diagnostic purposes, but may be a useful aid for the diagnostic pro-
cess. A positive finding of tumour markers has a diagnostic value; a negative finding does not necessarily mean the 
absence of cancer. Histopathological examination complemented by tumour marker demonstration is always decisive 
for the diagnosis. An increase in a tumour marker does not always necessarily mean cancer, it may be caused by in-
flammation, benign lesion, trauma, use of effective therapy or liver or kidney injury in the case of markers eliminated 
by these organs.
Only blood in the faeces (occult blood) is tested for screening; other markers are only tested for specific groups 
(calcitonin in families with medullary thyroid cancer, CA 15-3 in BRCA mutations). The use of other markers (not even 
PSA) for screening is not recommended at present.
27.3. Tumour Marker Evaluation
Tumour markers are assessed in terms of their specificity (true negativity in healthy individuals) and sensitivity 
(true positivity in individuals with the diseases), or their positive and negative predictive value (true positivity in all 
positive and true negativity in all negative results). ROC (receiver operating characteristic) curves and the area under 
the curve are used for marker evaluation.
The importance of laboratory diagnostics in oncology is constantly increasing. Tumour marker testing plays an 
important role, especially in monitoring patients with tumour diseases, and can detect a relapse of the disease earlier 
than imaging methods or before the disease manifests itself clinically. Laboratory examinations also provide informati-
on about the nutritional status, presence of inflammation or failure of organs affected by the tumour process. Selected 
tests may also help in the differential diagnosis process in patients with suspected tumour disease. Additional parame-
ters will probably be used in future; such tests could enable the effective targeted treatment of cancer.
CHAPTER 28
28. Cytochemical Examination of Cerebrospinal Fluid
Author: doc. MUDr. Milan Dastych, CSc.
Reviewer: MUDr. Ing. David Zeman, Ph.D.
28.1. Cerebrospinal Fluid Cytology
The Fuchs-Rosenthal chamber is used for the quantitative determination of cerebrospinal fluid elements. The num-
ber of red blood cells is determined in the native preparation, which is subsequently stained with fuchsine to highlight 
and count white blood cells. 0 - 3 elements per μl are considered normal. The chamber volume is 3.2 μl, so the total 
cell count found is divided by three.
Figure 28.1. Fuchs-Rosenthal chamber
Figure 28.2. Unstained (native – left) and stained (right) liquor in the Fuchs-Rosenthal chamber
The morphological differentiation of white blood cells into mononuclear and polynuclear leukocytes in the Fuchs-
-Rosenthal chamber is not very reliable. A permanent cytological preparation must be made for a more accurate diffe-
rentiation of elements. The basic staining method is Pappenheim’s stain. A permanent cytological preparation is made 
using cytosedimentation or careful cytocentrifugation methods.
The preparation is used for cytological diagnosis, and enables the evaluation of the counts of each cell type and 
the state of cell function.
Physiologically, only mononuclear elements are present in the liquor, with resting elements being predominant. 
The presence of red blood cells, polynuclear cells (except for an artificial admixture of blood or neonatal CSF), plasmo-
cytes and phagocytes is pathological.
28.1.1. Type of Cells in the CSF
28.1.1.1. Lymphocyte
The resting lymphocyte is a cell of 8 - 10 μm, has a narrow rim of plasma and a compact nucleus filling almost the 
whole cell. These cells can be found in normal cerebrospinal fluid. Following an encounter with an antigen, lymphoid 
cells transform and change appearance. An activated (reactive) lymphocyte is a lymphoid cell of 11 - 18 μm with a dis-
tinctive basophilic cytoplasm and a large nucleus. The lineage of T-lymphocyte development ends with lymphoid cells; 
only B-lymphocytes develop into plasmocytes. T-lymphocytes are responsible for cytolysis and the activation of macro-
phages. Plasmocytes are the largest lymphoid cells, up to 21 μm in size with basophilic plasma. They have a round or 
oval, usually eccentric, nucleus with visible nucleoli. The perinuclear halo of the cytoplasm is typical.
  
Figure 28.3. A slightly activated (reactive) lymphocyte
28.1.1.2. Plasmocyte
Plasmocytes are the ultimate stage of B-lymphocytes following immunological stimulation, and produce immuno-
globulins. Their presence in the cerebrospinal fluid is pathological; most commonly they can be found in patients with 
viral inflammations.
28.1.1.3. Monocyte
Monocytes are cells 15 - 30 μm in size. The nucleus usually has an irregular shape; most often it is horseshoe or 
bean-shaped. Stained plasma is lighter than stained lymphocytes. These cells have very varied morphology. Activated 
monocytes differ from resting monocytes by their larger size and vacuolated cytoplasm. They are capable of phagocy-
tosis of other cells or non-cellular elements. Activated monocytes with devoured material are called macrophages. Dif-
ferent types can be distinguished depending on the phagocytized material; such types include erythrophages, hemo-
siderophages, lipophages, etc. Monocytes are part of the normal cell count, but activated monocytes or macrophages 
suggest a pathological process.
Figure 28.4. Resting monocyte
28.1.1.4. Neutrophilic polymorphonuclear cell
Neutrophilic polynuclear cells are 10 - 15 μm in size. Under normal circumstances they can be found in the CSF only 
in their mature, segmented form. The characteristic morphology with a split nucleus and granules in the cytoplasm 
corresponds to blood neutrophils. Of the granulocytic lineage of leukocytes, these are the type most frequently found 
in the CSF, and accompany acute CNS inflammations, bacterial inflammations in particular. Granulocytes are also ca-
pable of phagocytosis; they engulf bacteria, for example. However, they are incapable of engulfing other leukocytes 
or erythrocytes. Eosinophil granulocytes are somewhat larger than neutrophils. The nucleus is mostly split into two 
parts and the cytoplasm contains many reddish granules. They are rather rare in the CSF – their presence may suggest 
a chronic process, or they can be seen in parasitic diseases.
Figure 28.5. Neutrophilic polynuclear cell
28.1.1.5. Tumour cells 
Tumour cells in the CSF originate much more often from extracranial tumours than intracranial tumours. Cytolo-
gical CTF examination and the search for tumour cells are important especially in patients with metastatic tumours, 
leukaemia, lymphomas, primary brain tumours and meningeal irritation of unknown origin. The generally accepted 
criteria of cell malignancy include a substantial change in the nuclear-cytoplasmic ratio in favour of the nucleus, large 
nucleoli, increased mitosis, the considerable cell size, and tendency to cell clustering.
Figure 28.6. Tumor cell
28.2. Types of Cytological Findings in CSF 
Depending on the prevalent cell lineage, pleocytosis or pathological oligocytosis is classified as granulocytic, lym-
phocytic, monocytic or tumorous.
Granulocytic pleocytosis with a prevalence of neutrophils occurs in purulent inflammations; eosinophils can often 
be found in parasitic and mycotic diseases or chronic pathological processes.
Figure 28.7. Granulocytic pleocytosis - neutrophils: segmented and banded
Granulocytic oligocytosis is common at the initial stage of non-purulent inflammations or brain ischaemia.
Lymphocytic pleocytosis occurs in non-purulent inflammations (viral infections and infections caused by Borrelia, 
Leptospira or tuberculosis bacilli).
Figure 28.8. Lymphocytic pleocytosis: Larger cells with a lighter nucleus are activated lymphocytes
Lymphocytic oligocytosis often occurs in multiple sclerosis.
Monocytic pleocytosis or oligocytosis with detected activated monocytes is a non-specific finding, typical of non-
-infectious diseases such as compression syndrome or autoimmune disease. The finding is also characteristic of the 
final stage of inflammation.
Tumorous pleocytosis or oligocytosis is indicative of a malignant disease.
Figure 28.9. Tumor cells in CSF
A normal cytological finding in the CSF is oligocytosis (cell count under 3 - 5 per μl), lymphocytes, monocytes are 
present, activated cell form counts are under 10%.
28.3. Biochemical Examination of Cerebrospinal Fluid
Appearance of CSF
• Clear and colourless CSF (normal finding)
• Sanguinolent CSF is caused by the pathological or artificial admixture of blood
• Xanthochromic CSF (yellowish) may be a sign of an old bleeding into the CSF system or occurs in a severe 
blood-CSF barrier dysfunction
• Turbid CSF can be found in purulent meningitis
Total protein – the total protein level in its normal condition is about 200 times lower than the serum protein level. 
Under normal circumstances, 80% of the total protein is of serum origin; the remaining 20% is of brain origin. Physio-
logical levels of the total protein from lumbar puncture are 0.15 - 0.40 g/l. The total protein in the ventricular system is 
markedly lower. Newborns have a higher CSF total protein level due to the immature blood-CSF barrier. Albumin is the 
most abundant component of the total protein. Some serum proteins such as prealbumin and transferrin are modified 
in the CSF space. Immunoglobulins transfer to the CSF from blood or are produced by intrathecal synthesis in CSF spa-
ces. Inflammatory markers include haptoglobin, C-reactive protein, C3 and C4 complement components, antithrombin 
III and α1-antitrypsin. Orosomucoid is a tumour marker.
Increased total protein is clinically important since it occurs in inflammations (in bacterial inflammations there is a 
pronounced increase up to tens of grams), CSF circulation disorders (prolapsed intervertebral disc) or intrathecal syn-
thesis of immunoglobulins following immune system activation.
Glucose is the basic source of energy for nerve tissue; the CSF glucose level depends on the serum glucose level, 
and is about 60% of the serum level. The CSF glucose/S glucose ratio is more significant, and is 0.6 in normal conditi-
ons. A reduction in CSF glucose or the CSF glucose/S glucose ratio is clinically significant; it is associated with bacterial 
inflammations, meningeal infiltration in tumour diseases and subarachnoid haemorrhage.
Lactate – the CSF lactate level does not depend on the plasma concentration; lactate practically does not pass 
the blood-CSF barrier. Physiological lactate levels are 1.2 – 2.1 mmol/l. Lactate is produced by glucose metabolism in 
the absence of oxygen. Elevated lactate levels are clinically significant. Increase occurs in inflammations, and a slight 
increase accompanies viral or tuberculous meningitis. A marked increase occurs in bacterial inflammations. The value 
for discriminating between types of meningitis is about 4 mmol/l. Lactate concentration is often increased in ischaemic 
vascular lesions.
Chlorides – physiological levels are 120 - 132 mmol/l; chloride testing is being abandoned. Chlorides are usually 
decreased in pronounced blood-CSF barrier dysfunction, particularly in specific inflammations such as tuberculous 
meningitis.
Albumin is synthesized in the liver and enters the CSF only through the blood-CSF barrier. It is used for assessing 
the function of the barrier. To assess the dysfunction of the blood-CSF barrier function, the sensitivity of the CSF/serum 
albumin ratio is higher than the absolute CSF albumin concentration.
The albumin quotient Qalb=CSFalb/Salb is calculated from the CSF and serum albumin concentration. Albumin 
quotient values depend not only on barrier permeability in the narrower sense of the word, but also on CSF turnover 
(circulation). It is markedly higher in newborns. Normal Qalb values are under 7.4; more precisely, the albumin quoti-
ent depends on age according to the formula Qalb ≤ 4 + (age in years/15). A slightly damaged barrier can be found in 
chronic neuroinfections or multiple sclerosis. Medium-severe barrier impairments can be seen in viral infections, for 
example, and severe barrier impairment is typical of bacterial meningitis, Guillain-Barré polyradiculoneuritis, malig-
nant meningeal infiltration or herpetic encephalitis.
Immunoglobulins – the source of immunoglobulins is either serum, which is where they come from if the barrier is 
damaged, or intrathecal synthesis in CSF spaces in CNS diseases connected with immune response.
28.4. Examination of Intrathecal Immunoglobulin Synthesis
Intrathecal antibody synthesis in the central nervous system comes from perivascular infiltrates of B-lymphocytes, 
which proliferate locally, ripen into plasmocytes and produce the relevant antibodies. Unlike the known and charac-
teristic reaction in the serum, where the generation of antibodies changes from the IgM class to the IgG class at the 
subacute or chronic stage of the disease, such transition does not take place in intrathecal synthesis. IgG/IgM/IgA class 
antibodies are generated right at the beginning of the disease and the generation is relatively constant. An intrathe-
cal antibody response need not always necessarily mean an acute disease. It may also be present in an inflammatory 
disease of the CNS manifested by an increased number of cells in the CSF, in residual intrathecal synthesis following a 
disease, or in a chronic inflammatory autoimmune process in the CNS. Today, modern diagnosis of multiple sclerosis 
from the CSF is primarily based on demonstrating the intrathecal synthesis of immunoglobulins.
28.4.1. Quantitative Demonstration of Intrathecal Immunoglobulin Synthesis
The CSF immunoglobulin concentration may be increased as a result of increased serum immunoglobulin concent-
ration, blood-CSF barrier dysfunction or both these factors. Protein diffusion from the serum to the CSF is the dominant 
mechanism of transport through the blood-CSF barrier. According to the physical laws of diffusion, larger molecules 
such as IgM pass more slowly than smaller molecules such as IgG and albumin. An increase in certain serum protein 
concentration results in an increase in the same protein in the CSF, but the gradient expressed by the CSF to serum 
protein ratio remains constant. If the blood-CSF barrier is impaired, there is a pathological increase in the CSF protein 
concentration, which is why albumin and the relevant immunoglobulins have to be tested in the serum and CSF at the 
same time. Determination of the intrathecal synthesis of IgG, IgM and IgA is the most significant for clinical diagnosis. 
Reiber’s formula, describing the relationship between the albumin quotient and relevant immunoglobulin quotient, is 
currently recommended for the demonstration of intrathecal immunoglobulin synthesis. The relationship is not linear 
but hyperbolic. The blue line represents the border between local immunoglobulin synthesis and passive immunoglo-
bulin transfer. Values above this line mean intrathecal synthesis and the range is shown with dotted lines and expressed 
as a percentage. The vertical dashed line separates the normal and impaired blood-CSF barrier.
Figure 28.10. Reiber’s diagram
28.4.2. Interpretation of pathological findings in relation to the blood-CSF barrier function and intra-
thecal synthesis:
• Zone 1 – normal finding
• Zone 2 – blood-CSF barrier dysfunction without intrathecal synthesis
• Zone 3 – blood-CSF barrier dysfunction with intrathecal immunoglobulin synthesis
• Zone 4 – intrathecal synthesis with blood-CSF barrier function preserved
• Zone 5 – analytical error zone
28.4.3. From the diagnostic point of view, the ability to distinguish between conditions is facilitated by 
presence of intrathecal synthesis of each immunoglobulin:
• Intrathecal Ig synthesis not demonstrated: early bacterial and viral meningitis, Guillain-Barré syndrome;
• Dominant intrathecal IgG-synthesis: multiple sclerosis, neurosyphilis, chronic HIV encephalitis;
• Dominant intrathecal IgA-synthesis: neurotuberculosis, brain abscess;
• Dominant intrathecal IgM-synthesis: neuroborreliosis.
28.4.4. 31.4.4 Qualitative Demonstration of Intrathecal Immunoglobulin Synthesis
The qualitative demonstration of intrathecal immunoglobulin synthesis consists in the detection of oligoclonal 
immunoglobulins by isoelectric focusing (IEF). Serum diluted to the concentration corresponding to the cerebrospinal 
fluid is tested by analogy at the same time. The demonstration of two or more oligoclonal bands in the CSF without 
their counterparts in the serum is indicative of intrathecal synthesis. The method of isoelectric focusing is used to divi-
de compounds that are amphoteric in nature (having acid and alkaline groups) with the pH gradient as the borderline 
depending on the isoelectric point. Based on international consensus, IEF of the CSF and serum reveals five recognized 
patterns:
Type 1: Normal condition with no oligoclonal bands (OCBs) demonstrated
Type 2: OCBs in CSF but not in S (typical of multiple sclerosis)
Type 3: OCBs in both materials, but additional bands in CSF (neuroborreliosis, cerebrospinal sclerosis)
Type 4: Identical OCBs in S and CSF (paraneoplastic syndromes, SLE)
Type 5: Monoclonal bands in CSF and S (monoclonal gammopathy)
Figure 28.11. Isoelectric focusing (blood - liquor)
Basic IEF patterns
The determination of oligoclonal bands is positive in up to 98% of patients with a diagnosis of multiple sclerosis. 
Oligoclonal bands can also be found in infectious processes and autoimmune or systemic diseases. The introduction 
of the specific MRZ (morbilli, rubeola and varicella zoster) reaction has brought important results for the diagnosis 
of multiple sclerosis based on CSF analysis, since it enables some chronic CNS diseases to be detected already at the 
time of first clinical signs. The MRZ reaction is an intrathecal synthesis of specific IgG antibodies against neurotropic 
measles, rubella and herpes zoster viruses. The presence of the MRZ reaction is explained by the modern theory of an 
immunological network, where every immune reaction induced by a specific antigen affects the entire immunological 
network. In addition to specific antibodies against the causative agent, each immune reaction produces an increased 
number of many other antibodies and autoantibodies, which is called a polyspecific immune response. Concentrations 
of each specific antibody in the CSF and serum are measured and their ratio relates to the ratio of “total” antibodies of 
the same class as the antibody index (AI). Values higher than 1.4 are pathological and indicate the intrathecal synthesis 
of specific antibodies. The MRZ reaction is specific to chronic autoimmune inflammatory diseases of the nervous sys-
tem, multiple sclerosis in particular.
28.5. Spectrophotometry of Cerebrospinal Fluid
CSF spectrophotometry is used if an intermeningeal haemorrhage is suspected. It is useful at early stages when no 
alterations can be found yet in the cytological analysis. Spectrophotometry is 10 times more sensitive than the human 
eye; a positive finding can be detected even in a seemingly colourless CSF. Spectrophotometry records visible light 
absorption (380 – 700 nm) and the presence of oxyhaemoglobin and bilirubin is detected.
The detection of oxyhaemoglobin may suggest a fresh haemorrhage; oxyhaemoglobin appears 4 - 8 hours after 
a haemorrhage has started. The absorbance maximum is at 415 nm; 2 minor peaks are at 540 nm and 580 nm. The 
maximum for bilirubin is reached 3 days after a haemorrhage has started, persists for 3 weeks, and the absorbance 
maximum is at 450 nm.
28.6. Microbiological Examination and Pathogenic Agent Detection
Basic procedures include culture and sensitivity testing, and the microscopic and bacteriological examination of 
smears. Specific antibodies are examined in the serum and CSF, and intrathecal antibody synthesis is demonstrated. 
Polymerase chain reaction (PCR) is a specific and very sensitive method for the detection of DNA pathogenic agents 
(most often used to detect Borrelia and herpetic viruses).
28.7. Prospects for New Advances in CSF Examination
Attention is currently turning to new opportunities in the diagnosis of degenerative and metabolic diseases of the 
central nervous system, as well as prion infections. The research so far has tended towards the experimental. For exam-
ple, an increased concentration of the 14 - 3-3 protein, which is currently considered a general CSF marker for tissue 
destruction, suggests in the CSF a diagnosis of Creutzfeldt-Jakob disease. The CSF-based diagnosis of Alzheimer’s disea-
se relies on the determination of β-amyloid, τ-protein and phospho-τ-protein. The β-amyloid protein is a component of 
amyloid plaques accumulating in the brain. The τ-protein can be found in the CNS cytoskeleton. Decreased β-amyloid 
and increased τ-protein values are found in Alzheimer’s disease. The τ/ β-amyloid index is usually increased. Another 
parameter that may help in the diagnosis of neurodegenerative diseases is cystatin C. Cystatin C is a cysteine protease 
inhibitor; it is quite stable in the circulatory system and is known in clinical practice as an indicator of estimated glome-
rular filtration. Increased cystatin C levels in the CSF are found in patients with neurodegenerative diseases of the CNS. 
Structural S-100 protein belongs to the family of calcium-binding proteins. Increased S100 (S100B) levels are a sign of 
the structural involvement of the CNS tissue; the S100 (S100B) protein can also be measured in the serum to estimate 
the prognosis and to monitor the patient’s status without lumbar puncture. β2 microglobulin is a protein present in all 
body fluids. An increase in β2 microglobulin concentration in the CSF can be found in conditions generally associated 
with the activation and multiplication of lymphocytic and macrophagic elements. The presence of neuronal antibodies 
has been examined in patients with multiple sclerosis – antibodies against myelin sheath molecules have been found 
in the CSF. In particular, it is the myelin basic protein (MBP) from the group of structural proteins which forms the basis 
of myelin. Antibodies against MBP reflect the level of myelin destruction.
28.8. Determination of Liquorrhoea
It is sometimes important to determine whether the secretion from a patient’s nose following head trauma is 
just an inflammatory mucosal discharge or cerebrospinal fluid. The latter case presents a serious condition with CSF 
passage into the nasal cavity, which endangers the patient by the transfer of bacterial flora to the meninges. CSF can 
be detected by determining the CSF-specific parameter. A beta-trace protein test is available – beta-trace protein is an 
enzyme synthesized in choroid plexus cells. CSF beta-trace protein concentrations are 20 - 30 times higher than serum 
concentrations. β2 transferrin is another parameter. Sialic acid residues cleave off from serum transferrin in CSF spaces 
(by neuraminidase in the brain) to form asialotransferrin, which can be detected by immunofixation electrophoresis in 
the β2-globulin region.
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29. Inherited Metabolic Diseases – Laboratory Diagnostics
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29.1. IMD Characteristics
Inherited metabolic diseases (IMDs, originally also referred to as “inborn errors of metabolism”) comprise a large 
group of more than 800 diseases which have a common characteristic – genetic defect in the production of proteins, 
most often enzymes. IMDs are rare diseases (i.e. diseases with an incidence under 1:2,000 in the population), and 
comprise about 10 - 15% of all known nosological entities.
29.2. Incidence
Incidence can only be determined for diseases tested in every individual born, i.e. only if neonatal screening of ge-
neral population is conducted. In the current IMD screening system in the CR, the expected incidence for the ten scree-
ned IMDs (see below) is about 1:4,000.The incidence of defects not included in the screening programme cannot be 
reliably determined due to the unknown proportion of patients who escaped correct diagnosis because the suspected 
IMD was not taken into account in the differential diagnosis, and special tests were not performed. About one hundred 
new patients with IMDs have been diagnosed annually by selective screening in the CR during the last decade (see 
Figure 1). On the basis of information from world (nebo jen literature) literature, the estimated cumulative incidence 
of all known IMDs is at least 1:500 of children born. It should be emphasized that the actual incidence is probably 
much higher, which means that every physician of any specialization meets patients with IMDs in their practice. With 
the ever widening offer of more and more advanced laboratory tests, it has transpired over the last few years that the 
number of patients with the first clinical manifestation of a metabolic disease in adult age is growing. These diseases 
may include for example, disorders of mitochondrial energy metabolism or metabolic urolithiases (cystinuria, inherited 
xanthinuria, 2,8-dihydroxyadenine lithiasis), kidney injury (familial juvenile hyperuricemic nephropathy and others). 
IMDs are by no means, therefore, only the preserve of paediatricians.
Figure 29.1. Incidence of IMD in Czech Republic
29.3. Pathophysiology
The underlying cause of this group of diseases is nuclear or mitochondrial gene mutations leading to a reduced 
production and/or changed function of the gene product (most often enzymes, transport or regulatory proteins, re-
ceptors, non-enzymatic blood proteins). These changes at the protein level subsequently cause substrate accumulation 
and insufficient generation of products in the relevant metabolic pathways. The combination of these mechanisms 
affects various organs, which leads to clinical signs explicable by several typical basic mechanisms.
Figure 29.2. Pathophysiology of IMD
Accumulation of substrates and absence of products
The reduced or zero activity of some enzymes leads to a metabolic block with physiological or atypical metabolite 
accumulation in tissues or body fluids. Substrates of enzymatic reactions accumulate in front of the block creating an 
absence behind it (analogous changes can be found in the case of the impaired transport of a substance between two 
compartments separated by membrane). This considerable accumulation of substrate is not to be underestimated (the 
relevant metabolite concentrations are often several orders higher than concentrations in a healthy individual) – see 
the schematic illustration in Figure 2. This feature of the considerable accumulation of a certain metabolite (sometimes 
an atypical metabolite not found in a healthy body) is then used in the diagnosis. Most special biochemistry assays 
focus on a rapid demonstration of the accumulating metabolites. The predominating pathogenetic mechanism of some 
IMDs is accumulation of substances (e.g. hyperammonemic coma in patients with urea cycle disorders, attack of me-
tabolic acidosis and unconsciousness in patients with organic acidurias), while symptoms of other diseases occur ma-
inly as a result of the lack of a product (e.g. hypoglycaemic coma in patients with fatty acid beta-oxidation disorders). 
Another factor forming the clinical presentation of the disease is the physical and chemical properties of substances in 
the metabolic pathway involved.
Small molecule diseases
Diseases involving small molecules are caused by disorders in the metabolism of substances supplied externally 
from food (e.g. carbohydrates, amino acids, fatty acids or purines). Most often they manifest themselves as acute pro-
blems in the neonatal period or by repeated attacks later in life. Attacks due to the accumulation of highly toxic small 
molecules typically manifest themselves as slowly progressing disturbances of consciousness, usually ending in coma, 
and are caused either by an increased intake of amino acids from food, or, much more often, by an increased supply of 
amino acids in catabolic conditions such as febrile infection. An increased supply of proteins or carbohydrates such as 
fructose and galactose from food may also be a factor inciting IMDs with acute signs similar to those of sepsis, intoxi-
cation or meningoencephalitis. Some patients with organic acid accumulation may have repeated attacks of acetonae-
mic vomiting and/or metabolic acidosis in their history. Many errors of small molecule metabolism may have subacute 
to chronic progression. Inherited metabolic disorders of small molecule also include the insufficient generation of in-
termediate products of energy metabolism (e.g. the release of glucose from glycogen in hepatic forms of glycogenosis 
or the insufficient generation of ketone bodies in fatty acid beta-oxidation disorders) with the development of clinical 
signs of hypoglycaemia following shorter or longer fasting periods. Situations involving higher expenditure of energy by 
the body are particularly clinically dangerous, especially during fever or increased muscular activity.
Complex molecule diseases
Complex molecule diseases are caused by the impaired generation, elimination or transport of endogenously syn-
thesized complex macromolecules such as mucopolysaccharides or complex glycosphingolipids, or by their decreased 
synthesis with subsequent impaired production of cell membranes and organelles, such as plasmalogens in peroxiso-
mal diseases. These genetic defects often manifest themselves by abnormalities of the cell membranes and organel-
les, lysosomes and peroxisomes in particular. When non-degraded complex molecules slowly accumulate, the course 
of the disease is very often chronic, with onset after an asymptomatic period of several months to decades. Some 
patients may be monitored for a neurodegenerative disease of unclear aetiology, which may also be similar to a ha-
emato-oncological or other tumour disease. An important role in the pathophysiology of some IMDs is played by the 
impaired synthesis of complex molecules and cell membranes; these diseases may already manifest themselves after 
birth as congenital developmental defects, and may imitate chromosomal aberrations. Unlike disorders involving small 
molecules, these diseases have a progressive course independent of exogenous stimuli and are usually not affected by 
catabolism or fever. Patients with complex molecule diseases quite often have structural organ involvement with cra-
niofacial dysmorphism, organomegaly or CNS involvement documented by MR examination. Table 1 shows the typical 
properties of the two basic types of metabolites – small and complex molecules, and also the characteristic signs of 
each disorder.
Small Molecules Complex Molecules
Typical relative molecular weight < 1500 > 1500
Character of substances Small, simple molecules with reacti-
ve functional groups
Complex molecules or macromole-
cules, usually containing carbohyd-
rates and lipids
Examples of substances Amino acids, ammonia, carboxylic 
acids, simple lipids, monosaccha-
rides including glucose and their 
phosphoesters, pyrimidines and 
purines including ATP and others
Glycosaminoglycans (mucopoly-
saccharides), glycoproteins, com-
plex glycolipids, plasmalogens, gly-
cogen and others
Acute manifestation of disease Common in highly toxic metabolites Usually not present
Origin of metabolite Predominantly exogenous Predominantly endogenous
Dependence of symptoms on food 
supply and/or catabolism
Common in highly toxic metabolites Usually not present
Chronic toxicity and/or chronic pro-
gression of disease
May exist in slightly toxic metabo-
lites
Typical symptom
Site of primary disorder within cell Cytosol, mitochondrion Membranes, other organelles (lyso-
somes, peroxisomes)
Site of symptoms within body Local symptoms in site of enzyme 
deficiency as well as systemic sym-
ptoms in distant organs
Typically only in tissues and organs 
with enzyme deficiency
Presence of dysmorphism, develop-
mental defects
Rare Frequent sign
CNS involvement Qualitative disturbances of cons-
ciousness, more or less stationary 
psychomotor retardation, epilepsy
Typically without qualitative distur-
bances of consciousness, progres-
sing psychomotor retardation, com-
mon abnormalities found by MRI 
of the brain or electrophysiological 
examinations
Organomegaly Relatively frequent isolated hepato-
megaly with hepatopathy
Relatively frequent hepatospleno-
megaly without hepatopathy, cardi-
omyopathy
Abnormalities in routine laboratory 
examinations
Common Rare
Treatment Diet and/or pharmacological doses 
of vitamins, usually effective
Diet and vitamins are ineffective; 
enzyme replacement therapy and 
transplantations are possible in 
some diseases
Table 29.1. IMDs with abnormal metabolism of small and complex molecules
29.4. Classification of IMDs and Characteristics of Basic Groups
The classification of IMDs reflects the growing knowledge of these diseases. These diseases are usually classified 
by the type of metabolite (e.g. errors of amino acid or carbohydrate metabolism) or the typical diagnostic method 
(e.g. organic aciduria or hyperammonaemia), or the organelle involved (e.g. peroxisomal, mitochondrial and lysosomal 
diseases).
Urea cycle disorders
This group of several diseases features a lower capability of the body to transform ammonia into urea; the main 
pathogenetic mechanism is the accumulation of ammonia leading to brain oedema and coma. These diseases with a 
peracute and intermittent course are difficult to treat with diet and the administration of substances detoxifying am-
monia.
Other disorders of amino acid metabolism
These are a group of several dozen small molecule diseases with variable clinical presentation, depending on the 
character of the accumulated metabolite, usually with a chronic course. Most of these diseases can be treated quite 
well with the relevant amino acid-controlled diet or administration of vitamin cofactors.
Organic acidurias
This roughly defined group of several dozen diseases featuring a demonstrably elevated urinary concentration of 
carboxylic acids coming mostly from the carbon skeleton of amino acids. Typically these are small molecule diseases 
with an accumulation of highly toxic substances and encephalopathy, and usually also metabolic acidosis; they have a 
peracute course in the neonatal period and decompensation attacks later in life.
Fatty acid beta-oxidation disorders
This group of more than 10 diseases is caused by the impaired transport of carnitine derivatives of fatty acids or 
their mitochondrial beta-oxidation; these are small molecule diseases for which the dominating mechanism is the 
insufficient generation of ketone bodies following prolonged fasting with subsequent hypoglycaemia or intolerance of 
muscular effort. Some diseases may also include toxic manifestations of some accumulated unprocessed fatty acids 
presented as myopathy or cardiomyopathy.
Disorders of gluconeogenesis
This group of several disorders of carbohydrate and glucogenic amino acid metabolism manifest themselves by 
fasting hypoglycaemia.
Disorders of monosaccharide metabolism
Disorders of galactose and fructose processing manifest themselves as acute small-molecule IMDs, particularly by 
hepatopathy and generalized tubulopathy.
Liver glycogenoses
This is a group of 7 types of glycogen storage diseases (GSDs) with impaired glycogen degradation, gluconeogenesis 
and glycogen synthesis.¨
Muscle glycogenoses
This is a group of 9 types of GSDs with symptoms of myopathy and/or cardiomyopathy.
Disorders of purine and pyrimidine metabolism
A group of more than 15 chronic small molecule diseases with predominant neurological and psychiatric sym-
ptoms; some diseases feature the accumulation of poorly soluble urates.
Lysosomal diseases – mucopolysaccharidoses and glycoproteinoses
These diseases usually have a chronic course. They are caused by the accumulation of complex glycoconjugates in 
lysosomes and are one of the most common groups of IMDs. Clinically they manifest themselves as a multi-system di-
sease with connective tissue involvement, hepatosplenomegaly, typical facial dysmorphism (gargoylism) and different 
levels of CNS involvement. The course of some mucopolysaccharidoses can be slowed down by enzyme replacement 
therapy; haematopoietic stem cell transplantation may be considered for some patients.
Lysosomal diseases – lipidoses and other diseases
These diseases are due to the lysosomal accumulation of complex glycolipids and constitute one of the most com-
mon groups of IMDs. They usually clinically manifest themselves as a multi-system disease with a chronic course. Some 
lipidoses feature parenchymatous organ involvement (spleen and liver in Gaucher’s disease and kidneys in Fabry’s 
disease), while in others different levels of central and peripheral nervous system involvement are dominant – from 
psychiatric signs to epilepsy. Some patients with lipidosis may be treated successfully with enzyme replacement thera-
py or substrate reduction therapy.
Peroxisomal diseases
This group of IMDs is caused by a disorder of peroxisome biogenesis with generalized impairment of peroxisomal 
functions (complex molecule diseases such as Zellweger syndrome) or isolated impairment of some peroxisomal func-
tion (e.g. X-linked adrenoleukodystrophy).
Disorders of mitochondrial energy metabolism
This clinically and biochemically heterogeneous group of diseases is caused by impairment of the respiratory chain 
enzyme function. Mitopathies are a prototype of diseases caused by deficient production of small ATP molecules. The 
pathogenesis also involves increased production of free radicals and reactive forms of oxygen.
Disorders of glycosylation (CDG syndromes)
Carbohydrate deficient glycoprotein (CDG) syndromes are a heterogeneous group of multi-system large molecule 
diseases with impaired protein glycosylation and many somatic alterations found during physical examination.
29.5. Clinical Symptoms and Indications for IMD Examination
The clinical symptoms of IMDs are extremely varied and non-specific. First clinical signs may manifest themselves 
at any age (from the neonatal period through childhood to adult age, but may also be manifested prenatally by hydrops 
fetalis) – Figure 32.3.
Figure 29.3. The clinical symptoms of IDMs- age
Inherited metabolic diseases may manifest themselves by the abnormal function and impaired structure of almost 
all organs and tissues, and may do so in a great variety of combinations – Figure 32.4.
Figure 29.4. The multisystemic manifestation of IMDs
This is the reason that clinical symptoms can be seen not only by paediatricians and internists, but also by physici-
ans of many other medical specializations (neurology, nephrology, haematology, ophthalmology, dermatology, gynae-
cology, psychiatry and others). The course of the IMD can be stationary, progressing or acute (with peracute or inter-
mittent character). It is absolutely clear from the above that any suspicion of IMD may only be raised after a thorough 
assessment of the history, clinical condition and routine laboratory and imaging examinations. At present there are no 
simple rules that could help the attending physician indicate specialized laboratory examinations. Table 2 shows a non-
-exhaustive list of examples of some of the most common clinical situations, typically requiring differential diagnosis 
specific to IMDs. In addition, Table 3 shows laboratory findings that may be used as an evidence of presence of the IMD 
in the patient.
Relation between signs and diet – aggravation following protein, fructose or galactose intake
Manifestation of signs during increased output of energy – especially during fasting and increased 
muscular activity
Relation between signs and febrile infection, when protein catabolism increases
Multi-system signs
Evidence of unusual metabolite accumulation
Abnormal colour of urine
Abnormal odour of urine and sweat
Insoluble substances in urine – crystalluria, urolithiasis
Selected deviations found in routine laboratory examinations – see Table 30.4
Table 29.2. Some auxiliary signs arousing suspicion of IMD
Urine examination
Abnormal odour may suggest the presence of small volatile molecules:
Sweaty feet (isovaleric aciduria)
Caramel/maple syrup (leucinosis)
Stewed cabbage (hypermethioninemia)
Fishy smell (trimethylaminuria) 
Mousy smell (phenylketonuria)
Abnormal colour of urine or nappies:
Red to orange (urates – disorders of purine metabolism)
Brown to black when left standing for a period of time (alkaptonuria)
Red to brown (myoglobinuria)
Blue (Hartnup disease)
Green (4-OH-butyric aciduria)
Crystalluria: the presence of crystals listed below may suggest an IMD
Cystine 2,8-dihydroxyadenine
Xanthine
Urates
Oxalates
Urine pH:
Elevated pH in absence of urinary tract infection (renal tubular acidosis)
Ketone bodies:
Increased excretion of ketone bodies with concurrent metabolic acidosis, particularly in newborns 
(organic aciduria)
Absence of or mild ketonuria with severe hypoglycaemia (fatty acid beta-oxidation disorders)
Uric acid:
Increased daily excretion (disorders of purine metabolism)
Decreased daily excretion (xanthine oxidase deficiency)
Myoglobin:
Exercise-induced myoglobinuria (disorders of fatty acid beta-oxidation and muscle glycogenosis)
Blood tests
Glucose level:
Fasting hypoglycaemia with ketonuria (liver glycogenoses, disorder of gluconeogenesis, mitochon-
drial diseases)
Hypoketotic hypoglycaemia from prolonged fasting and catabolic condition (disorders of fatty acid 
beta-oxidation)
Hypoglycaemia after ingestion of fructose/saccharose/sorbitol (intolerance of fructose)
Ammonia:
Hyperammonaemia (urea cycle disorders, some organic acidurias, disorder of ATP synthesis)
Acid-base balance tests (Astrup):
Metabolic acidosis (accumulation of organic acids – organic aciduria, lactate acidosis in mitochon-
drial disorders, loss of bicarbonate in generalized tubulopathy)
Respiratory alkalosis (hyperventilation in hyperammonaemia due to urea cycle disorders)
Aminotransferases/bilirubin:
Hepatopathy is a non-specific sign of liver parenchyma involvement in many small-molecule IMD 
types. 
Creatinine:
Decreased concentrations may occur in disorders of creatine biosynthesis
Increased concentrations occur in IMDs affecting renal functions
Cholesterol:
Decreased concentrations can be found in Smith-Lemli-Opitz syndrome and mevalonate kinase de-
ficiency
Increased concentrations can be found in many IMDs
Triacylglycerols:
Pseudotriacylglycerolaemia (without any corresponding finding in lipoprotein electrophoresis) is 
indicative of glycerol kinase deficiency
Increased triacylglycerol concentrations are a secondary sign in many IMDs
Alkaline phosphatase
Decrease (hypophosphatasia)
Increase (secondary in hepatopathy or tubulopathy accompanying some IMDs)
Uric acid:
Decreased concentration (isolated or combined xanthine oxidase deficiency, hereditary renal hy-
pouricemia)
Increased concentration (disorders of purine metabolism or renal transport)
Creatine kinase and myoglobin:
Increased concentrations (mitochondrial disease, type II glycogenosis)
Exercise-induced transitory increase (some disorders of fatty acid beta-oxidation, muscle glycoge-
nosis and some disorders of purine metabolism) 
Lactate:
Increased concentration (provided pre-analytical phase conditions are met) in absence of hypoxia 
may suggest mitochondrial diseases and some glycogenoses
Homocysteine:
Hypohomocysteinaemia occurs in sulphite oxidase deficiency
Pronounced hyperhomocysteinaemia in remethylation and transsulfuration forms of homocystinu-
ria
Blood count:
Macrocytic anaemia (disorders of homocysteine, folic acid and cobalamin metabolism, orotic acidu-
ria)
Thrombocytopenia (Gaucher’s disease)
Haemocoagulation:
Prolonged prothrombin time (disorders of glycosylation – CDG syndromes)
Severe hypoproductive coagulopathy (some IMDs affecting the liver)
Cerebrospinal fluid examination
Glycorrhachia:
Hypoglycorrhachia (disorder of glucose transport)
Total protein:
Pronounced hyperproteinorrhachia (some lysosomal diseases such as lipidoses)
Lactate:
Increased concentration (disorders of mitochondrial energy metabolism)
Table 29.3. Evidence for IMD from routine laboratory examinations
29.6. Diagnosis of IMDs
Since clinical symptoms are very varied and non-specific, it is possible to diagnose IMDs only using special labora-
tory examinations carried out by a specialized laboratory of biochemistry and genetics. There are two fundamentally 
different approaches to effective diagnosis:
a) Neonatal screening of the entire population of asymptomatic newborn infants;
b) Selective screening of a small selected group of symptomatic patients with suspected IMD.
29.6.1. Neonatal screening
Neonatal screening in the CR is performed in every newborn child born 48 - 72 hours after birth. A dried blood 
spot on a neonatal screening card is tested by tandem mass spectrometry. (Instructions for blood collection, laboratory 
operations and aftercare are specified by “Metodický návod k zajištění celoplošného novorozeneckého laboratorního 
screeningu a následné péče” – see Věstník MZ ČR 2009, Issue 6). This method is used in screening for 13 different IMDs 
out of about the 800 known.
• Disturbances of amino acid metabolism 
o Phenylketonuria
o Glutaric aciduria, Type I (glutaryl-CoA dehydrogenase deficiency)
o Isovaleryl-CoA dehydrogenase deficiency (Isovaleric acidemia)
o Maple syrup urine disease
• Disorders of fatty acid oxidation
o Carnitine uptake/transporter defects 
	 Carnitine-acylcarnitine translocase deficiency
	 Carnitine palmitoyl transferase I deficiency (CPT I)
	 Carnitine palmitoyl transferase II deficiency (CPT II)
o Very long chain acyl-CoA dehydrogenase deficiency (VLCADD)
o Long chain L-3 hydroxyacyl-CoA dehydrogenase deficiency (LCHADD)
o Medium chain acyl-CoA dehydrogenase deficiency (MCADD)
Despite the fact that most patients suffering from some of the IMDs being screened are detected, it should also be 
noted that mild forms of the disease are not necessarily detectable by the screening methods used several days after 
birth. Therefore, a potential IMD also has to be considered in patients with negative screening results if clinical signs of 
the disease begin to be manifested at a later time.
Selective screening for IMDs
Neonatal screening detects only a small proportion of patients with IMDs. Most patients are diagnosed worldwide 
in the selective screening system. Two factors play a role in the effective use of screening. The first is the availability of 
screening methods. Foreign experience suggests that it is useful to combine the methods in specialized centres where 
both screening tests and follow-up targeted tests for enzymes and molecules are available. The second factor is the ef-
fective indication of specialized examinations. The most critical step in selective screening is the expression of the sus-
picion of an IMD by the first-contact physician or specialist as part of their opinion based on differential diagnosis. This 
group of diseases is often considered only after other causes of the disease have been eliminated, which means the 
correct diagnosis of IMD is established late. An indication for selective screening is given by two fundamental aspects:
a) Positive family history
b) Clinical signs (including available laboratory examinations)
The problem is that some metabolic disorders often have non-specific clinical presentation and a relatively low 
incidence in the population. Therefore, it is not surprising that present clinical knowledge about metabolic diseases 
often lags behind knowledge of biochemistry and genetics.
For these reasons it is also quite common that staff from a specialized facility (biochemistry and genetics laborato-
ries for IMDs) provide the attending physician with a metabolic test interpretation, including a complete consultation 
and suggestions for further examinations and treatment. New defects from this group of diseases are also studied and 
discovered in specialized laboratories.
Given the great clinical variability of IMDs, there are no simple criteria, which, if met, would clearly point to a sus-
picion of these diseases. Nevertheless, there are some clinical situations where suspected IMD should be part of the 
early phases of standard differential diagnosis! Some selected common situations are listed in Tables 2 and 3, and more 
detailed information about IMD symptoms can be found in the literature (see Recommended Reading). As regards fa-
mily history, it is important to note that it does not always help establish the indication. Such cases include a first child 
with IMD with autosomal recessive inheritance.
The diagnosis of IMD is usually established gradually, in several stages involving specialized examinations of blood 
and urine metabolites, enzyme activities in blood cells or fibroblast cultures, or gene mutation tests. The laboratory 
diagnosis process takes place at the level of metabolites, enzymes/proteins, tissues/cells and DNA.
Metabolite assays include semiquantitative, quantitative and profile tests.
Enzyme screening tests can be indicated without prior agreement.
Targeted confirmatory enzyme and molecular genetics tests are made only by prior agreement with a specialized 
laboratory.
Tissue examination is also made by prior agreement. The most commonly collected specimens include blood (blo-
od smear), bone marrow (bone marrow smear), skin (also for fibroblast culture), liver or muscle, and, less commonly, 
myocardium, conjunctiva or other tissues. Biopsy as an invasive intervention should be made only after a thorough dif-
ferential diagnosis analysis, complete non-invasive examinations and following consultation with the laboratory where 
the biopsy specimen is going to be examined. This is the only way of avoiding a repeated biopsy.
Indications for biopsy/autopsy is skin biopsy/autopsy for fibroblast culture (collection and transport in the culture 
medium or, in emergency, sterile saline), receipt of material for enzyme assay (if a peripheral blood cell assay is not 
possible or reliable), histological, histochemical and electron microscopy examination (if required for the diagnosis), 
molecular genetics tests (mitochondrial disorders, nuclear genes, or if a peripheral blood cell assay is not possible or 
reliable), chorion biopsy or amniotic fluid collection for prenatal IMD diagnosis; also, post-mortem collection of tissue 
specimens (autopsy) is required if IMD is suspected in the case of sudden, unexpected or unavoidable death. The basic 
condition for adequate examination of a tissue specimen is proper specimen processing after collection and proper 
specimen transport to the laboratory.
29.7. Options for IMD Treatment and Prevention
As present knowledge develops, the number of successfully treatable hereditary metabolic disorders is growing. 
Some form of therapeutic action is nowadays possible in about one third of patients with IMDs, and treatments for 
many other IMDs are under research. This relatively high amount of diseases without available causal therapy is due to 
the fact that the pathogenesis of these defects is not known, despite the knowledge of clinical symptoms and causes at 
the level of molecular genetics. Haemodialysis or haemodiafiltration is used to eliminate toxic products in acute phases 
of IMD. Dietotherapy with a reduced supply of proteins supplemented with a mixture of selected essential amino acids 
in dietary preparations is used for the long-term maintenance of metabolic compensation of amino acid metabolism. 
A frequent diet with low fat content is recommended for disorders of fatty acid beta-oxidation, while a low-sugar diet 
is used for disorders of pyruvate dehydrogenase metabolism. The administration of high doses of specific vitamins 
or pharmacological chaperones is used to stabilize mutant enzymes in the treatment for some IMDs. A proportion of 
patients with lysosomal diseases responds favourably to parenteral administration of recombinant enzyme, whereas 
transplantation of haematopoietic stem cells or entire organs such as the liver, kidneys or heart is used for treatment 
of other lysosomal disorders. The effectiveness of treatment is different for different patients and diseases; effective 
treatment with minimum side effects enables the patient to live a normal life (e.g. administration of vitamins in vita-
min-sensitive IMDs).
Treatment for small-molecule IMDs in many patients includes dietary restrictions of substances that the patient 
cannot process, or an increased supply of the substance that the patient cannot produce in his/her body. Some pati-
ents may favourably respond to the administration of vitamins acting as cofactors for enzymatic reactions. Elimination 
treatment by haemodialysis or haemodiafiltration is a life-saving method in cases of acute attacks of the disease. As the 
cause of IMDs is genetic, primary prevention in the afflicted individual is not possible. Secondary prevention consisting 
in early diagnosis of the relevant disease type and timely treatment (if available) is very important. Neonatal screening 
programmes are a prime example of successful secondary prevention. Except for mitochondrial inherited diseases, 
the overwhelming majority of IMDs can be diagnosed in at-risk families by prenatal examination; the development of 
preimplantation diagnosis can be expected in the near future.
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30.1. Characteristics of Urinary Concrements
Urolithiasis is a disease characterized by the formation of concrements in the kidneys and the urinary tract. The 
formation of concrements is largely affected by biochemical and physiological factors (insufficient fluid intake for an 
extended period, food composition), genetic factors - especially in young individuals, and many cases of urolithiasis are 
affected by urinary tract infection or some diseases (hyperparathyroidism, cancer).
The process of lithogenesis results from the interaction of many factors:
• High concentration of lithogenous substances in the urine: hypercalciuria, hyperoxaluria, hyperuricosuria, 
hyperphosphaturia, cystinuria
• Presence of organic components forming nuclei of crystallization
• Urine pH
• Concentration of lithogenesis inhibitors: primarily magnesium and citrate
Substances found in urinary concrements are listed in Table 1. Since concrements are crystalline in nature, mine-
ralogical nomenclature is used.
Compound: Mineralogical Name:
Uric acid Uricite
Uric acid 2H
2
O  
Ammonium urate  
Sodium urate H
2
O  
Calcium oxalate H
2
O Whewellite
Calcium oxalate 2H
2
O Weddellite
Calcium phosphate (pure) Whitlockite
Calcium phosphate (apatite structure) Apatite
“Carbonate apatite” Dahllite
Calcium hydrogen phosphate 2H
2
O Brushite
Magnesium ammonium phosphate 6H
2
O Struvite
Protein  
Xanthine  
Cystine  
2.8-dihydroxyadenine  
Artefact/counterfeit of unknown origin  
Table 30.1. Components and mineralogical names of urinary concrements
Urinary concrements mostly occur in the form of a mixture. Two-component concrements are prevalent (about 
50%); single-component (about 30%) and three-component concrements (about 20%) are less common.
Urinary concrements are classified into several groups:
• Calcium oxalate concrements are the most common type of concrements (about 60% in the Czech popu-
lation).They consist of a mixture of whewellite and weddellite (40%), pure whewellite (15%) or a mixture 
of oxalate and uric acid (5%). The causes of their formation include hypercalciuria, hyperoxaluria, hyperu-
ricaemia, hyperuricosuria, hypocitraturia and primary hyperparathyroidism.
• Calcium phosphate concrements (about 10%) usually occur in a combination of apatite with oxalates. Pure 
apatite or brushite concrements occur sporadically. Possible causes of formation of these stones include 
hypercalciuria, hyperphosphaturia, primary hyperparathyroidism or renal tubular acidosis.
• Urate concrements (about 15%) consist primarily of uric acid (anhydride and dihydrate); other urates are 
rare. Urate concrements are the result of hyperuricaemia and hyperuricosuria, low diuresis and acidic 
urine pH.
• Infectious concrements (about 15%) consist of struvite, dahllite and sporadically ammonium urate. They 
occur in chronic urinary tract infections caused by urea-degrading bacteria, which is related to urine alka-
linization.
• Cystine concrements (less than 1%) occur in homozygous patients with cystinuria. Cystine crystallizes pri-
marily in acidic urine.
• The incidence of each type of lithiasis differs according to geographical region. As in the CR, calcium oxalate 
concrements dominate in Germany, while calcium phosphate concrements are most widespread in France, 
Sweden and the US.
30.2. Laboratory Diagnostics of Urolithiasis
Biochemical assays focus on the search for risk factors in the formation of concrements, and are used to monitor 
pharmacotherapy and dietary therapy and to establish the risk of relapse. The following analytes are tested in the se-
rum: Ca, Mg, inorganic phosphate and uric acid. The first step of urine examination is the chemical assay of urine sedi-
ment and urine. The quantitative assay for urinary wastes includes the following analytes: Ca, Mg, inorganic phospha-
te, uric acid, creatinine, oxalate, and sometimes citrate. Urine samples for the analysis of Ca, phosphates, oxalates and 
citrates should be acidified by adding HCl to avoid precipitation of salts, which would lead to falsely lower or negative 
findings. Alkalinization of urine specimens for a uric acid assay is required for the same reason. Additional special tests 
for hyperparathyroidism, renal tubular acidosis or a challenge test for hypercalciuria differentiation are made depen-
ding on the type of disorder detected.
30.3. Analysis of Urinary Concrements
Knowledge of the composition of the concrement is important for finding the metabolic background of urolithiasis. 
Previously used methods of chemical analysis have been replaced by more precise physical methods such as infrared 
spectroscopy, X-ray diffraction and polarized light microscopy. Examination under a polarizing microscope is based on 
the different optical properties of different crystalline substances in polarized light. The method of infrared spectrosco-
py is used to indentify compounds based on spectra, assessed quantitatively using a computer program by comparing 
them with a library of known urinary concrement spectra. A very small amount of concrement (30 mg) is sufficient for 
the assay. The accuracy of the assay is subject to an error of about 10%; the 10 - 15% range of analytical error is clini-
cally unimportant. Each concrement layer should be analyzed in justified cases to clarify the genesis of the concrement.
30.4. Case Reports
30.4.1. Case Report 1
A 61-year-old female incontinent patient in the long-term care of a hospital for terminal illnesses with a history of 
ethylic encephalopathy, polyneuropathy and hepatomegaly. A gynaecological examination indicated due to a discharge 
showed that the discharge has a primary urological aetiology. One morning, the patient found in her bed an object 
the size and shape of a small chicken egg, which was sent to the department of biochemistry for urinary concrement 
examination.
Result of examination:
Urinary concrement of grey to white colour, smooth surface, oval shape, size 47 x 36 x 29 mm, very hard. Overall 
composition: Struvite 100%.
Evaluation:
It is urinary concrement of infectious origin, located in the urinary bladder. The slackened sphincter and urethra 
permitted the spontaneous passage and expulsion of the large-sized object. Considering the history and immobility, 
the patient did not experience any problems.
30.4.2. Case Report 2
A 57-year-old male patient, first cystine concrement found in the right-hand kidney at the age of 23, the stone 
was removed surgically by pyelolithotomy. Later a relapse of the concrement in the left, but the patient did not have 
surgery nor metaphylaxis of the lithiasis. Currently, a complicated “casting” lithiasis in the left. The patient underwent 
repeated percutaneous extractions of the concrement. Removed concrements were analyzed in the department of 
biochemistry.
Result of examination:
1. Analysis: A large amount of similar pieces of light brown colour, slightly crystalline surface, irregular shape, sizes 
from 10 x 8 x 3 to 5 x 4 x 2 mm, very hard. Overall composition: dahllite 80%, whitlockite 20%.
2. Concrement: A large amount of pieces of light brown colour, crystalline surface in places, irregular shape, sizes 
from 10 x 7 x 7 to 3 x 3 x 3 mm, medium hard. Individual crystals of cystine are clearly visible under the polarizing 
microscope. Overall composition: Dahllite 40%, whitlockite 30%, cystine 30%.
Evaluation:
Cystine metabolism-dependent lithiasis. Since the appropriate diet and hydration were not followed, a relapse 
occurred because cystine crystal residues served as nuclei for crystallization of other components. Infection also took 
part in the formation of the concrement.
The region with cystine crystals was not removed during the first surgery, so cystine could not have been detected.
30.4.3. Case Report 3
A 63-year-old female patient, severely obese. The patient had problems with urolithiasis for many years, the first 
concrement was diagnosed in the left kidney 15 years ago. Underwent repeated extracorporeal shock wave lithotripsy. 
The patient is under long-term care of the metabolic unit due to urolithiasis, is administered metaphylaxis, has enough 
exercise but overeats.
Result of examination:
The evaluation included 5 fragments corresponding to the originally oval concrement, sized about 14 x 9 x 8 mm 
with visible layers. Individual layers were analyzed by means of polarizing microscope:
a) Nucleus: 5 x 4 x 3 mm, grey to white, composition: uricite (maybe with whewellite admixture - unable to distin-
guish).
b) Middle layer: about 2 – 3 mm, dark brown to black, orange after crushing, very hard, composition: whewellite.
c) Envelope: about 1 mm, orange, low hardness, composition: uricite
Overall composition: Whewellite 50%, uricite 50% (expresses average proportions in the entire concrement).
Evaluation:
Oxalate concrement formed by urine oversaturation with lithogenic substances as a result of their excess supply in 
the food, which is confirmed by results of supplementary biochemical tests:
Serum – glucose level 7.0 mmol/l, other analytes normal.
Urine – diuresis 1840 ml/day, pH 5.1, hypercalciuria 9.35 mmol/day (normal under 7.2), hypernatriuria 364 mmol/
day (normal under 220), elevated chloride output 381 mmol/day (normal under 270), slight hyperoxaluria 546 umol/d 
(normal under 500), corrected creatinine clearance
1.86 ml/s/1.73 m2 is within the normal range.
A detailed analysis of each layer may help clarify the formation and course of concrement depositing; this case 
probably reflects changes in the dietary habits of the patient.
Test questions: (correct answers)
1. The name whewellite is used for a urinary concrement composed of:
• Calcium oxalate2H
2
O
• Calcium hydrogen phosphate2H
2
O
• Calcium oxalate H
2
O
• Magnesium ammonium phosphate6H
2
O
2. Which urine pH is prevalent when phosphate concrements are formed:
• pH 5
• pH 6
• pH 7
• pH 8
3. Urinary tract infection leads to the formation of infectious concrements; these include:
• Struvite
• Brushite
• Carbonate apatite
• Weddellite
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31.1. Introduction
Pregnancy is connected to a change in some biochemical processes to adjust to the development of the foetus. The 
maternal organism also undergoes many hormonal changes. Some changes are physiological, others may be a sign of 
problems in the maternal organism or the developing foetus.
Over the last few years, prenatal diagnosis has become a standard aspect of care given to pregnant women. This is 
important not only from the individual’s point of view, but also from society’s perspective, considering the economic 
and social impacts. It is in the interest of parents and medical professionals to be well informed about possibilities of 
various preventive programmes, to be aware of what modern medicine is able to offer, and also to know at least the ba-
sic principles of preventive care. Prenatal diagnosis includes a series of examinations made in order to detect potential 
developmental defects of the still unborn child. This diagnosis is based on interdisciplinary cooperation of specialists 
from medical genetics, gynaecology and obstetrics, ultrasonic diagnosis, clinical biochemistry and other branches of 
medicine.
31.2. Laboratory Examinations during Pregnancy
31.2.1. Confirmation of Pregnancy
Human chorionic gonadotropin (hCG) is a hormone produced by a pregnant woman’s placenta immediately after 
conception, supporting the production of oestrogens and progesterone in the corpus luteum. The hCG level rises on 
day 8 to 10 after conception. Its quantity is determined from the serum and is used to confirm pregnancy. A qualitative 
analysis is performed using urine – the pregnancy test indicates levels over 20 IU/l. Absolute values may vary indivi-
dually during pregnancy; a rising trend is always important (hCG doubles every two to three days at the beginning of 
pregnancy). The trend can suggest a failing pregnancy, a drop may be indicative of a missed abortion. Repeated hCG 
blood tests are important for diagnosing ectopic pregnancy; the rise in hCG is usually less steep. If the increase in hCG 
concentration is less than 60% over 48 hours, it is an ectopic pregnancy or death in utero. HCG tests are also useful 
in diagnosing trophoblastic diseases, or as a germinal tumour marker; an elevated hCG level may also be caused by 
myomas and ovarian cysts.
31.2.2. Examinations during Pregnancy
A pregnant woman is admitted to counselling care organized by the attending gynaecologist. Examinations are 
performed based on the state of health of the pregnant woman and the length of pregnancy, while the extent of 
examinations must comply with the professionally recommended minimum. The Czech Gynaecological and Obstetri-
cal Society of the Czech Medical Society of J. E. Purkyně (ČLS JEP) has defined the basic frequency and extent of care 
for women during the physiological course of pregnancy. Based on the medical history and current clinical findings, 
pregnancy is rated by the degree of risk for the pregnant woman or developing foetus, and the frequency and types of 
examinations are adjusted accordingly. A family history of diabetes, congenital defects in the family, the outcome of a 
previous pregnancy, high blood pressure and similar factors may suggest potential future risks for the pregnancy, which 
then have to be monitored. Some examinations are made at every visit to the pregnancy counsellor – blood pressure, 
signs of foetus vitality, urine chemistry, etc. Other examinations are referred to as irregular. They are made in a specific 
week of pregnancy and include blood group, rhesus-D status or serological assays for specific antibodies. Table 1 shows 
the frequency and types of examinations.
The screening for gestational diabetes mellitus (GDM), associated with perinatal short-term and long-term com-
plications, is made by oral glucose tolerance test (oGTT) in all healthy pregnant women according to an established 
schedule between week 24 and 28 of pregnancy. According to the Recommendations of the Czech Diabetes Society 
(ČDS) and the Czech Society of Clinical Biochemistry (ČSKB), a load by 75 g of glucose is used and the plasma glucose 
level is assessed before and two hours after the challenge. Gestational DM is diagnosed from laboratory results if the 
plasma glucose level (FPG) is repeatedly ≥ 5.6 mmol/l or ≥ 7.7 mmol/l two hours after the load.
Week of Pregnancy Recommended Laboratory Tests 
11 - 13 Blood group, rhesus-D status, blood count, screening of irregular anti-erythrocyte antibod-
ies, HBsAg, HIV, syphilis, fasting glycaemia. Also advisable are fT4, TSH and antiTPO tests. 
11 - 13 DS screening in 1st trimester (PAPP-A, free β hCG, NT)
16 - 18 DS screening in 2nd trimester (AFP, hCG, uE3)
24 Gestational DM screening
28 Screening of irregular anti-erythrocyte antibodies in rhesus-D negative women, blood 
count, syphilis antibodies
36 - 38 Vaginal infection detection 
Table 31.1. Overview of laboratory tests in specific weeks of pregnancy
Irregular examinations also include an assessment of the risk of congenital chromosomal aberration (CHA) of the 
foetus.
31.2.3. Diagnosing Gestational Diabetes
The screening for gestational diabetes mellitus (GDM), associated with perinatal short-term and long-term com-
plications, is made by oral glucose tolerance test (oGTT) in all healthy pregnant women according to an established 
schedule between week 24 and 28 of pregnancy. According to the Recommendations of the Czech Diabetes Society 
(ČDS) and the Czech Society of Clinical Biochemistry (ČSKB), a load of 75 g of glucose is used and the plasma glucose 
level is assessed before and two hours after the load. Gestational DM is diagnosed from laboratory results if FPG is 
repeatedly ≥ 5.6 mmol/l or ≥ 7.7 mmol/l two hours after the load.
31.2.4. Changes in Haematological Parameters
Water retention increases during pregnancy. Qualitative and quantitative metabolic changes take place in the body 
as a result of the rapidly growing foetus and placenta as well as their increasing nutritional requirements. Metabolic 
changes are influenced by a change in the production and secretion of some maternal hormones and the production 
of new hormones in the foetoplacental unit, and, last but not least, also by the transplacental transfer of substances. 
O
2
 consumption and the basal metabolic rate increase during pregnancy, by up to 15–20% in the 3rd trimester.
The volume of plasma increases with the size of the foetus – the greater the foetus, the greater the plasma volume. 
The volume also increases depending on the woman’s height, parity and multiple pregnancies. As the plasma volume 
doubles compared to the red blood cell mass volume, the concentration of haemoglobin and haematocrit decreases 
and dilutional anaemia develops.
The absorption of Fe from food increases from the normal 5–10% up to 30% in the 2nd trimester, and up to 40% 
in the 3rd trimester of pregnancy. The average daily loss of Fe also decreases to roughly one half. Fe is transported by 
active transport through the placenta in one direction only – from the mother to the foetus, also from mothers with 
an Fe deficiency.
The overall white blood cell count increases up to 12.0 × 109/l during pregnancy; values of up to 16.0 × 109/l have 
been found in the 3rd trimester. The white blood cell count is up to 25–30 × 109/l during delivery. The lymphocyte and 
monocyte count is relatively stable; the polymorphonuclear cell count increases. The basophil granulocyte count de-
creases slightly. The eosinophil count increases in some pregnant women, or decreases or stays unchanged in others; 
the cause is unknown.
The erythrocyte sedimentation rate (FW test) increases to 44 to 114 mm/h during pregnancy, 78 mm/h on average. 
The high ESR is due to increased plasma globulin and fibrinogen levels. ESR is not used for diagnosis during pregnancy.
31.2.5. Changes in Biochemical Parameters
Enlarged kidneys and a dilated excretory system are typical of pregnancy. Renal functions change during preg-
nancy, mainly due to the increased production and secretion of some maternal and placental hormones (ACTH, ADH, 
aldosterone, cortisol, hPL) and due to the increased volume of plasma. While glomerular filtration markedly increases 
during pregnancy, the amount of urine does not increase. In this sense, the excretory system is more efficient during 
pregnancy than in non-pregnant women. Plasma urea, creatinine, uric acid, glucose and amino acid clearance grows 
and their levels decrease during pregnancy. In the 1st trimester, creatinine concentration drops from 73 to 65 µmol/l, 
then to 51 µmol/l in the 2nd trimester, and is roughly 47 µmol/l at the end of pregnancy. Plasma urea concentration 
decreases as a result of a lower elimination of proteins and elevated clearance. Respecting these physiological changes 
is important for timely detection of renal insufficiency during pregnancy. If the creatinine level at an advanced stage of 
pregnancy is over 75 µmol/l and urea is over 5.4 µmol/l, supplemental tests of renal functions are necessary. 
No morphological changes of the liver occur during normal pregnancy, only function changes. Alkaline phospha-
tase activity and the production of cholesterol, globulins and fibrinogen increase. Non-protein nitrogen and uric acid 
levels decrease. Concentrations of bilirubin, transaminases and bile acids remain unchanged. The overall fat level in the 
plasma increases from 6 g/l to 10 g/l during pregnancy depending on body weight gain. In the 2nd half of pregnancy, the 
triacylglycerol level triples, and phospholipid and cholesterol levels increase by 50%. 
The protein amount in urine changes only slightly during pregnancy. Daily protein loss in a healthy, non-pregnant 
woman is 200–300 mg; if a pregnant woman’s daily loss increases to more than 500 mg, the cause must be sought, 
since proteinuria may be the first sign of a pathological process.
Serum Electrolytes
Na+ – concentration decreases by 2–3 mmol/l (130–148 mmol/l)
K+ – concentration decreases by 0.2 - 0.3 mmol/l (3.8–5.1 mmol/l)
Ca+ – concentration decreases by 10% (2.25–2.75 mmol/l)
Mg+ – concentration decreases by 10–20% (0.75–1.25 mmol/l)
Cl- and phosphorus concentrations do not change markedly (98–106 and 0.65–1.62 mmol/l)
Normal ranges found in non-pregnant women are indicated in brackets.
Thyroid Gland
Increased renal clearance of iodine during pregnancy causes a decrease in iodine reserve in the body despite its 
sufficient supply from food. To compensate this change, the thyroid gland enlarges and the iodine uptake increases. 
This ensures sufficient synthesis of thyroid hormones, or euthyroid state of the body, respectively. The high oestrogen 
level stimulates thyroid binding globulin (TBG) production, which is why the interpretation of clinical tests dependent 
on the TBG level or on the thyroid’s ability to take up iodine must be corrected during pregnancy.
In addition, the high hCG level causes a decrease to the TSH level, so especially in the 1st trimester it is advisable to 
use specific reference intervals which are roughly 0.05 – 3.5 mU/l) for TSH.
FT4 levels under 10 pmol/l are serious because they may have a negative effect on the psychomotor development 
of the child. Assays for anti-TPO antibodies may reveal women at risk of postpartum thyroiditis (about 15% in the Czech 
population), which develops in half of positive women and may endanger not only the women herself but also any 
subsequent pregnancy.
Trends in the level of other hormones essential for pregnancy have been shown in Figure 34.1.
Figure 31.1. Trends in the level and concentration of hormones during pregnancy
Picture source: http://www.mfi.ku.dk/ppaulev/chapter29/Chapter%2029.htm
31.2.6. Conditions Threatening Pregnant Women
31.2.6.1. Pre-eclampsia
Pre-eclampsia is a serious condition occurring during pregnancy. Incidence is reported roughly 4–8% of pregnan-
cies. This condition features increased blood pressure (limit is 140/90) and protein in urine (0.5 g/24 hrs). Oedemas 
are not a typical symptom, as assumed before. It is caused by maternal endothelial dysfunction. This means that blood 
coagulant and anticoagulant factors are not balanced in the woman, and vascular cells produce more factors that indu-
ce vasoconstriction, the narrowing of blood vessels. Another factor is a poor growth of the placenta. Pre-eclampsia is 
manifested as hypertension. The first and mostly the only symptoms are headache, fatigue and nausea.
Laboratory Assays
Proteinuria – usually semiquantitative as + to +++, with values over 300 mg/day.
A rise in LDH, AST, ALT and bilirubin is found in the maternal serum. Elevated ALT levels may occur sporadically in 
pre-eclampsia without the HELLP syndrome. A full manifestation of the HELLP syndrome can be expected at a later 
phase in about one third of these cases.
Uric acid – a rise over 320 μmol/l is a marker of pre-eclampsia.
Malondialdehyde (MDA) – product of lipid peroxidation, a new marker of pre-eclampsia.
Supplementary serum assays: creatinine, urea, total protein
Blood count – abnormal, drop in platelet count
A rise in haemoglobin and haematocrit.
Changes in haemocoagulation – aPTT (activated partial thromboplastin time), fibrinogen and prothrombin time are 
usually normal; FDPs (fibrin degradation products) increase, and thrombin time becomes longer.
31.2.6.2. Markers of Pre-Eclampsia
PlGF and sFlt-1
Findings have shown that angiogenic growth factors such as PlGF (Placenta Growth Factor) and sFlt-1 (soluble fms-
-like tyrosine kinase-1, or VEGFR1) play a substantial role in the development of pre-eclampsia. PlGF is responsible for 
the normal function of the placenta, and therefore for a healthy pregnancy, while sFlt-1 affects the end of pregnancy 
in the last weeks of gestation. The level of these proteins circulating in the body changes in women affected by pre-
-eclampsia. The plasma sFlt-1 level increases both before diagnosis and at the time of clinical manifestations of pre-
-eclampsia, while the PlGF level is lower compared to normal pregnancy. The combined sFlt-1/PlGF ratio subsequently 
makes it possible to distinguish normal pregnancy from pregnancy with pre-eclampsia.
ADAM12
ADAM12 could be a valuable marker of complications during pregnancy. ADAM (A Disintegrin And Metaloprotea-
se) proteins are multidomain glycoproteins with adhesive and proteolytic activities. High concentrations of ADAM12-S 
are found in the placenta, can be found in the serum of pregnant women from the first trimester with a growing trend. 
ADAM12 was decreased in the first trimester in all women who subsequently developed pre-eclampsia. This marker is 
one of the promising markers of pre-eclampsia. ADAM 12 is also likely to affect leptin metabolism and may be a medi-
ator of the entire pre-eclampsia process. In addition to predicting pre-eclampsia, ADAM12 also speaks of chromosome 
abnormalities.
31.2.6.3. Complications of Pre-Eclampsia
Complications of pre-eclampsia include eclampsia, DIC and the HELLP syndrome.
Eclampsia is a life-threatening condition which usually follows pre-eclampsia. It is a paroxysmal disease manifested 
by tonic-clonic seizures occurring without any other pathology of the brain. Eclampsia is one of indications for termi-
nation of pregnancy irrespective of foetal age and maturity.
Disseminated intravascular coagulopathy (DIC) is a life-threatening condition. It is a breakdown of haemostasis 
with a production of thrombi in small veins followed by depletion of platelets, coagulation factors and uncontrollable 
bleeding. This condition can be cured if treated in time.
The HELLP syndrome is a serious complication of pregnancy occurring most commonly in connection with severe 
pre-eclampsia. This syndrome develops on a basis similar to that of pre-eclampsia and may or may not follow pre-
-eclampsia. HELLP usually occurs in the second or third trimester of pregnancy. Major symptoms are epigastric pain 
with nausea, vomiting, headache, hypertension, and protein in the urine. Typical laboratory findings are used for dia-
gnosis: haemolysis (H), elevated liver enzymes (EL) and low platelet count (LP). Treatment for the syndrome is similar 
to that for pre-eclampsia, and supplementary treatment depends on additional symptoms with the aim of stabilizing 
the mother’s general status, and adjusting the haemodynamic condition and impaired haemocoagulation.
Women with chronic renal or hepatic disease are exposed to this risk along with DM, pregnant women with au-
toimmune diseases or hypertension. Attention has been paid in recent years to carriers of thrombophilic mutations. 
The HELLP syndrome incidence in the Czech Republic, where prenatal care is at a high level, is estimated at around 4–5 
cases out of 1000 births.
31.3. Conditions and Extent of Screening
Irregular examinations also include an assessment of the risk of chromosomal aberration (CHA) of the foetus. An 
essential requirement for chromosomal aberration examinations is to understand the difference between screening 
and the diagnostic test. Screening examinations are always a statistical model and are intended to distinguish that 
group of examined individuals which has an increased risk of CHA of the foetus. A diagnostic test will then finally de-
termine which foetus has which developmental defect. Therefore, a positive screening result does not definitely mean 
the presence of a CHA. Informed consent is required for the screening test; the pregnant woman should accept the 
possibility of a false positive or false negative test result. Ultrasonic examinations are made by certified specialists on 
the appropriate instruments. Blood collections are scheduled depending on the gestational age found by ultrasonic 
examination, and biochemical markers are defined by a laboratory able to demonstrate external quality control of the 
markers tested. Appropriate and validated software is used to assess the risk. The screening centre is required to col-
laborate with medical genetics and foetal medicine facilities.
Recommendations for laboratory screening for congenital developmental defects in the first and second trimes-
ters of pregnancy were prepared in collaboration with the professional societies for genetics, biochemistry, immuno-
analysis and gynaecology in 2002. These recommendations are regularly updated (last update 2010) and are available 
(not only for laboratories) on the website of ČSKB ČLS JEP.
The first and second trimester screens use biochemical methods to calculate the risk of foetal harm by trisomy 21 
(Down syndrome). For each screening procedure the risk in the population, false positivity (FP) and recovery (DR) have 
been clearly defined. The resulting biochemical marker levels also make it possible to estimate the risk of foetal harm 
by other chromosomal aberrations (Trisomy 18, known as Edwards syndrome, or Trisomy 13, known as Patau syndro-
me), neural tube defects, neural tube defect (NTD), or metabolic disorders (cholesterol metabolism disorder, known as 
the Smith-Lemli-Opitz syndrome). Ultrasound methods are then used for the essential examination of nuchal translu-
cency (NT) in the 1st trimester, and a detailed examination of foetus morphology is made in the 20th week of pregnancy.
31.4. Most Common Developmental Defects
The most common defects that can be detected using prenatal biochemical screening combined with specialized 
ultrasound examination are chromosomal or NTD of the foetus.
31.4.1. Chromosomal Defects
Chromosomal aberrations are caused by the absence or excess of a part of the chromosome (or the whole chro-
mosome or even multiple chromosomes). Humans have a genetic set of 46 chromosomes in every cell. They consist 
of 44 autosomal (somatic) chromosomes and 2 sex chromosomes, X and Y, determining a person’s sex. Women have 
two X chromosomes (46,XX), men have one X and one Y chromosome (46,XY). An error in the chromosome count al-
ways means serious problems for the individual. Most of these diseases are not familial and their occurrence is purely 
accidental.
31.4.1.1. Somatic Chromosome Aberrations
Down syndrome
One of the most common and best known chromosomal aberrations is Down syndrome (previously referred to as 
mongolism). Down syndrome is named after J. L. H. Down, who was first to describe it in 1866. It is a characteristic phy-
sical and mental disorder caused by chromosome 21 trisomy. The karyotype of such child is 47, XX, +21 or 47, XY, +21. 
Figure 31.2. Karyotype – Down syndrome
Down Syndrome Karyotype” by Courtesy: National Human Genome Research Institute - Human Genome Project. 
Licensed under Public domain via Wikimedia Commons - http://commons.wikimedia.org/wiki/File:Down_Syndrome_
Karyotype.png#mediaviewer/File:Down_Syndrome_Karyotype.png
The incidence of Down syndrome in the Czech population is 1:700 - 800 live born children. Pregnancy is usually 
without complications, the children are born at full term, with normal birth weight. Individuals with Down syndrome 
have a stunted, squat stature (final height 144 - 155 cm), IQ 25 - 50 with a wide variability of skills. They are socially 
adaptable, love music, and are usually very friendly. They have typical facial features, short fingers and simian palmar 
creases. One third of the children have a heart disease, thyroid disorders and some other congenital developmental 
defects. Any woman may have a child with Down syndrome, but the risk increases with the mother’s age.
Age at birth
Risk of DS at full term 
(1:n)
20 1500
25 1400
29 1000
35 380
40 110
43 50
45 30
Table 31.2. The risk of development of a foetus with Down syndrome depending on maternal age
Edwards syndrome
Edwards syndrome is caused by an extra 18th chromosome. It is a severe malformation syndrome. Pregnancy is 
usually complicated by the stunted growth of the foetus, and intrauterine death is common. The prognosis for life is 
poor; most children die during the neonatal period, only about 12% survive infancy.
Patau syndrome
A severe malformation syndrome caused by an extra 13th chromosome. Pregnancy often ends in spontaneous mis-
carriage or premature birth. More than 90% of children die within 1 year of birth.
Other chromosomal aberrations of somatic chromosomes are rarer. In every case, only symptoms are treated, 
because an already-existing aberration is untreatable.
31.4.1.2. Sex Chromosome Aberrations
Sex chromosome aberrations, mainly affecting sex organ development, are quite common but are not necessarily 
phenotypically distinctive.
Klinefelter syndrome
Klinefelter syndrome afflicts males with an extra X chromosome (47,XXY). The incidence is 1 boy in 670 male new-
borns. The onset of puberty is delayed, common hypogenitalism, practically always aspermia (sterility), gynaecomastia 
and female fat distribution, long lower extremities are typical.
Turner syndrome
A woman suffering from Turner syndrome has only one X chromosome (45,X). The incidence is 1 girl in 2000 female 
newborns. The newborn is born at full term, children have a triangular face with drooping eyelids, malocclusion, and 
puberty does not develop. Maximum height at adult age is 105 - 155 cm, IQ is usually normal.
31.4.2. Foetal Abnormalities Not Skin Covered
Neural tube defect (spina bifida, cleft spine) is caused by an incompletely closed spinal canal at the early phases of 
embryonic development. This defect may occur anywhere in the spine; if the head part is afflicted, anencephalus will 
develop (almost complete absence of brain and skull). There are two types of abdominal wall defects: Omphalocele, in 
which abdominal organs of the embryo remain outside the abdomen in a sac in the place of umbilical cord attachment, 
or gastroschisis, in which a cleft forms in the existing abdominal wall, through which abdominal organs may protrude.
31.5. Screening for Congenital Defects
31.5.1. Non-Invasive Methods
Examinations using non-invasive methods include blood sample tests using immunoanalytical methods or ultraso-
nic examinations. The following basic parameters are specified for each screening system: sensitivity (rate of afflicted 
pregnancies identified) and false positivity (percentage of healthy foetuses falsely identified as positive). The objective 
is to perform screening with maximum attainable sensitivity (> 90%) and minimum false positivity (3 - 4%).
31.5.1.1. Immunoanalytical Methods
Blood for screened markers can be taken anytime during the day, because the assayed substances have minimum 
diurnal variability. The requirement of fasting blood collection is justified only if radioimmunoanalysis is used, because 
serum chylosis may affect the antigen-antibody complex precipitation. The test is made in the serum or plasma by 
immunochemical methods, the reproducibility of which is an essential requirement for the screening. Luminiscence, 
radioimmunoanalytical or fluorescence methods are used; enzymeimmuno-analysis is not recommended due to its 
insufficient accuracy.
First Trimester Screening
First trimester screening has been gradually developing over the last 10 years. The most common method is refer-
red to as the combined test. The test consists in a joint evaluation of the results from a biochemical test (PAPP-A, free 
beta-subunits of hCG) and ultrasound examination. The examination is made from the 11th to 13th week of pregnancy. 
In addition to the benefits of earlier response, this method also has higher sensitivity (about 85%) with a false positivity 
of about 4 - 5%. First trimester screening can be recommended to women who wish to obtain an early result and do 
not wish to undergo the second trimester test. The advantage of the combined test is its high reliability combined with 
minimum risk for the pregnant woman, accurate determination of gestational age, individual evaluation for multiple 
pregnancy, birth date determination and early detection of severe foetal malformations. A lower PAPP-A level warns of 
potential hazard for the foetus – a risk of chromosomal abnormality or abortion.
Biochemical markers for first trimester screening
PAPP-A
PAPP-A belongs to the group of Pregnancy Associated Plasma Proteins detected by immunochemical methods in 
the serum of pregnant women. There are 4 types of these proteins in total:
• A – Zn-dependent metalloproteinase able to degrade IGFBPs which play a role in the regulation of local 
proliferative reactions. IGFBP degradation activates IGF.
• B – The function is so far unknown.
• C – SP1 protein, previously used for screening, has enabled more precise determination of gestational age. 
• D – human placental lactogen (hPL)
The highest PAPP-A concentration is at the end of pregnancy, and decreases immediately after birth. The biological 
half-life is 3 - 4 days. The PAPP-A level is reduced in most chromosomal aberrations, but only in the first trimester in 
Down syndrome. Very low PAPP-A levels are found in at-risk pregnancies ending in spontaneous abortion.
Free β-subunit of hCG
The measurement of the free β-subunit of chorionic gonadotropin is used for first trimester screening. It is a pro-
blematic marker as regards the pre-analytical phase. To guarantee correct results, the material has to be cooled and 
quickly transported to the laboratory, where serum should be separated immediately. Serum and plasma stability is not 
longer than 6 hours at +20 to 25 °C or 1 day at +4 to 8 °C. If frozen to -20 °C, free β hCG is stable for 1 year.
Second Trimester Screening
It was discovered in the second half of the 1980s that mothers carrying a foetus with Down syndrome have diffe-
rent levels of some substances in their blood. This applies primarily to alpha-1-foetoprotein (AFP), which is reduced by 
about 25% compared with the usual mean value, and human chorionic gonadotropin (hCG), which is almost twice as 
high.
Screening for Down syndrome in mothers in the 2nd trimester of pregnancy has been carried out in the Czech Re-
public since the early 1990s; the test is available to every pregnant woman and is covered by health insurance. The 
organization of the test itself is very simple and consists in blood sampling in the 2nd trimester of pregnancy (preferably 
in week 16 - 17) and in the test for two or three biochemical parameters: AFP, hCG and/or free oestriol (uE3). This test, 
sometimes also referred to as the double or triple test, is evaluated using sophisticated software, which also considers 
the maternal age, weight and the ultrasound-determined gestational age to calculate the individual risk for each preg-
nant woman. The result is probability expressed as 1 : X, where there is a limit (usually 1:250 - 300), from which results 
are regarded as positive. A standard part of the test is the check made by a geneticist on all results (including negative 
ones). The sensitivity of this method of screening is about 65-70% and false positivity is about 6 - 7%. Every pregnant 
woman with a positive screening result is offered an invasive diagnostic procedure, amniotic fluid or chorionic villus 
sampling, to determine the karyotype of the foetus from the collected material culture.
From a modern perspective, with new developments in ultrasonic and genetic diagnosis, separately performed 
2nd trimester screening seems outdated, but it is important to preserve it. The first reason is that a certain percentage 
of women come to the gynaecologist too late to make an early examination. Another reason is connected with the 
determination of AFP, which is the only biochemical marker of the neural tube defect. This defect is usually detected 
by ultrasound examination in the 20th week of pregnancy, but AFP measured in the 16th week warns of the risk of this 
defect one month earlier. A significant and perhaps the main reason for preserving the second trimester screen is that 
it is possible to include it in the integrated test.
Biochemical markers for second trimester screening
AFP (α-1-foetoprotein)
AFP is an oncofoetal glycoprotein produced in the yolk sac and in the foetal liver. AFP transfers to the maternal 
serum through the placenta and is an important indicator of the physiological course of pregnancy. The transport 
function of AFP is important. AFP concentration grows as pregnancy progresses. The highest AFP concentration in the 
maternal serum is around the 30th week of pregnancy, and the level drops dramatically after birth.
hCG (human chorionic gonadotropin)
During early pregnancy, hCG stimulates progesterone synthesis in the corpus luteum. It is a glycoprotein compri-
sing two different subunits, α and β. The α-subunit is the same as for LH, FSH and TSH, so the β-subunit is considered 
specific for hCG. A steep increase is typical of hCG concentration at the beginning of pregnancy; hCG starts to fall after 
the 10th week.
uE3 (unconjugated oestriol)
Unconjugated oestriol is an oestrogenic hormone produced by the placenta. Its concentration expresses the intera-
ction of the foetus and the placenta. uE3 is an unstable structure which readily disintegrates, so measured uE3 concen-
trations may be biased by inadequate transport or storage. Since the uE3 assay also presents other problems, such as 
the effect of lipaemia or the different affinity of antibodies depending on the diagnostic set manufacturer, many labo-
ratories have stopped using uE3 assays. The low oestriol level itself may often change the screening result into positive, 
without this being caused by any congenital defect of the foetus. Nevertheless, a free oestriol assay may detect the risk 
of some rarer defects: Smith-Lemli-Opitz syndrome, where uE3 is very low; all of the three screening markers are low in 
Edwards syndrome. Free oestriol also warns of impaired placenta with a risk of complications at the end of pregnancy.
Figure 31.3. Changes in marker levels in the 2nd trimester: the dynamics in pregnant women with DS are delayed, hCG 
is higher, and AFP and uE3 are lower than in the healthy population.
Inhibin
Dimeric inhibin A is the fourth marker used worldwide for Down syndrome screening in the 2nd trimester, which is 
then called the quadruple test. Inhibin is a glycoprotein of placental origin similar to hCG. Maternal serum inhibin levels 
are relatively stable from the 15th to 18th week of pregnancy. Inhibin levels in foetuses afflicted by Down syndrome are 
about twice as high as healthy foetuses. Inhibin tests are not yet common in the Czech Republic.
Multiples of the Median
Since the all biochemical screening is based on a statistical assessment of the measured parameters, it is necessary 
to have a base set with which to compare the results. Every laboratory must have examined at least 50 women in each 
tested week of pregnancy (15th to 18th week) and calculate medians for each parameter from the measured values. The 
median is the central value in a set and is used for screening because the arithmetic mean includes extreme outliers 
that do exist but may affect the average. Results therefore are not given as absolute value but as MoMs (multiples of 
the median). MoM is the number by which to multiply the relevant median to obtain the value measured in the serum 
of the pregnant woman. If the median for the 16th week of pregnancy is, for example, 30kU/l and the measured value 
is 60 kU/l, the MoM is 2.0. The calculations are made by specialized evaluating software. The use of the MoM makes 
it possible to compare different methods, and external quality control usually requires not only the absolute value but 
also the MoM. An increased risk of Down syndrome is indicated by MoMs of hCG higher than 2.5, MoMs of AFP lower 
than 0.5, MoMs of free β-hCG higher than 2.0, and MoMs of PAPP-A lower than 0.4.
Integrated Test, Sequential Test, Serum Integrated Test
Another option in assessing the risk of Down syndrome in a foetus is to assess the combined results of the first 
and second trimester tests. The standard integrated test is described as a statistical evaluation of all data, i.e. the first 
trimester biochemical (PAPP-A, free β hCG) and ultrasound (NT) screening following the second trimester biochemical 
(AFP, hCG, uE3) screening. This approach has advantages and disadvantages. The most common drawback is the stress 
for the pregnant woman due to the delayed information about the result. For this reason the sequential test is a suita-
ble modification of the integrated test, because if a high risk is detected, the woman is already notified of the positive 
result after the first trimester part of the test. A low PAPP-A or a high NT present a positive result. The advantage of an 
early result is not thereby lost. Of course, the pregnant woman is then offered immediate invasive examination, or she 
may wait until the 2nd trimester for the overall test result.
If the first trimester combined test result is negative, the woman undergoes biochemical screening in the second 
trimester. Integration of the results provides a screening system having not only a sensitivity of far above 90%, but also 
a very low false positivity of around 1 - 2%.
Since proper NT measurement requires not only a high-quality ultrasonic scanner, but also a trained specialist cer-
tified by the Fetal Medicine Foundation (FMF) of London, high-quality nuchal translucency measurement is not availa-
ble to all women at present. The value of this parameter has a very heavy weight in the computing algorithm, and may 
considerably shift the resulting risk. There is also the option of a serum integrated test, which in the first trimester only 
includes the biochemical assay for PAPP-A, or sometimes also free beta hCG. This system can also be usefully applied in 
places where samples are brought collectively to the laboratory and the woman does not have to travel anywhere. The 
only problem remains the lower stability of free β hCG, which requires strict compliance with all pre-analytical phase 
requirements. This test has not only low false positivity (5%) but it also enables an NT screen to be added for that group 
of pregnant women who have PAPP-A under 0.35 MoM (only 2 - 3% of women). If the risk is high (over 1:30 – about 1 
woman out of 200), chorionic villus sampling (CVS) with subsequent karyotyping can be made.
The results of current extensive international studies and the practice of some centres in the Czech Republic show 
that the sequential form of the integrated test may be considered a screening system which meets professional requi-
rements on the one hand, and, on the other hand, gives pregnant women a higher level of certainty when their preg-
nancy is screened for congenital developmental defects.
31.5.1.2. Ultrasound Diagnosis
Imaging methods such as ultrasound are non-invasive and may warn of many diseases or defects.
As a minimum, the ultrasonic part of examination includes measurement of the nuchal translucency (NT) of the 
foetus. Some systems also include a screen for nasal bone (NB); the nasal bone is not visible in a foetus with Down 
syndrome. It is a disputable marker – if something cannot be seen it does not mean it is nonexistent. The sonographer 
has to be certified by the FMF and audited on a regular basis to be able to measure NT. Nuchal translucency (NT) is 
measured from the 11th to 13th week of pregnancy. The ultrasound measures accumulated fluid in the foetal neck 
subcutis. The presence of large amounts of fluid in this space is often connected with a heart defect or chromosomal 
aberration. About 70% of foetuses with Down syndrome have a significant oedema on the neck caused by accumulated 
fluid. The examination can usually be made through the abdominal wall. In addition to nuchal translucency, the foetus 
is thoroughly examined by ultrasound. The number of foetuses is determined, and if multiple pregnancy is found, a 
chorionicity scan is made and the gestational age confirmed or corrected based on the CRL (crown-rump length), and 
the morphology of the foetus is checked. The best staffed and equipped facilities are able to measure additional ul-
trasound markers that may increase the sensitivity of the result. Ultrasound screening for trisomy 21 markers such as 
nasal bone, tricuspid regurgitation, ductus venosus flow or other markers requires separate certification and regular 
auditing to renew licences for each marker (NT, NB, TR, DV). Sonographers may use only those markers for screening 
for which they hold a valid licence. At the end of the 1st trimester, ultrasound may rule out most serious defects of 
foetal morphology (the parameters include skull shape, width of brain ventricles, face of the foetus, shape of the chest 
and torso, basic heart anatomy, size of the urinary bladder, structure of the upper and lower extremities, neural tube 
and anterior abdominal wall defects). In practice, however, it is hard to achieve such extent in normal screening.
Prenatal diagnosis of normal pregnancy ends with the ultrasound examination in the 20th week of gestation.
False Positivity at 85% Recovery Recovery at 5% False Positivity
First trimester combined test  
PAPP-A, free β hCG + NT 3.8 – 6.8% 85%
Second trimester 
AFP, hCG + uE3 9.3 – 14% 69%
Integrated test 
PAPP-A (free β hCG) + 
AFP, hCG (uE3) 0.8 – 1.2% 94%
Serum integrated test 
PAPP-A (free β hCG) + AFP, hCG (uE3) 2.7 – 5.2% 85%
Table 31.3. Comparison of false positivity and recovery of each test (source: SURUSS and FASTER studies)
31.5.2. Invasive Methods
If the result of screening for congenital defects is positive, the pregnant woman is informed about the option to 
use invasive examination techniques. For the time being, a sample of the foetal genetic material for the test (either a 
cytogenetic or molecular genetics test), which is often essential to confirming or disproving the suspicion of chromoso-
mal developmental defects of the foetus, has to be taken using standard invasive methods. Commonly used methods 
include amniocentesis (amniotic fluid sampling), chorionic villus sampling (CVS) and cordocentesis (umbilical cord blo-
od sampling). Invasive prenatal diagnosis is made only in indicated cases under ultrasonic control. The problem of all 
invasive methods, a problem that should be communicated to the pregnant woman in advance, consists in the risk of 
complications which may lead to spontaneous abortion. The risk of abortion due to amniocentesis or chorion sampling 
is about 0.5 – 1%.
31.5.2.1. Amniocentesis (AMC)
Amniocentesis is amniotic fluid sampling for chromosomal and biochemical analysis and is usually made between 
week 15 and 17 of gestation. It is the most common method of invasive prenatal diagnosis in the Czech Republic. Previ-
ously, this test was automatically offered to women over 35 because of the steeply rising risk of genetic defects in that 
population (Table 2). The currently preferred opinion is that age is only one of the markers to assess the risk of foetal 
defect. Amniotic fluid is usually sampled through the abdominal wall of the pregnant woman using a very thin needle 
inserted into the amniotic sac with the aid of ultrasound guidance. Approximately 20 ml of amniotic fluid is extracted. 
The overall risk of complications in connection with the procedure is estimated at 0.5 - 1.0%. The results of the karyo-
typing are available within 2 weeks of sampling. The result of the PCR or FISH analysis is known within 48 hours, which 
considerably reduces the stress of the pregnant woman. However, these tests detect only the most common chromo-
somal defects; the result of complete karyotyping must always be known.
Figure 31.4. Method of amniotic fluid sampling
31.5.2.2. Chorionic Villus Sampling (CVS)
Chorionic villus sampling is usually made between week 11 and 13 of gestation, often following a positive first 
trimester screening result. Chorionic villi are part of the placenta. Biopsy can be made through the abdominal wall or 
vagina. The risk of abortion in connection with this procedure is similar to the risk of amniocentesis – below 1%. 
31.6. Cytogenetic Methods
Foetal cells obtained by amniocentesis or chorionic villus sampling are cultivated to detect all deviations in the 
number and structure of chromosomes. The test is used for cystic fibrosis, muscular dystrophy, haemophilia and other 
genetic defects in the family history. This test also exactly determines the child’s sex. 
31.6.1. New Methods for Genetic Analysis
Foetal cells are most often tested by fluorescence in situ hybridization (FISH). This technique of molecular cytoge-
netics is suitable to test for aneuploidy of the embryo, to determine the sex of the embryo, or determine whether the 
parents are carriers of structural aberrations. Fluorescence in situ hybridization is based on the principle of the hybridi-
zation of short, fluorescently labelled DNA sequences (probe) with relevant sections of the target DNA sequence in the 
tested embryonic cell. The result of this hybridization is read under the fluorescence microscope. This method gives an 
overview of the number of copies of the selected DNA section representing certain chromosome in the nucleus of the 
examined embryonic cell.
A molecular genetics method known as polymerase chain reaction (PCR) is used to detect monogenic diseases. PCR 
was developed in the 1980s and today it represents one of the most commonly used methods of molecular genetics-
-based diagnosis.
Information about the possibility of capturing the DNA of the foetus freely circulating in maternal blood was pub-
lished in 1997. Testing foetal DNA fragments in the maternal blood is safe for the foetus, and the method can detect a 
wide range of genetic diseases. The discovery of foetal DNA circulating in the maternal blood has surely been a major 
contribution to prenatal diagnosis. However, the clinical use of this discovery has been confronted with numerous ob-
stacles, many of which have yet to be overcome.
The first requirement was to prove that maternal blood contains the entire genome of the foetus. The blood con-
tains only fragments of foetal DNA, which are surrounded by multiple amounts of maternal DNA fragments. These 
fragments are separated by comparing them with paternal DNA. This way it is possible to create a map of the foetal 
genome coming from the father. It is more difficult to separate maternal DNA, which represents up to 90% of fragments 
in the plasma, from foetal DNA coming from the mother. Nevertheless, there is a difference between the average size 
of maternal and foetal DNA fragments. The solution to this problem has opened the way to using this technology for 
non-invasive diagnosis of genetic defects of the foetus.
Thi s area is still undergoing research, and new, partial discoveries continue to be made. Although this method is 
quite expensive, as the technology develops it will surely be cheaper and thereby become more available for a wide 
spectrum of diagnosis.
31.7. Conclusion
All the congenital developmental defect screening algorithms mentioned above are available in the Czech Repub-
lic, although not equally in all regions. This screening is a typical example of interdisciplinary collaboration, in which 
biochemistry and genetics laboratories participate with each other alongside gynaecologists. Only by their cooperation 
and willingness to support one another, without favouring any one component, is it possible to provide rapid and high-
-quality examination of the pregnant woman. The possibilities of developmental defect risk assessment are becoming 
more and more sophisticated and accurate, but with the increasing requirement for the high quality of each part of the 
screening process, they often become less available to a certain part of the pregnant population. As the awareness of 
pregnant women about this issue is growing, physicians as well as other medical professionals should also be aware of 
the options available to the pregnant woman. The economic aspect also plays a role because invasive procedures (CVS, 
amniocentesis) are then followed by other laboratory examinations which are very expensive, and if used pointlessly 
based on poor screening, they are ineffective and uneconomical.
Societal attitude towards induced abortions has changed quite dramatically in the 20th century. It has been influen-
ced by the tradition, culture, religion and history of each country. One can hardly claim that the official position set 
out in the legislation is supported by all citizens of the country. A person’s attitude towards induced abortion is highly 
individual.
The Czech Republic is one of the countries with liberal laws, where induced abortion is available on the written 
request of a pregnant woman whose pregnancy is not longer than 12 weeks, unless medical reasons prevent the inter-
vention. If genetic reasons suggest that pregnancy be artificially interrupted, it is allowed until the end of the twenty 
fourth week of pregnancy.
In 2010, the Parliamentary Assembly of the Council of Europe adopted Resolution 1763, which contains, among 
others, the following principles:
1. No person, hospital or institution shall be coerced, held liable or discriminated against in any manner because 
of a refusal to perform, accommodate, assist or submit to an abortion, the performance of a human miscarriage, or 
euthanasia or any act which could cause the death of a human foetus or embryo, for any reason.
2. The Parliamentary Assembly emphasizes the need to affirm the right of conscientious objection together with 
the responsibility of the state to ensure that patients are able to access lawful medical care in a timely manner.
31.8. Case Reports
31.8.1. Case Report 1
First trimester screening
Age at term: 31 years
Ultrasound normal, measured CRL of 53.8 mm corresponds to gestational age of 12+1
• NT 1.7 mm 1.2 MoM
• free β hCG 91.8 ng/ml 2.13 MoM
• PAPP-A 1.53 mIU/l 0.58 MoM
• Risk of DS estimated based on age 1:823
• Risk of DS (NT+age+biochemistry) 1:919
The conclusion of the first trimester screening was negative, although hCG was slightly elevated and PAPP-A was 
lower than expected for the given week of pregnancy.
Second trimester screening
• AFP: 29.4 ng/mL 1.02 MoM
• Total hCG: 146.67 kIU/L 3.93 MoM
• Gestational age at sampling by ultrasound 16+0 
• Risk of DS calculated from markers for second trimester:  1:70
The conclusion of the second trimester screening was positive. The hCG level was almost 4 times higher than the 
median for the given week of pregnancy.
When the first and second trimester screening results were combined, the integrated risk of DS was 1:190.
Conclusion of the integrated test: positive screening
Amniotic fluid was sampled and the material thus obtained confirmed trisomy 21 using the PCR technique. The 
culture confirmed the presence of Down syndrome in the tested foetus. The pregnancy was aborted at the request of 
the pregnant woman in the 20th week.
31.8.2. Case Report 2
First trimester screening
• Age at term: 35 years
• Ultrasound normal, measured CRL of 56 mm corresponds to gestational age of 12+3
• NT 2.1 mm  1.6 MoM
• free β hCG 7.6 ng/ml 0.2 MoM
• PAPP-A 0.1 mIU/l 0.15 MoM
• Risk of DS estimated based on age 1:286
• Risk of DS (NT+age+biochemistry) 1:14
• Risk of T18 and T13  1:19
The conclusion of the first trimester screening was positive; the risk of congenital developmental defect was very 
high for other trisomies as well. Foetal karyotyping was recommended. Chorionic villus sampling was made for this 
purpose in the 12th week. The culture confirmed a normal finding, 46 XX. The pregnancy nonetheless ended by spon-
taneous abortion in the 16th week. This was 4 weeks after the CVS, so the abortion could not have been related to the 
CVS. It is advisable to monitor all pregnancies with low PAPP-A levels, which may indicate an approaching abortion.
31.8.3. Case Report 3
Combined test – first trimester test
• Age at term: 29 years
Ultrasound normal, gestational age 11+4 based on CRL of 55.0 mm
• NT 1.7 mm  1.2 MoM
• free β hCG 18.0 ng/ml 0.327 MoM
• PAPP-A 0.35 mIU/l 0.231 MoM
• Risk of DS based on age 1:987
• Risk of DS (NT+age+biochemistry) 1 : 2 213
• Risk of DS (age+biochemistry)  1 : 550
• Risk of T13 and T18  1 : 150
Conclusion: Given the low measured nuchal translucency, the screening was evaluated as negative despite the 
higher risk of congenital defects T13 and T18. No other examination was offered, although the biochemical results are 
alarming. The pregnancy ended with the birth of a child with Down syndrome in week 38 of pregnancy. The low free 
β hCG level affected the calculation of risk. Not all foetuses with trisomy 21 have an elevated NT value, as shown by 
Case Report 1.
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32.1. Metabolic Differences
In terms of biochemistry and metabolism, children are a unique group; they are not miniature adults. For example, 
newborn and premature infants have immature hepatic, renal and pulmonary functions. This also has a significant 
effect on the pharmacokinetics of administered drugs. In most cases, reference limits for infants differ markedly from 
older children and adults in biochemical and haematological examinations. Gestational age (mature/immature) and 
birth weight (low/very low) should also be taken into account in newborns. This also applies to the reference range for 
creatinine.
Postnatal Age Unit Gestational Age 28 
Weeks
Gestational Age 32 
Weeks
Gestational Age 
36 Weeks
Gestational Age 40 
Weeks
S-creatinine S-creatinine S-creatinine S-creatinine
2 days umol/l 40-220 27-175 23-143 18-118
7 days umol/l 23-145 19-119 16-98 13-81
14 days umol/l 18-118 15-97 12-80 10-66
21 days umol/l 16-104 14-86 11-71 9-57
28 days umol/l 15-95 12-78 10-64 9-53
Table 32.1. Serum creatinine reference values for newborns based on the age and gestational age of the newborn
In the neonatal period, the oxygen consumption is 180–280 ml/min/m2 per kg of weight, while a 10–year-old child 
has 120–220 ml/min/m2 per kg of weight. The already high heart rate and a high cardiac output are limiting factors. 
Easy oxygen reserve depletion in newborns and infants is the cause of the fast development of cardiorespiratory insuf-
ficiency as a result of a higher oxygen requirement in the case of hypothermia, infection, stress, pain, and pulmonary 
or cardiac disease. Monitoring the water and ion balance is of paramount importance in children. Small children are 
easily subject to dehydration due to their relatively large skin surface (surface/weight ratio). The skin of immature 
and premature newborns is highly permeable and the risk of dehydration is huge. In addition, as a result of immature 
tubular renal function, this group exhibits very high salt losses and the inability of the kidneys to compensate haemo-
concentration due to insensible losses. Children under 1 year of age easily develop metabolic acidosis as a result of 
insufficiently effective urine acidification and a low renal threshold for bicarbonate re-absorption. Hypoglycaemia is 
often found in children. Children have a low reserve of glycogen and immature capacity for gluconeogenesis. Stress 
episodes quickly lead to hypoglycaemia. Physiological neonatal hyperbilirubinaemia and the differential diagnosis of 
pathological hyperbilirubinaemia in children is a regular part of paediatric laboratory diagnosis.
Another area is inherited metabolic diseases, which require specialized laboratories for their diagnosis. Neonatal 
screening for hypothyroidism, congenital adrenal hyperplasia, phenylketonuria and cystic fibrosis is based on bioche-
mical assays on a dried blood spot (TSH, 17-hydroxyprogesterone, phenylalanine and the phenylalanine to tyrosine 
ratio, and immunoreactive trypsinogen assays). If cystic fibrosis is suspected, basic tests in a laboratory of paediatric 
biochemistry also include chloride tests as part of the sweat test by pilocarpine iontophoresis.
Paediatric laboratory diagnosis is distinguished mostly by differences given by the growth and development of 
infants, the collection of paediatric biological specimens, reference limits for children, and the selection of instruments 
and methods to process very small amounts of biological samples (5 - 10 ul/test). Special requirements are imposed on 
the monitoring of drug levels due to the different pharmacokinetics of drugs administered to children.
32.2. Collection of Biological Material from Children
Collection of blood from puncture. Fingertip or heel puncture is less traumatizing for younger children and new-
borns. Another possible, although less advisable method is sampling from the big toe or earlobe. Lateral or medial 
parts of the sole or heel are preferred sites in newborns, and fingertips are preferred in infants and younger children. 
Calcaneal osteomyelitis is a potential complication of the heel puncture. The risk of calcaneal damage by the punctu-
re is greater in premature infants as the distance between the skin surface and periosteum grows as the infant gains 
weight. But calcaneal perichondrium injury will not occur if the puncture is not deeper than 2.4 mm. Since the distance 
from the skin surface to the perichondrium is lower on the posterior curvature of the heel, using this site for blood 
sampling is not recommended.
Figure 32.1. Convenient and inconvenient sites for heel puncture
Procedure for taking blood samples from newborns and infants for diagnostic purposes:
It is very important to heat the skin before puncturing, because the blood obtained is a mixture of arterial, venous 
and capillary blood, which also contains interstitial and intracellular fluid (this applies mainly to samples for blood 
gas analysis). The easiest way is using a cloth, such as a towel, soaked in hot water (38-42 °C). It has been proved that 
heating the skin at the site of puncture may increase blood flow up to seven times. The increase in blood flow is pri-
marily arterial. To prevent nosocomial infections, the person taking the sample must remove all jewellery from their 
hands, wash their hands and forearms up to the elbows and use a new pair of latex gloves. After heating the skin, the 
site should be cleaned with a 75% aqueous isopropanol solution. Then the site should be dried with sterile gauze to 
prevent haemolysis by residual alcohol. Betadine should not be used at all because it may lead to an increase in potas-
sium ion, phosphate or uric acid concentration in the sample. A short, sterile lancet or an automatic device making a 
puncture not deeper than 2.4 mm should be used. After selecting the site of puncture and puncturing, the first drop of 
blood should be wiped off because it often contains a lot of tissue fluid. Once the blood sample has been taken from 
the heel or fingertip, the extremity should be lifted above heart level and the site of puncture compressed with sterile 
gauze until bleeding stops. Using adhesive bandages (patches) is not recommended because the infant’s skin is highly 
sensitive. In addition, there is a risk of the patch being pulled off and subsequent aspiration. The infant’s heel should 
be grasped firmly with a gentle grip, putting the index finger on the arch of the foot, and the thumb under the site of 
puncture on the ankle. The puncture should be made smoothly, carefully and vertically to the surface of the skin. The 
thumb pressure should be relieved when blood drops are forming and flowing into the prepared collecting container. 
Strong massaging of the puncture site should be avoided due to the risk of haemolysis or interstitial fluid getting into 
the sample, which could lead to an increase in potassium ion and magnesium level in the sample. In comparison with 
venous blood collection, the levels of some analytes are different in this method; for example, the glucose level is 10% 
higher than venous blood glucose.
Venipuncture. This technique is used in older children, because they have larger and more visible veins and better 
tolerate the sight of the needle. In general, v. cephalica is most commonly used to obtain blood. The tourniquet should 
be applied midway between the elbow and the shoulder of the child to compress the vein, not the artery. The needle 
should be inserted in the axis of the vein and form an angle of 15° with the skin. The tourniquet should be removed as 
soon as the blood starts flowing into the syringe. After removing the needle, the puncture site should be compressed 
with cotton gauze until the bleeding stops (about 3 minutes), and covered with a patch. Creams and patches (EMLA 5%) 
are available to control pain during blood collection from paediatric patients. The only disadvantage is that the onset 
of puncture site anaesthesia is about one hour after application. The cream and the patch contain lidocaine (2.5%) and 
prilocaine (2.5%).
The difficulty of venipuncture has lead to the use of non-invasive transcutaneous methods (e.g. pulse oximetry, 
transcutaneous bilirubinometer).
Volume of sample. Although many modern analyzers use small reaction volumes and the analyzers have low sam-
ple consumption, the size of samples remains the primary issue in the paediatric laboratory. This is because the num-
ber of premature and immature infants is growing (particularly the number of children with a birth weight under 1000 
g has grown). The volume of plasma is relatively constant during lifetime, 4-5% of body weight. Although the total 
blood volume in a healthy newborn is about 85 ml/kg, it may be much less in a premature infant.
Figure 32.2. Proportion of a 10-ml blood sample in the total blood volume depending on age
1 ml of blood of a newborn weighing 1 kg corresponds to about 70 ml of an adult’s blood. This results in the need 
for transfusion if the volume of blood samples taken in 3 days exceeds more than 10% of the total blood volume. For 
example, transfusion is required if only 8 ml of blood is taken from a 750-g child. Good planning of required laborato-
ry tests for premature infants and all children in general will avoid excessive blood losses – nosocomial anaemia. It is 
necessary to monitor haematocrit and haemoglobin, and/or cover the losses if needed. The volume of blood taken for 
each sample from paediatric patients under 2.5–3.5 kg must not exceed 2.5 ml; the total amount for the whole time of 
hospitalization (shorter than 1 month) should not exceed 23 ml. Recommended maximum amounts of blood samples 
relative to the weight of the child (single samples and total amount of samples throughout hospitalization) are shown 
in Table 35.2.
Patient Weight 
(kg)
Maximum per 
Sample (ml)
Maximum per 
Month (ml)
0.5-0.9 1 8
0.9-1.8 1.5 12
1.8-3.0 2 17
3-4 2.5 23
4-5 3.5 30
5-7 5 40
7-9 10 60
9-11 10 70
11-14 10 80
14-16 10 100
16-18 10 130
18-21 20 140
21-23 20 160
23-25 20 180
25-27 20 200
27-30 25 220
30-32 30 240
32-34 30 250
34-36 30 270
36-39 30 290
39-41 30 310
41-43 30 330
43-46 30 350
Table 32.2. Maximum allowed amount of blood sample taken in a single collection and total amount throughout hos-
pitalization (Note: Recommendation of the Institute of Clinical Biochemistry and Pathochemistry at the Faculty Hospital 
Motol, Prague)
Sample evaporation may be the main problem of small volumes. The thickening of an uncovered serum sample is 
already noticeable after the first hour. The values of a 0.1-ml sample may change by up to 20% at room temperature in 
two hours; the changes are smaller in larger (5 ml) samples (Figures 3 and 4).
Figure 32.3. Serum sample evaporation (sample volume 0.1 ml) at room temperature
Figure 32.4. Serum sample evaporation (sample volume 5 ml) at room temperature
Considerable thickening by evaporation may occur in summer months. Small paediatric test tubes are sometimes 
difficult to label. Despite their high price, Microtainer tubes are preferred for serum or plasma collection from new-
borns. These test tubes have a serum separator and contain 600 µl of blood. They can be easily labelled. Serum is se-
parated from cells after simple, short centrifuging. In addition, the serum separator does not affect levels of commonly 
assayed analytes. Plasma can be obtained using Microtainer tubes with lithium heparin salt. If greater amounts of 
blood are required for certain analyses such as hormone tests, 2.5-ml Vacutainer test tubes may be used for sampling. 
They are not used often because the veins of small children easily collapse. Although most laboratories use serum to 
measure analytes in clinical biochemistry, plasma is recommended. The reason is that the TAT (turnaround time) is 
shorter because waiting for coagulation is unnecessary, and also because haemolysis less frequent. In most routine 
tests, there is no difference in the results obtained from serum and plasma. Plasma should be used to measure the 
concentration of potassium ions, especially in patients with a high platelet or white blood cell count. It is important to 
make sure that the anticoagulation agent used does not directly affect the analyte being measured.
Urine collection. Proper urine collection is one of the most difficult tasks in paediatric practice. Since 24-hour col-
lected urine volumes may be repeatedly inaccurate, it is good to know the estimated volume of urine of children of 
different age categories and so have an idea of the corresponding volume.
Figure 32.5. Daily urine volume relative to age
The figure shows expected volumes of urine in a healthy paediatric population. Samples for urine analysis must be 
refrigerated.
Stool collection. The patient and the parents should be informed that the stool sample must not be contaminated 
by urine.
32.3. Reference Range
Correct interpretation of laboratory data depends on the availability of suitable reference ranges (normal values) 
for the relevant child’s age and degree of development. It is very difficult to obtain a sufficiently large sample of the po-
pulation of healthy children in age groups from 1 day to 18 years, who could give samples, and obtain informed consent 
from their parents. This is why Hoffman’s method is used. Normal reference limits are set for the paediatric inpatient 
population. Chauvenet’s or Dixon’s criteria and percentage cumulative frequency versus laboratory values (or versus 
logarithm of laboratory values, if the data distribution is not normal) are used to construct the reference limits (2.5th 
and 97.5th percentile); see the chapter Reference Limits by Bartoš. The advantage of this method is that, among other 
things, it respects the fact that inpatients commonly have higher thyroxine levels and lower cholesterol levels. Of cour-
se, one should remember that the reference limits depend on the analytical method used for the relevant biochemical 
test. Detailed paediatric reference values for clinical biochemical and haematological tests for difference age groups 
and genders for about 240 analytes are listed in publications by Soldin et al. or Meites et al. (SOLDIN, SJ., BRUGNARA, 
C., HICKS, JM. Pediatric reference ranges. Washington: AACC Press, 2003, 248 p., MEITES, S. Pediatric clinical chemistry. 
Reference (normal) values. Washington: AACC Press, 1989, 330 p.). Laboratory values of cord blood serum are often 
close to maternal serum values and may also change quickly. For example, cord blood T4 levels range between 85 and 
225 nmol/l and increase to 142-278 nmol/l in 1-3 days of age. Serum proteins, immunoglobulins in particular, are also 
subject to significant changes throughout the development of a child from the postnatal period to adulthood.
1–5 days 16 days –
3 months
4 months – 1 year 1–6 years 6–15 years
5.7-12.7 2.3-6.6 2.2-11.2 5.5-14.7 6.7-15.0
Table 32.3. Example of dependence of reference limits on age. Reference limits for serum immunoglobulin G (g/l) by 
age groups
One analyte which shows marked changes with age is alkaline phosphatase. As newborns and children grow, the 
alkaline phosphatase level rises to levels deemed pathological in adults. These reference values are also different for 
each gender of the same age category.
Age pH pO2
0 min 7.11-7.35 1.07-3.2
5 min 7.09-7.30 4.41-10.0
10 min 7.21-7.38 4.13-11.3
30 min 7.26-7.49 7.2-10.7
60 min 7.29-7.45 7.2-12.7
2 days 7.36-7.45 11.1-14.4
Table 32.4. Example of dependence of reference limits on age. Reference limits for blood pH and pO2 (kPa) by age of 
the newborn
Normal blood gas values and pH are distinctively different in newborns and older children (pH 7.18–7.51 versus 
7.35–7.44, respectively). The same holds true for sodium and potassium cations and calcium. For example, ionized 
calcium values in newborns under 1 month of age are 1.0–1.5 mmol/l, while the values are 1.18–1.32 mmol/l in adults. 
Serum reference values of enzymes such as amylase, GMT and AST are subject to a significant change with age. The 
most marked changes in the neonatal period can be seen in uric acid, bilirubin, renal clearance and fractional excretion 
of substances. The sexual maturation of children brings about phenomenal changes in the reference values of hormo-
nes, and sexual differentiation affects reference limits of many other analytes (prepubertal and postpubertal reference 
limits).
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33.1. Introduction
Toxicology is a very broad domain, which derives knowledge from many basic sciences and scientific disciplines 
(chemistry, physics, biology, mathematics, statistics, medicine, pharmaceutics, ecology and others) and is applied to 
many areas of human activities (health care, hygiene, justice, legislation, forensic science, farming, public health, envi-
ronment, working environment, waste management and others).
Clinical laboratory staff also come into contact with toxicological issues, albeit not all of them, only with some se-
lected areas. Some laboratory principles and procedures are common to biochemistry and toxicology, however some 
methods, concepts and evaluations are different (e.g. the upper reference limit in biochemistry vs. maximum permis-
sible level in toxicology, etc.).
This text contains the basic information, definitions and terms of toxicology placing special emphasis on areas 
stemming from the practice in clinical laboratories.
33.2. Toxicology
33.2.1. Definitions, History
The history of toxicology is very long. From time immemorial, people have found naturally occurring toxic substan-
ces (hemlock, datura, arsenic, etc.) and used them for hunting and battles in addition to involuntary events (poisoning). 
Toxicology (the name is derived from the Greek word “toxikón” meaning poison in which arrowheads used to be so-
aked) is a scientific branch concerned with the study of adverse effects of substances on living organisms.
We continue to come across toxicology today. Nowadays the substances are not only naturally occurring, but, 
above all, refer to artificially made products and preparations used by people for specific purposes on the one hand, 
however on the other hand we are encountering problems with them.
Examples:
• Mother, whose little child accidentally drank Diava (furniture polish), is surely very interested as to whe-
ther the product is toxic and what the first aid procedure is.
• We all worry about food becoming contaminated with heavy metals, herbicides and other hazardous sub-
stances introduced into the environment.
Although such substances may bring on physical effects such as electromagnetic radiation or crushed glass from a 
general point of view, attention is typically only paid to chemicals.
33.2.2. Subdisciplines of Toxicology
Toxicology is a very wide field, from which many subdisciplines have evolved focusing on specific areas.
Subdiscipline Short Annotation
Environmental toxicology Everyone is interested in toxicity in the home and external environment.
Industrial toxicology Many people work in environments where toxic risks are present.
Clinical toxicology Healthcare facilities take care of intoxicated patients (random accidents, suicides, 
abused substances).
Forensic toxicology The criminal acts of poisoners are not just restricted to detective stories.
Military toxicology Armies throughout the world pursue the matter of toxic warfare agents, their ef-
fects, deployment and protection against them.
Pharmaceutical toxicology The application of almost every drug presents a risk of toxicity, either in the form of 
adverse effects or overdosing.
Experimental toxicology Many experiments study the toxic properties of substances.
Predictive toxicology Effort to predict toxicity without animal experiments using computer programs.
Table 33.1. Examples
33.3. Toxicological Indications in Clinical Laboratories
Various indications occur depending on the organization of laboratory disciplines in a specific medical facility. In 
smaller laboratories it tends to usually only involve the simple immunochemical monitoring of drug abuse, large con-
solidated (integrated) facilities also deal with special research and other requirements.
Subdiscipline Requirements From Reasons for Indication (Examples)
Clinical toxicology Anaesthetic/resuscitation clinic 
(ARC), emergency, trauma surge-
ry, internal medicine, psychiatry
Accidental and intentional intoxications, toxicological 
screening for unconsciousness of unknown aetiology, 
checking for drug overdose, checking for abstinence 
among drug addicts, etc.
Industrial toxicology Occupational medicine, hygie-
ne, practitioners and company 
doctors
Occupational exposure control, compliance with limits, 
detection of exposure effects, occupational diseases.
Environmental toxico-
logy
ARC, emergency, hygiene Accidental intoxications in the home and external envi-
ronments, most often children.
Forensic toxicology ARC, emergency, psychiatry, fo-
rensic medicine
Demonstration of substances of abuse (alcohol, drugs) 
e.g. after road accidents.
Table 33.2. Examples
33.3.1. Causes of Intoxications
For the purpose of illustration, the causes of intoxication can be divided into the following groups:
1. “Voluntary unknowing”. This group includes drug addicts (junkies) and sportspeople using some form of 
doping. These people are not aware of being intoxicated, and use drugs or doping agents voluntarily, re-
gardless of the consequences.
2. “Voluntary knowing”. This group definitely includes suicide attempts.
3. “Involuntary”. This group includes various accidents, i.e. accidental poisonings, for example due to a mista-
ke or unexpected contamination or concentration of substances. Accidents occur not only in the private 
sphere but also at work. To some extent, involuntary victims of crime also rank among this group.
 
Figure 33.1. Shows the relative incidence of groups 2 and 3, i.e. cases reported in various statistics. It is clear that the 
incidence of group 1, i.e. the number of people abusing drugs or sportspeople using doping, is not exactly recorded, so only 
rough estimates are available.
33.4. Poisons
33.4.1. Definition
“Poison is a substance that causes negative effects to living organisms already in a small amount.”
Almost all substances may have negative effects, the only difference is the dose required for the onset of toxicity.
For example, distilled water is not considered a poison because one would have to drink large amounts in order to 
be poisoned.
Physical actions carried out by substances (boiling water, ground glass, etc.) are usually not considered poisons 
either.
33.4.2. Sources and Forms of Toxic Substances
Humans have encountered natural poisons (hemlock, mushrooms, snake toxins, vegetable alkaloids, etc.) from 
time immemorial. Nowadays there is a huge amount of artificial substances (medicines, herbicides, pesticides, insecti-
cides, warfare agents, detergents, solvents, heavy metal compounds, synthetic drugs, etc.), which have emerged over 
the past one hundred years. They exist in various forms (inorganic, organic, solids, liquids, gases, aerosols, etc.), either 
separately or when mixed with other substances.
Various forms of toxic substances exhibit different levels of toxicity.
Nickel Compound Form Toxicity
Ni Lustrous metal Nickel allergy, nickel dermatitis
NiO Black powder insoluble in water Possibly carcinogenic
NiSO
4
, Ni(NO
3
)
2
Green crystals soluble in water Nephrotoxicity
Ni(CO)
4
Gaseous compound Proven to be carcinogenic
Table 33.3. Examples. Nickel compounds.
Dust Particles Example of Profession Consequence of Inhalation
Biological origin (vegetable dust, ani-
mal fur, etc.)
Agricultural workers Allergy, pulmonary involvement (farmer’s 
lung, bronchial asthma, etc.)
Contain asbestos particles Workers in asbestos mines, 
brake lining manufacture, con-
struction, etc.
Asbestosis, increased risk of lung and pleu-
ra tumour
Contains silica particles Quarrymen and coal miners Silicosis, coal worker’s pneumoconiosis
Table 33.4. Examples. It is important to identify the dust type in cases of frequent exposure to dust inhalation.
Xenobiotics such as organophosphates exist, which have adverse effects in any dose, or the adverse effect of which 
is proportional to the dose. There are also some xenobiotics, which are beneficial to the body when administered wi-
thin a certain optimal dose range, however their insufficiency is bad, and, conversely, overdosing has toxic effects. A 
typical example is selenium, a useful antioxidant on the one hand, yet a highly toxic poison on the other.
 Figure 33.2. Shows a diagram revealing the dependency of negative effects on the dose of selenium.
Sources of toxic substances are present in the external, working and home environments.
External environment Water, air, soil, food, plants, or animals may become contaminated with toxic substan-
ces. Spread in a large space, meaning concentrations are lower.
Home environment Paints, detergents, disinfectants, impregnating agents (formaldehyde), drugs, plants, 
etc. Enclosed space, long-term contact.
Working environment Different forms of technology use organic solvents, insecticides, additives, chemical 
compounds and other substances. High concentrations if the workplace and workers 
are not equipped with protective equipment (exhausts, PPE).
Accidents Mistakes, accidental leakages during breakdowns, combustion products of fires, etc. 
Concentrations may be extremely high.
Table 33.5. Examples
33.4.3. Rapidity and Intensity of Toxic Substance Effects
Rapidity and intensity of toxic substance effects are influenced by many factors. Table 6 shows the most important 
factors.
Timing of exposure Acute (shorter than 24 hrs), chronic (longer than 3 months).
Mode of exposure/route of poisoning Ingestion, inhalation, transdermal, sniffing, intravenous, intramuscular – inje-
ctions, etc.
Mode of poison effect Local (caustic agents), general (carcinogens, mutagens).
Site of action Hepatotoxic agents are activated upon entering the liver; nephrotoxic agents 
into the kidneys; CNS depressants into the brain, while irritating agents are 
already activated once they come into contact with the skin or lungs, and 
haemotoxic as soon as they enter the bloodstream.
Mode of biotransformation (metabo-
lism)
Usually a process where lipophilic substances change into hydrophylic ones, 
which are easier to eliminate from the body, mostly in two phases: 
Phase I: Metabolic transformation includes oxidation, reduction and hydroly-
sis. 
Phase II: e.g. conjugation with glucuronic acid.
Route of eliminating poison from the 
body
Either directly as a poison or in the form of various metabolites, in urine, 
stools, exhaled air, bile, sweat, hair, breast milk, etc.
Dose of poison The effect is generally directly proportional to the dose of poison.
Form of poison Physical and chemical properties such as solubility are important. Refer to 
Table 3 for examples of different forms of nickel compounds.
Enhancement or elimination of the 
effect of poison
A big proportion of poisonings is not caused by one poison but rather a mix-
ture of interacting substances.
Poison habit The basis of drug addiction consists of the habit and need to increase doses 
to obtain the same effect.
Resistance (susceptibility) Children are generally more susceptible to the effects of poison than adults. 
Women are usually more sensitive than men.
Health condition If an individual is compromised by poison as well as another disease, the 
adverse effects of poisoning are more serious. For example, impaired kidney 
function will reduce the capability to eliminate poison from the body.
Table 33.6. The most important factors
33.4.4. Legislation
The Czech Republic is a member of the European Union, therefore, the following regulations of the European Par-
liament, Council and Commission apply to the area of chemical substances: 
Regulation (EC) No. 1272/2008 of the European Parliament and of the Council entered into force in 2009. The 
regulation stipulates rules for the classification of substances and mixtures as hazardous, and rules for labelling and 
packaging hazardous substances and mixtures. European documents take precedence over basic Czech legislative do-
cuments concerning toxic substances. 
Act 350/2011 Coll., Section 122, Act on chemical substances and chemical preparations and on the modification to 
some laws. For example, the document can be found on: http://aplikace.mvcr.cz/sbirka-zakonu/start.aspx 
Decree 402/2011 Coll., Section 140 and annexes thereto, A decree to execute some provisions of the act on che-
mical substances and chemical preparations and on modifying several laws concerning the classification, packaging and 
labelling of hazardous chemical substances and chemical preparations. Almost 700 pages of text.
You can locate the document on: http://aplikace.mvcr.cz/sbirka-zakonu/start.aspx
The category of substances classified as T+, i.e. highly toxic substances, is important.
For example, these substances include sodium azide, a common part of commercially supplied sets for many rou-
tine biochemical tests. A frequently asked question is whether the sets should also be considered as highly toxic T+ 
substances. It is specified in Annex 2 of Physical act, where is writen that if the concentration of highly toxic substance 
in the product is under 2.5%, the product is not considered to be highly toxic. 
Note: Normal sodium azide concentration as a preservative in laboratory sets is 1%, therefore commercial sets are 
not considered to be highly toxic products.
33.4.5. Important Terms Related to Poisons
Toxic Dose The lowest amount of poison capable of causing signs of poisoning.
Lethal Dose Commonly referred to as LD50, i.e. the dose that causes 50% of afflicted individuals to die. 
The dose expresses the individual sensitivity of an organism to the poison.
These doses differ greatly; e.g. morphine LD50 is 900 mg/kg, botulin only 0.00001 mg/kg.
Therapeutic Dose Single and daily doses are used for drugs, and express what doses are therapeutically effe-
ctive yet still toxicologically tolerable.
Therapeutic Width The difference between therapeutic and toxic doses. Safer drugs have a large therapeutic 
width (atropine); drugs with a low therapeutic width (digoxin, lithium) are less safe.
Biological Half-Life The time required for the body to eliminate one half of the total amount of poison. The 
problem is that metabolites produced from the poison are sometimes much more toxic 
than the original poison. Examples: Alcohol – acetaldehyde, ethylene glycol – oxalic acid 
Xenobiotics In general terms, foreign substances that do not normally exist or exist in insignificant 
amounts in an organism, and are introduced voluntarily (drugs) or involuntarily (contami-
nants, mistakes, etc.) to the organism. Some of these substances are biologically inactive, 
but most of them are biologically active and may have positive or negative effects on the 
organism.
Biogenic Substances Foreign substances useful for the organism, the negative effects of which may not only be 
due to overdosing but also due to insufficiency (e.g. selenium, iodine and other trace ele-
ments).
Hazard Symbols Hazardous properties in substances can be identified by pictograms or letters on packages 
and catalogues: 
E  EXPLOSIVE
O  OXIDIZING
F+  EXTREMELY FLAMMABLE
F  HIGHLY FLAMMABLE
T  TOXIC
T+  HIGHLY TOXIC
Xn  HARMFUL
C  CORROSIVE
Xi  IRRITANT
N  DANGEROUS FOR THE ENVIRONMENT
See Annex 4 to Decree 402/2011 Coll. For example, the document can be found on:
 http://aplikace.mvcr.cz/sbirka-zakonu/start.aspx
Risk Phrases (R-Phra-
ses)
Standard phrases identifying the specific risk of a substance, which have to be shown on 
the packaging of chemicals. There are 68 basic R-phrases in total, which may appear in 
combinations. For example, R26/28 indicates that the substance is higly toxic by inhalation 
and if swallowed.  
Note: The identification of R-phrases is currently being changed to H-phrases (Hazard phra-
ses).
See Annex 5 to Decree 402/2011 Coll. For example, the document can be found on:
http://aplikace.mvcr.cz/sbirka-zakonu/start.aspx
S-Phrases (Safety Phra-
ses)
Standard instructions for safe handling of chemicals. There are 64 basic S-phrases in total, 
which may also be used in combinations. Example: S24/25 indicates that skin and eye con-
tact with the substance should be avoided, i.e. that protective gloves and goggles should be 
worn.
Note: The identification of S-phrases is currently being changed to P-phrases (Prevention 
phrases).
See Annex 6 to Decree 402/2011 Coll. For example, the document can be found on:
http://aplikace.mvcr.cz/sbirka-zakonu/start.aspx
MAC Maximum concentration of a toxic substance allowed. Usually specified for the concentrati-
on of a hazardous substance in the air, water, food, etc.
Example: The MAC for air toluene in the workplace is 200 mg/ m3.
Maximum Permissible 
Level
The highest concentration, which is still permissible, e.g. during professional handling of a 
toxic substance, in terms of the onset of negative effects of the poison. The value is affec-
ted by many factors (economics, health policy, toxicity level of the substance).
Example: MPL for professional lead exposure is 400 µg/l,
but only 100 µg/l for professionally non-exposed children.
Table 33.7. Examples
Labelling of Chemicals
Chemicals must be properly labelled and hazards identified. 
Examples of warning hazard symbols according to Regulation (ES) No. 1272/2008 of the European Parliament and 
of the Council:
    
Figure 36.3. Caustic to skin – Flammable – Carcinogenic – Highly toxic
  
Figure 36.4. Toxic – Toxic to aquatic life – Oxidiser – Gas under pressure
Figure 33.3. Example of a label on the chemical bottle with hazard symbols and R and S-phrases:
33.4.6. Toxicokinetics – “What the Body Does with the Hazardous Substance”
The processes which take place when the body is exposed to toxic substances can be outlined as follows:
Exposure → Absorption → Distribution (+ Excretion) → Biotransformation (metabolism) → Molecular target → 
Toxic action (negative effect induction)
Exposure
Exposure may be single, repeated or chronic. There are different routes of entry in the body depending on the si-
tuation and character of the hazardous substance (swallowing poison, inhalation – lungs, absorption through the skin).
Absorption of poison into the body
The hazardous substance has to penetrate through different barriers (membranes) in the intestine or lungs, for 
example, before it enters the blood stream. The rate of absorption is affected by the physical and chemical properties 
of poison, solubility, concentration and the mode of exposure.
Distribution of poison in the body
Following penetration into the blood stream, the poison is distributed, i.e. transported to various organs and 
tissues. 
Biotransformation (metabolism) of poison
The objective of biotransformation (metabolism) can be briefly characterized as a process where lipophilic sub-
stances transform into more hydrophilic substances, which can be eliminated from the body more easily.
The first phase includes oxidations, reductions, additions or removals of functional groups (-OH, -COOH, -NH
2
, etc.)
The second phase consists of conjugation with different substances such as glucuronic acid.
The course of biotransformation is affected by state of health, liver function (major biotransformation organ in the 
body), age and other factors.
Elimination (excretion) of poison
Biotransformation eliminates most substances from the body. There are many ways of excreting poison from the 
body. The major role in excretion is played by the kidneys (note that poison may be kept in the body due to renal im-
pairment). A common way is the lungs (exhalation), some amounts are excreted in bile from the liver, some hazardous 
substances deposit in the hair (interesting), and poison may also be excreted in breast milk (important).
Cumulative poisons, biological half-life
The term biological half-life defines the time required for the body to reduce the toxic substance level to half. Sub-
stances have very different biological half-lives. For example the biological half-life of toluene is 2 - 3 hours, while the 
biological half-life of cadmium is 20 years.
The term cumulative poison refers to a toxic substance with a long biological half-life, which slowly excretes from 
the body. When the body is next exposed, the hazardous substance from the previous exposure still persists in the 
body, and poison slowly accumulates.
Figure 33.4. Shows a diagram of the difference between repeated exposures to substances with short and long biologi-
cal half-lives.
The releasing of accumulated hazardous substances from the deposit site may sometimes pose a problem.
Example: Shortly after childbirth, a woman embarks on a weight-reducing diet to quickly regain her former shape. 
However, this releases toxic substances accumulated in fatty tissues, which may endanger the breast-fed baby.
33.4.7. Toxicodynamics – “What the Hazardous Substance Does with the Body”
Site, mode and time profile of effect
Some poisons act specifically on certain organs (e.g. lead and lead compounds impair haemoglobin synthesis, 
cadmium impairs renal tubules, etc.), other toxic substances act throughout the entire organism (e.g. carcinogens, 
mutagens, etc.).
Dose-effect
The relationship between the dose (i.e. the amount of toxic substance to which the human is exposed) and the size 
(i.e. significance) of negative toxic effects does not only depend on the size of the dose but also on a variety of other 
factors and circumstances.
Time profile and duration of ex-
posure
Acute (shorter than 24 hrs), chronic (longer than 3 months).
Mode of exposure/route of poi-
son entry into the body
Ingestion - GIT, inhalation - lungs, transdermal - skin, snuffing, intravenous, intra-
muscular – injections, etc.
Mode of poison action Local (caustic agents), general (carcinogens, mutagens).
Site of effect Hepatotoxic agents are not activated until they enter the liver; nephrotoxic 
agents into the kidneys; CNS depressants into the brain, while irritating agents 
already become activated when they come into contact with the skin or lungs, 
and haemotoxic as soon as they enter the bloodstream.
Mode of biotransformation (me-
tabolism)
Usually a process where lipophilic substances change into hydrophylic, which are 
better eliminable from the body, mostly in two phases:
Phase I: Metabolic transformation includes oxidation, reduction and hydrolysis.
Phase II: e.g. conjugation with glucuronic acid.
Route of poison elimination from 
the body
Either directly as a poison or in the form of various metabolites, in urine, stools, 
exhaled air, bile, sweat, hair, breast milk, etc.
Form of poison Physical and chemical properties such as solubility play an important role.
Enhancement or elimination of 
poison effect
A big proportion of poisonings is not caused by one poison but a mixture of inte-
racting substances.
Poison habit The basis of drug addiction consists in the habit and need to increase doses to 
obtain the same effect.
Resistance (susceptibility) Children are generally more susceptible to poison effects than adults. Women are 
usually more sensitive than men.
Health condition If an individual is compromised by poison and another disease, the adverse ef-
fects of poisoning are more serious. E.g. impaired kidney function will reduce the 
capacity to eliminate poison from the body.
Table 33.8. Examples
Methods of evaluation (quantification)
There are different methods and terms to quantify toxicity and characterize a specific substance in terms of toxicity.
Lethal Dose – usually denoted as LD
50
The dose that causes one half of individuals from an ex-
posed set to die
Toxic Dose The lowest amount which causes poisoning
Therapeutic Width of Drugs The difference between the toxic dose and therapeutic 
dose required for treatment
Maximum Allowable Concentration (MAC) The highest concentration in the air acceptable in the 
workplace
Maximum Permissible Level in Biological Exposure Tests 
(BET)
The highest allowable concentration in the biological ma-
terial of exposed organisms
Table 33.9. Examples
Differences in toxicity of different substances are in orders of magnitude.
Alcohol 10.000
NaCl 4.000
Morphine 900
Paracetamol 142
Strychnine 2
Nicotine 1
Curare 0.001
Botulinum toxin 0.00001
Table 33.10. Examples. Comparison of LD50 (mg/kg) of known substances
33.5. Toxicological Tests
The spectrum of toxicological tests is very wide and varied. The media publish information regarding analyses of 
suspected substances (landfills, contaminated food, baby toys, etc.), and/or about toxicological tests of the environ-
ment (outdoor or indoor air, drinking or waste water, contaminated soil), etc.
However, these indications usually do not occur in clinical laboratories. Toxicological tests in clinical laboratories 
generally include analyses of different biological materials taken from potentially intoxicated persons.
33.5.1. Reasons for Toxicological Tests
Acute intoxications Accidental (unlabelled or wrongly labelled containers), intentional (suicides, 
crimes) intoxication, unconscious patient with acute signs of intoxication.
Examples: Serum ethylene glycol after ingestion of Fridex from a soda water 
bottle. Serum paracetamol or salicylates after intoxicating a child or a suicide 
attempt. 
Chronic intoxications Differential diagnosis of signs of long-term exposure to hazardous substances.
Examples: Delta-aminolevulic acid and coproporphyrin III in urine after a long-
-term exposure to lead.
Drug abuse (toxicomania) Capture of new addicts, check of compliance with withdrawal treatment rules, 
checking whether people in control groups of studies do not use drugs.
Examples: Drugs and drug metabolites (THC, methamphetamine – pervitine, 
opiates, cocaine, ecstasy, buprenorphine, benzodiazepines), etc. in urine.
Professional intoxications Biological exposure tests, indemnification for occupational diseases.
Examples: Mandelic acid in urine after professional exposure to styrene, or tri-
chloroethanol and trichloroacetic acid after exposure to trichloroethylene.
Crimes Examples: Serum ethanol and osmolality in drivers, or demonstration of drug 
abuse at work.
Therapeutic Drug Monitoring 
(TDM)
Monitoring of administered drugs (especially those with a narrow therapeutic 
scope).
Examples: Digoxin, methotrexate, tacrolimus, sirolimus, theophylline, vancomy-
cin, gentamicin, phenytoin, valproate, carbamazepine, cyclosporin A, phenobar-
bital, etc. in the serum.
Experimental intoxications Animal research. Example: Detection of Cd in tissues after conducting experi-
mental research cadmium intoxication on a set of mice.
Table 33.11. Examples
33.5.2. Types of Toxicological Tests
33.5.2.1. Unknown Intoxication (Toxicological Screening)
Example: Two hours after midnight, a man unable to communicate, with acute signs, is brought to the hospital. It 
is necessary to find out as soon as possible whether he is intoxicated.
From an analytical point of view, it is one of the most difficult tasks. The condition may involve any toxic substances 
at any concentration. The spectrum of the most common poisonings slowly changes with newly emerging drugs and 
substances and their availability. If a substance is positively demonstrated, it is important to keep in mind that mixed 
poisonings with multiple poisons often occur, and then it is necessary to decide which component dominates. Any ad-
ditional information that one is able to procure is very important (e.g. the estimated time of intoxication, containers, 
residues, tablets found, texts, drugs given as first aid, etc.). In general, it is advisable to take the widest spectrum of 
materials (blood, urine, hair) as possible in sufficient amounts.
This difficult task requires extensive laboratory equipment with suitable analyzers.
The speed of response of the laboratory is very important in this type of toxicological test. Clinicians often make do 
with the qualitative finding, which may be quantified at a later stage.
33.5.2.2. Monitoring of Known Exposure
Examples: Therapeutic drug monitoring before and after administering another dose of the drug or professional 
exposure to a known substance such as organic solvent toluene, or alcohol level analysis in drivers and workers.
The biological half-life of the monitored hazardous substance should be taken into account and suitable material 
for capturing the poison should be selected accordingly. Example: It is useless to take urine to ascertain the toluene 
metabolite level one week after intoxication, because the half-life of toluene is about 2 - 3 hours. On the other hand, 
THC metabolites from chronic abuse can be demonstrated in urine up to even several weeks after the last application.
This test can be scheduled beforehand; the speed of response is not very important, while adequate accuracy, i.e. 
trueness and precision, is important (refer to the Analytical Properties of the Methods).
33.5.3. Materials Used for Toxicological Tests
The spectrum of materials used for toxicological tests in clinical laboratories is wide-ranging.
Blood, serum Invasive sampling (problematic in very little children), suitable 
only a couple of hours after intoxication.
Urine Non-invasive; poison is usually concentrated in urine, appears in 
urine later than in blood; it is possible to conduct the test for se-
veral days; problems associated with “adulteration”.
Hair, nails A unique opportunity to look at the history (1 cm of hair corre-
sponds to about 1 month). If possible, the hair should not be che-
mically damaged and contaminated (dyes, shampoos).
Exhaled air, saliva Useful to demonstrate ethanol or drug ingestion.
Other (gastric content, tissues) Uncommon in clinical laboratories - this is the domain of forensic 
medicine and pathology. 
Table 33.12. Examples
33.5.4. Focus of Toxicological Tests
The focus (objective) of toxicological tests depends, among other things, on the time passed from intoxication to 
biological material sampling.
Hazardous substance detection Usually in blood (serum, plasma) im-
mediately after intoxication.
Examples: Toluene, lead, drugs before 
and after administration of the next 
dose, etc. 
Hazardous substance metabolite de-
tection
Usually in urine; the test can be made 
even up to several days after intoxi-
cation takes place.
Examples: Hippuric acid, mandelic 
acid, drug metabolites, etc.
Determination of effects (negative 
effects of the hazardous substance)
Targeted tests depending on the type 
of damage. Examples: Liver tests, ha-
ematopoiesis tests, kidney tests, etc.
Examples: Liver tests after paraceta-
mol poisoning, porphyria tests after 
lead poisoning, etc.
Table 33.13. Examples
33.5.5. Forensic Issues
Forensic purposes generally require results confirmed by at least two methods based on different principles (e.g. 
gas chromatography and Widmark test for ethanol).
Toxicological tests made in clinical laboratories of biochemistry are mostly intended for acute clinical cases (e.g. a 
non-communicating person with signs of intoxication, requiring fast therapeutic action). They are not very useful for 
forensic purposes. One of the reasons is insufficient safeguarding the sample against accidental or intentional tampe-
ring (swapping or contaminating the sample, etc.).
33.6. Analytical Techniques
Toxicology requires very specialized equipment, not only for the analysis itself but also for the pre-analytical pre-
paration of specimens. The analysis itself requires the availability of a wide spectrum of analyzers and devices based 
on different principles.
Spectral systems UV, VIS and IR spectrophotometry, flame photometry, AAS, ICP-MS, etc.
Chromatographic systems TLC, GC-MS, LC, HPLC-MS, etc.
Immunochemical systems FPIA, MEIA, AMIA, CMIA, EIA, ELISA, etc.
Other Homogenization, lyophilization, isolation, mineralization, pre-concentration, etc.
Table 33.14. Examples
Selection of suitable analytical technique initially depends on the task, which can be very varied in toxicology, and 
usually involves individual situations rather than an extensive series of similar samples typical for routine biochemistry.
Toxicological screening for unknown substance intoxication often starts with the application of simple immuno-
chemical test cards. These systems usually only perform qualitative analyses, their specificity is rather problematic 
(cross reactions) and they are available only for a certain limited amount of substance types (e.g. 10 basic types of 
classical drugs), but they are very easy and fast to use at any time of the day and night, because they do not need the 
presence of a skilled specialist. The qualitative result, which is sufficient to clinicians at the first stage, can be quanti-
fied at a later stage, if necessary, using a suitable chromatographic or spectrophotometric method. Chromatographic 
techniques (GC-MS, HPLC, TLC, etc.) have a good specificity and make it possible to determine practically any organic 
substance, however they are lengthy, complicated, and require an experienced and qualified chromatographer. ICP-MS 
is the most suitable technique for screening inorganic substances such as heavy metals, though it is not used in clinical 
laboratories. Collaboration with specialized laboratories is required in indicated cases.
The situation is simpler, if monitoring of the known substance intoxication is needed. If the substance is known, 
the most adequate analytical technique can be used. Different commercially available quantitative immunochemical 
procedures such as FPIA, MEIA and others are used for therapeutic drug monitoring (TDM). Biological exposure tests 
(BET) in industrial toxicology and hygiene (test of toxic substances directly in the biological material of exposed per-
sons) employ various techniques such as targeted AAS for a specific heavy metal, etc.
33.6.1. Pre-Analytical Phase (Sampling and Sample Preparation)
Since samples are varied, they require different types of preparation before performing an analysis:
Solid samples such as hair must firstly be decontaminated (washed alternately in the aqueous and organic phases 
and dried), homogenized (by mixing, grinding, cutting, freezing), sometimes dried to a constant weight, while the 
amount of sample taken for analysis must always be weighed on the analytical balance. The sample has to be sub-
sequently converted into a solution, i.e. mineralized (today most often by microwave-assisted mineralization under 
pressure in a closed system with a mineralizing agent admixture). Pre-concentration is sometimes required to obtain a 
measurable concentration (e.g. almost complete evaporation of the mineralization residue and subsequent dissolving 
of the mineralization residue in a small amount of a suitable solvent).
 Even liquid samples often have to be treated before toxicological testing (e.g. adjustment of a sample pH by ad-
ding suitable agent). Some substances (e.g. drugs) have to be isolated before the test from a complex organic matrix of 
the biological specimen by extracting them into an adequate organic solvent, or alternatively chromatographic separa-
tion is used. This will reduce the number of potentially interfering substances and simplify identification. Solid-phase 
extraction (using silica gel, cation exchange, anion exchange) has become more and more widely used of late.
 Gas and volatile substances are isolated by distillation or headspace technique, in which the equilibrium gas phase 
above the liquid sample is analyzed.
33.6.2. Quality Control
The control of toxicological analysis quality is specific in some aspects. Toxicological tests mostly do not contain a 
large series of more or less identical samples, which is usual in routine clinical biochemistry. Requirements are often 
unique, or repeat at long or irregular time intervals. It is sometimes problematic to obtain suitable reference material 
with the same matrix. Interlaboratory control systems are not commonly available.
Nevertheless, quality control is important and absolutely essential, and as a mini-
mum it is necessary to verify the quality parameters of the method used (precision, true-
ness, accuracy, sensitivity, specificity, recovery, etc.) (Refer to Analytical Properties of Methods). 
It is clear what the negative consequences can be for the tested person due to a falsely positive (innocent person is 
included in the list of drug abusing persons) or, conversely, a falsely negative finding (no therapy for the late after-ef-
fects of intoxication caused by an unrecognized substance).
33.7. Most Common Forms of Intoxication
33.7.1. Haemoglobin Disorders
The best known and most common include carbon monoxide (CO) intoxication caused by incomplete coal or gas 
combustion (gas boilers in bathrooms) or exhaust gas accumulation in an enclosed space (garage). The frequency of 
poisonings is presently growing due to tightly sealed plastic windows. During intoxication (signs include headache, 
weakness, fatigue, dizziness), CO binds to haemoglobin to form carboxyhaemoglobin (COHb). The fact that COHb is 
unable to carry oxygen will manifest itself in most severe poisonings by tissue hypoxia with lactate acidosis. The CO 
bond to haemoglobin is reversible however is roughly 200 times stronger than the oxygen bond. Serious cases are the-
refore treated under higher oxygen pressure in the hyperbaric chamber. COHb is tested by acid-base balance analyzers.
COHb is also present in the blood of non-intoxicated people, but not higher than 5%. COHb levels over 10% can be 
found in smokers. So the information as to whether the patient is smoker or non-smoker is very important in checking 
for possible CO intoxication.
Another possible poisoning, disabling the transport function of haemoglobin, is the oxidation of Fe2+ in haemoglo-
bin to Fe3+ through the effect of nitrites, nitrates and some drugs to form methaemoglobin (MetHb). This is especially 
dangerous in newborns, which have an immature MetHb-reducing system. This is why the permissible level of nitrates 
in drinking water for infants is much lower than the level for adults.
There are also other, luckily rare, types of poisoning such as sulfhaemoglobin (SulfHb) formation due to hydrogen 
sulphide poisoning, or cyanhaemoglobin (CNHb) due to hydrogen cyanide and other cyanine poisoning.
33.7.2. Heavy Metal Poisonings
Heavy metals may be defined in a variety of ways. Some define heavy metals in terms of density, others in terms 
of atomic weight or toxicity. Heavy metals used by humans contaminate the external and working environments. Most 
of them have long biological half-lives, so they slowly accumulate in exposed organisms. Typical heavy metals include 
lead, cadmium, mercury, copper, chromium, manganese, aluminium, vanadium, nickel, etc.
In terms of the history of heavy metals, lead has most probably been used the longest (PbO as a sweetener, wa-
terworks, leaded petrol, accumulators, paints, radiation protection and other uses). Pb has a strong affinity to bones, 
where it accumulates. Pb is able to substitute other biologically important elements (Ca, Fe, Zn) in the bond to -SH, 
-NH
2
 and -COOH groups, in proteins and other molecules. When bound to Pb, these substances work differently, lea-
ding to many negative effects (toxicity).
Inhibition Effect
d-ALA - dehydratase Impaired haemoglobin synthesis
NMDA receptors in the brain Worsened long-term memory
Table 33.15. Examples
Many “famous” Pb intoxication stories can be found in history:
• Ludwig van Beethoven suffered from chronic abdomen pains from youth; his bones and hair were analyzed 
in 2002 to find high lead concentrations.
• Francisco Goya – painter, intoxicated by lead paints.
• Sir John Franklin – polar explorer, died along with all his team members in Greenland due to tins sealed 
with lead.
Lead poisonings do continue to occur today (both at home and abroad), often in various unexpected circumstan-
ces:
• A doctor family became acutely intoxicated from a ceramic pot with Pb glaze, in which they made lemon 
tea because they did not want to drink chlorinated tap water.
• A young woman had Pb poisoning from using an over-the-counter product, Femikalp. Unfortunately, dried 
Indian plants contained in the product to enhance vital functions were heavily contaminated with lead.
• A large group of relatives was extremely exposed to lead because they confused red paprika powder with 
red lead, a powder primer (triplumbic tetroxide) of exactly the colour of red paprika.
• A group of restorers was exposed to Pb while restoring 300 year old wall paintings in the Teplá monastery. 
The old historical paints contained Pb.
Gradual improvement of knowledge about toxicity of substances, here the specifically discussed Pb and Pb com-
pounds, leads to the gradual lowering of maximum permissible levels. For example, the maximum permissible level of 
Pb in the blood of children was reduced from 600 µg/l in the 1960 - 70 to 100 µg/l used at present.
Treatment of intoxicated people primarily involves eliminating accumulated lead from the body by injections of 
chelates that release Pb deposited in bones and excrete it through urine.
Cadmium is associated with the globally known itai-itai syndrome, an effect of Cd intoxication from factory waste 
dumping to seawater and the consequent consumption of contaminated fish. Damage to proximal renal tubule cells is 
typical and may even lead to tubular necrosis. Cd concentration is tested in serum, urine and hair; optionally beta-2-
-microglobulins may be tested in urine as an indicator of tubular injury.
Mercury is also connected with the Japanese name Minamata as a synonym for human poisoning by Hg from the 
environment. Toxic actions of inorganic and organic mercury compounds differ. Neurological injuries are most com-
monly reported, but the kidneys and lungs are also often damaged. Early signs are non-specific and include weakness, 
fatigue, headache, later the characteristic shiver and tremor (handwriting test is recommended). Mercury concentra-
tion in blood, urine and hair is measured.
33.7.3. Alcohol Intoxication
The use of ethanol is widespread in the CR with generally known symptoms.
The use of greater doses can be considered intoxication with acute and chronic effects. Like all 
forms of alcohol, which generally metabolize to aldehyde and then to acid, ethanol metabolizes due 
to the effect of an alcohol dehydrogenase enzyme to form acetaldehyde and subsequently acetic acid. 
A markedly greater serum osmolality occurs in ethanol and, analogically, other forms of alcohol intoxication. Osmola-
lity can be measured or computed from the following formula: 2 x Na + urea + glucose.
The difference between the measured and computed values (osmolal gap) is evaluated. Refer to the chapter about 
osmolality.
Methanol intoxication is relatively frequent and is due to substituting ethanol for methanol. Methanol metaboli-
zes to formaldehyde and then to formic acid. It is a highly toxic substance (a lethal dose for adults amounts to 50 ml 
of methanol). The typical permanent consequence of methanol intoxication is optic nerve injury leading to blindness. 
Severe metabolic acidosis also develops. Analogical metabolism is used as a form of treatment, while ethanol is admi-
nistered as an antidote. The alcohol dehydrogenase enzyme then “busies itself” with excess ethanol and forms limited 
amounts of formaldehyde responsible for optic nerve injury.
Similarly, confusions (unlabelled containers) or suicides involve ethylene glycol contained in anti-freezing fluids 
(Fridex). Ethylene glycol metabolizes to oxalic acid. This harms the kidneys. Severe metabolic acidosis develops. A flood 
of calcium oxalate crystals can be found in urine. The increase to serum osmolality is significant. Ethanol is administe-
red as an antidote here as well in addition to other treatments such as dialysis in serious cases.
33.7.4. Drug Intoxication
Drug intoxication occur not only as a result of suicide but also due to mistakes (a child confuses coloured pills for 
sweets) and errors (a different dose or higher drug concentration is administered by mistake). The drug concentration 
measured in blood is evaluated in relation to the time passed between intoxication and sampling. There are various 
nomograms for this purpose.
For example, it is possible to determine by drawing a line in the nomogram for the evaluation of significance of 
paracetamol concentration that 50 mg/l (50 µg/ml) paracetamol measured in a sample taken 8 hours after intoxication 
rules out significant liver injury.
*
*
Figure 33.5. Nomograms evaluating the significance of the probable toxic effects of paracetamol and salicylates at the 
measured level and time from intoxication
Paracetamol (acetaminophen) contained in many drugs such as Paralen may cause severe injury to the liver due 
to overdosing.
Salicylates (acetylsalicylic acid) contained in drugs such as Aspirin cause metabolic acidosis, after penetrating into 
the CNS irritate the respiratory centre, which leads to respiratory alkalosis.
(Refer to the chapter about the ABB.)
33.7.5. Drugs
The issue of drug-taking among humans has been present throughout history, i.e. often involving abuse and habit-
-forming substances. Each society has adopted some basic rules for how to handle “their” drugs over time; hence the 
situation was generally tolerable, although personal tragedies did of course occur. Problems escalated worldwide when 
drugs were introduced to new places as part of globalization.
Example: We know from history the damage alcohol (commonly used in Europe) caused to Indians in America. 
Conversely, opiates from Asia or cocaine from South America are now causing huge problems in Europe.
The situation gets even more complicated by the fact that new, synthetic drugs are emerging in addition to long-
-known, natural drugs. The new drugs are produced for gain, irrespective of the consequences faced by addicts (ruined 
health, crime, negative social impact on family and society).
Classic drugs
“Classic” drugs can be generally divided into four basic groups distinguished from each other by appearance, ef-
fects, course of addiction and extent of risk presented to the user.
Some of these substances are also used for therapeutic purposes (e.g. opiates as painkillers), other drugs are pu-
rely abused (e.g. stimulating substances from the family of amphetamins).
Laboratories commonly use simple aids (cards) making it possible to detect the presence of drugs on the immuno-
chemical principle.
Figure 33.6. Example of a screening card to detect 10 types of abused substances found in urine. The evaluation is sim-
ple: 2 lines = negative, 1 line = positive
Cannabis drugs
Probably the best known is marijuana, a mixture of leaves, flowers and stalks of the Cannabis sativa (indica) plant. 
It is applied by smoking (joints), and symptoms include disorders of perception, emotions, thinking and short-term me-
mory. It is also referred to as THC after the active substance tetrahydrocannabinol, and ranks among soft drugs. There 
has been a long ideological struggle between those who wish to legalize the drug (analogically to ethanol and nicotine), 
and their opponents, who argue by saying that THC is often an initial phase for using hard drugs.
Hashish is a hemp resin with similar but much stronger effects than marijuana.
Opiates
Opioids represent a wide group of alkaloids with a chemical structure similar to that of morphine, which can be 
found along with other substances (codeine, thebaine and papaverine) in the juice from unripe Papaver somniferum 
poppy-heads.
In addition to these purely natural opioids, there are a lot of semi-synthetic substances such as heroin (semi-syn-
thetic morphine derivative) or buprenorphine (semi-synthetic thebaine derivative), known as SUBUTEX, a drug used 
for replacement therapy.
Another substance given to addicts for replacement therapy is the synthetic preparation methadone.
Opioids are applied primarily by intravenous injections, but also by smoking or sniffing. Application initially induces 
euphoria and pain control. Intoxication by a higher dose leads to sedation, somnolence, vomiting, contraction of the 
pupils or even respiratory arrest (naltrexone - a clinically used antidote is used).
As a result of addiction, discontinuation of habitual dose leads to withdrawal symptoms such as sweating, malaise, 
anxiety, depression, insomnia and fever. The addict will do anything to get another dose, which has to be stronger and 
stronger.
Stimulants
The best known stimulant is alkaloid cocaine isolated from the Erythroxylon coca bush growing in South America. 
It is applied by powder inhalation or chewing coca leaves. Cocaine is a strong CNS stimulant, induces euphoria and a 
sense of tirelessness. However, it causes a strong psychological dependence.
In addition, this group includes the synthetic drug methamphetamine (meth known as “glass”, “crystal” or “tik” 
and in CR as „pervitine“).
Ecstasy (party drug), a derivative of methamphetamine applied in the form of tablets, is very widespread among 
young people.
Hallucinogens
There are natural hallucinogens such as psilocybin contained in magic mushrooms (Psilocybe bohemica) or trypta-
mines on toad skin, and synthetic hallucinogens such as the best known lysergic acid (LSD). As the name suggests, 
substances from this group cause euphoria and hallucinations.
For example, an urban legend popularizes the belief that after licking a toad a girl may think she sees a prince (like 
in fairy tales).
Regrettably, this also brings about depression, paranoia, liver and kidney damage.
New drugs
New, fully synthetic drugs so far unidentifiable by methods available to routine laboratories keep emerging.
GHB (gamma-hydroxybutyrate) known as “liquid ecstasy”
• 1,4-butanediol known as “thunder nectar”
• Ketamine, a veterinary anaesthetic, often mixed with ecstasy
• Tryptamines, synthetic and natural serotonin-like substances
Problem of “adulteration”
When monitoring people suspected of using addictive drugs, it is necessary to pay attention to “adulterating” ef-
forts, i.e. attempts to make drug detection impossible by diluting the urine sample or by adding bleach, acid, base or 
other substances. This is why special detection cards exist, which, in addition to the drug detection test, also contain 
auxiliary tests demonstrating unwanted intervention in the sample by changed colour of the check field.
33.7.6. Other Poisonings
As mentioned in the introduction, one can be poisoned practically by anything, if the dose is large enough. However, 
covering the whole topic would exceed the scope of this text.
This is why only some examples have been provided:
• Organophosphate poisonings are common. Organophosphates are not only used as warfare agents (sarin, 
soman, etc.), but they are also commonly used in farming, for rodent control and other purposes. The 
maximum permissible level for professional activities is 30% depression of cholinesterase activity. People 
with acute intoxication die in convulsions as a result of acetylcholinesterase enzyme inhibition at the neu-
romuscular junction.
• Frequent chronic and also acute intoxications by organic solvents (toluene, xylenes, benzene, trichloro-
ethylene, styrene, etc.) used for dying, painting, laminating, solving, cleaning and other purposes. The test 
involves the detection of urinary metabolites such as mandelic acid for styrene, hippuric acid for toluene, 
phenol for benzene, trichloroethanol and trichloroacetic acid for trichloroethylene and other substances. 
Organic solvent intoxication causes liver damage, abortions, addictions and other effects.
• There are many toxic plants in the environment and at home, which are responsible for many poisonings, 
most commonly of children.
Plant Toxic Substance (Symptoms) Photo (source: Internet – Wikipedia)
Giant hogweed Phototoxic coumarins (causes difficult-to-treat photo-
dermatitis in contact with the skin)
*
Dieffenbachia Oxalic acid (acidosis, kidney injury)
*
Datura Atropine alkaloid (abused – excitation, hallucinati-
ons)
*
Belladonna Tropine and atropine alkaloids (even death due to 
respiratory paralysis)
*
European yew Buxamine alkaloid (spasmodic poison, vomiting, 
colic, muscle pain)
*
E u p h o r b i a 
(crown-of-thorns)
Irritating latex (skin, mucosa and eye irritation, 
even loss of vision)
*
Death cap Cyclic peptides amanitine and phalloidine (liver 
and kidney damage after 3 - 4 days)
*
Table 33.16. Examples
• A huge amount of various products are commonly used in households.
Product Comments
Potassium permanganate Available in the form of violet crystals under the name of HYPERMANGAN
Sodium hypochloride In detergents and bleaches such as SAVO
Rat poison Coloured granules (anticoagulant). 
Acids Lime-scale removers
Lyes Drain cleaners
Bluestone Copper(II) sulphate, protects plants against fungus, products such as KUPRIKOL
Table 33.17. Examples
33.7.7. Causes: Mix-Ups, Unlabelled or Wrongly Labelled Containers
One of the most frequent causes of poisoning is wrongly labelled or unlabelled containers. This leads to mistakes 
being made, often with tragic outcomes.
Examples:
Yellowish hydrochloric acid stored in a cognac bottle.
Trichloroethylene poured into a soda water bottle.
Also manufacturers often choose an inappropriate label design.
Product Photo
Drain cleaner (KRTEK) – sodium hy-
droxide (picture of a mole is attra-
ctive for children and the contents 
looks like a powdered soft drink)
Gel candles looking like drinks
(resemble a fruit jelly)
Table 33.18. Examples
70 - 90% of child poisoning cases occur in the home. Toddlers (1 - 3 years) are at the greatest risk as their motor 
skills develop, they can get where they could not get before, are inquisitive, and explore their surroundings by putting 
things into their mouths.
CHAPTER 34
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34.1. Hormone Tests for Ovarian and Testicular Disorders
Sex hormone or sex hormone metabolite testing forms an inherent part of gynaecological examinations, assisted 
reproduction, urology and endocrinology. Women are often tested for the diagnosis of infertility, menstrual cycle di-
sorders, and differential diagnosis of hirsutism and virilization. Sex hormone testing is a supplementary examination 
for male gonadal diseases, infertility and cancer of the male genito-urinary system. As regards children, the major in-
dication group is the differential diagnosis of hypogonadism and hyperfunction syndromes associated with symptoms 
of precocious puberty. Some specific aspects typical of this group have to be taken into account when testing sex hor-
mones. One should keep in mind that hormones are excreted in a circadian rhythm, frequently in the pulse. The phase 
of the woman’s current menstrual cycle also has to be taken into account. In addition, one should not ignore analytical 
differences in the reference values of each laboratory, so it is very advisable to use one laboratory for the tests and 
work only with the predefined, constant reference range within the relevant laboratory.
34.1.1. LH Tests
34.1.1.1. LH - Introduction
LH, luteinizing hormone or lutropin is a glycoprotein with a relative molecular weight of about 32 kDa, which is 
secreted through basophilic gonadotrophic cells of the anterior pituitary. Like the FSH, LH consists of an α-subunit com-
mon to some other anterior pituitary hormones, and a β-subunit specific to LH, which defines the biological and immu-
nological specificity of LH and makes it possible to distinguish the LH from other glycoprotein hormones. LH secretion 
is controlled by hypothalamic decapeptide GnRH produced in the hypothalamus, from where it is released in the pulse 
(every 30 - 60 minutes) through the portal venous system to the pituitary gland. LH secretion is regulated centrally by 
CNS neurotransmitters and also peripherally through the action of sex steroid hormones. LH secretion is thus affected 
by a complex mechanism of positive and negative feedback. LH receptors rank among a group of receptors coupled 
with adenylate cyclase activated by G-proteins. The function of LH is to act on ovarian theca cells where stimulation of 
steroid synthesis takes place. The steroids subsequently transform into oestradiol with the contribution of FSH. In ad-
dition, LH is responsible for the final maturation of ovarian follicles and also invokes ovulation and early development 
of the corpus luteum with subsequent progesterone secretion. In males, LH stimulates testosterone synthesis in Leydig 
cells in the interstitial tissue of the testicles. FSH and LH tests can be used as part of carving out a differential diagnosis 
between peripheral and central hypogonadism. LH and FSH levels are increased in peripheral hypogonadism (known 
as hypergonadotropic hypogonadism), while the levels are normal or more often decreased in central hypogonadism. 
Determination of the LH and FSH also plays an important role in diagnosing polycystic ovary syndrome where the FSH 
level decreases or is normal, and the LH level increases, so the LH/FSH ratio increases in contrast to healthy individuals.
34.1.1.2. Analytical Phase of LH Testing
The most suitable material for LH testing is blood serum, so sampling sets with accelerated haemocoagulation 
should be used for blood sampling. The menstrual cycle phase is important in fertile women, so the day of the cycle 
should be recorded. The sample must be transported to the laboratory on the day of sampling, and the material proce-
ssed within 8 hours of sampling. Tightly covered samples are stored at 7 ±5 °C no longer than 48 hours. Where longer 
storage is required, samples should be stored at -20 °C. Thawed samples should not be frozen again. The most common 
methods used for testing are RIA and CMIA.
34.1.1.3. Indications for LH Testing
Amenorrhoea, dysmenorrhoea, oligomenorrhoea, infertility, primary and secondary hypogonadism, conditions 
following cytostatic treatment or radiation, atypical sexual maturation in children, pituitary traumas and tumours, go-
nadal dysgenesis, selected chromosomal aberrations and hypothalamic-pituitary-gonadal axis disorders.
34.1.1.4. Reference Ranges
Gender Age, (phase of the menstrual cycle 
in women)
Reference ranges
Both genders 0 - 1 year 0.02 - 8 IU/l
both gender 1 - 10 years 0.04 - 3.9 IU/l
Males 10 - 15 years 0.56 - 7.8 IU/l
Males over 15 years 1.2 - 10 IU/l
Fertile women Follicular phase of the cycle 2 - 13 IU/l
Ovulation peak 15 - 80 IU/l
Luteal phase of the cycle 1 - 19 IU/l
Menopausal women 10 - 60 IU
34.1.1.5. Interpretation
34.1.1.6. Elevated levels
Primary ovarian insufficiency, Turner syndrome, climacterium praecox, gonadotropinomas, physiologically eleva-
ted values in the menopausal period, primary hypogonadism in males.
34.1.1.7. Reduced levels
Pituitary traumas and tumours, anorexia nervosa, secondary ovarian insufficiency, pseudopubertas praecox.
34.1.2. FSH Tests
34.1.2.1. FSH - Introduction
FSH, a follicle stimulating hormone or follitropin is a glycoprotein with a relative molecular weight of about 30 kDa, 
which is secreted by basophilic gonadotrophic cells of the anterior pituitary. The LH structure consists of two non-co-
valently bound subunits, α and β. The α-subunit is common to all glycoprotein hormones of the hypophysis (TSH, LH). 
The β-subunit is specific to the relevant hormone and defines its biological and immunological specificity. FSH produc-
tion is controlled by a complex mechanism of positive and negative feedback. FSH is secreted in the pulse through the 
action of secretion of the LH-FSH releasing hormone from the hypothalamus. FSH production is inhibited by inhibin, a 
dimeric glycoprotein from the family of cytokines. FSH receptors are also common to LH. These are snake-like recep-
tors coupled with adenylate cyclase by G-proteins. The function of FSH is to stimulate the growth and maturation of 
ovarian follicles; FSH together with LH support oestrogen secretion and participate in endometrium transformation in 
the proliferative phase of the menstrual cycle. When the ovarian follicles stop working during menopause, steroid pro-
duction decreases and feedback FSH secretion inhibition is slowly reduced. This is why FSH levels during menopause 
are markedly higher than FSH levels in the fertile period. The stimulation of Sertoli cells by the FSH helps maintain male 
spermatogenic epithelium, and affects the synthesis of inhibin and binding protein for androgens (SHBG) in seminife-
rous tubules. FSH and LH tests can be used for differential diagnosis of hypogonadism, i.e. to distinguish between the 
peripheral and central causes. LH and FSH levels are increased in peripheral hypogonadism (known as hypergonadot-
ropic hypogonadism), while the levels are normal or more often decreased in central hypogonadism. The LH and FSH 
assay is also important for diagnosing polycystic ovary syndrome where the FSH level decreases or is normal, and the 
LH level increases, so the LH/FSH ratio increases in contrast to healthy individuals.
34.1.2.2. Analytical Phase of FSH Testing
The most suitable material for FSH testing is blood serum, so sampling sets with accelerated haemocoagulation 
should be used for blood sampling. The menstrual cycle phase is important in fertile women, so the day of the cycle 
should be recorded. The sample must be transported to the laboratory on the day of sampling, and the material has to 
be processed within 8 hours of sampling. Tightly covered samples are stored at 7 ±5 °C no longer than 48 hours. Where 
longer storage is required, samples should be stored at -20 °C. Thawed samples should not be refrozen. Methods most 
commonly used for testing are RIA and CMIA.
34.1.2.3. Indications
Amenorrhoea, dysmenorrhoea, oligomenorrhoea, infertility, primary and secondary hypogonadism, conditions 
following cytostatic treatment or radiation, atypical sexual maturation in children, pituitary traumas and tumours, go-
nadal dysgenesis, selected chromosomal aberrations and hypothalamic-pituitary-gonadal axis disorders.
34.1.2.4. Reference Ranges
Gender Age, (phase of the menstrual cycle 
in women)
Reference ranges
Both genders 0 - 1 year 0.02 - 8 IU/l
Both gender 1 - 10 years 0.04 - 3.9 IU/l
Males 10 - 15 years 0.56 - 7.8 IU/l
Males over 15 years 1.2 - 10 IU/l
Fertile women Follicular phase of the cycle 2 - 13 IU/l
Ovulation peak 15 - 80 IU/l
Luteal phase of the cycle 1 - 19 IU/l
Menopausal women 10 - 60 IU/l
34.1.2.5. Interpretation
34.1.2.6. Elevated levels
Primary ovarian insufficiency, Turner syndrome, climacterium praecox, gonadotropinomas, physiologically eleva-
ted values in the menopausal period, primary hypogonadism in males.
34.1.2.7. Reduced levels
Pituitary traumas and tumours, anorexia nervosa, secondary ovarian insufficiency, pseudopubertas praecox.
34.1.3. Sex Hormone-Binding Globulin (SHBG) Tests
34.1.3.1. Introduction
SHBG or sex hormone-binding globulin is a protein with a molecular weight of 90 kDa, which consists of two sub-
units, is produced in the liver and has a biological half-life of about 7 days. SHBG can be found in the zone of β-globulins 
when tested by electrophoresis. The main function of SHBG is to transport steroid hormones to target cells within the 
entire body. The transport in the SHBG-hormone complex is applied primarily in the transportation of testosterone, 
oestradiol, oestriol, oestrone, dehydroepiandrosterone (DHEA) and 5-dihydrotestosterone (DHT). Due to the high affi-
nity of hormones to SHBG, about 98% of circulating hormones are bound to this protein. As the affinity of hormones 
to SHBG is about 100 times higher than their affinity to albumin, hormones bound to albumin are more easily available 
to the target cells.
34.1.3.2. Analytical Phase
The most suitable material for SHBG testing is blood serum, so sampling sets with accelerated haemocoagulation 
should be used for blood sampling. Blood should be sampled on an empty stomach. The sample must be transported 
to the laboratory on the day of sampling, and the material processed within 8 hours of sampling. Tightly covered sam-
ples are stored at 7 ±5 °C no longer than 48 hours. Where longer storage is required, samples should be stored at -20 
°C. Thawed samples should not be refrozen. Methods most commonly used for testing are RIA and ECLIA - electroche-
miluminescence immunoassay.
34.1.3.3. Indications
Hyperandrogenism; the assay is also recommended for cases of high or low clinically mute testosterone levels. The 
SHBG assay is important for testosterone free index calculation (see 2.3.6 TFI Index).
34.1.3.4. Reference Ranges
Gender Age Reference ranges
Males 18 - 60 years 14.5 - 48.4 nmol/l
Females 18 - 55 years 26.1 - 110 nmol/l
Post - menopausal women (without 
hormone substitution)
14.1 - 68.9 nmol/l
34.1.3.5. Interpretation
34.1.3.6. Elevated levels
Hyperthyroidism, use of hormonal contraceptives and anti-epileptic drugs, physiologically during pregnancy and in 
elderly males, hepatic cirrhosis, hepatitis.
34.1.3.7. Reduced levels
Obese patients, hypothyroidism, elevated androgen levels, alopecia, polycystic ovaries, hirsutism.
34.1.3.8. TFI Index
Determination of SHBG is important for calculating the testosterone free index (TFI index), which provides better 
information as to the potential increase in the biologically active free testosterone fraction.
TFI = Testosterone (nmol/l) / SHBG (nmol/l)
34.1.4. Testosterone Tests
34.1.4.1. Introduction
Testosterone is one of the principal male sex hormones. This hormone has a molecular weight of 288.4 kDa. Tes-
tosterone synthesis starts by creating pregnenolone from cholesterol in a reaction catalyzed by 20α-hydroxylase. Tes-
tosterone is produced in males under the influence of the luteinizing hormone in Leydig cells of the testicles; the main 
testosterone producing organ in females are the ovaries, and smaller amounts are also produced in the adrenal cortex. 
However, on a daily basis females produce only about 5 - 10% of the amount produced by males. Circulating testoste-
rone has three different forms. There is a small amount (1 - 2.5%) of free testosterone, a fraction bound by a weak 
bond to albumin, and the last fraction forms a strong bond to SHBG. The different strengths of the testosterone-protein 
bond also define the biological availability of testosterone. This is why the weak testosterone-albumin bond and the 
free testosterone fraction form bioavailable testosterone. Testosterone levels exhibit large age and gender-dependent 
differences during development. Testosterone levels in male newborns are slightly higher than levels found in female 
newborns after childbirth. For the next three months, testosterone levels rise and then decrease in boys until the end 
of the first year, although the levels are slightly higher compared with girls. At the age of 6 - 7, the onset of puberty is 
connected with nocturnal pulses of LH, which lead to an increase in testosterone levels. Increased testosterone level 
in this period is important for proper development of secondary sex characteristics and bone density. At the age of 
16 - 19, puberty is complete; testosterone levels become stabilized and remain about the same throughout adult age. 
At about 50 years of age, testosterone slowly decreases in males, but there are great interindividual differences. This 
decrease is responsible for lower sexual activity and lower physical performance. This condition is referred to as the 
andropause, a condition equivalent to the female menopause. Like most other sex hormones, testosterone exhibits a 
diurnal rhythm, with morning levels about 25 - 30% lower than evening levels. Male testosterone is responsible for the 
development of secondary sex characteristics, voice, affects bone density and muscle mass, and plays a unique role 
in sexual functions and libido. Female testosterone affects the growth of pubic and axillary hair, and affects libido like 
male testosterone. Pathologically decreased testosterone level is responsible for the condition called hypogonadism, 
which comprises 3 large subgroups: Hypogonadotropic hypogonadism, hypergonadotropic hypogonadism and “tes-
ticular feminization syndrome”. Hypogonadotropic (secondary) hypogonadism is due to decreased function of intact 
gonads, most often caused by congenital or acquired panhypopituitarism, GnRH deficiency, hyperprolactinaemia, mal-
nutrition or anorexia nervosa. Decreased LH and FSH levels are typical. Hypergonadotropic (primary) hypogonadism 
is caused by gonad dysfunction, and patients have higher LH and FSH levels. Causes of hypergonadotropic hypogona-
dism include gonad injury (radiation, diseases, developmental defects, tumours, drugs), poor gonad development in 
patients with chromosomal aberrations, and enzyme defects of androgen synthesis. Testicular feminization syndrome 
is caused by an androgen receptor defect; afflicted individuals are feminine in appearance, whose genitals consist of 
a blind-pouched vagina and present testicles. Testosterone levels in these patients are normal or slightly heightened. 
High testosterone levels in females cause virilization characterized by typical enlargement of the clitoris and excess 
body hair connected with increased proliferation of and secretion from sebaceous glands. Acne, facial hair growth and 
deepening of the voice are also often present.
34.1.4.2. Analytical Phase
The most suitable material for testing testosterone is blood serum, so clean sampling sets or sampling sets with 
accelerated haemocoagulation should be used for blood sampling. The sample has to be transported to the laboratory 
on the day of sampling, and the material has to be processed within 8 hours of sampling. Samples can be stored at 2 - 
8 °C for 2 days, or frozen to -20 °C for longer periods of storage (1 month). Thawed samples may not be refrozen. The 
most commonly used methods for testing are RIA and CMIA.
34.1.4.3. Indications
Males: Hypogonadism, infertility, diff. dg. of pubertas paecox in boys, replacement therapy monitoring.
Females: Androgenic conditions, hirsutism, menstrual disorders, acne.
34.1.4.4. Reference Ranges
Gender Age Reference ranges
Males 15 - 60 years 10 - 30 nmol/l l
Males over 60 years 0 - 10 nmol/l
Females over 15 years 0.15 - 2.6 nmol/l
34.1.4.5. Interpretation
34.1.4.6. Elevated levels
Short-term intensive physical strain, tumours of the testes and ovaries, adrenal tumours, use of anabolic agents.
34.1.4.7. Reduced levels
Enzyme defects of testosterone synthesis, primary and secondary hypogonadism, long-term physical strain, drug 
abuse, liver disease, drugs such as ketoconazole, Klinefelter syndrome.
34.1.5. Progesterone Tests
34.1.5.1. Introduction
Progesterone is a C
21
 steroid hormone (molecular weight: 314.5 kDa) produced by the corpus luteum, placenta 
and small amounts also by ovarian follicles and the adrenal cortex. It is an important intermediary product in steroid 
hormone biosynthesis in all steroidogenic tissues, and small amounts are transferred to the blood in the testicles and 
in the adrenal cortex. Circulating progesterone occurs in a free form (about 2% of the total amount) as well as in a 
form bound to albumin (18% of total progesterone) or SHBG (80% of total progesterone). Progesterone has a relatively 
short half-life. The first step of inactivation is chemical reduction, in which the following substances may be formed 
depending on the degree of reduction: 1) pregnanediones, 2) pregnanolones and 3) pregnanediols. These reduced 
compounds subsequently conjugate with glucuronic acid and are excreted in urine as water-soluble glucuronides. Pro-
gesterone secretion is primarily regulated by the luteinizing hormone. Progesterone levels are low in the second half 
of the follicular phase of the menstrual cycle, however levels dramatically increase during the luteal phase, i.e. 6 - 8 
days after ovulation, i.e. on the 20th to 22nd day of the menstrual cycle. Progesterone reaches its peak values from 30 to 
65 nmol/l. This rise in progesterone is caused by secretion from the corpus luteum. If fertilization does not occur, the 
levels subsequently decrease. In the case of fertilization, progesterone secretion from the corpus luteum is maintained 
by human choriogonadotropin. As the pregnancy progresses, progesterone is also produced in the placenta. The most 
important target organs for progesterone are the uterus, breasts and the brain. Progesterone in the uterus stimulates 
vascularization of the endometrium; endometrial glands become coiled and produce serous secretion. As soon as 
corpus luteum regression occurs, hormonal stimulation of the endometrium declines and the endometrium turns into 
the menstrual phase. Progesterone has an anti-oestrogenic effect on myometrium cells, reduces their irritability and 
sensitivity to oxytocin, which is why it is essential for maintaining pregnancy. Progesterone in the breasts stimulates 
the development of lobules and alveoli. Progesterone supports differentiation of duct tissue ready for oestrogens and 
supports the secretory function of lactating breasts. Due to its thermogenetic effect, progesterone also causes an in-
crease to the basal temperature.
34.1.5.2. Analytical Phase
The most suitable material for progesterone testing is blood serum, so sampling sets with accelerated haemocoa-
gulation should be used for blood sampling. The menstrual cycle phase is an important factor in fertile women, mea-
ning the day of the cycle should be recorded. The sample must be transported to the laboratory on the day of sampling, 
and the material processed within 8 hours of sampling. Tightly covered samples are stored at 7 ±5 °C no longer than 48 
hours. Where longer storage is required, samples should be stored at -20 °C. Thawed samples should not be refrozen. 
The most commonly used methods for testing are RIA and CMIA.
34.1.5.3. Indications
Infertility, evaluation of the corpus luteum function, ovulation cycle demonstration.
34.1.5.4. Reference Ranges
Gender Age Reference ranges
Both genders 0 - 10 years 0.2 - 1.7 nmol/l
Males 10 - 15 years 0.3 - 4.3 nmol/l 
Males over 15 years 0.89 - 3.88 nmol/l
Females 10 - 15 years 0.3 - 41 nmol/l
Females over 15 years 0.48 - 89.14 nmol/l
34.1.5.5. Interpretation
Progesterone levels reach their maximum 6 to 8 days after ovulation. This rise is subject to the secretion of pro-
gesterone from the corpus luteum, i.e. proving that ovulation occurred. If progesterone levels are under 25 nmol/l 
on these days, it is a sign that most likely there was no ovulation. Lower progesterone levels produced by the corpus 
luteum may also be a sign of luteal phase deficiency (LPD) associated with infertility and early spontaneous abortions. 
Women on oral contraceptives have decreased progesterone levels.
34.1.6. Oestradiol Tests
34.1.6.1. Introduction
Oestradiol is one of the most biologically active substances from the group of female steroid hormones responsible 
for developing and maintaining female sex organs and secondary sex characteristics. In conjunction with progesterone, 
oestradiol plays a role in the menstrual cycle, breast and uterus development, and is involved in maintaining pregnan-
cy, when oestradiol concentration steadily grows. Oestrogens also play a role in calcium homeostasis and support good 
bone density. A long-term decline in oestrogens therefore leads to bone density reduction with consequent osteopo-
rosis. Oestrogens also have a protective effect on lowering cardiovascular risk, because they increase the catabolism 
of circulating LDLs, probably by increasing the number of LDL receptors in the liver. Healthy women produce the most 
part of oestradiol in the ovarian follicle and corpus luteum, and in the placenta during pregnancy. Small amounts of 
oestradiol are also produced in the adrenal cortex and male testicles. Unlike the testicles, ovaries have a highly active 
aromatase system, which quickly converts androgens such as testosterone into oestrogens. More than 20 oestrogens 
are known today, however laboratory tests may be clinically used for 17β-oestradiol and oestriol only. Plasma oestra-
diol concentration has two peaks of secretion: one immediately before ovulation and the second in the middle of the 
luteal phase. The rate of oestradiol secretion is 36 μg/day (133 nmol/day) during the early follicular phase, 380 μg/day 
immediately prior to ovulation and 250 μg/day in the middle of the luteal phase. It is the high levels prior to ovulation 
that affect LH secretion at the pituitary level, leading to massive secretion of the LH which triggers ovulation. Oestrogen 
secretion drops down to low levels after the menopause. At least 97% of oestradiol circulating in the blood plasma is 
bound to plasma proteins such as SHBG and albumin. The main site of oestrogen inactivation is the liver, where oest-
rogens are subject to hydroxylation, oxidation, reduction and methylation to form oestrone, which further conjugates 
with glucuronic acid to form water-soluble glucuronides excreted in urine. The function of oestrogens consists of en-
dometrium proliferation stimulation. The uterine mucus gets thinner and more alkaline due to oestrogens, which are 
changes helping the sperm survive and move, enlarge uterine muscle mass and increase the content of contractile pro-
teins. Oestrogens make the uterine muscle more active and sensitive; action potentials propagate in individual fibres, 
increasing uterine sensitivity to oxytocin.
34.1.6.2. Analytical Phase
A test tube with accelerated haemocoagulation or lithium heparin. The sample must be transported to the labo-
ratory on the day of sampling, and the material processed within 8 hours of sampling. If samples are not processed 
within 8 hours of sampling, they should be stored tightly covered at 7 ± 5 °C no longer than 48 hours. Where longer 
storage is required, samples should be stored at -20 ± 5 °C. Thawed samples must not be refrozen. The most commonly 
used methods for testing are RIA and CMIA.
34.1.6.3. Indications
Males: Differential diagnosis of gynaecomastia; can also be used as a tumour marker in germinal tumours of tes-
ticles, choriocarcinoma, hepatoma and oestradiol-producing adrenal tumours.
Females: Monitoring of ovulation induction and ovarian hyperstimulation, diff. dg. of ovarian insufficiency, men-
strual cycle disorders; can also be used as a tumour marker in germinal tumours of testicles, choriocarcinoma, hepato-
ma and oestradiol-producing adrenal tumours.
34.1.7. Reference Ranges
Gender Age, (phase of the menstrual cycle 
in women)
Reference ranges
Males All age groups 29 - 94 pmol/l
Females Follicular phase of the cycle 46 - 607 pmol/l
Ovulation phase 315 - 1,828 pmol/l 
Luteal phase 161 - 774 pmol/l
Post-menopausal period <201 pmol/l
34.1.7.1. Interpretation
34.1.7.2. Elevated levels
Oestrogen-producing tumours, slight increase in hepatic cirrhosis and obesity.
34.1.7.3. Reduced levels
Primary ovarian insufficiency, anovulatory cycles, corpus luteum insufficiency.
34.1.8. Dehydroepiandrosterone Sulphate - DHEAS
34.1.8.1. Introduction
Dehydroepiandrosterone sulphate (DHEA-SO
4, 
DHEA-S) is a steroid hormone secreted physiologically exclusively in 
the adrenal gland, only a small part comes from male testicles. Given the sole production of this steroid hormone in 
the adrenal gland, increased DHEAS levels are a major indicator of adrenal pathology. DHEAS only has slight androgenic 
effects, however may metabolize to stronger androgens such as androstendione and testosterone, thus indirectly cau-
sing hyperandrogenism in hirsutism or virilization. DHEAS concentrations start to increase at the beginning of puberty, 
at about 6 - 7 years of age, when the entire complex of changes is initiated by the presence of nocturnal pulses of LH. 
DHEAS production becomes reduced from the age of about 30. Increased DHEAS levels in women with signs of virilizati-
on or hirsutism allow us to distinguish between adrenal and ovarian causes of hirsutism or virilization. Higher DHEAS 
levels are caused by adrenal system pathology, e.g. adrenal tumours, bilateral adrenocortical hyperplasia or congenital 
adrenal hyperplasia connected with 21-hydroxylase, 11β-hydroxylase or 3β-HSD deficiency.
34.1.8.2. Analytical Phase
A test tube with accelerated haemocoagulation. The sample has to be transported to the laboratory on the day of 
sampling, and centrifuged after delivery to the laboratory. The sample has to subsequently be processed within 8 hours 
of sampling. If samples are not processed within 8 hours of sampling, they should be stored tightly covered at 7 ± 5 
°C no longer than 48 hours. Where longer storage is required, samples should be stored at -20 ± 5 °C no longer than 2 
months. Thawed samples must not be refrozen.
The most commonly used methods for testing are RIA and ECLIA.
34.1.8.3. Indications
Differential diagnosis of hirsutism and virilization, suspected adrenal tumour, congenital adrenal hyperplasia.
34.1.8.4. Reference Ranges (in µmol/l)
Gender Age, (phase of the menstrual 
cycle in women)
Reference ranges
Both genders Day 0 - 7 2.93 - 16.50
Both gender Day 7 - 28 0.86 - 11.70
Both genders Day 28 - 365 0.09 - 3.35
Both genders 1 - 5 years 0.01 - 0.53
Both genders 5 - 10 years 0.08 - 2.31
Males 10 - 15 years 0.66 - 6.70
Males 15 - 20 years 1.91 - 13.40
Males 20 - 25 years 5.73 - 13.40
Males 25 - 35 years 4.34 - 12.20
Males 35 - 45 years 2.41 - 11.60
Males 45 - 55 years 1.20 - 8.98
Males 55 - 65 years 1.40 - 8.01
Males 65 - 75 years 0.91 - 6.76
Males 75 - 150 years 0.44 - 3.34
Females 10 - 15 years 0.92 - 7.60
Females 15 - 20 years 1.77 - 9.99
Females 20 - 25 years 4.02 - 11.00
Females 25 - 35 years 2.68 - 9.23
Females 35 - 45 years 1.65 - 9.15
Females 45 - 55 years 0.96 - 6.95
Females 55 - 65 years 0.51 - 5.56
Females 65 - 75 years 0.26 - 6.68
Females 75 - 150 years 0.33 - 4.18
34.1.8.5. Interpretation
34.1.8.6. Elevated levels
Adrenal tumours, bilateral adrenocortical hyperplasia or congenital adrenal hyperplasia, polycystic ovary syndro-
me.
34.1.8.7. Reduced levels 
Adrenal cortex insufficiency.
34.1.9. AMH Testing
34.1.9.1. Introduction
Anti-Müllerian hormone is a dimeric glycoprotein from the cytokine class XVI, which includes other inhibin and 
activin glycoproteins that play an important role in the growth and differentiation of tissues. The AMH molecule conta-
ins 2 monomeric units linked by disulphide bridges, forming a unit with a molecular weight of 72 kDa. The gene coding 
human AMH is located on the short arm of chromosome 19. The AMH is produced in male Sertoli cells of the testicles, 
and females produce the AMH only in the postnatal period in ovarian granulosa cells. As the name of the AMH makes 
clear, the AMH regulates sexual differentiation of a male foetus. Specifically, the role of this hormone is to induce and 
maintain physiological regression of Müllerian ducts, which is completed in about the 9th week of intrauterine develop-
ment. It is the absence of the AMH, which is essential in the development of female sex organs in the female embryo. 
The AMH has no function in adult males, so the AMH level remains relatively low. However, the situation is different 
in adult females. It has been proved that the AMH inhibits primordial follicle formation and inhibits the sensitivity of 
growing follicles to the FSH at the same time. It has been proven that the AMH level is therefore directly proportional 
to the number of antral follicles and is a very good indicator of ovarian reserve.
34.1.9.2. Indications
Differential diagnosis of intersexual conditions, tumours of Sertoli cells of the testes, gonadal dysgenesis, tumours 
of ovarian granulosa cells, polycystic ovary syndrome, disorders of metabolism and testosterone production, diff. dg. 
and therapy of infertility, tests for IVF.
34.1.9.3. Analytical Phase
The AMH can be tested in human serum or plasma. Blood is therefore collected into test tubes without additives 
or test tubes with a gel separator, lithium heparin or EDTA. The sample must be transported to the laboratory on the 
day of sampling, and centrifuged after delivery to the laboratory. The serum or plasma samples can then be stored at 
2 - 8 °C for 24 hours. Where longer storage is required, samples should be frozen at < -18°C. The test method is enzyme 
immunoassay (EIA), for example.
34.1.9.4. Reference Ranges
Sample – Serum Median Age Reference Interval (µg/L)
Boys 4.8 3.8 - 160
Girls 5.0 ND - 8.9
Males 38 1.3 - 14.8
Females 30 ND - 12.6
Post-menopausal females 71 ND
Note: ND - Not Detected; the values were taken over from the instructions for use of the Beckman Coulter AMH gen II 
ELISA assay.
34.1.9.5. Interpretation
34.1.9.6. Elevated levels
Tumours of Sertoli cells of the testes, tumours of ovarian granulosa cells, polycystic ovary syndrome, testicular 
dysgenesis, testotoxicosis in boys, some biosynthesis disorders and androgen insensitivity syndromes.
34.1.9.7. Reduced levels
Cryptorchidism, anorchia, testicular dysgenesis, precocious menopause.
34.1.10. Inhibin Tests
34.1.10.1. Introduction
Inhibins belong to the cytokine class XVI. These glycoproteins have a unique function in human reproductive phy-
siology. The basis of the molecule of both inhibin types is a glycosylated α-subunit with a molecular weight of 18,000, 
and a non-glycosylated subunit βA for inhibin A and βB for inhibin B. Both β-subunits are coupled with the α-subunit 
by means of disulphide bridges. Inhibins can also be found in the complex with binding proteins follistatin or α2-
macroglobulin. The activin-follistatin bond affects its biological and immunochemical activity. Inhibins are produced in 
female granulosa cells within the follicle and in male Sertoli cells of the testes.
34.1.10.2. Inhibin A
The inhibin A molecule is a heterodimer consisting of two subunits, α a β
A
. This inhibin is produced primarily in ova-
rian granulosa cells, in the placenta during pregnancy, and small amounts in male Sertoli cells of the testes. The major 
function of inhibin A is feedback FSH secretion inhibition, although inhibin B is the major inhibitor. Inhibin A is used in 
clinical practice for trisomy 21 diagnosis. If included in the prenatal screening with AFPm hCG and non-conjugated E3, 
Down syndrome detection rate increases by up to 20%. Other potentially useful indications for inhibin A investigations 
are include diagnosis for pre-eclampsia, premature birth and the differential diagnosis of infertility. Inhibin A may also 
be used as a marker of embryo transfer in IVF.
34.1.10.3. Inhibin B
The inhibin B molecule structure is the same as that of inhibin A, it only contains βB-subunit instead of βA-subunit. 
The main site of hormone production of this type in males is Sertoli cells of the testes, but recent research has shown 
that Leydig cells are also capable of producing inhibin subunits, especially after the end of sexual maturation. This fact 
is also confirmed by studies in which inhibin B levels increased following administration of recombinant FSH to hypo-
gonadotropic males. The main role of this hormone is to regulate gametogenesis influenced by feedback mechanism 
by means of the FSH. Inhibin B is produced in females primarily in small antral follicles, which corresponds to the fact 
that inhibin B is a sensitive marker of the current number of follicles of the ovarian reserve. This is why inhibin B investi-
gations are very important in the differential diagnosis of infertility and is a good marker of precocious menopause at 
the same time. Inhibin B investigations are clinically important in males for the recognition of bilateral cryptorchidism 
and anorchia, in the diagnosis of Sertoli cell tumours and the differential diagnosis of infertility and pubertas praecox.
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35.1. Introduction
Drugs act at different levels: at the level of the entire organism, at the level of organs and tissues and at the level 
of cells and molecules. The determining factor of pharmacological action is drug concentration at the site of action. 
The aim is to create an objective basis for rational drug dosing and also for individual treatment, taking the individual 
differences of patients into account. Making an effort to adjust doses to individual needs is very important in ensuring 
effective treatment and reducing the rate of adverse drug effects.
Most drugs show a characteristic relation between the dose and the effect. A more detailed analysis has shown 
that the intensity of the pharmacological action of drugs better correlates with the drug concentration in system cir-
culation than the drug dose. These basic premises are essential for Therapeutic Drug Monitoring (TDM), aimed at the 
clinical use of the measured drug concentration in the body with the objective of adjusting the dose individually. Indi-
vidual dose adjustment relies on reaching the specific concentration of the target drug. This reduces the main source 
of drug concentration variability caused by individual differences in pharmacokinetics at the level of each patient and 
in the relevant group of patients.
The aim is to understand more precisely the pharmacokinetics and pharmacodynamics of a drug in individual pa-
tients (Figure 38.1). Drug concentrations do not have to be measured in situations where easy clinical monitoring of 
the drug effect is possible (antihypertensive drugs, analgetics, hypnotic drugs) or simple laboratory tests are available 
(anticoagulants, hormones, hypolipidemic agents).
Figure 35.1. Processes after drug administration
35.2. Indications for Drug Level Determination
The following properties are drug characteristics suitable for monitoring:
• Narrow therapeutic width
• Risk of toxicity
• High interindividual variability
• Steep dependence between the dose and the effect
• Concentration-effect relationship is closer than the dose-effect relationship
• Non-linear pharmacokinetics
TDM is beneficial for the patient in the following cases:
• Elimination of patient non-compliance
• Changes during physiological conditions (pregnancy, childhood, old age)
• Changes during pathological conditions (fever, renal, hepatic or cardiac failure)
• Drug interactions
TDM is currently used for the following groups of drugs:
• Antibiotics – aminoglycosides (gentamicin, amikacin), vancomycin
• Bronchodilatants – theophylline
• Antiepileptics – phenobarbital, primidone, phenytoin, ethosuximide, carbamazepine, valproic acid, clona-
zepam, lamotrigine, topiramate, levetiracetam
• Cytostatics – methotrexate, busulfan
• Cardiacs – amiodarone, digoxin
• Immunosuppressive drugs – cyclosporin A, tacrolimus, sirolimus, everolimus, mycophenolate
• Psychoactive drugs – lithium, diazepam, antidepressants, antipsychotics
 In certain cases it is advisable to determine the basic metabolite of the parent active substance:
• Carbamazepine – 10,11 epoxycarbamazepine
• Primidone – phenobarbital
• Amiodarone – desethylamiodarone
• Diazepam – desmethyldiazepam
• Metoprolol – hydroxy metoprolol
TDM has been performed on a routine basis since the mid-1970s as part of the concept of clinical pharmacology 
as an independent branch together with the fundamental principles of pharmacokinetics and pharmacodynamics. In 
1967, Baastrup and Schou demonstrated the relationship between the concentration and pharmacological effect of 
lithium, and Buchtal described the relationship between the plasma concentration of phenytoin and frequency of sei-
zures in patients being treated for epilepsy in 1960.
35.2.1. TDM in Practice 
TDM in practice comprises three basic parts: The analytical determination of drug concentration, usually by im-
munoassays or chromatographic methods. Immunoassays are more commonly used, and include homogeneous met-
hods (no need to separate the bound indicator) and nonhomogeneous, mostly competitive methods of determination. 
There are many benefits to immunoassays including simple handling of the sample without the need to extract the 
sample. Regular instruments found in a biochemical laboratory can be used. Homogeneous immunoassays can be 
performed on biochemical analyzers with photometric detection and heterogeneous immunoassays on immunoassay 
analyzers from different manufacturers. Drug concentrations can be determined in the random access mode, also for 
a whole series of samples for pharmacokinetics profiles. The drawback of immunoassays is certain overestimation of 
the drug concentration due to the cross reaction of metabolites, which invariably occur when the administered drug is 
metabolized and are present in the systemic circulation. The structure of metabolites is often very similar to the parent 
substance, so they can bind to the detection antibody used in the immunoassay, which leads to overestimation of the 
concentration found. However, this does not matter in many cases.
Chromatographic methods primarily use gas chromatography (GC) and high-performance liquid chromatography 
(HPLC) with different types of detection, recently with the detector based on mass spectrometry, which makes it 
possible to detect not only the administered parent substance but sometimes also major metabolites of the adminis-
tered drug.
The next step is drug concentration interpretation, sometimes with pharmacokinetic analysis. The laboratory re-
sult is interpreted by the clinical pharmacologist (clinical biochemist); the numerical result is supplemented by recom-
mendations to the clinician concerning dose or dosing interval (schedule) adjustment.
Feedback between the clinician and the result interpretation is essential, since acceptance of the recommendati-
ons and further follow-up based on this recommendation ensures a change of the dosing and rational pharmacothera-
py. Failure to take heed of the recommendation and merely inserting the result to the medical record only brings about 
unnecessary increases to the overall cost of treatment.
35.2.2. Information Required for TDM
Samples of blood for testing drugs which create stable levels (drugs with a long elimination half-life) should be 
taken before administering the next dose. Cyclosporin A is such drug. Testing digoxin level is recommended 6-11 hours 
after administration, at which point blood digoxin concentration better reflects the levels in the myocardium. In any 
case, it is necessary to wait until equilibrium has been reached. Equilibrium has been reached provided the time equal 
to 4-5 elimination half-lives has passed since the beginning of administration.
The concentration of drugs, the level of which changes quickly (drugs with a short elimination half-life), is deter-
mined: 
• Before administration – basal value (trough value) - t
0 
• After administration when the maximum concentration is reached (peak value) - t
max
The route of administering the drug is also important – maximum concentration in the blood following i.v. appli-
cation is reached within 30 minutes, following i.m. application in an hour, following oral administration even after a 
longer time depending on the pharmaceutical form of the drug administered (tablets, capsules, matrix tablets, film-
-coated tablets with extended release, etc.). The entire dose is absorbed after i.v. application, while different portions 
are absorbed after oral administration, and depend on the type of the drug, galenical form of the drug and condition 
of the GIT.
Correct interpretation in terms of the concentration of the drug thus requires filling in a lot of information on the 
request for laboratory analysis:
Information about the drug type and form
• Dose history, current dose, compliance, length of therapy
• Patient’s condition (age, weight, height, organ functions)
• Time of administering the dose and time of blood sampling
• Type of biological material (blood, plasma, serum)
• Medication history (concurrently administered drugs)
35.2.3. Pharmacokinetic Analysis
Pharmacokinetics is the study of the fate of drugs in the body including drug absorption, distribution, biotransfor-
mation (metabolism) and elimination. These processes can be described by mathematical methods and a pharmacoki-
netic analysis can be used to determine the pharmacokinetic parameters. Pharmacokinetic information acquired when 
registering the drug registration and further information gained at subsequent stages of clinical testing form the basis 
to understand the parameters of the population pharmacokinetic curve for the relevant drug and its pharmaceutical 
form. It is possible to compare this information to even just one measured drug concentration for the examined pati-
ent. Together with the drug type, the measured drug concentration, dose, time of administration and time of biological 
sample collection, patient’s weight and age and other data are entered onto a special computer program, which evalu-
ates whether the measured concentration complies with the average population pharmacokinetics.
In the event unexpected concentrations are found, it is necessary to consider whether the wrong dose has been 
taken, drugs have interacted with one another, the drug has been used inappropriately, whether absorption disorders 
are present, collection took place at the wrong time, kidney and liver disease are present, there has been a change in 
the strength of the bond to serum proteins or the possibility of patient non-compliance (use of a higher or lower dose).
35.2.4. Target Drug Concentration Range
If the measured values do not range within certain therapeutic limits and there is no doubt that all the entered data 
is correct, the program allows for a change of dose to be simulated or for the dosing interval to comply with require-
ments for optimum method of treatment.
The drug concentration should be within the target range. The concept of the target drug concentration range 
(replaces the older term “therapeutic range”) is based on two concepts – the minimum effective concentration and 
maximum safe concentration for the relevant medicine. Values between these concentrations represent the maximum 
therapeutic effect and at the same time a minimum risk of toxicity and side effects for most patients. Regrettably, this 
simple theory does not have to be fully valid in all aspects and the target range has to be always connected with, not 
replaced by, a clinical assessment of the patient’s condition. The objective is not to reach the “target range” but to treat 
patient’s health problems.
Figure 35.2. An intravenous dose of 0.125 mg of digoxin was administered to a patient (65 years) over a period of 24 
hours. The digoxin level prior to administration was low – 0.36 ng/ml. Digoxin levels were normal 1 hour after administra-
tion. Prepared by the MW-PHARM program for pharmacokinetic analysis.
35.3. ADTM (Advanced Therapeutic Drug Monitoring)
Further development in this area leads to ADTM, which introduces the determination of free (pharmacologically 
effective) drug fraction, metabolites of the drug, determination of drug concentration in target tissues (e.g. immuno-
suppressive drugs in lymphocytes), and each patient is tested while taking into account genetic and phenotype pre-
dispositions for the metabolism of each drug group.
35.3.1. Biotransformation of Drugs
The study of administered drug movement within the body also includes the monitoring of processes which chan-
ge the structure of the drug. The number of medicines in use is big yet their biotransformation in the body is based 
on a relatively small number of reactions. The aim is to create more hydrophilic, more polar metabolites, excreted 
from the body more easily than the original lipophilic substance. It is important to have knowledge regarding enzymes 
producing biotransformation activity localized primarily in the endoplasmic reticulum and cytosol of the cell. A greater 
part of biotransformation oxidation reactions is catalyzed by the cytochrome P450 monooxygenase system. Although 
more than 50 different cytochrome P450 proteins have been described in humans, drugs are metabolized primarily 
using five to six major enzymatic pathways. The main forms of cytochrome in the human liver are CYP2D6, CYP1A2, 
CYP2A6, CYP2C9, CYP2E1 and CYP3A4.
The capability of the body to metabolize and eliminate the drug is often affected by the genetic predisposition of 
the body. About 40% of drugs are eliminated using a genetically polymorphic pathway, of which cytochrome P450 2D6 
(CYP2D6) is the most important. Metabolic pathway polymorphism means that the population includes individuals in 
which the relevant enzymatic activity is inactive (poor metabolizers – PMs), individuals with incomplete enzyme acti-
vity deficiency (intermediate metabolizers – IMs) and a group of extensive metabolizers (EMs) with normal metabolic 
transformation activity. For enzyme 2D6 cytochrome P450 there is also a group of ultrarapid metabolizers (UMs), i.e. 
people with unusually high CYP2D6 metabolic pathway activity.
If usual drug doses are administered, poor metabolizers accumulate the substances. High drug concentrations in 
target tissues may manifest themselves as toxic and adverse effects of drugs. Conversely, ultrarapid metabolizers do 
not reach equilibrium and drug concentrations in target tissues may be lower than minimal effective concentrations. 
This is why these people are resistant to common therapeutic dosages.
 
Figure 35.3. Diagram of correct therapeutic drug monitoring
35.4. Pharmacogenetics – Polymorphism – Genotype – Phenotype
Some promising methods focus on discovering genetic polymorphism in drug metabolism based on gene mutati-
ons. Phenotype and genotype are determined in vivo. The genotype can be determined by DNA analysis using the PCR 
(polymerase chain reaction). The analysis is based on restriction fragment length polymorphism (RFLP). DNA is cleaved 
to the fragments by endonucleases at the site of the sequence of bases specific to each enzyme.
Pharmacogenetics not only attempts to describe these determinants but also use this knowledge to personalise 
therapy and predict metabolic transformation and the patient’s response to the specific drug. Present knowledge im-
plies that many other external factors are decisive for current metabolic activity (phenotype) in addition to the geno-
type of cytochrome P450 forms. These factors involve processes of metabolic induction and inhibition of metabolizing 
enzymes triggered by other concurrently administered drugs or food components. An important role in internal factors 
is played by diseased conditions such as hepatic cirrhosis, which lead to the reduced synthesis of many enzymes. The 
resulting metabolic activity of each enzyme – drug metabolism phenotype – is tested using model substrates (Table 
38.1).
CYP4503A2D62C92C191A2
midazolamdextromethor-
phan
losartanomeprazolkorein
Model substancessimvastatindebrisochintolbutamidmetfenytointeofylin
chininmetoprololdiklofenak
Table 35.1. Examples of specific substrates (model substances) for determining metabolic activity 
The principle of phenotype determination comprises administering a substance, which is a highly specific substrate 
for the tested enzyme. The rate of model substance biotransformation has to depend primarily on the enzyme activity 
studied, not on the flow rate of blood through the liver. The parent substance/metabolite ratio is decisive for putting 
the tested subject to the relevant group referred to as “poor metabolizers” or “extensive metabolizers”.
For more details about pharmacogenomics and genetic polymorphism of selected enzymes, see Chapter 39, Trends 
in Laboratory Medicine, Section 4.6. Pharmacogenomics.
35.5. Personalized Pharmacotherapy
Clinical pharmacology utilizes results of phenotyping and genotyping to detect interindividual differences in drug 
metabolism, which contributes to treatment optimization and a lower incidence of adverse effects. Phenotyping is 
more important than genotyping to determine the current activity of each cytochrome for individualized drug dosing; 
genotyping is important for qualitative rather than quantitative use.
It is to say that therapeutic drug level monitoring is an indispensable, yet not fully clinically appreciated method 
for personalized medicine in the area of personalising drug dosage. TDM supplemented by ADTM, phenotyping and/or 
genotyping reaches an even a higher level.
Table 35.2. Common target therapeutic drug ranges
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36.1. POCT (Point-Of-Care Testing)
36.1.1. Definition of POCT
POCT (Point-Of-Care-Testing, Near-Patient Testing, Bedside Testing…) is defined as laboratory testing performed 
at or near the site of patient care, with the result leading to a potential change in patient care. The test is performed 
outside the laboratory, by personnel without primary laboratory education. POCT also includes patient self-monitoring 
at home.
POCT offers an improvement of the diagnostic process by integrating measurement, monitoring and physiological 
observation at the site of patient care where required and necessary.
In the 1950s, the POCT system saw considerable growth in terms of technological development and widespread 
use. As it turned out, the use of POCT is very convenient wherever no laboratory is available to provide results suffici-
ently fast given the importance of treatment. In conjunction with this development, a systematic method of monitoring 
POCT analysis quality was created to avoid significant differences between measurement results from central clinical 
laboratories and POCT analyses. Regrettably, many countries have omitted this systematic way of quality monitoring, 
and as a result of market-moving development of POCT, they continue to struggle with the problem of POCT quality 
and its links to the laboratory medicine analytics today.
Nowadays, POCT is an important part of laboratory diagnosis and has a firm place in the organisational structure 
of laboratory medicine.
36.1.2. POCT Instruments
POCT tools and equipment are usually operated by people who do not have primary training or qualifications for 
laboratory work. The reaction principle, operating procedure, overall technical solution and the instrument design are 
all adjusted to this fact. The instruments may be portable or fixed. The test is usually performed on whole blood, wi-
thout centrifuging, which would delay the time before the result is obtained. Hence the benefits of these instruments 
include the use of whole blood, very small sample volumes (micro-volumes), a short time of analysis and a shorter 
turnaround time (TAT – time between sample collection and getting the result). Internal quality control as well as an 
independent external quality control programme (control sera, samples with specific concentration of the analyte me-
asured) should be available for the POCT instrument.
It is true, however, that many POCT systems have not been verified sufficiently and reliably enough and their docu-
mentation is insufficient as regards basic analytical features of the measurement method used. NOKLUS/SKUP, a Nor-
wegian organisation for POCT system control, has revealed that based on measurement results compared with results 
from clinical laboratories, many of these analyzers do not provide reliable tests which could be used for clinical decisi-
ons. As the spectrum of POCT systems with their varied measurement technologies keeps developing and growing, it 
has become more and more imperative to rely on standards and other documents recommending adequate methods 
for their implementation and use.
There are many POCT instruments of varying quality on the market, so great attention should be paid to sele-
cting the right POCT instrument. 
It follows from the definition that like all laboratory instruments, POCT instruments rank among the category of 
in vitro diagnostic medical devices covered by European Directive 98/79/EC and Czech Government Regulation No. 
453/2004 Coll., as amended. The user’s basic responsibility here is to verify POCT system performance parameters 
specified by the manufacturer. This verification is impossible without collaboration with a clinical laboratory!!!
Examples of POCT instruments (blood gas, ion and metabolite analyzers; CRP, lactate, glucose, haemoglobin, ACT, 
troponin, alcohol analyzers, etc.)
36.1.3. Purchase and Implementation of POCT Instruments
Where is POCT equipment most commonly used?
• At the hospital
o Intensive care units, metabolic units, operation theatres, post-operative wards, central admission, ...
• Decentralised hospital sites
• Health-care facilities other than hospitals
o Outpatient offices, nursing institutes, hospices
• At the patient’s home
• Field use
o Rescue and emergency services, police
 
When is the right time to buy a POCT instrument and how to do it?
POCT instruments are needed in particular where tests for important parameters are poorly available or unavai-
lable in the required time. Given the purpose of acquisition, the new equipment has to help demonstrably improve 
patient care and has to be analytically acceptable.
The POCT TAT has to be shorter than the lab TAT. Depending on the nature of the test and considering the local 
conditions, one should determine which difference between the two TATs can be medically and economically justified. 
The only exception to this rule are situations whereby a lab test result is not available round the clock (in the afternoon, 
at night, on weekends and holidays, etc.), and the test is “acute” – leading to an immediate and urgent reaction of the 
attending physician.
The following questions should be answered when deciding about purchasing a POCT instrument:
Clinical character (physician):
1. TAT, TTAT (turnaround time, therapeutic turnaround time)
2. Purpose of use (diagnosis, monitoring, screening and other aspects)
3. The range of tests measured      
4. Expected number of tests within an interval of time (frequency)
5. Critical limits and the way of reacting to results exceeding them
6. Test reporting to healthcare payers
7. Patient benefit to cost ratio
The following issues should be assessed before purchasing a POCT (analyst):
h. Pre-analytical issues:
• Method of requesting the test (order slip), identification and documentation of requests
• Type of collection kit
• Type of anticoagulant and other admixtures (potential measurement interference)
• Type of sample (capillary, venous or arterial blood, saliva, urine, ...)
• Number of steps in handling the sample before analysis (sample treatment – the more steps, the more 
likely a pre-analytical error is)
• How fast the sample is prepared for analysis (influence of time on the resulting value)
• Suitability of the POCT for use in the target group of patients
• Storing of reagents
i. Analytical issues:
• Sufficient scope of the method for the intended purpose
• Same measurement units on the POCT and laboratory instruments
• Comparable cut-offs of the POCT and laboratory instruments
• Assessing the influence of calibration to the plasma or whole blood, inclusion of correction factors in the 
electronics of the instrument
• Assessing the influence of interfering substances
• Verification of basic analytical features of the measurement method (LoD, LoQ, analytical sensitivity, bias, 
precision, measurement range, calibration curve, comparison with the routine laboratory method, interfe-
rences), or a reference to relevant independent and renowned sources of this information
• Quality management (internal quality control, external quality control, comparability of the same test re-
sults (if exists) with an associated clinical laboratory, etc.) If an independent external control programme 
is unavailable for the POCT system, then it cannot be recommended for use as the quality of the measure-
ment results cannot be checked on a regular basis.
• Evaluation in line with good laboratory practice principles
j. Post-analytical issues:
• Possibility to connect the POCT instrument to the LIS and NIS (hospital)
• Unique identification of measurement results from POCT equipment in order to distinguish them from the 
same test performed in the lab
• Possibility to report to insurance companies
• Required use of the correction factor specified by the manufacturer (whole blood to plasma conversion, 
or correction to haematocrit)
• Method of keeping and archiving technical and laboratory documents (maintenance, repairs, findings, 
results, etc.)
*laboratory assistance is required; option to ask the dealer for a demo version of the instrument for some time to 
assess the pre, post and analytical phases of the POCT instrument.
Implementation of the POCT Instrument
k. Hospitals and their field sites
l. Outpatient departments and other health-care facilities
m. Self-monitoring
a) Hospitals and their field sites
Since POCT forms an integral part of laboratory diagnosis and has its firm place in the organisational structure 
of laboratory medicine, the hospital should also have a multi-disciplinary POCT team, whose main goal it is to unify, 
improve and streamline the processes of bedside laboratory diagnosis and, if possible, unify POCT instruments within 
the healthcare facility.
The POCT team should have permanent members and flexible members. Permanent members should include a 
POCT team leader (ideally laboratory personnel), supervisors for each laboratory specialisation (laboratory personnel), 
a POCT quality manager (laboratory personnel), requesting site representative, technical and operating representative, 
financial and analysis representative, legal representative, IT representative, the POCT physician also plays an impor-
tant role, and/or other members. Flexible members should include representatives of clinical sites where the POCT 
instrument is located.
Example of POCT instrument purchase and implementation:
The prospective POCT buyer – clinical site representative addresses the POCT team leader. The POCT team leader 
instructs the supervisor, and assesses the benefit of POCT instrument implementation with the clinician (to discuss the 
clinical, analytical, pre and post-analytical aspects of the request). Following consensus, the supervisor provides a demo 
version of the POCT instrument and prepares specifications for the public contract. The POCT team leader coordinates 
the technical and operating representative and the legal representative to make the purchase, while also instructs the IT 
representative to provide IT to connect the instrument to the network (if the POCT instrument allows it). The requesting 
site representative familiarizes himself/herself with the new consumable item. The supervisor with the technical and 
operating representative and the IT representative ensure installation of the instrument. Before commissioning, the 
supervisor ensures that the instrument is verified in the clinical laboratory and prepares the relevant documents. The 
POCT quality manager sets up the quality management system.  Together with the supervisor, the dealer demonstrably 
trains users. The supervisor determines the trial period, and after that gives permission for regular use. The clinical site 
appoints a “coordinating nurse”, who is responsible for the instrument and communicates with the supervisor. The su-
pervisor oversees the whole POCT process throughout the entire use of the POCT at the hospital.
 
Successful use of POCT equipment to the patient’s benefit is dependent on the physician’s (user’s) collaboration 
with the clinical lab!!!
b) Outpatient departments and other health-care facilities
After answering clinical questions, the prospective POCT instrument buyer (doctor) should choose and ask a clini-
cal laboratory for assistance on assessing the pre-analytical and analytical phases. Following the purchase and training 
on the instrument, the instrument should be sent to the associated clinical laboratory for verifying the measurement 
method. The laboratory issues a verification protocol and recommends a quality management system (as recommen-
ded by the manufacturer and professional society). The doctor is responsible for successful internal and external qua-
lity control. Prior to introducing the POCT method, POCT users are required to attend a single introductory course on 
the POCT topic, if such a course exists.
c) Self-monitoring
A POCT instrument lent by the healthcare facility to the patient in home care should be checked on a regular and 
demonstrable basis through internal controls (at least before lending and after returning) and verified in the associated 
clinical laboratory. The healthcare facility has to keep the required documents for the POCT instrument. The patient has 
to be duly and demonstrably trained.
Prescription POCT instrument or POCT instrument gained by the patient from other sources:
The doctor should check whether the patient was trained and can handle the POCT instrument correctly. The 
doctor should inform the patient about the importance of internal controls and the possibility of verifying the POCT 
instrument in the clinical laboratory when in doubt about any measurement.
36.1.4. Regular Education
Regular education is the basis for obtaining a correct result, especially when the operating personnel do not have 
a specialised laboratory qualification. Education is guaranteed by supervisors or special courses containing:
• Theoretical background for the relevant test and technology used;
• Character, collection, storage and method of biological material application;
• Procurement and storage of required consumables, reagents and replacement parts;
• Equipment operation, calibration and measurement procedure;
• Sharing results, transfer to the LIS/NIS, documenting and archiving;
• Evaluation of results and clinical significance of the test;
• Sources of errors at all phases of the measurement process;
• Quality management, documenting and archiving of internal and external quality control results;
• User maintenance and service of POCT instruments.
 Absence of verification, internal and external quality control, inadequately trained user and poor knowledge of 
the pre-analytical phase of the test are the most common causes of incorrect results, causing potential damage to 
the patient. The user must not be satisfied with any result; they must require the correct result!
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36.3. Automation and Consolidation
36.3.1. Definition of Automation
The use of control systems for equipment and process control.
36.3.2. History
In the early days classical quantitative analytical techniques were used in biochemistry laboratories. The only in-
struments available were pH-meters, polarimeters, simple photometers, chromatographic techniques were only at 
the stage of development. First multi-channel analyzers were developed in the 1960s, first microprocessors converting 
the analytic signal to analyte concentration in the 1970s, and the first protocol allowing communication between the 
analyzer and the laboratory information system emerged. The 1980s are an important milestone in automation – first 
biochemistry analyzers to process larger numbers of samples appeared. In early 1990s a trend of laboratory test de-
centralisation emerged; biochemistry analyzers appear at the patient’s bedside, in operation theatres or physicians’ 
offices (POCT technology).
36.3.3. Types of Automation
• Total laboratory automation means that all processes (from the receipt of samples to releasing the result) 
are automatic and part of a complex line. Major benefits of total automation include the processing of 
a large number of samples at a defined rate, reduced number of errors due to human factor limitation, 
higher personnel safety, lower number of operators and related lower personnel costs.
• Modular laboratory automation means the automation of some laboratory processes only. These are ba-
sically stand-alone pre-analytical and analytical systems.
36.3.4. Pre-Analytical Phase Automation 
The pre-analytical phase of laboratory testing is the most common source of errors caused mainly by the human 
factor.  Pre-analytical modules were developed with the aim of minimizing these errors.
Capabilities of the pre-analytical system:
• Identification of material with a barcode
• Primary test tube type discrimination
• Sorting of samples
• Sample amount and quality check
• De-capping of test tubes
• Preparation of aliquot tubes 
• Overview of sample movement within the lab
• Traceability of samples (e.g. when additional parameters are required)
• Capping of primary tubes
• Archiving of primary tubes
• Increased laboratory staff safety (minimal staff exposure to biological risks)
• Reduced risk of confusing samples
• Saving of primary test tubes
• Faster turnaround time (TAT)
Pre-analytical phase automation also includes pneumatic tube transport, transport equipment connecting the lab 
and other departments for transporting material automatically. Speed is the greatest asset of pneumatic tube trans-
port. The acquisition cost is a drawback.
36.3.5. Analytical Phase Automation
Currently the most sophisticated phase thanks to high-performance biochemistry and immunochemistry analy-
zers, a growing number of which are capable of connecting the pre-analytical and post-analytical system. Automated 
analyzers can perform up to thousands of different analyses per hour.
The following activities have been automated:
• Sample and patient identification
• Sample and reagent dosing
• Incubation of mixtures
• Method calibration
• Measuring the resulting analytical signal
• Recording, analysis and saving of data
Analyzers are categorised based on different criteria, basically into a) continuous flow analyzers and b) discrete 
analyzers. Depending on the sample analysis arrangement, analyses are divided into sequential, serial, parallel and 
random-access analyses, where any method in any sequence of any sample can be selected.
Sample and reagent consumption has also decreased significantly. Sample consumption in the analyzer usual-
ly does not exceed 5 µl (range 1–30 µl); total reagent consumption does not exceed 250 µl. Methods are generally 
designed as 1-reagent or 2-reagent methods.
The automation of the analytical part of the test guarantees accurate, comparable and reproducible results.
36.3.6. Post-Analytical Phase Automation
The post-analytical phase has an inter-disciplinary character of collaboration between the lab and the indicating 
physician. Among other things, it consists of the interpretation of results in relation to physiological values, other test 
results and the patient’s clinical condition. The post-analytical phase of clinical lab testing includes methods of keeping 
and storing the biological material after the test, validation, release, interpretation and comments on results, consul-
ting and education. The tools of process automation include computer programs facilitating the result check, which 
are part of the laboratory information system and give the user an option to preset different criteria for checking the 
results (e.g. setting reference, pathological, warning and critical limits for each parameter). Results sent to the labora-
tory system following the analytical check by the lab staff and which fulfil the preset criteria proceed to a subsequent 
automatic medical check and are released to the requester. Results which do not fulfil the preset criteria are not re-
leased and have to be reviewed by either a physician or authorized staff with university qualification. Only after this 
review has been made are the results released from the lab.
The data and information transfer between the lab and the requesting physician is most often done via electronic 
communication between the laboratory and hospital information systems. Results can be sent to external requesters 
by mail or secured electronic communication.
36.3.7. Major Advantages of Automation 
• Less collection tubes – better usage of the biological material – more careful for the patient)
• Shorter turnaround time
• Elimination of errors
• Reduced costs
• Higher efficiency and productivity of work
• Higher occupational safety
Further development leads to a greater use of POCT, miniaturisation of laboratory tests using microfluid and nano-
chip technologies, or further development of molecular biology.
36.3.8. Consolidation
• Combining different analytical technologies or strategies in one instrument or a group of instruments –the 
idea of a centralised laboratory
• Integration – connection of analytical instruments or instrument groups with pre-analytical and post-ana-
lytical equipment
• Consolidation may combine sites of biochemistry, genetics, haematology, immunology, molecular biology, 
microbiology, parasitology, virology and in vitro nuclear medicine methods
• This is not any “liquidation” of the disciplines, but interdisciplinary collaboration
• Analytical parts of the disciplines are consolidated, not interpretation parts, which, conversely, benefits 
from the consolidation – comprehensive picture of the patient (all test results together) and thus the com-
prehensive interpretation of results
• The benefits include lower operating costs (collective purchase of reagents and other material, lower per-
sonnel costs), uniform material receipt and processing, fewer collection tubes, all of which is more consi-
derate for the patient, shorter turnaround time, fewer errors, one single collection site
• It is also associated with certain problems – consolidation often ends by collective receipt and processing 
of material; the disciples sometimes have different opinions on the sense of consolidation
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36.5. EBM
36.5.1. Introduction  
Evidence-Based Medicine (EBM) is “conscientious, explicit and judicious use of current best evidence in making 
decisions about the care of individual patients”.
Moreover, every patient is unique and the human genome is also unique. As the newest part of modern medicine, 
genetic analysis is based on examining the individual characteristics of each gene. Personalized medicine provides each 
patient with the best, highly effective tailored treatment with minimal side effects. This leads to a streamlined trea-
tment process and, last but not least, less suffering. Individual treatment is one of the most sought after improvements 
offered by predictive genetics in modern medicine.
36.5.2. Principles of EBM
Evidence-based medicine integrates:
• External findings (evidence) of the clinical research; this mainly involves exploring the scientific basis of 
validity of the problem to be solved (diagnosis, treatment, prognosis, etc.) in line with latest published and 
critically reviewed results of clinical research;
• The physician’s clinical experience comprising the physician’s expertise and ability to use new knowledge 
and skills properly to assess the patient’s clinical condition;
• Patient’s expectations, firstly respecting the patient’s wishes, opinions, preferences and needs.
Evidence-based medicine forms part of the managerial decision-making process. This approach requires the un-
derstanding of inconsistent results and the assessment of quality and cogency of evidence (published or not pub-
lished). In the final phase, the physician has to be able to apply this approach to a specific patient in the context of that 
particular health system.
The EBM decision-making process can be divided into six inter-related steps:
• Transforming a problem into the clinical question;
• Use of “internal evidence” to answer a clinical question;
• Searching for “external evidence” to answer a clinical question;
• Critical assessment of external evidence;
• Integrating external and internal evidence;
• Evaluating the decision-making process.
EBM is a practical continuation of clinical epidemiology because when making the decision, the physician obtains 
the required scientific evidence from published epidemiological studies, among other things. Clinical decision-making 
involves many open questions due to the difference between the theory of each medical discipline and clinical prac-
tice. Sometimes the opinion of an “authority” can be considered, but these people sometimes contradict each other. 
Another option is to seek the answer in professional literature, i.e. assess the validity of research results. Every physici-
an, although they do not wish to be involved in research work, should understand the principles of research to be able 
to interpret the research results.
36.5.3. Sources of Information
To answer questions arising in connection with patient care (clinical questions), physicians use different sources of 
information:
22. Their own experience;
23. Experience of their colleagues;
24. Scientific literature.
MEDLINE, the global bibliographic database freely available on the Internet at the PubMed (www.pubmed.gov) 
information portal, is the best known source. The database offers tools to categorise found articles according to the 
study type, called EBM filters. Selected items may include review articles, controlled clinical trials, recommended pro-
cedures, meta-analyses, etc. A method for the processing of a new type of review articles, the systematic review, has 
been created in the system for EBM purposes.  The evidence pyramid (Fig. 1) ranks systematic reviews among the most 
significant types in the hierarchy of publications as they seek to answer a specific clinical question in a comprehensive 
way. Systematic reviews spare the time for searching, study and the reader’s own critical assessment of a large amount 
of literature. 
Figure 36.1. Hierarchy of Scientific Evidence in Biomedicine
36.5.4. Personalised Medicine
Personalised medicine is a multidisciplinary branch of science which studies the optimisation of therapeutic and 
diagnostic procedures in a specific patient using modern methods. It is often referred to as “The right diagnostics, right 
treatment to the right patient at the right time”. It has evolved in reaction to the modern development of drugs and 
diagnostic/therapeutic procedures, including drugs which are often marketed as soon as the condition of efficiency 
verified in phase III clinical studies has been met with standard summary significance. These procedures do not deal 
with specific patient treatment, and before personalised medicine emerged, nobody was interested in why some drugs 
do not work in a fraction of patients.
While classical medicine aims to cure most patients (and puts up with a drug being efficient in 97% patients), per-
sonalised medicine asks “How to do it if I wish to increase the likelihood of curing a specific patient?”
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36.7. OMICS
36.7.1. INTRODUCTION
Research teams consisting of geneticists, organic chemists and biochemists, computer and other specialists de-
eply investigate into the discipline called functional genomics. This discipline studies concurrent action of hundreds to 
thousands of genes and develops software for such studies. Structural genomics aimed at determining the structure 
of most proteins coded by certain genome is one of subdisciplines of functional genomics. Three-dimensional protein 
structures and functions are the key for targeted drug designs. Transcriptomics is a subdiscipline determining the 
connection and disconnection of a set of mRNA transcripts in a certain type of cells or tissues, and changes in the ex-
pression of genes caused by diseases. Proteomics establishes which protein sets are present in the cell and what their 
mutual interactions are. Finally, metabolomics analyzes the metabolome, a complete set of small molecules in the cell, 
and identifies its changes.
Figure 36.2.  Genomics, proteomics, metabolomics, transcriptomics
36.7.2. 39.4.2. GENOMICS
Genomics is a discipline in molecular genetics which studies the genome of organisms. The discipline involves DNA 
sequencing, genetic mapping and genome annotations, i.e. searching for genes and other functional elements (effort 
to identify the meaning of the sequence), and intergenomic research – effort to compare the genomes of different 
organisms to better understand the process of evolution. Molecular biology and bioinformatics methods are widely 
used in genomics.
Research areas in genomics:
• Structural genomics – research into the structure of genes and whole genomes (distribution of genes wi-
thin the genome).
• Functional genomics – particularly the annotation of genomes, searching for genes, determining the gene 
function.
• Comparative genomics – comparing the genomes of different organisms.
• Population genomics – comparing genomes within a particular population of a particular organism, resear-
ching the effects of specific conditions.
• Computational genomics – work with genomics data using computing methods in bioinformatics.
• Personal genomics – sequencing genomes (or genome parts) of human individuals and analysing these; 
effort to provide doctors with precise information about the patient’s genetic predispositions in the future.
Basic methods and approaches in genomics include:
• Sequencing – Sanger sequencing method
• Bioinformatics
36.7.3. TRANSCRIPTOMICS
The study of transcriptomics examines the expression of genes within the whole genome (genome-wide expression 
profiling). The gene expression is identified indirectly from analysing the mRNA converted into complementary cDNA.
Transcriptome – a set of genome-wide messenger RNA (mRNA) referred to as “transcripts” in one type or a popu-
lation of cells, tissue or organism. Like the proteome, and unlike the genome, the transcriptome is dynamic; changes 
based on external influences.
Genome-wide methods of the gene expression study include:
• cDNA microarrays and oligo-microarrays
• SAGE (Serial Analysis of Gene Expression)
• cDNA-AFLP (Amplified Fragment Length Polymorphism)
36.7.4. PROTEOMICS 
A scientific discipline which studies (analyses) the expression of genetic information at the protein level (proteome) 
in a sample (organelle, cell, tissue, fluid, etc.). In addition, proteomics examines the three-dimensional structure of 
proteins and protein interactions.
Proteome – the entire set of proteins in a cell (sometimes in a sample) under specific external conditions. The first 
studies in proteomics date back to 1975 when O’Farrell, Klose and Scheele began mapping proteins from Escherichia 
coli and mammals using 2D gel.
More generally, proteome can be seen as cellular and complete proteome.
Cellular proteome is a set of proteins found in a particular cell or a particular cell type under a particular set of 
conditions. Example: Hematopoietic cells in the anaphase splitting into the proteome.
Complete proteome subsequently refers to the proteome of an organism, a sum of proteomes of all cell types. 
This term also includes proteins which may be present in the organism but are not synthesized at the given moment.
Proteome is larger than the genome, particularly in eukaryotes. This is mainly the result of alternative splicing and 
post-translational protein modifications such as phosphorylation or peptide chain splitting.
While the genome is relatively stable, proteins change very fast and in different ways in the cell. This makes the 
proteome analysis more difficult. All the cell’s proteins are analysed at the same time.
Types of proteomics:
• Protein expression proteomics – approach comparing changes in protein expression between samples 
(such as in the study of causes of diseases, study of pathogenesis, study of virulence factors in microorga-
nisms, etc.)
• Structural proteomics – analysing the expression and function of proteins in sub-cellular structures (such 
as organelles or complexes).
• Functional proteomics
• Post-translational modification – phosphoproteome
• Protein-protein interaction (yeast two-hybrid assay – interactomics)
• Proteomics in drug research
Two major approaches in proteomics:
• Classical proteomics – 2D separation techniques – protein separation – identification (MALDI-TOF)
• “Shotgun” proteomics – separation (usually by ESI-HPLC) of protein peptides (fragments) following prote-
olysis of the complex protein mix by trypsin, identification using LC-MS/MS analysis
Separation in proteomics:
• Gel-based vs. non-gel-based separation
• [HPLC (High Performance Liquid Chromatography), GC (gas chromatography), CE (capillary electrophore-
sis)]
Identification in proteomics:
• Mass spectrometry (MS), tandem MS
• (MS/MS, MSn) – the MS units separate collision cells where the selected fragment is split by inert gas
Quantification:
• In gel or MS/MS
Ettan™ DIGE System – Fluorescent staining of two protein samples with two dyes in gel vs. iTRAQ using MS
36.7.5. METABOLOMICS 
Metabolomics is a scientific study of metabolic (low-molecular weight) profiles of specific cellular processes. It 
examines dynamic changes in the presence (quantity) of metabolites in the biological system as a result of exogenous 
stimuli, pathophysiological changes or genetic disposition – “metabolic fingerprint”.
Metabolome is the (quantitative) collection of metabolites (metabolic intermediates, hormones, metabolites of 
endogenous and exogenous agent biotransformation, secondary metabolites, etc.) in a biological sample (whole orga-
nism) analysed by a specific method.
It closely follows the functional state of a biological system.
In 2007, scientists from the University of Alberta completed the human metabolome in urine, blood and cerebro-
spinal fluid. They catalogued 6500 metabolites, 1500 drugs and 2000 food components (see the Human Metabolome 
Database (HMDB) at http://www.hmdb.ca)
Metabolomic approaches and analytical methods:
37. Extraction of metabolites from biological samples
38. Separation techniques
39. Detection
40. Identification and quantification
Separation methods:
• Gas Chromatography – very effective for volatile, low-molecular weight substances, especially in connec-
tion with MS
• High Performance Liquid Chromatography (HPLC) – wider spectrum of analytes
• Capillary Electrophoresis (CE)
Detection methods:
• Mass Spectrometry (MS) – mainly in connection with GC-MS, HPLC-MS.
• Nuclear Magnetic Resonance (NMR)
• Fourier Transform Infra-Red spectrometry (FT-IR)
• Electrospray Ionisation Mass Spectrometry (ESI-MS)
36.7.6. Pharmacogenomics
Pharmacogenomics study the expression and sequencing of nucleic acids with the aim of contributing to the deve-
lopment of new medicines and identification of their mechanisms of action. A much wider spectrum of drug response 
variability causes than mere variability of metabolizing enzymes have been described such as variability of transport 
mechanisms, receptors and post-receptor mechanisms for drugs, all of which play a role in pharmacokinetic and phar-
macodynamic parameters of the drug. Pharmacogenetic procedures contribute to an ever more complex study of 
these phenomena.
Genetic Polymorphism
Genetic changes in the activity of drug-metabolising enzymes are a substantial source of a variety of the drug’s 
pharmacokinetic parameters between individuals leading to a variety of different therapeutic responses from patients. 
Inter-individual differences may be significant, from failure of therapy to toxicity manifestations and a marked inciden-
ce of drug interactions. The variability of metabolic activity is caused by the presence of several types of alleles for the 
particular enzyme, which predetermine the varied activity of the coded enzyme. Hence there are alleles in the popu-
lation, the carriers of which are likely to have a fast metabolism of specific enzyme substrates (Fast Metabolizers, FMs), 
and alleles causing substantial reduction of enzyme’s metabolic capacity of their carrier (Slow Metabolizers, SMs). For 
the FM phenotype alleles are dominant which means that the SM phenotype is expressed only in homozygotes for 
defective alleles, yet enzyme activity in heterozygotes is either normal or slightly reduced (Intermediate Metabolizers, 
IMs). An enzyme is referred to as polymorphic, if more than 1% of SMs exist within the population. If the incidence of 
variant alleles varies in different populations, the enzyme may be polymorphic in one population, and non-polymor-
phic in another.
The frequency of each allele occurring in populations is a result of natural selection. According to the Darwin mo-
del, the heterozygous genotype is more favourable than the homozygous genotype in terms of survival and reproduc-
tion. Alleles are thus maintained in the population owing to the balance between the incidence of a favourable and 
unfavourable genotype. The glucose-6-phosphate dehydrogenase polymorphism is a well-known example: the variant 
alleles expose hemizygous males and homozygous females to a high risk of severe damage (or death) by neonatal jaun-
dice and haemolysis, while heterozygous individuals are more resistant to malaria.
Polymorphism of Some Enzymes
Cytochrome P-450
Cytochromes P-450 are proteins which play a major role in the catabolism of most xenobiotics, metabolism of 
some endogeneous substrates (thromboxanes, prostaglandins) and in steroid biosynthesis.
Cytochromes from 14 families and 20 subfamilies have been found in the human body. As regards drug meta-
bolism, the representatives of 4 families are of the greatest importance. Cytochromes are bound in membranes of 
smooth endoplasmic reticulum and mitochondria, particularly in the liver, but also the kidneys, lungs, small intestine 
mucosa, brain, adrenal glands, gonads and other organs.
Reactions catalysed by cytochromes in humans lead to easier excretion of xenobiotics from the body to prevent 
their accumulation. In addition to detoxifying the organism, they are also important for the processing of carcinogene-
sis and activation of procarcinogens. Isoenzymes metabolising drugs and xenobiotics are not strictly substrate-specific. 
Several metabolic pathways catalysed by multiple cytochromes have been described for many substances.
CYP2D6
This cytochrome P-450 isoenzyme ranks among enzymes, whose potential clinical impact of polymorphism on 
pharmacotherapy is generally accepted as it is a catalyzing enzyme of many commonly used drugs from groups inclu-
ding antidepressants, antipsychotics, analgesics, beta-blockers and artiarrhythmics.
CYP2C9
The polymorphism of CYP2C9 is primarily important for the metabolism of hypoglycaemizing antidiabetics, which 
may cause serious hypoglycaemias in the slowed-down metabolism of SMs, and anticoagulants (S-warfarin).
CYP2C19
CYP 2C19 isoenzyme substrates include drugs such as omeprazole and some antidepressants. Area Under the 
Curve (AUC) values for omeprazole have been reported as twelve times as high in SMs vs. FMs . As omeprazole is an 
inductor of another isoenzyme, CYP-450 1A2, following omeprazole administration SMs may show considerably ele-
vated CYP1A2 activity levels as well as accelerated metabolism of drugs and other substances acting as a substrate for 
this enzyme.
At the same time, CYP2C19 is an enzyme catalyzing the conversion of a proquanil antimalarial drug into an active 
metabolite, which may lead to insufficient therapy for malaria, especially in some Asian populations with up to 20% of 
SMs.
CYP2E1
CYP2E1 is especially known for its role in ethanol metabolism (also its inductor), but it is also involved in the meta-
bolism of many other xenobiotics. Among drugs, anaesthetics such as halothane, enflurane, isoflurane are substrates 
for this isoenzyme, and together with CYP3A4, CYP2E1 is one of the ways to form reactive hepatotoxic metabolites of 
paracetamol.
Other Cytochrome P-450 Enzymes
The activity of the other two enzymes (CYP3A4 and CYP1A2) largely involved in drug metabolism features a marked 
inter-individual variability. Rather than genetic polymorphism, this variability is probably caused by many non-genetic 
influences, to which the two proteins are quite sensitive (induction and inhibition by drugs, physiological and patholo-
gical processes of the body, diet, etc.).
Cholinesterase
Cholinesterase exhibits polymorphism important for succinylcholine hydrolysis. The gene for this enzyme has a se-
ries of relatively rare alleles, which lead to the expression of an enzyme with reduced activity in roughly 2% of people, 
while the activity is completely undetectable in roughly 1% of people. This metabolic defect may result in an apnoea 
prolonged for up to several hours.
Glucuronyltransferases
Glucuronidation is the most common conjugation reaction in drug metabolism. There are also congenital glucu-
ronication disorders such as the Gilbert’s syndrome characterised not only by the affected bilirubin metabolism, but 
also reduced clearance of many drugs including tolbutamide, acetaminophen, rifampicin and irinotecan. The genetic 
basis of the syndrome in patients with milder symptoms is the mutation of the non-coding region of glucuronidase 
gene leading to lower gene expression. The other form with more serious symptoms is probably caused by a mutation 
encoding sequences of the gene for glucuronidase.
N-Acetyltransferases
Polymorphism of N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2) have been described.
The molecular basis of NAT2 polymorphism is the presence of more than 15 allelic forms, most of which reduce 
enzyme activity. The inability to acetylate drugs leads to adverse effects such as peripheral neuropathy in patients using 
isoniazid, or hypersensitivity reactions following administration of sulphonamides. By contrast, fast acetylators are at 
risk of leukopenia following the administration of amonafide, a pro-drug used in chemotherapy.
Increased activity of the polymorphic enzyme NAT1 leads to an increased risk of colon cancer, but the importance 
for drug metabolism is not clear so far.
Glutathione S-Transferases
The polymorphism of glutathione S-transferases (GSTs) is very pronounced.
GSTs represent important detoxification pathways; their polymorphism has been primarily studied in relation to 
tumour chemotherapy. For example, carriers of one variant allele (GST P3) are less susceptible to cytotoxic symptoms 
of cisplatin treatment than other patients.
Methyltransferases
This is a group of enzymes catalyzing many reactions where variability or polymorphism is present. The importan-
ce of polymorphism in this group of drugs has been identified for substances such as thiopurine S-methyltransferases 
(TSMT) where 4 types of alleles have been described. TSMT represents an important catalytic pathway of cytotoxic 
agents 6-mercaptopurine, 6-thiopurine and azathioprine. Fatal myelosuppressions caused by high drug concentrations 
have been described repeatedly in patients with a TSMT deficiency. There is also an elevated risk of secondary malig-
nancies (brain tumours and acute leukaemias) endangering patients with some allele variants.
Transport Proteins
P-glycoprotein (P-gp) is the first described and best-known protein from the large group of membrane transporters 
referred to as ABC proteins, whose activity depends on ATP hydrolysis. Transported substrates are excreted from the 
intracellular space by their action. The localisation of P-gp in the liver, kidney and intestine cell membranes leads to the 
elimination of substrates in bile and urine, and to reduced biological availability of drugs from the GIT. In addition, P-gp 
is largely expressed in endothelial CNS cells, which prevents penetration of substrates through the blood-brain barrier. 
Increased P-gp expression in tumour cells leads to the known phenomenon of multiple drug resistance.
The gene encoding P-gp is highly polymorphic. Many alleles do not lead to a change of P-gp activity, however it is 
likely that not all variants are known so far. In addition to this, P-gp inducibility is variable, while its extent depends on 
the presence of allelic variants.
The efflux system of P-gp interacts with other pathways leading to the elimination of xenobiotics from the body. For 
example, CYP3A4 and P-gp have many common substrates, and also have a high activity in some similar localisations 
as P-gp (liver, intestine).
All of these factors point to the fact that the clinical importance of P-gp is still very poorly described, and un-
derstanding this area is an outlook for the future which is sure to bring about some therapeutic procedures. It is alrea-
dy known, however, that the induction of P-gp by rifampicin leads to a significant decrease in biological availability of 
digoxin. The biological availability of cyclosporin also depends on P-gp activity.
Pharmacogenetics in Cardiovascular Disease Treatment
The introduction of facts known from pharmacogenetics in cardiovascular disease treatment has advanced from 
the phase of theoretical assumptions to the phase of practical use, especially in antithrombotic therapy. The basis of in-
ter-individual differences in the drug effects is usually the polymorphism of transformation enzymes, transport systems 
ensuring the drug’s fate within the body, and receptors, enzymes or signal molecules affecting the drug’s effect itself.
The polymorphism of efflux P-glycoprotein P (ABCB1 3435C→T) in drug resorption or polymorphism of CYP2C19 
isoenzyme in bioactivation of clopidogrel are clinically important in antithrombotic therapy. P-glycoprotein (P-gp) ge-
notyping is important for determining the biological availability of clopidogrel; the 3435CC genotype is related to low 
P-gp activity, higher availability of clopidogrel and therefore a more reliable antithrombotic effect; by contrast, the 
3435TT variant is related to high activity and insufficient availability. The detection of the CYP2C19 genotype, namely 
CYP2C19*2 or CYP2C19*3, is also important; clopidogrel bioactivation is slower in these allele carriers, and higher 
amounts of the prodrug are degraded by esterases. Vitamin K reductase genotyping is similarly important in endange-
red people. VKORC1AA carriers constitute a warfarin-sensitive subpopulation, and the same portion of individuals with 
the VKORC1BB variant are less sensitive to warfarin, meaning they are a warfarin-resistant subpopulation.  Similarly, 
there is a subpopulation with varying speeds of warfarin biodegradation by isoenzymes CYP2C9 and CYP4F2. Resulting 
combinations of responses at the vitamin K reductase level are co-responsible for the resulting therapeutic dose of 
antivitamin K.
Given the high clinical importance of different types of polymorphism in the drug effect, there is a trend to intro-
duce new drugs (prasugrel, ticagrelor) with pharmacokinetics independent of the different activity of metabolic and 
transport systems.
Tumour Biology
Many different biomarkers have been tested in clinical practice to personalise cancer treatment. In other words, 
based on laboratory testing of these biomarkets to establish whether further cancer treatment would be beneficial for 
the patient when compared with mere monitoring after radical surgical resection, indicate what type of chemotherapy 
should be selected from the standard options considering the potential toxicity of chemotherapy, and whether or not 
biological treatment is indicated in addition to chemotherapy. The rising costs of tumour disease pharmacotherapy are 
another important reason for properly targeted treatment.
Examples of some biomarkers used
According to the results of many studies, adjuvant fluoropyrimidine-based chemotherapy for stage II of colorectal 
carcinoma with MSI (microsatellite instability) is seen as beneficial. MSI and other biomarkers such as allelic imbalance 
on chromosome 18q are currently being tested as part of prospective clinical trials in adjuvant chemotherapy indicati-
on.
Other biomarkers are being sought for predicting chemotherapy toxicity. One of them is UGT1A1*28 polymor-
phism, which is accompanied by a significant decrease in enzyme activity and thereby an increased risk of severe 
neutropenia.
K-ras mutations are currently a biomarker used on a routine basis. K-ras mutation identification is a unique marker 
of the absence of a response to the EGFR inhibitor (cetuximab or panitumumab) therapy. As shown by OPUS study 
results, the cetuximab/FOLFOX combination worsens therapy results when compared with chemotherapy alone in a 
population with a mutant K-ras form. The same results were confirmed by analyzing CRYSTAL and PACCE studies, whe-
re irinotecan was used instead of oxaliplatin. An assay for the presence of K-ras mutation is a minimum condition for 
initiating cetuximab or panitumumab therapy.
Breast cancer is the most common cancer in women worldwide. Luckily enough, despite the high incidence of this 
disease, more and more patients are successfully treated thanks to continuous improvement in diagnosis and trea-
tment. Great hope is given to targeted biological treatment able to find tumour cells and stop their growth or destroy 
them. One of the new drugs is Herceptin, which, as a specific antibody, is effective in treating breast cancer with an ele-
vated expression of epidermal growth factor 2 (HER2 gene). In this HER2-positive tumour type, Herceptin is a specific 
HER2 receptor blocker, which stops the tumour from growing and may even make it recede.
Monitoring the parametric profile of patients with breast cancer treated with Herceptin therefore presents a 
unique opportunity to describe the epidemiological situation of HER2-positive patients in the Czech Republic, which 
may be used by professionals not only for modelling the relationship of risk factors and survival achieved, but also for 
economic estimates such as planning antitumour therapy costs.
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37.1. Blood Coagulation Physiology
The haemostatic system has two basic functions:
• Haemostasis if a vessel is injured
• Maintaining blood in a liquid state, i.e. preventing blood from clotting inside the vessel
Four systems are used to maintain the equilibrium:
• Primary haemostasis system
• Plasma clotting system
• Inhibitors of coagulation
• Fibrinolytic system
Trauma causes the vessel to contract and restrict the blood flow. Platelets at the site of injury adhere to collagen 
in the subendothelial ligament of the injured vessel, aggregate, and the content of cytoplasmic granules is released to 
form a primary haemostatic plug.
Blood clotting begins at the same time. Fibrin coagulum is formed by gradual activation of coagulation factors. 
Coagulation factors are glycoproteins primarily produced in the liver. The coagulation capacity of factors II, VII, IX and 
X depends on the presence of vitamin K. Most factors have a character of serine proteases, are present in plasma in 
their inactive form under steady state conditions, and gradually become activated when clotting is triggered – the co-
agulation cascade is activated. The coagulation system becomes activated in two possible ways: the intrinsic pathway 
through factor XII (FXII) and kallikrein, and the extrinsic pathway through factor VII. Starting from factor X, the two 
systems join to a common pathway. Calcium ion and platelet phospholipids have to be present for proper activation. 
The aim of activation is to produce a sufficient amount of factor II (thrombin). Thrombin releases fibrin monomers from 
fibrinogen, and fibrin monomers crosslink to form polymers. Factor XIII reinforces the fibrin network (scaffold) to form 
final fibrin coagulum. Coagulation system activation using the extrinsic and the intrinsic pathways separately is mainly 
performed in laboratory conditions. The extrinsic coagulation pathway is the primary pathway for in vivo blood coagu-
lation. The action of extrinsic tenase (FVIIa + tissue factor) initiates blood clotting and a small amount of thrombin is 
produced. The intrinsic coagulation pathway is activated by thrombin feedback through intrinsic tenase (FIXa+FVIIIa). 
The process is amplified and prothrombinase (FXa + FVa) is produced. Prothrombinase cleaves inactive prothrombin 
to active thrombin, which is capable of converting fibrinogen to fibrin coagulum. The activation of clotting factors 
leads simultaneously to activation of regulatory system – coagulation inhibitors. Major coagulation inhibitors include 
antithrombin (AT), protein C (PC) and protein S (PS). All three of them are produced in the liver, and the function of PC 
and PS depends on the presence of vitamin K. Thrombin formed in the coagulation process binds to transmembrane 
glycoprotein thrombomodulin on the vessel endothelium, which activates C protein. The complex of activated PC, PS, 
thrombin and thrombomodulin, bound to the endothelial protein C receptor, inhibits activated factors V and VIII (Va, 
VIIIa). AT activity is directed against activated factors II and X (IIa, Xa) and also against activated factors IX, XI and XII 
(IXa, XIa, XIIa). AT is a slow inhibitor; the reaction of AT with target factors is greatly accelerated by the presence of 
heparin. The fibrinolytic system has a regulatory function. As soon as a clot is formed inside the circulatory system, 
inactive plasminogen is converted to active plasmin. This conversion is enabled by a tissue plasminogen activator or 
urokinase. The resulting plasmin cleaves fibrin to form degradation products – the clot is dissolved. The resulting plas-
min is eliminated by α2-antiplasmin, and the fibrinolytic system is inactivated by plasminogen activator inhibitors (PAI) 
at the same time.
37.2. Laboratory Tests
Laboratory tests are used in haematology to examine haemorrhagic conditions, conditions with a tendency for ex-
cessive blood clotting (thrombophilic conditions) and to monitor anticoagulant therapy. Most haemocoagulation tests 
are performed from plasma. Plasma is obtained from blood taken in a test tube with an anticoagulant. The anticoagu-
lant binds calcium ions; the coagulation process is inhibited if they are absent. Most haemostasis tests use 3.8% sodium 
citrate (1 portion of citrate to 9 portions of blood) as an anticoagulant. Commercially available collection tubes have 
to be filled with blood up to the mark to keep this ratio. The principle of coagulation tests is to measure the time from 
activation of the coagulation system to the formation of fibrin coagulum. Chromogenic tests employ the enzymatic 
action of coagulation factors to measure the amount of pigment released from the chromogenic substrate.
Tests for monitoring anticoagulant therapy
Activated partial thromboplastin time (APTT) test – coagulation test depending on the level of intrinsic system 
factors (XII, XI, IX, VIII, prekallikrein, high-molecular-weight kininogens). The test is less sensitive to the deficiency of 
common pathway factors (X, V, II, fibrinogen). APTT is extended if the above factors are deficient or in the presence 
of specific and non-specific inhibitors, high titres of products of fibrin and fibrinogen cleavage and heparin. The test is 
used to monitor anticoagulant therapy with standard heparin. The test result is shown as the patient’s time, mentio-
ning normal plasma time (normal plasma is a pool of plasma from healthy donors), or as an APTT-R, i.e. patient’s time 
to normal plasma time ratio.
Prothrombin time (PT) (Quick test) – coagulation test depending on the level of the extrinsic system and common 
pathway factors (VII, X, V, II, fibrinogen). PT is extended if the factors listed above are deficient, rarely in the presence of 
specific or non-specific inhibitors. Like APTT, PT is expressed as the patient’s time, mentioning normal plasma time, or 
as a ratio of the two times. PT is also expressed as the international normalized ratio (INR), which considers the sensi-
tivity of the reagent used to reduce vitamin K-dependent factors, referred to as the international sensitivity index (ISI). 
The test expressed by the INR is used to monitor anticoagulant therapy with antivitamins K (Warfarin).
Anti Xa test – a chromogenic test measuring the X factor inhibition in the plasma of a patient on heparin therapy. 
The resulting value is read from the calibration curve and expressed in U/ml. The test is used to monitor anticoagulant 
therapy with low-molecular-weight heparin and can also be used to monitor therapy with standard heparin.
37.3. Laboratory Monitoring of Anticoagulant Therapy
Objective: Reach such decrease of blood coagulation capacity that minimizes the risk of thrombosis on the one 
hand, and the risk of bleeding on the other hand, i.e. reach the therapeutic level.
37.3.1. Warfarin
Mechanism of action: Warfarin interferes with the synthesis of vitamin K-dependent factors (II, VII, IX, X) and inhi-
bitors (protein C and protein S), thereby decreasing their function activity.
Indications: Prophylaxis and treatment of venous thrombosis and pulmonary embolism.
Dosage: Adults Children
5 - 15 mg/day; dose is adjusted based on INR 0.1 – 0.35 mg/kg/day; 
(maximum dose: 15 mg) 
the dose is adjusted based on INR
Laboratory control: INR
Therapeutic and preventive range: 2 – 3
2.5 – 3.5 for patients at high risk of thrombosis (mechanical heart valve, 
repeated pulmonary embolism)
37.3.2. Standard Heparin
Mechanism of action: Standard heparin acts through antithrombin and prevents the conversion of fibrinogen to 
fibrin coagulum. Standard heparin is not thrombolytic itself, but prevents fibrin coagulum from growing.
Indications: Treatment of venous and arterial thrombosis, prevention of blood clotting during extracorporeal cir-
culation and dialysis.
Dosage: 
(thrombosis treatment)
Adults Children
Bolus: 75 U/kg IV 75 U/kg IV
Maintenance dose: 18 U/kg/hr IV - for continuous infusion 20 - 28 U/kg/hr IV - for continuous infu-
sion
Dose is adjusted based on APTT Dose is adjusted based on APTT/anti Xa
Laboratory control: APTT R Anti Xa test (more 
adequate for children)
Therapeutic range: 1.5 – 2.5 0.4 – 0.7 U/ml
37.3.3. Low-Molecular-Weight Heparin (LMWH)
Mechanism of action: By binding to antithrombin, LMWH enhances the inhibitory effect on the activated X (Xa) 
factor and, to a lesser extent, factor II (IIa).
Indications: Prevention and treatment of venous and arterial thrombosis.
Dosage: Adults Children
Prevention 2000 - 4000 aXa IU (20 - 40mg)/24 hrs s.c. < 2 months:
75 aXa IU (0.75 mg)/ kg/12 hrs s.c.
2 – 12 months:
50 aXa IU (0.5 mg)/ kg/12 hrs s.c.
>12 months:
100 aXa IU (1mg)/kg/24 hrs s.c.
Treatment 100 aXa IU (1mg)/kg/12 hrs or  
150 aXa IU (1.5mg)/kg/24 hrs s.c.
< 2 months:
150 aXa IU (0.75 mg)/ kg/12 hrs s.c.
>2 months:
100 aXa IU (1mg)/kg/12 hrs s.c.
Dose should be adjusted based on antiXa test 
result
Laboratory control: Anti Xa test 
(first sampling 4 hours after 2nd dose; if dose is changed, 4 hours after the next dose)
Preventive range: 0.2 – 0.4 U/ml
Therapeutic range: 0.5 – 1.0 U/ml
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38.1. General Nutrition Disorders
Two extreme nutrition disorders are encountered in clinical practice: undernutrition on the one hand and obesity 
on the other. While obesity is, for a greater part, a problem of the developed, civilized world, the opposite condition – 
undernutrition – occurs both in countries with a low social and economic standard as well as in developed countries. 
Malnutrition in developed countries is usually connected to an underlying disease.
Individuals at risk of or already facing malnutrition can be seen in everyday hospital practice. The course of the 
disease is worse and is often complicated by fatal impacts of malnutrition. The text below deals with malnutrition ex-
perienced by hospitalized patients, the causes, impact and possible options for treating malnutrition.
38.2. Causes of Undernutrition
In general, undernutrition results from taking an unbalanced diet in which certain nutrients are lacking. This imba-
lance (negative balance) occurs in the following situations:
• Lower food intake (anorexia nervosa, diseases of the teeth and oral cavity, swallowing problems, tumours 
of the oesophagus, stomach and pancreas, loss of appetite, poverty of the homeless and tramps connec-
ted to both malnutrition as well as alcoholism);
• Digestion and absorption disorders (gastrectomy, pancreatopathy, cystic fibrosis, hepatopathy, biliary pa-
thology, lactase deficiency, celiac disease, conditions after bowel resection, blind loop syndrome, inflam-
matory bowel diseases, intestinal fistulas);
• Metabolic diseases (hepatic and renal insufficiency);
• Increased losses and catabolism due to a disease (fistulas, operations, sepsis, tumours, traumas, infections, 
abscess).
38.3. Incidence of Hospital Malnutrition
Back in 1885, Florence Nightingale warned at her nursing lessons that “Thousands of patients are annually star-
ved in the midst of plenty, from want of attention to the ways which alone make it possible for them to take food”. 
Screening studies confirmed this assumption, and about 15 - 20% of hospital deaths are correlated with malnutrition. 
Malnutrition occurs in 30 - 35% of hospitalized patients. Table 1 shows the incidence of malnutrition in some diseases.
Geriatrics 50%
Inflammatory bowel diseases 75%
Tumours 20 - 80%
Pulmonary diseases 45%
Malnutrition developed during hospitalization 20 - 25%
Total hospital malnutrition 30  -  35%
Table 38.1. Incidence of malnutrition in selected diseases
38.4. Risks and Impacts of Hospital Malnutrition
Malnutrition due to catabolism with increased proteolysis and gluconeogenesis leads to the loss of muscle mass 
and visceral protein in the body. Reduced protein pool, or reduced functional capacity of the protein system within the 
body, results in a weaker defensive and reparative immune response. This situation leads to the increased incidence of 
infectious complications (urinary and respiratory tract infections, early infections) and considerably worse healing of 
wounds. Another major impact is the loss of muscle mass and strength leading to long-term immobilization, develo-
pment of decubitus and respiratory failure with consequent dependence of artificial pulmonary ventilation. All these 
changes result in a longer stay in hospital, higher morbidity and mortality rates as well as increased cost of treatment. 
Early diagnosis and treatment of malnutrition may prevent these effects.
38.5. Diagnosis of Malnutrition
38.5.1. Patient History
From historical data, the question about weight loss over a certain period of time is essential. Clinically significant 
weight loss is a loss of 5% in one month or 10% in 2 - 6 months. Another important question is about the amount of 
food taken in the past ten days. A food intake under ¾ of portions signals a risk of malnutrition. Supplementary ques-
tions include analysing dietary habits, questions about indigestion related to food intake, the presence or absence of 
diarrhoea, social status, or the state of teeth.
38.5.2. Anthropometry and Physical Examination
Basic anthropometric data include weight (kg) and height (cm). However, practice reveals that about 30% of hos-
pitalized patients are not weighed and height is measured only very occasionally. This wrong approach contributes to 
underestimation of malnutrition, which can be corrected by simple organisational measures. Weight and height values 
are used to compute the body mass index BMI = weight [kg] / height [m]2, to classify patients (Table 2) and serve to 
carry out an objective nutritional status. Malnutrition in the population aged 18 - 70 is defined as BMI < 18.5, life-threa-
tening malnutrition as BMI < 12.5. The BMI < 20 is considered a malnutrition limit in patients over 70.
BMI kg/m2 
Higher than 40 Class III obesity
35 – 40 Class II obesity
30 – 35 Class I obesity
25 – 30 Overweight
20 – 25 Normal range
Lower than 18.5 Malnutrition
Lower than 12.5 Life-threatening malnutrition
Table 38.2. BMI Classification
Another useful index found from the difference of height (cm) – 100 is the Broca index to calculate ideal body 
weight. This simple calculation is used in practice to determine the dose of proteins and calories for enteral and paren-
teral nutrition. Example: A patient weighing 120 kg, 160 cm tall has a Broca index of 60, which means that his/her ideal 
weight is 60 kg. The dose of energy and nutrients is then calculated for this weight so as not to „feed the fatty tissue“.
Upper-arm circumference (UAC) (characterizes the muscle reserve) and triceps skin fold (TSF) (characterizes the 
adipose tissue) measurements are special examinations that are not commonly used to diagnose malnutrition. There 
is an exception of assessing malnutrition in oedema conditions such as hepatic cirrhosis. Values between the 5th and 
15th percentiles are indicative of malnutrition even with a normal BMI; values under the 5th percentile suggest severe 
malnutrition as shown in Table 3.
Males UAC (cm) TSF (mm)
15th percentile 27 7
5th percentile 25 5
Females
15th percentile 25 15
5th percentile 23 11
Table 38.3. Limit upper-arm circumference and triceps skinfold values in a nutritional status assessment
The physical examination inquires into the main body structure types - asthenic, normosthenic, obese; aspects 
to be noted include oedemas of the lower extremities, ascites, alopecia, nail and skin condition, healing of wounds, 
haematomas or goitre.
38.5.3. Laboratory Tests
Although many laboratory indicators are available, some basic biochemical parameters are sufficient for diagno-
sing malnutrition. Tests for serum protein (total protein, albumin, prealbumin) and one of inflammatory reaction mar-
kers, preferably C-reactive protein, are important. It is difficult to evaluate the level of anabolic protein (albumin, pre-
albumin, transferrin) in patients with hepatic failure. Low levels in these conditions are indicative of reduced synthetic 
function of the liver rather than the degree of malnutrition. Assessing the inflammatory condition of the body based 
on the inflammatory marker (CRP) is essential for diagnosing stress starvation.
The biological half-life of albumin is 21 days, and albumin levels correlate not only with the amount of proteins 
within the body but are also greatly affected by the inflammatory response of the body, leading to higher permeabi-
lity of capillaries and albumin seepage into the third space. Rapid drops in albumin level within a short period of time 
are therefore an indicator of the scale of the stress reaction (a new attack of sepsis, bleeding) and the severity of the 
disease rather than only an indicator of malnutrition. Stress-induced malnutrition, however, is always present. Albu-
min levels are assessed with respect to the long-term nutritional status preferably from three weeks values, because 
fluctuations at shorter intervals are indicative of the severity of the disease or albumin losses through proteinuria or 
exudative enteropathy. From this point of view, the current protein status of the body is better characterized by total 
protein. Albumin levels < 28 g/l measured for a long time are considered as an indicator of malnutrition. Prealbumin, 
an anabolic phase protein with a biological half-life of 2 - 3 days, is a good short-term indicator which can be used to 
evaluate the adequacy of the selected nutritional intervention. Like albumin, a prealbumin level assessment is limited 
to non-stress conditions, since the prealbumin level in stress metabolism decreases in direct proportion to the severity 
of the disease. Prealbumin level assessment is further limited in patients with renal failure, where falsely high values 
can be found due to decreased glomerular filtration.
The trace element (Zn) and cholesterol levels are suitable indicators of long-term nutritional status. Their levels 
decrease in people with poor nutrition over a long time. Blood count is a simple and inexpensive indicator detecting 
malnutrition expressed by typical normocytic anaemia and/or leucopenia.
38.6. Two Types of Malnutrition
38.6.1. Cachexia
The first characteristic type is simple cachexia – marasmus (synonyms: marasmic malnutrition, simple starvation, 
protein-energy malnutrition, the “skin and bone” look). This type of malnutrition occurs due to inadequate intake of 
energy substrates (carbohydrates, lipids) and proteins. In clinical terms, this condition is characterized by low weight 
and a low BMI. Laboratory findings are poor. In metabolic terms, simple starvation is characterized by the use of fat re-
serves as a source of energy. Lipolysis (beta-oxidation) produces active metabolite, acetyl-CoA. Acetyl-CoA is metaboli-
zed in the Krebs cycle to produce reduced coenzymes, which are further processed in the respiratory chain to generate 
energy in the form of ATP. Acetyl-CoA is also used for gluconeogenesis.. When the Krebs cycle capacity has been excee-
ded, excess acetyl-Coa leads to the synthesis of alternative sources of energy – ketone bodies (β-hydroxybutyric acid, 
acetoacetic acid, acetone). The reason for this metabolic change is considerable reduction of protein catabolism and 
maintenance of their function. During developed simple starvation, protein catabolism is limited to 10 - 20 g/day. This 
primarily involves slow elimination of muscle protein. Released amino acids are used for synthesizing plasma proteins, 
the level of which remains normal. If normal body fat percentage (20 - 25%) is taken into account, this reserve in a 70-
kg individual can be the source of 126,000 kcal, i.e. an energy reserve for 60 - 70 days. This assumption corresponds to 
actual observations in concentration camps during World War Two.
38.6.2. Kwashiorkor
Another type of malnutrition is kwashiorkor (the name is derived from the African Ga language and translates as 
“the sickness the baby gets when a new baby comes”). In African conditions, this type of malnutrition has exogenous 
causes (see the note). “Kwashiorkor-like malnutrition“ = protein malnutrition = stress starvation has endogenous 
causes in our conditions. Aetiopathogenesis can be varied. This type of malnutrition is due to insufficient protein inta-
ke, increased losses (proteinuria, exudative enteropathy), increased degradation (catabolism) or reduced synthesis 
(hepatic cirrhosis) of proteins, i.e. absolute deficiency of proteins. In clinical terms, this type of malnutrition is charac-
terized by fluid retention, oedemas, ascites and weight gain. Laboratory tests show a marked drop in serum proteins 
and albumin, and elevated acute phase proteins (CRP, orosomucoid, caeruloplasmin, α
1
-antitrypsin) in patients with 
an inflammatory reaction. In developed countries, KW-like malnutrition is most commonly related to a stress situation 
(polytrauma, surgery, sepsis, acute pancreatitis, burns). Metabolic changes are regulated by the hormonal environ-
ment in the body. Metabolic stress induces a drop in the production of insulin and elevated output of counterregulato-
ry hormones such as cortisone, glucagon and adrenalin. This results in the blockade of lipolysis, accelerated proteolysis 
and gluconeogenesis from proteins. Proteins thus lose their phyologenetic function (i.e. structural support, signalling, 
transport, defence), and become the source of energy for glucose-dependent tissues (brain, erythrocytes, lymphocy-
tes, renal cortex) as well as other tissues such as the heart and liver resulting from of the absence of ketone bodies. 
Their deaminated carbon chain is a reservoir of energy, like carbon chains of triacylglycerides derived from fatty acids. 
The organism is unable to survive if more than 50% of body protein reserve is lost. If protein catabolism with losses of 
30 g N (about 180 g of protein) per day and average 20 kg of protein tissue in the body is considered, then maximum 
time of survival with this type of starvation is 10 - 14 days. Compared to simple starvation, stress starvation is a more 
severe clinical condition with rapid development and a potentially fatal outcome.
Pure protein malnutrition occurs in nephrotic syndrome. Combined malnutrition occurs in patients with hepatic 
cirrhosis, where the synthetic function of the liver is reduced. An inflammatory component is often present in patients 
with exudative enteropathy, however the drop in albumin is more pronounced than a drop corresponding to an inflam-
matory reaction. The basic differences between the two types of malnutrition are shown in Table 4.
Indicator Cachexia Stress starvation
Inflammation Absent Present
Albumin Normal Reduced
Body water and Na content Reduced Elevated
Body weight Reduced Elevated
REE Reduced Elevated
Fat Reduced Normal
Disease Anorexia nervosa, Crohn’s disease, 
chronic pancreatitis
Polytrauma, sepsis, operation
Table 38.4. Differences between cachexia and stress starvation
Note:
Kwashiorkor (KW) in the classical “African“ form is typical of children 1-4 years old when a mother weans her child, 
replacing breast milk with a diet high in starches, but deficient in proteins (corn, cassava). KW pathogenesis involves 
high insulin secretion and conservation of muscle proteins at the expense of plasma proteins (drop in albumin, develop-
ment of oedemas, reduced lipoprotein synthesis in the liver, development of hepatic steatosis). Clinically similar conditi-
ons can be found in the CR (hypoalbuminaemia, retention of fluids with oedemas, ascites) in people with a pronounced 
inflammatory reaction to stress (polytrauma, burns, sepsis, major surgery, severe acute pancreatitis). As this condition 
is clinically similar to classical KW, this malnutrition is sometimes referred to as KW-like malnutrition. The pathogenesis 
of this condition is different, and is induced by stress hormone elevation (adrenalin, glucagon, cortisol) and develop-
ment of insulin resistance (stress diabetes). This results in rapid catabolism of muscle proteins in particular, increased 
capillary permeability with albumin seepage into the interstitium, and fluid retention. Unlike the classical KW (weeks), 
this condition develops faster, within days.
38.7. Who Requires Nutritional Intervention?
Two types of patients requiring nutritional intervention can be found in hospital. These are primary poorly nou-
rished patients in which malnutrition can be recognized on admission (BMI < 18.5, clinically significant weight loss, 
albumin < 28 g/l). The second case is malnutrition developing during hospitalization. These are typically inpatients, 
which have no or minimal oral food intake for 3 - 5 days, most often due to a disease and examination procedures (dif-
ficulty in swallowing – cerebrovascular diseases, dysphagia, abdominal pain, acute abdomen).
38.8. Types of Nutritional Intervention – What We Can Offer to Patients
• Instruction by dietitian
• Fortified diet
• Sipping
• Enteral nutrition
• Parenteral nutrition
Instruction from a dietitian:
Consultation with a dietitian specialist often leads to a substantial impact on food intake. The dietitian specialist 
selects the appropriate type of nutrition according to the individual’s needs (culinary preparation, ingredients, mecha-
nical treatment), evaluates the amount of food taken, calculates the dose of nutrients taken, recommends whether 
enteral nutrition should be used and instructs patients on a specific type of diet.
Fortified diet
Powder protein and oligosaccharide concentrates are added to food. Their taste is neutral so the taste of the food 
is minimally changed. Products available include Protifar (proteins – casein) and Fantomalt (maltodextrin).
Sipping
Sipping is the most widespread nutritional intervention. Sipping means drinking flavoured balanced enteral nutri-
tion products by little amounts as a supplement to the food taken. They usually represent a daily intake of 300 - 600 
kcal, i.e. 1 - 2 packages. There is a wide selection of products differing in energy density, protein content, presence of 
fibre etc. Examples: Nutridrink, Fresubin, Resource, Ensure, Prosure.
Enteral nutrition
Tube feeding is often used as a synonymic term. This nutritional intervention means the delivery of balanced en-
teral nutrition products by a feeding tube into the gastrointestinal tract if the patient is unable to take food. Enteral 
feeding is delivered to the digestive tract by a nasogastric or nasojejunal tube. Jejunostomy or gastrostomy is used as 
entry into the GIT for long-term enteral feeding. Enteral product solutions are balanced to cover the daily requirement 
of energy and all nutrients at the same time. In practice this means that if the daily requirement is 2000 kcal (75% of all 
patients on EN), the patient is given 2000 ml of enteral product with an energy density of 1 kcal/ml. Enteral nutrition 
is a preferred approach to patient feeding because it is physiological, does not have adverse pharmacological effects 
and is safer and cheaper compared to parenteral nutrition. Contraindications for tube feeding are sudden abdominal 
incidents, bleeding to the GIT, ileus.
Parenteral nutrition
This nutritional intervention refers to the delivery of nutritional substrates outside the digestive tract, intravenous-
ly. This method of feeding is non-physiological and is associated with many complications connected with administrati-
on through vein access such as the pneumothorax, bleeding and embolism, as well as subacute complications such as 
venous thrombosis, cannula sepsis, and hepatobiliary complications. Parenteral nutrition is administered in the form of 
all-in-one (AIO) bags, most commonly into the central vein (v. jugularis, v subclavia, v. femoralis). AIO bags use solutions 
of amino acids, glucose, lipids, ions, vitamins and trace elements. Parenteral nutrition is indicated to ensure feeding in 
the event that enteral nutrition is contraindicated and nutrition through the GIT is impossible.
38.9. Monitoring Nutritional Status in Hospital
38.9.1. Anthropometry
Anthropometric monitoring depends on the severity of the condition and the method of nutritional intervention. 
The basic parameter to be monitored is body weight. Weight of patients with severe conditions (e.g. sepsis, organ 
failure, circulatory instability) hospitalized at intensive care units has to be measured on a daily basis. Daily weight fluc-
tuations are a good indicator of water balance and easily detect any water retention. The weekly weighing of stabilized 
patients on enteral nutrition is sufficient. Daily monitoring of the weight of patients with short bowel syndrome and 
high losses through ostomies, fistulas or drains is an essential prerequisite for correct crystalloid balance. Stand-on 
scales, chair scales and bed scales are used for measuring the weight. Upper-arm circumference is a suitable anthropo-
metric marker to evaluate the nutritional status of bedridden patients on aftercare beds, which are often not equipped 
with bed scales. Calculation: UAC – 5 = BMI gives approximate BMI and body weight, if the patient’s height is known.
38.9.2. Biochemical Parameters
When initiating nutritional intervention, the potential development of refeeding syndrome and overfeeding syn-
drome has to be taken into account.
The basis of refeeding syndrome is a drop in plasma concentrations of potassium, magnesium and phosphorus. 
In anabolic processes these substances move intracellularly and become part of synthesized protein macromolecules. 
Their reduced levels and reduced availability in tissues result in the disturbed transfer of nerve and neuromuscular 
impulses and relative ATP deficiency with serious clinical effects. The P, Mg and K reserve is reduced in undernourished 
patients. Administration of nutritional substrates with insufficient coverage of the ions listed above, leads to a very fast 
drop in their plasma levels. Clinical signs of this syndrome include muscular weakness, muscle spasms, paralysis, diso-
rientation, disturbance of consciousness, and may result in death due to cardiac arrhythmia or diaphragm paralysis. A 
fatal example of this syndrome from history is deaths of prisoners released from concentration camps. The facts above 
prove the necessity of regular monitoring of K, Mg and P concentrations and consistent coverage of their requirement.
Overfeeding syndrome – overloading by nutritional substrates occurs if required dose of nutrients is poorly esti-
mated in undernourished patients. Laboratory results show development of hyperglycaemia, elevated triacylglycerols, 
increased liver test parameters, development of jaundice and elevated urea. This is why the laboratory parameters in-
dicated above should be monitored repeatedly if nutritional intervention is administered, especially to undernourished 
patients. Clinical signs of overfeeding include elevated body temperature, development of jaundice with hepatomegaly 
and polyuria.
Thiamine deficiency is often important in patients with diabetes mellitus, hepatic cirrhosis, in chronic ethylic pa-
tients and severely undernourished patients (anorexia nervosa). When nutritional intervention is started in these pa-
tients, incorrigible lactate acidosis may develop as a result of reduced pyruvate decarboxylase activity with thiamine 
as a cofactor. The finding of metabolic acidosis and an elevated lactate level with good tissue oxygenation is an un-
mistakable sign of this condition.
Prealbumin level monitoring is used to evaluate the effectiveness of selected nutritional intervention and the 
onset of anabolism. An increase in plasma prealbumin concentration within 3 - 5 days is an indicator of an ongoing 
anabolism. Similarly, the monitoring of nitrogen loss reveals details as to the current metabolic situation. In general, 
catabolism occurs if daily nitrogen losses are higher than 15 g.
To give some practical examples, listed we have included the frequencies of specific tests for ICU patients here 
below:
Note:
The monitoring of biochemical indicators, their extent and frequency of tests depend on the patient’s clinical con-
dition. Urea, creatinine, ions, P, Mg, total protein, albumin, CRP and glucose assays are indicated for stabilized under-
nourished patients on supplementary or full enteral nutrition in the first week. After the next 3 - 4 days urea, creatinine, 
ions, P, Mg and blood glucose profile, and after another 7 - 10 days the parameters listed above plus albumin, CRP, total 
protein and prealbumin. Follow-up laboratory tests are advisable after 3 weeks at 4 - 6 week intervals.
Vitamin, trace element, iron, triglycerol and cholesterol levels are checked at the beginning of treatment and sub-
sequently every 4 - 6 weeks.
Stricter monitoring is required for patients in intensive care, often on parenteral nutrition. Urea, creatinine, ions, P 
and Mg are usually monitored on a daily basis. Blood glucose is tested 4 times a day. If the glucose profile is satisfactory, 
testing twice a week is sufficient. Bilirubin, liver test parameters, TAG and CRP are checked twice a week; albumin, total 
protein, prealbumin, Zn and Se are checked once a week. Vitamin levels are not tested regularly. Vitamin D, vitamin C, 
vitamin A, folic acid and vitamin B12 are sometimes monitored only in complicated cases in metabolic care ICUs. The 
laboratory tests listed above are used to evaluate the nutritional status, monitor the kind of nutritional intervention 
selected and detect possible adverse effects (refeeding syndrome, overfeeding, hepatopathy associated with parente-
ral nutrition). Additional laboratory tests depend on the specific patient’s situation – ventilation and respiration, blood 
gases, acid-base balance, monitoring of inflammatory reaction development (procalcitonin, CRP), etc.
38.9.3. Nitrogen Balance
Nitrogen balance is essential in order to evaluate the metabolic situation of the body. Nitrogen balance is defined 
as the measure of nitrogen output subtracted from nitrogen input. Nitrogen balance can be positive, even or negative. 
Nitrogen losses are determined from daily losses of urea as a final metabolite of amino acid (protein) catabolism. Many 
studies have proven that urea losses in urine represent 80% of total nitrogen losses. So if daily urea losses are known, 
one can find out relatively accurate daily nitrogen losses using a simple formula (urea losses mmol/24 hrs * 0.0336 = 
total nitrogen losses/g/24 hrs).
Figure 38.1. Example of nitrogen loss determination (also nitrogen intake in the food or enteral/parenteral nutrition 
has to be known to determine the nitrogen balance
Nitrogen metabolism is balanced when healthy, which means that the nitrogen (protein) input is in equilibrium 
with nitrogen losses. Nitrogen balance in anabolic situations (recovery from a disease, pregnancy, bodybuilding, trai-
ning) is positive – the body produces increased amounts of proteins (covers losses, forms new tissues). In sickness, 
under the influence of acute (sepsis) or chronic (tumour, cardiac failure) inflammatory reaction of the body, proteolysis 
is stimulated, proteosynthesis suppressed, gluconeogenesis enhanced and lipolysis influenced. This results in a negati-
ve nitrogen balance with protein losses higher than protein input. It is interesting that artificial delivery of pure amino 
acids in the form of parenteral nutrition (PN) cannot prevent but can only reduce catabolism of endogenous proteins. 
Body’s own proteins (muscle, albumin, immunoglobulins) are used in preference. This observation has led to abando-
ning the effort to reach even nitrogen balance in severe catabolism. Increased delivery of substrates in PN greatly bur-
dens intermediary metabolism and has adverse effects (hepatic failure – icterus, cholestasis, hyperglycaemia, uraemia, 
hypertriglyceridaemia) which increase mortality. Therefore, if protein catabolism is found (urinary nitrogen losses of 
more than 15 g/24 hrs = 90 g, amino acids = 450 g of muscle), the physician should search for the cause and try to solve 
the situation (treatment for sepsis, abscess or autoimmune disease). Another basic procedure is selecting nutritional 
intervention (EN or PN) with a stress ratio of nutrients, respecting their maximum doses per kilogram of ideal weight, 
without even making an effort to maintain the balance. Carbohydrates and lipids are used as an energy substrate in the 
anabolic phase. Proteins perform specific functions. Contrary to this, proteins are used as a source of energy in stress 
metabolism, and so protein consumption increases and carbohydrate and lipid availability decreases. Stress-related 
and anabolic ratios of nutrients have been shown in Table 5.
38.9.4. Nutrient Doses
Nutrient ratio in anabolism
Carbohydrates Lipids Amino acids
6 g/kg 1 - 1.5 g/kg 1 g/kg
Nutrient ratio in stress
Carbohydrates Lipids Amino acids
2 - 3 g/kg 0.7 g/kg 1.5 - 2 g/kg
Table 38.5. Stress-related and anabolic ratios of nutrients
38.10. Determination of Energy Requirement
Three approaches to energy requirement determination are available:
38.10.1. Estimated Energy Requirement
Basal metabolic rate (BMR) = 1 kcal/kg/hour = 24 kcal/kg/day
Total energy requirement (BMR + AF + DF) = 30 - 35 kcal/kg/day
(BMR – Basal Metabolic Rate, AF – Activity Factor, DF – Disease Factor)
Energy requirements for the AF and DF are included in an increase in energy requirement by 5 - 10 kcal/kg/day 
against calculated energy requirement for the BMR. This calculated total energy requirement is usually not exceeded 
in clinical practice. There is an exception of convalescing patients with anabolism after overcoming catabolic conditions 
(polytrauma, major surgery), when the total energy requirement often amounts to 40 - 45 kcal/kg/day.
Energy dose is determined both in terms of the current and ideal weight of the patient. Ideal weight is calculated 
from the Broca index. For patients with a BMI under 17, energy requirement should be calculated for their current 
weight, and after 10 - 14 days, the dose of energy should be increased to the ideal weight in order to prevent refeeding 
syndrome. (See above.)
38.10.2. Calculated Energy Requirement
The Harris-Benedict equation taking the age, weight, height and gender of the patient into account is most com-
monly used to calculate the energy requirement.
Males: BMR = 66.473 + 13.7516 x W + 5.0033 x H – 6.755 x A (kcal/24 hrs)
Females: BMR = 655.0955 + 9.5634 x W + 1.8496 x H – 4.6756 x A (kcal/24 hrs)
(W – weight in kg, H – height in cm, A – age)
38.10.3. Measured Energy Requirement
Indirect calorimetry is used to measure energy expenditure. This method is used to calculate current resting energy 
expenditure equal to BMR + DF (BMR – Basal Metabolic Rate, DF – Disease Factor), which is indicative of the current 
metabolic state of the patient. Indirect calorimetry employs the knowledge about the nature of breathing discovered 
by A.L. Lavoisier (1743 - 1794): “Oxygen is consumed during respiration and oxygen consumption is proportional to 
energy expenditure.” This scientist stated the law of conservation of mass in 1774 and is considered father of calori-
metry. Indirect calorimeter measures oxygen consumed and carbon dioxide eliminated. Energy expenditure can be 
calculated from O
2 
consumed per minute, and the CO
2
/O
2
 ratio is used to calculate the respiratory quotient (RQ), which 
corresponds to nutrient utilization. (RQ = 1 corresponds to pure glucose utilization, RQ = 0.7 corresponds to fat utilizati-
on, RQ = 0.8 corresponds to amino acid utilization.) If nitrogen output and therefore protein losses are known, one can 
determine the amount of oxygen required for their metabolism and the amount of carbon dioxide produced. When 
these values are deduced from overall O
2
 consumption measured and CO
2
 expenditure, the resulting non-protein RQ is 
indicative of the prevailing type of utilized nutrients (carbohydrates [RQ close to 1] or fats [RQ close to 0.7]).
This method of energy requirement determination is suitable for obese people, severe cachexia and patients not 
responding well to the calculated dose of nutrients.
Below you can find stechiometric formulas showing nutrient oxidation and explaining the RQ values for each nu-
trient:
Glucose:
C
6
H12O6 + 6 O2 => 6 CO2 + 6 H2O
RQ=1, 1gG = 0.74l O2 + 0.74 CO2, 1gG = 4kcal
260 litres of oxygen is required for a daily dose of glucose (350 g) 
Fat:
CH3(CH2)14COOH + 23 O2 => 16 CO2 + 16 H2O
RQ=0.7, 1g fat = 2.03l O2 + 1.43l CO2, 1g fat = 9kcal
142 litres of oxygen is required for a daily dose of fat (70g)
Proteins:
2 C3H7O2N + 6 O2 => (NH2)2CO + 5 CO2 + 5 H2O
RQ = 0.8, 1gP = 0.966l O2 + 0.782lCO2, 1g P = 4kcal
77 litres of oxygen is required for a daily dose of fat (80g)
The Weir equation is used to calculate resting energy expenditure from known oxygen uptake and carbon dioxide 
output:
REE = 3.95xVO
2
 + 1.11xVCO
2
 (kcal/24 hrs)
Oxidation of each substrate is calculated from the equation below, requiring the knowledge of daily oxygen uptake, 
and carbon dioxide and nitrogen output:
Protein oxidation (g/24 hrs) = nitrogen output/24 hrs x 6.25
Carbohydrate oxidation (mg/min) = 4.534xVCO
2
 – 3.195xVO
2
 – NUx2.0
Fat oxidation (mg/min) =1.669xVO
2
 – 1.669xVCO
2
 – NUx1.331
38.11. Body Composition
Males Females
Proteins 15 - 16 14 - 16
Carbohydrates 1 - 1.5 1 - 1.5
Fat 15 - 22 22 - 28
Water 55 - 64 50 - 58
Minerals 5 5
Table 38.6. Average normal body composition expressed as a percentage
Males Females
Muscular tissue 28 17
Fat tissue 15 19
Bones 12 10
Liver + GIT 2 - 3 2
Brain 1.4 1.2
Heart 0.33 0.24
Kidneys 0.31 0.27
Other 9.3 7.3
Total 70 58
Table 38.7. Body composition, by tissue types in a 70-kg man and a 58-kg woman
38.11.1. Fat Tissue and Fat-Free Tissue
Fat tissue contains 80% of fat, 18% of water and 2% of proteins. From this point of view, the human body can be 
divided into the fat-free mass (FFM) and the fat mass (FM). FFM comprises all body components except lipids. FM is 
body fat: triglycerides, cholesterol and other lipids. A further method divides the body composition into the adipose 
tissue mass (ATM) and the lean body mass (LBM). In addition to fat, ATM also comprises adipocyte membrane protein 
and water. LBM represents the rest of the body: bones, muscles and internal organs. Given the water and protein con-
tent, adipose tissue mass (ATM) is greater than fat mass (FM). The division above is described to be able to understand 
abbreviations used as an output from bioelectrical impedance instruments.
38.11.2. Bioelectrical Impedance Analysis
The bioelectrical impedance analysis (BIA) is a method that employs Ohm’s law (I = U/R) to measure tissue re-
sistance (bioelectrical impedance). The instrument works with a high-frequency and low-voltage current. The impe-
dance measurement is used to determine the amount of fat mass (FM) and fat-free mass (FFM), or lean body mass 
(LBM). Newer instruments work with multiple frequency currents and use the fact that higher-frequency current (over 
100 Hz) penetrates transcellularly and lower-frequency current paracellularly. These instruments, referred to as dual 
BIA, work with several electrodes on the body surface and by alternately measuring impedance between the electro-
des emitting currents of different frequencies, they divide the body into different segments, the composition of each 
is analyzed separately. The extent of the body segment depends on the place where the electrodes are applied. The 
body is most commonly divided into 5 segments: upper extremities, lower extremities and the torso. The output of 
the measurement is %FM, %FFM or %LBM corresponding to the muscular tissue. If the body weight is known, it is 
easy to determine absolute values. In addition, dual BIA measures total body water (TBW), extracellular water (ECW), 
intracellular water (ICW), body cell mass (BCM) and segmental distribution of fat and muscle, including oedema and 
retained fluid detection is determined. This examination is used in clinical practice for monitoring body muscle growth 
during convalescence and adequate physical therapy, body composition and water content monitoring in patients with 
chronic renal failure for possible adequate dry weight adjustment. The determination of body composition and BCM in 
particular may detect incipient malnutrition in patients with hepatic cirrhosis, nephrotic syndrome or cardiac failure. 
The examination motivates obese patients, evaluates possible fluid retention and monitors the loss of FM. This exami-
nation may also be used to monitor correctness of selected nutritional intervention.
38.11.3. Body Density Measurement
Body density measurement is used to calculate the content of fat tissue. This method requires complete submer-
sion of the body under water. It is known that body density is given by weight per unit of volume, so if body weight 
(kg) and body volume (volume of water in litres by complete body immersion) is measured, body density can be deter-
mined. Obese people usually have lower body density. Fat density is 0.9 g/ml, fat-free mass (FFM) density is 1.1 g/ml. 
Equation used to calculate fat percentage from known body density:
%FM = ((4.95/density)-4.5)*100
38.12. Examples – PN Specification for All-in-One Bags
38.12.1. Example 1: PN with anabolic nutrient ratio (Table 41.5.)
30-year-old patient with Crohn’s disease, chronic activity, terminal ileus stenosis, subileus, weight 50 kg, height 175 
cm, usual weight 65 kg, alb 30 g/l, CRP 2 mg/l.
Amino acids: 1 g/kg of ideal weight (height – 100) =1*75= 75 g = 500 ml 10% Aminoplasmal (50g amino acid) + 500 
ml 5% Aminoplasmal (25g amino acid)
Glucose: 6 g/kg of current weight = 6 * 50 = 300 g G = 500 ml 40 % Glucose + 500 ml 20% Glucose
Fat: 1 g/kg of current weight = 1 * 50 = 50 g = 250 ml 20% Lipofundin
Daily doses of minerals, trace elements and vitamins. After a week if metabolically tolerated, the dose of glucose 
may be increased by 50 g and fat by 25 g.
38.12.2. Example 2: PN with stress nutrient ratio (Table 5)
55year-old patient with severe acute pancreatitis, weight 75 kg, height 172 cm, usual weight 75 kg, alb 22 g/l, CRP 
280 mg/l
Amino acids: 2 g/kg of ideal weight = 2*75 = 150 g = 1000 ml 15% Aminoplasmal 
Glucose: 2.5 g/kg of current weight = 2.5 * 75 = 200 g G = 500 ml 40% Glucose
Fat: 0.7 g/kg of current weight = 0.7 * 75 = 50 g = 250 ml 20% Lipofundin
Daily doses of minerals, trace elements and vitamins. The glucose and fat dose has to be adjusted according to the 
triglyceride level and blood glucose profile.
